<SEC-DOCUMENT>0000950170-22-005202.txt : 20220331
<SEC-HEADER>0000950170-22-005202.hdr.sgml : 20220331
<ACCEPTANCE-DATETIME>20220331161130
ACCESSION NUMBER:		0000950170-22-005202
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220331
DATE AS OF CHANGE:		20220331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silverback Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		22792603

	BUSINESS ADDRESS:	
		STREET 1:		500 FAIRVIEW AVENUE NORTH, SUITE 600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-456-2900

	MAIL ADDRESS:	
		STREET 1:		500 FAIRVIEW AVENUE NORTH, SUITE 600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sbtx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-31T11:06:52.0395+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:sbtx="http://silverbacktx.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6dd793ec-6f70-46ed-8a3f-fa231106ddad" name="dei:CurrentFiscalYearEndDate" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1">--12-31</ix:nonNumeric><ix:nonFraction id="F_bccce8e7-b750-4510-8968-19eaaaafc25d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_3b0dfa37-784d-45c7-8f21-ff9ebf044985" name="dei:DocumentFiscalPeriodFocus" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1">FY</ix:nonNumeric><ix:nonNumeric id="F_3b4ac3f3-428c-4001-b111-9d1d1e14ee86" name="dei:EntityCentralIndexKey" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1">0001671858</ix:nonNumeric><ix:nonNumeric id="F_ca838e9c-0123-4130-b628-3d17164372f6" name="dei:AmendmentFlag" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1">false</ix:nonNumeric><ix:nonFraction id="F_83270064-b0cb-4fde-82f9-0810d07e13c1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sbtx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_494bd466-afac-4c94-b8ad-1da406d99780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67cef16b-8904-4ef1-a280-f5782cc3332b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_babe8ce4-149b-4c33-b021-b0e162ec46a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:RedeemableStockExcersibleOnAgreedUponMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86a8a0b7-29df-47b1-afc9-35b1ed2b1497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_360c64d4-e8a6-45e9-bf20-6dafe7757ce5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7fa8844-58a6-4654-9ddd-9b5375a9b363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sbtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cf07191-8e06-40b3-853c-f995a1f625ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6798eb1-f0de-4695-9641-5ea592a32344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfaeded9-f33c-4994-a098-63eb660e83ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1043a11-9233-4df8-b363-ce3a0f3f3bb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sbtx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_270d424e-2ea7-451c-a3be-3e4a447e5b40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5d577b3-d7af-45d0-860e-6ec6922cad1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sbtx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b97d231-61a7-4be6-94e9-44926c823685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sbtx:RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_828913ed-d805-418b-ab38-3ca1860cfe83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13e17b88-9a3e-4334-afaa-25c79b7864bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_860dbe58-a733-4b54-b5e8-6248758d43eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45c71f8d-3cda-45b7-9581-ba0f5e84dd52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sbtx:RestructuringPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-28</xbrli:startDate><xbrli:endDate>2022-03-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e29ac877-2d55-4d24-814b-9d73b1312fe1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60f52c8b-32d5-4e85-b1f0-31ec9fab4c12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b60a8ab1-2e21-4152-9230-5951eda009db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74e41f57-c0d7-4daf-b14d-df2e105f7efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37ebbd60-fda0-4900-9609-d33c5ffa0fd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10924f8e-1bb8-4859-a19f-53e9eeda573c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2266970-9935-4502-9c86-ada2228e4e21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5a118de-b5ae-416d-953c-fca753351c6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ec30bfe-5f48-45a5-b118-07bc27b0ff78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sbtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40425c84-7c43-4d68-9c93-740efc67f686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sbtx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7066a98-3245-4333-b828-b75b16bd6d9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:AmendedLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95368c9c-2ef3-4cdf-bc71-1cff6b42577a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6a0662a-dd26-49c0-af88-491b9b800275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dcf4afe-a66f-4353-a22e-83f64aa9613d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_954e4039-8ad8-4dde-9cc7-9b313b208185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71b567b9-dd67-488e-9bff-940240379336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62d36620-ca03-4b03-8439-9f51726efcf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_443c7d79-857f-4272-94c9-734cc7988aea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2f82abf-51d1-4cd8-bb42-2d8d43b73153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4fb8c88-21a6-408b-bd27-cec75b99333f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e77106ce-582d-481d-b3e4-30663c6abfa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ebc2a75-c6af-4453-bbcf-d1d071452f7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eccc60cc-900f-452b-bd4e-6dc984c5cd7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a05456f3-88fe-43ff-b244-8a5ee75b83e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3eec66cf-b934-4764-b8db-f29c238527a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3166a85-f0b6-454d-9e3b-4e94972eab35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b13a7ea-2f2e-41d9-8210-704162e848d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c917bb6b-c19f-402a-a7f9-3796e47702e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sbtx:WuxiBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-31</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f23b5346-4ed5-45a9-a974-16fe675333f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21761b55-f888-4dd6-90d9-c5d5d39d5076"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d3afa03-0c39-46e2-aac4-cf6089a8b67d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:RedeemableStockExcersibleOnAgreedUponMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14436cef-6d24-48bf-b8b6-de5a96e7c9a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f92b4f8-fdec-497d-8f93-b488d3246949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">sbtx:SeriesCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de83bac2-93f2-420e-9e2b-4c5157a75113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a83a64a1-7741-4e16-9288-99ee9079606f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5733b7d9-e5ce-4ff8-9092-59c9faf284e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:EsppWithholdingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3839233e-c975-49e1-a075-fef15f80e6d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cac55f6-3aef-4c64-94d0-8fe6535c4bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea504935-5339-4904-9013-2798d8f23b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12ca2440-8311-4748-a39b-7117c1ed0a1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2cc1fdc9-b760-4892-a859-13fea165b6d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d8d0169-89f0-4155-948a-25ed3e8d9d13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_225e24dd-9d34-41db-bc46-1555b81b2a47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4efba159-4be0-4651-ade7-fb31bf28b994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c706ed5d-e2ad-40ca-806a-0467398698b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1589284-886e-47d9-8e01-e13b1c2af513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sbtx:WuxiBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d3b5176-144a-4079-966a-a3f6e8176386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14dc9fe4-584f-4c31-87a5-09ff8302a12e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:UnvestedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51f68c66-981f-4114-9f1d-8af004dee45d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_384f1405-e75d-4b1f-ba71-caf76e7127d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebe0d08f-4b7c-4a30-a659-5090f617fde9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee566949-7a9b-49b6-abae-885b6d7b031f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f17035af-547b-47a2-b23c-ce99dd795100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_415738ce-5fb5-4ca7-93ff-db3c98f51fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57a90811-c613-469c-93e9-bd4b4838cbe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e9ffb89-6ff5-4676-b044-c5c124536efd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sbtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95651084-dc63-4d7f-8062-7d70db969b9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6eefba5e-4e7c-4fd7-92ec-5996101fb022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1bdc0b1-781e-4d6a-9638-314ec56b0e99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_032f1a5d-9136-4a8d-bfd5-8652354d9726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1306218-ebfe-4f46-b53a-08722ba81bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:EsppWithholdingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6d7fae1-66f6-4760-b28a-988192f19155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">sbtx:SeriesCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54e777a7-e252-4927-8dfc-437c38de5255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sbtx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a51e457e-525d-410b-a470-5e6bf9556468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2765e183-1081-430a-a0a8-58ce32c0c954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fe4ab25-1247-4234-81ff-cc9c1674c66c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:0.750pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.5pt;line-height:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac8701aa-ad39-482d-80f7-8ded69555b25" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.5pt;line-height:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1f91a0f-aa8d-444a-a0e4-16fe0268f30e" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edb2c4af-b3ff-4dd2-93bc-86c16d87d1b6" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db78d427-be30-4bb5-bcea-80e88127a5e4" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_788cf80e-b966-4ea9-9b05-a57c9788cee0" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the transition period from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">                    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">                    </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_354adca1-0784-4af0-b66a-c669c9ecb8d8" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-39756</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.5pt;line-height:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8a186ca-a1ad-4b5d-ae9a-25c70afa43e2" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.5pt;line-height:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_235972b8-1a52-4af0-bf35-c87238d7fbe1" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b3cef92-c503-4a78-919e-71fd85f1075e" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">81-1489190</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23e37d72-dc82-4d15-bc34-29d4cda50299" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">500 Fairview Ave N</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">, </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88c5840d-9bf2-4385-a2ff-0927635a0ba2" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Suite 600</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8732d783-41e6-40c7-b4c1-f441cca60dfc" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Seattle</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">, </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20be1cb4-9055-40a9-879e-b11305b394bf" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Washington</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b38b438-7886-43a0-827e-2fda4a7aea02" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">98109</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1740f63-e16e-4697-9ad5-3b6aaaaa6c3f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">206</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">) </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f55bd76a-f44d-47a4-9d7b-012b5818f969" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">456-2900</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.5pt;line-height:0.7pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Title of each class</span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Symbol(s)</span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Name of each exchange</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">on which registered</span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b3bc659-1151-4b44-9867-e172053e4aaa" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Common Stock</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">, par value $0.0001 per share</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f921c00c-d2d6-4243-9fe0-d1e15ed20bc1" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">SBTX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe458de5-496f-4ace-8f9b-504754344a76" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> Yes  &#9744;   </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b42c4a6-1905-4297-8ae0-668fa7e352fc" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes  &#9744;  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc6588c3-333a-4916-9f21-27552fec86d2" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38472115-c51c-4f5a-8ea5-69cfc875b757" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;    No  &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e898a8c-61e2-4b65-8819-5b0da2879eec" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">  &#9746;    No  &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.276%;"></td>
    <td style="width:51.67%;"></td>
    <td style="width:24.015%;"></td>
    <td style="width:3.039%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_346cabeb-0373-4994-aba5-cacf1dd9899f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95aecd37-fba8-425e-bc2c-4cc1f130d0ac" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f2f9be6-2566-4539-bf79-097fad94d886" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_497e02c0-384d-406b-874d-0347d4219089" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e823422-eb67-4bf5-ad65-85840084778f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  &#9744;    No  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6558799-f7a9-4682-b488-4086122014f3" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">As of March 28, 2022 there were </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4310f66d-2de1-4bf8-96cf-30a20a0cd1d4" contextRef="C_b60a8ab1-2e21-4152-9230-5951eda009db" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">35,143,186</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> shares of registrant&#x2019;s common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $</span><span style="font-size:7.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b29f4fd9-3ecf-4eb5-953f-544407123ddd" contextRef="C_225e24dd-9d34-41db-bc46-1555b81b2a47" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">676.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:Times New Roman;"> million as of June 30, 2021 (the last trading day of the registrant&#x2019;s most recently completed second quarter) based on the closing price of $30.89 as reported on the Nasdaq Global Market on such date. Shares of the registrant&#x2019;s common stock held by executive officers, directors, and their affiliates have been excluded from this calculation. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_11285903-aa77-44c5-9f9b-b45eb4454b49" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Portions of the registrant&#x2019;s definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.416%;"></td>
    <td style="width:82.662%;"></td>
    <td style="width:7.922%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9c"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure regarding Foreign Jurisdiction that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item12"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);text-indent:3.6pt;word-break:break-word;vertical-align:top;"><p style="margin-left:3.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K (this Annual Report) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our plans to research, develop, and commercialize SBT8230 and any future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain regulatory approval of product candidates arising from our ImmunoTAC technology platform, including from our SBT8230 program, in any of the indications for which we plan to develop them; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain funding for our operations, including funding necessary to commence and complete our planned clinical trials, conduct additional manufacturing and conduct preclinical studies of any of our product candidates, including from our SBT8230 program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success, cost, and timing of our research and development activities, including our preclinical studies and planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the markets for our product candidates, and our ability to serve those markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the rate and degree of market acceptance of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments in the United States and foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the performance of our third-party service providers, including our contract research organizations (CROs), suppliers, and manufacturers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the safety, efficacy, and market success of competing therapies that are or become available; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract and retain key scientific and management personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing upon the intellectual property rights of others; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic on our business and operations; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other risks and uncertainties, including those described under Part I, Item 1A, &#x201c;Risk Factors&#x201d; of this Annual Report. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any forward-looking statements in this Annual Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A, &#x201c;Risk Factors&#x201d; of this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless the context otherwise indicates, references in this Annual Report to the terms &#x201c;Silverback&#x201d;, &#x201c;the Company&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d; and &#x201c;us&#x201d; refer to Silverback Therapeutics, Inc., and references to our &#x201c;common stock&#x201d; refers to our voting common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part I, Item 1A, &#x201c;Risk Factors&#x201d; in this Annual Report.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of the material risks associated with our business include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has had, and could continue to have, an adverse impact on our business, including on our preclinical studies and planned clinical trials, supply chain, and business development activities. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical and clinical development is a lengthy, expensive, and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials, including from our SBT8230 program, may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may rely on third parties to conduct, supervise, and monitor our planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We contract with third parties for the manufacture and supply of certain of our product candidates for use in preclinical testing and planned clinical trials and will rely on third parties for commercial supply, which supply may become limited or interrupted or may not be of satisfactory quality and quantity. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors, and others in the medical community necessary for commercial success. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not realize the benefits of any acquisitions, in-license, or strategic alliances that we enter into. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face substantial competition, which may result in others discovering, developing, or commercializing products more quickly or marketing them more successfully than us.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently party to an in-license agreement under which we were granted rights to manufacture certain components of our product candidates. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these technologies or both, which would adversely affect our business and prospects. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may rely on trade secret and proprietary know-how, which can be difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The price of our common stock could be subject to volatility related or unrelated to our operations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, &#x201c;Silverback,&#x201d; &#x201c;our company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Silverback Therapeutics, Inc., a Delaware corporation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a biopharmaceutical company focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Our ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Many potentially promising systemic therapies fail to maximize their therapeutic potential due to toxicities in healthy tissues.  Our approach is designed to expand the therapeutic window and avert unacceptable toxicities by directly targeting specific disease sites where our therapeutics are locally active.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July of 2020, we initiated clinical development of our first ImmunoTAC product candidate, a TLR8 agonist conjugated to a HER2 antibody, SBT6050.  Preclinical data suggested that we would be able to demonstrate a therapeutic window and advance SBT6050 through clinical development as a monotherapy and in combination with standard-of-care agents that had a complementary mechanism-of-action.  Our Phase 1/1b program was designed to measure safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity as monotherapy and in combination with pembrolizumab.  On March 28, 2022, we made the decision to discontinue our clinical development program for SBT6050 due to limited monotherapy activity and dose-limiting adverse events when used in combination with pembrolizumab. SBT6290, comprised of the same linker payload conjugated to a Nectin4 antibody, was expected to show a similar clinical profile and, therefore, we also terminated this program prior to dosing patients.  We have prioritized our resources to focus on the development of SBT8230 and early-stage discovery programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our understanding of TLR8 conjugates in preclinical species and in the clinic guides our interpretation of the preclinical characteristics of SBT8230, an ASGR1 antibody conjugated to a TLR8 agonist linker payload for the treatment of chronic hepatitis B virus (cHBV), which is currently in preclinical development. ASGR1 is highly expressed in liver and is restricted in its expression to this organ. Other ASGR1-directed agents, such as those used in RNAi therapies, have shown robust liver localization.  SBT8230 shows biodistribution profiles in non-human primates (NHP) consistent with these agents, which is distinct from SBT6050 and SBT6290. We believe that efficient liver targeting of SBT8230 via ASGR1 binding has the potential to lead to markedly lower serum exposures of SBT8230 in patients compared to those observed with SBT6050 in the clinic at any dose evaluated.  We believe the preclinical to clinical experience for SBT6050, coupled with the NHP PK, PD, and tolerability data for SBT8230, suggest that the clinical safety, PK and PD profiles for SBT8230 has the potential to be notably different than those for SBT6050, given the large differences in serum exposures and overall conjugate disposition for SBT8230 that are expected in patients due to its efficient liver targeting. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver.  The anti-viral immune response is achieved through activation of myeloid cells and subsequent activation of immune cells that drive an IFN&#x3b3; signal, which has been observed in the clinic with SBT6050.  This has been shown by others to drive seroconversion, an important determinant of a functional cure.  We see a significant opportunity in liver-localized immunotherapies as a potential way of achieving durable responses in these patients. We are focused on advancing SBT8230, our liver-targeted conjugate designed to </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potently activate human myeloid cells in the liver for the treatment of cHBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further support for investigating TLR8 agonism for the treatment of cHBV comes from selgantolimod (GS-9688), an existing untargeted, orally administered TLR8 agonist being developed by Gilead Sciences.  Selgantolimod has generated anti-viral immune responses in a cHBV animal model. The clinical development of this untargeted TLR8 agonist has shown promise, but we believe that toxicity prevented the use of a sufficient dose to elicit optimal clinical activity. We believe liver-localized TLR8 agonism could better realize the potential for effective therapy and potentially lead to functional cure, which is defined as sustained loss of hepatitis B surface antigen (HBsAg) in the blood, in patients suffering from cHBV. We presented a preclinical update on SBT8230 in the fourth quarter of 2021. In the first quarter of 2022, we began a Phase 1-enabling toxicology study. We plan to complete a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">P</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hase 1 regulatory submission in the fourth quarter of 2022 and begin a Phase 1 single ascending dose (SAD) study in healthy volunteers in the first half of 2023.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> After completing the SAD study, we anticipate initiating a Phase 1 multiple ascending dose (MAD) study in patients with chronic HBV, who are virally suppressed on nucleoside reverse transcriptase inhibitors (NRTI) therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our internal discovery programs are focused on evaluating and developing new antigen binding domains specific for targets of interest (including antibodies), next-generation linker technologies, and both agonist and antagonist small molecule payloads, that may be combined to create novel tissue-targeted antibody conjugates. The integration of medicinal chemistry, bioconjugation, protein engineering, bioinformatics, pharmacology, and translational medicine expertise focused on developing tissue-targeted therapies allows us to leverage key learnings from our previous clinical program to bring forward the next generation of therapeutics.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  We anticipate providing an update on our discovery pipeline in the fourth quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our ImmunoTAC Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ImmunoTAC platform is the result of a focused effort to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. Many potentially promising systemic therapies fail to maximize their therapeutic potential due to toxicities in healthy tissues. Our approach is designed to localize disease-modifying payloads to specific sites of disease where our therapeutics are locally active.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Development Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ImmunoTAC platform drives our development pipeline of tissue targeted therapeutic candidates as summarized in the chart below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_0.jpg" alt="img238320182_0.jpg" style="width:718px;height:197px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our goal is to transform the treatment of cHBV, cancer and other serious diseases with unmet need using our ImmunoTAC platform to deliver a new class of systemically delivered, tissue-directed, and locally active therapies. The key elements of our business strategy are to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Demonstrate anti-viral properties of TLR8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in cHBV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are applying learnings from our TLR8 agonist oncology programs and clinical experience to maximize the potential of SBT8230. Our understanding of TLR8 conjugates in preclinical species and in the clinic guides our interpretation of the preclinical characteristics of SBT8230, an ASGR1 antibody conjugated to a TLR8 agonist linker payload for the treatment of cHBV that is currently in preclinical development. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Maximize the therapeutic potential of SBT8230. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The immune activating mechanism of SBT8230 is complimentary to other treatments for cHBV that interfere with components of the viral life cycle such as nucleoside and nucleotide analogs, capsid inhibitors, and RNAi-based therapies.  Furthermore, our ASGR1 antibody does not cross block GalNAc, allowing for combinations with RNAi-based therapies.    </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leverage our ImmunoTAC platform for promising new antibody-linker-payload combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We are strategically pairing our disease-modulating payloads with tissue targeted binding domains to create new therapeutic agents with the goal of providing benefits to patients. We plan to continue to leverage our ImmunoTAC platform, discovery of antigen binding domains (including antibodies), new linker technologies and therapeutic discovery infrastructure to discover and develop novel small molecule therapeutics conjugated to antibodies.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internally and externally source potentially transformative assets and technologies that align with our mission to develop tissue-targeted therapies.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have extensive expertise in protein engineering, small molecule linker and payload chemistry, and translational medicine that we apply to the discovery and advancement of new tissue-targeted agents to the clinic.&#x202f; Our clinical development team is a seasoned group with experience in developing antibody-drug conjugates and other therapeutics across all phases of development.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have robust internal discovery capabilities, we also believe that innovative technologies can be acquired through business development activities. We therefore plan to continue to pursue synergistic, in-licensing opportunities to augment our internal discovery efforts. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evaluate opportunities to accelerate development timelines and/or enhance the commercial potential of our programs in partnership with third parties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We plan to selectively explore potential strategic partnerships on a program-by-program basis with biopharmaceutical partners whose research, development, commercial, and/or geographic capabilities complement our own. We believe strategic partnerships can help mitigate clinical and commercial risk, accelerate timelines, and/or maximize global commercial potential.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an accomplished management team with a proven track record of therapeutic research and development expertise and of generating meaningful stockholder value. The members of our team have deep experience in discovering and developing therapeutics, including acalabrutinib, brentuximab vedotin, entrectinib, etanercept, ibrutinib, lisocabtagene maraleucel, sunitinib, tezepelumab, tucatinib, and venetoclax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Activating the Myeloid Cell Compartment Through Liver-Targeted TLR8 Agonism</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As shown in the figure below, TLR8 activation of human myeloid cells plays an important role in the anti-viral immune response in cHBV. HBV-infected liver is highly immunosuppressive and the activation of macrophages and other myeloid cells in the liver can serve to overcome this immunosuppression. We believe TLR8 is the optimal target for activating these myeloid cell types due to its restricted expression and function within these cells. TLR8 is also highly expressed in conventional dendritic cells which promote antigen presentation and the production of cytokines important for the generation of T and B cell responses against hepatitis B virus. TLR8 is not expressed in T or B lymphocytes, but TLR8 activation in human myeloid cells secondarily induces IFN&#x3b3; production by T cells and antibody production by B cells, both shown to be associated with the generation of functional cure in cHBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TLR8 is Highly Expressed in Human Myeloid Cell Types That Drive Anti-Viral Responses when Activated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><img src="img238320182_1.jpg" alt="img238320182_1.jpg" style="width:720px;height:268px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Silverback&#x2019;s Preclinical and Clinical Development Experience with a HER2-Directed TLR8 Agonist Conjugate, SBT6050</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have gained pre-clinical and clinical experience with TLR8 conjugates through our recently discontinued SBT6050 program. In this program, a HER2-TLR8 agonist conjugate was administered to 58 patients as monotherapy and in combination with a checkpoint inhibitor at dose levels ranging from 0.15 mg/kg through 1.2 mg/kg with the length of patient experience ranging from 2 weeks through 41 weeks. We observed a dose response for adverse events related to immune activation, serum PK, serum pharmacodynamic markers, tumor exposure and intratumoral pharmacodynamic markers inclusive of data that demonstrates activation of immune mechanisms in biopsies collected from patients after treatment.  However, antitumor activity was limited in the monotherapy arm, and increased toxicity in combination with checkpoint inhibitors limited dose escalation beyond 0.3 mg/kg. In the 18 patients treated in combination with pembrolizumab, while we observed decreasing volume stable disease in some patients, we did not see responses meeting RECIST criteria.  Furthermore, at 0.3 mg/kg in combination with pembrolizumab, although there were no DLTs with additional patients and longer follow-up, it was determined that long-term tolerability was challenging. Several patients experienced grade 3 adverse events in later cycles, including grade 3 hypotension.  Finally, PK and PD at 0.3 mg/kg were suboptimal.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On the other hand,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there were important learnings from the SBT6050 clinical program that we are applying to SBT8230. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the SBT6050 clinical trial, exposures increased with dose</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the data demonstrated that the</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> conjugate was stable in circulation.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ree payload was undetectable in ~98% of blood samples evaluated and in the few samples in which payload was detectable, the levels were at least an order of magnitude below </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the lowest </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">active concentrations of payload.  SBT6050 induced PD activity indicative of myeloid and natural killer (NK) and/or T cell activation at all dose levels, confirming the proposed mechanism of action of TLR8 agonism, and PD activity was maintained with repeat dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our understanding of TLR8 conjugates in preclinical species and in the clinic guides our interpretation of the preclinical characteristics of SBT8230, an ASGR1 antibody conjugated to a TLR8 agonist linker payload for the treatment of cHBV currently in preclinical development.  ASGR1 is highly expressed in liver and is restricted in its expression to this organ. Other ASGR1-directed agents, such as those used by RNAi therapies, have shown robust liver localization.  SBT8230 shows biodistribution profiles in NHP consistent with these agents and is distinct from SBT6050 and SBT6290 in this regard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SBT8230: TLR8 Agonist Conjugated to an ASGR1 Antibody</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have engineered SBT8230 to treat cHBV by eliciting an anti-viral immune response through targeting TLR8 activation to the liver. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to the same TLR8 linker-payload as SBT6050, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">but with an average drug antibody ratio (DAR) of about 2 as opposed to the average DAR of about 4 used in SBT6050.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cHBV infection remains a worldwide problem affecting approximately 257 million people and contributing to an estimated 887,000 deaths in 2015. In the United States alone, approximately 860,000 people suffer from cHBV. cHBV is estimated to be the cause of 60-80% of the world&#x2019;s primary liver cancers. There is a significant unmet need for therapies that can elicit a functional cure for the disease, which is defined as sustained loss of HBsAg in the blood. Many of the approved therapies for cHBV have low functional cure rates or lack durability over time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical and preclinical evidence by third parties have demonstrated that IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-mediated immune responses, including the activation of IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ T cell and IgG B cell anti-viral responses, can lead to a functional cure in cHBV patients and animal models of HBV. In HBV transgenic mice, HBV-specific CD4 and CD8 T cells have exhibited the ability to inhibit hepatocellular replication by a noncytopathic process that is mediated primarily by IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In acutely infected chimpanzees, viral replication was almost completely abolished soon after CD3 and IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> mRNA increased in the liver. Evidence by third parties has demonstrated that HBV-specific IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> producing CD4 T cells were associated with viral clearance in patients with cHBV infection. Additionally, these studies have demonstrated that TLR8 agonists were particularly effective in activation of myeloid cells and the induction of IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The figure below shows IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">production after human blood or liver-derived mononuclear cells were stimulated with the indicated TLR agonist. TLR8 was unique in its ability to induce IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TLR8 Drove IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Production from Liver Mononuclear Cells in Third Party Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_2.jpg" alt="img238320182_2.jpg" style="width:346px;height:419px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the figures below show concentrations of individual cytokines quantified in the supernatant of purified peripheral blood mononuclear cells (PBMC) or isolated mononuclear cells from the liver after stimulation with either a TLR8 or TLR7 agonist. TLR8 agonism, but not TLR7 agonism, induced IFN&#x3b3; production, along with the production of other cytokines important in the generation of anti-viral immunity such as TNF&#x3b1;, IL-1&#xdf;, and IL-6, from both liver and blood immune cells. We believe these data from third parties demonstrate that TLR8 is the agonist of choice for improving the outcome for patients with cHBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TLR8 Agonism Drove Cytokine Production</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_3.jpg" alt="img238320182_3.jpg" style="width:563px;height:219px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Figure source: Jo et al, PLOS Pathogens, 2014.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a preclinical woodchuck model of cHBV conducted by a third party, oral administration of a TLR8 agonist small molecule, GS-9688 (selgantolimod), was shown to drive seroconversion and reduce woodchuck hepatitis virus S antigen and woodchuck hepatitis B viral levels. Selgantolimod&#x2019;s effectiveness in cHBV patients has been limited, however. We believe (i) this is due to not achieving necessary exposures because of DLTs associated with activation of myeloid cells outside of the liver and (ii) that systemically delivered but liver localized TLR8 agonism could improve the potential for effective therapy and lead to functional cures in cHBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 is a Liver-Localized TLR8 Agonist Designed to Combine with other cHBV Drugs to Achieve Functional Cure in cHBV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As shown in the figure below, we designed SBT8230 to be comprised of an ASGR1 monoclonal antibody conjugated to a TLR8 linker-payload with the goal of activating the myeloid cell compartment in liver tissue only. The conjugate is designed to be internalized in myeloid cells in an FcR-mediated manner when ASGR1 is present on adjacent liver cells.   In addition, the ASGR1 mAb of SBT8230 was designed to bind to an epitope distinct from that recognized by GalNAc to allow for combination with GalNAc-based therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 ImmunoTAC is Designed for Liver-localized TLR8 Activation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_4.jpg" alt="img238320182_4.jpg" style="width:277px;height:282px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Background on ASGR1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As with all ADC-based therapeutics, an expression profile differential of the target antigen on healthy tissue relative to target tissues is critical. As shown in the figure below, the expression of ASGR1 is a liver-restricted scavenger receptor that is highly restricted to this organ. Furthermore, it is a clinically validated target that has been successfully targeted by GalNAc-based therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ASGR1 Expression is Restricted to the Liver</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_5.jpg" alt="img238320182_5.jpg" style="width:441px;height:233px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The antibody backbone of SBT8230 has been designed to possess high affinity and specificity for ASGR1 and is not an efficient binder to ASGR2 or CLEC10A.  The specificity and binding profile of the SBT8230 antibody is identical between human and monkey (not shown).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230&#x2019;s Backbone Antibody is Highly Specific to ASGR1</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_6.jpg" alt="img238320182_6.jpg" style="width:334px;height:164px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SBT8230 antibody has also been designed to recognize an epitope distinct from that bound by the ASGR1 ligand, GalNAc, allowing for possible combination of SBT8230 with GalNAc-targeted RNAi therapies currently in development for cHBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230&#x2019;s Backbone Antibody Does Not Block Ligand Binding Allowing for Combination Therapy with GalNAc Targeted Molecules</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_7.jpg" alt="img238320182_7.jpg" style="width:227px;height:374px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Potential Mechanism of Action: SBT8230 is Designed to Localize TLR8 Activation of Myeloid Cells in the Liver Via a Directed ASGR1 Antibody</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The diagram below walks through the potential mechanism of action of SBT8230.  SBT8230 is designed to be administered subcutaneously.  In the liver, the ASGR1 binding domain engages hepatocytes and the Fc domain of the conjugate binds to the Fc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R receptors on myeloid cells.  The increase in Fc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R binding avidity is a result of ASGR co-binding and results in the internalization of the conjugate into the endo-lysosome where TLR8 resides.  SBT8230 directly activates myeloid cells, and these cells in turn activate anti-viral IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ T cell and anti-viral B cell immune responses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_8.jpg" alt="img238320182_8.jpg" style="width:720px;height:270px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As shown in the figures below, ASGR1-TLR8 induced IFN&#x3b3;-promoting activity through activation of myeloid cells in our preclinical studies utilizing human PBMCs ex vivo.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ASGR1-TLR8 Potently Activated Human Myeloid Cells, Resulting in a Robust IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Response</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_9.jpg" alt="img238320182_9.jpg" style="width:720px;height:330px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activation of human myeloid cells by TLR8 was mirrored in mouse myeloid cells by TLR7 as was previously demonstrated in our SBT6050 program. Therefore, to evaluate the ability of a liver-targeted myeloid cell agonist conjugate to drive seroconversion in a mouse model of cHBV, we engineered a surrogate for SBT8230 comprised of an anti-mouse ASGR1 monoclonal antibody conjugated to a TLR7 agonist (SBT8230-S). The antibody contained an IgG2a Fc domain to facilitate uptake into mouse myeloid cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Seroconversion, together with reductions in HBsAg levels and expansion of IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-producing anti-viral T cells, is associated with achievement of functional cures in cHBV. The AAV-HBV (adenovirus-hepatis B virus) mouse model is a commonly used preclinical model for cHBV. Paralleling their inability to drive seroconversion in cHBV patients, cHBV standard-of-care therapies and other agents that target the HBV life cycle such as capsid inhibitors, have not resulted in seroconversion in this or similar models. In contrast, statistically significant increases in seroconversion and reductions in HBsAg were demonstrated with SBT8230-S as compared to the vehicle and unconjugated antibody control groups in the AAV-HBV model, as shown in the figures below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230-S Reduced HBsAg and Drove Seroconversion in Mouse AAV-HBV Model</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_10.jpg" alt="img238320182_10.jpg" style="width:720px;height:354px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, SBT8230-S treatment generated potent anti-viral T cell and B cell immune responses, as indicated by the significantly increased anti-HBV core and S antigen IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ T cells and anti-HBsAg+ B cells, as shown in the figures below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230-S Increased IFN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">g</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">+ Anti-Viral T Cells</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_11.jpg" alt="img238320182_11.jpg" style="width:464px;height:259px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230-S Increased B Cells Producing Anti-HBs Antigen Antibodies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_12.jpg" alt="img238320182_12.jpg" style="width:473px;height:255px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Importantly, as shown in the figures below, no changes in serum ALT or body weight were noted after treatment with SBT8230-S as compared to controls. In addition, there were no findings in the liver by histopathology after treatment with SBT8230-S. Together, these data indicated that SBT8230-S was well tolerated in the mouse AAV-HBV model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230-S was Well Tolerated in Mice</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_13.jpg" alt="img238320182_13.jpg" style="width:717px;height:279px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 is Highly Localized to the Liver in Non-Human Primates, Suggestive of Pharmacological Activity at Low Doses in the Clinic</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SBT8230 demonstrates comparable activity on NHP immune cells, supporting the use of NHP to characterize its tolerability, efficiency of liver uptake, and ability to produce robust and localized PD effects. As shown in the figure below, SBT8230 was targeted to the liver with high efficiency in NHP.  SBT8230 liver exposures (area under the curve, AUC) were over 300 times greater than serum exposures, the latter of which also displayed a very short half-life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 concentration in NHP liver vs serum</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_14.jpg" alt="img238320182_14.jpg" style="width:430px;height:321px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the robust liver-localization of SBT8230, the systemic (serum) exposure of SBT8230 is distinct from SBT6050.  As shown in the figure below, when SBT8230 and SBT6050 are dosed at equivalent dose levels, SBT8230 has far lower serum exposure than SBT6050 due to its efficient localization to liver. The mean estimated liver SBT8230 concentration at this dose in NHP was ~300-fold the maximum serum exposure, which is consistent with the reported liver to plasma exposure ratio of ~260 in NHP for the approved GalNAc-siRNA givosiran (US FDA Pharmacology Review, Givlaari).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Serum exposures of SBT8230 vs SBT6050 in NHP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_15.jpg" alt="img238320182_15.jpg" style="width:487px;height:208px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liver PD assessments demonstrate that the highly efficient liver uptake of SBT8230 in NHP leads to robust liver-localized PD effects.  The figures below illustrate that RNA levels for multiple markers of myeloid cell activation in liver are markedly increased with SBT8230 treatment.  Of note, PD effects at 0.5 mg/kg are similar overall to those at higher doses, indicating that maximal liver PD effects are achieved at this dose level.  Based on the totality of our preclinical data, we believe that SBT8230 has the potential to induce pharmacological effects in the liver at doses as low as 0.03 mg/kg.  This is below the lowest dose level evaluated for SBT6050, 0.15 mg/kg, that was found to be well-tolerated in patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 Induced Cytokine mRNA in the Liver but not in Serum</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_16.jpg" alt="img238320182_16.jpg" style="width:589px;height:421px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The non-clinical safety and tolerability of SBT8230 has been assessed in two NHP toxicity studies.   In a dose range finding non-GLP study, dose levels of 6, 12 and 25 mg/kg were administered every 2 weeks (Q2W) for 4 doses.  The 6 and 12 mg/kg dose levels were well-tolerated.  At the 25 mg/kg dose level the first dose was well tolerated, but the second or third doses were associated with toxicities that included injection site reactions.  This dose level is &gt;800-fold higher than the dose noted above (0.03 mg/kg) that is expected to be pharmacologically active in patients with HBV.  Across all dose levels, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">here were transient, dose-related hematological, clinical chemistry, and cytokine and chemokine changes reflective of the potential mechanism of action of SBT8230.  There was no evidence of cytokine release syndrome (CRS) or liver enzyme elevations observed at any dose level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 Phase 1-Enabling Study Update</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initiated a Phase 1-enabling GLP toxicology study in the first quarter of 2022.  Dose levels of 6, 12 and 18 mg/kg were evaluated on a Q2W schedule for 4 doses.  The in-life portion has recently completed, and bioanalytical assessments are now in progress.  SBT8230 was generally well-tolerated.  Two animals out of 26, one in the 12 mg/kg group and one in the 18 mg/kg group, displayed clinical signs consistent with ADA-mediated toxicity after the fourth and third doses, respectively, and were euthanized.  Repeat administration of fully human or humanized proteins, such as the mAb in SBT8230, to NHP can frequently lead to the generation of ADA and development of associated toxicities, which have been extensively investigated over the years and found to generally not be predictive of toxicities in humans (van Meer 2013; Kronenberg 2017). Similar toxicities were also observed with SBT6050 in NHP studies (at 12 mg/kg dose level), but acute ADA-mediated toxicities were not observed in patients dosed with SBT6050.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As noted above, we believe that SBT8230 has the potential to be pharmacologically active in the liver at doses as low as 0.03 mg/kg in humans.   Additional assessments (e.g., histopathology, PK, PD) are ongoing in the GLP toxicology study, and we believe that overall results of the study has the potential to provide favorable safety margins in support of the first-in-human study.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SBT8230 Next Steps</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon completion of the GLP toxicology studies and GMP manufacturing of SBT8230, we plan to complete a Phase 1 regulatory submission in the fourth quarter of 2022, which includes an umbrella trial with a Phase 1 SAD study in healthy volunteers anticipated to start in the first half of 2023. GMP manufacturing of the antibody intermediate and ADC drug substance have been completed, with release testing in progress. Manufacturing and release of lyophilized SBT8230 drug product is on track to be completed in the third quarter of 2022. After completing the SAD study, we anticipate initiating a Phase 1 MAD study in patients with chronic HBV, who are virally suppressed on NRTI therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Additional ImmunoTAC conjugates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our internal discovery programs are focused on evaluating and developing new antigen binding domains specific for targets of interest (including antibodies), next-generation linker technologies, and both agonist and antagonist small molecule payloads, that may be combined to create novel tissue-targeted antibody conjugates. The integration of medicinal chemistry, bioconjugation, protein engineering, bioinformatics, pharmacology, and translational medicine expertise focused on developing tissue-targeted therapies allows us to leverage key learnings from our previous clinical program to bring forward the next generation of therapeutics.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We anticipate providing an update on our discovery pipeline in the fourth quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The pharmaceutical industry is highly competitive and dynamic, owing to rapidly advancing technologies. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing treatments and new treatments that may become available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We compete with other companies working to develop immunotherapies and tissue targeted therapies for the treatment of hepatitis B virus infections, cancer, and other serious diseases, including divisions of large pharmaceutical and biotechnology companies of various sizes. These companies are developing therapies of many different modalities including small molecules, monoclonal antibodies, antibody-drug conjugates, bi-specific antibodies, cell therapies, oncolytic viruses and vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specifically, there are many companies pursuing a variety of approaches to immune modulation and more specifically TLR-directed therapies. Companies engaging in TLR-directed therapies include Ambrx, Apros Therapeutics, Ascendis, BioNTech, Bolt Biotherapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, CureVac, Exicure, Galderma, Gilead, Idera, Mologen, Nektar, Novartis, Primmune Therapeutics, Roche, Seven&amp;Eight Biopharmaceuticals, Shanghai De Novo, Sumitomo Dainippon, Tallac Therapeutics, TriSalus, and UroGen. Other companies using antibody-drug conjugates to target innate immune receptors include Actym Therapeutics, Mersana, and Takeda Pharmaceuticals. Immunotherapy and validated pathway approaches are further being pursued by many smaller biotechnology companies as well as larger pharmaceutical companies. We also face competition from</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) validated pathway therapy treatments offered by companies such as AstraZeneca, Byondis, Daiichi Sankyo, Klus Pharma, MacroGenics, Pieris, Puma, RemeGen, Seagen, Spectrum Pharmaceuticals, and Zymeworks; (ii) companies that continue to invest in innovation in the antibody-drug conjugate field, including but not limited to AbbVie, ADC Therapeutics, Astellas, BioAtla, Bicycle Therapeutics, Celldex, CytomX, Eli Lilly and Company, GlaxoSmithKline, Genmab, ImmunoGen, Millennium Pharmaceuticals, MorphoSys AG, Novartis, Pfizer, Sanofi, Seagen, and Sutro Biopharma; and (iii) companies that are developing assets for the treatment of chronic HBV infection, which include 3SBio, AICuris, Albireo, Aligos, Allovir, Alnylam, Altimmune, Antios, Arbutus, Arcus, Arrowhead, Ascentage, Assembly Biosciences, Blue Jay Therapeutics, Bristol Myers Squibb, Door Pharmaceuticals, Enanta, ENYO Pharma, Excision Bio, Finch Therapeutics, GC Pharma, Gilead, GlaxoSmithKline, Golden Biotechnology Group, Grifols,  HEC Pharm, Hepion, Immunocore, ISA pharmaceuticals, Johnson &amp; Johnson, Kineta, Lupin Limited, Merck, Nucorion, Replicor, Roche, SciClone Pharma, Shanghai Henlius Group, Spring Bank, Tasly, TeneoTen, TRACON, Vaccitech, VBI Vaccines, VenatoRx, Vir, VLP Biotech, and Zydus Cadila.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and convenience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our antibody-drug conjugate is produced by chemical conjugation of a non-cytotoxic linker-payload to a monoclonal antibody. We have significant internal expertise in engineering and humanization of antibodies and designing linker-payloads to customize the drug conjugate for a desired target profile. The small molecule linker-payload is chemically synthesized, and the antibody is produced by conventional biological process technology. The manufacturing process involves production of the linker-payload and antibody process intermediates, the conjugation of the intermediates to produce bulk therapeutic substance, and fill/finish of the therapeutic product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities subject to compliance with current good manufacturing practices (cGMP). We operate on an outsourced model and rely on contracts with third-party development and manufacturing organizations designed to comply with cGMPs to produce and test the intermediates, therapeutic substance and therapeutic product to support clinical development, and commercialization, if any of our product candidates obtain marketing approval. We are working with these manufacturers to scale up our manufacturing capabilities to support our clinical plans. We also rely on third parties to package, label, store and distribute our product candidates, as well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest on our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the design and development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commercialization Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to retain significant development and commercial rights to our product candidates and, if we obtain marketing approval, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities and have no experience as a company commercializing products. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, we entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (WuXi Bio), pursuant to which we received a non-exclusive, worldwide, sublicensable license under certain of WuXi Bio&#x2019;s intellectual property rights, know-how and biological materials (WuXi Bio Licensed Technology), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (WuXi Bio Licensed Product). The WuXi Bio Licensed Technology is used to manufacture a component of our ImmunoTAC platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2020, we paid a license fee of $100,000 to WuXi Bio. In December 2020, we incurred an additional license fee of $50,000 to WuXi Bio. Additionally, if we do not engage WuXi Bio to manufacture the WuXi Bio Licensed Products for our clinical and commercial supplies, we are required to make milestone payments to WuXi Bio upon the achievement of certain sales milestones. Under such scenarios, upon achieving certain thresholds for the aggregate annual net sales of a WuXi Bio Licensed Product, we would owe WuXi Bio aggregate milestone payments of up to $10.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The WuXi Bio Agreement will continue indefinitely unless terminated in accordance with the agreement. The WuXi Bio Agreement may be terminated (i) by us upon six months&#x2019; written notice provided we pay all amounts due to WuXi Bio through the effective date of termination, (ii) by either party for the other party&#x2019;s material breach that remains uncured for 30 days after written notice, and (iii) by WuXi Bio after 45 days&#x2019; written notice if we fail to make a payment within 30 days after receiving notice of such failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We own the issued patents and patent applications relating to our ImmunoTAC platform and SBT8230. Our policy includes seeking to protect our proprietary position by, among other methods, filing patent applications, in the United States and in jurisdictions outside of the United States, directed to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continued innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immunotherapy. We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets and know-how; to obtain and maintain licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 28, 2022, our licensed and owned patent portfolio included five owned U.S. patents, 30 owned U.S. provisional and non-provisional patent applications, eight owned patent applications filed under the Patent Cooperation Treaty (PCT), 19 owned foreign patents, 118 owned foreign patent applications filed in a number of different foreign jurisdictions, including in Australia, Brazil, Canada, China, European region, Hong Kong, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, Taiwan, and South Africa, directed to TLR8 agonists and conjugates, including SBT8230, TGF&#xdf;R1 antagonists and conjugates, TGF&#xdf;R2 antagonists and conjugates, TLR7 agonists and conjugates, and various applications of our proprietary antibody conjugates and antibodies, including antibodies specific for ASGR1, as well as certain of our other proprietary antibodies, compounds, conjugates, formulations, technology, inventions, improvements, and other product candidates. Any patents that issue from these pending patent applications will expire between March 2038 and November 2042, absent any patent term adjustments or extensions. We also possess and/or in-license substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specifically, our patent portfolio includes the following families and/or groups of families:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TLR8 Agonists and Conjugates and Combination Therapies. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have four issued U.S. patents with composition of matter, method of treatment, and method of making claims to TLR8 agonist payloads, linker-payloads and conjugates. The issued U.S. patents are projected to expire in March 2038, absent any patent term extensions. As of February 28, 2022, we have eight pending U.S. patent applications, one pending PCT application, 19 granted foreign patents, and 56 pending foreign patent applications filed in a number of different foreign jurisdictions, including Australia, Brazil, Canada, China, European region, Hong Kong, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, Taiwan and South Africa, with composition of matter claims directed to TLR8 agonists, conjugates and formulations, including substituted TLR8 agonist variants and conjugates, as well as claims to methods of administering TLR8 agonists and conjugates, to methods of treatment with TLR8 agonists and conjugates, in combination with other therapies. Any patents that issue from these pending patent applications are projected to expire between March 2038 and October 2040, absent any patent term adjustments or extensions. We own all the issued U.S. patents and all the pending patent applications in these patent families.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-ASGR1 Antibodies and Conjugates in Viral Infections.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 28, 2022, we have five pending U.S. patent applications, one pending PCT application, and 37 pending foreign patent applications filed in a number of different foreign jurisdictions, including Australia, Brazil, Canada, China, European region, Hong Kong, Israel, India, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, and South Africa, with composition of matter claims and method of treatment claims directed to our product candidate, SBT8230, including claims directed to anti-ASGR1 antibodies, anti-ASGR1 antibody conjugates to TLR8 or TLR7 agonists, as well as to methods for treating viral infection, such as chronic HBV infections.  Any patents that issue from these pending patent applications will expire between December 2038 and July 2041, absent any patent term adjustments or extensions. We own all the pending patent applications in these patent families.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to our product candidates and processes, we intend to develop and commercialize in the normal course of business, and we intend to pursue patent protection directed to, when possible, compositions, methods of use, methods of making, dosing, and formulations. We may also pursue patent protection with respect to manufacturing, therapeutic development processes and technologies, and therapeutic delivery technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that is directed to or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its claims, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of immunotherapy has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and enforce the patent rights that we license, which could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned intellectual property, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even the issued patents that we license do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and the issued patents that we in-license and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents that we own or exclusively in-license. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, such as our investigational medicines and any future investigational medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal to approve marketing applications, withdrawal of an approval, import/export delays, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulatory Approval in the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (FDCA), and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post- approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of new drug applications, NDAs. Biological products, such as our ImmunoTAC product candidates, are approved for marketing under provisions of the Public Health Service Act (PHSA), via a biologics license application (BLA). However, the application process and requirements for approval of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United States. The process generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an institutional review board (IRB) or independent ethics committee at each clinical trial site before each clinical trial may be commenced; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of a BLA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payment of any user fees for FDA review of the BLA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with any post-approval requirements, including REMS, where applicable, and post- approval studies required by the FDA as a condition of approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product candidates and formulations, as well as </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well- designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product candidate, and, if possible, early evidence of effectiveness. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These Phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA Review Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States. The cost of preparing and submitting a BLA is substantial. Under the PDUFA, each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The applicant under an approved BLA is also subject to an annual program fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA for a new molecular entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. Additionally, the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a condition of BLA approval, the FDA may require a REMS to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#x2019;s safe use (ETASU). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#x2019;s safety or efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for off-label uses, the competitor&#x2019;s product could be used for the orphan indication despite another product&#x2019;s orphan exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA&#x2019;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is based on a determination of sameness of the monoclonal antibody element and the functional element of the conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#x2019;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#x2019;s BLA before the application is complete. This &#x201c;rolling review&#x201d; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#x2019;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of diseases in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#x2019;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#x2019;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Additional Controls for Biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. PREA generally does not apply to any biological product for an indication for which orphan designation has been granted but does apply to BLAs for orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that the FDA has determined is substantially relevant to the growth or progression of a pediatric cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Best Pharmaceuticals for Children Act (the BPCA) provides a six-month extension of any exclusivity&#x2014;patent or non-patent&#x2014;for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#x2019;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA approved labeling.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adverse event reporting and submission of periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#x2019;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning or other enforcement-related letters or holds on post-approval clinical studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Term Restoration and Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of FDA approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act, informally known as the Hatch-Waxman Act. The Hatch Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent term extension (PTE), however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The PTE period is generally one half the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for such an extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any PTE or restoration. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, we or our licensors may apply for PTE for our owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. However, an extension might not be granted because of, for example, our or our licensors&#x2019; failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested. There is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether any extensions should be granted, and if granted, the length of such extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biosimilars and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biologics Price Competition and Innovation Act of 2009 (the BPCIA) created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#x201c;First licensure&#x201d; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The BPCIA is complex and only recently implemented by the FDA. Recent government proposals have sought to reduce the twelve-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">International Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Healthcare Laws and Regulations and Legislative Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare and Privacy Laws and Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, including physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to CMS, the U.S. Department of Health and Human Services (HHS) (including the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. The healthcare laws that may affect our ability to operate include, but are not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal civil and criminal false claims laws, such as the FCA, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Health Insurance Portability and Accountability Act of 1996, as amended (HIPAA), among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them, and their covered subcontractors, that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act (the Affordable Care Act), which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#x2019;s immediate family members. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers, and state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; and state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legislative Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the Affordable Care Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extended manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a licensure framework for follow-on biologic products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. For example, in 2017, the U.S. Congress enacted legislation informally titled the Tax Cuts and Jobs Act (the Tax Act), which eliminated the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Patient Protection and Affordable Care Act (&#x201c;PPACA&#x201d;) will be subject to judicial or Congressional challenges in the future.  It is unclear how any such challenges, and the healthcare reform measures of the Biden administration will impact the Affordable Care Act.  It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, absent additional Congressional action. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In addition, in 2012, the U.S. Congress enacted the American Taxpayer Relief Act, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Moreover, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#x2019;s proposals. As a result, the FDA released a final rule and guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January1, 2023. On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 27, 2021, CMS issued a final rule that rescinded the Most Favored Nation interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. Congress is also considering additional health reform measures.   Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Environmental, Health and Safety Laws and Regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pharmaceutical Coverage, Pricing and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;	a covered benefit under its health plan;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;	safe, effective and medically necessary;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;	appropriate for the specific patient;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;	cost-effective; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:5.653%;text-indent:-2.462%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;	neither experimental nor investigational.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost- effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, private payors often, but not always, follow Medicare coverage and reimbursement policies with respect to newly approved products. It is difficult to predict what third- party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#x2019;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. In addition to third-party payors, professional organizations and patient advocacy groups can influence decisions about reimbursement for new medicines by determining standards for care. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reimbursement agencies in Europe may be more restrictive than payors in the United States. In Europe, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional health technology assessments that compare the cost-effectiveness of a particular product candidate to currently available therapies. Within the European Union legislation relating to and regulation of the reimbursement of medicinal products, and to control the prices of such products, is a matter for individual member states. European Union member states may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated under the laws of the State of Delaware on January 4, 2016. Our principal executive offices are located at 500 Fairview Ave N, Suite 600, Seattle, Washington 98109, and our telephone number is (206) 456-2900. Our corporate website address is www.silverbacktx.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K. Our periodic and current reports are available on our website, free of charge, as soon as reasonably practicable after filing. We have included our website in this Annual Report on Form 10-K solely as an inactive textual reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Silverback Therapeutics,&#x201d; &#x201c;Silverback,&#x201d; the Silverback logo, &#x201c;ImmunoTAC,&#x201d; &#x201c;Seeking Victory for Patients,&#x201d; and other trademarks, trade names or service marks of Silverback Therapeutics, Inc. appearing in this Annual Report on Form 10-K are the property of Silverback Therapeutics, Inc. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees and Human Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 90 full-time employees. Of these employees, 31 held Ph.D., Pharm.D. or M.D. degrees, and 65 were engaged in research, development and technical operations. As of such date, we had 77 employees based at our headquarters and satellite office in Seattle, Washington. On March 28, 2022, our board of directors approved a corporate restructuring plan pursuant to which, among other things, our workforce will be reduced by 27%, with substantially all of the reduction in personnel expected to be completed by July 15, 2022. For further information, see Part II, Item 9B, &#x201c;Other Information&#x201d; in this Annual Report. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and integrating our existing and additional employees. We believe that we have been successful in attracting and retaining talented personnel to support our expanding business, though competition for personnel in our industry is intense. We monitor recruiting efforts using a variety of metrics, including cycle times, cost per hire, information on the retention of business-critical hires (such as medical directors and executives), and the percentage of budgeted openings filled on time and on budget. We also track voluntary and involuntary turnover rates for business-critical talent, time in role, and job level.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We offer competitive pay and benefits designed to attract and retain exceptional talent and drive company performance. In setting appropriate compensation levels, we look at the average base pay rate for each position based on market data.  We also offer an annual cash incentive program and long-term equity incentive plans designed to assist in attracting, retaining, and motivating employees and promoting the creation of long-term value for stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our standard employee benefits include paid and unpaid leaves, medical, dental and vision insurance coverage, a 401(k) plan, short- and long-term disability, life insurance, flexible spending accounts, and an employee stock purchase plan. We also offer a variety of voluntary benefits that allow employees to select options that meet their needs, including a long-term care plan, telehealth, an employee assistance program, and wellness programs. We benchmark our benefits program against others in our industry on an annual basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:1.133%;text-indent:-10.097%;padding-left:9.067%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A.	Risk </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Annual Report on Form 10-K and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business and Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an early-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to organizing and staffing our company, business planning, business development, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies for our lead program and other development programs, undertaking clinical trials for our now discontinued SBT6050 and SBT6290 programs, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. All of our product candidates are in preclinical development, and none have been approved for commercial sale. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations. For the years ended December 31, 2021 and 2020, our net losses were $89.5 million and $32.9 million, respectively. We expect that it will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates through clinical development. Our prior losses, combined with expected future losses, had and will continue to have an adverse effect on our stockholders&#x2019; deficit and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company listed on the Nasdaq Global Market, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and the Nasdaq Global Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#x201c;say on pay&#x201d; and proxy access. Recent legislation permits smaller &#x201c;emerging growth companies&#x201d; to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to continue to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time- consuming and costlier. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain our current levels of such coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have used substantial amounts of cash to fund our operations and expect we will continue to incur significant losses for the foreseeable future. The development of biopharmaceutical product candidates is capital intensive. As our product candidates enter and advance through preclinical studies and potential clinical trials, we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, following the completion of our initial public offering in December 2020, we have incurred and expect to continue to incur additional costs associated with operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $319.1 million in cash, cash equivalents, restricted cash, and investments. Based upon our current operating plan, we estimate following our corporate restructuring plan approved in March 2022, that our existing cash, cash equivalents, restricted cash, and investments will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2026. However, we believe that our existing cash, cash equivalents, restricted cash, and investments will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, trial design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates, and in particular future clinical trials for SBT8230; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and characteristics of product candidates that we pursue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing, and costs of seeking FDA, EMA and any other regulatory approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of manufacturing our product candidates and commercial manufacturing activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical activities increase; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of commercialization activities for any of our product candidates, if approved, including marketing, sales and distribution costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the emergence of competing therapies and other adverse market developments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we in-license or acquire other products and technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our need and ability to retain key management and hire scientific, technical, business, and medical personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our implementation of additional internal systems and infrastructure, including operational, financial and management information systems; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our costs associated with expanding our facilities or building out our laboratory space; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we do not expect to generate revenue from product sales for many years, if at all, we will need to obtain substantial additional funding in connection with our continuing operations and expected increases in expenses. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses or other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The impact of the COVID-19 pandemic on capital markets may affect the availability, amount and type of financing available to us in the future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions, such as further limitations on our ability to incur additional debt, make capital expenditures or declare dividends.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The COVID-19 pandemic has had, and could continue to have, an adverse impact on our business, including on our preclinical studies and planned clinical trials, supply chain, and business development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, COVID-19, a novel strain of coronavirus, was first reported in Wuhan, China and has since become a global pandemic. The President of the United States declared the COVID-19 pandemic a national emergency and many states and municipalities in the Unites States have taken aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing &#x201c;shelter-in-place&#x201d; orders which direct individuals to shelter at their places of residence (subject to limited exceptions). For example, on March 23, 2020, the Office of the Governor issued Proclamation 20-25, ordering all individuals in the State of Washington to stay at their place of residence except as needed to maintain continuity of operations of the federal critical infrastructure sectors. As a result of the Washington state order, almost all of our non-lab based employees were telecommuting, which impacted certain of our operations and may continue to do so over the long term. We may experience further limitations on employee resources in the future, including because of sickness of employees or their families. The effects of government actions and our own policies and those of third parties to reduce the spread of COVID-19 may negatively impact productivity and slow down or delay our preclinical studies, future clinical trials and research and development activities, and may cause disruptions to our supply chain and impair our ability to execute our business development strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, and our operations may be further limited or curtailed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As COVID-19 continues to spread, we may experience ongoing disruptions that could severely impact our business, preclinical studies and planned clinical trials, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in our operations, which may impact our ability to conduct and produce preclinical results required for submission of an IND; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in clinical site initiation due to staff shortages at clinical sites or with our contract research organizations (CROs);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or difficulties in enrolling patients in our planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties in recruiting clinical site investigators and clinical site staff; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in clinical sites receiving the supplies and materials needed to conduct our planned clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in local regulations and policies as part of a response to the COVID-19 outbreak, which may require us to change the ways in which our planned clinical trials are conducted including slower enrollment, and may result in unexpected costs or the clinical site discontinuing the clinical trial altogether; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk that participants enrolled in our planned clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to accept data from clinical trials in affected geographies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other disruptions in our operations and the global economy could negatively impact our business, operating results, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our prior clinical trials for SBT6050 and SBT6290 were, and our future clinical trials may be, affected by the COVID-19 pandemic. For example, some of our prior clinical trial sites slowed down or stopped further enrollment of new patients in clinical trials, and otherwise curtailed certain operations. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be adversely impacted. Our planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory agencies. We and our CROs may need to make certain adjustments to the operation of our planned trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA. Many of these adjustments may be new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. These events could delay our planned clinical trials, increase the cost of completing our planned clinical trials and negatively impact the integrity, reliability or robustness of the data from our planned clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities or CROs upon which we rely, or the availability or cost of materials or supplies, which could disrupt the supply chain for our product candidates or for performing preclinical studies. For example, we depend on the availability of various animals, including rodents and non-human primates, to conduct certain preclinical studies that we are required to complete prior to submitting an IND and initiating clinical development or to continue clinical development, including pharmacological and toxicology evaluations. There is currently a global shortage of animals available for drug development, due in part to an increase in demand from companies and other institutions developing vaccines and treatments for COVID-19. This has caused the cost of obtaining animals for our preclinical studies to increase dramatically and, if the shortage continues, could also result in delays to our development timelines. To the extent our suppliers and service providers are unable to comply with their obligations under our agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the COVID-19 pandemic, our ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face risks related to the health, safety, morale, and productivity of our employees, including the safe occupancy of our sites during the pandemic. In the third quarter of 2021, we transitioned to a return-to-site phase for our non-lab based employees. Our job site enhancements and risk protocols, which include health screenings and COVID-19 testing and vaccine requirements, do not guarantee that we can maintain the continued safe occupancy of our sites and may adversely impact employee recruitment and retention. On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns.  In the fourth quarter of 2021 and continuing to the present, the Omicron variant affected our staff, our clinical sites, our CROs and our third-party manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The spread of COVID-19 and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COVID-19 and actions taken to reduce its spread continue to rapidly evolve. The extent to which COVID-19 has or may continue to impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our preclinical studies and future clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the COVID-19 pandemic otherwise adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#x201c;Risk Factors&#x201d; section, such as those relating to the timing and results of our planned clinical trials and our financing needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Discovery, Development, and Regulatory Approval of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are early in our development efforts and all of our product candidates and research programs are in preclinical development or discovery stage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are early in our development efforts and most of our operations to date have been limited to developing our platform technologies and conducting drug discovery and preclinical studies. While we performed limited clinical trials for our now discontinued SBT6050 and SBT6290 programs, we have not begun clinical trials for any of our current product candidates or development programs. Our current product candidates remain in the preclinical and discovery stage. As a result, we have limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, and cannot be certain that our planned clinical trials will be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the early stage of development of our products candidates, our ability to eventually generate significant revenues from product sales will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successful completion of additional preclinical studies with favorable results; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission and acceptance of INDs by the FDA or similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successful enrollment in, and completion of, clinical trials and achieving positive results from the trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demonstrating a risk-benefit profile acceptable to regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing manufacturing capabilities or arrangements with third-party manufacturers for clinical supply and, if and when approved, for commercial supply; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in combination with others; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effectively competing with other therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developing and implementing marketing and reimbursement strategies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining a continued acceptable safety profile of any product following approval, if any. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we do not achieve one or more of these requirements in a timely manner, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical and clinical development is a lengthy, expensive, and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials, including from our SBT8230 program, may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research and development of drugs and biological products is extremely risky. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Preclinical and clinical development is expensive and can take many years to complete, and their outcome is inherently uncertain. We may face unforeseen challenges in our product candidate development strategy, and we can provide no assurances that we will ultimately be successful in our future clinical trials or that our product candidates will be able to receive regulatory approval. The results of preclinical studies and early clinical trials of our product candidates and other products, even those with the same or similar mechanisms of action, may not be predictive of the results of later-stage clinical trials. For example, it is not uncommon for product candidates to exhibit unforeseen safety or efficacy issues when tested in humans despite promising results in preclinical animal models. Future results of preclinical and clinical testing of our product candidates are also less certain due to the novel and relatively untested nature of our approach to TLR8 and related platform technologies. In general, clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. For example, on March 28, 2022, we made the decision to discontinue our clinical development programs for SBT6050 and SBT6290 due to SBT6050 exhibiting limited monotherapy activity and dose-limiting adverse events when used in combination with pembrolizumab.  A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring their alteration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the results of our future clinical trials are inconclusive or if there are safety concerns or other adverse events associated with our product candidates, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incur unplanned costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in or prevented from continuing clinical development and obtaining marketing approval for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings including boxed warnings; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to changes or limitations in the way the product is administered; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified Risk Evaluation and Mitigation Strategy (REMS); </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be sued; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience damage to our reputation. </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treatment of patients with chronic disease, such as HBV infection, with our product candidates may be used in combination with other drugs, such as monoclonal antibodies or other protein-based drugs, small molecule agents, and RNAi therapeutics which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our future clinical trials. Additionally, our product candidates could potentially cause adverse events. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products. Because all of our product candidates are derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived likelihood that our other product candidates will experience similar failures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#x2019; approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete clinical testing and receive approval of a biologics license application (BLA) or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have concentrated our research and development efforts on product candidates using our platform technologies, and our future success depends on the successful development of this approach. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our planned clinical trials or commercializing any products on a timely or profitable basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the clinical trial requirements of the FDA, EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cHBV market is also rapidly developing and our competitors may introduce new technologies that effectively target the virus lifecycle or modulate the immune response to the virus that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The TLR field is also rapidly evolving and as competitors use or develop alternative TLR technologies, any failures of such technologies could adversely impact our programs. For example, companies are developing other TLR8, TLR7, TLR7/8 and TLR9 agonists, some of which are conjugated to monoclonal antibodies. Regardless of our belief that our approach to activating the innate immune system has advantages, issues encountered with other TLR programs will create a negative perception of or increase scrutiny for our technologies and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we experience delays or difficulties enrolling in our planned clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to initiate or continue our planned clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of healthy volunteers or eligible patients to participate in these trials as required by the FDA or other regulatory agencies. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, the design of the clinical trial, competing clinical trials and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment or retention in our planned clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity of patients to study sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the design of the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain patient consents; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our planned clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we continue developing our product candidates and initiate any future clinical trials of our product candidates, serious adverse events (SAEs), undesirable side effects, relapse of disease, or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. Should we observe any SAEs in our planned clinical trials or identify other undesirable side effects or other unexpected findings, depending on their severity, our trials could be delayed or even stopped and our development programs may be halted entirely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our TLR8 agonist containing product candidates, including from our SBT8230 program, activate dendritic cells among other innate immune cells, which can amplify anti-drug antibodies. As a result, significant anti-drug antibodies (ADA) generation could neutralize the effects of SBT8230 by reducing exposure. The development of ADAs could also trigger hypersensitivity reactions that manifest as SAEs. If patients experience adverse events due to ADAs, our preclinical studies and future trials could be delayed or stopped and our development programs may be halted entirely if this is observed during clinical development. Even if ADAs are not detected in the early clinical trials, they may be detected after product launch and may significantly reduce the commercial potential or even result in the product being pulled from the market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if our product candidates initially show promise in early clinical trials, the side effects of biological products are frequently only detectable after they are tested in larger, longer, and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined to be attributed to our product candidate, we may be required to develop a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or ADAs caused by such products, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require additional warnings on the label, including &#x201c;boxed&#x201d; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to change the way a product is administered or conduct additional clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the product may become less competitive, and our reputation may suffer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may decide to remove the product from the marketplace; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, topline and preliminary data from our preclinical studies or planned clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publicly disclose preliminary, interim, or topline data from our preclinical studies or planned clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and treatment continues and more data become available. Adverse differences between previous preliminary or interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of a preclinical study or planned clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development, research, testing, manufacturing, labeling, approval, selling, import, export, marketing, promotion and distribution of drug products are subject to extensive and evolving regulation by federal, state and local governmental authorities in the United States, principally the FDA, and by foreign regulatory authorities, which regulations differ from country to country. Neither we nor any current or future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of a BLA from the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining regulatory approval of a BLA can be a lengthy, expensive and uncertain process. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. The number of preclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results from preclinical studies and planned clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all indications. The FDA may also require us to conduct additional studies or trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program such as the number of subjects in our future clinical trials from the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or the applicable foreign regulatory agency&#x2019;s disagreement with the design or implementation of our planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that our product candidates are safe and effective for the proposed indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement with the interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s requirement for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete our planned clinical testing and receive approval of a BLA or foreign marketing application for our product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or in the case of the FDA, the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or a narrower patient population than we originally requested, and the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates, but we may not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the product candidate may be eligible for Fast Track Designation. The benefits of fast track designation include more frequent meetings with FDA to discuss the drug&#x2019;s development plan and ensure collection of appropriate data needed to support drug approval, more frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers, eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and rolling review, which means that a drug company can submit completed sections of its BLA for review by FDA, rather than waiting until every section of the BLA is completed before the entire application can be reviewed. BLA review usually does not begin until the entire application has been submitted to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies by the FDA may be eligible for all features of Fast Track designation, intensive guidance on an efficient drug development program, beginning as early as Phase 1, and organizational commitment involving senior managers at FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible, we cannot assure you that the FDA would decide to grant it. Even if we have obtained Fast Track Designation and/or Breakthrough Therapy Designation for one or more of our product candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. In addition, the FDA may withdraw Fast Track Designation or Breakthrough Therapy Designation if it believes that the designation is no longer supported. These designations do not guarantee qualification for the FDA&#x2019;s priority review procedures or a faster review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain regulatory approval for any of our product candidates, they will be subject to extensive and ongoing regulatory requirements for manufacturing, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, sampling and record-keeping. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations, as well as GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Such regulatory requirements may differ from country to country depending on where we have received regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. Moreover, if there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issuing warning or untitled letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mandating modifications to promotional materials or require us to provide corrective information to healthcare practitioners, or require other restrictions on the labeling or marketing of such products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seeking an injunction or imposing civil or criminal penalties or monetary fines; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspension or imposition of restrictions on operations, including product manufacturing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seizure or detention of products, refusal to permit the import or export of products or request that we initiate a product recall; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspension, modification or withdrawal of our marketing authorizations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal to approve pending applications or supplements to applications submitted by us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal to permit the import or export of products; or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the FDA and other regulatory authorities strictly regulate the promotional claims that may be made about biologic products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#x2019;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#x2019;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the global COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020 the FDA resumed certain on-site inspections of domestic manufacturing facilities on a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. For example, on March 28, 2022, we made the decision to discontinue our clinical development programs for SBT6050 and SBT6290 and to prioritize resources on the development of SBT8230 and our early-stage discovery programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to design such product candidates with the properties that we desire; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Manufacturing, Commercialization, and Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may rely on third parties to conduct, supervise, and monitor our planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have the ability to conduct all aspects of our preclinical testing or planned clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our preclinical studies, including GLP toxicology studies, and any future clinical trials of our product candidates. Specifically, CROs that manage preclinical studies, GLP toxicology studies and our planned clinical trials as well as consultants play a significant role in the conduct of our preclinical studies and future clinical studies and the subsequent collection and analysis of data. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or future clinical trial sites fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies and planned clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of COVID-19, including quarantines and shelter-in-place orders, which have also adversely impacted the supply chain for many research and clinical supplies, including animals for preclinical testing. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We contract with third parties for the manufacture and supply of certain of our product candidates for use in preclinical testing and clinical trials and will rely on third parties for commercial supply, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of product for evaluation in our research programs. We rely on third parties for the manufacture of a portion of our product candidates for preclinical testing and all of our product candidates for clinical testing and we will continue to rely on such third parties for commercial manufacture if any of our product candidates are approved. We currently have limited manufacturing arrangements and expect that each of our product candidates, including from our SBT8230 program, will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#x2019;s GLP regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contract manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not control the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the COVID-19 pandemic, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our or a third-party&#x2019;s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and timelines and comply with cGMP requirements could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to meet our product specifications and quality requirements consistently; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an inability to initiate or continue preclinical studies or clinical trials of our product candidates under development; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of the cooperation of future collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to cease development or to recall batches of our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Manufacturing antibody drug conjugate products is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturing antibody drug conjugate products is complex and require the use of innovative technologies to handle living cells. Manufacturing these products requires facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at manufacturing facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency, significant lead times and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that we or our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due to the early nature of our product candidates, the drug product may not be stable over time causing changes to be made to the manufacturing or storage process which may result in delays or stopping the development of the product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in methods of product candidate manufacturing may result in additional costs or delays.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. Our product candidate targets mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">efficacy and potential advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer our products for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of marketing and distribution support; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, one third-party payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new product&#x2019;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, the Centers for Medicine and Medicaid Services (CMS) revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the Affordable Care Act) signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action, court decisions or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any approved products are subject to biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial opportunity will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are focused on developing tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, such as SBT8230 for cHBV. Our projections of addressable patient populations that have the potential to benefit from treatment with a current or future product candidate are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets through breach of our agreements with third parties, independent development, or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Factors that may inhibit our efforts to commercialize future products on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product portfolios; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our In-Licenses and Other Strategic Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not realize the benefits of any acquisitions, in-license, or strategic alliances that we enter into.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into in-license agreements with a licensor and in the future may seek and form strategic alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our existing technologies and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#x2019;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in-license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, or if there are materially adverse impacts on our or the counterparty&#x2019;s operations resulting from COVID-19, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may, in the future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of those product candidates, including in territories outside the United States or for certain indications. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. We may be unable to in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impairment of our business reputation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs due to related litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">distraction of management&#x2019;s attention from our primary business; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to patients or other claimants; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our product candidates, if approved for commercial sale. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our product liability insurance coverage is sufficient in light of our current programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims, or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients with infectious disease, such as cHBV, and other diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conduct substantially all of our operations at our facilities in Seattle. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock units that vest over time. The value to employees of stock options and restricted stock units that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#x201c;key person&#x201d; insurance policies on the lives of these individuals or the lives of any of our employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 90 employees which represents an increase of 34 employees since January 1, 2021. However, on March 28, 2022, we approved a corporate restructuring plan to discontinue our clinical development programs for SBT6050 and SBT6290 and in connection with this plan, our workforce will be reduced by 27%, with substantially all of the reduction in personnel expected to be completed by July 15, 2022. As we advance our research and development programs, we may be required to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify, recruit integrate, maintain and motivate additional qualified personnel; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates, both as a monotherapy and in combination with other therapeutics; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">improve our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time, to managing these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and commercialization of new products is highly competitive. We largely compete in the segments of the pharmaceutical, biotechnology and other related markets that develop treatments for infectious diseases. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, if ever, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. Moreover, with the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other products in a similar class as some of our product candidates have already been approved and other products in the same class are further along in development. As more product candidates within a particular class of biopharmaceutical products proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specifically, there are many companies pursuing a variety of approaches to </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immune modulation and more specifically TLR-directed therapies. Companies engaging in TLR-directed therapies include Ambrx, Apros Therapeutics, Ascendis, BioNTech, Bolt Biotherapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, CureVac, Exicure, Galderma, Gilead, Idera, Mologen, Nektar, Novartis, Primmune Therapeutics, Roche, Seven&amp;Eight Biopharmaceuticals, Shanghai De Novo, Sumitomo Dainippon, Tallac Therapeutics, TriSalus, and UroGen. Other companies using antibody-drug conjugates to target innate immune receptors include Actym Therapeutics, Mersana, and Takeda Pharmaceuticals. Immunotherapy and validated pathway approaches are further being pursued by many smaller biotechnology companies as well as larger pharmaceutical companies. We also face competition from (i) validated pathway therapy treatments offered by companies such as AstraZeneca, Byondis, Daiichi Sankyo, Klus Pharma, MacroGenics, Pieris, Puma, RemeGen, Seagen, Spectrum Pharmaceuticals, and Zymeworks; (ii) companies that continue to invest in innovation in the antibody-drug conjugate field, including but not limited to AbbVie, ADC Therapeutics, Astellas, BioAtla, Bicycle Therapeutics, Celldex, CytomX, Eli Lilly and Company, GlaxoSmithKline, Genmab, ImmunoGen, Millennium Pharmaceuticals, MorphoSys AG, Novartis, Pfizer, Sanofi, Seagen, and Sutro Biopharma; and (iii) companies that are developing assets for the treatment of chronic HBV infection, which include 3SBio, AICuris, Albireo, Aligos, Allovir, Alnylam, Altimmune, Antios, Arbutus, Arcus, Arrowhead, Ascentage, Assembly Biosciences, Blue Jay Therapeutics, Bristol Myers Squibb, Door Pharmaceuticals, Enanta, ENYO Pharma, Excision Bio, Finch Therapeutics, GC Pharma, Gilead, GlaxoSmithKline, Golden Biotechnology Group, Grifols,  HEC Pharm, Hepion, Immunocore, ISA pharmaceuticals, Johnson &amp; Johnson, Kineta, Lupin Limited, Merck, Nucorion, Replicor, Roche, SciClone Pharma, Shanghai Henlius Group, Spring Bank, Tasly, TeneoTen, TRACON, Vaccitech, VBI Vaccines, VenatoRx, Vir, VLP Biotech, and Zydus Cadila</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">never achieve profitability. Unused U.S. federal net operating loss carryforwards (NOLs) for taxable years beginning before January 1, 2018, may be carried forward to offset future taxable income, if any, until such unused NOLs expire. Under current law, U.S. federal NOLs incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely, but the deductibility of such U.S. federal NOLs in taxable years beginning after December 31, 2020, is limited to 80% of taxable income.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $160.3 million of U.S. federal NOLs. If not used, $18.2 million of the U.S. federal NOLs will begin to expire in 2036 and $142.1 million can be carried forward indefinitely under current law. As of December 31, 2021, we also had aggregate U.S. federal research and development (R&amp;D) credits of approximately $2.7 million. Our NOL carryforwards and R&amp;D credits are subject to review and possible adjustment by the U.S. and state tax authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#x201c;ownership change,&#x201d; which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards, R&amp;D credits and certain other tax attributes to offset its post-change income or taxes may be limited. This could limit the amount of NOLs, R&amp;D credit carryforwards or other applicable tax attributes that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs, R&amp;D credits and other applicable tax attributes carried forward may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws, privacy laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not currently have any products on the market, our operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws, the Physician Payments Sunshine Act, and the Health Insurance Portability and Accountability Act (HIPAA), and their implementing regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal false claims, including the False Claims Act, which can be enforced through whistleblower actions, and Civil Monetary Penalties Laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them, and their covered subcontractors, that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act, enacted as part of the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program to report annually to the CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2010, the Affordable Care Act was enacted, which includes measures that have significantly changed the way health</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">care is financed by both governmental and private insurers. There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example,  in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2031, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless Congress takes additional action. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#x2019;s proposals. As a result, the FDA released a final rule and guidance in September  2020, providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#x2019;s Most Favored Nation (MFN) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinded the MFN interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of other health reform initiatives. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs of pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, or collectively, Trade Laws, prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, and/or adverse publicity and could negatively affect our operating results and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. For example, we may obtain clinical trial data from research institutions. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, numerous federal, state, and local laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. For example, HIPAA as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The California Consumer Privacy Act (the CCPA) gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, it is anticipated that the California Privacy Rights Act of 2020 (the CPRA), effective January 1, 2023, will expand the CCPA. Additionally, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of enforcement. At this time, we do not collect personal information relating to residents of California, but should we begin to do so, the CCPA and CPRA will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other states have enacted data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which become effective in 2023. Additionally, several states and localities have enacted statutes banning or restricting the collection of biometric information. In addition, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts. Privacy advocates and industry groups have also regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security.  For example, the European Union&#x2019;s General Data Protection Regulation (the EU GDPR), the United Kingdom&#x2019;s GDPR (the UK GDPR), Brazil&#x2019;s General Data Protection Law (the Lei Geral de Prote&#xe7;&#xe3;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018), and China&#x2019;s Personal Information Protection Law (the PIPL) impose strict requirements for processing personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater.  Further, individuals may initiate litigation related to processing of their personal data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal data transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area (the EEA) that the European Commission does not consider to provide an adequate level of data privacy and security, such as the United States.  The European Commission released a set of &#x201c;Standard Contractual Clauses&#x201d; (the SCCs) that are designed to be a valid mechanism to facilitate personal data transfers out of the EEA to these jurisdictions. Currently, these Standard Contractual Clauses are a valid mechanism to transfer personal data outside of the EEA, but there exists some uncertainty regarding whether the SCCs will remain a valid mechanism. Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties that are subject to such cross-border data transfer or localization laws; or requiring us to increase our personal data processing capabilities and infrastructure in foreign jurisdictions at significant expense. At this time, we do not believe we are subject to the GDPR, but should this change, the GDPR will increase our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If we  or our collaborators and third-party providers fail, or are perceived to have failed, to comply with U.S. and foreign data privacy and security laws and regulations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e,g,, investigations, fines, penalties, audits, inspections, and similar), private litigation (including class-related claims), additional reporting requirements and/or oversight, bans on processing personal data, orders to destroy or not use personal data, and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to, loss of customers, interruptions or stoppages in our business operations (including, as relevant, clinical trials), inability to process personal data or to operate in certain jurisdictions, limited ability to develop or commercialize our products, expenditure of time and resources to defend any claim or inquiry, adverse publicity, or revision or restructuring of our operations. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data privacy and security laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain effective disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we are subject to requirements of the Sarbanes-Oxley Act, the rules and regulations of the Nasdaq Global Market, the rules and regulations of the Securities and Exchange Commission. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly and place significant strain on our personnel, systems and resources. Company responsibilities required by the Sarbanes-Oxley Act include, among other things, that we maintain corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Securities Exchange Act of 1934, as amended (the Exchange Act) is accumulated and communicated to our principal executive and financial officers. We are also continuing to improve our internal control over financial reporting. In order to develop, maintain, and improve the effectiveness of our internal controls and procedures, and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain, or any disruptions or difficulties in implementing or using, such a system could adversely affect our controls and harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. In addition, we may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#x2019;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business, results of operations, and financial condition and could cause a decline in the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Recent Accounting Pronouncements.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New income, sales, use, or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the legislation informally titled the Tax Cuts and Jobs Act (the Tax Act) enacted in 2017 enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, legislation enacted on March 27, 2020, entitled the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) modified certain provisions of the Tax Act, and it is possible that the Biden administration and Congress may enact proposed legislation that could have an adverse effect on our operations, cash flows and results of operations and contribute to overall market volatility. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely upon a combination of patents, know-how and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued or that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner, including delays as a result of the COVID-19 pandemic impacting our or our licensors&#x2019; operations. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#x201c;off-label.&#x201d; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party pre-issuance submissions of prior art to the USPTO or our issued patents may be subject to post-grant review (PGR) proceedings, oppositions, derivations, reexaminations, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review (IPR) proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if and when patents may issue based on our patent applications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of protection of any patent issuing based on our patent applications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether the claims of any patent issuing based on our patent applications will provide protection against competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether or not third parties will find ways to invalidate or circumvent our patent rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; and/or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#x201c;prior art,&#x201d; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent protection is available on a national or regional level. Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. As such, our intellectual property rights outside the United States may not extend to all other possible countries outside the United States and we may not be able to prevent third parties from practicing our inventions in countries outside the United States where we do not have patent protection, or from selling in and importing products into other jurisdictions made using our inventions in such countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products or technology and may export otherwise infringing products or technology to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Further, the legal systems of certain countries particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any such lawsuits that we initiate and the damages and other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. We currently have and may in the future enter into more contract research and manufacturing relationships with organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties at nominal or no consideration. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if enforced, a court may not hold that our patents are valid, enforceable and infringed; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent application covering such intellectual property; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may fail to adequately protect and police our trademarks and trade secrets; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these or similar events occur, they could significantly harm our business, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are currently party to an in-license agreement under which we were granted rights to manufacture certain components of our product candidates. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these technologies or both, which would adversely affect our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely, in part, on license and other strategic agreements, which subject us to various obligations, including payment obligations for achievement of certain milestones on product sales. For example, with respect to SBT8230, we have licensed a cell line to manufacture a component of this product under an agreement with WuXi Biologics. If we fail to comply with the obligations under our license agreements, including as a result of COVID-19 impacting our operations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are terminated, we may experience significant delays, difficulties, and costs in developing new cell lines and identifying an alternative source to manufacture components of our candidate products covered by our agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the sublicensing of patent and other rights; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us alone or with our licensors and partners; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope and duration of our payment obligations; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described herein. If we or our licensor fail to adequately protect this intellectual property, our ability to develop, manufacture, or commercialize products could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently own intellectual property directed to our product candidates and other proprietary technologies. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, some of our owned and in-licensed patents or patent applications or future patents are or may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. For example, we have identified certain third-party patents that may be asserted against us with respect to our ImmunoTAC conjugate SBT8230. These patents may expire prior to commercial launch of SBT8230, if approved. We believe that the relevant claims of these third-party patents are likely invalid or unenforceable, and we may choose to challenge those patents, though the outcome of any challenge that we may initiate in the future is uncertain. We may also decide in the future to seek a license to those third-party patents, but we might not be able to do so on reasonable terms. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third-party&#x2019;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing candidate product or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing candidate product or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be aware of patents that have already been issued and that a third-party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may choose to challenge the enforceability or validity of claims in a third-party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ex-parte</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> re-exam, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#x2019;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are found to infringe a third-party&#x2019;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing, or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop non-infringing technology, which may not be possible on a cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#x2019; fees for willful infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming, and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors or other third parties may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#x2019;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271I(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our preclinical studies, initiate and continue planned clinical trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensor&#x2019;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Assoc. for Molecular Pathology v.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Myriad Genetics, Inc.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse, including due to the effect of the COVID-19 pandemic on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may rely on trade secret and proprietary know-how, which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our product candidate, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity incident) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#x2019;s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The term of a United States patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent. A patent term extension (PTE) based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous PTEs in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Securities Markets and Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may not continue to be developed or be sustained, which may make it difficult for you to sell your shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to our initial public offering in December 2020, there had been no public market for our common stock. The trading market for our common stock on The Nasdaq Global Market has been limited and an active trading market for our shares may not be sustained. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares at a price that is attractive to you, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The price of our common stock could be subject to volatility related or unrelated to our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price may be volatile. The stock market in general and the market for biotechnology and pharmaceutical companies, in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares at a price that is attractive to you, or at all. The market price for our common stock may be influenced by numerous factors, many of which are beyond our control, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results from future clinical trials with our current and future product candidates or of our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse results or delays in preclinical studies or prior and future clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including without limitation the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses related to future product candidates or clinical development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our failure to achieve product development goals in the timeframe we announce; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the economy as a whole and market conditions in our industry; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expiration of market standoff or contractual lock-up agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of our market float; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">political uncertainty and/or instability in the United States; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ongoing and future impact of the COVID-19 pandemic and actions taken to slow its spread; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any other events or factors discussed in this report. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immune-oncology companies. Stock prices of many immune-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of other biopharmaceutical companies have also been highly volatile as a result of the COVID-19 pandemic. In the past, stockholders have filed securities class action lawsuits following periods of market volatility. For example, following a decline in our stock price, a federal securities class action complaint was filed against us and certain of our officers and directors in the U.S. District for the Western District of Washington, captioned Dresner v. Silverback Therapeutics, Inc., et al., Case No. 2:21-cv-01499, which alleges violations of (i) Sections 11 and 15 of the Securities Act of 1933, as amended (the Securities Act); and (ii) Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. Even if we are successful in defending against this action or any similar claims that may be brought in the future, such litigation could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. As a result of their share ownership, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If there are substantial sales of shares of our common stock, the price of our common stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. As of December 31, 2021, we had 35,133,934 outstanding shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the COVID-19 pandemic and actions taken to slow its spread, as well as actual or perceived changes in interest rates and economic inflation, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. In addition, government efforts to stimulate economic activity in the face of the COVID-19 pandemic have caused interest rates to fluctuate and created uncertainty as to future fluctuations. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to our 2020 Plan, our management is authorized to grant stock options, restricted stock units and other equity-based awards to our employees, directors and consultants. The number of shares of our common stock reserved for issuance under our 2020 Plan will automatically increase on January 1 of each calendar year through January 1, 2030, in an amount equal to the lesser of (i) 5.0% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase; or (ii) a lesser number of shares determined by our board of directors prior to the applicable January 1st. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek additional capital through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses, or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to securities class action litigation and may be subject to additional litigation in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. For example, following a decline in our stock price, a federal securities class action complaint was filed against us and certain of our officers and directors in the U.S. District for the Western District of Washington, captioned Dresner v. Silverback Therapeutics, Inc., et al., Case No. 2:21-cv-01499, which alleges violations of (i) Sections 11 and 15 of the Securities Act; and (ii) Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder.  Even if we are successful in defending against this action or any similar claims that may be brought in the future, such litigation could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an &#x201c;emerging growth company,&#x201d; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as an &#x201c;emerging growth company&#x201d; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have at least $1.07 billion in annual revenue; (ii) the date upon which we are deemed to be a &#x201c;large accelerated filer,&#x201d; as defined in Rule 12b-2 under the Exchange Act; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the prior three-year period; and (iv) December 31, 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement for the affirmative vote of holders of at least 66-2/3% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#x2019;s own slate of directors or otherwise attempting to obtain control of us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation designates the state courts the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, and the federal district courts of the United States of America to be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our  amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could seriously harm our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#x2019; development programs, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, share, and transmit (collectively, processing) proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and proprietary business information (collectively, sensitive information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such sensitive information. We also have outsourced elements of our operations to third parties, including, without limitation, third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, and other functions, and as a result we manage a number of third-party contractors who have access to our sensitive information. Moreover, we may share or receive sensitive information with or from third parties. Our ability to monitor these third parties&#x2019; information security practice, is limited, and these third parties may not have adequate information security measures in place.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite the implementation of security measures, given the size and complexity and the increasing amounts of sensitive information that we maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to cyberattacks, malicious internet-based activity, and online and offline fraud. These threats are prevalent, continue to increase, and are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#x201c;hackers,&#x201d; threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actor. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to from cyberattacks by malicious third parties (including but not limited to malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), ransomware attacks, denial-of-service attacks (such as credential stuffing), social engineering attacks (including through phishing attacks), supply-chain attacks and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), personnel misconduct or error, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, and other similar threats which may compromise our system infrastructure or lead to data leakage. Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks have increased in frequency and severity </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#x2019; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us and our services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The COVID-19 pandemic and our remote workforce also poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#x2019; systems and technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the previously identified or similar threats could cause a security incident or other interruption. To the extent that any disruption or security incident were to result in unauthorized, unlawful, or accidental acquisition, modification, destruction, a loss, alteration, encryption, disclosure of, or access to sensitive information, we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information. We cannot assure you that our data privacy and security efforts and our investment in information technology will prevent significant breakdowns or security incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.  Security incidents and attendant consequences may cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our headquarters and main research facility are located in Seattle, Washington, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our preclinical studies and future clinical trials, our development plans and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolved Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Properties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters is located in Seattle, Washington, where we lease approximately 19,829 square feet of office, laboratory and storage space pursuant to a lease agreement that commenced on November 1, 2016 and expires on October 31, 2026. In addition, we lease approximately 9,166 square feet of office space in Seattle, Washington pursuant to a lease that commenced on August 1, 2021 and expires on July 31, 2023. We believe that our existing facilities are adequate for the foreseeable future. As we expand, we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 5, 2021, a securities class action complaint was filed against us and certain of our officers and directors in the U.S. District for the Western District of Washington, captioned Dresner v. Silverback Therapeutics, Inc., et al., Case No. 2:21-cv-01499. The complaint alleges that between December 3, 2020 and September 10, 2021, we and certain of our officers and directors violated (1) Sections 11 and 15 of the Securities Act; and (2) Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder, by making allegedly false and misleading statements in various SEC filings and press releases regarding the clinical and commercial prospects of our product candidate, SBT6050, which is now discontinued. The complaint seeks unspecified damages and interest, as well as attorneys&#x2019; fees and other costs. The court recently appointed lead plaintiff and lead plaintiff's counsel. We and the other defendants have not yet filed a response to the complaint, and do not anticipate doing so until after the filing of an amended complaint.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Safety </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="tx155579_41"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has been listed on the Nasdaq Global Market under the symbol &#x201c;SBTX&#x201d; since December 4, 2020. Prior to that date, there was no public market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 15, 2022, there were approximately eight holders of record of our common stock. Because most of our common stock is held by brokers, nominees, and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 3, 2020, we commenced our initial public offering (IPO) pursuant to a registration statement on Form S-1 (File No. 333-250009) that was declared effective by the SEC on December 3, 2020, for 11,500,000 shares of our common stock for sale to the public at a price of $21.00 per share. In addition, in December 2020, the underwriters exercised their over-allotment option to purchase 1,725,000 additional shares of our common stock in the initial public offering at the public offering price of $21.00 per share, such that the aggregate offering price of our initial public offering was $277.7 million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were $255.3 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates. The underwriters for our initial public offering were Goldman Sachs &amp; Co. LLC, SVB Leerink LLC, Stifel, Nicolaus &amp; Company, Incorporated, and H.C. Wainwright &amp; Co., LLC.</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net proceeds from our IPO are held in cash and cash equivalents, primarily in treasury money market accounts, and</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investments, primarily in U.S. Treasury securities. Through December 31, 2021, we have used approximately $45.0 million of the net proceeds from our IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following information updates the planned use of proceeds information from our IPO that we previously disclosed in the final prospectus filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act on December 4, 2020: we intend to use the remaining net proceeds from the IPO, together with our existing cash and cash equivalents, to fund the development of our SBT8230 program for cHBV, including IND-enabling studies, a Phase 1 SAD study, and a Phase 1 MAD study. We intend to use the remainder to fund our other research and development activities, including activities related to our internal discovery programs, as well as for working capital and other general corporate purposes. We may also use a portion of the net proceeds from the IPO to in-license, acquire or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. [Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7.	Management&#x2019;s Discussion and Analysis o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">f Financial Condition and Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis together with our financial statements and related notes included in &#x201c;Item 8. Financial Statements and Supplementary Data&#x201d; in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that involve risks and uncertainties. For a complete discussion of forward-looking statements, see the section above entitled &#x201c;Forward Looking Statements.&#x201d; Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption &#x201c;Item 1A. Risk Factors.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a biopharmaceutical company focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Our ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Many potentially promising systemic therapies fail to maximize their therapeutic potential due to toxicities in healthy tissues.  Our approach is designed to expand the therapeutic window and avert unacceptable toxicities by directly targeting specific disease sites where our therapeutics are locally active.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2020, we initiated clinical development of our first ImmunoTAC product candidate, a TLR8 agonist conjugated to a HER2 antibody, SBT6050.  Preclinical data suggested that we would be able to demonstrate a therapeutic window and advance SBT6050 through clinical development as a monotherapy and in combination with standard-of-care agents that had a complementary mechanism-of-action.  Our Phase 1/1b program was designed to measure safety and tolerability, PK, PD and anti-tumor activity as monotherapy and in combination with pembrolizumab.  On March 28, 2022, we made the decision to discontinue our clinical development program for SBT6050 due to limited monotherapy activity and dose-limiting adverse events when used in combination with pembrolizumab. SBT6290, comprised of the same linker payload conjugated to a Nectin4 antibody was expected to show a similar clinical profile and, therefore, we also terminated this program prior to dosing patients.  We have prioritized our resources to focus on the development of SBT8230 and early-stage discovery programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our understanding of TLR8 conjugates in preclinical species and in the clinic guides our interpretation of the preclinical characteristics of SBT8230, an ASGR1 antibody conjugated to a TLR8 agonist linker payload for the treatment of cHBV, which is currently in preclinical development. ASGR1 is highly expressed in liver and is restricted in its expression to this organ. Other ASGR1-directed agents, such as those used in RNAi therapies, have shown robust liver localization.  SBT8230 shows biodistribution profiles in NHP consistent with these agents, which is distinct from SBT6050 and SBT6290. We believe that efficient liver targeting of SBT8230 via ASGR1 binding has the potential to lead to markedly lower serum exposures of SBT8230 in patients compared to those observed with SBT6050 in the clinic at any dose evaluated.  We believe the preclinical to clinical experience for SBT6050, coupled with the NHP PK, PD, and tolerability data for SBT8230, suggest that the clinical safety, PK and PD profiles for SBT8230 has the potential to be notably different than those for SBT6050, given the large differences in serum exposures and overall conjugate disposition for SBT8230 that are expected in patients due to its efficient liver targeting. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver.  The anti-viral immune response is achieved through activation of myeloid cells and subsequent activation of immune cells that drive an IFN&#x3b3; signal, which has been observed in the clinic with SBT6050.  This has been shown by others to drive seroconversion, an important determinant of a functional cure.  We see a significant opportunity in liver-localized immunotherapies as a potential way of achieving durable responses in these patients. We are focused on advancing SBT8230, our liver-targeted conjugate designed to </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potently activate human myeloid cells in the liver for the treatment of cHBV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further support for investigating TLR8 agonism for the treatment of cHBV comes from selgantolimod (GS-9688), an existing untargeted, orally administered TLR8 agonist being developed by Gilead Sciences.  Selgantolimod has generated anti-viral immune responses in a cHBV animal model. The clinical development of this untargeted TLR8 agonist has shown promise, but we believe that toxicity prevented the use of a sufficient dose to elicit optimal clinical activity. We believe liver-localized TLR8 agonism could better realize the potential for effective therapy and potentially lead to functional cure, which is defined as sustained loss of HBsAg in the blood, in patients suffering from cHBV. We presented a preclinical update on SBT8230 in the fourth quarter of 2021. In the first quarter of 2022, we began a Phase 1-enabling toxicology study. We plan to complete a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">P</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hase 1 regulatory submission in the fourth quarter of 2022 and begin a Phase 1 SAD study in healthy volunteers in the first half of 2023.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> After completing the SAD study, we anticipate initiating a Phase 1 MAD study in patients with chronic HBV, who are virally suppressed on NRTI therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our internal discovery programs are focused on evaluating and developing new antigen binding domains specific for targets of interest (including antibodies), next-generation linker technologies, and both agonist and antagonist small molecule payloads, that may be combined to create novel tissue-targeted antibody conjugates. The integration of medicinal chemistry, bioconjugation, protein engineering, bioinformatics, pharmacology, and translational medicine expertise focused on developing tissue-targeted therapies allows us to leverage key learnings from our previous clinical program to bring forward the next generation of therapeutics.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We anticipate providing an update on our discovery pipeline in the fourth quarter of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ImmunoTAC platform drives our development pipeline of tissue targeted therapeutic candidates as summarized in the chart below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img238320182_17.jpg" alt="img238320182_17.jpg" style="width:720px;height:197px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant operating losses since our inception. As of December 31, 2021, we had an accumulated deficit of $186.2 million. Our net losses were $89.5 million and $32.9 million for the years ended December 31, 2021 and 2020, respectively. Our losses have resulted primarily from research and development activities and general and administrative expenses. We do not have any products approved for sale and have not generated any revenue from product sales or otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect we will continue to incur significant losses for the foreseeable future as we continue our development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products, seek to expand our product pipeline, invest in our organization and technology platform, as well as incur expenses associated with operating as a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on a variety of factors including the timing and scope of our preclinical studies and clinical trials. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses or other similar arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, our board of directors approved a corporate restructuring plan to discontinue our clinical development programs for SBT6050 and SBT6290 and to prioritize resources on the development of SBT8230 and early-stage discovery programs (the Restructuring Plan). In connection with the Restructuring Plan, our workforce will be reduced by 27%, with substantially all of the reduction in personnel expected to be completed by July 15, 2022. We initiated the reduction in force on March 31, 2022 and expect to provide severance payments, continuation of group health insurance coverage, and other benefits for a specified period to the affected employees. We currently estimate that we will incur costs of approximately $2.0 million for termination benefits related to the Restructuring Plan, all of which will be cash expenditures paid in 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Our Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of our ImmunoTAC technology platform, product candidates, discovery efforts and preclinical studies and clinical trial activities related to our program pipeline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our direct costs include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred under agreements with CROs and other vendors that conduct our preclinical and clinical activities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses associated with manufacturing our product candidates including under agreements with CDMOs and other vendors; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consulting fees. </span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our indirect costs include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other unallocated research and development expenses incurred in connection with our research and development programs, including laboratory materials and supplies and license fees. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expense research and development costs as incurred. Advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are performed. In-licensing fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are not separately classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We  expect that our research and development expenses will decrease in 2022 due to discontinuation of the clinical development of SBT6050 and SBT6290 and the Restructuring Plan. However, following 2022, we expect that our research and development expenses will begin to increase again for the foreseeable future as we continue the development of our preclinical and discovery programs, particularly as they move into later stages of development which increases costs considerably. We cannot reasonably determine the timing of initiation, the duration or the completion costs of these future preclinical studies and clinical trials due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which development candidates and discovery programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses, and facility related expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our general and administrative expenses will decrease in 2022 due to the Restructuring Plan. However, following 2022, we expect that our general and administrative expenses will begin to increase again to the extent needed to support growth in our research and development activities. We also expect to continue to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Interest Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income (expense), net includes interest earned on our cash, cash equivalents, and long-term investments carried at fair value, and interest expense on our borrowings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.906%;"></td>
    <td style="width:1.044%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:9.905%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.044%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:9.801%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.044%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:9.801%;"></td>
    <td style="width:1.079%;"></td>
    <td style="width:1.044%;"></td>
    <td style="width:0.789%;"></td>
    <td style="width:8.815%;"></td>
    <td style="width:2.702%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Dollar</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,501</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,577</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,924</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,083</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,341</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,742</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">237</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,584</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,918</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,666</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,584</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(32,918</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(56,666</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income (expense), net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,478</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(32,947</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(56,531</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">*	Not meaningful</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.235%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:10.036%;"></td>
    <td style="width:0.673%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:10.036%;"></td>
    <td style="width:0.673%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:9.897%;"></td>
    <td style="width:0.673%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:0.789%;"></td>
    <td style="width:9.177%;"></td>
    <td style="width:2.715%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Dollar</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SBT6050</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,150</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,710</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,440</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">222</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SBT6290</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,217</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,049</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,168</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">202</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinical programs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,932</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,059</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,873</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total direct costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,299</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,818</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,481</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">199</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indirect costs:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel-related expenses, including stock-based <br />&#160;&#160;&#160;compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,045</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,657</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,388</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Facility and equipment related expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,972</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,426</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">546</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other unallocated research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,185</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,676</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,509</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,501</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,577</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,924</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An investigational new drug application for SBT6290 was cleared by the FDA in the fourth quarter of 2021 and we opened enrollment for a Phase 1 clinical trial of SBT6290 in the first quarter of 2022, which is now discontinued. As a result, we have separated direct costs for the development of SBT6290 from preclinical programs for the year ended December 31, 2021 and, for comparability purposes, the year ended December 31, 2020. This change had no effect on net loss, total research and development expenses, stockholders' equity, or cash flows as previously reported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses were $61.5 million and $24.6 million for the years ended December 31, 2021 and 2020, respectively. The increase of $36.9 million was due primarily to an increase of $10.4 million in direct costs related to the development of SBT6050 as we continued to advance the program through a Phase 1/1b clinical trial. The increase was also due to an increase of $6.2 million in direct costs related to the development of SBT6290 as we advanced the program through FDA clearance of its investigational new drug application and prepared to initiate a Phase 1 clinical trial in the first quarter of 2022 and due to an increase in direct costs for our preclinical programs of $4.9 million as we continued to advance SBT8230 and other preclinical research efforts. The remaining increase was due to increases in personnel-related expenses of $13.4 million resulting from increased headcount during the year ended December 31, 2021 as well as increases in salaries, bonuses, stock-based compensation, and recruiting expenses. To a lesser extent, the increase in research and development expenses was due to facility and equipment related expenses of $0.5 million, and other unallocated research and development expenses of $1.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses were $28.1 million and $8.3 million for the years ended December 31, 2021 and 2020, respectively. The increase of $19.7 million was due primarily to an increase of $13.5 million in personnel-related expenses due to increased headcount during the year ended December 31, 2021, including executives that were new in 2020 being present for a full year in 2021, as well as increases in salaries, bonuses, stock-based compensation, and recruiting expenses. To a lesser extent, the increase in general and administrative expenses was due to an increase in professional fees of $5.4 million primarily attributable to legal, insurance, and outside consultant costs, and $0.8 million in other various general and administrative expenses as we operated as a public company for the full year of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income (expense), net was $0.1 million and $(29,000) for the years ended December 31, 2021 and 2020, respectively. The change of $0.1 million was primarily due to a decrease in principal on our notes payable and an increase in our cash balance. Also contributing to the change was the investment in higher interest-bearing assets during the period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. Since our inception, we have funded our operations almost exclusively with proceeds from the sale and issuance of shares of our redeemable convertible preferred stock and common stock, and debt financings. We will need to raise substantial additional capital in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had $319.1 million in cash, cash equivalents, restricted cash, and investments. The following table sets forth a summary of the net cash flow activity for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.709%;"></td>
    <td style="width:1.519%;"></td>
    <td style="width:1.682%;"></td>
    <td style="width:13.929%;"></td>
    <td style="width:1.125%;"></td>
    <td style="width:1.519%;"></td>
    <td style="width:1.682%;"></td>
    <td style="width:13.709%;"></td>
    <td style="width:1.125%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash (used in) provided by:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(66,760</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(31,196</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(66,478</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(917</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">614</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">408,506</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(132,624</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">376,393</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, net cash used in operating activities was $66.8 million. This consisted primarily of a net loss of $89.5 million, partially offset by non-cash charges of $21.2 million and a decrease in our operating assets and liabilities of $1.5 million. The non-cash charges primarily consisted of stock-based compensation expense of $19.2 million, non-cash lease expense of $1.2 million, and depreciation expense of $0.8 million. The decrease in our operating assets and liabilities was primarily due to an increase in accounts payable and accrued expenses of $6.0 million. The decrease was partially offset by a decrease in lease liability of $1.1 million and an increase in prepaid expenses and other assets of $3.4 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, net cash used in operating activities was $31.2 million. This consisted primarily of a net loss of $32.9 million and an increase in our operating assets and liabilities of $2.6 million, partially offset by charges of $4.4 million. The charges primarily consisted of stock-based compensation expense of $2.6 million, lease expense of $1.1 million, and depreciation expense of $0.6 million. The increase in our operating assets and liabilities was primarily due to an increase in prepaid expenses and other assets of $3.5 million and a decrease in our lease liability of $0.9 million, partially offset by an increase in accounts payable and accrued expenses of $1.8 million after adjusting for items. The increase in prepaid expenses and other assets was primarily due to the purchase of $2.6 million in prepaid insurance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, cash used in investing activities was $66.5 million. This consisted of purchases of U.S. Treasury Securities of $65.1 million and purchases of property and equipment of $1.4 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, cash used in investing activities was $0.9 million due to purchases of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, cash provided by financing activities was $0.6 million. This was primarily driven by proceeds from the exercise of common stock options and the employee stock purchase plan of $1.5 million, which was partially offset by $0.8 million of principal payments on the term loan payable.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, cash provided by financing activities was $408.5 million. This consisted primarily of net proceeds received from the issuance of our common stock in connection with our initial public offering of $255.7 million, net proceeds received from the issuance of shares of our redeemable convertible preferred stock of $153.4 million, and proceeds from the exercise of common stock options of $0.2 million, which were partially offset by principal payments on the term loan payable of $0.7 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our cash, cash equivalents, restricted cash, and investments of $319.1 million at December 31, 2021 will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2026 following the Restructuring Plan. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, trial design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates, and in particular future clinical trials for SBT8230; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and characteristics of product candidates that we pursue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing and costs of seeking FDA, EMA and any other regulatory approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of manufacturing our product candidates and commercial manufacturing activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical activities increase; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of commercialization activities for any of our product candidates, if approved, including marketing, sales and distribution costs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the emergence of competing therapies and other adverse market developments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we in-license or acquire other products and technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our need and ability to retain key management and hire scientific, technical, business, and medical personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our implementation of additional internal systems and infrastructure, including operational, financial and management information systems; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our costs associated with expanding our facilities or building out our laboratory space; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Material Cash Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our material cash requirements include the following contractual and other obligations as of December 31, 2021:</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.608%;"></td>
    <td style="width:3.018%;"></td>
    <td style="width:1.598%;"></td>
    <td style="width:8.785%;"></td>
    <td style="width:0.693%;"></td>
    <td style="width:3.577%;"></td>
    <td style="width:1.598%;"></td>
    <td style="width:8.662%;"></td>
    <td style="width:0.693%;"></td>
    <td style="width:3.442%;"></td>
    <td style="width:1.598%;"></td>
    <td style="width:7.656%;"></td>
    <td style="width:0.693%;"></td>
    <td style="width:3.711%;"></td>
    <td style="width:1.598%;"></td>
    <td style="width:8.103%;"></td>
    <td style="width:0.693%;"></td>
    <td style="width:3.711%;"></td>
    <td style="width:1.598%;"></td>
    <td style="width:8.271%;"></td>
    <td style="width:0.693%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Payments Due by Period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less than 1 year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1-3 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">3-5 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More than 5 years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease obligations (1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,917</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,481</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,250</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,917</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,481</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,250</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Refer to Note 6 to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under our license agreements, we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sales of products developed under those agreements. As of December 31, 2021 and 2020, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales and, therefore, any related payments are not included in the table above. For additional details regarding these agreements, see Part I, Item 1 of this Annual Report on Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-K under the section titled &#x201c;License Agreement&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, we entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (WuXi Bio), pursuant to which we received a non-exclusive, worldwide, sublicensable license under certain of WuXi Bio&#x2019;s intellectual property rights, know-how and biological materials (the WuXi Bio Licensed Technology) to make, use, sell, offer for sale and import developed through the use of the WuXi Bio Licensed Technology (the WuXi Bio Licensed Product). In consideration for the license, we paid a license fee of $100,000 to WuXi Bio which was recorded in research and development expense in 2019. In 2020 we incurred an additional license fee of $50,000 to WuXi Bio which was recorded in research and development expense in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if we do not engage WuXi Bio to manufacture the WuXi Bio Licensed Products for our clinical and commercial supplies, we are required to make aggregate milestone payments of up to $10.8 million to WuXi Bio upon the achievement of certain sales milestones. To date, other than the license fee, no payments have been made under this agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enter into contracts in the normal course of business with vendors for clinical studies, preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, stock-based compensation, and valuation allowances for deferred tax assets. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our significant accounting policies are more fully described in Note 2 to our audited financial statements appearing in Part II, Item 8 of this Annual Report on Form-10-K. Not all of our significant accounting policies require that we make estimates and assumptions that we believe are critical accounting estimates. Our estimates relating to research and development expenses, stock-based compensation, and income taxes have had or are reasonably likely to have a material impact on our financial statements and we consider them to be our critical accounting policies and critical accounting estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when we do not expect the goods to be delivered or services to be performed. We estimate the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, we will adjust the amounts recorded accordingly. We have not experienced any material differences between accrued or prepaid costs and actual costs since our inception.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as a reduction of stock-based compensation expense as they occur. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For all periods prior to our initial public offering, the fair value of the shares of common stock underlying our share-based awards was estimated on each grant date by our board of directors. To determine the fair value of our common stock underlying option grants, our board of directors considered, among other things, input from management, valuations of our common stock prepared by unrelated third-party valuation firms in accordance with the guidance provided by the American Institute of Certified Public Accountants 2013 Practice Aid,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Practice Aid). Following the closing of our initial public offering, the fair market value of our common stock is based on its closing price as reported on the primary stock exchange on which our common stock is traded. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Given our limited historical stock price volatility data, we derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within our peer group that were deemed to be representative of future stock price trends as we have limited trading history for our common stock. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the options. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We have never paid dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Therefore, we used an expected dividend yield of zero. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize deferred income taxes for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. In evaluating our valuation allowance, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had net operating loss carryforwards for income tax purposes of approximately $160.3 million. If not used, $18.2 million of this carryforward will begin to expire in 2036 and $142.1 million has no expiration. We also have research and development tax credits of approximately $2.7 million which will begin to expire in 2037 if left unused.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Sections 382 and 383 of the Code, substantial changes in our ownership may limit the amount of NOL and research and development credit carryforwards that could be used annually in the future to offset taxable income. The tax benefits related to future utilization of federal and state NOL carryforwards, credit carryforwards, and other deferred tax assets may be limited or lost if cumulative changes in ownership exceeds 50% within any three-year period. We have not completed a Section 382/383 analysis under the Code regarding the limitation of NOL and credit carryforwards. If a change in ownership were to have occurred, the annual limitation may result in the expiration of NOL carryforwards and credits before utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we did not have any liabilities for unrecognized income tax benefits associated with uncertain tax positions, including any interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 2 to our audited financial statements appearing in Part II, Item 8 of this Annual Report on Form 10-K for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an emerging growth company, as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have at least $1.07 billion in annual revenue; (ii) the date upon which we are deemed to be a &#x201c;large accelerated filer,&#x201d; as defined in Rule 12b-2 under the Exchange Act; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt securities during the prior three-year period; and (iv) December 31, 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A.	Quantitative and Qualitative</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Disclosures About Market Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable to a &#x201c;smaller reporting company&#x201d; as defined under Item 10(f)(1) of Regulation S-K of the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8.	Financial Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> and Supplementary Data</span></p>
  <p style="text-indent:-9.971%;padding-left:9.067%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#audit_opinion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3e70b60-9cbe-41ab-b1b6-6c0a752b7bd6" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balancesheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statementofoperations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#sose"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_statements_of_cash_flow"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="audit_opinion"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and Board of Directors of Silverback Therapeutics, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying balance sheets of Silverback Therapeutics, Inc. (the Company), as of December 31, 2021 and 2020, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the two years then ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years then ended in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbd6fddb-08ce-49f0-998c-03e52b7a9eee" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_591841c4-6bf9-4bcf-b1c9-90ae0e71dec6" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Seattle, Washington</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balancesheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and par value data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.433%;"></td>
    <td style="width:1.584%;"></td>
    <td style="width:1.584%;"></td>
    <td style="width:1.228%;"></td>
    <td style="width:12.884%;"></td>
    <td style="width:0.806%;"></td>
    <td style="width:1.584%;"></td>
    <td style="width:1.228%;"></td>
    <td style="width:12.865%;"></td>
    <td style="width:0.806%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b632a5e4-cd7b-4450-810c-84de1c144bd7" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,045</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13f856d8-ee6f-4448-83e6-0ba7da36ee37" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,569</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8561af84-8825-499f-8700-b552757ca12d" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d9475ed-233f-4821-bcf3-c918fc73e3f6" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,087</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_109980cb-3a99-420e-8e8f-f8a75213e6c4" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,492</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ab42095-75e0-4518-b992-2e737eacf8c9" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">390,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1eba484-1dd0-47d4-b1ad-e4d41cd23874" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9ec03c7-d154-47b3-ba08-976fa3ba85c3" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd11e032-540b-464a-8a36-247c42d99d15" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b83e1884-e088-4f00-a1a1-a5421bdc06dd" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e51d3fad-1c46-43d7-875e-be7b6bd419dd" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_777d1d19-537e-40bf-aa51-093a61c44df2" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8339eeba-f9ed-432a-bb7e-97890e65af8b" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,212</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44513b18-3883-4568-870d-1cea90f5c6d3" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_238d5af8-a854-456d-b94a-5d00e5ae6ce0" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eaf24fb3-ba92-4cf2-b861-8b0be6c28c7e" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_580d1c72-66a4-430c-a872-e2c5ac068528" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,078</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_739c2211-6a41-43cd-b77c-c1d6676ebbb5" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,583</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70db9856-4437-477b-b419-b13ca39fbd2e" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a86d46af-1ac1-44cb-8d17-9513d2c52e70" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Term loan payable, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16bf35ce-e965-43cd-9cc3-e28e6fb0f53e" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LoansPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7f8caf9-68d0-4bd6-ab19-7179666305de" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:LoansPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0ca6b28-c61c-42b8-b9cb-71ee5c7762ed" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,087</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fbb173e-aa43-45b6-a81e-d310a3a0abff" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2ec6834-1a20-4ef3-85ec-df04d1b80973" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,892</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f04ae9d1-1772-425e-af3d-2de80778659b" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdaa39de-fc4e-4d3a-82ec-1dfab2fb8064" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55804153-9d05-4dd2-a429-fd4be2b6a7c0" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98bc6907-02ca-48b6-9d86-8aeb270ea6c3" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8838ff90-b5dc-45fd-9941-f877b34bad24" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bccce8e7-b750-4510-8968-19eaaaafc25d;"><span style="-sec-ix-hidden:F_83270064-b0cb-4fde-82f9-0810d07e13c1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencies</span></span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(Note 12)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred Stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7cc416a-d9c3-4d67-8590-a49531b73110" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4"><ix:nonFraction id="F_b4148ffb-f55a-4345-99df-f5caa995f9a2" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_511b3d73-768c-433d-802c-855c1dfd3fae" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6a087116-74ee-449c-9815-05c784b92b76" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized at <br />&#160;&#160;&#160;December 31, 2021 and 2020; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98dfa270-6250-42a1-8354-fbd50647b7ec" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_324c223d-c481-439e-8b0c-d4db76bf2b67" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4a7618d2-9d73-47e8-b81e-b307958e00ae" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_69ecff3f-1f97-4ff8-b1bd-d87b094c1916" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding at December 31, 2021       <br />&#160;&#160;&#160;and 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79b8801b-a170-497c-b690-ec16ff8e4a2f" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0d60ce4-9a70-4f3a-9968-c86e083c7fa4" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ccee07f-3910-4b32-9844-31859d875cbb" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4"><ix:nonFraction id="F_c3584671-578e-456f-9fb7-21dc9bb29ae4" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value per share; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b3a7f75-bdae-4edb-a8fd-2096b163b598" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_356505f6-4630-46fb-863f-923a8f1400ff" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized at <br />&#160;&#160;&#160;December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4f48202-54d5-4fef-ad01-e14cc3572d60" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,133,934</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f352a96-2ed2-46e1-a04e-3506a176e7ae" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,801,537</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32a2f350-b89e-46f0-b444-37f47a0d50f0" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,107,651</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;<br />&#160;&#160;&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06cd82b0-d056-4d98-b37c-af2d1ebd4462" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,701,274</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares outstanding at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3be29756-caf3-4ef4-af17-242cd5c59d1b" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2d20647-cf97-4adb-9e51-ae0bdc522232" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_669fcfa0-9533-439f-99d4-6bc8106a3f50" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d49c7790-a835-4d3e-aae9-32a24747b8ee" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479,608</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e3709ec-ffc8-4045-8abd-faf069268b5f" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb72c812-685c-44ff-b819-90a7730616ed" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a18adf29-ccdc-4720-a13e-cb60d73265ee" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">186,212</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07b093a1-c2e2-4ecc-86ff-93aa54c73e13" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">96,734</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26ffdf74-6036-4dc9-b10c-9c57766c5c93" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79d4baa2-7c9e-4041-b590-7f27977307c5" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46bd222a-2d7f-44d6-b27a-0fbf860d936a" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">333,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca141177-5aac-43cd-a764-6b81487b7cbe" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statementofoperations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.951%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.364%;"></td>
    <td style="width:12.717%;"></td>
    <td style="width:0.826%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.364%;"></td>
    <td style="width:12.708%;"></td>
    <td style="width:0.826%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2239501-32a1-4b6c-a3e4-dd5bbaa65054" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,501</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17beb5a5-5924-4235-be0f-d64fe1354e0a" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,577</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a443618b-2da2-4be7-88a8-7a783527647c" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a1faca4-1b94-4cec-afd1-dc66a9d2f865" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abced928-ed3a-481e-96de-86810ea2e29e" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c622b3ca-fea3-4363-8c9a-979dab2ca19c" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,918</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7e499a6-3448-4436-835f-335e2d210998" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2734748e-a47d-47e9-ac00-3d95c5394053" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,918</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income (expense), net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ad71160-652a-4009-92c2-aaa87e845869" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eda56e70-2941-4d7c-8042-af5eca21cfff" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_125c1aa5-f1b3-41a5-828f-7aaec017dea5" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb428470-2a05-431e-9c76-03c963c69c77" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea3b8409-40ec-463c-afe3-2ed6c515026f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa6dd4ef-f337-4057-89f9-bf59b29b9641" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss attributable to common stockholders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea68d3b1-40ce-4497-990f-7cee9e787041" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0aea9577-3442-41fc-b880-a28d62258a52" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders,<br />&#160;&#160;&#160;basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_defe7542-c859-45fd-a369-bacf90dd654e" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_261eb47f-507b-4778-8b76-28216a405f15" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">11.33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares used in computing net loss per share<br />&#160;&#160;&#160;attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6a7cda4-d509-4c57-a87e-fe88b0dd4b88" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">34,926,403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bc1e98d-aab1-4434-9c88-765289b16134" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,907,542</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="sose"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Redeemable Convertible </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.774%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:7.767%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.841%;"></td>
    <td style="width:7.35%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:0.695%;"></td>
    <td style="width:0.695%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:7.913%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.841%;"></td>
    <td style="width:7.489%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.841%;"></td>
    <td style="width:7.489%;"></td>
    <td style="width:0.417%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.862%;"></td>
    <td style="width:6.557%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.841%;"></td>
    <td style="width:7.35%;"></td>
    <td style="width:0.563%;"></td>
    <td style="width:0.8%;"></td>
    <td style="width:0.841%;"></td>
    <td style="width:7.35%;"></td>
    <td style="width:0.563%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Redeemable Convertible<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additional<br />Paid-in</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;<br />'Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Comprehensive Loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance as of January 1, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50319925-1f42-412b-9579-55f17c477910" contextRef="C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,714,283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2c82dbd-148f-44ae-baea-c5af255546b9" contextRef="C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_485356ae-4e6f-4117-8081-731d35883cce" contextRef="C_21761b55-f888-4dd6-90d9-c5d5d39d5076" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">664,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1dfd089-6572-44e9-92c4-e87c35291580" contextRef="C_384f1405-e75d-4b1f-ba71-caf76e7127d1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,010</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3398fb50-2a69-43ea-923e-313cb68ed0fe" contextRef="C_360c64d4-e8a6-45e9-bf20-6dafe7757ce5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ae78a20-e351-421d-81a3-951c1adbf600" contextRef="C_270d424e-2ea7-451c-a3be-3e4a447e5b40" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,777</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of Series B redeemable convertible preferred<br />&#160;&#160;&#160;stock for cash, net of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b02bd6f6-c40d-460a-8bce-c216b30d6e08" contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255" name="sbtx:StockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;in issuance costs (Note 8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69db4a7b-0296-41e9-a53b-fad4fc5132be" contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255" name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,760,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a1cb032-a582-4886-8490-57ed23eb2f67" contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255" name="sbtx:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of Series B redeemable convertible preferred<br />&#160;&#160;&#160;stock upon conversion of convertible notes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a76dbfd0-e320-4a04-9f93-0d2791650ea7" contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255" name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,673,388</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7b7e841-1178-4578-8f70-d772f86cebf0" contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255" name="sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of Series C redeemable convertible preferred stock upon conversion of convertible notes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d64e621d-cce2-49a8-b5b9-866358146104" contextRef="C_40425c84-7c43-4d68-9c93-740efc67f686" name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">24,926,685</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09a49798-2960-4a0d-8b88-dd6da1df1b51" contextRef="C_40425c84-7c43-4d68-9c93-740efc67f686" name="sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,897</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock converted into shares of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6227f8b9-a95e-405f-83ec-c560944fea98" contextRef="C_86a8a0b7-29df-47b1-afc9-35b1ed2b1497" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">77,074,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c4025be-f4a2-4531-b34f-742835d41e28" contextRef="C_13e17b88-9a3e-4334-afaa-25c79b7864bb" name="sbtx:TemporaryequityValues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">216,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc5c2057-4acf-4f8c-ac86-5920e2285963" contextRef="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">20,758,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_114f30a9-b9b3-4b98-b12a-3e760a9370bf" contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0" name="sbtx:TemporaryequityValues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98019034-a7d0-44c1-bbff-69cd53be6dc2" contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100" name="sbtx:TemporaryequityValues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,565</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0b02270-c467-4169-80eb-79677acb5490" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:TemporaryequityValues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Initial public offering of common stock, net of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa417b79-501e-4a39-8bd3-0c34a4dcad56" contextRef="C_95651084-dc63-4d7f-8062-7d70db969b9b" name="sbtx:StockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,386</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;in issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c13a915c-e164-4f56-b51a-f3a7a74e144a" contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,225,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b75257fd-3a49-43bc-aceb-9319cce9ee47" contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b042100a-1854-4320-9956-f8397885c690" contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">255,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c10d92d6-7851-4247-b32d-0b67baad0618" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">255,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercise of common stock options and vesting of early<br />&#160;&#160;&#160;exercised common stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aff40967-d705-4b55-8b5e-f222f19aad06" contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">53,745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c80634d6-f538-441d-99a4-c2048e2e1cab" contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08ea1452-6511-419d-954e-cc9c4b9765a3" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b83c741b-8692-4977-b727-ecd9b0df4454" contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b5e8082-c297-4ea4-9297-d46fbaec1010" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be1669b1-4f7f-4844-b607-0b63f62a3cd1" contextRef="C_e5a118de-b5ae-416d-953c-fca753351c6e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7d07ec2-525a-41cb-9f13-fad9c75bd2d6" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5aaa7ad4-fa6d-4c74-bc99-f4458f746176" contextRef="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">34,701,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_643d0d97-8c9c-478e-917b-b496d284b789" contextRef="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_823f6290-ca9d-4f58-94be-0879a32c9dfb" contextRef="C_de83bac2-93f2-420e-9e2b-4c5157a75113" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479,608</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_784e51a5-0b26-40ef-bc04-43d7b468b4d5" contextRef="C_e6a0662a-dd26-49c0-af88-491b9b800275" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">96,734</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e166e1a-a7ce-45d5-a8b0-477a5f7201f2" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercise of common stock options, shares issued<br />&#160;&#160;&#160;under the employee stock purchase plan, and <br />&#160;&#160;&#160;vesting of early exercised common stock <br />&#160;&#160;&#160;options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50005ad0-9901-4b07-8744-9153ac7af008" contextRef="C_ebe0d08f-4b7c-4a30-a659-5090f617fde9" name="sbtx:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">406,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79c6f5fa-f24a-4c69-9ff4-452c01eeb775" contextRef="C_ebe0d08f-4b7c-4a30-a659-5090f617fde9" name="sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40521e77-6f08-4f64-9afa-32deafe257aa" contextRef="C_828913ed-d805-418b-ab38-3ca1860cfe83" name="sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,554</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4d9a198-adc0-4ed0-825d-d23e8e7f1db3" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c99f56d-0c4b-421d-89b9-6d483d964b71" contextRef="C_828913ed-d805-418b-ab38-3ca1860cfe83" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,187</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ff025f0-32a7-4a4c-90e7-930d90d910af" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,187</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13dc134c-95f9-47ca-ae58-dfa75b59d3c7" contextRef="C_4efba159-4be0-4651-ade7-fb31bf28b994" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4c28f7e-48e6-49f6-a764-64d82bc90b5f" contextRef="C_6ebc2a75-c6af-4453-bbcf-d1d071452f7a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d845fa7f-46fe-4217-847e-8f2053c19481" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3dd5919-aad1-4d69-8bfc-20196b5f0e65" contextRef="C_494bd466-afac-4c94-b8ad-1da406d99780" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">35,107,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f0bc6f4-ee80-43a8-8236-5a494bd9002d" contextRef="C_494bd466-afac-4c94-b8ad-1da406d99780" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d41e757f-b0b0-408c-ac9e-1f4ae3755df3" contextRef="C_9b13a7ea-2f2e-41d9-8210-704162e848d4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3332aae7-d335-4093-bbb4-a3ec68095d03" contextRef="C_d2266970-9935-4502-9c86-ada2228e4e21" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28320e5a-644d-47c7-b7e1-930b607da85c" contextRef="C_74e41f57-c0d7-4daf-b14d-df2e105f7efb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">186,212</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c99cfc98-a3d2-428f-9c98-5a0892e22068" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_statements_of_cash_flow"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.623%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.08%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.08%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1cfce95-23dc-48fb-9144-b3e5173f0bfb" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ee3012b-5547-457e-85b4-ecca9d58e7ea" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_192f2092-b20e-4f9e-9911-6cdd2f9a17aa" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">783</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df7a2b69-6003-4bff-a8e5-a8a9e1de6416" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">637</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cbbeb1d-6280-4030-8bbf-9a0af144d45f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,187</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e4335ed-82a5-4cf9-815c-c2f041d012f8" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b488dbdf-5f36-4f4a-b32a-074fd381ea80" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1099be86-ee47-470e-bc05-0b312f3a1c0f" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,073</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization of debt issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b6dfbae-2a9e-43c2-8439-a234739e20a4" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb69ec70-7065-4cd6-9a43-59d5353832e5" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f8bc1a2-2b70-4295-8b77-26ddb4606aa3" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0831861b-1a98-47f4-b112-7e8b4758a54b" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:40.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de6c775c-3731-4d8b-adeb-a6c1fbaaab07" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,034</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a4f3e51-1f68-4088-b1e5-9c47e1fd84df" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a14184b6-5aba-4009-b07c-aa07974bc9de" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,074</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bb23745-392a-45ea-aef5-405808ecfaa7" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">885</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08046855-b677-4bb0-a3ee-11749891a5fd" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_535129e8-2442-403b-bf8d-0a330878c9d4" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,196</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of available-for-sale securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21c4a6c9-2837-4c8a-afb3-b23a5768e22a" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41ab00c0-0874-4ca0-869b-b30330a8a73f" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5adf4c09-ec21-4fab-8905-d2e338e793de" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e54d046-aeaf-4b09-8e78-9ac41c8140d1" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9e7652f-32c8-41f7-ba29-c5f76267a91d" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_776ea7d9-e973-4b2e-b19b-648c4cc91dcf" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4160758-48b0-489e-a177-1ee1b9968b28" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a1151e4-51b9-47ab-ac74-7439fcfcaabc" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153,351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9941b1bf-a999-4a0e-a1b6-b3a5f752945c" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a643e35-7e6b-4889-b37b-1bf4e0c35ce8" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">258,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of deferred offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0ee2cc6-35f8-4c0c-a389-4abd02aec860" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:PaymentOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1245fdb-80ab-4338-8d01-701930112de1" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:PaymentOfDeferredOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,606</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal payments on term loan payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ff9f977-f997-49d7-9c9f-a5cb67240a25" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:RepaymentsOfBankDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d021acf-ed71-400a-852f-0d2b34b0ea51" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:RepaymentsOfBankDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from exercise of common stock options and employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cd7e7e5-b756-43fe-a4e3-db60bc7091f8" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_683325f6-8fd5-4575-9e3b-9175707fcaef" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30c14f98-99f2-441c-93a3-6160b1d95ea2" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9bc26cd-0e41-4fb8-b9b8-1116d524dd6f" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">408,506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71ee832c-2b2b-44a8-abb9-d987c9220eee" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NetCashProvidedByUsedInContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">132,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7775d52-5f3e-41f1-a8ae-985ac91f1738" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:NetCashProvidedByUsedInContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">376,393</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41ffe5bf-f26c-4785-aacd-872ca4151897" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_149812ea-d138-46e6-b09f-2681f84fcd8c" contextRef="C_270d424e-2ea7-451c-a3be-3e4a447e5b40" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,526</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1d4b6fa-d4bf-4e2c-b5ec-282a74c27cd7" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9150be9-3208-410f-a5ee-3dfb5502b7ed" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;Unpaid initial public offering costs included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72a289ee-fd28-4701-89b8-44ce4d63df42" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39667f47-61b8-41eb-9a22-e7e56929e14d" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets and lease liabilities recognized</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f476b4fc-c19e-46a1-ba22-2fee8ebb342d" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:RightOfUseAssetsAndLeaseLiabilitiesRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eba433e4-509d-4d47-a48f-7332cf84c2c2" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:RightOfUseAssetsAndLeaseLiabilitiesRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of Series B redeemable convertible preferred stock upon conversion of<br />&#160;&#160;&#160;convertible notes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd26034a-854f-4010-b5bb-5fc42756b0db" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20098acc-03c0-4347-856c-d3a23e8c2e4f" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of redeemable convertible preferred stock upon closing of initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1ba3ab2-57e0-4617-a201-383a567a17b3" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55714236-a041-488b-8ea5-455462b1524f" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a278a00a-04ee-4e61-8045-df39314b25ed" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. (&#x201c;Silverback&#x201d; or &#x201c;the Company&#x201d;) is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company&#x2019;s ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. The Company&#x2019;s platform enables it to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January 4, 2016.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company completed its initial public offering of common stock (&#x201c;IPO&#x201d;) of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aff04ebb-933f-4d49-bb17-05825393ccbb" contextRef="C_6cac55f6-3aef-4c64-94d0-8fe6535c4bb5" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,225,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e2bb0b1-5b21-4ca4-a5e8-415a9f97506f" contextRef="C_6cac55f6-3aef-4c64-94d0-8fe6535c4bb5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7a56740-2c7d-4d1d-b0df-8274cce41690" contextRef="C_e4fb8c88-21a6-408b-bd27-cec75b99333f" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">255.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and offering expenses paid by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e4b83d2-e68a-4fda-933a-62cf576a18cb" contextRef="C_eccc60cc-900f-452b-bd4e-6dc984c5cd7a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">77,074,884</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock outstanding at the time of the IPO converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e95a0b5f-a92a-4e91-bc81-0a64d1b074b4" contextRef="C_c2f82abf-51d1-4cd8-bb42-2d8d43b73153" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">20,758,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock. Additionally, in November 2020, the Company&#x2019;s Board of Directors approved an amendment to the Company&#x2019;s certificate of incorporation to effect a reverse split of shares of the Company&#x2019;s common stock on a one-for-3.713 basis, which was effected on November 30, 2020 (the &#x201c;Reverse Stock Split&#x201d;) in anticipation of the IPO.  All references to common stock and options to purchase common stock share data, per share data, and related information contained in the financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the Company&#x2019;s existing products under development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c69f956c-69bd-4860-bfe0-35ff0afee0c9" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">186.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company had cash, cash equivalents, restricted cash, and investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf68eb33-15b6-48da-a0f0-39983dbd3e59" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:CashCashEquivalentsAndLongTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">319.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily through the issuance of redeemable convertible preferred stock, convertible notes, and the sale of common stock in connection with the IPO. The Company&#x2019;s currently available cash, cash equivalents, restricted cash, and investments as of December 31, 2021 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date the financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management expects operating losses to continue for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical development activities as well as the commercialization of the Company&#x2019;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd13f93a-4d6f-4a69-b4e2-9ce4f1f0e4f4" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_cd13f93a-4d6f-4a69-b4e2-9ce4f1f0e4f4_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97b202dd-765f-47c2-8c18-a10129a69038" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dfc1ad6-c434-41ed-9586-4c4786347f50" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_8dfc1ad6-c434-41ed-9586-4c4786347f50_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_8dfc1ad6-c434-41ed-9586-4c4786347f50_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the coronavirus (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trial and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dabebf2-f4b0-494a-9dab-2af8dc15ff2e" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing tissue targeted therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84828662-3706-45fc-abc0-d561be96b9ee" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true" continuedAt="F_84828662-3706-45fc-abc0-d561be96b9ee_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_84828662-3706-45fc-abc0-d561be96b9ee_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents, restricted cash, and investments are carried at fair value. Accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. The term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43a697b3-b38c-4f87-a22a-5f97d72d88a7" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_43a697b3-b38c-4f87-a22a-5f97d72d88a7_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_43a697b3-b38c-4f87-a22a-5f97d72d88a7_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At December 31, 2021 and December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company&#x2019;s cash equivalents consisted of money market funds.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93950d9f-9de6-408b-9334-8c054448616d" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the operating lease for the Company&#x2019;s headquarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3111d0f1-5e19-4861-9bc1-5f7246d59774" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.095%;"></td>
          <td style="width:1.512%;"></td>
          <td style="width:2.003%;"></td>
          <td style="width:17.496%;"></td>
          <td style="width:0.942%;"></td>
          <td style="width:1.512%;"></td>
          <td style="width:2.003%;"></td>
          <td style="width:17.496%;"></td>
          <td style="width:0.942%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_601fa620-ccb2-4104-8730-e46d26fc5b18" contextRef="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,045</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_735bf811-7c92-4bf5-a0f1-59d7f77def68" contextRef="C_0d3b5176-144a-4079-966a-a3f6e8176386" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,569</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89d8a932-78f0-454b-a9de-c65dd3c0d8f0" contextRef="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">250</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc531557-5e42-44e4-afb9-b5a9b71358fb" contextRef="C_0d3b5176-144a-4079-966a-a3f6e8176386" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">350</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash and cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a00099c7-1e7e-4f8c-a600-14a40d3de24b" contextRef="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254,295</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d11e5345-afe4-4b39-b648-904af3e67787" contextRef="C_0d3b5176-144a-4079-966a-a3f6e8176386" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,919</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f6cf90c-5eba-429d-a765-70a12c089e16" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests excess cash in investment grade intermediate-term fixed income securities. These investments are included in long-term investments on the balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Realized gains and losses on the sale of these securities are recognized in net loss.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company periodically evaluates whether declines in fair values of its investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the investments, duration and severity of the decline in value, and the Company's strategy and intentions for holding the investment.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd7c87ae-105b-4477-867b-2616b43c41a7" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_cd7c87ae-105b-4477-867b-2616b43c41a7_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_cd7c87ae-105b-4477-867b-2616b43c41a7_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to credit risk from holding its cash and cash equivalents at a limited number of commercial banks. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings and U.S. Treasury securities. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84b02dac-e47f-4886-8bc1-44425eab9098" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:PrepaidExpensesAndOtherAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prepaid Expenses and Other Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses consist primarily of operating expenses paid in advance of when services are provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88ac2cfb-70b0-478e-bd08-7497f1e59be2" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of furniture and fixtures and laboratory equipment and is stated at cost, less accumulated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">depreciation. Furniture and fixtures and laboratory equipment are depreciated over the estimated useful lives of the assets (each three to five years) using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Repairs and maintenance costs are charged to expense as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_721572f7-ad58-426a-87bc-13b37f47becc" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_721572f7-ad58-426a-87bc-13b37f47becc_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leases consist of the Company&#x2019;s operating leases. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s leases include options to extend or terminate the leases. Periods covered by an option to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate a lease are included in the lease term when it is reasonably certain that the Company will not exercise that option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_721572f7-ad58-426a-87bc-13b37f47becc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and non-lease components. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bd3b905-de2e-4352-98ee-5769f76cc671" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets consist of property and equipment and ROU assets. These assets are reviewed for impairment whenever facts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses through December 31, 2021.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a465dfc-04dc-414b-9d4d-f9f81224fc67" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#x2019;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#x2019;s program pipeline. Direct costs include expenses incurred under agreements with CROs and other vendors that conduct the Company&#x2019;s preclinical and clinical activities, expenses associated with manufacturing the Company&#x2019;s product candidates including under agreements with contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#x2019;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#x2019;s research and development efforts and have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1943b6fe-fd11-4d0c-86b9-f3582e0b3e1f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. General and administrative costs are expensed as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_983d88ef-9cb3-4a07-8dc0-d98e72156d5d" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true" continuedAt="F_983d88ef-9cb3-4a07-8dc0-d98e72156d5d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_983d88ef-9cb3-4a07-8dc0-d98e72156d5d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#x2019;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1767b3a5-47cb-4114-ae01-5d4c572abbc4" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:EmployeeStockPurchasePlanPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) became effective, pursuant to which eligible employees can purchase shares of the Company&#x2019;s common stock at a discount to the fair market value at semi-annual intervals. In determining the grant date fair value of shares expected to be purchased under the ESPP, the Company uses the Black-Scholes option pricing model. Black-Scholes inputs are determined in the same manner as for stock option awards. The estimated grant date fair value of shares expected to be purchased is recognized into expense on a straight-line basis over the requisite service period.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e492a4c4-1bb6-4196-82e4-4e977c685fd1" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company is more likely than not able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes in the period in which the adjustment is made.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the basis of the technical merits of the position and (2) for those tax positions that meet the recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. The Company did not have any uncertain tax positions as of December 31, 2021 and 2020.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ecf119f-3a36-4636-9a34-f8be642f34e7" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company presents one continuous Statement of Operations and Comprehensive Loss. The Company&#x2019;s comprehensive loss includes unrealized gains and losses on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa69d44a-9ae0-4aba-b18c-e600a40784a3" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_fa69d44a-9ae0-4aba-b18c-e600a40784a3_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_fa69d44a-9ae0-4aba-b18c-e600a40784a3_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_659aff0b-70bf-4404-8053-3048ea53249c" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true" continuedAt="F_659aff0b-70bf-4404-8053-3048ea53249c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_659aff0b-70bf-4404-8053-3048ea53249c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff22f63b-54a1-4505-b530-09aa83d2c2ee" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_ff22f63b-54a1-4505-b530-09aa83d2c2ee_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_ff22f63b-54a1-4505-b530-09aa83d2c2ee_1"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_cd13f93a-4d6f-4a69-b4e2-9ce4f1f0e4f4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.</span></ix:continuation></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfb00e37-fe8c-4171-a2ee-5b0bfd48fcc2" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.963%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:93.037%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Quoted prices in Active Markets for identical assets or liabilities.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.963%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:93.037%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.963%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:93.037%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs that are supported by little or no market activity.</span></p></td>
     </tr>
    </table><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bcc016a-82fb-41b6-8ce6-d36ec90f2892" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table identifies the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.954%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:7.39%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:11.566%;"></td>
        <td style="width:0.661%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:10.905%;"></td>
        <td style="width:0.661%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:10.522%;"></td>
        <td style="width:1.079%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:9.06%;"></td>
        <td style="width:0.661%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross unrealized gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross unrealized losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dff97513-a830-4ea2-9853-3f446b9c6b6e" contextRef="C_a83a64a1-7741-4e16-9288-99ee9079606f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b885a6af-e387-474a-9622-eb8ab0d02f79" contextRef="C_a83a64a1-7741-4e16-9288-99ee9079606f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term investments - U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5268ed54-784e-4965-98c0-ffd442f80d0e" contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfd81ed8-b889-43e2-82cd-5b79d98f6a85" contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56518bb8-cbdc-4ee4-814a-dbba44d016c5" contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_805b03bd-93bc-45e3-8984-ec8614c802ad" contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,780</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84cc9a96-c096-422b-bf87-12117369f5d3" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="sbtx:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319,051</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4134c640-f90a-4158-aa6d-507fcab37b67" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd710ac-512c-4da2-9137-837217e14101" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2c52902-9d3f-4e25-bc57-a430f2e2a52f" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="sbtx:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318,725</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4b6e757-ee8a-4069-b529-e7c08b8875f5" contextRef="C_57a90811-c613-469c-93e9-bd4b4838cbe5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,369</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fcf4bd8-abef-44e0-b2d0-fdb67629020d" contextRef="C_57a90811-c613-469c-93e9-bd4b4838cbe5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,369</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebae4cff-5957-439c-8b0d-694905e98a6a" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d4071b70-f2f1-44d9-96d0-1003f5e6ad0f" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_73768fca-3f19-484e-be71-ccb85d76a978" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a74f1705-0dd3-487b-bef0-368d251c8127" contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s long-term investments portfolio contains investments in U.S. Treasury securities that have an effective maturity date that is more than one year, but less than two years, from the respective balance sheet date. The Company evaluated its investments for other-than-temporary impairment and considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. For the investments, it is not more-likely-than-not that the Company will be required to sell the investments, and the Company does not intend to do so prior to the recovery of the amortized cost basis.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e57d9e9-804a-47b2-a188-16bb4e5adb2b" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f292537-9b29-4adb-a622-1f3267d1fad4" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are summarized as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:ARIAL;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.849%;"></td>
        <td style="width:2.935%;"></td>
        <td style="width:1.682%;"></td>
        <td style="width:13.701%;"></td>
        <td style="width:1.114%;"></td>
        <td style="width:4.374%;"></td>
        <td style="width:1.682%;"></td>
        <td style="width:13.55%;"></td>
        <td style="width:1.114%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53e85eaa-1e04-4609-b105-632d3d444030" contextRef="C_95368c9c-2ef3-4cdf-bc71-1cff6b42577a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02339c44-83b8-496c-89c6-ebdec709c24b" contextRef="C_e77106ce-582d-481d-b3e4-30663c6abfa7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5514c1a-0057-4dce-84c1-3aecc947ccd2" contextRef="C_e1043a11-9233-4df8-b363-ce3a0f3f3bb8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59b41e04-8029-4b8c-a5fc-18fcc4e445c6" contextRef="C_d5d577b3-d7af-45d0-860e-6ec6922cad1b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c180519e-021b-4803-95b5-d3122747bd75" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b129087-3c88-4f38-bcc2-7c416075f1cb" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,670</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5586cc61-56b7-4c7b-9d8a-62190c423a44" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6603ca7a-06e7-4bc5-a5ae-2c56f9949cda" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,052</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c4f9c1e-fb57-4f5a-a2df-862ec84bfe15" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b678116-e627-4fe0-afbc-e2b528a50fe1" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f97f31b9-04bd-4b11-8b2f-1c698c9fcbb0" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0dec216-ff5b-4f8c-ab78-e0d95db80b65" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e20d39e9-d268-4a0f-8329-73bd18067fef" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc4fc332-5beb-4103-b7ce-dd261f5eda46" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.816%;"></td>
        <td style="width:1.949%;"></td>
        <td style="width:1.706%;"></td>
        <td style="width:12.671%;"></td>
        <td style="width:0.766%;"></td>
        <td style="width:1.949%;"></td>
        <td style="width:1.706%;"></td>
        <td style="width:12.671%;"></td>
        <td style="width:0.766%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8c54b4a-df09-42be-8a05-3233d8064242" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,528</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65cc88f3-70f2-4b45-a1e9-dbc8d6c55c6b" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="sbtx:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,063</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64eebbaf-afe9-4b04-b593-6e8a2468ef17" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,605</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_265d1b1d-7a28-4ea5-a760-806a87e71baa" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,634</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional services and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa27cd99-f4d6-4ee7-974a-b02d911162d6" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a756527b-cf45-49d4-a510-a8dc69330952" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1004d5e1-56f5-49af-82ea-2e84fab385d0" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,727</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a4faa53-0eff-4dcb-b8f1-68a8766a17ed" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6137da14-0ed4-4356-9995-9034fa452030" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1b57b57-156a-4082-89d9-ce6609d9a8ca" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.478%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:1.682%;"></td>
        <td style="width:14.049%;"></td>
        <td style="width:0.742%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:1.682%;"></td>
        <td style="width:13.561%;"></td>
        <td style="width:0.742%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_916e653d-542b-4a65-a3e8-e40e5676c4c6" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,452</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8c8b14d-e455-4433-a5a6-db90e9363c29" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,388</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57de1630-6345-4385-94c9-37925ea298ca" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">459</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9914a56c-9247-4866-926e-f7dd6be0e314" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d87456cd-8a5b-4ec9-a25b-11acebb193b6" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,911</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf04abcf-050c-4d1f-9366-738b9509fc6c" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,774</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash outflows from operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6546a9b5-ad6f-4887-adad-6eee94513c38" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,841</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4e38f96-4c49-444b-8a04-9bcc4c55e1a3" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a2fff31-99ba-4ee9-8280-a8ea1628da6c" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 1, 2021, the Company entered into a sublease agreement for additional office space in Seattle, Washington. The commencement date of the sublease was August 1, 2021. The contractual term of the sublease is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d34b6e5-8f39-4434-9fe6-021d328bb7ec" contextRef="C_2cc1fdc9-b760-4892-a859-13fea165b6d3" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bed4536e-0a33-4d12-a8ee-f0738da10379" contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e" name="us-gaap:LesseeOperatingSubleaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend for one additional year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a5b9918-d3ea-4b9a-8870-615c73aac65c" contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e" name="us-gaap:LesseeOperatingSubleaseOptionToTerminate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to terminate after one year subject to a termination fee</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The annual minimum rent payable by the Company under the sublease is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dad8c312-6599-444d-82d2-9c10418ae64d" contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e" name="us-gaap:OperatingLeasesRentExpenseMinimumRentals" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million annually. The ROU asset obtained in exchange for the new operating lease liability was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a257a926-9699-4fcc-84e4-c56c142fc027" contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of the lease commencement date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining term on the Company's leases was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49637932-0b6a-4e99-a9d7-b9955a749e6a" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fec9d82b-4e65-4577-a0cf-c9dc77814168" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years as of December 31, 2021 and 2020, respectively. To compute the present value of the lease liabilities, the Company used weighted average discount rates of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07d37d58-6d3c-417f-a6be-0f9d6b158301" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d0a1e86-e139-4c7a-82c5-e80274fd4aa3" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% as of December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, there was a change in the expected lease term of the Company&#x2019;s Seattle, Washington headquarters, whereby the Company became reasonably certain that it will not exercise its option to terminate the lease. As a result, the ROU asset and lease liability were remeasured using the present value of the remaining lease payments. The re-measurement resulted in an addition to the ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dcd74fe-0a30-4c73-95b0-f3c97ee6d57b" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The change in the expected lease term has no effect on the classification of the lease.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc482d51-2270-4386-b29c-69b4aa4ba95a" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum commitments due under the operating lease agreements as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.706%;"></td>
        <td style="width:1.654%;"></td>
        <td style="width:2.974%;"></td>
        <td style="width:17.677%;"></td>
        <td style="width:1.989%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04c101c7-ade9-4829-8b4b-c89b874f7448" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59bb17ce-2d8c-4d5f-8154-689ed7edfced" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,513</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64178ec4-fd1d-42c2-a415-4f0ad85a94c6" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_012798ef-8e1d-494a-8937-3abedfccaf97" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8187fe4-2540-4466-bdbd-925b003c7eae" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fcaa204c-b577-4c5d-bb7b-bb57ff32af17" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f209218f-63c4-4145-99fd-b96867bdf29f" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,070</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total present value of lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c506fef-1c77-426f-8119-188deff4f2c8" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17932d14-b9e1-4c48-abb7-7ac9b4c3706b" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_17932d14-b9e1-4c48-abb7-7ac9b4c3706b_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Term Loan Payable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (&#x201c;SVB&#x201d;) and borrowed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3836bdfb-bbcf-402c-9c31-d92ca31e0431" contextRef="C_ee566949-7a9b-49b6-abae-885b6d7b031f" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a term loan. The outstanding principal amount of the term loan accrued interest at an annual rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6df9707c-a70c-4ffa-bdb2-b799f96f0cab" contextRef="C_ee566949-7a9b-49b6-abae-885b6d7b031f" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. At closing, the Company incurred de minimis debt issuance costs and owed a final payment fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ba799ff-51c1-4a6a-b93f-75e6b4b29cf5" contextRef="C_12ca2440-8311-4748-a39b-7117c1ed0a1c" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate of the Company&#x2019;s term loan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c5def97-6a9c-4cd1-b103-1be3870dd242" contextRef="C_3839233e-c975-49e1-a075-fef15f80e6d8" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.14</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term loan&#x2019;s original maturity date was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67257117-3659-4779-8a9a-a197484d2411" contextRef="C_12ca2440-8311-4748-a39b-7117c1ed0a1c" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. However, in April 2020, the Company amended the loan and security agreement to defer principal payments for six months and extend the maturity date to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17737762-04a3-4efe-94f3-f855cac4a4fe" contextRef="C_b7066a98-3245-4333-b828-b75b16bd6d9b" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification and amortized the remaining debt discount over the remaining term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_17932d14-b9e1-4c48-abb7-7ac9b4c3706b_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On May 1, 2021, the Company made its final scheduled payment to SVB under the loan and security agreement including the final payment fee.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_212ca7b7-da81-4c8e-83b5-7152a17e158a" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Authorized Shares</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s current Amended and Restated Certificate of Incorporation authorizes </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e68e606-73c2-4ebc-87c1-2d9a1cae57b8" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c76b1335-587a-4ccd-a570-da95e862f948" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06b4b588-dc52-4754-a7aa-0394ec8fc84b" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2a1f7a5-3835-4865-a3c9-ff0ebaab4384" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to its conversion to common stock in December 2020, the Company&#x2019;s redeemable convertible preferred stock was classified as mezzanine equity on the Company&#x2019;s balance sheets as the shares are contingently redeemable upon a deemed liquidation such as a change in control and in that event, there is no guarantee that all stockholders would be entitled to receive the same form of consideration. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36877a87-6261-405b-ab9b-7e3cb36af4c8" contextRef="C_13e17b88-9a3e-4334-afaa-25c79b7864bb" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accretion to redemption value was recorded during the year ended December 31, 2020 as a deemed liquidation event was not considered probable.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company issued convertible preferred stock as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2ed3858-086d-4acf-bcbe-e44f5a3fe34e" contextRef="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4" name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,701,054</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series B redeemable convertible preferred stock, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69a6f759-e250-4174-9707-5e094e99797d" contextRef="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4" name="sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,673,388</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued upon conversion of then outstanding convertible notes and accrued interest, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f842da5d-7472-40c0-b2ac-af263bc7d238" contextRef="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4" name="sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,027,666</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_040053b7-df54-4411-979c-d7efe0fcec8b" contextRef="C_a51e457e-525d-410b-a470-5e6bf9556468" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">2.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dde81a71-71f0-4987-86ad-aa3e19025235" contextRef="C_babe8ce4-149b-4c33-b021-b0e162ec46a0" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Series B purchase agreement provided that the Company would issue, and the Series B holders would purchase, an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_844d55a0-2c66-48fb-a86c-60a2ea5c3cdd" contextRef="C_3d3afa03-0c39-46e2-aac4-cf6089a8b67d" name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,732,862</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad25927c-c22a-4c57-a2f5-673010578736" contextRef="C_3d3afa03-0c39-46e2-aac4-cf6089a8b67d" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">46.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the event that certain agreed upon milestones were achieved or the preferred majority approved their closing. The Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 1, 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0264d041-9fd9-44cd-b55c-e6aa0583632f" contextRef="C_f23b5346-4ed5-45a9-a974-16fe675333f0" name="sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,669,834</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe0f9565-c647-495e-bfc0-12622c64d91c" contextRef="C_e29ac877-2d55-4d24-814b-9d73b1312fe1" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">2.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_211acc7f-89fd-4369-861d-8c8996631157" contextRef="C_f23b5346-4ed5-45a9-a974-16fe675333f0" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04c3221b-108b-4edb-994d-2c23bc618da0" contextRef="C_c706ed5d-e2ad-40ca-806a-0467398698b8" name="sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,063,028</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e71bc89c-1677-44df-9b76-458b64416d68" contextRef="C_6eefba5e-4e7c-4fd7-92ec-5996101fb022" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.16</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_435b9f04-3f5b-4e3a-8d9b-df17854907e7" contextRef="C_c706ed5d-e2ad-40ca-806a-0467398698b8" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2042e124-6411-407a-a72b-f2700abb841a" contextRef="C_1f92b4f8-fdec-497d-8f93-b488d3246949" name="sbtx:IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">24,926,685</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series C redeemable convertible preferred stock for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0956f3f7-63ec-40bf-80c1-6592dc242152" contextRef="C_f6d7fae1-66f6-4760-b28a-988192f19155" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.41</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc5cacf0-5d08-4770-99a4-fb4ffe90703d" contextRef="C_1f92b4f8-fdec-497d-8f93-b488d3246949" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">84.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Series C purchase agreement did not contain any embedded features that meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d98240ea-b0cf-4ee6-96d0-a6ba475d15e0" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved shares of common stock for the following potential future issuances:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.528%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:14.279%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:14.279%;"></td>
        <td style="width:0.963%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying outstanding equity awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe8176b4-a0fa-4778-9940-47c9f5ec33de" contextRef="C_71b567b9-dd67-488e-9bff-940240379336" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,370,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_661d1864-340c-4770-89f9-fc4972f584a1" contextRef="C_a05456f3-88fe-43ff-b244-8a5ee75b83e1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,316,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future equity award grants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43189cdd-65ac-4f5c-a835-1df3058ba815" contextRef="C_443c7d79-857f-4272-94c9-734cc7988aea" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,931,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_746c7230-4980-430e-9fff-586fd56f9a4b" contextRef="C_b1bdc0b1-781e-4d6a-9638-314ec56b0e99" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,506,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying early exercised equity awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87f6d99e-0b6d-4a51-a545-478aba4090b0" contextRef="C_67cef16b-8904-4ef1-a280-f5782cc3332b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,283</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3835a575-7e49-45a2-9200-df5fe4deef2a" contextRef="C_2765e183-1081-430a-a0a8-58ce32c0c954" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">100,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying ESPP withholdings</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56a2f2e5-fc92-40bb-9209-e0d6017fc50e" contextRef="C_14436cef-6d24-48bf-b8b6-de5a96e7c9a6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86351fa2-4478-4f52-ab16-b11877ded921" contextRef="C_954e4039-8ad8-4dde-9cc7-9b313b208185" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98530b85-cde1-4a6f-a610-5755357c2bd5" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,328,168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61b46557-202f-42de-a6e4-85f93844ecb1" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,928,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_3ecbe504-2214-4029-9993-5862cd432ce0" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1aa1267-e255-46b6-8efa-786074f855a1" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.777%;"></td>
        <td style="width:1.577%;"></td>
        <td style="width:1.433%;"></td>
        <td style="width:13.524%;"></td>
        <td style="width:0.649%;"></td>
        <td style="width:1.577%;"></td>
        <td style="width:1.433%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:0.649%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cf18680-ff20-4a61-9063-22195e8131d8" contextRef="C_1d8d0169-89f0-4155-948a-25ed3e8d9d13" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_493d325f-6a7d-4083-a2c8-64f7f0e35728" contextRef="C_37ebbd60-fda0-4900-9609-d33c5ffa0fd1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2404a0ca-5a4b-4107-9c2f-4f607fae12c0" contextRef="C_9fe4ab25-1247-4234-81ff-cc9c1674c66c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,856</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6516818-6561-400e-9789-927e4d8326c6" contextRef="C_3eec66cf-b934-4764-b8db-f29c238527a9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8183d13f-4dca-42e0-87c3-dda1b9461611" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10439835-b13d-4af3-aea1-56cfb3b9c597" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the total unrecognized stock-based compensation expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70d0ab66-9c56-4ccb-9a63-d8d7dda1b56d" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_142dfc7f-ecb0-4217-8390-a627cad88d7a" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.49</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company&#x2019;s equity incentive plans authorized a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c519572-aa4a-46c0-84b3-28a068eec9ee" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,564,798</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6fecaa3-037d-4363-96fa-7016ecb68eb0" contextRef="C_860dbe58-a733-4b54-b5e8-6248758d43eb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,931,012</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are available for future grant, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be2483c4-874d-42c1-84ce-11f096ef84bb" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,370,873</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are outstanding. Not included in the outstanding option balance are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06262e43-cced-4018-890b-ef8671899860" contextRef="C_10924f8e-1bb8-4859-a19f-53e9eeda573c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,283</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares pursuant to stock options that were early exercised and subject to repurchase that remain unvested as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options granted under the Company&#x2019;s equity incentive plans expire no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54070967-7d3e-4ffb-8a9e-7c1a63fe490f" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years from the date of grant and generally vest over a four year period, with vesting either occurring at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8be2871e-f48a-45f4-a0bd-f5d860a0158a" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% at the end of the first and thereafter in 36 equal monthly installments or on a monthly basis. In the case of awards granted to our non-employee board members, vesting generally occurs on a monthly basis over three years or in full on an annual basis. The Company issues new shares of common stock upon the exercise of stock options.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_beeef8bc-fe3a-4374-b1f1-8818e72fabf4" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#x2019;s stock option activity for the year ended December 31, 2021 is as follows (in thousands, except share and per share data and years):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.416%;"></td>
        <td style="width:1.033%;"></td>
        <td style="width:0.859%;"></td>
        <td style="width:11.312%;"></td>
        <td style="width:1.079%;"></td>
        <td style="width:1.033%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:9.99%;"></td>
        <td style="width:0.661%;"></td>
        <td style="width:1.033%;"></td>
        <td style="width:0.847%;"></td>
        <td style="width:11.301%;"></td>
        <td style="width:0.661%;"></td>
        <td style="width:1.033%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:11.858%;"></td>
        <td style="width:0.661%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stock Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares<br />Subject to<br />Options<br />Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a04d84e-c156-4355-bb10-ef64a43af662" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,316,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2aed5245-36a2-4409-b51e-dba599b85600" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fe38976-fc43-453e-b875-6dfd5fe3dbb9" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">511,773</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e40cef18-a72b-44a4-bd03-26e5d26244aa" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">261,567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c715566-e854-4064-8079-dac8862e2a5a" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:StockIssuedDuringPeriodSharesStockOptionsCancelled" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">195,902</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c68fa4b1-c474-493d-91e0-01fe4513c5ef" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,370,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fc24b2f-a810-48bd-8077-92dca4f06bf4" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39a8393d-085d-40a5-9b12-a7692bf6cb27" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.58</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5042577e-0961-4595-b3e7-d884e2a8cedd" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,385,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b1812bd-b5a3-42e0-b4a0-ca9b39d377d0" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,974,776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_914095e7-7bd8-43a2-8133-f3a9090a2881" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c0c0956-5331-4847-bca8-b781929b9501" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.14</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e5daed9-b4d7-4128-ab7c-4fea73f98871" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,887,808</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#x2019;s common stock for all options that were in-the-money at December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e79d4196-486e-49dc-866d-cf4e08ce1bd8" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea935df9-9cf0-44e1-9aa5-ad9475ae37f0" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value per share of option grants for the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a58378f4-5655-4273-bb7b-94b54a2a89a0" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">22.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d001c7ea-3cc1-49cd-8a6f-22e42e58f673" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.  The total fair value of shares vested during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c127b22-1f26-4c0a-acbe-eb85d7d34958" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05423998-051c-4809-a630-9ee59d948eff" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_492a035a-9897-4037-952e-c3b973f929a9" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.272%;"></td>
        <td style="width:1.412%;"></td>
        <td style="width:1.078%;"></td>
        <td style="width:13.638%;"></td>
        <td style="width:4.942%;"></td>
        <td style="width:1.078%;"></td>
        <td style="width:13.638%;"></td>
        <td style="width:4.942%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5c153b7-b845-4577-8eff-c97d45aedf52" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_355775ef-0706-4894-a81e-3a165ad3412e" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55158488-d417-47a9-9c5b-873f09d238c5" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cd7f652-f125-4008-a5bb-528c19837f0b" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c90aa162-f0c5-4385-87ce-0f9658f8d2db" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.98</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9439153f-11d6-466f-a007-3e54d8af11ba" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_039a79be-8189-4a87-8f0c-adb18cf6c709" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e749fd51-9281-4b0b-9539-dc7336dfd7a3" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:0.982%;"></td>
      <td style="width:93.036%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Prior to the Company's initial public offering in 2020, the grant date fair market value of the shares of common stock underlying stock options was determined by the Company&#x2019;s board of directors. Following the closing of the Company&#x2019;s IPO, the fair market value of the Company's common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#x2019;s common stock is traded. Prior to the Company&#x2019;s IPO, because there was no public market for the Company&#x2019;s common stock, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included contemporaneous valuations performed by an independent third-party, the Company&#x2019;s results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#x2019;s business, progress of the Company&#x2019;s research and development activities, the Company&#x2019;s business conditions and projections, the lack of marketability of the Company&#x2019;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#x2019;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key personnel and the experience of management, trends and developments in the Company&#x2019;s industry and external market conditions affecting the life sciences and biotechnology industry sectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:0.982%;"></td>
      <td style="width:93.036%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:0.982%;"></td>
      <td style="width:93.036%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Given the Company&#x2019;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:0.982%;"></td>
      <td style="width:93.036%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"></td>
      <td style="width:1.0%;"></td>
      <td style="width:0.982%;"></td>
      <td style="width:93.036%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero.</span></p></td>
     </tr>
    </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_113ded34-14d8-47f2-a98d-22e82a4f0fb6" contextRef="C_4e9ffb89-6ff5-4676-b044-c5c124536efd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company&#x2019;s board of directors and stockholders approved and adopted the 2020 ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1218d60d-5054-41af-ad6b-7273e0508d3a" contextRef="C_4e9ffb89-6ff5-4676-b044-c5c124536efd" name="sbtx:EligibleEarnings" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ca38fa2-f3f7-4f80-b5ee-ebc06abc741e" contextRef="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3" name="sbtx:SharesWereReservedUnderTheEspp" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">698,015</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were reserved under the ESPP, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_277556c6-4e6f-422c-a0d4-16e3bcee424b" contextRef="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">627,185</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are available for future issuance and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11667b3b-b11c-45ad-9807-6025f9252b31" contextRef="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">70,830</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued. The weighted average per share fair value rights granted during the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce4c2216-78e7-4ab5-bd00-a7c2a8e06fa1" contextRef="C_d7fa8844-58a6-4654-9ddd-9b5375a9b363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79d5321f-f7a3-430b-ac8e-20ec91ca4fc0" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_79d5321f-f7a3-430b-ac8e-20ec91ca4fc0_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_79d5321f-f7a3-430b-ac8e-20ec91ca4fc0_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.489%;"></td>
        <td style="width:11.076%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:13.51%;"></td>
        <td style="width:4.906%;"></td>
        <td style="width:1.301%;"></td>
        <td style="width:13.51%;"></td>
        <td style="width:4.906%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d611f63-e449-42a2-aedd-886bc43b33b7" contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59138ce0-27e6-40c3-a4fa-18e183c128cc" contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0993e13c-bc5b-47b3-b0ef-8b300df86e8d" contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_520c3ac7-737e-4a7c-9a95-36be215796bd" contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c61c01be-e1a7-443a-9ea2-3aa21d4febf1" contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa124862-63a2-4801-b0c9-10957e3c093d" contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bdf5f77-2dc8-42f0-bb46-1ad686940b30" contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab0bb71f-f09e-4dfe-828f-cb7fb75f47ea" contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c114b9a0-f082-402e-a653-ca4879b36458" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Income Taxes</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_698a692b-218b-40dc-8b92-f747f359aa71" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s effective tax rates for the years ended December 31, 2021 and 2020 differ from the U.S. federal statutory rate as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.649%;"></td>
        <td style="width:4.467%;"></td>
        <td style="width:1.682%;"></td>
        <td style="width:13.888%;"></td>
        <td style="width:1.114%;"></td>
        <td style="width:3.84%;"></td>
        <td style="width:1.682%;"></td>
        <td style="width:13.563%;"></td>
        <td style="width:1.114%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax at the federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af1d90a5-51d9-4b4d-aa3a-cd007366a403" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">18,790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7bc668a1-71da-4e0e-96fe-1f97d3bd4760" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Benefit from R&amp;D tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4dee961-7fbd-4bbe-90ba-2aa777240435" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:BenefitFromRDTaxCredits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8787bea0-873c-4b7d-9918-573c933a5f0a" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:BenefitFromRDTaxCredits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2338f6bb-5e22-4e54-b5cb-94974a9a1289" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_139f19ca-2803-4a30-a2f5-5f7852308400" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible executive compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ec2ae38-bf2b-4239-9035-3f03a4f0c4f9" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_640654ea-aefa-42d5-a779-3cd53efe50f3" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other temporary and permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b26266b-e1da-44cf-8152-ad1e4691ce00" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:OtherTemporaryAndPermanentDifferences" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f6fcdd2-c9ac-4d3c-b37a-3f0afcd9b37f" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="sbtx:OtherTemporaryAndPermanentDifferences" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0d306ba-170f-47b3-b16b-3dcf3f392ba9" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bacdcad-6ed4-415d-a1eb-f4dd0c4d1bb4" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_850b4d0f-f642-4e0f-95e4-ded8a347a6ba" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9addd2da-ae02-4b66-a8c4-5de911700e89" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3ab0677-45e4-44e7-aed7-e2c9ebbfbb2c" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.348%;"></td>
        <td style="width:2.494%;"></td>
        <td style="width:1.671%;"></td>
        <td style="width:13.527%;"></td>
        <td style="width:1.114%;"></td>
        <td style="width:4.536%;"></td>
        <td style="width:1.671%;"></td>
        <td style="width:13.527%;"></td>
        <td style="width:1.114%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcc23dd9-c528-4546-8b25-8d9fb1f5516c" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_542a0a05-4bad-4041-ad73-53dc19ff5e07" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ed1ab96-740e-498b-b767-7bfe8d2841b9" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75e34d01-17c5-42b4-82e8-5874cd1fc77c" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="sbtx:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D tax credit carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bedbb2dd-2a66-4441-965c-829f3edc854f" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:RDTaxCreditCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,746</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39d9f168-71c9-4d1c-bf77-35a88aa47b37" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="sbtx:RDTaxCreditCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb052f3d-0755-40ac-a7c2-5842aa189793" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f93173ac-e3cd-4142-9e55-e472eac3738d" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_973e624a-2a10-4087-bbc3-6ff4e42dec28" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">237</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_291e9da4-9685-4b8c-a48b-76394d2ace37" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1edb9f5-33e6-4472-8790-b57eafe7f412" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b081685-04c9-40e3-a26d-46f66bfdaa94" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities - Right of use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdc98f4d-e2d1-4d41-9f33-3e332279af5b" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b4708ec-41eb-4d5c-9468-a589eb6ac775" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">458</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9973c3f-65bb-4fc5-8527-f2427ce13d6f" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,039</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc9cd764-8a95-42b3-9c3c-8a97f40fb1d7" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,889</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b7e66bd-f768-4d94-8b25-767078b62776" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4758271c-15a9-4716-a617-fa378679aa52" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, the Company had net operating loss carryforwards for income tax purposes of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2e65472-5134-41aa-80c8-423ecce5fc64" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">160.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. If not used, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf5917b9-4c95-4487-ac87-1e251dd9b0c8" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:OperatingLossCarryforwardsAmountToExpireIfNotUsed" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of this carryforward will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0214c16-4cd7-4c40-ab47-5a8ba2ed1740" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dfdac86-7578-48c8-81e8-98b503ace1f4" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="sbtx:OperatingLossCarryforwardsAmountNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">142.1</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has no expiration. At December 31, 2021, the Company also had research and development tax credits of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0bbee95c-7389-43d5-bc41-70e334809776" contextRef="C_7ec30bfe-5f48-45a5-b118-07bc27b0ff78" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4134c31-bc3e-4aaa-a6a2-a2a8f6e35fd8" contextRef="C_415738ce-5fb5-4ca7-93ff-db3c98f51fea" name="sbtx:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> if left unused. The Company did not have any foreign tax provision and did not generate material net operating losses in any states with an income tax.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FASB ASC 740 requires that the tax benefit of net operating losses, temporary differences, and credit carryforwards be recorded as an asset to the extent that management assesses the realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits from the net operating losses or credit carryforwards, if any, is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the applicable carryforward period. Because of the Company&#x2019;s recent history of operating losses, the Company maintains a full valuation allowance in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97c9025e-adc0-4a48-a73b-b1c4aad00beb" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ea35365-8506-4841-a6f7-3911b60679b7" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.9</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may have already experienced one or more ownership changes. Depending on the timing of any future utilization of its carryforwards, the Company may be limited as to the amount that can be utilized each year as a result of such previous ownership changes. However, the Company does not believe such limitations will cause its carryforwards to expire unutilized.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future changes in the Company&#x2019;s stock ownership as well as other changes that may be outside the Company&#x2019;s control could potentially result in further limitations on the Company&#x2019;s ability to utilize its net operating loss and tax credit carryforwards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a28482e2-082f-4f33-a7e1-eefa64af9425" contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_51acb122-add4-4f0e-87a4-199433ee6cbf" contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any liabilities for unrecognized income tax benefits associated with uncertain tax positions, including any interest and penalties.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1300f816-5a53-49c2-9e70-3f389c769bcf" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="sbtx:LicensingAgreementTextBlock" escape="true" continuedAt="F_1300f816-5a53-49c2-9e70-3f389c769bcf_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Licensing Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Bio&#x201d;). Under the license agreement, WuXi Bio granted the Company a non-exclusive, worldwide, sublicensable, under certain of WuXi Bio&#x2019;s intellectual property rights, know-how and biological materials (&#x201c;WuXi Bio Licensed Technology&#x201d;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#x201c;WuXi Bio Licensed Product&#x201d;). The WuXi Bio Licensed Technology is currently used to manufacture a component of the Company&#x2019;s ImmunoTAC platform. The Company has paid an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3ee64bc-f56d-40fe-8786-2658e35dff92" contextRef="C_c917bb6b-c19f-402a-a7f9-3796e47702e8" name="sbtx:LicenseFeesPaid" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in license fees that were recorded in research and development expense when incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f276341c-3522-4cff-9517-3221aaa28f4a" contextRef="C_f1589284-886e-47d9-8e01-e13b1c2af513" name="sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_1300f816-5a53-49c2-9e70-3f389c769bcf_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them through the termination date. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8751bc03-0c30-4cc6-bb13-3397f7cff03b" contextRef="C_f1589284-886e-47d9-8e01-e13b1c2af513" name="sbtx:AgreementPaymentAndLicenseTermDesciption"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party may terminate the license immediately upon written notice to the other party.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b51cb2d-aca3-46b7-a60c-3797f0f47580" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_5b51cb2d-aca3-46b7-a60c-3797f0f47580_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 5, 2021, a securities class action complaint was filed against the Company and certain of the Company's officers and directors in the U.S. District for the Western District of Washington, captioned Dresner v. Silverback Therapeutics, Inc., et al., Case No. 2:21-cv-01499.  The complaint alleges that between December 3, 2020 and September 10, 2021, the Company and certain of the Company's officers and directors violated (1) Sections 11 and 15 of the Securities Act of 1933, as amended; and (2) Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission (&#x201c;SEC&#x201d;) Rule 10b-5 promulgated thereunder, by making allegedly false and misleading statements in various SEC filings and press releases regarding the clinical and commercial prospects of the Company&#x2019;s product candidate, SBT6050, which is now discontinued.  The complaint seeks unspecified damages and interest, as well as attorneys&#x2019; fees and other costs. The court recently appointed lead plaintiff and lead plaintiff's counsel. The Company and the other defendants have not yet filed a response to the complaint, and do not anticipate doing so until after the filing of an amended complaint.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company cannot predict the outcome of this suit, and failure by the Company to obtain a favorable resolution could have a material adverse effect on its business, results of operations and financial condition. The Company&#x2019;s chances of success on the merits are still uncertain and any possible loss or range of loss cannot be reasonably estimated and as such the Company has not recorded a liability as of December 31, 2021.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions or related to any indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global COVID-19 pandemic continues to rapidly evolve, and management continue to monitor the situation closely. The extent of the impact of COVID-19 on the Company&#x2019;s business, operations, planned preclinical studies and clinical trials, and manufacturing timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#x2019;s CROs, third-party manufacturers, supply chains necessary for research and development and manufacturing, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the Company&#x2019;s key scientific and management personnel. For example, the COVID-19 pandemic has caused the cost of obtaining animals for our preclinical studies to increase dramatically and, if the shortage continues, could also result in delays to our development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_5b51cb2d-aca3-46b7-a60c-3797f0f47580_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and some of the Company&#x2019;s non-lab based employees working remotely. Management will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter Company operations, including those that may be required by federal, state or local authorities, or that management determines are in the best interests of the Company&#x2019;s employees and other third parties with whom the Company does business. At this point, the extent to which the COVID-19 pandemic may further affect the Company&#x2019;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b379e1a0-ab75-453b-bf51-17199e14f747" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true" continuedAt="F_b379e1a0-ab75-453b-bf51-17199e14f747_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Employee Benefit Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_b379e1a0-ab75-453b-bf51-17199e14f747_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#x2019;s U.S. employees. The plan allows eligible employees to defer, at the employee&#x2019;s discretion, pretax compensation up to the IRS annual limits. The Company did not match contributions made by employees through December 31, 2021. The Company began matching </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18d5bf47-2518-462d-be95-c523fa527941" contextRef="C_8cf07191-8e06-40b3-853c-f995a1f625ad" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of employee contributions in 2022.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c7f2c83-2537-45cd-8961-098000300d11" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e26b493-bb39-4d85-b4b6-13f12ed40ddd" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.997%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:0.809%;"></td>
        <td style="width:17.292%;"></td>
        <td style="width:0.809%;"></td>
        <td style="width:1.591%;"></td>
        <td style="width:0.809%;"></td>
        <td style="width:17.292%;"></td>
        <td style="width:0.809%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9cc0e816-6a56-48c9-a205-cc42ff5a5bcf" contextRef="C_032f1a5d-9136-4a8d-bfd5-8652354d9726" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,370,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0de2ba4e-ab53-4c40-aa90-6c8692a75d4e" contextRef="C_a6798eb1-f0de-4695-9641-5ea592a32344" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,316,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7d14940-1ed1-40c3-ba88-5b52b95ebd03" contextRef="C_10924f8e-1bb8-4859-a19f-53e9eeda573c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,283</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55a5759a-ff95-4481-8b4d-c87968e6c938" contextRef="C_14dc9fe4-584f-4c31-87a5-09ff8302a12e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">100,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ESPP withholdings</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d165f6d9-fb9c-4ee4-b510-7e81de9b7e87" contextRef="C_5733b7d9-e5ce-4ff8-9092-59c9faf284e9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3dd47e5e-3153-45f9-89bb-6f1eca2e9fbb" contextRef="C_f1306218-ebfe-4f46-b53a-08722ba81bc1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total potentially dilutive shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae179e9a-f0c3-43b0-8c12-b775f9967858" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,397,156</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42822c2d-24a3-4fac-a7ec-a8c1f8695fc2" contextRef="C_ea504935-5339-4904-9013-2798d8f23b79" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,421,225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4868e1e9-b9f8-4745-b941-38e3253c7787" contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to December 31, 2021 through March 31, 2022, the Company&#x2019;s board of directors approved the grant of options to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a621f524-168a-4459-9bda-ebcd2370c213" contextRef="C_4dcf4afe-a66f-4353-a22e-83f64aa9613d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,815,926</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6613147-1447-4e8a-8741-dd4d54631ae5" contextRef="C_cfaeded9-f33c-4994-a098-63eb660e83ee" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The unrecognized stock-based compensation expense for these grants is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37686382-43fe-49d5-8c45-65bec887e47b" contextRef="C_cfaeded9-f33c-4994-a098-63eb660e83ee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Additionally, the Company&#x2019;s board of directors approved the grant of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bde0c80a-79c7-44be-9c74-8a2a9ddc4e5c" contextRef="C_60f52c8b-32d5-4e85-b1f0-31ec9fab4c12" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266,744</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> restricted stock units. The unrecognized stock-based compensation expense for these awards is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b280db1f-ca6f-438d-91b9-3c7be56e9d47" contextRef="C_cfaeded9-f33c-4994-a098-63eb660e83ee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, the Company&#x2019;s board of directors approved a corporate restructuring plan to discontinue the Company&#x2019;s clinical development programs for SBT6050 and SBT6290 and to prioritize resources on the development of SBT8230 and early-stage discovery programs (the &#x201c;Restructuring Plan&#x201d;). In connection with the Restructuring Plan, the Company&#x2019;s workforce will be reduced by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3c36a57-6b75-4a1c-a82b-805d050c59bf" contextRef="C_45c71f8d-3cda-45b7-9581-ba0f5e84dd52" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">27</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, with substantially all of the reduction in personnel expected to be completed by </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57e1a2c3-3f2e-4687-acce-97edfb9889c4" contextRef="C_45c71f8d-3cda-45b7-9581-ba0f5e84dd52" name="sbtx:RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 15, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company initiated the reduction in force on March 31, 2022 and expects to provide severance payments, continuation of group health insurance coverage, and other benefits for a specified period to the affected employees. The Company currently estimates that it will incur costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_132e7b8c-dcde-418b-b7a0-d06c65b12eee" contextRef="C_0b97d231-61a7-4be6-94e9-44926c823685" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for termination benefits related to the Restructuring Plan, all of which will be cash expenditures paid in 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term &#x201c;disclosure controls and procedures&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, our board of directors approved a corporate restructuring plan to discontinue our clinical development programs for SBT6050 and SBT6290 and to prioritize resources on the development of SBT8230 and early-stage discovery programs (the Restructuring Plan). In connection with the Restructuring Plan, our workforce will be reduced by 27%, with substantially all of the reduction in personnel expected to be completed by July 15, 2022. We initiated the reduction in force on March 31, 2022 and expect to provide severance payments, continuation of group health insurance coverage, and other benefits for a specified period to the affected employees. We currently estimate that we will incur costs of approximately $2.0 million for termination benefits related to the Restructuring Plan, all of which will be cash expenditures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9c"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 9C. Disclosure regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item and not set forth below will be set forth in the sections headed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Election of Directors </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Executive Officers </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in our definitive Proxy Statement to be filed with the Commission within 120 days after the conclusion of our year ended December 31, 2021 (the Proxy Statement) pursuant to General Instructions G(3) of Form 10-K and is incorporated herein by reference.</span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Business Conduct and Ethics that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. A current copy of the Code of Business Conduct and Ethics is available on the Corporate Governance section of our website at www.silverbacktx.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executive Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item will be set forth in our Proxy Statement in the sections headed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Executive Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary Compensation Table for Fiscal 2021 and 2020 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in our Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item12"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be set forth in the sections headed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Security Ownership of Certain Beneficial Owners and Management, Executive Compensation, and Non-Employee Director Compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in our Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be set forth in the sections headed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain Related-Person Transactions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Information Regarding the Board of Directors and Corporate Governance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in our Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accountant Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be set forth in the sections headed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ratification of Selection of Independent Registered Public Accounting Firm </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contained in our Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits, Financial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Documents filed as part of this report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following financial statements of Silverback Therapeutics, Inc., together with the report of Ernst &amp; Young LLP, an independent registered public accounting firm, required to be filed pursuant to Part II, Item 8 of this Annual Report on Form 10-K are included on the following pages:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#audit_opinion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balancesheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statementofoperations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#sose"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_statements_of_cash_flow"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Statement Schedules.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">List of exhibits required by Item 601 of Regulation S-K</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  See part (b) below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(b)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.222%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:87.778%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant&#x2019;s Current Report on Form 8-K, filed with the SEC on December 8, 2020).</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant&#x2019;s Current Report on Form 8-K, filed with the SEC on December 8, 2020).</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reference is made to </span><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit 3.1</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">3.2</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520304858/d67046dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Common Stock Certificate of the registrant (incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 30, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Investors&#x2019; Rights Agreement, by and between the registrant and certain of its stockholders, dated September 22, 2020 (incorporated by reference to Exhibit 4.2 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312521098283/d109083dex46.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Registrant&#x2019;s Common Stock (incorporated by reference to Exhibit 4.6 to the registrant&#x2019;s Annual Report on Form 10-K, filed with the SEC on March 29, 2021).</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnity Agreement, by and between the registrant and its directors and officers (incorporated by reference to Exhibit 10.1 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:24.5pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. 2016 Equity Incentive Plan, as amended, and Forms of Option Agreement, Notice of Exercise, Notice of Early Exercise, Restricted Stock Grant Notice and Restricted Stock Award Agreement thereunder (incorporated by reference to Exhibit 10.2 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520304858/d67046dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. 2020 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 10.3 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 30, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520304858/d67046dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 30, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5+&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement, by and between the registrant and Laura Shawver, Ph.D., dated March 6, 2020, as amended (incorporated by reference to Exhibit 10.5 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.222%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:87.778%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6+&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement, by and between the registrant and Valerie Odegard, Ph.D., dated July 23, 2016 (incorporated by reference to Exhibit 10.6 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7+&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement, by and between the registrant and Naomi Hunder, M.D., dated December 22, 2018 (incorporated by reference to Exhibit 10.7 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8+&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter Agreement, by and between the registrant and Jonathan Piazza, dated November 3, 2020 (incorporated by reference to Exhibit 10.8 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease, by and between the registrant and BMR-500 Fairview Avenue LLC, dated June 8, 2016 (incorporated by reference to Exhibit 10.9 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10*&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated October 11, 2019 (incorporated by reference to Exhibit 10.12 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. 2020 Change in Control and Severance Benefit Plan (incorporated by reference to Exhibit 10.14 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 10, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312520304858/d67046dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.15 to the registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-250009), as amended, filed with the SEC on November 30, 2020).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000119312521098283/d109083dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated January 12, 2021 (incorporated by reference to Exhibit 10.16 to the registrant&#x2019;s Annual Report on Form 10-K, filed with the SEC on March 29, 2021).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14&#165;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1671858/000095017021004106/sbtx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sublease Agreement, by and between the registrant and Delta Dental of Washington, dated July 1, 2021 (incorporated by reference to Exhibit 10.1 to the registrant's Quarterly Report on Form 10-Q, filed with the SEC on November 10, 2021.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sbtx-ex10_15.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Silverback Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sbtx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney (see signature page).</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sbtx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sbtx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="sbtx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+        Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#165;        Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*        Certain portions of this exhibit are omitted because they are not material and would likely cause competitive harm to the registrant if disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">**      Certain information in this exhibit is omitted because it is both not material and is the type that the registrant treats as private or confidential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item16"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ATURES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:41.462%;"></td>
    <td style="width:6.456%;"></td>
    <td style="width:6.029%;"></td>
    <td style="width:46.053%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SILVERBACK THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Laura Shawver, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laura Shawver, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Laura Shawver and Jonathan Piazza, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Laura Shawver, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laura Shawver, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jonathan Piazza</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jonathan Piazza</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Russ Hawkinson</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Senior Vice President of Finance</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Russ Hawkinson</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Peter Thompson, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Peter Thompson, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Vickie L. Capps</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vickie L. Capps</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Robert Hershberg, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robert Hershberg, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Saqib Islam, J.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Saqib Islam, J.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Powell, J.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Andrew Powell, J.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jonathan Root, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jonathan Root, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Thilo Schroeder, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thilo Schroeder, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Maria Koehler, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 31, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maria Koehler, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sbtx-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">THIS SUBLEASE AGREEMENT (&#x201c;Sublease&#x201d;) is entered and effective this 1st day of July, 2021, by DELTA DENTAL OF WASHINGTON, a(n) Washington nonprofit corporation, (&#x201c;Tenant&#x201d;), and SILVERBACK THERAPEUTICS, INC., a(n) Delaware corporation (&#x201c;Subtenant&#x201d;). Tenant entered into that certain lease agreement dated October 16th, 2016 (&#x201c;Master Lease&#x201d;) with T-C/SK 400 FAIRVIEW OWNER LLC, a(n) Delaware limited liability company as (&#x201c;Landlord&#x201d;), for the leased premises legally described in the attached Exhibit 1 (the &#x201c;Master Premises&#x201d;). The Master Premises is located in that certain building commonly known as 400 Fairview (the &#x201c;Building&#x201d;), and situated on real property legally described in the Master Lease (the &#x201c;Property&#x201d;). A copy of the Master Lease, including all amendments and addenda thereto, is attached as Exhibit 2.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Tenant and Subtenant agree as follows:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE SUMMARY.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Subleased Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Tenant leases to Subtenant and Subtenant leases from Tenant that portion of the Master Premises (the &#x201c;Subleased Premises&#x201d;) consisting of an agreed area of 9,188 rentable square feet on the 6th floor(s) of the Master Premises, as outlined on the floor plan attached as Exhibit 3 (except that Tenant shall not have access to the stairwell depicted thereon) and commonly known as 400 Fairview Avenue North, Seattle, WA 98109 (Suite 600).</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sublease Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The term of this Sublease shall commence upon the later of (i) receipt of Landlord&#x2019;s written consent to this Sublease in a form acceptable to Subtenant, (ii) possession of the Subleased Premises is delivered to Subtenant and (iii) Tenant&#x2019;s Work (cap of the stairwell) is completed (the &#x201c;Sublease Commencement Date&#x201d;), but this date may not occur prior to July 1, 2021 unless Subtenant agrees. </font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Sublease Termination Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The term of this Sublease shall terminate at midnight on the last day of the 24th full month following the Sublease Commencement Date, or one (1) day prior to the termination date of the Master Lease, whichever is earlier, unless sooner terminated in accordance with the terms of this Sublease (the &#x201c;Sublease Termination Date&#x201d;). So long as Subtenant is not in default (beyond applicable notice and cure periods) of its obligations under this Sublease, Subtenant shall have the right to terminate this sublease any time following the twelfth (12th) month of the sublease term by providing at least 90 days prior written notice. Subtenant shall pay a termination fee equal to one month of rent due at the time of written notice to Tenant. So long as Subtenant is not in default (beyond applicable notice and cure periods) of its obligations under this Sublease, Subtenant shall have the option to extend the Sublease term for a period of twelve-months (the &#x201c;Extended Sublease Term&#x201d;). Subtenant shall provide three-months&#x2019; written notice of its exercise of this option to extend prior to the Sublease Termination Date unless sooner terminated pursuant to the provisions of the Sublease Agreement. The monthly base rent for the Extended Sublease Term shall be </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">$30,054.42</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Base Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant shall pay to Tenant monthly base rent (check one): </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">$28,329.67 for the first twelve months, then $29,179.56 thereafter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> according to the Rent Rider attached hereto (&#x201c;Base Rent). Rent shall be payable at Tenant&#x2019;s address shown in Section 1(h) below, or such other place designated in writing by Tenant. Provided Subtenant shall faithfully perform all of the terms and conditions of the Sublease, Subtenant shall not be required to pay any Rent for the first full calendar month of the Term of this Sublease.  For the avoidance of doubt, the parties to this Sublease intend that this Base Rent payment is the only payment owing by Subtenant to Sublandlord for use of the Subleased Premises, and Subtenant shall not be responsible for paying any portion of the Operating Costs, utility costs or other costs owing under the Master Lease. Sublandlord at its sole cost shall timely pay Landlord for all Operating Costs, utility charges and other charges and fees owing under the Master Lease throughout the Term of this Sublease.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Prepaid Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Upon execution of this Sublease, Subtenant shall deliver to Tenant the sum of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">$28,329.67</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, as prepaid rent to be applied to Rent due for month 2 of the Sublease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Security Deposit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Upon execution of this Sublease, Subtenant shall deliver to Tenant the sum of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">$29,179.56 (equal to last month's rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">) to be held as a security deposit pursuant to Section 5 below. The security deposit shall be in the form of (check one):  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> cash, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> check or wire transfer, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> letter of credit, or according to the Letter of Credit Rider (CBA Form LCR) attached hereto.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Permitted Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The Subleased Premises shall be used only for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">office and administrative use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">, subject to the Master Lease, applicable zoning, and other laws, and for no other purpose without the prior written consent of Tenant (the &#x201c;Permitted Use&#x201d;).</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Notice and Payment Addresses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: DELTA DENTAL OF WASHINGTON</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">400 Fairview Avenue N, Suite 800</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Seattle, WA 98109</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                     </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Attn: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Ryan Bartlett</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                     </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Email:   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">rbartlett@deltadentalwa.com</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                          </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Subtenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">: SILVERBACK THERAPEUTICS, INC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                                                </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                                                </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Email:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">   </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                                    </font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Subtenant&#x2019;s Sublease Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant&#x2019;s Sublease Share of any operating costs, common area charges, additional rent, or other amounts payable by Tenant under the Master Lease is 0% of such amounts, based upon the ratio of the rentable area of the Subleased Premises to the rentable area of the Master Premises.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">PREMISES</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Lease of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Tenant leases to Subtenant, and Subtenant leases from Tenant the Subleased Premises upon the terms specified in this Sublease.  In addition to use of the Subleased Premises, Subtenant shall have the same rights of ingress and egress to the Subleased Premises, and any common areas and the benefit of any appurtenant easements and rights of way, all on such conditions and at such times as permitted by Landlord and granted under the Master Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Acceptance of Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Except as specified elsewhere in this Sublease, Tenant makes no representations or warranties to Subtenant regarding the Subleased Premises, including the structural condition of the Subleased Premises or the condition of all mechanical, electrical, and other systems on the Subleased Premises. Except for any subtenant improvements to be completed by Tenant as described in the Work Letter attached as Exhibit 4 (&#x201c;Tenant&#x2019;s Work&#x201d;), Subtenant shall accept the Subleased Premises and its appurtenances in their respective AS-IS, WHERE-IS condition, and shall further be responsible for performing any work necessary to bring the Subleased Premises into a condition satisfactory to Subtenant. By signing this Sublease, Subtenant acknowledges that it has had adequate opportunity to investigate the Subleased Premises, acknowledges responsibility for making any corrections, alterations and repairs to the Subleased Premises (other than Tenant&#x2019;s Work), and acknowledges that the time needed to complete any such items shall not delay the Sublease Commencement Date.  However, Sublandlord shall at its cost deliver the Subleased Premises to Subtenant (i) broom clean; and (ii) with the Tenant&#x2019;s Work (cap of the stairwell) substantially completed.  Sublandlord further agrees to work in good faith with Subtenant and Landlord to facilitate Subtenant&#x2019;s use of existing cabling infrastructure within the Subleased Premises (while ensuring that Sublandlord&#x2019;s data and network security and performance is not compromised).  To Sublandlord&#x2019;s knowledge, all lighting, electrical outlets, and any other electrical/mechanical systems are in a fully functional condition consistent with a class A building in Seattle.  Notwithstanding anything to the contrary in this Sublease, Subtenant shall have no obligation to correct any defects in the Subleased Premises (including, without limitation, any condition that is a default under the Master Lease) existing as of the Commencement Date of this Sublease, and Sublandlord shall be responsible at its cost for correcting any such defects or defaults to the extent such obligations are Sublandlord&#x2019;s obligation to maintain pursuant to the Master Lease.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Subtenant Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The Work Letter attached as Exhibit 4 sets forth all of Tenant&#x2019;s Work, if any, and all improvements to be completed by Subtenant (&#x201c;Subtenant&#x2019;s Work&#x201d;), if any, that will be performed on the Subleased Premises. Responsibility for design, payment and performance of all such work shall be as set forth in the Work Letter.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">TERM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. The term of this Sublease shall commence on the Commencement Date and shall end on the Termination Date (the &#x201c;Term&#x201d;).</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Early Possession</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant acknowledges that Tenant may need to obtain Landlord&#x2019;s consent to this Sublease prior to Subtenant occupying the Subleased Premises, and that Subtenant shall not occupy the Subleased Premises without the prior written consent of Tenant. In the event Tenant gives Subtenant access to the Subleased Premises preceding the Sublease Commencement Date for the purpose of installing Subtenant&#x2019;s furniture, telecommunications, fixtures, telephone systems and computer cabling and the performance of Subtenant&#x2019;s Work, if any, such access shall be fully coordinated with Tenant in advance and Subtenant shall not interfere with Tenant&#x2019;s Work. In no event shall Subtenant have access to any portion of the Master Premises except for the Subleased Premises. All of the terms and conditions of this Sublease, including Subtenant&#x2019;s insurance and indemnification obligations, shall apply during such time, except for payment of Base Rent. If Subtenant occupies the Subleased Premises before the Sublease Commencement Date specified in Section 1, then such date of occupancy shall not advance the Sublease Commencement Date or Sublease Termination Date set forth above. Subtenant shall have fifteen (15) days early access to the Premises for FF&amp;E at no additional cost.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Delayed Possession</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Tenant shall act diligently to make the Subleased Premises available to Subtenant, provided, however, that neither Tenant nor any agent or employee of Tenant shall be liable for any damage or loss due to Tenant&#x2019;s inability or failure to deliver possession of the Premises to Subtenant as provided in this Sublease. If possession is delayed, the Sublease Commencement Date set forth in Section 1 shall also be delayed, but the Sublease Termination Date shall not be extended by such delay. If the Sublease Commencement Date does not occur within ___days ((60) days if not filled in) after the mutual execution and delivery of this Sublease : </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> Subtenant may elect to cancel this Sublease by giving written notice to Tenant no later than ((10) days if not filled in) after such time period ends, or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> then all Base Rent and Additional Rent (as defined below) shall be abated for each one (1) day after the Sublease Commencement Date during which possession of the Subleased Premises has not been delivered to Subtenant. If Subtenant gives notice of cancellation, as Subtenant&#x2019;s sole and exclusive remedy, this Sublease shall be cancelled, all prepaid rent and security deposits shall be refunded to Subtenant, and neither Tenant nor Subtenant shall have any further obligations to the other.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:10.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Notwithstanding anything in this Section 3 to the contrary, to the extent that any portions of the Tenant&#x2019;s Work or the Subtenant&#x2019;s Work have not been completed in time for the Subtenant to occupy or take possession of the Subleased Premises on the Sublease Commencement Date due to the failure of Subtenant to fulfill any of its obligations under this Sublease (&#x201c;Subtenant Delays&#x201d;), the Sublease shall nevertheless commence on the Sublease Commencement Date, including without limitation, Subtenant&#x2019;s obligation to pay Base Rent and Additional Rent, as set forth in Section 1, or upon the date that the Sublease Commencement Date would have occurred but for the Subtenant Delays.</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">RENT</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Payment of Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant shall pay Tenant without notice, demand, deduction or offset, in lawful money of the United States, the monthly Base Rent stated in Section 1 in advance on or before the first day of each month during the Sublease Term beginning on (check one): </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  the Sublease Commencement Date, or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> ___ (if no date specified, then on the Sublease Commencement Date), and any other additional payments due to Tenant (&#x201c;Additional Rent&#x201d;, and together with Base Rent, the &#x201c;Rent&#x201d;) when required under this Sublease. Payments for any partial month during the Term shall be prorated. All payments due to Tenant under this Sublease, including late fees and interest, shall also constitute Additional Rent, and upon Subtenant&#x2019;s failure to pay any such costs, charges or expenses, Tenant shall have the same rights and remedies as otherwise provided in this Sublease for the failure of Subtenant to pay Rent.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Late Charges; Default Interest</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. If any sums payable by Subtenant to Tenant under this Sublease are not received within five (5) days of their due date, Subtenant shall pay Tenant an amount equal to the sum which would be payable by Tenant to the Landlord for or 5% of the delinquent amount for the cost of collecting and handling such late payment in addition to the amount due and as Additional Rent, whichever is greater. All delinquent sums not paid by Subtenant within five (5) business days of the due date shall, at Tenant&#x2019;s option, bear interest at the rate the Tenant would pay the Landlord under the Master Lease for an equivalent default or the highest rate of interest allowable by law, whichever is less. Interest on all delinquent amounts shall be calculated from the original due date to the date of payment.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Less Than Full Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Tenant&#x2019;s acceptance of less than the full amount of any payment due from Subtenant shall not be deemed an accord and satisfaction or compromise of such payment unless Tenant specifically consents in writing to payment of such lesser sum as an accord and satisfaction or compromise of the amount which Tenant claims. Any portion that remains to be paid by Tenant shall be subject to the late charges and default interest provisions of this Section.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SECURITY DEPOSIT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Upon execution of this Sublease, Subtenant shall deliver to Tenant the security deposit specified in Section 1 above. Tenant&#x2019;s obligations with respect to the security deposit are those of a debtor and not of a trustee, and Tenant may commingle the security deposit with its other funds. If Subtenant defaults in the performance of any covenant or condition of this Sublease, Tenant shall have the right, but not the obligation, to use or retain all or any portion of the security deposit for the payment of: (i) Base Rent, Additional Rent, or any other sum as to which Subtenant is in default; or (ii) the amount Tenant spends or may become obligated to spend, or to compensate Tenant for any losses incurred by reason of Subtenant&#x2019;s default. Subtenant acknowledges, however, that the security deposit shall not be considered as a measure of Subtenant&#x2019;s damages in case of default by Subtenant, and any payment to Tenant from the security deposit shall not be construed as a payment of liquidated damages for Subtenant&#x2019;s default. If at any time during the Term of the Sublease the security deposit delivered by Subtenant becomes insufficient to cover the amounts required under this Section 5, whether or not due to Tenant&#x2019;s application of all or a portion of the security deposit contemplated by this Section, Subtenant shall, within five (5) days after written demand therefore by Tenant, deposit with Tenant an amount sufficient to replenish the security deposit to the amount required in Section 1 above. If Subtenant is not in default of any covenant or condition of this Sublease at the end of the Term, Tenant shall return any unused portion of the security deposit without interest within 30 days after the surrender of the Subleased Premises by Subtenant in the condition required by Section 9 of this Sublease.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">MASTER LEASE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Tenant represents to Subtenant that as of the effective date of this Sublease: (a) Tenant has delivered to Subtenant a complete copy of the Master Lease (which may contain redacted business terms), which represents all agreements between Landlord and Tenant relating to the leasing, use, and occupancy of the Subleased Premises, and (b) Tenant has not received notice from Landlord of a breach under the Master Lease that is uncured as of the date of mutual execution and delivery of this Sublease. Tenant shall not agree to an amendment to the Master Lease which would have an adverse effect on Subtenant&#x2019;s occupancy of the Subleased Premises or its intended use of the Subleased Premises, without obtaining Subtenant&#x2019;s prior written consent, which consent shall not be unreasonably withheld, conditioned, or delayed. Subtenant represents that it has read and is familiar with the terms of the Master Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Sublease is subject to and subordinate to the Master Lease. If the Master Lease terminates, this Sublease shall automatically terminate. Tenant and Subtenant shall not, by their omission or act, do or permit anything to be done which would cause a default under the Master Lease. If the Master Lease terminates or is forfeited as a result of a default or breach by Tenant or Subtenant under this Sublease and/or the Master Lease, then the defaulting party shall be liable to the non-defaulting party for the actual damage suffered as a result of such termination or forfeiture provided that in no event shall one party be liable to the other for consequential damages. Tenant shall exercise diligent, commercially reasonable efforts to cause Landlord to perform its obligations under the Master Lease for the benefit of the Subtenant, provided that in no event shall the foregoing requirements require Tenant to file a lawsuit.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Except as set forth below and except as may be inconsistent with the terms contained in this Sublease, all the terms, covenants and conditions contained in the Master Lease are incorporated into and made a part of this Sublease by this reference with the following modified definitions : (i) all references in the Master Lease to &#x201c;Landlord&#x201d; shall be deemed to mean Tenant, (ii) all references in the Master Lease to &#x201c;Tenant&#x201d; shall be deemed to mean Subtenant, (iii) all references in the Master Lease to &#x201c;Lease&#x201d; shall mean this Sublease, (iv) all references in the Master Lease to &#x201c;Premises&#x201d; shall mean Subleased Premises, (v) all references in the Master Lease to &#x201c;Commencement Date&#x201d; shall mean Sublease Commencement Date, and (vi) all references in the Master Lease to &#x201c;Term&#x201d; shall mean &#x201c;Sublease Term&#x201d;. Tenant and Subtenant agree that as between Tenant and Subtenant the following terms of the Master Lease shall not be incorporated into this Sublease:  the entire Lease Summary; Sections 1.1, 1.3, 1.5, 1.6, 2, 3, 4, 7, 8.1.9, 8.6, 10, 11, 15, 16, 18, and 20, 22.14, 22.17, 22.18, Exhibits A, C, D, E, G, and H. Notwithstanding the foregoing incorporation of the terms and conditions of the Master Lease, Tenant shall not be responsible for the performance of any obligations to be performed by Landlord under the Master Lease, and Subtenant agrees to look solely to Landlord for the performance of such obligations.  Tenant shall not be liable to Subtenant for any failure by Landlord to perform its obligations under the Master Lease, nor shall such failure by Landlord excuse performance by Subtenant of its obligations hereunder. The parties acknowledge that Subtenant has no &#x201c;Guarantor&#x201d; as defined in the Master Lease, and no performance of obligations by or notice to any guarantor shall be required under the terms of this Sublease.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">CONSENT OF LANDLORD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.  Notwithstanding anything to the contrary in this Sublease, whenever the consent of Landlord is required under the Master Lease, Subtenant shall obtain the consent of both Tenant and Landlord, but in all instances Subtenant shall first request and obtain the consent of Tenant before requesting the consent of Landlord. This Sublease shall not become effective until Landlord has provided its written consent to this Sublease.  If Landlord does not consent to this Sublease within sixty (60) days of the parties&#x2019; execution of this Sublease, then this Sublease shall be deemed void and the parties shall have no further rights or obligations hereunder.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ALTERATIONS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant may make alterations, additions or improvements to the Subleased Premises (the &#x201c;Alterations&#x201d;), only with the prior written consent of Tenant which shall not be unreasonably withheld, conditioned or delayed, and, to the extent required by the Master Lease, Landlord. The term &#x201c;Alterations&#x201d; shall not include: (i) any of Subtenant&#x2019;s Work approved by Tenant pursuant to Exhibit 4, and (ii)the installation of shelves, movable partitions, or Subtenant&#x2019;s equipment and trade fixtures, which may be installed and removed without damaging existing improvements or the structural integrity of the Subleased Premises, Master Premises, Building, or Property, and Tenant&#x2019;s consent shall not be required for Subtenant&#x2019;s installation of those items except to the extent Tenant must obtain the consent of Landlord under the Master Lease for such installations. Subtenant shall perform all work within the Subleased Premises at Subtenant&#x2019;s expense in compliance with all applicable laws and shall complete all Alterations in accordance with plans and specifications approved by Tenant, using contractors approved by Tenant, and in a manner so as to not unreasonably interfere with other tenants. Subtenant shall pay when due, all claims for labor or materials furnished to or for Subtenant at or for use in the Subleased Premises, which claims are or may be secured by any mechanics&#x2019; or materialmens&#x2019; liens against the Subleased Premises or Property or any interest therein. Except as otherwise provided in the Work Letter attached as Exhibit 4 with respect to Subtenant&#x2019;s Work, Subtenant shall remove all Alterations at the end of the Sublease term unless Tenant conditioned its consent upon Subtenant leaving a specified Alteration at the Subleased Premises, in which case Subtenant shall not remove such Alteration and it shall become Tenant&#x2019;s property. Subtenant shall immediately repair any damage to the Subleased Premises or adjacent portions of the Master Premises, Building and Property caused by installation and/or removal of improvements performed as part of Subtenant&#x2019;s Work and/or Alterations. Notwithstanding anything to the contrary, Subtenant shall have no obligation to remove or restore any alterations or improvements present upon the Subleased Premises as of the Commencement Date of this Sublease.  Subtenant shall remove any cabling that was installed in the Subleased Premises by Subtenant only upon request by Tenant.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">REPAIRS AND MAINTENANCE; SURRENDER</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant shall, at its sole cost and expense, maintain the Subleased Premises in good condition and promptly make all repairs and replacements, whether structural or non-structural, necessary to keep the Subleased Premises safe and in good condition, including all utilities and other systems serving the Subleased Premises. Subtenant shall not damage any demising wall or disturb the structural integrity of the Subleased Premises and shall promptly repair any damage or injury done to any such demising walls or structural elements caused by Subtenant or its employees, officers, agents, servants, contractors, customers, clients, visitors, guests, or other licensees or invitees. If Subtenant fails to maintain or repair the Subleased Premises, Tenant may enter the Subleased Premises and perform such repair or maintenance on behalf of Subtenant. In such case, Subtenant shall be obligated to pay to Tenant immediately upon receipt of demand for payment, as Additional Rent, all costs incurred by Tenant in performing such repair or maintenance on behalf of Subtenant. Subtenant shall be obligated to repair or maintain only those portions of the Subleased Premises as required of Tenant under the Master Lease. Tenant shall not be required to perform any maintenance, repairs, or improvements that are the obligation of Landlord under the Master Lease (provided that Tenant shall exercise diligent, commercially reasonable efforts to cause Landlord to perform its obligations under the Master Lease for the benefit of the Subtenant) or to make any changes to the Subleased Premises because of the enactment of any law, ordinance, regulation, order or code during the Term. Notwithstanding anything in this Section to the contrary, Subtenant shall not be responsible for any repairs to the Subleased Premises made necessary by the acts of Tenant, Landlord, or their respective employees, officers, agents, servants, contractors, customers, clients, visitors, guests, or other licensees or invitees. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Upon expiration or earlier termination of the Term, Subtenant shall promptly and peacefully surrender the Subleased Premises to Tenant, together with all keys, in as good condition as when received by Subtenant or as thereafter improved (but subject to any obligations to remove any Subtenant&#x2019;s Work and Alterations and/or to restore the same as provided elsewhere in this Sublease), reasonable wear and tear and insured casualty excepted.</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ACCESS AND RIGHT OF ENTRY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. After reasonable written notice from Tenant (except in cases of emergency, where no notice is required) and subject to any and all rights of Landlord to enter the Premises under the Master Lease, Subtenant shall permit Tenant and/or Landlord and their respective agents, employees and contractors to enter the Subleased Premises at reasonable times to make repairs, alterations, improvements or inspections. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">This Section shall not impose any repair or other obligation upon Tenant or Landlord not expressly stated</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> elsewhere in this Sublease. After reasonable notice to Subtenant, each of Tenant and Landlord, as the case may be, shall have the right to enter the Subleased Premises for the purpose of (a) showing the Subleased Premises to prospective purchasers or lenders at any time, and to prospective tenants within 180 days prior to the expiration or sooner termination of the Term; and (b) posting &#x201c;for lease&#x201d; signs within 180 days prior to the expiration or sooner termination of the Term.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">DESTRUCTON OR CONDEMNATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Damage and Repair</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. If either Landlord or Tenant terminates the Master Lease as a result of condemnation of or casualty to the Subleased Premises, Master Premises, or Building or Property in accordance with the Master Lease, this Sublease shall terminate on the same date and in accordance therewith. If the Sublease is not terminated pursuant to the prior sentence and the Subleased Premises or the portion of the Building or Property reasonably necessary for Subtenant&#x2019;s occupancy are damaged, destroyed or rendered untenantable, by fire or other casualty, Tenant may, at its option: (a) terminate this Sublease, or (b) restore (or cause Subtenant to restore) the Subleased Premises and the portion of the Building and Property reasonably necessary for Subtenant&#x2019;s occupancy to the same or substantially similar condition that existed before the casualty event. Provided, however, if such casualty event occurs during the last six (6) months of the Term, then either Subtenant or Tenant may elect to terminate this Sublease. If, within 60 days after Tenant&#x2019;s receipt of written notice from Subtenant that Subtenant deems the Subleased Premises or the portion of the Property reasonably necessary for Subtenant&#x2019;s occupancy untenantable, Tenant fails to notify Subtenant of its election to restore those areas, or if Tenant is unable to restore those areas which Tenant is expressly required hereunder to restore within six (6) months of the date of the casualty event, then Subtenant may elect to terminate this Sublease by written notice given to Tenant at any time prior to the date on which Tenant substantially completes restoration of those areas which it is required hereunder to restore.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:10.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If Tenant restores the Subleased Premises or the Property as provided under this Section, Tenant shall proceed with reasonable diligence to complete the work, and Base Rent shall be abated in the same proportion as the untenantable portion of the Subleased Premises bears to the whole Subleased Premises, provided that there shall be a Base Rent abatement only if the damage or destruction of the Subleased Premises or the Property did not result from, or was not contributed to directly or indirectly by, the act, fault or neglect of Subtenant or Subtenant&#x2019;s employees, officers, agents, servants, contractors, customers, clients, visitors, guests, or other licensees or invitees. No damages, compensation or claim shall be payable by Tenant for Subtenant&#x2019;s inconvenience, loss of business or annoyance directly, incidentally or consequentially arising from any repair or restoration of any portion of the Subleased Premises, Master Premises, Building, or Property. Tenant shall have no obligation to carry insurance of any kind for the protection of Subtenant or any Alterations or improvements paid for or installed by or on behalf of Subtenant; any Tenant&#x2019;s Work or Subtenant&#x2019;s Work identified in Exhibit 4 (regardless of who may have completed them); Subtenant&#x2019;s furniture; or on any fixtures, equipment, improvements or appurtenances of Subtenant under this Sublease; and Tenant shall not be obligated to repair any damage thereto or replace the same unless the damage is caused by Tenant&#x2019;s gross negligence or willful misconduct.</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Condemnation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. If either Landlord or Tenant terminates the Master Lease based on any provision in the Master Lease relating to eminent domain or conveyance under threat of condemnation, this Sublease shall terminate on the same date and in accordance therewith. If the Sublease is not terminated pursuant to the prior sentence and the Subleased Premises, the portion of the Building or Property reasonably necessary for Subtenant&#x2019;s occupancy, or 50% or more of the total rentable area of the Property are made untenantable by eminent domain, or conveyed under a threat of condemnation, this Sublease shall terminate at the option of each of Tenant and Subtenant as of the earlier of the date title vests in the condemning authority or the condemning authority first has possession of the portion of the Property taken by the condemning authority. All Rent and other payments required under this Sublease shall be paid to that date.</font></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:10.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If the condemning authority takes a portion of the Subleased Premises or the portion of the Property necessary for Subtenant&#x2019;s occupancy that does not render them untenantable, then this Sublease shall continue in full force and effect and the Base Rent shall be equitably reduced based on the proportion by which the floor area of the Subleased Premises is reduced. The reduction in Base Rent shall be effective on the earlier of the date the condemning authority first has possession of such portion or title vests in the condemning authority. The Subleased Premises or the portion of the property reasonably necessary for Subtenant&#x2019;s occupancy shall not be deemed untenantable if 25% or less of each of those areas is condemned. As between Tenant and Subtenant, Tenant shall be entitled to the entire award from the condemning authority attributable to the value of the Master Premises, Subleased Premises, or the Property or Building, and Subtenant shall make no claim for the value of its subleasehold estate or the Subtenant&#x2019;s Work or any Alterations. Subtenant shall be permitted to make a separate claim against the condemning authority for moving expenses or damages resulting from interruption in its business if this Sublease is terminated under this Section, provided that in no event shall Subtenant&#x2019;s claim reduce Landlord&#x2019;s or Tenant&#x2019;s awards.</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">INSURANCE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant shall procure and maintain, at its sole cost and expense, such insurance as is required to be carried by Tenant under the Master Lease, and shall comply with all requirements with respect to the insurance of Tenant under the Master Lease, including, without limitation, obtaining additional insured endorsement(s) naming Tenant and Landlord as additional insureds, in the manner required therein, and property insurance as is required to be carried by Tenant under the Master Lease to the extent property insurance pertains to the Subleased Premises. If the Master Lease requires Tenant to insure leasehold improvements or Alterations, then Tenant shall insure the leasehold improvements which are located in the Subleased Premises, as well as the Tenant&#x2019;s Work, and Subtenant shall insure any Alterations in the Subleased Premises performed by or on behalf of Subtenant. Subtenant shall furnish to Tenant certificates of Subtenant&#x2019;s insurance policies and copies of any endorsements required hereunder not later than 10 days prior to Subtenant&#x2019;s taking possession of the Subleased Premises. Tenant shall carry insurance as required by the Master Lease and shall not be obligated to carry property or liability insurance to the extent such insurance is an obligation of Landlord under the Master Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Tenant and Subtenant hereby release each other and their respective employees, officers, agents, servants, contractors, customers, clients, visitors, guests, or other licensees or invitees, from responsibility for and waive their respective claims for recovery of any loss or damage arising from any cause covered by insurance required to be carried by each of them. Each party shall provide notice to the insurance carrier or carriers of this mutual waiver of subrogation, and shall cause its respective insurance carriers to waive all rights of subrogation against the other. This waiver shall not apply to the extent of the deductible amounts to any such policies or to the extent of liability exceeding the limits of such policies. Tenant agrees to use reasonable efforts to obtain from Landlord for the benefit of Subtenant the same waiver of claims for any loss or damage arising from any cause covered by insurance required to be carried by Landlord under the Master Lease and, if and to the extent of such waiver received from Landlord, Subtenant agrees to grant the same waiver to Landlord.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">In no event shall Sublandlord be liable to Subtenant for business losses or consequential damages.  In no event shall Subtenant be liable to Sublandlord for business losses or consequential damages.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ASSIGNMENT AND SUBLETTING</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant shall not assign, sublet, mortgage, encumber or otherwise transfer any interest in this Sublease or any part of the Subleased Premises (collectively referred to as a &#x201c;Transfer&#x201d;), without first obtaining the written consent of Tenant, which shall not be unreasonably withheld, conditioned or delayed. Tenant may condition its consent on (a) obtaining any required consent from Landlord; (b) Subtenant satisfying any conditions to the Transfer imposed by Landlord and/or required to be satisfied by Tenant under the Master Lease; and (c) such other reasonable conditions that Tenant may impose. No Transfer shall relieve Subtenant of any liability under this Sublease notwithstanding Tenant&#x2019;s consent to such Transfer. Consent to any Transfer shall not operate as a waiver of the necessity for Tenant&#x2019;s consent to any subsequent Transfer. In connection with each request for consent to a Transfer, Subtenant shall pay the reasonable cost of processing same, including attorneys&#x2019; fees and any cost charged by Landlord for granting its consent under the Master Lease, upon demand of Tenant.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Any transfer of this Sublease by merger, consolidation, redemption or liquidation of Subtenant, or any change in the ownership of, or power to vote, which singularly or collectively represents a majority of the beneficial interest in Subtenant, shall constitute a Transfer.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As a condition to the Landlord&#x2019;s and Tenant&#x2019;s approval, if given, any potential assignee or sublessee otherwise approved shall assume all obligations of Subtenant under this Sublease and shall be jointly and severally liable with Subtenant and any guarantor for the payment of Rent and other charges due hereunder and performance of all obligations of Subtenant under this Sublease. In connection with any Transfer, Subtenant shall provide Landlord and Tenant with copies of all assignments, subleases and assumption agreements and related documents.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">MORTGAGE SUBORDINATION AND ATTORNMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This Sublease shall automatically be subordinate to any mortgage or deed of trust created by Landlord to the extent the Master Lease is subordinate to the same mortgage or deed of trust, and Subtenant shall attorn upon the same terms and conditions as the Tenant in the Master Lease, provided Subtenant shall enjoy the terms and conditions relating to such subordination and attornment to the same extent as Tenant under the terms of the Master Lease.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">HOLDOVER</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. If Subtenant shall, without the written consent of Tenant, remain in possession of the Subleased Premises and shall fail to return the Subleased Premises to Tenant after the expiration or termination of the Sublease, the tenancy shall be a holdover tenancy at sufferance, which may be terminated in accordance with Washington law; provided that, upon expiration of the Master Lease, such holdover tenancy by Subtenant shall automatically be deemed a tenancy at sufferance, terminable immediately.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Unless Tenant agrees in writing to a different rental rate Subtenant agrees to pay to Tenant 150% of the rate of Base Rent last payable under this Sublease, during any holdover tenancy, in addition to all Additional Rent and other sums due under this Sublease. All other terms of the Sublease shall remain in effect. Nothing herein shall be deemed Tenant&#x2019;s consent to holdover by Subtenant, or be deemed to permit Subtenant to remain in possession of the Subleased Premises on and after expiration of the Master Lease.</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">NOTICES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. All notices under this Sublease shall be in writing and effective (i) when delivered in person or via overnight courier to the other party, or (ii) three (3) days after being sent by registered or certified mail to the other party at the addresses set forth in Section 1. The addresses for notices and payment of Rent set forth in Section 1 may be modified by either party only by written notice delivered in conformance with this Section.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">ESTOPPEL CERTIFICATES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Upon the written request of Tenant, Subtenant shall execute and deliver to Tenant and/or Landlord or their designee a written estoppel certificate on the same terms and conditions as required of Tenant under the Master Lease.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">GENERAL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Heirs and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This Sublease shall apply to and be binding upon Tenant and Subtenant and their respective heirs, executors, administrators, successors and assigns.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Brokers&#x2019; Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Subtenant represents and warrants to Tenant that except for Subtenant&#x2019;s Broker, if any, described and disclosed in Section 20 of this Sublease, it has not engaged any firm, finder or other person who would be entitled to any commission or fees for the negotiation, execution or delivery of this Sublease and shall indemnify and hold harmless Tenant against any loss, cost, liability or expense incurred by Tenant as a result of any claim asserted by any such firm, finder or other person on the basis of any arrangements or agreements made or alleged to have been made by or on behalf of Subtenant. Tenant represents and warrants to Subtenant that except for Tenant&#x2019;s Broker, if any, described and disclosed in Section 20, it has not engaged any firm, finder or other person who would be entitled to any commission or fees for the negotiation, execution or delivery of this Sublease and shall indemnify and hold harmless Subtenant against any loss, cost, liability or expense incurred by Subtenant as a result of any claim asserted by any such firm, finder or other person on the basis of any arrangements or agreements made or alleged to have been made by or on behalf of Tenant.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This Sublease, which incorporates portions of the Master Lease, contains all of the covenants and agreements between Tenant and Subtenant relating to the Subleased Premises. No prior or contemporaneous agreements or understandings pertaining to the Sublease shall be valid or of any force or effect and the covenants and agreements of this Sublease shall not be altered, modified, or amended to except in writing signed by Tenant and Subtenant.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Any provision of this Sublease which shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other provision of this Sublease.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. This Sublease shall be governed by and construed in accordance with the laws of the State of Washington.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Memorandum of Sublease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Neither this Sublease nor any memorandum or &#x201c;short form&#x201d; thereof shall be recorded without Tenant&#x2019;s prior consent.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Submission of Sublease Form Not an Offer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. One party&#x2019;s submission of this Sublease to the other for review shall not constitute an offer to sublease the Subleased Premises. This Sublease shall not become effective and binding upon Tenant and Subtenant until it has been fully executed by both Tenant and Subtenant, and consented to by Landlord (if required by the Master Lease).</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Authority of Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. Each party to this Sublease represents and warrants to the other that the person executing this Sublease on behalf of such party has the authority to enter into this Sublease on behalf of this Sublease, that the execution and delivery of this Sublease has been duly authorized, and that upon such execution and delivery this Sublease shall be binding upon and enforceable against such party upon execution and delivery.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">EXHIBITS AND RIDERS. The following exhibits and riders are made a part of this Sublease:</font></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exhibit 1: Legal Description of the Master Premises or Property</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exhibit 2: Master Lease</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exhibit 3: Outline of Subleased Premises</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Exhibit 4: Work Letter</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Other: Parking Rider, FF&amp;E</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">AGENCY DISCLOSURE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. At the signing of this Sublease, Tenant is represented by Adam Chapman of Jones Lang LaSalle Brokerage, Inc. (insert name of Broker and Firm as licensed) (the &#x201c;Tenant&#x2019;s Broker&#x201d;); and Subtenant is represented Hans Kemp and Austin Arper Flinn Ferguson (insert name of Broker and Firm as licensed) (the &#x201c;Subtenant&#x2019;s Broker&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This Agency Disclosure creates an agency relationship between Subtenant, Subtenant&#x2019;s Broker (if any such person is disclosed), and any managing brokers who supervise Subtenant&#x2019;s Broker&#x2019;s performance (collectively the &#x201c;Supervising Brokers&#x201d;). In addition, this Agency Disclosure creates an agency relationship between Tenant, Tenant&#x2019;s Broker (if any such person is disclosed), and any managing brokers who supervise Tenant&#x2019;s Broker&#x2019;s performance (also collectively the &#x201c;Supervising Brokers&#x201d;). If Tenant&#x2019;s Broker and Subtenant&#x2019;s Broker are different real estate licensees affiliated with the same Firm, then both Tenant and Subtenant confirm their consent to that Firm and both Tenant&#x2019;s and Subtenant&#x2019;s Supervising Brokers acting as dual agents. If Tenant&#x2019;s Broker and Subtenant&#x2019;s Broker are the same real estate licensee who represents both parties, then both Subtenant and Tenant acknowledge that the Broker, his or her Supervising Brokers, and his or her Firm are acting as dual agents and hereby consent to such dual agency. If Tenant&#x2019;s Broker, Subtenant&#x2019;s Broker, their Supervising Brokers, or their Firm are dual agents, Subtenant and Tenant consent to Tenant&#x2019;s Broker, Subtenant&#x2019;s Broker, and their Firm being compensated based on a percentage of the rent or as otherwise disclosed on an attached addendum. Neither Tenant&#x2019;s Broker, Subtenant&#x2019;s Broker nor either of their Firms are receiving compensation from more than one party to this transaction unless otherwise disclosed on an attached addendum, in which case Subtenant and Tenant consent to such compensation. Subtenant and Tenant confirm receipt of the pamphlet entitled &#x201c;The Law of Real Estate Agency.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">COMMISSION AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. If Tenant has not entered into a listing agreement (or other compensation agreement with Tenant&#x2019;s Firm), Tenant agrees to pay a commission to Tenant&#x2019;s Firm (as identified in the Agency Disclosure Section above) as follows:</font></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">$1.25 per RSF per year to Subtenant's Broker &amp; $0.75 per RSF per year to Tenant's Broker</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">            </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% of the gross rent payable pursuant to this Sublease</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">         $ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">per rentable square foot of the Subleased Premises</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">         Other</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                          </font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Tenant&#x2019;s Broker </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shall not (shall not if not filled in) be entitled to a commission upon the extension by Subtenant of the Term pursuant to any right reserved to Subtenant under the Sublease calculated </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as provided above or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as follows </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (if no box is checked, as provided above). Tenant&#x2019;s Broker </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shall not (shall not if not filled in) be entitled to a commission upon any expansion of the Subleased Premises pursuant to any right reserved to Subtenant under the Sublease, calculated </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> as provided above or &#9744;as follows </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">             </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> (if no box is checked, as provided above).</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">With respect to any commission earned upon execution of this Sublease or pursuant to any expansion of the Subleased Premises, Tenant shall pay upon EXECUTION OF THE SUBLEASE. With respect to any commission earned upon extension of the Term of this Sublease, Tenant shall pay one-half upon execution of any amendment/addenda to the Sublease extending the Term. Tenant&#x2019;s Broker shall pay to Subtenant&#x2019;s Broker (as identified in the Agency Disclosure section above), the amount stated in a separate agreement between them or, if there is no agreement, $</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">                     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">                   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">% (complete only one) of any commission paid to Tenant&#x2019;s Broker, within five (5) days after receipt by Tenant&#x2019;s Broker.</font></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">If any other lease or sale is entered into between Tenant and Subtenant pursuant to a right reserved to Subtenant under the Sublease, Tenant </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> shall not (shall not if not filled in) pay an additional commission according to any commission agreement or, in the absence of one, according to Tenant&#x2019;s Broker&#x2019;s commission schedule in effect as of the execution of this Sublease. Tenant&#x2019;s successor shall be obligated to pay any unpaid commissions upon any transfer of this Sublease and any such transfer shall not release the transferor from liability to pay such commissions.</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="margin-left:6.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Notwithstanding anything to the contrary herein, Tenant represents and warrants that it has not used any broker in connection with this Sublease except for Tenant&#x2019;s Broker and Subtenant represents and warrants that it has not used any broker in connection with this Sublease except for Subtenant&#x2019;s Broker.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.989278055754109%;">22.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">BROKER PROVISIONS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">. TENANT&#x2019;S BROKER AND SUBTENANT&#x2019;S BROKER HAVE MADE NO REPRESENTATIONS OR WARRANTIES CONCERNING THE SUBLEASED PREMISES; THE MEANING OF THE TERMS AND CONDITIONS OF THIS SUBLEASE; LANDLORD&#x2019;S, TENANT&#x2019;S OR SUBTENANT&#x2019;S FINANCIAL STANDING; ZONING; COMPLIANCE OF THE SUBLEASED PREMISES WITH APPLICABLE LAWS; SERVICE OR CAPACITY OF UTILITIES; OPERATING COSTS; OR HAZARDOUS MATERIALS. LANDLORD, TENANT AND SUBTENANT ARE EACH ADVISED TO SEEK INDEPENDENT LEGAL ADVICE ON THESE AND OTHER MATTERS ARISING UNDER THIS SUBLEASE.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.361%;"></td>
    <td style="width:51.639%;"></td>
   </tr>
   <tr style="height:167.5pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">DELTA DENTAL OF WASHINGTON,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a Washington nonprofit corporation</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                        </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">TENANT</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                        </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">TENANT</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">/s/ Brad A. Berg</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Chief Operating Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                     </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Its:</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                        </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">SILVERBACK THERAPEUTICS, INC.,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">a Delaware corporation</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                        </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">SUBTENANT</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                        </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">SUBTENANT</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">/s/ Laura K. Mawry</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                            </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">By:</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">Chief Exec Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                             </font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Its:</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                                        </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">STATE OF WASHINGTON</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">COUNTY OF  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">   King</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                         </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This record was acknowledged before me on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">     June 24            </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">_</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">_, by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">         Brad A. Berg     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">as</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">            COO &amp; CFO                                          </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">       Delta Dental of Washington</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">            /s/ Julie Stewart</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                                 </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">My commission expires:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">          3-04-2024</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                      </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">STATE OF WASHINGTON</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">COUNTY OF  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">   KING</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                        </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">This record was acknowledged before me on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">     July 1st             </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">20 _</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">_, by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">     LAURA SHAWVER </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">  as</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">            CEO                                         </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">       SILVERBACK THERAPEUTICS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                          </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">            /s/ Veronique Moleres</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                                        </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">My commission expires:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Arial;">          4/26/25</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">                         </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">EXHIBIT 1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Legal Description of Master Premises or Property]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Omitted]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:39.0%;"></td>
    <td style="width:21.0%;"></td>
    <td style="width:9.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_0.jpg" alt="img42437169_0.jpg" style="width:91px;height:40px;">&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Jones Lang LaSalle</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">601 Union St. Ste 2800</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Seattle, WA 98101</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Phone: 206-607-1700</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Fax: 206-607-1701</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#169; Commercial Brokers</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Association ALL RIGHTS RESERVED</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Form: SUB_LS</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;SubleaseAgreement</font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Rev. 9/2020</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;"> </font></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">Page </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Arial;">&#160;of 20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42437169_1.jpg" alt="img42437169_1.jpg" style="width:48px;height:27px;">&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">EXHIBIT 2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Master Lease]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Omitted]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">EXHIBIT 3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Outline of the Subleased Premises]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Omitted]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">SUBLEASE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">EXHIBIT 4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Work Letter]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">[Omitted]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>sbtx-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
  <title>EX-10.15</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;"><br>RSU Award</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> Grant Notice<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;">(</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;">2020 Equity Incentive Plan)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) has awarded to you (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Your RSU Award is subject to all the terms and conditions as set forth herein and in the Company&#x2019;s 2020 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and the Award Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Participant:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                      </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Date of Grant:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                 </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vesting Commencement Date:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                       </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Number of Restricted Stock Units:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                 </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                            </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vesting Schedule: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1/4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the Restricted Stock Units shall vest on the first anniversary of the Vesting Commencement Date.  Thereafter 1/4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the Restricted Stock Units shall vest on the second, third, and fourth anniversary of the Vesting Commencement Date (and if there is no corresponding day, the last day of such month) such that the RSU Award is fully vested on the fourth anniversary of the Vesting Commencement Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, vesting shall terminate upon the Participant&#x2019;s termination of Continuous Service.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Issuance Schedule: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">One share of Common Stock will be issued at the time set forth in Section 5 of the Agreement for each restricted stock unit which vests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">IMPORTANT INFORMATION REGARDING SELL-TO-COVER ELECTION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Please read this Restricted Stock Unit Grant Notice, the Agreement, the Plan, and the Company&#x2019;s Sell-to-Cover Election (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Sell-to-Cover Election</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) carefully.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By accepting this RSU Award, Participant hereby agrees and acknowledges that (1) during the next &#x201c;open window period&#x201d; following the date hereof applicable to Participant, as determined by the Company in accordance with the Company&#x2019;s then-effective policy or policies on trading in Company securities, or (2) on the next date following the date hereof when Participant is otherwise permitted to trade in Company securities, Participant will execute the Sell-to-Cover Election with respect to this RSU Award and each Restricted Stock Unit granted to Participant by the Company following the date hereof (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Sell-to-Cover Election Obligation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">If Participant fails to fulfill Participant&#x2019;s Sell-to-Cover Election Obligation, this RSU Award will be cancelled and Participant&#x2019;s eligibility for any future or additional benefits under this RSU Award will terminate, effective immediately as of such failure to fulfill Participant&#x2019;s Sell-to-Cover Election Obligation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Terms/Acknowledgements:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The RSU Award is governed by this RSU Award Grant Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and the provisions of the Plan and the Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU Award </font></div></div>
  <hr style="page-break-after:always;">
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">You consent to receive this Grant Notice, the Agreement, the Plan, the Sell-to-Cover Election, the Prospectus, and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement, the Sell-to-Cover Election, and the Prospectus.  In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.:                          Participant:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                                 </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">            </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                                        </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                           Signature                                                                        Signature</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">                                                              </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">            Date:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                              </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Date:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">                                                               </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Attachments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> RSU Award Agreement, 2020 Equity Incentive Plan, Sell-to-Cover Election</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Attachment I</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc.</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> <br></font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">Award Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">(2020 Equity Incentive Plan)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As reflected by your RSU Award Grant Notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Grant Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), Silverback Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) has granted you a RSU Award under the Company&#x2019;s 2020 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for the number of restricted stock units as indicated in your Grant Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The terms of your RSU Award as specified in this Award Agreement for your RSU Award (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and the Grant Notice constitute your &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">RSU Award Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.&#x201d;  Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The general terms applicable to your RSU Award are as follows:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governing Plan Document.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Your RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in:</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 6 of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award;</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 9(e) of the Plan regarding the Company&#x2019;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award; and</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 8 of the Plan regarding the tax consequences of your RSU Award.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Grant of the RSU Award.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This RSU Award represents your right to be issued on a future date the number of shares of the Company&#x2019;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Dividends.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment; provided, however, that this sentence will not apply with respect to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Withholding Obligations.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As further provided in Section 8 of the Plan, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with your RSU Award (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Withholding Obligation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in accordance with the withholding procedures established by the Company.  Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award.  In the event the Withholding Obligation of the Company arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount </font></div></div>
  <hr style="page-break-after:always;">
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Date of Issuance.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner.  Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 above, and subject to any different provisions in the Grant Notice).  Each issuance date determined by this paragraph is referred to as an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Original Issuance Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;.</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day. In addition, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">if</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></div></div>
  <div style="margin-left:13.593%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Original Issuance Date does not occur (1) during an &#x201c;open window period&#x201d; applicable to you, as determined by the Company in accordance with the Company&#x2019;s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company&#x2019;s policies (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">10b5-1 Arrangement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">and</font></div></div>
  <div style="margin-left:13.593%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">either (1) a Withholding Obligation does not apply or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this RSU Award, and (B) not to permit you to enter into a &#x201c;same day sale&#x201d; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding Obligation in cash, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">then</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#x2019;s Common Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">if and only if</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this RSU Award are no longer subject to a &#x201c;substantial risk of forfeiture&#x201d; within the meaning of Treasury Regulations Section 1.409A-1(d).</font></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To the extent the RSU Award is a Non-Exempt RSU Award, the provisions of Section 11 of the Plan shall apply.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Transferability.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Corporate Transaction.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No Liability For Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal </font></div></div>
  <hr style="page-break-after:always;">
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Other Documents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.  In addition, you acknowledge receipt of the Company&#x2019;s Trading Policy.</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Questions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">*          *          *</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">This Agreement will be deemed to be accepted by you upon the signing (which may be electronic) by you of the Restricted Stock Unit Grant Notice to which it is attached or by the deemed acceptance of this Agreement, as described in the Restricted Stock Unit Grant Notice.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>sbtx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Form S-3 No. 333-261979 of Silverback Therapeutics, Inc. and </font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Form S-8 Nos. 333-261980, 333-254827 and 333-251143 of Silverback Therapeutics, Inc. pertaining to the equity and option plans of Silverback Therapeutics, Inc. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of our report dated March 31, 2022, with respect to the consolidated financial statements of Silverback Therapeutics, Inc., included in this Annual Report (Form 10-K) of Silverback Therapeutics, Inc. for the year ended December 31, 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Seattle, Washington</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">March 31, 2022</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sbtx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Laura Shawver, certify that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.    I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of Silverback Therapeutics, Inc. (&#34;the registrant&#34;);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.    The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.    The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.0%;"></td>
    <td style="width:9.38%;"></td>
    <td style="width:6.62%;"></td>
    <td style="width:42.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Laura Shawver, Ph.D.</font></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laura Shawver, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sbtx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Jonathan Piazza, certify that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.    I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of Silverback Therapeutics, Inc. (&#34;the registrant&#34;);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.    The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.    The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.0%;"></td>
    <td style="width:9.38%;"></td>
    <td style="width:6.62%;"></td>
    <td style="width:42.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jonathan Piazza</font></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jonathan Piazza</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sbtx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSURANT TO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Silverback Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2021, to which this Certification is attached, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned officers of the Company herby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.0%;"></td>
    <td style="width:9.38%;"></td>
    <td style="width:3.083%;"></td>
    <td style="width:45.537%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Laura Shawver, Ph.D.</font></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laura Shawver, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 31, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jonathan Piazza</font></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jonathan Piazza</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img42437169_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42437169_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  H %L# 2(  A$! Q$!_\0
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* & . !110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img42437169_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42437169_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; # # 2(  A$! Q$!_\0
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116Z,Q;RTVYP"><5Z!0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img238320182_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H Z+PA_R'-._Z_K7_P!'QUE4^"7^%_DQ,YVM1A0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4D[)WOSJRUWY;7'8\_\ %.K:3K>AZ<(KEEOM.MDMS:F%_F/[M6?SO]6%4(2
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MXRMQA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<XP.])M1U;27GH!4I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M2O:V$-D]I#;%S+;M'<*Q==SI>@O%=B1?E**<KNW.^XK'6<)OVB3DW=O9Z?\
M@.\1+<XKXEC$.BA_]?\ V3;>9G_6?=XWY^;[V_&>^[OFNBAO4MMSNPUU/+*Z
MR@H ^H?%?BO2_!^L&^,=U-JC6"1HH,:VNQBQ4MSYF[</F^5AC[H!YKR:=.56
M'+=*'-?K?_(S2.(U*;3]&\.Z4@L;-IM5@GCENI(E,D2@JIE0@ F5?-#+(S$K
MLV@$'Y=XJ4JD_>E:+323T?EZ:;%=3T/Q%X;T'3K2XM'M42".T)CDATRZ>9'5
M-PE?48P\3 8W,&"@<^:Q7(/-"<Y--/6^J<U;TY=_ZT)..UO24TG2H+?3=(@O
MK2?2GN)M0* RQS&-G:03\A/* $HC)_>Y$4>-I!WC+FDW*;BU.RCTM?:WGM?I
MNQG226%MJ.OV\=W%'<(OAI'594610XE8!@&! 89.#U&3BLKN,&XMK][TTZ"Z
M?,Y?1GT_2M"T2>33[.[GU"ZEMY9)XE9O+-TZD]/F<+M",^[RP, 8)%;2YI3J
M)2DE%)I)^0^XOB/P]I^FV'B/R+>)6MKFR\AMBEH5E:!W6)B"R*?,8$*0-IVX
MVX%*$Y2E2NWJI7\[7W#L6O&FABP232M-T>![%;:)DU';LD5RZC>UR?O\D Q9
MWL"6Y3BE2E>TY3?-=^[T^[IZ@CJM>\+V":5J2S6EDDEK:-)&;>PEMS&ZQLX*
MWCG;<\@9$87;]V4'.*QA.7-&TI6;L[R3Z_R]/G\A'DWQ8_X_-/\ ^P3:_P#H
M<]=N'VE_C?Z%([OPW9W'B2TL=-U>RO+5K:V#6.J6KE$2)HP4+LIV*S(%4@EG
M)/*1Y8US3:IN4H23N_>@^]_Z_P""+;8H37$P\$M#:6EK>BWNI[:1UMRZI%'#
M,&OAACLG PPN#P-_3D522]M=MJZ36MM6U[OIY!U.BM_"%M/XELYX["%]+;35
M9F$$9MFE(?!;Y?+:0@H02"Q&&Z#(S=1JG)<SYN;N[V_.PKZ'/^#]-2TT33+R
MRTV'4;B\O66ZFDB,KVZ),ZJZL.8=JHK!\A%/)!9P:TJ.\YQE)Q2CHKVOI^(V
M6M;L+:[OO%,T\4<LEO;VS1.Z*S1L;<Y:-F!*$X'*D'@>E*+:C12;2;=_/4.Q
MTL7AC0+&SM[>2V2>UEM%9Y(],NKJXD9USYHOK<.L><[@FS(XVE5VXRYYMMIV
M:>W.DEY<KW%J<OIN@6EWX:V0V$*7 L)IFFN+9BTA*Y2>&_0ND97.\6\@\P\+
MB-%+'64VJFLG;F2LGMY./7U_,?4^=J],L* "@ H * "@#V7P3]A_X175_P"U
M//\ L?G6OF?9O+\[_6)LV>;\GW]N[=_!NQSBN&KS>UAR6O9VOMMY$O=6.P\*
M^+K?Q)K82TA>.ST_29H8UF;,LBAH,F1@6P2%"_>8]6+9; PJ4W3AJ_>E--VV
M6^PFK&$;.T\4:;I>HP6%E:7$FKI:LD2>7#)%B1]LH7E@5158G<Q.XKMW;:TN
MZ<IP<I-<E]=6GY!L=)XS\-V"Z)<2BTMA<6]U!&AMK&33SAIHXV0/(Q\\,KD"
M93Y))! RN:SISESI7=FGO)2Z-]-O3<$1>)_#-A=P6YCLH+&W&H6<$F;=[6YC
M21UCE4R@M'=JV_(EC8(N.&D92:(3DF_>;?+)K6Z=M5IO'T!$WC?0]%M-.O8O
MLJ0M!&#;/;Z7=1%'4 @2WP5X)E<X!8E%&2&)89"I2FY1=]][S3^Z.Z!'B/@8
M7[ZM;QV'GE3/ UPL'F$&!9X]QE"<>4I(W%_D&1GK7?5Y5!\UMG:]M[/;S*9L
M_%>SG@\174\L<B13M&8G9&5) L$08HQ #[3PVTG!X/-1AVO9I)ZJ]_+5B6QY
MO744% !0 4 % !0 4 % !0 4 % 'T]XQ\6:7X1UJZNDBNIM5FM$B +1BT"L
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 'TW_P 11]:AVE^'^8<P?\*@UKUA_P"^F_\ B*/K4.TOP_S#F#_A4&M>L/\
MWTW_ ,11]:AVE^'^8<P?\*@UKUA_[Z;_ .(H^M0[2_#_ ##F#_A4&M>L/_?3
M?_$4?6H=I?A_F','_"H-:]8?^^F_^(H^M0[2_#_,.8/^%0:UZP_]]-_\11]:
MAVE^'^8<P?\ "H-:]8?^^F_^(H^M0[2_#_,.8/\ A4&M>L/_ 'TW_P 11]:A
MVE^'^87#_A4&M>L/_?3?_$4?6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S
M#F#_ (5!K7K#_P!]-_\ $4?6H=I?A_F','_"H-:]8?\ OIO_ (BCZU#M+\/\
MPY@_X5!K7K#_ -]-_P#$4?6H=I?A_F','_"H-:]8?^^F_P#B*/K4.TOP_P P
MY@_X5!K7K#_WTW_Q%'UJ':7X?YAS!_PJ#6O6'_OIO_B*/K4.TOP_S#F#_A4&
MM>L/_?3?_$4?6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#
M_P!]-_\ $4?6H=I?A_F','_"H-:]8?\ OIO_ (BCZU#M+\/\PY@_X5!K7K#_
M -]-_P#$4?6H=I?A_F','_"H-:]8?^^F_P#B*/K4.TOP_P PYBCIWPSU'5HC
M<6<L$L0DEB+ R ;X9&BE7YHP<I(C*>,$C()&#1]:AVE^'^8<Q>_X5!K7K#_W
MTW_Q%'UJ':7X?YAS!_PJ#6O6'_OIO_B*/K4.TOP_S#F#_A4&M>L/_?3?_$4?
M6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\ $4?6
MH=I?A_F','_"H-:]8?\ OIO_ (BCZU#M+\/\PY@_X5!K7K#_ -]-_P#$4?6H
M=I?A_F','_"H-:]8?^^F_P#B*/K4.TOP_P PY@_X5!K7K#_WTW_Q%'UJ':7X
M?YAS!_PJ#6O6'_OIO_B*/K4.TOP_S#F#_A4&M>L/_?3?_$4?6H=I?A_F','_
M  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\ $4?6H=I?A_F','_"
MH-:]8?\ OIO_ (BCZU#M+\/\PY@_X5!K7K#_ -]-_P#$4?6H=I?A_F','_"H
M-:]8?^^F_P#B*/K4.TOP_P PY@_X5!K7K#_WTW_Q%'UJ':7X?YAS"'X0ZRN
M6@&3@?,W7K_<H^M0[2_#_,+B_P#"H-:]8?\ OIO_ (BCZU#M+\/\PY@_X5!K
M7K#_ -]-_P#$4?6H=I?A_F','_"H-:]8?^^F_P#B*/K4.TOP_P PY@_X5!K7
MK#_WTW_Q%'UJ':7X?YAS!_PJ#6O6'_OIO_B*/K4.TOP_S#F#_A4&M>L/_?3?
M_$4?6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\
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M_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\ $4?6H=I?A_F','_"H-:]8?\
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M_$4?6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\
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M_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\ $4?6H=I?A_F','_"H-:]8?\
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M-=.J]17/HRP_X]XO^N:?^@BO+(+= !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!YW\+_^0,W_ &$=5_\ 3E=4 >B4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % %>;[R?[_\ [*U(98IB"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H KV_1O]]OYTD,L4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MI::E-;_896EN(7@\T3;&MYY(&'F*J*V3&3\HP,X!8#<0#JZ "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /S$\0?\A6__P"O^\_]*9:]2E\"^?YL
MU6QDUN4% !0 4 % !0 4 % !0 4 % !0 4 % !0!]+?"#XO_ -F^7H&OR?Z+
MPEK=.?\ 4]EAF8_\L>T<A_U/W6_=8,7'5I7]Z&_5$-=4?776N S()OO)_O\
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MXV>=LSN^;;NPN=H .DH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ%U*L"HVG !>\->*]*\7VOV[1;A+N ,49E#*RL.=KQR*DB'!! =1D$$9!!H
MZ&@ H * "@ H * "@#SWXC6E[K%A%H6GJP;5;A()YS$\L5O;(#/.\VUD&R5(
MOLX1I(S(9MB,&(( ,.#3M:\/>)TU&<)J$&JV;VUP+"SDMECFL@9K1I?-O+E
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M;QS2Q@QNI:&.0!AM/S$ @&K=^(+"RTUM:FF5=/6 7)F 9E\DJ'5PJJ7;<I!
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M9XH0Y R0ID90Q Y(&2!0!=L[R#4(4N;22.>"4;DEB=7C=?574E6'N"10!9H
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M)J=KXIFO=-E@:Y@CBB;3XX5:949;61X#YC?NRSCS<MU4'#@';^$O^2E>)/\
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MYFBGM4C?<5+C:LCC:&"G=EE) ( ."T'Q#KB:9H&NWM^UW_;%Q:VUS;&WMHX
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MF(>/:54N )5D3*$ [?5=,O'\6:=:17T\<BZ1?>9=^5:M<NHNK,_(# +1'+;
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M)H W-(\):9H=PUW9Q.)VB6 /+//<&.!6+B"#[1++]G@W$'R8/+B)5,H?+3:
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M0#%T_P "Z-I<\=Q;PN#;EVMXWN+F6WMV?.XVUK+,]M;$ E5,$4>Q&9$VH2I
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M[V'3)'VW5U'++%'M<[D@,8E;<%*+M,J<,P+;OE!P< &E0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M G)H JW=GX<TS5[RS\6K:)86EG9PZ0FH;/(6UC@"W LQ+^[,XE4"7R1]HVB
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M*E^S_8=4N+S4%B$.'AUG2R((X\1XW/)I2112RF,I;0+%+N5[A)!N /?Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *.I?\>LO^X:
M 'V'_'O%_P!<T_\ 010!;H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /._A?_P @9O\ L(ZK_P"G*ZH ]$H * "@ H * "@ H * "@ H * "@ H
M* "@ H * *\WWD_W_P#V5J0RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!7M^C?[[?SI(98IB"@ H * "@ H * "@ H * "@ H * "@ H * "@"
MO/\ P?[X_K28RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@.9]W]X?:YO^>C_]]-_C0',^[^\/M<W_ #T?_OIO\: YGW?WA]KF_P">C_\
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M_>)]JF/\;_\ ?1_QH#F?=_>+]KF_YZ/_ -]-_C0',^[^\/M<W_/1_P#OIO\
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M /?3?XT!S/N_O#[7-_ST?_OIO\: YGW?WA]KF_YZ/_WTW^- <S[O[P^US?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H Z]KB:VTBV-NSHYF<?(2"?F? ('49['(/I3Z'7
M=QIQY6T[O;YF]Y(N+FW:?<L[6C-+M9HVR-F,["I');CIQC'%,VM>4>;XN77H
M^G;YF)8Z9:7%D"(R]P8W8Y=D<8SM:-#A'3IDYQ]3P QC"+CM[UF][/Y+9HBE
MLK.SMX5>&2:6YA\SS$8Y4E=P 0?*0N><] ,G-(3C&,5=-MJ]UT^1>32K&":&
MPDA>1YH]QF#LN#@GA1\N!COT!&<T_(OD@FH--MK>_P"A7@T*&\2,0CYXKEH9
MSEOF123NP20#M 'RX&2?3@L)4U)*VZDT_3_ANQ9MM)T^19KHJGE"8QHLDS1H
MJK@$[QN)9CE@#D8QTH*4(:RTM>RNVE]_F0Q:9IZ27;X^T0P(DB;)"<9#%EW*
M<'D8R<D#WYH)4()R>Z235G^!#;:9:ZS"'M(_)=)U61=[,?*;OR>W8X&=II"4
M(U%>"LT]=;Z,Q;HQ0Z@?LB92.50B9+;BI P,Y)WL#CKUP/2@Q=E/W%HGHO3_
M #.HO91J<,MU$\NR,H9[67(7"D$JC?P$X).W)/?&0*9TR?.G)-V5KQ?EV[#]
M7BAO+^WM_(+,R*2PD*Y3;(0GH,$;BP^8@$"@<TI3C'EZ=^FNA6U#1K3RX'A5
M4,ERL+>3*TPVG=G!8#YACICCOFBQ,J<;1<5:\DM'?^F%W8Z;&# JQB9YA%'L
MF=V +;=[KG"L.<J1C/&:- E&"]VRO>RLV_F_\B34](TZVBE0&..6),H?/)D9
M@,X:)L 9Z#;DG/&*+#G"$4UHFEI[VK]49GA+_C[?G;^X?GTY3G\*2,J'Q/T?
MZ&M%>V]TUK8I-)<LLI=ICOC;&Q^ Q(<?>'0]!UI^1JI*7+!-RUO?5='\RD+.
MTC@N+N>)YVBNY$ #N"5XP&;).,DDM]XG&301RQ2E*2;M)K=EH>'[4WQ3!6$6
MXF\MG(P22NTMRP48R3DD'VXHL7[*//;IRWM<EM+.S@O[62T:,,WFAXXY?- Q
M$^"&.&YZ'( Z8Z'(.,8J<7"W6Z3OT90>UCDM8-VXB2]*,-[[=I=P<+NV@X_B
M #>](S:3C'SG;=]WT)KG3;!C=V\,3)):QF02>8QR0-VW:21@<#G)(SR#R64X
M0]Z*5G%7O<L1:)I\,,2W)C5I8PS2/.4<%AGY(\;&4$X!)'N#18I4X)+FMJMW
M*S^2V.!=0C%0=P!(R.AP>H^M2<&PV@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M^% 6?9_<'V>7^XW_ 'R?\* L^S^X/L\O]QO^^3_A0%GV?W!]GE_N-_WR?\*
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M&'_ 3_A0'*^B?W'JUA_Q[Q?]<T_]!%:'M%N@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H \[^%_\ R!F_[".J_P#IRNJ /1* "@ H * "@ H * "@
M H * "@ H * "@ H * "@"O-]Y/]_P#]E:D,L4Q!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 5[?HW^^W\Z2&6*8@H * "@ H * "@ H * "@ H *
M"@ H * "@ H KS_P?[X_K28RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M']:3&6*8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@"CJ7_'K+_N&@!]A_Q[Q?]<T_]!% %N@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _./4O%>LZ7?WMM97][;0
M)?WNV*&YFCC7==3,<(CJHRQ).!R22>37I4HQ<$VE?7HN[-4M"I_PG7B+_H*Z
MC_X&W/\ \<K;DC_*ON0[(/\ A.O$7_05U'_P-N?_ (Y1R1_E7W(+(/\ A.O$
M7_05U'_P-N?_ (Y1R1_E7W(+(/\ A.O$7_05U'_P-N?_ (Y1R1_E7W(+(/\
MA.O$7_05U'_P-N?_ (Y1R1_E7W(+(/\ A.O$7_05U'_P-N?_ (Y1R1_E7W(+
M(T=)^)?B32;J.\74+NX\ILF*XN)IH9!T*O&[D$$9&1AE^\C*P!$NG%JUDO16
M"R/N+P/XXL?'5B+RS.R5,+<6[$%X7(Z'IN1L$QR  . >%=71?-G!TW9_)F35
MCM*S$% !0 4 % !0 4 % !0!7F^\G^__ .RM2&6*8@H * "@ H * "@ H *
M"@ H * "@ H * "@ H * *]OT;_?;^=)#+%,04 % !0 4 % !0 4 % !0 4
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M H * "@ H * "@ H * "@ H * "@ H KV_1O]]OYTD,L4Q!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!7G_@_P!\?UI,98IB"@ H * "@ H * "@ H *
M "@ H * "@ H * *<NH6L$OV>2:))A$T_EM(H?R4(5Y=I(;RT9E#28VJ6 )!
M(H EMKF&]B2XMG2:&50\<D;!T=&&59&4E65@00P)!'(- #+J]M[$(;F6. 2R
M)#&9'5 \LAVQQIN(W2.W"(,LQX4$T 6J "@"M#>03R20121O+;E5F175GB9U
M#J)%!)0LC*ZA@"5(89!!H LT % !0!6^V0>>;3S(_M C$IAWKY@C+%!)LSNV
M%@5#XVE@1G(Q0!9H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * *.I?\>LO^X: 'V'_ ![Q?]<T
M_P#010!;H ^8?A[(!\)+TYY%CK //0D7./Q.1COR/6@"SI/C+6M%T[PKH6@P
M6EQ-J^F-@W32(J/!!&X<O&?]6J;V= C.^ J,K=0"]_PM[5K+1+Z6^M+5M<L-
M4725BA>06LDTA'ERY=C(L> _RE]S;5RT>XA #FX;C6$\7ZK)XDBLC>1^$KDL
MEH\YMI8Q/&P^^4F3=\R. ^X8W(XR, %__A8&I>%/"N@RZ1:65I;7D#&6XN%O
MI+&SVD;(F\II[E?.+$))+(RJ1\QVY9 #J+CXB>(-7O;/1?#=OIS7\VEIJEU+
M<SR26BHSK'Y=N]N=TA+D;9"2N&7(X8@ Q_[9DTKQS=:OJ</E2VO@XW5S!&P?
M8\5Q'+-$C\*^TJR*W1L ]#0!+9_$[Q/:II6L:Q::<NBZ]=06T"VTDYO(#= M
M"TQD_=.-JLQ$:C@8.PD @&E9_$K6)?%KZ!=PV-G:+<O!%%.;B*]GB7.R[MY'
M46<T<G!$*-Y^"0 <9(!P%C^T;<7NHQ;4L/L%Q=K;K: 7O]HK&\@1;AI3%]A(
MP=_E*^_G9G^*@#9\>>,_$'B&V\16.EVUD-&TB*:TNI)WE%W(YB;S'@"9B CY
M.R1?G4##[F(0 ]J^'G_(KZ/_ -@NP_\ 26*@#L: "@ H \X^'O\ K=;_ .P[
M=_\ HBUH XGPWKU_H?AO28],6!Y=2UN_LR;CS-BI+=ZK,)!Y9#$J8D8#I(N4
MRA<2H =)<>.K_0H-8CU)+>ZN]&^R&)K=)+>*X%\JK;JT<DMRT1$^Y)#YSC9A
MP%Y% %69-7B\7Z*NKR6<Y^QZJ4DM(IH,,19>9&T4LUSD)A"DPF!DWLK01>6&
ME ,^S\:7EEH6G75M#9Z7:7$]\MS<I93S65DL-S-''NMK::%HA<.-TES).L$3
M+(9!^]4H =;)XEU'4KRSTG2I+%9Y[#^T)[LK)>6IC++$BVJ1SVK2B61BZRM,
MJI$GW)&D!4 Q+W4I='\2_P!H:D$,EGX9NIYQ!N*,8;N%W\K?A@&VG:&R5R 6
M;&X@%V+Q1K=A'INHZF+)[/6+BW@^SV\4R36IO.;<FX>>2.ZV?+'-BVMMQ8R)
M@+L8 GT3Q=>WNM2Z9?/:63+-.D=A-#<0W<EO'YHBN[:Z>0P7RR>5O>*"W401
MN?,FWQ;9@#F])^)>IZN+74;6WDGL[VXC3[(FDZKYL=M)(8A<?VH1]@D,8VSR
MH(5CV;XEG9D$K@!XNUS5]>T3Q%+9?8X].L(M0L3%+',;B?R;9EN9EN$E$<.Q
MF?R8FM9?-,6UI8EE$D0!ZUH'_(-M/^O:#_T4M &O0 4 % !0!A>)_P#D$7W_
M %YW/_HEZ /#_ /B!/ &BS6-UEXHM*MM:L(^<R+=QJL]M'U&[^T6PBC!S>1C
M&"* (?#GVSP!!XHNR4GU*UMK2^G:3+1R7DMK-<SY"LC&/SG95"LI\L* 10![
M!=^(KBWU;2=.58_*U2&\DF)#;U:WB@=!&=X !,C;MRN2 ,%3DD \;TV?5;?1
M= 72[J.T6X\07\+AHI9-Y:ZU=P)?+NK<26^$.^W(&^3RY!*OE[7 .]UCQ'<Z
M'>ZNRPV;W>F^'H[[[0(&1YID^VGRY#YS/]E#P[HX?,+)O?\ ?,3NH O6OB;6
M+2[TO^U!9M:ZX7C2.W299;6;[.US%NFDE9;J-DCD1R+>U9'*$!EW4 <1H'BN
M7P[HEI:6JYN=2U;5XTD-M<WBPI%>WDTLAM;,?:+AL*$6-&C WF5Y52,JX!Z;
MX,U^^UH7,>H0NAM956*Y-G=V$=U&Z!P\=M>YGC:-B8I 7D4LH=7PX50#MJ "
M@ H _,3Q!_R%;_\ Z_[S_P!*9:]2E\"^?YLU6QDUN4% !0 4 % !0 4 % '9
M> M2UG3-9@?P\&DO9&V"(<I,AY>.49 \K W,Q(\O'F!D9 PSFHN+Y]A/S/T:
M@,C1J9E5)"H+JK%E5L#<%8JI8 Y 8JI(YVCI7D>AB2T % !0 4 % !0 4 5Y
MOO)_O_\ LK4AEBF(* "@ H * "@ H * "@ H * "@ H * "@ H * "@"O;]&
M_P!]OYTD,L4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!7G_@_WQ_6D
MQG*^/=8U;0='FOM!M/[1OH]NR#:[Y!8!F\N,K))M'.Q"&;L:8B]X1U+4-7TB
MUO=8MOL%]-'NFM^?W;;B!PQ+)O4*_EL2\>[8Y+*30!XE\8/$6GZS#J>B3WEO
M;Q:59O(UN\\<<UY?R0E[:)(RXDDBM599F 4J]R\"C+6\B@ ZJ>>U\9:QI>DN
M\=YHITN>_:-'$EM>3PW%K B3;28YTMV+2>4VY/- ,B$HNT T(-/M_"GBRSL=
M&C2TLM4LKR2YM(%$=N);5K417*PH!''*RR-"[J!YBA0X+(A !V/BFPT6XM?M
M?B*."6SL0TQ^U /;H=NTR-"^8GD )6-F1I%WLL1!D8, >,6-G>6NA:1I=XLM
MO9:SKC+]DD+!HM,D6ZN;>PD&251TBC62$G B9H' &]0 =AI^C6>E^)[W0+&(
M6NF:AI$5S-;6Q:WB6?SY;5I(EA,8@DFAVK(\)1W,*,3N4-0!!X:TNRB\7W,W
MAN&*STRRLOL5_P#946*VFU 3"6.+RXPL,D]I$T@FE ,D1F^SN0=RJ 5[S0-.
MMO%.FVGAN".WO+)I;K5;B'._[)+&56*^FR7N)KR<K)&L[RS'RI+@X WD ]5U
M76K?10C7"7+B0D#[-9W=V1C&=PM()B@YX+A0W.TG!P 5=,\36FK3?9X([U'V
MELW&G:A:I@8S^]N;6&+=SPN_<>< X- 'F'BR/2)/&"C6[(ZE"-%.R,:?-J!5
M_MC?,(X8)S&2N5$C!%YV[P30 FD7_B'PU8:)H@6);K4KF]B'VXR3O:VJ)<7-
MN',<P,LD%NB*T9E^?:(?.C/[U0"_J_C?5(+ZXTFT:,7&F0P^=*-'U6_CN+F:
M(2A42QE86404KS-/<2,7("XB+2@&I#XLU77)['3K"&/2KNYT_P#M&Z%_#+.;
M=2ZPBV6!);-WE,K-F1WB"QQY,1:0", SKQ[B/Q1"]ZL+W"^&K\RJ@9H&<7=E
MN #X8QL1]ULD*=I9L;B 0:3XJU2ZA\/V&E1:?9_VMI3W3YAE,-KY*695;>WB
MFCW1XF:-83+'@;'$W[LQR@#I_%UQ=Z? U];V<]W;>([;2Y=T3-#O%XD0NK='
MD9H91&ZR0EI)##)W?% '1Z?K>L:_>7;:<;.&QTZ]-DT5Q%,\]PT.PW,BSQSI
M';*/,*0J;:Y+%-[E0X5 #G-6^(ESIU^!%);W-HNI06$L4-CJ$@02S) 6.K@K
M8"XC,BR2VWDDQN&M/-:5?,(!N^$_^1C\1_\ 7W8?^FNUH U+3Q%<3ZMJVG,L
M8BTN&SDA(#;V:XBG=Q(=Y! ,:[=JH0"<EC@@ Y.R\;:QJD&@+:I9QW&OV4]Q
M,\J3&.!HHK>3=%&LH:11YCCR6E0O\O[^/:=P Z3QWJ-K;W-C+';2:Q!JMOI4
M<BK(EI(UVL<T-RT1E>5%CMY2TL G=G>(JDR^8NP KVD]_IWBV\FU:2R=[?0$
MD6=/,M+<QK=SONG$KW)ME1MRNXEN%\M1-\I)B0 ET+QQJ&J:E'I7FP2_;[&>
MYM;C^RM2LHXY(C#M^6\G7[?"ZS!M]O)!PG.WS4*@&)X;\6ZMH/A&#5=0F349
M;J=+6U'D7+2K+->R0;[AUGNIKI4R'2*"".4J@@3>SJZ@';^$_$NI:G?S6%[$
M\L*0+-'>C3-0TN,L7V/;M#?F1FD VR*\<K*R%@44IE@#T2@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MHZE_QZR_[AH ?8?\>\7_ %S3_P!!% %N@#QF[^!NAW,LWEW&I6UE=RF:XT^"
M\:.RE=CEB\.PMR<<+(-H ";0   =I-X&TY]1TS5(_,@?08IH;2&(HL CFA\@
MJZE&8A(_]7L=,'[VX<4 8MY\*=&O[?4K2Y-Q(FM78O9B9$#0SCE6MV6-=@4]
M _F9!(8LI(H @TGX2:9I,\]Y]IU&[N;VPFTZ>:[N1/(\,S(Q8LT>1(@14CVX
MC5<YC9B6H +SX2Z==:?9:9'>:G:1Z; ]LDEK=+#++!(07CN"L6R16VC($:_K
M0 R_^#VC70M&M);[2YM.MA:1SV-R8)GMP2?*E<JY=2Q8DC:Q+$9Q@  V+;X<
M:3;7WV\"9P=)713!(X>%K-2IPV4\UI"%",YE(*DY7<=U &%H_P &=&TBZM[G
MS]1NX;"3S;.SNKLRVEK(#E7AAV*04/*[F;D G)&: +T?PKTQ=776I+C4)C'=
M27L5G)=%K**YE9G:6*#8"K;W9@-^WG&,<4 5;3X16.EW:W.F:AK&GVZSBX^P
M6U\4LBV\.RF$QL?+D(PZ[^5)4$"@!-;^#NC:Y?75^\U_;#4@/M=M;71BMKAP
MI59)8@AWNI.X MY9?)9&W.& /1=&TN+0["VTRW+M#96\5O&SD%RD,:QJ7*JJ
MEBJ@L0J@G.% XH TZ "@ H XR[\&))<W%W87M]I;7^TW26C6VR614\L38N;:
MX:&8QA4:2W:%G"(S9=0] %F7P=I[0:?:PA[>#1KA+FV2-LY>.*:("5I!(\BD
M3NSDL)'?#-(3NW $5[X*T_47U%[GS9!K,5O%<)N"JHME<1-"54.C@OOW%FPZ
MJ5"X((!!8^"(K;4;?5[J]OK^\LXI8(GN7@VB*8)N4QP6\$>X%-WFA!,Y;$TD
MJ)"L8 EMX(33K*&PTZ_O[%;;[1AXGMF9Q<S&=Q(D]M- 2KG]U(L*S1KE5DP\
MF\ C7X?V5HEFNES76F2Z;;FTAFMFA:1K=L%HI5NH;F&12ZK)EHMZR#*,H+ @
M&@G@^S^TK=SO/<NNGOIKB=PXEADD621I25#M*[+@D,J;6($8&, %"Q\!6]I)
M;>==WMY;::P>SM+AX#!;LHVQ,#';Q3S- A*0FZGGV@[CF0*X +*>#HVOX=0N
M;N]NULY99K6WG>$PP22JZ%E9($N9-D<CQQBXN)E16X&50J 1Z7X*CT9UCL[V
M^BL(I3*FGB2$6Z$L7V+(+<7HA$GS^3]K\H\Q,C6Y:$@%/4_AU::D+V$75];6
M>K%VN[2"2%(9)9$"-*&:![B-FPKR)'.D,S+MFBDC>5) #N+.V6R@CMHR2D*)
M&I;&2$4*"< #.!S@ 9["@"S0 4 % !0!4O[--0MI;24D)<1O$Q7 8+(I4E20
M0" >,@C/4&@#D+KX>:7>+I*S>:W_  CXC%L=R@R+$L05;C"8D7?##,0H0>;&
MK# !4@&E)X1L9Y=2EG#RKK<4<-U&S#9Y<<+0 1[55UW(QW$NQW8*E<4 9FF>
M X;"\M-0FO;^^GTV*2"W^TR0;%BD14*F."W@1FPH)F*^>YP)99%5%4 7_A +
M---@TJ&>Z@%E>/?6]PC1>?'/)//.Q&^%X'7-Q+'LDA=3&P!!<;Z *OB?P<;N
MSU6YM6FN=2U#19--57:%5D9(KGRFX2)$EDEG(=MR1#C"1@&@"30?!"636-W?
M7%Y=2Z="1;6]Q+$\5K)+$L<I1HXEEF=4W1(]S/<E$9Q&PW$D D'P^L8[.&T@
MFNH);.[GO;:[C>,7$$UQ+++-M+1-"\;K-)"T4T,B-"V&#. X .HTK37TV-EE
MN;B^DD;<TMRT>X\!0%2"*""-0 .(H4W'+ON=F8@&I0 4 % 'YB>(/^0K?_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * *.I?\>LO^X: 'V'_'O%_US3_T$4 6Z "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#SOX7_ /(&;_L(ZK_Z<KJ@#T2@ H * "@ H *
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M_P!PT /L/^/>+_KFG_H(H MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'G?PO\ ^0,W_81U7_TY75 'HE !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!7F^\G^__P"RM2&6*8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * *]OT;_ 'V_G20RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M%>?^#_?']:3&6*8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M/1H3;6DKQ1&6:7: I^>>5YI#EPQRSNS'G&2=JJN% !H_V9)_S\2?]\Q__$4
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M (VE.V,SR<'(^6/K_P!\4 +_ &9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 R71VE0HT\A5A@C;'
M_10?UH VJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M+*B-E'4@,C  $]I>07T8GM9(YXB6 >-U="48HX#*2"5=61AG*LI4X((H L4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M9&';G(X- ';T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M0QW,4LCPQNC20[?,16!9-PW+O4'*[E^9=P&1R.* )J "@ H YC7_  POB [)
M;N\@MI(_)N;:%XA#=0EB6CE\R&22,.K/&\EK);3/&VUI#LC* %_6]#@UZV%C
M<LZVWF1O)'&559DC8/Y$N58F!V5?-1"AD0&-F,;NC &Q0 4 9NCZ5%HEHEE
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H JWMC;ZE"]K>11W-O*-KQ3(LD;C.<,C@JPR <$$9%
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ9,-C EMETC@99IKAX2 (S,BJ >N4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M[?>9O(W&3]Z3YGS4 =#0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MXG7EO;274.E28LM*M]5O1<3_ &<VZ3"9GM0/(D9[M%BWHC)'&Z[O-EMW5$E
M++^,=0L-6U:>\2(Z-I<=K"B12[KEKJ5?-4+$UM'NFNA<VL/ER74<4)","WFR
M.@ ^Z^(5[I N8-3TY1?VJZ<\=M9W?VD3C4;E[6*-9)+>UV3))%)N1D\O:%83
M88E0#:\4ZWJ.CZ!)>,L%OJ1V(D4,OVD%WF";+7SH[4W5TT19K:W,*F:YV0A)
M ?G (? .H7FI17DMQ<S7EJEVT5J]W';PW@6-$25;B&V@MEA_?!VBBF@CNEC8
M&=5)5$ .^H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)C( :FO^'H]>$#&:>TGLI_M%O/;^49(Y#%)"Q"W$,\+!HII$(DB?&[<NU@K
M FT+0X=!A>*)Y)Y+B9[B>>8J99IG"AI'\M(XE.U$15BCCC5$550 4 ;5 !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
G% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img238320182_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $, M # 2(  A$! Q$!_\0
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M5UZ&OGBO6OABQ/AJ8$D@7+ >W K.K24(W1G4IJ*NCM****YS$**** "BBB@
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M WFFQ6\L21Z8RQZ-'-'NC0DW ]3U)]JYWQ3]D?4+6:U\C][9Q/,(,!1(1\W
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MZMIUQ9Q6DED_R()B[R1[F4/]T#!V\$$^AP173T %%%% !1110 4444 %%%%
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MY]?^3(GV=+^?\#2_LO3_ /GQMO\ ORO^%']EZ?\ \^-M_P!^5_PK-_X1UO\
MG_E_+_Z]'_".M_S_ ,OY?_7H^L8G_GU_Y,@Y*?\ /^#-+^R]/_Y\;;_ORO\
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MKAS'^!\U^:-\-_$^\WJ*K:A?V^EZ=<7UV^RW@0R.V,X I;&Z^VV$%UY3Q"9
MX1\;E!&1G'>NXY[J]BQ1110,**** "BBB@ HHHH *9+_ *E_]TT^F2_ZE_\
M=-*6S&MS&\-?\>L__73^E;E8?AK_ (]9_P#KI_2MRN/+O]V@;8G^*PHHHKM,
M HHHH **** "BBB@ HHHH P=(_Y#=_\ C_.MZL'2/^0W?_C_ #K>KAR_^#\W
M^9OB/C^2_(****[C **** "BBB@ HHHH **** "L?3-2FN]5O+=XXU2+.TJ,
M$\XYK8K&TS4I;O5;RW>.-4BSM*C!/..:I;,:-FBBBI$%%%% !1110 4444 %
M%%% !6/>ZC-!KEI:+&ACEQN8CD<UL5CWNI2P:Y:6BQQE)<98CD<]JJ(T;%%%
M%2(**** "BBB@ HHHH **** "BBB@#'9]0_X215 D^Q;>>/ESC_&MBL=GU#_
M (215 D^Q;>3CY<X]?K6Q5,;"BBBI$%%%% !1110 4444 %%%% !61XC\06W
MAS3/M4RM++(XAMX$^]-(W"J/\>PK7KS7XL7)TVZ\+ZLP+16>H;W7MT!_D#6E
M**G-)@SJ)X+Y[S37NE#S@ S-$IV*<\@>PKHJ@M)X[JV2>%P\4BAT8'@@\@U/
M7+3HJ$YR_F=RY3YDEV"@D 9)P*K7VH6>F6CW5]<Q6\"#+22-@"N,N;_4O'%W
M;VVG03V?AU)5DN+V8%'N@IR$C4\[21R373&#EKT(.\HI <C-+4 %%%% !16;
M_;VG#7_[$-P!?^2)A&>Z^Q]>^/2M*@2:>QS>K:Q<Q^,]%T6"588ITDN)F(R7
M"CA!Z9/)^E=)7(>//#5WK%I;:EI,ACUC3F\VW(ZN.Z_Y_K2>"_'5MXDC-G=J
M+76(>);=N-Q'4KG]1U%3?74P53EJ.$^NQV%96I6,]U?6LL04I&?FR<=ZU:JW
MFHVE@UNES,L;W,HAA4]7<]@*BM2C5CRRV.J-3V;YC#^(-J]YX#U:-,[A#OP.
M^T@G^5/\"ZRNM^#]/N<_O$C$,OLR\'\^#^-6?%]W%9>$-6FF.%^RNOU+# 'Y
MFN+^#!<>'+X'.W[5QZ?=&:O[1QRE;$I=T>G444CNJ(SNP55&22< "J.H6BD5
ME=0RL&5AD$'((I: "BBB@ HHHH J:A)>1Q*;.,2/GD'TK-:YUQE*FT3!&/\
M/-6]<U[3O#FFO?ZG<"&!>!W9CZ*.YKST_'31?.VC2[\Q9^_\N<>N,UE+ U:[
M<H2DEY;&D:R@K-)G764>KV$;I%:@ACDYQ_C6A:W&K/<HMQ;*L1/S$=OUK&T[
MXG>$=1B#+JT=NQZQW(,;#\^*U;3Q=X=OIQ#;:U8R2DX""89/TK&GELZ-DI2L
MNG](N6(4[WBC:HHHKK, HHHH **** "BBB@ HHHH P=(_P"0W?\ X_SK>JA9
MZ;]EO9[CS-WF]L=.<U?KEP=.5.ERS5G=_F;5I*4KKR"BBBNHQ"BBB@ HHHH
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M0=I [\\@UH2*'4,F2PZL3U7I_D5"-,DW+)<&-Y%/*(>!Z$TV^N_*/F;@Q4$
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M8SB3$@.SZ^GXUE]=CV+]@^YT%%8$=Z\L8DBN3(C<AD?<#]"*=]IG_P">S_\
M?5'UV/8/8/N;,,$=O&(XEVH"2%'09YJ2L+[3/_SV?_OJHKG4A9P-/=7@@A7
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MG_Y[/_WU1]IG_P">S_\ ?5'UV/8/8/N;M%87VF?_ )[/_P!]4?:9_P#GL_\
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MQ_J-QKFCW&H0745LNG2I:&X6(+G>N0#Y9W$-DX^M=YB/_GH__?/_ ->C$?\
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M/G:2<VZD>;YB;26Q]_&<'KZ55N;:WA\>:C<:YI%Q?P745NNGS):&=8@N=ZY
M.P[L-DX^M=SMA_YZ/_WQ_P#7I<0_\]7_ .^/_KT >07\_C'5=,\16NI)/(C0
MR*+-;1_E(E79L?: V5YX9L]>*O&7Q!I5RXL8K]8YM<N7DAAM<F9"R -O*D!<
M;CSMR.C<5ZCB+_GK)_WQ_P#7HQ#_ ,]9/^^/_KT6%8C.,G'2DJ3;#_ST?_OC
M_P"O1MA_YZ/_ -\?_7H&1T=JDVP_\]'_ .^/_KT;8?\ GH__ 'Q_]>@#6O\
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MJ: .5U#Q%J-QI]LD$<-M)>I;7$4B3,2L4DRH5) X;YAR/]K'(K8U;7!I-S!
MJ),28A*N7+JKR",-D @#)/+$9P:O1:7I\*NL5C;H'<.P6,#+ Y!_ \CWIUQI
M]E=SQS7-I!-+'C8[H"5P<C!^O- ',7?BO4AIC3PVEI%)(C20%I&<82=8FW#
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M0_8[*&5[HV\*2!C*TNT @[<%L^N."?2GV]U;W88V\\<H7&XH<XR P_,$'\:
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M8((R"*]"QG8I:,DRZ3 ]Q,TTTP\YV)R 7^; _P!D9 'TJ]0      . !VHH
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M' /)XS46E>*;>\LH)[M3;O.0P01/B)&?8A=CP,D8STS0!GP6>MV\-FDAU&6
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MGRH=JDKCG ]/7%<L_A*2.X>:TBM86-Q"Z%3M(18#&XZ<98]._4U':^#Y;6*
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M0&WAQ+_K!Y8^?_>]?QJ6B@!%540(BJJJ,!5& !["EHHH **** "BBB@!\/\
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M[E+^S(?[S_F*/[,A_O/^8J[11["E_*'M)=R*.W2. P@G:<]>O-5_[,A_O/\
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M9QVF[RRQW==QJQ11=A<H-I-NS%BTF2<]1_A2?V/;_P!Z3\Q_A6A11=A=F?\
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BX4?V/;_WI/S'^%:%%%V%V9_]CV^?O2?F/\*T***5Q7/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img238320182_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &C 5H# 2(  A$! Q$!_\0
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M>PK]JOV_O^30_B+_ ->L'_I3%7XJ]A7UF4?P9>HT%(WW32TC?=->X4/\0?\
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MHBCP>OR#TK!F^ ?@B'4M0U?2]!M='U^\DGN#JUDFV=+B52'N!_"9/FSD@\T
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M]O>!-4&NW*Z4NK^0VB^1%Y+R&RO")C)M\P,!Q@-M]J]YKPG]H_2M1_MGP)J
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M .)J6@]*]W^R\'_S[)YY=S7U#P[HUTMB[VEP,6D2@"Z/0+Q_#5/_ (1/0_\
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MYN([8Z3XYLYM-UO3]^2A6=H_*NU.#@$B0XX9R,5[]\0WU)?!NK'1]'_M_4S
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M50_A1]#!A7TW_P $W?\ D[SPI_UZWO\ Z(:OF2OIO_@F]_R=WX3_ .O6]_\
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M(Y4'@]J\6_X=]? 7OX$C/_;_ '/_ ,<KVLOQ]/"TW":;U(/QBH%?L[_P[Y^
MG_0AQ?\ @?<__'*/^'?7P$!!_P"$$B_\#[G_ ..5Z?\ ;%#^5_A_F%C\5O$W
M_(0MO^O.'_T&LBOV_NO^">OP#O9%>;P'&[*BQ@_;[D?*!@#_ %E0_P##NO\
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M_95O9)M0UT^,(;?QO=^([/Q+_:-KHRQ6"SVUN]NJFT\W+!XY)-[&3<6(.1M
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MV>O?M8>'--'APZ;I6O:R^I^(&\/7=K'I-REUITRV[3_O8#'O#%?+95(&Y7+
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M=    #H)/VD/!(T/2]1ANM3O9=2N+FTMM*M-)N9=1,UN<7*-:K'YJ&(_?W*
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MX/P?U3XF>%M;U74KF3P_J?BSP!#X9N=/N;7=)I\Y6<N[8?#8:X(VC'W/O<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCC0?A[;MX@\1Z7I>K:/;ZI!KB0SW4XN+F\EDQ.T*>6?)MO(3;,RQG<S8?&
M?:?F"EW U\M:;IOQ/A\56WB:YUCQ?!:ZC-XCNKG3?LPN(--LU;R=/A2VV_/+
MDI.O.Y@KKTXKN/V=_&6HQZ?:^$O$BZU-XK\FXU"6?43+)OMTE6&.=_- >V\\
M[G2WD^8!9,<+0!Z=J'Q#\+Z7XILO#5YXBTNU\17HW6VE37<:W,PP3\L9.X\
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MS=^"_A7X1T"_M[>UO=+TJVLYH;60R1AXXE5MK%5SDC.<#K0!U]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!6NK>*X:,2Q)*$<2+O4-M8<AAGH1ZU.O>BB@!U%%% !1110 4444 <YXL
M\ >'/B!##;>)-%L]:@MG\R&.\B$BHQ!!(!]1P?45O6L,=M;QPPQK%%&H1(XU
M"JJC@  = !110!+5>*WBCNI94B199,;Y%4!GQTR>^,]Z** +%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img238320182_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #; C,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5^(USXLL_"=W+
MX(L=-U'Q&I7[/;ZM,T5NP)^;<R@D<5\I> ?VP/BUXB^'/Q&\<:IX.\,6VA^#
MUO;:1+:^E::6\M\#;@C_ %9/>OM>OD/P=^S#XTT/]FWXT>"+G[!_;?BS4]3N
M].V39C\N=LQ[SCY3Z^E '8_&3]I#7O '[/O@KQUHVC:=>:UXEGTRV6SOIVCM
MH6NPN27'.U2?R%>:WW[=/BOPQX/^)@UOP?I5UXG\&W5C;/<Z-?-/I3K<M@2/
M*!E G5AVIGB3X(_&'XO? SPQ\//%WA+P_I=OH&I:.08-3,RWEK;D"?>-O!VC
M@=\UB>,?V-?B)X5T7XF>#OAV-.'P[UO4;76K729KGRY+@!A]JT]GQE8WQP23
MC&.] 'NO[+/Q_P!>^-%YXTT[6]/TJ3_A';R.VBU[P],\VG:@'C#GRV89RN<&
MO?J^9/V/O@?XG^%.O>.=3OM#L_ ?A;6IH7TSP3I]Y]JBL71<23;\  N<<#TK
MZ;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,7Q.^LP^'=0?P]!:W.M+$QLXKYV2%I.P=E&0OTKY3\%_M/?
M&;5Y?B3/JWA/PC!I_@![FWU0VU].TDLT<!E7R@5P5)P,FOL:OF?PU^S_ .*=
M.TO]HNVN?L@?QWJ%S<:05ER"CVWECS/[OS4 5_'W[6>L^$_V-]#^,MMH-E<:
MOJ,%I(=+EF80(TS[2-_7 K/^&_[3GQ*\>>)/&G@1/#/AB?QSI&E6^K6%UI^I
M/-I4RRL!Y4T@&4<#M7G&K?L^_'+QU^R='\&]8\,>'M,72[>RCL[Z'53+]J\J
M7+AUV_*-M>H_"7]G7Q1^SS\3?'$_@;3],3P1X@T6.X@T]IMK6NKQQ[<#(SY;
M]3SQ0!9_9W_:%^(WQ(^-?C;P'XM\-:#90^%;>+[;J.B7<DT8N9,%8,L!D@9)
M]*^FUKQ3]DOX)ZE\%?AI-%XDDAN_&NNWTVKZ]>0MN$ES(Q.T-W55PHKVV@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHKBXBL[>2>>18H8U+
MO(YPJJ!DDGL*\RB_::^&UQX#U7QG#XE@G\.:;>-I\UY&CMNN 0/*1<9=B2
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MZCDAFB<D,K 1@_K7TBO4C\J /+_^&>]$_P"@_P"*?_!U+1_PSWHG_0?\4_\
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M@\5?^#J6O4J* /+?^&>=$_Z&#Q5_X.I:/^&>=$_Z&#Q5_P"#J6O4J* /+?\
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MRV,<T5M$EQ()[A$"R3!=N]NYQVSZ5Y)^T\N/"?A?_L9]-_\ 1M>QT +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y=^TQ_R1G7/
M^NMI_P"E,5>HUY;^TS_R1G6_^NMI_P"E,5 'J*_='TKRC7_^3E_"?_8 O/\
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M*HA=VQ"!_H_E. HZ9Z5]B6WAS2K,60M]-M(!8J5M1'"JB '@A,#Y0?:J6C^
M_#?A_5KK5=,T#3=/U*Z_U]W:VJ1RR9Y.Y@,F@#Y$^'_Q.UB^L_A?XFL_B!?>
M(O&?B'7&L]9\+R2KY,4)9Q*GV<#,/DA1\QZ]\YKG;/Q5+XP7X=Z]KOQ#OKOQ
M3?>/D@N?"<TR>3 L=RZJBPXW1[%53N[YK[>T_P "^&])UZYUNRT'3;36+G_7
M7\%HB32>N7 R<_K38_ 'AB'6)]73P]I::K,XEDO19Q^<[CHQ?&<CUZT >7?&
MIFE^./P1M9L_8&U*_F(SP9TMCY>?<9;%>*>(O&'C'1;+4O'D?C;69)['XBKH
M4.D/(OV+[$]R(VB9,9;AB0<Y&!7U5X^^'EGX_;P_+/<RV5[H>IQ:G9W4 !=7
M7(*\_P +*2#6[)X=TFYA:"33+.2%YOM1C:!2IF!SYA&/O9_BZT ?/_B/7/B)
M#\2[N"S'C[^QQJ 5/LVFV+6GE[AG:[?.4QW/.*Y#Q!=K\#_B-J_B?PSXGT'Q
M8_BKQ7;B\\*O;(]_&\FV)_)D5BRLF-Q#+C@]*^P=@/K^=<_;_#[POI_B!]=M
M_#NF0:T^2VH1V<8G.>IW@9R: /+/AFQA_:D^+UO;EA9O9Z7/*O\ #Y_EN"?K
MM _*NI_:1_Y(3XU_[![_ ,Q6[X(^'-EX-USQ3K$=S->:CXAO1>74TV/E"H$C
MC7'\*J./K6'^TE_R0OQK_P!@]_YB@#N?#7_(NZ5_UZ1?^@"BCPU_R+NE?]>D
M7_H HH ^0?VN/B GB&UU3P+\3/!7CCPOX*AU*&ZT_P =>$56[C;RR&1W" R0
MD-G)QQ@<UVW[(=AX$M3J>I>$/C=K?Q474(TC-KKVL_:GM=A))6)L,AYYR.U=
M-^UK\8O$'P8^'FD:GX;M])GU"_UNUTQCKTODV*1R;MQFE_Y9KP/F-?&/A[X^
M>#_B1^T!X#\5Z5\/_!>E7EG?65EJ\NGWOEZG)>7$DD.ZW:(A9H4*!B&!R&S0
M!^GY8XS7S_\ MK>"M;\>_"2TTW1-$N=7D&KVMQ//I^#?:?$C;C<VRD@/*O8$
M]Z^@!UIV!Z4 ?FYX;^"?Q#\'Z/;7UY\.]0\06VI>'=8\/VT)6,WB37$P:&[N
MU)PC.#EV'3%;-M^SK\0+%3\/I?#,TVH76N:;K"^,@RFV@@@M%C=/,SO#!U*A
M1U!K]"Z3 ]* /BCX _!OQ7<>,_#$&J^&+_P5:^%_"M[X=U#5 Z127UQ--N62
MW=22P &_>>A:O2/A5\-XOAC^TIJUA'X@USQ%]H\+0RF?7KPW,J8N7&%8C@5]
M'UY%;_\ )UE]_P!BC%_Z5/0!ZZOW12T44 %%%% !1110!XY^T]_R*?A?_L9]
M-_\ 1M>QUXY^T]_R*?A?_L9]-_\ 1M>QT %>7?M$>.O&/P^\!-J?@K01XAU3
MSXT>WP3LC+ %^/R_&O4:\"\:Z+?>/OVDO^$<F\3^(=&T:V\,"^6VT6^:U5IC
M<["S$#D[>,4 9OCWXT?%O09/APND^ EOFUH ZNNQ_P#1'P<I^7/X5]&0LS1(
MSC:Q4$CT->/W'[/-K';SNOCSQYN5&(_XG\GI]*W?V?-2OM6^#OAJYU*\N-0O
M3 RR7-VQ:63:[*"Q/4X YH ]&HI*6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\M_:9_Y(QK?_76T_P#2F*O4J\N_:8_Y(SKG_76T_P#2F*@#TB]M
M1>6<UN9'B$L9C\R,[77((RI['T-?.O@_X51_#']I+0U3Q-XA\1&\T&[+?V[?
M&Y\K$B?<R.*^D5 VCCM7E.O_ /)RWA/_ + %Y_Z,2@#U<=*6BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&X!KXB_;T_;D\8?LK^./#.C>'-#TO5;;5+&2
MYEDORX965\ #::^W3TK\H?\ @L%HNIZI\6O ;V.F7M\BZ3,&:UMGE /F=RH.
M* ,/_A\1\4?^A/\ #G_?4O\ C36_X+$_%%1_R)_ASJ/XY?7ZU\1_\(CX@[^'
M]6_\ )?_ (FD;PCX@.,>']7'S+_RX2^H_P!F@#^D/PCJ\OB#PIHVJ3(L<U[9
M0W+HGW59T#$#VYK+UWXB:;H/CSPYX3G68ZGKL5Q+:LB9C A56?<>W##%3_#5
M6C^'?A=64JRZ7:@JPP0?*7@UXY\?=9?P7\=/A;XJN=)U;4=%L+?4H;F72;%[
MIHGDC0(&5>0#@_E0![';>,$D\4:IH]Q:26,=H(1%>W$J".Y>0$[$&<[ACH1W
MK5N-:LK1;AI[VW@%L@>?S9541*>A;)^4?6ODKQ1X%U?XJ:[\7M9TW3]2M6FM
M-'UGP]/<Q/"QNK=6<*JGD-P5*_[5<QXA\'^,?%WPSTWX@:OH^IZ?)XB\4Q:M
MXATE[,W-Q;:?'&8X(WM\_.J,-Q7ONSB@#[77Q#IK:?'?_P!I6@LI!NCN?M">
M4P'.0V<&L3Q]\1]-\!?#W5O%TSB]TZQMC<)]G<-YY. BH>AW$@ ^]?*</P?L
M_$6C^"[.T@UCQ%X7O_'(O;ZSN=+?3[>WA\@A@L/40$X)[$U[%^U7HEOH?[.]
MU;:9:1VVD:3=V$\EK"F$2UBN8V=0/0*#^5 'K-KXHM(-+L)M6N;32+RXBB=[
M2XN$4QNX!V<D9.21[XK:5OER3@XKY;^)GPELOB)\6/B3J^I>')-9M?\ A"(E
MT>X=6:,W&)6_=8./,!V<CD<55D^!?BGXA>$?!NIW6CZ/=Z@N@6D%VVN7=Y#=
M^:J88.(V"Y_6@#UCXC?M&:3\/?$5]HZZ+K.OS:5:)J&KRZ5 '33K=LX>0DC)
MP"VU<G S6SI'Q>T_6OB'8>&HXMUOJFC+K6EZBK@I=1[@'4#L5W*?H:^>_C1X
M3B\,3:AIV@OXLL?&NO>'HM+FTSP[9-/I]^P4I&3-(I$>W)!8D';74:+X3NO"
MWQH^!'AK*R7OA[PK>#4)(^R>7'$ ?8N/TH ^G5KS;]I+_DA?C7_L'M_,5Z4O
M3TKS7]I+_DA?C7_L'M_,4 =SX:_Y%W2O^O2+_P! %%'AK_D7=*_Z](O_ $ 4
M4 ?/?[?7C6Z\#_ <R1RZ+9VFI:M9Z;>ZAKUJ+NWLH)'PTWDG[[+P?;KVKYL_
M93\??"6S^/EYX:\1^(OA_P"-+ZQ:UN/#'BK3='2QN)+V8%7MT"C:Q50O/:OI
MOXU>%?CK=>(K^7PM#X$\<^#KATEB\.^*K5XYK=E4 A91E6!/.6&1FN2^'OPE
M^-.K>,=$U+7_  K\*_AWHME=I<SPZ)IHO-1E5>3&DA 6//\ >'([4 ?7"M\V
M*?3%ZYQ@>]5=8U:QT+2[G4-2NX;&PMD,DUQ<2!(XU'4ECP!0!=HKA9OC9X!M
MO#^FZW-XOTB+2-3F\BSO)+I5CGDSC:I)YP:U)OB/X6MO%EMX8E\0:<GB&ZB\
MZ'3#<+Y\B8SE5SR,<B@#IJ\AM_\ DZR^_P"Q2B_]*GKN?#GQ$\,>,-4U+3=#
MU_3]5O\ 37\N\MK6=7D@;IA@#QS7#6_'[5E[G_H4HOQ_TIZ /7J*** "BBB@
M HHHH \<_:>_Y%/PO_V,^F_^C:]CKQS]I[_D4_"__8SZ;_Z-KV.@ JNUI!]J
M^T^2GVC9L,VT;]N<[<^F:L44 9/B2UU"^T.^@TN_72M1DB(@O6@$PA;LQ0X#
M?2O/OV;=2\2:[\,;'5?$FKV^JW5W)(T?V6P2TCA179-H520<E<Y]Z]2F_P!5
M)_NG^5>9_LT?\D5\/_\ ;?\ ]'24 >H4M%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5Y=^TQ_P D9US_ *ZVG_I3%7J->7?M,?\ )&=<_P"NMI_Z
M4Q4 >H+]T?2O*-?_ .3E_"?_ & +S_T8E>K*1M'TKRG7_P#DY;PI_P!@"\_]
M&)0!ZQ1110 4444 %%%% !1110 4444 %%%% !1110 5');Q3$&2)'(Z;E!J
M2B@"#[#;?\^\7_? H^PVW_/O%_WP*GHH 0 +P!@4M%% !1110 52U;2;/7=+
MN].U"W2[L;J)H9H)!E9$88(/L15VB@"II>GP:5I]K8VD0AM;:-88HP<A44 *
M/P JU2T4 (U8\/A72H/$ESX@CLXUUFXMUM9+S'SF)22J?3))K9HH :E>;?M)
M?\D+\:_]@]OYBO2Z\T_:2_Y(7XU_[![_ ,Q0!W/AK_D7=*_Z](O_ $ 44>&O
M^1=TK_KTB_\ 0!10!X=^VQ\8?$7P3^#L.N^&]3TS0[VXU>TT^;5]5B\Z*PBE
M?:\WE?Q[1V_&L[]DWXD:OX\U3Q!%J?QM\+_%I+:*)D@\/Z2+)K,DGYG(9MP.
M,#TQ4W[=GC"]\'_!2WDM9--TZVO]9M+&\US5K!;VWTB"1R&NS$002O !(XW5
MY]^PYXHB7XF>/?".F>+-#^)>B:?96EY'XOTC1X+&3S)&8-:RF%0CX ##'3-
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M1K__ "<OX3_[ %Y_Z,2@#U>EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA.!2;LC(% #J*0-FEH **** "BBB@ HHHH **** "BBB@ KRW]IG_DC&M_\
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M17UK%<P2++!,H>.1>C*1D$?A4U-55C4*JA548"@8 IU !1110 4444 %%%%
M!7EW[3'_ "1G7/\ KK:?^E,5>HUY=^TQ_P D9US_ *ZVG_I3%0!Z@OW1]*\H
MU_\ Y.7\)_\ 8 O/_1B5ZNOW1]*\IU__ ).6\)_]@&\_]&)0!ZO1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %17$AAA>0*S[5)VJ,L<=A[U+24
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M2Y\SSQ)TQTV\YKZ2^.G_ "1OQK_V"+G_ -%FOSOD=O\ A#W&]L?V<?\ T70
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M.4WEN86\P*&X!)R,$5ZDOW10 M%%% !1110 4444 %>6_M,_\D8UO_KK:?\
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MQ7I=>:?M)?\ )"_&O_8/?^8H [GPU_R+NE?]>D7_ * **/#7_(NZ5_UZ1?\
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MFWZ'MVKY,U+]N[X,7'QLL=;C^+>L1^%18O+<649E6U^U*RA$V;,X*[B1T)H
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M.RM8ECB@0Y"*!T%:-? __!*_XX>//C/I?Q ?QMXFN_$3:?/;1VINB#Y09&+
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M:5\"_$+5O#&F:#>33/K^D/K%FQAV1I"CA&1_[KACC;[5ZJD@D+ $94X(STH
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M=4\P-!:HMI%]HC&?O$KE1QWSQ7U2/XAG_.:;#;Q0M(R1HC2'<Y50"QQU/J:
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L&&XPC;^]#J!C.,$U]A6,"VMG# A++$BQ@GKP *?@<#UIZ?=% #J*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img238320182_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: 14# 2(  A$! Q$!_\0
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M*-D:EU4_-EBV,=A7H%% 'A>F^']<:'0/#.J:=>I;Z9KLJ2M;&40M:O&SKB0
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MK%TMJOG6\[_<6==N_P!@<XS[5#JP3Y;ZFBHU''FMH='1115F84444 !HH-%
M!1110 4444 %%%% !1110!'<%UMI6C^^$)7ZXXKP310HG^T7*>:[,6?=U+$\
MY_&O:+CQ1H5I=FUGU:T28'!0R#@^_I7FFM:;'I7B"1H&22PO&,UO(ARO/WER
M/0_H17!CK\G-'H>C@$N9QDMS>A\/Z/K]MFW7R;@<[?>K>F:Y?>'+M-,UQVDM
M"=L5TW)3T#'N/?M6'9S26DBR0M@CTKI9)[;Q#I[6]P%$X'!/>N&ABD_ATE^#
M.JO0<=):Q_%'1W5S=;TALH [.N[SG/[M!^')/L/S%%MIL<,WVF9VN+O&/.D_
MA'HHZ*/I^.:Y'POK,NE7PT2_<F!CMMI&_@/]P^Q[?E7=U[%"O&M#FB>35I.E
M+E84445J9!1110 4444 %%%% !1110 4444 (S!5+,0% R2>@KS;7O%E]XAO
M&TGPZSI;9VRW2<-)ZA3V'OWI/&WB*;5K]O#VF.1 K;;J1#]]O[@]AW_*M?2;
M2S\+:4I*J;IQT]*XJU=7<4[);L[J-#E2G)7;V1D6O@^RTFU$E](/,/.T=<UB
MZM!'"/-M\JRL&0CJ"#Q6W=74M[,TLK'Z>E5]-MH]4UJ/SG2.QM");B1R O'W
M5R?4_H#7A^U]O74*2/3NZ5-N;/3H"[6\9D^^5!;ZXYJ2LJV\2Z)=W(M[?5+6
M24G 42#D^WK6K7U":>Q\_)-;H****8@-%!HH **** "BBB@ HHHH *Y?Q_J=
MSI?A29[1RDTSK ''5 W4CWP#745B^+-).M>&[NTC&9MHDB_WUY _'I^-14OR
MNVY=*RFN;8\M\/6&DL@BOHCE_P".MG4O!,L%F9M+N&>WSO\ +!XSZX]:QM-
MDA!(P1P0>H-=9HVLR6)$4GS0G@@UX,<1#FY*GWGNU*4TN>G]QR]A>$.;><;9
M%X(-;,9*D,IP>V*F\4Z+#<(-2L, ]3CM6/:S7<-BEU-"SVQ)4RH,A6'4-Z'Z
MUQ8G#R3;AK_6Y<:RE'4N:C";F%F8G>.0W<&O0/#FI-JNA6US(<RXV2?[R\'_
M !_&O-KC5[?R#M=>1ZU!HGQ';1+(V<&E-=)YK.TIFVYR>PP:[\AA7G.2MH<.
M8<O(NY[+17):!\0]%UV9;9F>RO&X$-Q@;CZ*W0_SKK:^AE"47:2/*"BBBI *
M*** "BBB@ HHHH *Q_%.JMH_AV[NXC^^V[(O]]N!^6<_A65K_P 0]%T.9K9&
M>^O%X,-O@[3Z,W0?SKA/$'Q$DUVQ6RGTDVL?G+()/.W8QZC JIT:OLW**Z%T
MN5S2EM<ET*#[#MG(WR'G+=SZUK3327,ADE;)K'M=3MQ"-SKP/6EOKNZ_LR2]
MCA9+52%$KC =CT5?4_2OC9^VJR<(GT4I0CJ)JNJ);1^7'RYX '>JVE>'-2UD
M S;S#NW[2?D!]<>OO5_PEX<?5;G[;??ZM>3GI77:IJL<$?V.P 1!P2M=M*C#
M#TG.3_X)SRG*4^6*N_R.1O\ P_%9QF,%6('5>U=]X+OY]0\.1M<L7EA=H2YZ
ML%Z$_@:XB_G\J!BQ)9N@[DUZ%X:TUM*T&VMI!B4C?)_O-R?RZ?A6^53E4J2D
MOA,<P:Y$GN:U%%%>X>0!HH-% !1110 4444 %%%% !1110!Y]XM\/2:?=R:Q
M8QDVTAW7,2C[A_O@>A[_ )UE6\B3(&0@YKU4@$$$ @]0:XO6/!<D<SW>B%4+
M'+6K'"D_[)[?3I7C9AE[G[]+?L>IA<;9<E3[S+CFD6)H@QV-U%6?!DYMM?N[
M \Q7$7F;>VY>/Y']*QY9KZT;RKG3[F.7I@Q$Y^A'6N>_X2+4[37'_LK;%=*#
M$S2Q[BG/( /?BN+*L-BI8I*VB-L7.G[)^9Z7XZTBU7P9J\MI90)<>3DND0#;
M006YQZ9KR?0[NWLRKRVZS(>H/I77IXN\6:?$1K-A#J5C(I63:GEMM/7!''Z5
MY^)+:&]F@MG=K<-F(R##!3T##U'3\*^WH4N6+C^1XMV]ST&3PKI'B:P:?3&$
M<X&3&?6IO"_C&\T&_70?$CL8<[(+N3JGHKGN/0_G7'Z7JMSI5RL]O(5(ZCUK
MJ-8EL?%^D&8!4OHU^9?[U*4?LRU7Y >L @C(Y%%>9?#?Q9*)AX;U.0LZ _8Y
M6/+ =8R?4#I[?2O3:XJE-PE9@%%%%0 4444 !( R>!7EOBKQI=ZY?-H7AR1A
M"3LGNX^K^JH>P]3^52?$GQ;()&\.:;(5=E'VR53RJGI&#ZD=?;ZU0\._8O#&
ME?;I@K73C]TGI772I<L>=K7H!:@\,:3X5TY;G4MLMR1E8_>N.U[44U#<PA2)
M!T"CM4VK:O<ZM=--<.3D\#TK%:6UEO8H;J1DMMV9B@RQ4=0H]3T_&NJG%WO+
M<#VKP+I%JW@S2);NR@>X\G(=X@6VDDKSCTQ6%X^F-[XCLM-Z06T7FE1TW,<?
MH!^M8MS\1/$%TJQ:-:0Z?:1J%C79YCA1P,D\#\JQ3XBU+4=9C?4]LMTP$2M'
M'M+\\ @=^:\G'X:JZ4I06N]NIU8.<557.=Z=0$-@EG:#8@'S$=ZSY94@0O(W
MOS5:WDOKEA%;:?<R2=,"(C'U)Z5TVC^#)))5NM;97(.5M5.5!_VCW^G2OE5A
ML1BYV:LCU*E>E16A7\+:%)J-W'J]\A6VC.ZWC8??/]\^P[5WM(    , = *6
MOI,/AX4(*$3QJM6567,PHHHK<R T4&B@ HHHH **** "BBB@ HHHH **** "
MOG74+>33_$NJ6TA(ECNI#GU!.0?R(KZ*KS/XG^%Y9"OB*QC+/$@2[C4<E!T?
M\.A]OI73A9I2Y7U Q?#WBJ2S<6UZ!-:MP0W.*L>+_"-I>6?]L:*1@#<RKVKC
M(I%E0,IS6[HOB"XTIRA)>W;AT/3%=3@XOFB,YJVN<DQR#:Z\$&KT<KQ-NC8J
M?:GZG#ILNOQ3,7CLYG"R,GWHP>-P]<=<5>UCPAK^@.QDM6O;0<K<VRE@1[KU
M'\O>M&XZ>8C&GFFMIHKV!RMQ XE1AV8'(KZ(TR]74M*M+Y!A;B%9 /3(SBOG
M:.VO=4?R+:VEZX>1D(2,'C+'' KWOPT\,.CV^FIE9;.)8G1CSP.&'J#U!KFQ
M=K+N!LT445P@%5-3O5TW2KN^<96WA:0CUP,U;KFO%%['=Z?>:5&Z@21&.XF(
MR(@PP !W8]A515WJ!XC%++=2RWEPQ:>=S)(Q[L3DU8DFDE WN2!TS4%Q8:EH
ML_V34+&>*0?=S&2&'J".M;&C^$-?U]U*6K65IU:YN5*@#V7J?Y>]>K)I:MZ!
M<Y^ZNMO[N/ESTKI?"'@R35G-U<G9"O+,:R=/TRTN]?DCMG8VBR;%DD/+J.-Q
M],]<5U^M>)4M;)=*TL[(D&&<?Q&IJ2?PP ?K>KZ=I*&PTF%"R\-*1FN0LH9=
M3\4:9!'_ *V2ZC.1V .2?R!JO-,%#.[<]<FO1/AAX7EC+>(KZ,J\J%+1&'(0
M]7_'H/;ZU+M2@V#/3****\P HHHH ****  T4&B@ HHHH **** "BBB@ HHH
MH **** "D(!!! (/4&EHH \B\:> 9M+FDU70X6DLV)::U09,7JRCNOMV^E<9
M;RI. 5-?2%<WJO@;0M4G:Y>V-O<-RTMN=A8^XZ'\J[*>)TM,#QJ>R:>'RT4L
MS< #N3TKZ T^.2'3;6*7_6)"BO\ 4 9KC18:'X8E$X+SSIRK3$':?4 =Z:/'
M]N9MNX8SZUC7Q$962(E4BGJSO&170JRAE88((X-<K?Z?+I-Q%+;2;(0VV"0\
M^23_  -ZQD_E6II>NV^H("CC-3ZXH?0KT=?W1-9192:>J)M.O1?V23[2C<JZ
M'^%AP1^=6JYK3H+V<W1M)Q"@FPRDYRVT$GI5W[%J_P#S_K_G\*&ABZ[J36D2
MP0R".612S2D9\J,=6QW/8>YJOHVCC]W=W,94+\T$+')7/5W]7/Z5G:A%,FH^
M5=.)I2(?GSQM,OW<8]J[ \4WH@"JVH1R3:;=11'$CPNJ?4@XJCJFNV^GH2[C
M-<R?']N)MNX=?6L^=)D2J1CN>:VUK):Q;""CK\K#H01UJM<S) "6->K&PT/Q
M/*9R7@G?EVA(&X^I![UK:5X&T'2YUN4MC<7"\K+<'>5/L.@_*O06*@U<I--:
M'#>"_ ,VJ31ZKKD+1V:D-#:N,&7T+#LOMW^E>N !0   !P *6BN6I5=1W8PH
MHHK, HHHH ****  T4&B@ HHHH **** "BBB@ HHHH **** "BBB@ JCJES]
MFLW?T%7JQ_$91=*E>1U10.K'%)["EL>27LEQXAUU[;S6C@C&^5AU ]![FMO3
M_ -IJMK*UO$(_+X#F1MQ/UK#TB9+3Q!<PS93[4H\LL,9(/3\<UU=O<WEF)$M
MIGC63[P'>O Q.(<,1:HWR^6APTX1E=R5SF-%NKK0]=-C+(64$%&_O+7K-Q,+
MGPY<OD',+?RKR"8C4?%2+ =ZP*(V8="V<FO2IM*E_L21A<M' %$KQ ?>*CCG
MTZ9^E>M@Y2E!.6YKANJZ%BP@O96NC9S+"@EPP8YRVU>>E7/LFL_\_L?^?^ T
M[0?N7O\ U\'_ -!6M:NQO4ZCD;R.:/4]ETXDF_<'>#QM\SIC KI+^X%O;,VX
M XX&>:YWQ#"+G4I;=F*B6&)"R]1F0C(JS<:+*FGS-=7)N;DHJ+)MV[0O3 ]3
MU-*6PGL>9ZQ<W.NZ]]ACE*)RTC_W5'7\:V--\ 6>IVDKQ1@>7QO>1M['Z]JP
MK>0:;XK<7)"K.AC#G@!LY'YUU<-Q>6BR1V\[QK)]X#O7@8K$.&(M4ORVZ:'%
M",97<E<Y2PEN/#^N+:F5GB;YHV/4C.,'W%>S:7<_:;-']17B^I,MYXBMK>$[
MS;J1(1SAB>GZ5[#H,31:=&&]*]+!SE.FG(O#:-KH:M%%%=AUA1110 4444 %
M%%%  :*#10 4444 %%%% !1110 4444 %%%% !15>[O;>QC#SOMW'"J!EG/H
M .2:J&&\U(YN"]I:?\\4;]Y(/]IA]T>PY]^U.P#Y]2+3M;6,7VF<<.<XCB_W
MF]?89-(FE*[_ &B\D^TW./E9AA8_]Q>WUZ^]7H88K>)8H8UCC48"J, 4^BX'
MG'BCP9]L=I(EYZ\5RW_".:ZX^SM>W1AZ;=YZ?7K7M[*K#!&:C^S19SL%82HQ
MD[M'/+#QD[G">%O!ZV&UW3!%;7B[Q!I^@:,\%PS-/<1E8H8QEC[^P]ZZ4!4'
M& !7@&O:JVO>(KV_9B8C(4A'I&O _P ?QKKPU%2>NR-804%9'H/@WQUI>H7T
MNGR++:W-Q+OA67&U_E P"._'2N^)"J68@ <DGM7A5]H23>'(]5LLI-"P)*]5
M(Y!KJ_%'BY[KX96,T3[+K5 ('V]5Q_K/Y$?C6U2@FUR=="RKKGQ#TIM>8VD-
MQ=0IY:--'@*2C[CMSU%>AZ3J]AXBTQ;RQE\R%OE((PRGN".QKPW0;*VEO8K>
M=/D?Y?I76^$9)?#'CQ](D8BVOE*@'IO RI_+(JJM&'+:.Z U_%/@Y;[<Z)DF
MN/\ ^$<UU!]G6]NA#TV[ST^O6O;RH88(S4?V:+.=@KS9T8RW1A/#QD[GGOA?
MP9]C=9)%YZ\UZ)%&(HP@Z"G*JKT&*6KC%(TA!05D%%%%46%%%% !1110 444
M4 !HH-% !1110 45SOB'QIIOAN_MK&ZM[^XN;F)Y4CL[5IFV)C<Q"] ,UJ:/
MK%AK^DV^J:9<">TN%W1R $9YP00>0001B@"]116/X?\ $5MXBCU![6*6,6-[
M+9/YH W.F,D8)XYH V***9+((H7D()"*6('M0 ^JMXUYA([../<YPTLA^6,>
MN.K'VX^M4_#.OV_BCP[9:U:12Q07:ED27&X88CG!([54U;Q?;:/J45C/IFJR
MR3/Y<+06I=)6VEB%.>> ?R- &K:Z=%;R>?(S3W1&#/)RWT'91["KE9NFZW:Z
MK=7EM"LR3V9C$Z2Q[2A= X'UP1FLO2/'6D:Q<6L44=[ MV'-K+<VY2.?9G=M
M;ID $X..!0!TU%<_I?C/2M7OX+2W%TAN4>2TEF@9([E5^\8V/7&0?IS704 %
M%%% &9XBNC9>&M3N0<&.VD8'WVG%?/MFNVV0=\5[GX[;;X&U@_\ 3N1^9%>'
MPC$2_2N_"KW&P/1?!T*WWAC4;5^1M)%>=7%T[);Z4Q.RRFF=1_OD?X&N^\ 7
M.R.^B)X,9->>S_-KMTW^V:TIKWY S2TY_+U"!AV<5VGCB/['JNA:O'PR3Q,3
M_P "%<)"VR9&]"*[3Q]="7PWI;9Y^4_J*4E[\0/5Z*:AS&I]A3J\T HHHH *
M*** "BBB@ HHHH ****  T4&B@ HHHH \[\7Z'K&J_$G09-,NKG3XTL+E)+^
M*W$HCR5^7YN 3V[UQGCCPG>:1:6WA_1-$O+FVM--8VE\(I[AVG+LS8\ME6)^
M<[V!SP,'I7N]% 'AD^FZROBO3_"S^>;+Q%]DU2Z+N0T1B7-PI[C<RI^)I[:-
MJD32'4M(U.?P^?$E_-?V=M$YDF1E'DOM7YGCW9Z5[$='T\ZV-9-JAU$0?9A.
M<[A'G=M'8<\U>H \)N-,UV/PO9V4OA^]GTR?4[I[6.ZCGN'L[<@>4KPQN&.3
MNQN/RU'9:/K3Z=X:7Q-I&N7]G'IEQ"D$(D,D-WYIV,^""/DP%8\#UKWJB@#S
M+X?:8-/TCP9!J6C:I'JEO:7*K-L98K?+'*RC( +#&W(-=7XBMIY]=\,R10R2
M)#?.\K*I(1?)D&3Z#) _&NBHH XK3+LZ7X[\2)=65^%O[BW-O*EI(\; 0JI.
M\ @8/!R:YOPOX?U71H?"VH36U]=DQ7$#6=R#ML96#%'48^4'!0DYP''3FO6:
M* /*O!6GWMIK^D2)9ZEGR)EOH+VV:.#3BWS;;8G@ M\N 6RHSD5ZK110 44$
M@#). *S#>SZBQCTXA80<-=LN1]$'\1]^GUHL!D^/[N)?"&J6H)>=[<ML09*J
M/XCZ#W->+0',*_2O>M2T>$^'-2LX$)>XMY SL<M(Q4\D]S7@-DVZV7/4#FN_
M"OW&@-[0]4&FR3L3P\96N:23?J<S>IS5USA":8VG-;:5IVJ$?+>2S)G_ '"
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M=K]]'C8'Z$&E+XTN^@,]/HI <@'UI:\T HHHH **** "BBB@ HHHH ****
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MP!GD\< =*Y77/ :W%Q8/I45B+>U2=1:W7FA0TKAV<,C!LY'0\<]J ,JW>_\
M$^L-;:_:^=/;:/;7D6E"1K>.664OO+ DD[-JKSD#)XR:;JT<.H?";5FMX;W2
MUT\72FTCNRX\R,L,%^I4$9 R!756W@VQDT73;/6"VH7=C'L6\+O'+SU =6W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 !HH-% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img238320182_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I ;D# 2(  A$! Q$!_\0
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MKYF6#9RK A0V,<X'-;EU_P ><W_7-OY4 2T444 %)_&?H*6D_C/T% "T444
M%%%% !1110 @ZM]?Z4M(.K?7^E+0 4444 %%%% !2#JWU_I2T@ZM]?Z4 +11
M10 4444 %%%% "+T_$_SI:1>GXG^=+0 4444 %%%% !2+T_$_P Z6D7I^)_G
M0 M%%% !1110 4444 (OW!]*6D7[@^E+0 4444 %%%% !2+]P?2EI%^X/I0
MM%%% $2_\?DG_7-/YM4M1+_Q^2?]<T_FU2T %%%% "-G:=H!.. 3BN9?1=4M
MK33KJT%G-JD$\EQ<)-*T<<K2*P<!PA( )&#M/" <9R.GHH XI?">J013643V
M<EIJ,2+?2-(RO&V]VD,:[2'#;R!DKMQGGI7877_'G-_US;^52U%=?\><W_7-
MOY4"L28/]X_I1@_WC^E+10,3!_O']*3!W'YCT%.I/XS]!0 8/]X_I1@_WC^E
M+10 F#_>/Z48/]X_I2T4 )@_WC^E&#_>/Z4M% #0#EOF/6EP?[Q_2@=6^O\
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M'YT +12?-Z#\Z/F]!^= "T4GS>@_.CYO0?G0 +]P?2EIJ[MHX'3UI?F]!^=
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M?7^E+2#JWU_I0 M%%% !1110 4444 (O3\3_ #I:1>GXG^=+0 4444 %%%%
M!2+T_$_SI:1>GXG^= "T444 %%%% !1110 B_<'TI:1?N#Z4M !1110 5Y1X
MG_Y&W5?^ND?_ *)CKU>O*/$__(VZK_UTC_\ 1,==.%^-^G^1K2W9ET@Z"EI!
MT%=QN7M'_P"0W8?]?,?_ *$*]>KR'1_^0W8?]?,?_H0KUZN+%;HPJ[D2_P#'
MY)_US3^;5+42_P#'Y)_US3^;5+7*9')>)O#%QJE^UW!;QW2R0K#) VK7=AD
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M\/SHW+_>'YT +7E'B?\ Y&W5?^ND?_HF.O5MR_WA^=>4^)R/^$MU7D?ZR/\
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M$BE?,A<HZ^X(Z&L(^$48><^LZFVI"42+J/[D3+A60*%$?E[=KL,%/XB>N#2
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M(5Z]7D&C@?VW8<#_ (^8_P#T(5Z]M7^Z/RKBQ6Z,*NY&O_'Y)_US3^;5+4*
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MW5EI]W=0"Z01.;FZGN52//(C5Y,1MCHPZ''!QBM^W@BM;:*W@0)%$@1$'15
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M<UJ447#R"BBB@ K+U3P]8:O<PW%T;Q)H49$DM;Z:V.UB"03$ZY&0.N>E:E%
M&6_AS2I;%[.2U\R"2?[0ZO([%I/4DG)SC!&<$$@Y!-)=>'=/N]2%^WVN*XRI
M8VU[- LA7H71'"OZ?,#QQTK5HH KV5E;Z=:1VEK'Y<$>=J[B<9.>IYZFK%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img238320182_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #; ;X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#H?%OQ!\0:
M1XJO["SF@6WA90@:$,>5!Z_4UB_\+2\4_P#/Q;?^ XJC\0/^1[U7_?3_ - 6
MN:KT(4X\JT+2.S_X6EXI_P"?BV_\!Q1_PM+Q3_S\6W_@.*XRBJ]G#L%CL_\
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MXI_Y^+;_ ,!Q1_PM+Q3_ ,_%M_X#BN,HH]G#L%CL_P#A:7BG_GXMO_ <4?\
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MFD=[^U\]U< ;#QP/SI;/1(9/"&HZY=22+Y4R6]LJXP[GKGV HY:=KV#0U_\
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M_P !Q1_PM+Q3_P _%M_X#BN,HH]G#L%CL_\ A:7BG_GXMO\ P'%'_"TO%/\
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M37T?_:Z_\^B?G_\ 6H_M=?\ GT3\_P#ZU'UA]@YCYPV/_<?_ +Y-&Q_[C_\
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M\7:</!/_  E7S_8O(\X)QOSG&STW;N*3P?XKA\7Z3-?PV<MIY5PT#1RL"<@
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MY]U_,T7 HVGWIO\ KB]5ZVH88 7VP*,H0>3TJ/R+;_GW7\S2N!DT5K>1;?\
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M444 %%%% !1110 ^+JW^X:93XNK?[AIE !1110 4444 %%%% !1110 4444
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M\;F.X#&!GU(QUJWI]Y9>$;_Q5X:\4:C?Z*NH:@;VUU2U# RH3G"N ?;MW(H
M[/5?'>I:%X'N]>U;PU+9WEM<) UF\X*ON(^=7 Y7G]*72?'M\_B>TT#Q!X>D
MTJZOH3-:.EPLR2@ G' X/!KS&\U&^U3X#:Y->7UW>HNL(EO/=,69H@5QR?\
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MB;YGB=Q\A#>F<YXKO2,'%>)>(/WGP<^'UL@S<37EJ(L=<X;_ !%>WOS(WU-
M#:OVO^H7\?YU0J_:_P"H7\?YT 5;G_CX;\/Y5%4MS_Q\-^'\JBH **** "BB
MB@ H(!!! (/4$444 )L7CY%^7IP./IZ4ACC+^88T+XV[BHSCTSZ4ZB@! B @
MA%! P"%' ]*"JE@Q4%AT)'(I:* &)#%$S-'%&C-]XJ@!/UQ2R11S+MEC21?1
MU##]:=10 W8FP)L38.B[1C\J4JK8W*IQTR,XI:* &>3#_P \8O\ O@4^BB@
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M-^0HL!HT5G?;KK_GLWY"C[==?\]F_(46 T:*SOMUU_SV;\A1]NNO^>S?D*+
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ME<MY+ YWYZ_Q?B:]DW').3DT D=#BBP"<=CD4444P"BBB@ HHHH L6GWIO\
MKB]5ZL6GWIO^N+U7I %<-XOMOM/Q \%H\!E@+W*RC;E=I0 @_6NYHR0,9ZT
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M*Z/6M+BUW1KG2[F6:."Y38[1-AMN02!GUQ5BTM8;&R@L[9 D$$:QQJ.R@8%
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K*/L\/_/)/^^11S <K70:1_QX+_O&K7V>'_GDG_?(IZJJ#"J /0"DV!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img238320182_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V .,# 2(  A$! Q$!_\0
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M598N67&Q&W=]P]>?=*XG33\+QJ=M_9?_  A_V_S!]G^R_9O-W]MFWG/TKMJ
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M7_L%77_HIJ/ G_)//#7_ &"K7_T4M 'G_P"T=_R3S3_^PK'_ .BI:\ KW_\
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M/X6-GV/X$_Y)YX:_[!5K_P"BEKH*Y_P)_P D\\-?]@JU_P#12UT%<1 4444
M%%%% !7QGX2_Y!4O_7<_^@K7V97QGX2_Y!4O_7<_^@K6M'XAK<WJ***ZRSN?
MV>/^0KXT_P"N]O\ ^A3U[K7A7[/'_(5\:?\ 7>W_ /0IZ]UK@>YF%%%%( HH
MHH *YWQ/+XEL9+74M!BAOH(-PO--?Y9)T.,-$_0.N#P>"">^*Z*N ^)?@6_\
M9#3GL_[.N%M/,W66I/.D+EMN'S"P;<H4@9R/F- '*>$?$?C#Q-XS-W9SZ@U@
MFH2)=PS^2MO;P!F 0I_K%D "C'7.3R,U[57#:5\.H]/AT.[&H2P:WIXC2>\M
ML@740/,,@8G>FWY5)^884YXQ7<T %><?$.RN-5\8>$K.Q\26NC7T;W$T'G6Y
MF:1]@ **1L) W?>(^]QFO1ZQO$?A30_%MG'::YI\=Y%&VY-S,K(?9E((_ \T
M >00^([_ ,1ZAX-.O26\QT_Q-<6$ERJA8[AT13')CH"2W&.XXKK/ DLUOJOQ
M&FTJV%W''JCO;6ZR!%EN!'ET#'A26V@GMFNMG\$^&[GPRGAR72+<Z0AREL,J
M%.<[@P.X-R><YY/K5[1-!TOPWID>FZ/91VEHA)$:9.2>I)/+'W))H \X\6>)
M_'=QX-UR&\^'7V2UDT^X2:X_MN"3RD,;!GV@9; R<#KBNX\"?\D\\-?]@JU_
M]%+1X[_Y)YXE_P"P5=?^BFH\"?\ )//#7_8*M?\ T4M 'G_[1W_)/-/_ .PK
M'_Z*EKP"O?\ ]H[_ ))YI_\ V%8__14M> 5T4.I40JO??\><GX?S%6*KWW_'
MG)^'\Q6L_A8V?8_@3_DGGAK_ +!5K_Z*6N@KG_ G_)//#7_8*M?_ $4M=!7$
M0%%%% !1110 5\9^$O\ D%2_]=S_ .@K7V97QGX2_P"05+_UW/\ Z"M:T?B&
MMS>HHHKK+.Y_9X_Y"OC3_KO;_P#H4]>ZUX5^SQ_R%?&G_7>W_P#0IZ]UK@>Y
MF%%%%( HHHH **** "BBB@ HHHH **** .?\=_\ )//$O_8*NO\ T4U'@3_D
MGGAK_L%6O_HI:/'?_)//$O\ V"KK_P!%-1X$_P"2>>&O^P5:_P#HI: //_VC
MO^2>:?\ ]A6/_P!%2UX!7O\ ^T=_R3S3_P#L*Q_^BI:\ KHH=2HA5>^_X\Y/
MP_F*L57OO^/.3\/YBM9_"QL^Q_ G_)//#7_8*M?_ $4M=!7/^!/^2>>&O^P5
M:_\ HI:Z"N(@**KWNH66FP">^N[>UA+;?,GD"+GTR3UK/_X2WPW_ -##I/\
MX&Q_XT ;%%5+'5=.U0.=/O[6[$> YMYEDVYZ9P3BK= !7QGX2_Y!4O\ UW/_
M *"M?9E?&?A+_D%2_P#7<_\ H*UK1^(:W-ZBBBNLL[G]GC_D*^-/^N]O_P"A
M3U[K7A7[/'_(5\:?]=[?_P!"GKW6N![F84444@"BBB@ HHHH **** "BBB@
MHHHH Y_QW_R3SQ+_ -@JZ_\ 134>!/\ DGGAK_L%6O\ Z*6CQW_R3SQ+_P!@
MJZ_]%-1X$_Y)YX:_[!5K_P"BEH \_P#VCO\ DGFG_P#85C_]%2UX!7O_ .T=
M_P D\T__ +"L?_HJ6O *Z*'4J(57OO\ CSD_#^8JQ5>^_P"/.3\/YBM9_"QL
M^Q_ G_)//#7_ &"K7_T4M;D\\-K;RW%Q+'#!$A>221@JHH&223P !SFL/P)_
MR3SPU_V"K7_T4M'CO_DGGB7_ +!5U_Z*:N(@;)XV\&2ILD\3Z Z^C7\)'_H5
M<]=>)_!;>.-*F77- -LFFWJ.XNX=@<R6I4$YQDA7Q]#Z&O&O!W@[0=5\*65[
M>V'FW$F_>_G2+G#L!P& Z 5N?\*]\+?] O\ \F)?_BJM0;%<]IB\:>"H01%X
MFT",'J$OX1G_ ,>K;L;^SU.SCO+"[@N[63.R:"02(V"0<,.#@@C\*^;=;\"^
M&[30=1N8-.V30VLLB-Y\APP4D'!;UKUKX)?\DAT+_MX_]*)*EQL,] KXS\)?
M\@J7_KN?_05K[,KXS\)?\@J7_KN?_05K2C\0UN;U%%%=99W/[/'_ "%?&G_7
M>W_]"GKW6O"OV>/^0KXT_P"N]O\ ^A3U[K7 ]S,****0!1110 4444 %%%%
M!1110!PWQ#U?5(+GP]H.D7AL)]:O3#)>*@9HHE&YMH/\1XP?K3/ 6OWP3Q+I
M?B'4DN)-!O&C-]*%CW0%=RLYX4$ ')_/U-WQUX;U+6'T;5=$:W_M31[O[1#%
M<DB.92,.A(Z$C&#[>]1^"O"E[I]GKEQXD6SGO]<NGGNH(AOA6,KM$7S#Y@!D
M'/'..>I *WC3QIX5NO OB&WM_$NC33RZ9<I'''?Q,SL8F   ;))/&*/!?C3P
MK:^!?#UO<>)=&AGBTRV22.2_B5D81*"""V00>,5N?\()X/\ ^A4T/_P70_\
MQ-'_  @G@_\ Z%30_P#P70__ !- 'E?Q]\2Z#K/@6QM]+UO3;Z==3C=H[6Z2
M5@OE2C)"DG&2!GW%>(>?#_SUC_[Z%?8?_"">#_\ H5-#_P#!=#_\31_P@G@_
M_H5-#_\ !=#_ /$U<)\HT['QYY\/_/6/_OH5!>31M:N%D0DXX##UKZ2\,>$_
M#=Q\4O'MG-X?TJ2UM?[/^SPO91E(MT#%MJD87)Y..M=Q_P ()X/_ .A4T/\
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M .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")HA+E=P1\S_VG8?\
M/];?]_5_QH_M.P_Y_K;_ +^K_C7L'Q)\)^&['_A$?L?A_2K?S_$MG!-Y-E&G
MF1MOW(V!RIP,@\&NX_X03P?_ -"IH?\ X+H?_B:U]N^Q7,>,? GQ!HND:GXN
M?4]7L+)9YH#";FY2,2 &;.W<1G&1T]17L_\ PG?@_P#Z&O0__!C#_P#%4?\
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MDD=\@#(TR@GR,=F('&< ]/7$7AWQO>W^O#0?$6@2Z'JDL)N+6-IUF2>,=0'
M WKW7\: .SHHHH ***P?%FOW?AK25U.#2Y-0MHI1]L6%\210\[I%7^+''''&
M3VH UKJPL[[R/MEI!<>1*L\/G1A_+D7[KKGHPR<$<BK%>:6OQ/OGDLM8N-'B
M_P"$0U"[:TMM1AF+2Q$.45Y4(X5BI^G?G /I= !1110 4444 %%%% !1110
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M0>@50HZGBKOP_P# VFZQH6D^(YX[[3X[IEOGT2*X/V'S@QVRB,YP#@.%S@9
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MG]K_ +V62WX^9MPSM9@2N[G&#CFN^Z# HZ# HH **** "BBB@ HHHH ****
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M0#[I<$#?STVYQG'5>#_ FDVB6FM2:1+I]VY-RNFM<,\%I*V<LD?W5;'I]W)
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MY[[3DN/-T^&X0,UFG9 Y)+ '.#U XKI* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img238320182_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M\O/T]?;W^/GZ_\  $0@"L@<R P$1  (1 0,1 ?_:  P# 0 "$0,1 #\ ^RZ
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M$++MC)W'B@#L_&-VO@+XF6OBC65==(O;06ZW01G2"3RC&0=H)!! 8@#.R5F
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M\3;#5/#VZ?3]$ML7-Z$=8V;$Y" LJDY,JQJ#RW[Q@"BYH ^LZ "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MSV+LZY^[C;UYZ=>: ![2!XQ T:-$,80JI08Z84C QVXXH G50@"J  !@ <
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MT&P@K@=AC H +2R@L(_)M8XX(QR$C144?\!4 ?I0!9H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MP.1ZT .LM0MM2C\^SFBN8B2 \+K(F1U&Y"1D=QF@"W0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ..\>>#H?'FCRZ)<
M2R6T4[1LTD84L/+D60 !N,$J,^U '.^,/A+I?C33=/TN]DF1-)\L1/'L#NB1
MK&R/N4@+($4MMP05&#0!?\8_#FT\87.EW4DTEJ=#N!/"L2J5?#0L$;<.%'DJ
M/EYP3[4 >)_'2[@^(.I6?@32(9+C5H+I99Y]C+':0O%\^YB!N5D=)'8?( BJ
M&:1@H /H"?P+I5WX?7PK<1>9IZ6\=N%^ZP$87;(&'W9 RB0-_?Y.02" ><Z/
M\&;_ $5X8;?Q'JPT^U=&CM R@!$8,L1?=@Q\;2@C"E<C: : .SE^'=M)XL3Q
MD9Y1<16YMA!A?+*E'3<3C=G#D^G% '(:K\$XCJ5SJOA[4[W0'U')NXK7!BD+
M$EF5<H8V)9FZL%9B4"Y(H W-.^$>DZ1X;NO"UDTL<>HHPN+IMKSR.V 9&. O
M &%4 *HSU8LQ (-0^#NDZIX7MO"=W)*\=@,V]T-JS1R;G.\#!4@ARK(1AE]&
M"L #D+G]GN'5(8UU?6=2U"XMG0P2S,&6&),YBCB=G WG:7<L3\B@ <Y /HK.
M* /"_$'P*T^_U)];T.]O/#]].2TK638C=F.6;8"C*6/+!7"$\[,DD@&SIGPH
M@72KW1]>O[W78]2,9=[M_FB,6=C0$ES&P8AL[B,J/EP6! ,?1?@]?Z))!'%X
MCU8V%I)&T=IN4+LC8,L3/N(,9QM9!&%*Y  % '7#X>6H\6?\)GY\OVG[/]G\
MC"^5MV>7NW8W9QSZ9H 7P/\ #VV\"W&HW-M/+.VKW'VF02!0(VW2MM3;U'[T
M]>>!0 GB+X=VOB;7M.\07D\O_$G^:&U 3RFDW%_,8D;L[A&>./W:^] %[Q_X
M(M/B%I3:/>N\*&2.5)8PI>-XSU4,".5+(<]F/>@#DO%'P;L/%%M8>9=7-MJF
MDPQP0ZC"56=EB "F0# )!RX*LC*Q8AL,10!N^&O 4VE6-[I^L:G>:ZFI)Y4A
MNV^Y&4>-EB&YRN]7^8[NH!QG.0#F/"WP97PQ8W^D+JM[<Z=J%M-;1V\@4);"
M?.^5%#%#+R<D(@)))'- '<^$_!%IX5T!/#(=[NU5)XV:4*&=+AY'=6"\8_>%
M>.U &!\-/A/IWPR^TM92RW4EX4!DF"!D2/=MC7:!P2Q+'N0/2@#G9?@9 FHW
MEUI^J7^GV&K.7O;&W9567<6+J)?O(C%W&-I8*[(&VG  -_0OA'INB^&;KP@\
MTUQ9WSR.SMM61#((\;< KF-HU=20<D<@CB@#(TOX,?8O#U[X7NM5O+RSOEA2
M+S /]$2&3S=L*%G4!S@-@*, 8 Q0!M:S\(])U[P]9>'+MYO^)5'&MK=H52>-
MHU"[QP5^< ;TQ@X!&&56 !D:-\%XH=3M]9\0:E>Z_<:?C[(MT0(H2""K%07+
MNK ,"6 + ,X8@8 .IM?AU;6GBR?QFL\IN+JW%NT!"^6JA(4W _>SB$'GC)-
M#M+^'EMI7BB]\7)/*]QJ,"P/"0OEH%$(RI W$_N!UX^8^U 'H5 !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!7CM((I7N$C19I=HDD
M5%#N%&%WL!N;:.%R3@<"@"QF@!,T )F@ S0 F:8#<T )NH 3=0 FZ@!-U,!-
M] !OH 3?0,-] !OH 7?0(7?0 ;J0#MU "[J %W4 +F@!<T +FD M !F@!: "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@!,T &: $W4 )NI@&Z@!=U(!<T &: %H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M 2@!,T )FF F: &[J &EJ &EZ8#"] QI>@!IDI@-,E #?-H ;YM.P">;18!/
M-HL >;18!?-HL OFT6 7S:5@%$E #A)0 \24 .#T@'!Z 'AJ!#@U(!P:@!0:
M '9I +0 9H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MD*RYJ,XSCWBTU^!Q2BX.TDT_-6)Q(*U)'AJ!#P:0#LT % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MA\<KX>?O=8/2:^75>:NO,\BI1G1^-:=UM]_^9II*#7I6.<G5Z0B0&D Z@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 2@!,T
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M]C<ZJ5Y?5LM4DF[<Z7OR_P "WBO/XO0]NCA(P7M*]M-;=%ZOK^7J2V'ALO\
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M_I]QTT-R&&0:^]5I)2BTTU=-:IKNGV/&:MHR^DF:!$X-(0^D 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * &T (33 86H B+4P(F>F,Q-1URVT[B1L
MO_<7EOQ'0?B16L:<I[+3NQ;'#W_BFYN<K!^X3VY<_P# NWX ?6NZ-&,?BU?X
M"N<R[ER68DD]23DG\373MHB32L-&O-2_X]XV9?[Y^5/^^C@?ED^U9RG&'Q/Y
M=1G9V/@4##7DN?\ 8BX'XLPS^2CZUQRQ'2"^;_R'8Z^ST:RT_P#U$2*P_B(W
M-_WTV3^5<DJDI;M_H.QIYK(8F:0Q,T )FD,3=0 FZ@ W4@$W47 -U%P#=0 ;
MJ+@&ZBX!NH 7=0 NZF N: %S3$+F@!<TQ$<L4<Z[)55U/9@"/R---K5: <U>
M^#["ZR8@;=O5#\O_ 'R<C\L5TQKSCOJO/_,5CC;_ ,&WMKEH=MP@_N\/_P!\
MGK_P$FNR->,M'H_P)L<K)$\+%)%*,.JL""/P/-=2=]4(L6U]-9G]TQ4>G5?R
M/%1**ENAWL=-9^(U;"W V'^\.5_$=1^M<LJ+6L=?(JYTT-TL@#(0RGH0<BN5
MJVC*+J35-@+*2TK"+*R5($RO2 E#4A$@- #@:0#J %H * "@ H * "@ H *
M"@ H * "@#ROXW?\B5JO_7!?_1T5 'F_@?X)^%/$_A/3[FYM#'>75I'(]U%+
M*LHD89W@%S'G/.TH5]J ,_X;>)KNSTSQ+X6\0$ZLGAR.Y"^:Q!GME6='@9_F
M8*?*&PG<R+(5&0B@ &UHWQ)L/!OP^L_$.E:8MM9O<M +(7+MY>Z>97D,[Q.\
MA+(7(9,G=C/ H Z.U^,GEZ9?^(M5TZXT_2;?R?[.D<_OM0\TN%\N-@H3=M1E
MY8!&WEL T 58OBWJ^D7-D?%.BMI.G:M*L-O<K=).T4DG,:W,:HICW#EL[2H#
M?*=K  &KXR^*\FC:NOACP_82:WK)0220I((HH$(# RR$, =I#$':JAERX+!:
M .+^)GC7Q;;^#)KJ;3)-'NWF,4TL%ZA:UB5X-DZM& S"X9F@VHV4&6+8.* /
M0?A!KNL:UHD']L6+V2PVMH+>YDN%G:^5HOFG( W1D[58B0LQ,G)R#0!ZO0 4
M % !0 4 % !0 4 % !0 4 % $8F0MY89=X_AR-WY=: .9\2>$[?Q2]L+Z68V
MEK)YSVB,%@N74JT7VD;=SI$R[UC#!&8@N&  H W#J=HH+&>$!9?()\Q,"8D
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MO/M0(YUO!FK6^J3:[9""2XBU:ZNX8)92B3VEW96UK*AD5'\F<-#NC)1UXPV
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !2 * "@ H * "@ H * "@ S3 * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 E #2:8#": (F:F,JS3K"I=R%5>22< 525]$!P>J^+"<Q6/'8R$?^@J?
MYG\J[H4.L_N_S)OV.)DD:5B\A+,>22<D_B:[4K:+0DW=)\-W>JX=1Y4)_P"6
MCC /^Z.K?H/>L)U8T]-WV0['I.E^&[/2L,J^;*/^6CX)!_V1T7\.?<UYTZLI
MZ;+LBK&\37.4-S2 :6J1C2U*X[#"U*X[#2U*X[#2]*X[#2]*X[#2]*X[#=]*
MX6$WTKCL-WT7"P;Z5QV$WT7"P;Z+A8-]%PL&^BX6%WT7"PN^G<5AV^G<5A0]
M%PL.#T[BL.#T[BL.#4[BL/#55Q6'!J=Q6'!J=Q#@:8#@:8B.XMXKM#%.BR(>
MH89'_P!8^XYJU)Q=XNS$<'JO@@',FGMCOY3GC_@+]OHW_?5=T,1TG]Z_5$V/
M/[BVEM',4ZM&XZJPP?K[CW'%=Z:DKQ=T26+/49K(_(<KW4]/P]#]*B4%+??N
M-.QV-AJT=WP#M?NIZ_AZC_.*XI4W#T[FB9N1S5C8"ZDM18"TDE(195ZD"96H
M$2 T@'@T@%H 6@ H * "@ H * "@ H * "@! H7H /I0 M  2%Y/ H * $P
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M685]5&3Y6_M5'JY?]NW^]^1Z^+J*G%4(:76OE%;+Y_D=D6P:_1SP2)FH 86
M'- %%)@&)[4P)Q*6^Z#0(RA9SSQ.FI>5<+YI>,"/ 5 <Q@AB<NO][UJ4KZ2L
M]3E5.4DXXGDFN9N*Y=$D[QNG?WEW,>.;+?;(( FIS+Y?D3RA':!),,X"EA@
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M^FX>M'%T88FG\,XI^CZI^:=T_0\:<'3DX/=,Z>VES6K1B::-FH))A2 6@ H
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MKH;@, 5.0>A%<;5M"C0CFJ; 74EJ+"+2/2 G5J0B4&D \&@!U(!: "@ H *
M"@ H * "@#S?XO:A<Z5X2U*\L99+:XBA4QRQ,4="98QE64@@X)&0>AH \;\&
M>"]6\1:38ZM/XNU.&6[BCF:#SR0I;DIS."?3D9]J ,7XU>/K34?$MEX8N;R[
ML](M&)U3[,LJ2/(065!M4F10H3!4,H,C,0608 .'U_Q?X;\1:[I^C7-W?_\
M"):99! @%P)I9PK?-*H3S&8DH#)LX"D*5W$T ?5>K_$;PY\/EM]$DDFFF@MX
MPEO;Q27,Z0(BJCR[1\OR@$ER&(^;&#F@#K=!\8Z1XDTS^VM/N4>Q4.9)6_=B
M+RQEQ*'VF,H.6# ?+AN5() .&TWXY>%M7U*+2;&6>>2XF6".5+:7R&D8[5'F
M%00"?XBNW'S9QS0!YY:_M#6@\675C=R;-#BBV6[):S&=[G="&\S[S!0QF (1
M5P%)R2"0#U7Q1\7?#WA&].EWDDTMW&@DEBMH))S"A (:4H,)P0V,E@I!( (R
M >A:??1:G;17MN2T-S&DL9*LI*2*'4E6 925(.& (Z$4 6Z "@ H * "@ H
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MP N &89VA0 #ZAH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MRU"2R/'S)W4_S'H?\FIE!2]>XT[':V=^ERNY#]1W!]"*X)1<79FGH:\4U96
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M_6+_ %EIHQ&$NF BC ;=N1 6PYZ%MPR#R#Q@ ]#H * "@ H * "@ H * "@
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M,V"^[=NVJ3G9LS\N[<<4 =O0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 -H 833
MB9J8%.XN$MT,DA"(HR2>@_S^M4DV[(9Y9K>O/J;&./*6X/ [O[M_1>W?FO3I
MTE#5_%^7H0V9-E8S:A*(+==SG\@.Y8]@/7\!S6TI*"O+81Z[HF@0Z,F1B2=A
M\TA'Z+Z+^I[^@\BI5=339=O\RTK&X37.6,+8J1V(BU278A9JFY5B%GJ;EI$+
M/47*2(6DJ;EI$+/4W+L1,]3<JQ$TE3<JQ"9*FY=B,R4KE<I&9#4W*L,W&@=C
M*U;2+77(D@O5+I%-%<( S+B6%M\;94@D!N2IX/0BFFXZKT^\EQ4M'WO]PFMZ
M-:^(K.33M04R6\VTNH9D)V.KK\RD,,,H/!YZ=*(MQ=UN$HJ2Y7L9FM^$=.U^
M:.ZN!+%=0*4CN+::2WG"$Y,9DB92R$\[6R <D8R:<9N.BV[/5$RIJ6KW[IV9
MR?C/P?Y^CVNE6,<UY$NIVDTZS2O.[0^83.TDDSEBNT\C. #A16D)^\Y.RT=N
MGH9SI^ZHQ3?O)OKZG2:7X&TK2+M;^(3S3PJR0-<W,UP+=&X*P"5V$8(^7(^;
M;QG&:AS;5M+=;*U_4T5.,7=7NMKMNWH4+GX::%=F<2QSF"[=Y);87,ZVWFR?
M>E6!7"+)GY@P'RMAE (&&JDE;;3K97^\GV,7?>SZ7=O6QJZQX/T[7!;&X$T<
ME@"MO+!/)#,BE55D\R-@Q5E4!@>N/<Y2FXWMUWT*=-2M>^FUG9D6K>"M-UBY
M-](+BWNG0122VMQ+;/+&. DQB91( . 6&X#@'&*%-Q5M+>:N#IQD[ZI^3M?U
M+;>$M(;2_P"PC;1_V=C'D<X!SNW[L[_,W?-YF[?NYW9I<\K\U]1^SCR\EM.Q
M1L]!MO!\$][9"_OI%BPL+W,MR[*IR(X4F?8I)Z$8..,GH6Y.=D[+Y6^\E05-
M-J[TVO?[BCX$\.S:7]LU?4(H[?4=9N#<311D,($&1%#N'#.H+/*PX:1CZ54Y
M7M&.T5;U\Q4X.-Y25G)WMV\C:A\)Z?;:I)K4(ECN;C_7*LT@@E;9Y>^2#/EN
MX7@,5Z\_>YJ.9VY>BV[_ 'E\B4N9;]==/N,RW^'NDV4PEM3=VT8D$PMH;RXC
MM=X;?GR%D" %N2@PAZ;<<57M)/>WK97^\CV45M=>2;M]QW6XUF;6'!R*!6)!
M)3N3RDBR55R;$JR55R;$HDIW)L3*]5<BQ*LE5<FQ.KU5R+$RO5W(L3*]5<FQ
M*&J[D6)5:F38E!JB0=%F4QR ,K#!!&00>Q%4G;5"/+_$/A5K#-S9@O!U9.K1
M^_J4]^J]\CFO4I5N;W9Z/OW_ ."0U8XU':-@R'!'0BNQJ^C).HL];CV_OCM8
M>@)!]^.GTKRL1*.&7/.ZA>U[-V];;>IT0BZCY8[^MC7BUNV_OG_OEO\ "O*>
M/P_\[_\  9?Y'1]7J=OQ1HQZW;?WS_WRW^%9O,,-_.__  &7^0OJU3^7\5_F
M74UNU_OG_OEO\*C^T<-_._\ P&7^0?5JO\OXK_,M+K5K_?/_ 'RW^%3_ &CA
MOYW_ . R_P @^K5?Y?Q7^9,NLVO]\_\ ?+?X5/\ :6%_G?\ X#+_ "#ZM5_E
M_%?YDHUFU_OG_OEO\*7]I87^=_\ @,O\@^JU?Y?Q7^8[^V+7^^?^^6_PI?VG
MA?YW_P" R_R#ZK5_E_%?YB_VQ:_WS_WRW^%']IX7^?\ \EE_D'U6K_+^*_S#
M^V+7^^?^^6_PH_M/"_SO_P !E_D'U6K_ "_BO\P_MBU_OG_OEO\ "C^T\+_.
M_P#P&7^0?5:O\OXK_,/[8M?[Y_[Y;_"C^T\+_.__  &7^0?5:O\ +^*_S#^V
M+7^^?^^6_P */[3PO\[_ / 9?Y!]5J_R_BO\P_MBU_OG_OEO\*/[3PO\[_\
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M%2!*&I .I +0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MA5:>HN:I$9DS4E6&[Z $WT##?0 F^D ;Z $WT##?0 ;Z $WT &^@ WT &^@
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M^9?>CJ;:WEQ]Q_\ OD_X5YTJ%7_GW/\ \!E_D5SP_FC]Z--;:7^X_P#WR?\
M"N=T*O\ S[G_ . 2_P A\\/YH_>A_P!FE_N/_P!\G_"I]A5_Y]S_ / )?Y!S
MP_FC]Z$:"2,9964>I4@?RJ)4JD%S3A)+NXM+[VBE*+T33?DT15B6/CC:5@J
MLQZ 5I"$JDE"FG*3V25V2VHJ\G9>9T5GH71KD_\  !_4_P!!^=?58;*=IXM_
M]N1?_I4OT7WGDU<7]FC_ .!/]%_G]QT4<:Q*%0!5'0#BOJ80C3BH4THQ6R2L
MCRFW)WD[OS'5H2% !0 4 % '!ZWX,T?QM>Z?K4TC2R:/,9+9K>5?++B2-F#X
M#!L/$H(#*1R#0!WE !0! MW"\K6ZR(9HP&>,,I=5;[I9 =P![$@ ]J )Z "@
M#*U?7=/\/Q+/JES!91.XC5YY$B5G()" N0"Q ) '. ?2@#5!SR.E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4@$J1C"<5#8R,FH
M;*(RU8ME6(BU8MEI$9-8MEV(R:R;*L,)K-LJPTFHN4-S4W 2D,*0"4#"@ H
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MD"=6I 2 T@'4@%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@!* &DTP(F- '%>(?%*:;FWML27'0GJL?U]6_V>W\7H>R
ME1<O>EI'\P/,6=YW,TS%Y'.23R?\_P AP*])))66B)+MA8RZC,MO ,LWY*.[
M$]@/_K#DU,I*"YI; >SZ7ID.D0"&+D]7?N[>I]O0=A^)KQ9S=1W?R78M*Q=+
M9X%8E"^5QESM _SR:+=QWZ(RKC7;2T^6/]ZP_N]/Q8\?EFL)5H0T6K\O\SJC
MAZD]9>ZO/_(PY_$MQ)Q&%C'_ 'T?S/'Z5RNO)_#9?B=D<+!?%=_@OZ^9ER:E
M<R_>E?\ !L#\A@5BYR>\G]YTJE".T5]W^96,K'J2?J36=S3E2V2$$A'0G\Z
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M'4>A_P #VKAG%Q=NG0U6IO0S5@P-.*6H8&A&]2(M*U2(G!I /!I .% !0 4
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MN!0!W?P!N=)NO#;/H5M-96WVV8&.XG$[F39$2V\(@"[2JA0HQMR2222 =/\
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MJPR<,",F@#ZLA^XO^Z/Y4 24 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M"50RG@_YQ7GRCRNS-39AEK-H#4BDJ!%^-Z@1:5J0B8&D \4@%H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * &-3
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M4E^AY,GS-ON[_>=YIR]*S9BSKK88%8,DTEJ222D $ ]:32>X;;!3 * "@ H
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MLJU2!85L5($H-(!PI +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M 6D>H&6D:I G5JD"84@%%(!: "@ H * "@ H * "@ H * "@ H * "@ H *
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M4Z>SY^;]Y?X?S5O(=WS\MO=[D.I>$M"DNK25;IW%P0UPXE; SRK$J<)E\ =
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M"K*1P58$$$=0<T 6* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M 2JU2!91ZD"TCU(%M&J!EI6J +"M2 D%2 X4 % !0 4 % !0 4 % !0 4 %
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M2J&'X^Q]*X)1Y78UW-Z"6LF!K0R5FQ&C&U0(MJ:0B<&D \4@%H * "@ H *
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M_M#4HR1F.W/G.>WR_<'XOC\ :\_$2M'E[G=1CK<]U%>4=XM(84 % !0 4 %
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MD@"0[R -VW<<4GAYN"H^ZDMI=7;;3\]?0/K44_:)2YGNNB[V?Y:'!>(=;O\
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MX/4FDH-VVUTU:TV7O=EVN-I*^^B[;^G?8J7NBR:=:RWLCQD1SM'M#$MAEP'
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MI % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M4L9&36;*(F-8MEH@8USMEI$)-<[9HB,FL&RT1DUFRAM0,2D,*0!0 4 % !0
M4 % !0 4 %, I@+0(*8"BF(44P."\<0,@@NX_O!C$P]01N7\B&Q]:H[*#U<?
MF<Q9ZJ/NMP1U!X(JT['4XG2V=ZC'J*VC(YY1?0YOQA*C2PD$<(W_ *$*^RRG
M6%2W\R_(^/S1/GIZ?9?YGG%U.-QQ7T3E8\N$'8QY+@NVR,;F/85P3K)/ECK+
MHEO_ ,!>;/35.T;RT1Z[X#L6M;-I9!B2=R3_ +J_*H^F=Q_&O/G=M\V_Y>1T
MPM;W=CT):P-AU2,* "@ H * "@ H * #I0 X4 /!Q0!.K5(%I'J +B-4 6T:
MI&65.*@"<&D X4@%H * "@ H * "@ H * "@ H * "@ H * "@ H * $9@@+
M,0 !DD\ #U)H \ZUCQ+-J4GV#20S;OE,B_>;U"?W5]7...F!R?0A24%SU?N[
M>OGY"]#8T'PQ%I0$\^)+CKG^&/\ W<]3ZL>?3'?*I5<_=CI'\_Z[ D;<\_9?
MSK!(9E2M6J&>::U??;)R%/[N/*K[^I_$]/8"O1IQY5YLAFCX4TG^T;KS)!F&
M##-Z%OX5_,9/L,=ZSK3Y(V6[T_S!'K<A%>46.C7:OIGG_/X4 2TA!0 4 % !
M0!PGC;7[S3#:Z;I6Q;_4I'2.20;EBCC ,DFTX#-ED5 ?ERQ8@A=I3TT6YZ6$
MH0K.<ZS:I4X\TK;O6R2]3S%(;B.<V>IR07#7/VDSSE%<RS2D1R+)L8&+RXDB
M2,1[-BJI R*\7$XR>'G%7BH;-[JZ>SUNCWH4*=2,IT5/W>7E5[-12NK75I-M
MRO>]SNO#>O7\&H1Z;?2B[AN%=8I"JK+#-$F_RY"@"R1RQ!GCD*AB5(8DDA>^
MA7C75XM73LTNC_RZI]4>/B</"$/:4TXM6NGLT^J[-/1QZ'I]=AXX4 5KV[2P
MMY;J7(C@C>5\==J*6;'X T%13DU%;MI+YGS1K>N>)-8ET^=I+9(M4>46UNT2
MNML&C9=^2<O,(V9-TFY 7<HB\8B\NFES[&GA,-2YZ;<^>DDZC3M=+6R[*]OU
M#1]1\2Z+>:A]GEM\::L#7$'EJL=SLCV!S@YBE:-%C9H=JGRT=D8Y!=Y=;>[N
M1/#X6I&"O.]1OV3_ )4];/35<U]]DSZ2TO4(]6LX+Z'(CN8HYE!ZA9$#@'W
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M6BTT6B\C.C">(J1HQE9SDEJW;U?HM3QZ)M^HC4I+:R@OH0)$5/GC!3<C1;E
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 A%
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MV-ITKZUL\]G:6%KC%8-F;.LM8<5BR#8C7%9B+ %(0M !0 4 % !0 4 % !0
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MPVIP1>?+ %?*1G9AF?;Y>2)$(7=NPV<4 9%KXT>Y\2S^&#8W2);6ZSB^9?\
M1W+!#L4XQ_'M!W$ET==HVYH [F@#AO'7C-_!4%O/'8W6IFZN4MREJNXQA@3O
M; ;TPJX 9N-RT :VI>+=+TC4+72+N<1WVHDBVAVNS28SDY52J@8/+LHSP,T
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MT<+BI89\G,U2D[R2MO9V:O\ ([#5_ -IX7A74I8//BBDB>39.XD1C(B!2TC
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MZS$:,;5(BTIJ1$HH >*0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/XOU\O(FL[/IQ7UC9Y[.OL;/&.*Q;(.MM+;%8-D&[#'BLR2XHQ2$/I % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/_9*SI_"!6\9:QJOB'Q7;^#-,NI-,MA!]HN[B#B=AM+[$;JH"[0,$99R6R%
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M76I76KVKW\;0&\(>:%Q<6PF7S.K1O^[*@GY2&'?) /M=F" LQP ,DGH .I-
M'YY7WB7P_P"*HO%>HZM=K#J&IR(NF1LDK'RK1O,APR1LB^:J11?,RXPQ/!S0
M![W8_%B33OAC%XCAVRW]O$EB-_(%RC" .X[_ " 3D?Q9 /6@#1\"?#[7;Q+#
MQ)K'B#4I;J;R;N2T23;:&-\2BW:,$*05(5RJJO)"I@ D \ITSP5>7?Q,U+2T
MU?4()HK19S>1OBXD5A:L(';/,2B0*!_=C0=J /2['5]2U#XFZMH#WERE@-+'
MEQ+*X2*1X;,>;&N<)(#([!A@AB3F@#E?"?Q(U/P[X7\1VFN7$D^K^'YI(HY9
MG9I&-P3! 0S$LP6=68>B%>U &7XJU3Q'X6\%Z!<3:C>C4=0OTEN)#/)YACGC
M9T@9MV=BQ[,H3C?N.* )OBIX9N;KXC:1$FHWD)U(,T3HV&L@H92ML?X0Q4LW
M^T[4 =7XQO=6^&GB+P_=RZA>7>CW 33[T3RLR/, 4^T2)G:)'602DCDM"Q[F
M@#8\-:SJ?BSXBZGY5S.NBZ#$MN;=9&$$ETR[#O0$*Q#^>V2"08X_04 ?05 !
M0 4 9FJ:M!I$7FSGD_=0?>8^@'\R>!6D(.;M'[^P'!P6E[XOF$]P3#:(?E Z
M?1 ?O-_><\#M_=KN;CAURQUE_6_^1)Z%;6L.FQ""W4(J]AU)]2>I)[D\UP-N
M;O(H8[%CS36@%9SBJ&49&J@/,];O/M=R0#\D?RK^'WC^)_0"O2IQY8^;U(9L
M>#M,^V77VAQ^[ML'V+G[H_#EOJ!65>?+'E6[_+J"/5W->6455YD _P ]*?09
M=%2(6@ H * "@ H * *]W:1WL3V\P#)(I4CV8$''H<'@]J5D]TGZZC3<=4[>
MA\@>)]&N?"\#Z3?P.X@.;&\CC)+C/R!7"XWL!MDA;D-RH*E6/NPG&=IQ=GU7
M]?F2>J^!O#6I>%+^35+^>*>SN($@_=%]ZDNK1O/&PPFS+1D*[[2YYVUPU:L:
MR48JS3O_ ,,*YZIK-X9;=[2Q<&ZN4>.)E((B)4CSF(Z+'D-ZDX4<GCDBK.[V
M7]6'?L?*FL>$;GPQ+8PZVZWENQDQ%:B1XV:/9LCD<J#OE9BWEA>0IY8DX]B-
M55;J'NVMO;^M /:?AKX9N(I)M=U"%;5KI$CMK?8$,4*DMN=,?(SG&U3\RJN6
MP6('!B)1E:$=>76[UU\BDVMG:Y[!7&(X+5=4TC3?$EC;R2R6^J7T4B*L:_NK
MB)%<HER<%05<.ULQ*ON61%;8SJP!H:SXTL-%NOL#)=7=T(Q-)#9VTUT\43$J
MLDHB1A&K%6"!CO?:=JD T 2ZQXPT_1##'.9I+F[3?#:P02S73H,;F\B-&D15
MR SR!$5OE+!N* ,^Z\?V%E9Q7L\-]&;FZ%G%;O9SK<O.4:0(L+*&(**Q#C*'
M! ;((H LV'CK2KV"YN&DDM/[.V_:XKJ&2":#>,QEXI%#$2#_ %;(&60\(2>*
M -;0M=L_$UBFI:<YDMI]X1F1XR3&[1-E)%5U(=&&&4'B@#B/BCHEMJ-@MW.T
ML;VVX!H6"EDDV[HVW!EVMM!+8RN,@]0=HU704I)75KM>A,GRIOL4_"NH"63R
MK2WAMI@\BRB!<0R_*KARVU%9QGDGY^3GBN:C76)A[57M=I7\FUIY=B(R<NEF
M<KXNG@U$&W>(1R@P/<7:@)=DF9MJQ,\;!XUQC:3LZ!.:F>,^JU:=.UW-VBNF
MV]OS?0SE4<79+U^9[;X?T6TT"RCL[%2D0&XECEW9N6>1OXG;N>@X  4 #HE-
MU'S2W.D\;^*-Y-I=\XM0L9N+"1E#)O$\Q;R2%'59XXRIB9>2[+D'BHI8##U9
MRQ-2"E-VC*_PN/=QV?:[Z'4L15C!4HRM%.ZMNO)/>U];';?"_6%U72BL;,\=
MK((49F+$#RHW*;CDML9V49)PNU>U=-:FJ4E&*25M$M$ELK+IH<S;;;;NWU/1
MF8(,L0!ZDX%<PCG[_P 3V.G[]S>88L[PFWY2.JDLRKN_V021W KSJF-H4I.#
MFG*.Z5KI]M]_+<[Z6#K5;.,;)[-WU\]$W;SV,C4_%S6$T1\M1;3P)*C/E7W-
MDE7'6+"XQN0@DD9X(K#$XSZMRSY&X.-^M[]FMU]S.FA@E6C)<UIQDXM*UK+J
MGM+7LU^)9L_'.D764,PBD3'F*ZN%C8\@/+M\H<8(._&"#QFO3P\_K5*.(I)\
MLKVNK/31JWDSSJU)T)NE*UUVVUU1?\4/(='NWM@)'^S2% .=XVDX&.NX9 QU
MR*Z86YE?:Z,#Q+P'HVIP:]$]W;RVTBM/=RLX.Q8)X0D<*GE _F'=)&/F5E);
M[HKNK2A*#Y6F[I+OIN_N%?H?1M>:,* *]W:0WT+VUPBRPRJ4=&&0RD8(/^<C
MJ.::;3NM&@/ =(M[+P]JMQ9)";FW>Z2$>>?-N82$8H;8!-P5-Q^?<93P23MS
M6,\:YUEAVK2Y;W6B:N_\M?5=SF]H^;EMI>WF=YKFIO;VZ27\*W2>0'CCD7=&
M79XT#S##*  _5AP22!FM:DU1A*HK^ZF]-[)-V1I*7*KE'P#X>L&GGUC#O=+/
M,JJ6#00&0[G^S#8AVMN(RX+JI,8(&<E/%/$THM:1:^^W?^O,(2YE=^AZ?>6<
M.H0/:W"B2&92CJPR"K#!'^'H>133<7=;HU/#['3-/\.:C):2QF_43QHD\X0W
M-N3'B/R-B;R%!YD&&)P0ORDUG4QMZL<.])23=EL[7=VOEZ7TZF#G:7+;3_,[
M'6=0$FGH^IP+=1/$C+%(H,4DA:,(TO+@*I;=EP@!.<9 QI.:HJ51.W+?Y(J4
MN57,?X>>'K-KFXU-]S7$,\J1QDJ8;?S#O;R-JC/#%0S %4.T <DJGB_K-*+C
MI%_C;2[^[Y[CA+F6NECV"@T"@#EM?\5PZ%/#8I!<7]]=+))%;6JHTACBVB25
MVEDBBCC4NB[GD7<S!5#'. #)O/'HM9[:Q33M0FO;RWDNA;*MLLL444B1N9?-
MNHX]P9UPJ.^X$$&@#*O_ (K6MEIYUB*PU"YL(@PN)42W0V\L<S02P31S7,4H
MFCD&&"HZ8(*NPR0 ;)\="WCC^V:??VUU<RM%;692WDN)]B"221!#<21K%&I^
M=Y9(P#@=67(!(/'EG-917UG;WU[YTDL7D6]J[3Q26[%)TG5BB0M&XVD2.NX_
MZO?UH D3QQ9W.G1:I807E\D\CQ"&WMV:>.2,LLJ3(Y00M&R,C^:RC< %+$C(
M! /B)I4EA#J$(N)FNYWM8;1(6^UM<Q%Q- 8&VE'A\MS*79415+,^T@D W] \
M06OB.V-U:;U\N1X98I4,<T,T9Q)%+&>4=3C(Y!!#*2K D VZ "@ H * "@#)
MUO31JEH\'\>-R'T=>1^?0^Q-:TY<DD^G7T \,(*DJ1@C@CT(ZBO:(.@T^?>@
MSU7@UQSC9FRU1T5O)7.P-F!ZS8C4B:H$7D-2!.II")!2 6@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *  T 1,M,"E-%F
MJ0S#NK7-:)E'-W%J8SD5Y..RVAF,?WJY:B7NU(_$O)_S+R?R:.NE7E1VUCU3
MV_X RSU":Q;,3%?53]T_4=/QZU^?5,+F&12=2DW*E?644Y4W_CC]E^;MY2/7
M4J.*7+)>]V>C7H^O]:'7V?B6&7"W \IO4<K_ (C\<_6O>PN?4:MHXI>RE_,K
MR@_UC\TUYGGU,%*.M)\R[;/_ "?]:'01O'.-T95QZ@@C]*^MIU(5H\]*491[
MQ::_ \R47!VDFGYZ#R@K4D0+B@ Q0!'Y>3F@"0+0 X+0!'-/';+NE94'N<?Y
M_"N>K6IX>//6G&$>\FE]W?Y%QA*;M!-OR1SEYXFC3*VJ[S_>;A?P'4_I7R&*
MS^G"\,''GE_/*ZBO1?$_GRGJ4\%)ZU79=EJ_OV7XGGVJ^(-S$R,9I>R@\+^7
M"_0<UY=#+<?G4U7Q4G"ETG-65O\ IW3T^_1>;.YU*6&7)32OV7ZLY262:_;=
M*>!T4<*/P]?<\U^F8++\/EL.3#Q]Y_%.6LY>KZ+^ZK(\NI5E5=Y/3HNB-*TL
M?:O2;.>YU5G8XQQ6+9!U%K:[:Q;(-V&';6;)+ZKBI$2 4@%H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \
M?\5V_P 0X=3DG\-S:7+ITBH(X+M7$D3! ';<BJ6W/EAF1@!@;1SD K_#;X>W
M?@ZXU#Q)XDNX;C5=4.ZX>/Y+>&-3O(#,$SDXR2J*JHH&>6(!XM\,_"EIXA\?
MW^I:6YGT#2+N:Z@(SY)N[A5&(NQ",K,K#^"&(]&7(![;X^TSQKJTMS8:5'HU
MUI%Y"(E6]$OFQ,R;9'(5=C?,2R</C X[4 <W<_!.X_X0 >#HKE&O4D^TB5@P
M@,WF%S&."ZQ[24#;<[OG*C)4 $M]\-O$'C?PNFD^)IK2VU;3YXY-/N+7>R 0
MQ*BF?."6<E]Y0 #Y'"Y4H0#8\.V_Q&6[MXM9&B&RB=?M$T0F^T31C[Q0;1&L
MC=<[$&>PI 6/#O@/4-(\<:MXIF:$V6I6Z10JK,9@RBV!WJ4"@?N6P0[=1QZ0
MWH,C^'_@2_\ "NOZ]J]XT+0:S<K-;B-F9U42SN?,!10IQ*O"LPR#SZYREHBD
MCC-!^%&KZ7X:U_1)GMC<ZU/));%9',:JV,>:QB!4\<A5?ZFLY35XOL4HL?JO
MP=NM6\)Z5I!N([76="&^"X0LT7F%RS+NVAPIQ&P<)E70':1D5A[51DW:\67R
M77F=;X/'CE;H+XH;3&LTB9=UKYGGR2_+L<Y C"X#;@ G)X7M7-4=.W[OFOY[
M&D>;K:QF_&3P/J/CS3+:STIH5FMKM;@^>[(I58Y$P"J/SEAP0!C/-31J1I2;
MG>S5M/4<XN2T.9U3PAX_\:P'3==OM.TW3Y<"=;!)'EE0'E"7 X/<>8JG^)6'
M%6JE&D^:$9.72_3^O07+.6C:2\CI?$_PFLM5\-V_AW3'-DVFNLUG,?F(F7=N
M:7&"?-+,SLHR&(95(7:<85W&;J2UOHUY>7H6X)QY5I8CT"#X@K=6\6KC139Q
M.OVB:(2^?+&.I0;0BR-USL09]*<G1LW#GOT71"2GUM8?H?@2_P!-\;ZEXHE:
M$V5_;B*)59C,& MQ\ZE H'[EN0YZCCGA2JQ=*-)7NG=]NO\ F-1:DY=&+\(_
M E[X&TZ\LM4,$K7=V\ZB%F=?+:-$VMN1.3M.1@C!ZT5ZJJRBX7T5M>]Q0BXI
MIG)^ /@W=^%/$3ZE>2Q3:=9_:?[,B5F9XS</C<ZL@52L1(.UFRQ!XQ6M7$*<
M.6*:D[<WR_X),:;C*[V6QL^)? .N6/B"3Q7X0FM5N+R)8KRTO0WDR[0H#JR@
MD$A$)&4(8$AR&*U$*L'#V59.RV:W0W%I\T/FC=M])\4:SHNIV.OC38KF]MI(
M+5;/S B>9$Z'SF<,3EF4@KNP >.E1S4XSA*GS63N[^O0JTFFG;78U?AIX9NO
M!WAZUT>_:-KBV\[>T3%H_GFDD&&94)PK#.5'.?K45IJI-SCL[;^A4%RI)GSW
MXD\.V?C?XCBSTB43V;K;W.K^40T(>V)RI8$JS.!&AQTDD;G(;'H0DZ5"\U9Z
MJ-]]?Z^Y'.TI3LMNI]@=.G%>.=84 % !5 +0(* %%4(6F!'<#]VV/2M8?$@1
MP6MSA;,C^*X<*!WY;<?R4?RKHF[1?F=E->^O(;:C8JUG'0UENS;!&*Z#E/(/
MB8 ;FVS_ ,\G_P#0Q7U^4+W*G^)?D>#CW:4;=G^9Y[("BA%XX+'\<?\ ZJ]&
M@_;5:N(Z1?LH>D=9/YO\ Q*^KT*&$ZR7MI^L](+_ +=BOO.NT1Q!-".R!"?J
M>37H35TSYO>[[M_AH=1X<06GB&Z@D(60"4)G_EI%*ZS1X]2H8GZ-CM7E5O>I
M*2Z63^5T>K1?+)=I)V]>J_ ]2KRCTPH * "@ H * "@"IJ$#75K- F TL,D:
MYX&71E&?;)YXZ4 ?/OA7P;\0?!UB-,TV?2! KO)^\\UVW/C=\WE#C@8XK%*4
M596 Z'7? >O7%[8>*=-GM8_$%K;K#=QN'%K<?*RMM(&X##,F"!E=I#(R\MQ>
MDEN!:\/^!M8OO$"^*_%<EL;FVC\JTM;3>8HAAAN9GY)&]R!EB6;<6 4+347?
MFD!B6W@'Q1X(U"ZF\'SV4NGW\AE:VO=X\IR21MV#G;DJ&5P63 ="5!I<KB_=
MM;S N>(?!/B:\U+2_%%H]C+JUA!Y-S#*9%MF8F7+PG;NP1*P(.QE(5E)Z4.+
MNI*UT!?\(^"-=TWQ1<^)M:FM9S?6GE.+?S%\N3,.(T1UYC18MH<ON;J5Y-"B
MT[L#,T#X7:KIGA/5_#\KVQNM4G:2%E=S&%/E8\QC&&4_NST5NU2HM)H"+Q/\
M,O$^K^'=)\-V4]FD%C"/MJ/+*JS3(V8P&6(L\2@DX.P[SG&0I$N+LD!VOA_P
MYXNNHFT3Q(=)&A2VDMJT-@KI*BM'LC$>Y H"]>O8'FE9[,9D:!X3^(?@JV&B
M:1+HU_I\)86TUXLJS1HS%MK*@'0DD#,F,X#;< 1:P'1_$/X<:MXF_LO7-(N(
M+7Q%HZI\Q#"VE/#.JG:2JB3>4#(59'9' R"$!S5_\-O&GBK6-(U_7[G3_,TN
M[C=K6W\Q(XH$DCD=D9E<R3RE?F4D(H5,/R0$![QXRL;_ %31;VQTAHTO;FW>
M&)Y6*(ID&QF+*KL"J,Q7"GY@/K0!RWPZ^&]GX2T"VTF_@M;FZC5VN)/+60-)
M([,VUW0,54$(N0/E4<"@#SCP[\$+NUTK6_"^HRPC2M2N!<:>\3.\MNZ.2C21
MLB+G:D(95<[MKKD9#4 :_@S0_B/X::TT>ZFTJZTFS>.-IV,WVDVJ$#RT^4#>
M(QM3>I(P 7.,T 1^)?A_XGL?&3^+_"LEDWVVW2WN8KPR#:%$:,5"#Y@5B1E(
M8$,""I4\@'0:9X U"S^(%[XN=H/L%W9K;QH&;S@X2V4EDV! N86Y#D\CCK@
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M\TDA/0\RKTB#V[P]IW]F621$8D;YW_WFYQ_P$87\*\:K+GDWTV19JR&LAE6
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MV88=M9DEY4Q4@2@4A"T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!F:UH]MX@L9],OE\RVNXVBE4$J
M2K#!P1R".H(Y!P10!7\.^&].\*62:;I$"6MM'DA$R26/5W8DL[M@9=R6. ,X
M % &W0 4 %(!M2QD;&LF60L:PDRT5V-<TF:(B)KF;-$1$UBRQE0,2I&%( H
M* "@ I@%( H 1E# J1D$8(/<'J/QI@<OX6\%Z1X+A>WT:W6W65MTC9+R2'G&
MYV)8A<G:H(5<G &3G6=251WF[V)C%1V.IK$H* "@ J@%H$+5 +3$**8&;J6K
M6FEH?M3A21P@Y=OHHY_$X'O5+35%QBY?"CS!7EU.832C;''Q$GH/4^K'C)_
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M4@ &O"$2T#"@#$%SI.B(+$/:6<:@D0;HHE <EF/EY4 .69CQ\Q))R2: *O\
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M'':H;)-B&UVUFV2:<<.*@1:5<4A$H%(!: "@ H * "@ H * "@ H * "@ H
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MC)H )/A]I7V&VL+836G]GR/+;7$$K+<QRR;O.D\YM[2-/O?SO-#K+N.X' P
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M:"&H LJ:0B04@'4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !B@!A6F!"T= RK) #57 H26@-5<90DL1Z55QE%]
M/'I57'<J-IWM57'<B.F^U%PN(--]J+A<F73O:BX7+4>GX[5-Q7+T=B!VJ;BN
M7X[0"IN(O1VX%3<1;6/%2!,%Q0(>!2 6@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M*0"4F,C:LV40L:YY,M%=C7-)FB(6KF;-$1&L&:#*@8E2,*0!0 50#PM6D22!
M*U42;C]E:<A-QI2H<;#3(B,5@U8L94%!2 * "@ H P]:UV+2%"X\R=AE8\XX
M_O,>R_J>W<BC>G2=1Z:+JSSZXU.]U(_OI653_!&2B#\%.3_P(FFCT53A#97?
M=C8K*,')&3ZGDUHH@Y6VT-&-%3H*T2L9-ED/CH*HBPA8GI2&(%8^U :(D\DX
MIV%<A=#T(I#13(:W?,:@+]YFQDCT ]SV'X]!7TN704Z%:%[-RC^6YX&,J>RQ
M6'J6YN52TO:^_7\_(R-2$J,7=UMT?H%7=*WN3VY]P/QKZJFK12CK9)'RE249
M3DW'F;E)M[13;=[;W_'U*$$L1(627S!W65,X^C8X/7THFZD=8PYO223^YZ/[
MS2G"E4TE)4GT=I<OS<+M?^ M%R;28W&^%AL.,%6/!]"K#GZJ1FL%BH?#/W9=
MIKE?XZ?B=;P%9+GIKVD-^:#516[WAJOG&ZZF7+HDA^ZZG_OH'\MN?RS7<II[
M?H>:WR:2T_+[_P!'9C(-!FD.(W7/I\^?_0:'-+=?D',MAS6UU9_Q'@XR-PP?
MJ0*+I_TA718AU:_A^XS-M]&SQ],U+IP>Z7W%)N/PMK\#:L?%TJL%N1N![XP?
MJ.QKEGAHOX-&=,,14AN^9>?^>YWEK=1W<8EB.5/Z>QKR9P=-\LCUZ=2-5<T?
MFNJ+%9FP4 % !0 4 % !0 4 .% $J'%("U&:A@78S4,"]&:AC+2FH L"D X4
M@"@ H * "@ H * "@"M=WD5A$9IV"(O4G^0'4D]@.351BY.T=P."=[SQA)LC
MS;V"'DGJ^/\ T)O]G[J]\FNZT<.KO6?Y?U][%N=O8V$&EQ""V7:HZGNQ]6/<
M_P#ZA@<5Q2DYN\AE@T@$H 2@!AI@0L:8%20U2&<KXBN?(MF4=9"$'TZG]!C\
M:Z:2O+TU$]#S^.-I76-.6<A1]2<"O0;MJ0>\6\"6<*6ZD!8D"_7 _J>:\1MR
M;EW99%(RG +*-P)_+M_GFFM.@&//)&X'SJ/,)'7H!V]P??GWK9)KH] .<GNH
MXF$RN@*R!5Y/R[3U]P<=#V/6MDF]+/89Z6CA]KJ<JXR#ZYY'Z9KS]M!$E( H
M * "@ H * "@ H \5^+TWDS:43]U9YI#Z958P#^3-^9KT<*KN?H!Y+HVHP1Z
MC?RJPV&;;"?[I22,Q!?3:WW1VKLE%^S2Z]?N$?8E>$,P]7\0VNCE87WSW<P)
MAM8%WSRXX)5,@*@/WI9&2%/XY%H RH-(O]9D6YUJ3R(D97CL+:1@@*G<INIU
MVO<." ?+39;@C!6; >@#4L?#UO8:G>:Q&SF?44MDE5BNQ1:K(L>P!0P)$C;L
MLV2!C'< QYO!$(U"74[&[O=.>[=)+J*VDB$-PZ *'=)89=CLBJCO"8V=0-Q)
M&: (-0M[NY\66#_9MUE:6%ZYNB.$N)I+>-8U.>',:.<8Y5FYX- %Y/!=BL&J
M6K&1XM>DEDN@Q7@S6\=LPCPHVC9&"-VXALG.,  '1:;9#3;6&S5WE%O%'$'D
M(+N(U"AG*A068#+$* 23@"@">4_=7^\?T')_EC\:: \!^(6I6U[JY@>6%/LI
M@@RQ.X-(3(_0@8 9<C /^T*]O#1E&G=)^]S/3RT1-KNUMDG^?^1YY:7$%C"Z
MI)"OF7'E.<LK*G!63Y6 VDGC<&_W@>1Z<DY-73TBFMM^QQ4[Q48I?%.:^YS=
M_/8WX7L2VH3-+:Q/;CRU(+ RKN*AU.\G+=\[@2.@K%\Z5.-I-/6VED^S-8+F
M<I**OS.-TM7;SW^0D5S9SZIY;R121Q>1' HW$-(6R)54ER,-D^9G:$7?CGER
M@U37NN[O*5[:*VW3IT[NQSJ5YRJ2;5.ZI0WM*5_>>G9^[Y*,GL+I;3^';D:C
M8+*MJTKK*T;&0^9N8Q^8['$D+YP$.W&XNHW$,*C&E.$Z-6W.TG%RZ);I6U3\
M]>S.7%+$JK1K8=MP@VJE.+2YE+2[OH[;VNGU6I],:=J4&I0"Y@8%#U[;3QE3
MG&",_B,$9!!KY:<73?++0]Q:[&5J_BS3]&&)7,L@7?Y<6&8(<@,Q+*B@D$+N
M8;B#MS@X<(.IK#;OT&TUH]&9EKXGM?$=BNH6:RQQK(P$DH2,JR9#J S$2 @E
M3MWH<GDE2!4H.F^65KD,X>\U*P\'Z@+A!%<#YC(ZN_\ HYEP^SR 6\D,OS;R
M#G(RJYY*6%@W*I!<LY=;+WK>?6Q"@HNZ.ZT3Q_I&M%HUF6"5<?),RIN![QL2
M X]AAAQE1FKG0G3U:NO+]>QJ=#JNM6>B6_VJ]E2&+@ DCYB>@4?Q$^W0<G !
M-13I3JRY*<6WY+9=WV,YSC35YR45>RNTM7LM>OD>)>*-5N?$,,UTA'V$-Y6P
MQ!E\G>"V9"=J&3:&<C>5"KC;CGVZ,(45[.44YR5[WV=NBZVZ;?,Y:M.56<)Q
MFX*#NTDO>\F^B[VWVNC"N-0@26UA#QQ6Y1H&MRSGRT0K'D('!(53N7#?,O\
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MK-B-*,U BVIJ1$PH >*0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % "$4 ,*TP(S&*!D+0BF! UN*=P(C;"G
M<8S[*/2BX""U'I1<!XMAZ47 F6W I7$3+"!2N!,L8%("4+B@0\"D O2@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M?I7@UL-4HOVV D]-72;NO^W4_P GKV?0^KPV.P^,7U;-81N]%72Y9+MSM?\
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M9_PD6G"+S_/386V=\[L9QLQNZ<_=Z<]*/93OR\KOO_3V"Z)/[=L!(D/GQ[Y
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M&TDW &N&2LVC<W[=ZR8C<@:LF(U8C4"+J&I L"D(>*0"T % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #3
M0 PTP&&@"%I$7J0/J13LQC!+&>C*?H13LP'@BD H(H D!% #P:0AX- #A2 6
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0[DW5G&QZJ-I_#_ZV*\"O'EJ.W74]K#2YJ:79M?Y&M7*=@4 % !0 4 % !0
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M36FZ3^7ZFWM82I.NU>GRN335]%>^GR%@T<IIEQ-:6RQ(A+%T8(2%)9 5 (8
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M BTIJ1$PI .% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M)+2O2$2 T@'4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M8KAGG)8^F!V P. .@'TK>*459=")MR?-+=_+\M$ET2T1Z]X+GSYD?L#^1_\
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MMP&LV(U(C68BZE(1,*0#Q2 * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^/)_K7-/65CMIJT;]V.A2A(39L6\=;)'/)FK&F*V2,&RVJ5H9DH7%,D=B@#
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M"=[/8PSV_P!D4>5&!A0G&,=.!U'J#U^O-8*;4N;=^9"]W4YVRNY=(E^QW?\
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MTJ0)Q2$/%(!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * $)H PM:UE-)BSPTK_<3U_VC_LCOZ]![;4X.;\ENRDKG%Z1H\VOS
M&[NRWE9Y;H7(_A7T4="1P.@YZ=DYJDN2&_Y>IHWRZ(],BB2V01Q*$11@ #
MKSFVW=[F(I;-(#.??NPG- $@AD8<MCZ4 <%\3=*NK[PQJ%G9QO<3S0JJ1QJ6
M=CYL9PJCDG )X["@#%U#P;!XB\72W.IVTDMFNCVT<<@>:)//%U.7C#Q/'N8(
MRL5). 0<<T 6KGP;'JVK:I8W4,B:;<Z1IMM%*-WRR02WA!BD)),UN6BD!R65
MMC$\T 5?AOIFJ0S:HVOPYNFO(0)2O[NY\FRBM3=19&-LZJS,!]UG=#R"* (O
M!7AEM3MY]0BO)8&:<V,,UHT>Y;/39);:&'=+%*NUG$DK@+DL4^;"\L#9\!^&
M+[2+;?=75\2+F_/V:8P^45>\N"DI58%DS(I68$2!2SY"A2%" ]$#8.#Q0 DD
MXB% !;S[J +X.X8/0T >?>(?#7D9O+$$*/F>,?P_[2>WJO;J..!WTJM_<G\G
M^C-8RZ,JZ1JYEQ%*?G'0_P!X?X^OKUHJ4^75;?D#1V$%QFN1H@TXY,U(BP#2
M$/I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MTT+"2&)MLHV$],'(/XTEH[/035U>.IK0GY0?6MT<S6ISGB"T,96_AX>,@/\
M3^$GZ?=/L1Z5UTI7O3>SV''^5FO97*W,:RKT89^A[C\#6<ERNQFU;0T5-9B%
M- Q*!#33 0T 1M3 K/5#,^8U2 \PUQ]UY)[;1^2BO3IZ11#.K\!Q_-<2>@1?
MS+$_R%<V(?PKU&COWKA JO5(92DJT(SY:T0&?**T0&9,M:(1FR1YJQE&6*J
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M+;QW"&.55D1NJNH93@YY!!!Y /(Z\T@)P* ' 4 /Q2 7% #@*0#@* ' 4#%
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MW#YIHWE"L8U(QD X'QS*)$\<.ARILM'92#Q@P,01]10!]-V/_'O%_P!<T_\
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MQ*+D0B0!!^X^YC:,?\"]?PKEIV]FN6]M=]]SECL;-BO K&0,Z"->*P9!)MI
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MT>G^1<79G Z7=;/D/;I]*ZJD>IHT=M9SYQ7(T9F_"^:R9)<4TA#Z0!0 4 %
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MW;AMH S-<^-=O:ZI-H>@:=>^(+NS)%S]D7]W$P.&4OM<EE/RL=H3=\H8L"
M>?\ QB^*6MZ?8Z4VGVNH:2U\T4\S%0IP3*IL2VW*W!V+(5!5MC+D#)% 'T1X
M2\03>)K 7UQ97.EN9'3[/=KLE 4X#%<#Y6_AH Z:@ H * "@ H * "@ H *
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M"=>:WCH<TC65LUNCF#>HZD#\:H0Y9$/ 8?F*!&1K.GB^*'H45@#_ +Q&1^)
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M2GS+D$<@C@@CH17?390[Q3;P:I96^IVD=S<2*HCNIYB2BLN,#Y\CKD952,'
MY-%)N$I4Y.*6\4M[?(UHRY6XMV3_ #_KS-O0KLZ]I0L9) ;BT_U4*0$B.$D9
ME=@H;*@$9P.X"G.:RFO93YTO=ENW+=]DC&I'DEI>W3S[C=-ESP>#_GUIR1#+
MNN0B6T ==T7F(91C/R#/)'HIP2>V,UAI?78S.J\+)NN7)^_*"7!&&(4+Y;D<
M'[IQ[Y%<,FNAI8]1AA""N1LHGQ4C#% #60,,&GL(\]\9V*S0JAR,%F)!Q\H
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M.\CJH\R1G8EB6;<W)X!QT%,#C?#Z'4M5-PW(4O+^N%_+(Q]*]&I[E/E7DO\
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M%C0$\DA4 49/)XYH M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !2
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MN79=3A/%.O\ EVYAM\;I#(L7<CS,&27.[.\]'X\K</E'S9KG<T_\*O\ CO\
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MGAM(%X,DTBQH">@W.0,G' SD]J ,[0_%FC^)=XTB]MKTQ??$$J2,H/0LJDD
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MVO5]SIG!5(\\=--%MUZG?M<6E\$U"UDV+<3,P#LSS)$@VCS5+*H+,.!NW_4
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MI$WK:N9E&_;5FQ&W!63$:D50(N)4@3"D(<* "@ H * "@ H * "@ H * "@
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M3NR4^^WZFE96I4C=M))&"H)YQD[L@X_&N.K5Y'>+O;7O_E?LS*50TDTH$ H
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MS\RB*+YNI,:DDD"@#7_9YT#36\)SZQ]GB.H*][#]IVCS1'Y2?)NZ[<'I[^]
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ML7<7JQY)R=L0O(T&?]E$51["@#[IA^XO^Z/Y4 24 % !0 4 % !0 4 % !0
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MLM9^QP07MG<Z]#:VT4I M-TL=NL;.S*X6VC8;E*J5VJ@CX*D)-).VU_D!2U
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MBJ!%Q*D1,*0#A0 4 % !0 4 % !0 4 % !0 4 % &=J&IPZ<N9#ES]U!U/\
M@/<_AFM(P<]MNXTKG$7NMW-X2-WEI_=3C\SU/Z#VKMC3C'S?F:)6,BM1A0 4
M % !0 4 % !0 UJ *%STJT-'HW@__D'_ $D?^E>?7^/Y(SEN;4P+<#O7,0+%
M"L0Z4 +-$)!QP1TH S9SYL;PLS1,RE=Z8#+G^)<Y&1VR#4R7,G%-JZW6Z]"X
M2Y)*;BI6:?*]G;H[=&4O](L([>"PB66+>J3$X4A"/FD & 23\S>N>!S6#4J2
MA&E%-7M+IIU?^9VQ=/$2JU,1-PERN4-VG);0N[NUM$4_]+6:XL(GM-T*K- 7
MC(\G<W 90-IPH)#J=V>HKG]]2E2BX:>]&ZMRW?;;;JCN2I<E+$SC6M-N%1*:
M?/9:M/=7=O=:M;9G*Z]=H#<1W#0M-:P#RXHAF)I)MJRS$*!AR&*B-B2PPW!K
MBJR5Y*?+S1CHE\+<K<TM.NNS/9PM-VIRI*:A4J/FG/2:C"[A33>\59-R25GH
M>=06L:WA$+*RR(N&5#&,C*,-I)((8')R03R*^2S*T+.+NK+I;;?0]A3DT^=-
M23>CDI.SU3NK:-/0O:E#]GNAGNBX!/7&>U>'AIMPVTYG=.Z3V:OMH1&5X_-E
MJVN G/"]SBM'0YW>V_\ 6AE(T8;H", '(/(.,<&IEA]U9?KIYF%M3.O)]PXK
M-4>38Z(:%N> +:*Q!!V#)/3[HQBN6$TY\J3NIRN[Z6Z*UMUKK?4<9^\UTN</
MIHC\TQ."6=\QJ6\M >@=I "P[A0.,C.:_2,,E[&*EN]4KV7JWOZ$U'+G<X;1
M5I-+FEWY5&]O-^3L>P^$Y7M+=XXX?MED QN) 2Q#%2Q2",C]Y'T7C!9R6(%>
MC0;BFE'GA]I_*]HKJOS9Y&-BJDXRE/V5>Z]G&R5TFDI5))^[+=ZW2C9)G5V\
MEYIMM;6]M"LZR$_-@0I!#D,%9,DAPAP!W8<UV1<Z<80A'FN]_A48[V:[V_$\
MBHJ-:I5JUIN#BMK^TE4G:S:>BY7)7]'H23P17%V89[@L24GAA!V%!'\I.5Y=
M68\AN*T<5*?+.7:48[6MOMNF81G*%'VE*FDK2IU*C]Y2Y]4K/2+2V:-S<%KJ
M/-*=Q<+C:.:8$MHV* )=6/\ H,__ %R?_P!!-7#XH^J&MT?.>M'#Q_1OYBO:
M1TH=9GI4L1TMN:S$:B4B244@"@ H * -&QU2?3S^[.4[HW*_AZ'W'XYK.4%+
M??N)H[K3=5CU($*"KK]X$9'X-T_D?:N*<'#T,VK',>/?AYIOQ#M8[74C+$]M
M)YL$\#A)8G(P2I*LI#8&05/*J1@@&LA',:/\$](TC5+37C<ZC=ZE9%F^T7-R
M)FF+(4 EW(?E120BQE, \[CS0!U7A_X?Z?X;U?4->M'G:YUAMTZR,AC4[B_[
MM0BLHRQ^\S<4 -\-?#W3?"U_J6IVC3/+K<OFW*RLC1@[Y7Q&H12%)E889GXP
M,^H!S7A3X,:3X-OI[W3+B^6&Z25#9M,IMD\X ,RIY88LH&U&=F('!+4 =9X%
M\#6'P]TXZ5IC320-,\Y,[*S[G5%(RB1C;A!@;<]>: .QDC652C@,K JP/(((
MP01Z$<&@#SCP%\*M&^',ES-I/G,][M#F9U?8B%B(X]J)A,MSG<3M7)XH T-/
M^'VG:;XBN_%<+SF^U"$0RJSJ80H$(RBA P.(4Y+L/O<<C  >!OA]IW@"TGL=
M-::6*[G:>3[0R.=S(J$#:B#;M4<$$]>: //T_9YT"-KB)+G4DT^Z9G;3TNMM
MJ)&&%?8$RYCX,?F,^"J[MX&* .@O_@WHNH^'[/PM-)=BRTV8S0LLD8F+$RG#
MMY14K^^;@(IZ<\'(!ZPJ[ %'0#'Y4 +0 4 % !0 4 % !0 4 % !0 4 % !0
M 4@$J1D;5FRB$UBRQ!4H#Y>^)O/B6;/:WMP/^^"?YFOK<)_ CZR_,RZD?@ZY
M^SW7ID5=570',:^PDU:1AZ?U-=$-*:%U-CPQ/Y%XAZ<UE45XC/3?"DPE\4S$
M=[*3_P!&PUY>*5L.O\:_*0UN>N170MI/+DX1CP?0^_L?Y_6O IU.1\DMGMY,
MUE&ZNMR*_P!'$S&:W(CD/)'\+?7'0^XZ]QWHK8=5/>AI+\'_ )!"IRZ/5&3Y
MLMJ=MPI0^O\ "?HPX->-.G.GI--?E]YV)J7PLM),K=#611)N% A<@4 2&"0Q
MB6,;P>PZ_EW_  _*NOV$W!5(:I]%NO\ ,SYTGRO0I)<J3M/!'4'@BN5Z:/1F
MI8# ]*0AU '#^-KG;%#;#K(Y<_1!@?\ CS?I3.[#1]YR[+\SF+%<5M$ZYFYT
M%;',9EU)UK.1M%&IX1M?.N9+DCB%=J_[S]?R4'_OJL498B5HJ"ZZ_<=IJR[[
M.=?^F3_^@DU1PT])Q]4>2P'FI1[3-8'E?K70CED;T;<5LCG9-FM48LI7#5HB
M&5@^Q W8/_2F2>5_$J7;=6Q'3RG_ /0A7;2?[N:ZW1FHR=>G-+W5=-]GYG V
M&FW>K%EM(WEV<LP'RJ/5F.%7\36E-^_%->2.FNK4Y:]4_P 3L+'PDD94W\O/
M]R+GIS@N?_91]#7;.@U:5GJ[63:NY:+TL[7?S/.IU;IQNERJ]VD[*.LO6ZOH
M:+ZJFGIY=FHAC4G@=\_WCU8^YS_*O2IX:,8J$TGLK6W:ZKJ<DJTG)RIMIZN]
M[V3Z/I:^Q5^V?:L,>?IP<>GI^E>DJ;BOW3MV4O>7XN_XGFRJQ<K5HZ7U<?=?
MX)Q_\EOYA:7!N]T<G++D,/[R],_4=_P-="5DK_TS@J)1E>.W3R.TTN(P_982
M<_.2/8 Y'_H?YUSS^T_+^OR,MW<].-?/'U!YUXSLMC+<*.'&#]1_];%>UA9W
MCR]OR/$Q$.2I=;2U^?4X&=]\(D'WDX/U7I^8Q^5>/FE.5.KA\93TE&:@WZN\
M;^3=T_)GT^25(U*6+RVLKPG3=2*^5IV\U[LEYHR[^,+<EE^[.NX?[V ?\*^I
MA)3A&:V:3^_I\CY+E=)RHR^*G)Q?FD]&O)K5>1%:2>5L;^XQ7\#R/R.156TL
M)[OS5_FM'^A]#Z+<"YLXG']W!_#BOG*\>6H_/4]7#2O3MV;7Z_J:AKF.TS[R
M(2HR-RK J1[$8/Z52=M1K35'(_"&\:PN;_093AHW\Z,'OM/ER8^H\MOIDUMC
M8\T85EVL_P U^IZ-;WE&JMFK?K_F>O7K,H8MPH%?.ROUV)A;2QXQ+J4ND3S>
M9'(L<C;T.QMI!'4'&,&N%<RERQ3;;T5M[[6/=]UQYG))16KOM;>_H:&EW<FH
M.MXXRB<QH.2&[.WN/X1V//44YJ=.7+.+4ENNJ$G"4?<=T^O1KR_4Z2;4A'%N
MN6"GGKUQVX]::;M[VYDH*_N+0\:\5R?VGEH %53Z<GZCTKZ' 8-<ZK8B.B7N
MP:WOUDOR6]]>AYV,Q+5-T,/-J3^*<79QMTBUUON]NFMV>82(8FV'(/TQSWQ[
M5.,H+#5.6-^5KFC?IW7R?X6/9RW%O&T>:;BYQ;BW%IW2^&3MLY+==[VT-WPW
MKIT.X_><V\G#C&>HP?P(X-/#5U33I5/@=VGUC+2S]';7?N<F98*==PKX?^)%
MI-7TE#6]DU\2O=-.-]4V]$>KZ;FW?[9H\Z;">8Y& !7@X.<JR\]3@\<C->M.
MG>RY;W2^'6]^ODWY=#Y*GB(M3]JY>[.2YI)1Y;6NEM[JV=];WOJ>D:=?PW[>
M7*1'.!GR@P*O_P!<VS_XZ?F_NDUP2I.GK]GOV\F;^TYE9;_<[=UY>90U.^-X
M^Q,A5.#GCD'ICVKAJ3TY([=?/_@';2IV?/):].Z[W\RHHP*Y#T$/ I 2J*8C
M6TR?RI-AZ'I]:ZZ4KKD?JOU//KQM^\7H_P!/Z]#I)8SN5QTQC]<UHSFC;8TH
M>:S&<M<O]MU(XY6 8_%>O_CQ_2NI>[#U_K\C3:/J=) M<[,R^*@0^D TTP&F
M@")J8%62J&9DU:(#S'6%V7<GN0?S KTJ?PHAG:> I/EN(_>-OT8?TKCQ*^%^
MOZ#1W[5Q#*[4P(&%4(JN*H"JXJT!3<5: AQ5",*/PSI,%U_:$=E:I=DEO/6"
M,2[CG+;PN[<<G+9R<G)I66]AF@NGVR))$L48CG+M*H10LC2##M(N,.7'#E@2
MPZYI@<WX@TJ\NDA@L+;2[BVB&#!?QOM1EP(VA\M'50J@C9L!Z;64#%)KM;Y@
M0Z#X22PL[BWU3R;Z749WN;L>4!;LSA%6..)]V(HDC1$#9/R[C@G $K*SZB-F
M+1[?38672H+:UE$1CC*PJJ#&YD5Q&%8QAV+%01G+$$$YIVMMH!Q=GX0O;B^M
MKJ_CTVS@L9S="+3HG5KFY"/&DDSND>%C$CL$ <EB,O@5/+KK96[#.MOO#NDZ
MS(MU>6EK=R* %EDACD; Z .5)('89(%59/=(#4%I"DOVA8T$Q01F0* Y122J
M;L;M@))"YP"20,TP(/[+M/(-IY$/V=B6:'RT\LDMO)*8VDE_G)(R6^8\\T66
MP&9>Z?H_B.1[>[BM;^2R8*Z2)'*T#.H=00P)0NN& XW#!YHT>]M ([J\T719
M[2TN&M;:X.8[*(A%=0^$*P*!E%;A#M"J>%)[472LM/(#:%E K2.(HPUP )CL
M7,H"[0)#CYP%^4!LX7CI3 BT_3+32(A;6$,5K""6$<*+&@9CECM4 9)ZG%"5
MM$(J77AW3+V%;6XM+:6"-F=(GAC**[$EF52N%9B26( +$G.<TK+:P&G!;QVL
M:PP(L448"HB*%55'0*J@  >@&*>PR;% @Q0 8H I7TB6L+SR<)&I8_0>GO5Q
M3DU%;L-CAY6EU2YBA,,JJRLX15R7Y4 _O%5<#)_O<G@=Z[DE3BW==%?M]VI#
M=]!]M8VZ:?>)<7#6LD3/^Y.U3C)8;@O!W#'3L=HH<GSP<8\R=M=?P$<MK7CW
M[=96W]GQ"VGMR&\P[<G;D,%'\77D<'!SCTZ:>'Y)2YW=/2Q=NYR.I:K<ZK=B
M\N)&9WS$&8[1@KN4CI@[67((QGG/.1U0A&G'DBM%K;^O0>B/H.WL))&"*#N(
M#8 P#E>>O;)Q],^U>"Y):_(9S/BNWFMHK;SLQ6_G;7D !:+ (RK$'R]QP"PZ
M#VKQ\?5G"E*6'5YVNDNNJOIU=KM+JSFK-V5M%?5FQX,1I (P=UN]Q,+>24JS
MR*L;'&QEVMW^8$],XY!J:%2=2DI5$T[;/1K72]MG;=!2;:U[Z%?Q6K1LJN?+
MM$NI$EEB8*RGRT.W"KMCYP,^_09S66+JU:5+FH)N5XZ)7;C?WK+J[7L%2ZTO
M97_KT)O#]G<75JC!<I)+(5;:$:3:2%D? &YB,$L>6]:]##5'*DI5%:5E=/=7
MZ%TV^57-$V,D;,""/+PI)&>.IZ?ECT..E=W,G;S-CY]@U2ZT2:>XM':*25I/
MF!SG+_(I!ZD#<3@$@E<D#(KWG"-1*,E=*WY:L-#J=)\;MIFGR6,T7VJ>Y9@9
M,9.YL,Q8=?EW?C@C  KFG04YJ:?*HVT_+\B;=CK;NVLYX+*WL9WO)7928?,#
M?*!@L-^\+C(Y &3\O?CFBY)SE.*BEUM;7Y6($C^T:5<30K Y6,*[(V"5SNS@
MI@$'&<[<Y!R.Y'RS2?,M;J_?[_\ ,:=M#MK*:.YB66(@JRJW49&X9 ('0^U<
M,DXMI]"RYBH ,4 &* ."TP$>+M3_ .P?IN/^^[NH7Q/T7ZC.3AURY\/_ -K7
M%I&D\DWB6*U"2$JI$\5K&<,/ND$CYL,!SE3TJ;VO;^;_ " U=>UW6K!+W2[D
MVL=U)IEU>VES;B8(!;@+/&R-)O65 ZM#*KA22&9!M*EMM73MM= 6;+5]0T[0
MK"6[N[%+BYBAVO+%<N75H$956%)6FGN,Y,KJP7&6""B[26J_$#C]5\<P2+H/
MB.^7RDAGU594C#',D-O+ 1&'"L!(ZC;Y@4H&_>$;6-2Y?#)^8'9:GXON]'AL
M;>]:SM[[4A-*7(FDMK>&,*V,1$R7$G[R.,,K1QNQ9P50 -3E:U[7?W(#H?".
MOOXBM9)95426\\ENSQB00R[ K+-")0'".KJ=K9*L&7<V,FD[H#J\50"XI" "
M@!<4 .Q0 [% Q0*0"XH$2(*0RY&*@"V@J&!:05($ZU(RPM2!)G:"3VY_*D!\
M]R-O=F_O,3^9S7O+30@LVPKFGN;1V-ZV%8,9O6XK)B-N"LV(U(Z@1;6I$3"D
M Z@ H * "@ H * "@ H * "@ H RM6U-=-CR.9&X1?ZGV'ZGBM80YWY+<:5S
MSF65YW,DA+,W))_S^0[5Z"26BV-2.F 4 2B"0\A&(_W3_A2NNZ 7[/+_ ''_
M .^6_P *+KNOO /L\O\ <?\ [Y;_  HNNZ^\ ^SR_P!Q_P#OEO\ "BZ[K[P#
M[/+_ ''_ .^6_P *+KNOO /L\O\ <?\ [Y;_  HNNZ^\ ^SR_P!Q_P#OEO\
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MS,Q"L0 "< T 8GCOQO%X&TQ-5>VN+]))HXA';+EQY@8AVST7"X&>KLJ\;L@
M[2"7SXUD 9=ZAMK###(SAAV89P1V/% !-+Y$;2$,VQ2VU1EC@9PH[DXP!W-
M'G_A/XCV7B319O$-S%-I-K:R2)+]L&TJL>TF3(SE?F"G'(<,G)&2 =GI&KVF
MO6D6HZ?()[6X7?%( RAER1D!@K#D'J!0!HT % !0 4 % !0!YA8?$8WOC.Z\
M&?9=HL[47/VKS<[\K VSRO+&W_78W>8?N].> #T^@ H * "@ H * "@ H *
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MA5 ZLQS@#) Z GZ#UXJXQ<W9!>QPETD^M_:+E(YG$9 4#8!&JA2>N23]YOE
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MY;;/;;_(1UNG6T]I"([FX>\E!),LB1QL<G@;(E1 %Z#C/J2:M: 7L4 .Q0
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M+CW*/<[]H?&.F_V_?3)#/"I6&"/!YZ8(QEW8@=N.,#C)\J-\//V$$W%[R?\
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MDJJLP */A/XE7][KC>%?$U@-)U0P_:+?RYA/#<1#);:P'# !CC+ ['!VLN"
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M<HG22S8GZK+%C_T(UYF*5\/%]I_FF..YZO)7R<SK15-<;-D-J!A2 * "@ H
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MC.17=3?LH<\]$W\VK?@0]7H><>//$$NJ3C3;R%(7L\ 88X=B, AE'RC_ 'L
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M#FIGV-(FU;+7.RS>MEK)B.2^+2_\4?JF/^?=?_1T58RV)/%?'Z$_#OPN,?\
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M^^_X^91_?"2#\5&?Y_I7%A?=C[-)KE<E9]E)V^5COQEYR59M/FC%MKNX1O\
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M+FC)_JK:Z<^XB7_V=OY4+ 3ZRBOO_P @]C/NOQ*$GQ7NKCY=,TPD]FD9W_\
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M2NX)52V.6"Y...U $'@'PS)X0T&RT:X=)I;*,HTB A22[ME=P# 8;'- '8T
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MZ..1C.< US8>I*<.:HFI=+Z.WFN@X-_+HR*]TL[A%"F$155%4?*  .F.,?\
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MR_.F>:1V.U2=D2 *"<ECCDMW$>C 50Q<4A"XH&2*M("=14@2J*0$JBD!,!2
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MKK*SQCBL6R&=3:V^VL6R3:BCQ69);48I"'T@"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M"=2[<I<JNGT5]/O^8L7*4*=N6,5+1K[3MKIY?(Z3Q?;ZU+I5O->RP+;Q;?\
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M#R". 1WKMHMI2Y5=VV^9+/$?&5O;6NI2BTN7G7Y"Q,P^]G^\Q).!T !"DY)
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M5S#FL63[O%;*315RBRR)U&?TK13&,6X:+H&4_P"R?\,5?,F!9769X^!-,O\
MP-_\:5H]E]P6!M<G/6:8_P# G_QHM#LON"Q2DU(O][S'^IS_ #)IW2V"Q6:\
M<_<0#Z\_RQ1S#(&\^;AF('H.!^E+F DBL/:HN%S5@T_VJ&R;FY;:?CM6;9-S
MH+:QQVK-LFYNP6NVLFR35BBQ4"+:KBD(D I +0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MHQ]_0=NIYZ<E2I]F/S(;Z(ZVN0@* "@ H * "@ H * "@ H * "@ H * "@
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MCVPQ&#^9'ZUSXB%X6C]G;Y?\ FG-\ZG+[5^;U>_XGM48Q7SYZI>C%0QEQ!4
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M)X^A%<56-GS+K^9FU8Z6N8D* "@ H * "@ H * "@ H * "@ H * "@ H *
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MZH.7L=;8ZI!>#,3 GNIX8?4=?QZ5R2@X[HAJQKI(*S)+2M4@2@TA#J "@ H
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MA9UEU!4 6!4@/%(!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MKK;LAI79;@CKE9N;5O'6;$;=O'6;)-J!,5FQ&K$M9B+R"I L**0AXI .H *
M"@ H * "@ H * "@ H XOQ+8B-A=(,!_E?'][L?Q'!^@]:[*4K^Z_D7%]#E*
MZBR[IUV;&=9AT!PP]5/!_P 1[@5$H\R:$SU%6# $<@C(/M7F&0M !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % #2: .?U?7X-+&S_63=D!Z>['^$?J>P[UO
M"FYZ[+O_ )%)7.+2'4?%$FX\1 ]3E8E^@_B/YGU(KLO"@K=?Q--(G9:;X7M+
M##.//D'\3C@'_93H/QR?>N2564M%HO+_ #(<FSHONCCI7.01F4#KQ0!&UPJ]
MZ *QNMQP*8%E'X[T@'^:!UXH =O% #1** *MYI]MJ*[;A%?T/1A]&'(_.KC*
M4/A=AIVV.'U'PG/9GSK!C(%YV])%^A& WX8/L:[8UE+W9Z?D:*71D&G^(GB/
ME7>1CC?C!!_VA_4?B*<Z76'W?Y#<>QVD%TK@,I!!Z$=*XFK:&9H)+FIL(L!J
M0AX-(!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M[T=SJA*VC.U3GI7 ;E@5(#Q2 * "@ H * "@ H * "@ H * "@ H * "@ H
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MNS,[6-F*;-9V)+BM4B) :0"T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?0Z&K71UUCF=0,C!'H!SCOC]/6N66QJERLZG2;>3AE!Q^E<,M#H;6QZ#I\A
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M8IE88,3>8SK&>,QL %!R&P&R/J<'G+<_9XQW3T3['E4ZCE\1R.O;+@[)K?\
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MNI6TTT1C"W6-25);S" 2>HQR<^^?6II5*U>NHXB"INBG*R=^=R]U2C_=2O\
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M R/#GB'58O$3^'KZZMM7A^Q&[^U6T/D/;.)5C$-PBS31_O02\1W(Y"-E2.0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % "5(QI%0QD3"LFBB!A7.T:(A(KG:-$5KB06\;2-DA1GBL6C2.K
MLCSR6TNM=N"X&!TW'[B+V ]?H.2>:AJQZ2E&E&W_  [.UT[3H]-B$,7U9CU9
MO4_T'85%CBG-S=W]W8XG4)1->2/CC=M'T7Y?Z5HE8[8JT4OZU)XMN*V1++0
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M.C%KF5OYYO2W\JUW(M7ML[6'3<X_DP_F:]!NUO0\JCJY?+_(+VV,UNDN/ND
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MS8C6ACQ4,1I1IBH$7$6I G I"'BD Z@ H * "@ H * "@ H * "@ H * "@
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M?O@^AH >8U'  P.0,# /L.@H 4J"0S8RO0X&1]#V_"@"$'>=D8"J/08_E^M
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ME8VCK[6;-<S1F;,;9J!%@&I$.H * "@ H * "@ H * "@ H * "@ H * "@
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M\#P?QZCV->I+WXJ2]3HW1U]C<9Q7$T9G3V\F:Q9!HJ:D1**0!0 4 % !0 4
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MT >"_%CXB7>B'1G\.7D+17VHBVN&B\BX5DS'E-Q$@4X8\J0W/6@#WV@ H *
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MY=#<%;_8S^F:]/#=5YH\BMI%^C/*]0MRS$^]?31E9'DJ)E6]AF4$CA<G\O\
MZ^*MRL:-:6(Q8[SG')/\Z3D:)6-BZL=RA0.K_P!"/ZUSRG97[*X4HZV773[V
M:$-ASR.,'_#^E?,T&XTJ\UO*R^^_^9])B&I5:$.D6W]UO\@AL."<?>;^6?\
M&O<A[D5%=$E]R/&F^:3EW;?WLT[>QVY..@/^%4Y&=B>*QQVI<P6-[3K;8V?:
ML)RT%%>\C6,=<USI&>71< \NBX'+^(+3>Z-C^$C]1_C791E9->9C-:IEW4+3
M$<*@<*F/R J82UD_,&MO0N65ONM63_:R/T-9R=I)E):%ZPC\ML>M9S=T-&F\
M8SD5C?H43+TJ1CJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * &F@",BF! RTQE21*H#.ECJD,X36/#H9C<V>$EZLG1']?]UC^
M1/IUKMIU;>[+;OU0K',#/(8%64X93P0?0C_.>HKL\T1L=7X;\1-I+^1,2ULY
M^IC)_B'M_>'XCG.>:K2Y]8_%^8'KJ.LJAT(96&01R"#T(->5MHRAU(!,4 )3
M 2F W&*!"4 )BF W% "8H 2F 4@"@ H :13 HSP!A6B=A'/7=E[5TQD(YRXM
M"M=*D28EQ8JX(QC=SWQGLQ7."1ZD5LI6$6;N]_M)[=-3C1K:W/S!%)).,!B,
M=!Z<\D'.!4*/(I.FWS/N,RSX5L=>U21[5S;01(&C7[H+'=E@I'3C'3YCUR.N
MGMITJ:4E>3>I2?1'++X+NS%<7J!)(+=L+M."RPG'7G[P&.2?7KC'3[>*<8.Z
M;7YE<QA3:+?VEFMQ)'(%FR%QSN:1A@GN"RY4GKR .K5LIQ<G%-:?H.Z$FTZZ
MAGBMVC<.Q+(OEYP JA3@#!"G.0.N 3U H4HM.5U;KKYA=%]["YE,"Q(^Z*VA
MW[5SC;))D'T((SC^+;CO7CX.24L5=K7%5+?^ 4ST\7;EH_\ 7M&=!HU[/8M=
M)%(8T!'8#(=3G'!QP=W4Y5<'' ]ASBI<K:O_ , \VZ3-^7P9>P?99Y@L<5Q(
M S$EL;P"5.[J"V[J2?F SQFL57B^:*U:7IL3S'60^$]/T'4E^WR>?#)"/0A=
MN!\V!CGC!/<'O7*ZTZL'[-6:9+?1FA870TM+BVT^*/[-,S>67R"H/4XQR,Y(
M'''MBIE'G<93;YEO8FY#!:;552681C"AF) XQD G _IT'%4WN]-0-FWM":Q<
MK =':66.U<TI%'100!!7,V,O*,5F,=2 * "@!<4Q"XI#% H =BD M #NE Q:
M0"T +2 6@#G?$&OQZ-'M7#W#CY$]/]IO8=A_$>!W(Z*5-U'VBMW^@MCQR>=[
MF1I96+NYRQ/4G_/0= .!7K)**LM$B2(#/ K.4NB-8QZLO0Q5@S0UH(:AB-F"
M&LVQ&O#%4,DU(H\5F!?1,5(BTJTA$H%(!](!: "@ H * "@ H * "@ H * "
M@ H * "@ H * //=?LOLMP74827YA[-_$/SY_&N^E+FC;JC1&%6Y1MZ!>_9+
MD*QPDORGV/\ "?SX_&L:D>:/FB6CT2O/,PH PO%&NQ>&=*N]7F^Y90238/\
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M0#%>>W=MOJ8A*P5232 H0Q*3O(Y- BZ N,8H&9,P"3#T(IB+BDCI2&6%YZT
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MEF0JV2 0^$],UWQ[\*'TS3)2]U#=/$B,^TRVT3)(;;>2 !\_RAB%(58R0IX
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M[AA\J=E_VG]!Z#JW;C)'13I.H[O2/?\ R%L>/7%Q)=2--,Q=W.23_G@#H .
M*]9)15EHD20@9X%1*5M$:1CU9<ABK!FIJP0UFQ&Q!#4-B->&*LV(U(H\5 C0
MC3%0(M*M("<"D(>*0#NE !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!E
M:S9?;;9E4?.GS+]1U'XC(^N*UIRY9>6PUH>:UZ)J'2@#TG2-16_A&3^]0 ./
M_9OH?Y\5YTX<C\NAFU8UJR).6\7>&%\6VD>GS2M#;BZMYYU50WGQP2"7R&R1
MM61U3<PR<#&.: &^)?"R>(9;"Z64VUQI5XEW%(JABRA626!@2N$GC8JQ!R,
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M]'ZO/V?,I:)W5[:^I[6'K?6*:J\KAJURR:;T_P +:L=*J[>E<IUG.^+;?SK
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MDP'8I#$VB@ VB@!"BGJ.G-&P Z[EQ0M $B7;38AY%(8^D 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 E #"*8$3+3
MKNE,91DCJD!FS15:&8.H:>MRN#P1]UNX_P#K>HK:$G!Z U<XJ>W>V<HXP1^1
M'J*[TU)71GL;N@>(I=';8V9+=C\R=U_VD]#ZCHWL>:QJ4E4U6DN_^8;'K]I=
MQ7L0F@8.C="/Y$=B.X/(KRG%Q=I:,HGQ4@% "=*8"4 )3 3% A,4 )0(3% Q
M,4P$Q0 4 )0 A%,")X@::8C/FM U:*5@,F:P]JW4A&5+8>U:J0BB]B15\P%9
MK,CM5<PB&2P$JE'&588(]C3YBHMP:E%V:=T^S1A:M:26PB:-Y&G+A(I'8DQ
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 -H :13
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MD,-0Q&M##6;8C5AAJ&Q&I%%BH$:$<>*@1<1:D"PHQ2$2 4 .%(!: "@ H *
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ML?* 4_B%XTU7PU->3Q>+K;[=;RNT&E0V,<B; YVP2RJL@6;9@-YH'S9!89W
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!"*0"8H&&* #% !B@
MQ3 ,4 &*0 !0 [% AA%4 8H 4"@ Q2&+B@08H 7% !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 8H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MIV'+(DA8=.2*0'HN0#C/)Z#N?H*8'&S>)Y8O%$7AP1H8I=,DOS+D[PZ7"PA
M/N[2&W$]<^U(!OP\\4R^--#@UB>-+>2=[A#&A)4>3/)"""W/(0$^YH [;%,!
M:!A0 N*0!0 M !BD M "XH .E '&ZSXP@LLQ6F)YAQG_ )9J?<C[Q]EX]3VK
MKIT'+66B_'_@"N>8WE[-?R&:X<NY]>@'HHZ >PKTHQ4%:*LB2K0VD4E<E2(G
MK6#=S9*VQ?B@J+@:4,%0V!J0P5#8C4AAQ6=Q&E%%4B+\<>*@1;1*0$ZK4B)0
M* 'T@%Z4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQ/#'(CR0G)&)$4ED.01\P'(- &K0 4 % !0!!%=0S.\4;H[Q$"158%D)&0'
M.5)'(!QD<T 3T 4M2L(M5M9K&XW>3<Q/#)M8JVR12C;6'*G!.".10!XI!^SO
MX<62,W4VI7UO P:.UN;O= N.@VK&C;>V PR.#D4 >ZQ1) BQQJ$1 %55  50
M,  #@  8 ' % #Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M2BAJ+@:,<6*@1>CCQ4B+:)BI G5:0B0"@!^*0"]* "@ H * "@ H * "@ H
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M\'G'(!6U3XS0Z)I5A=7VG7::OJS.MOI"@FYRLK1@N61"BOA2I\LLQ<!58!F
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MO[#2M1<):ZA.-BR!B LGE%!B,AE8XD9PA#[".* /H2@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MS?CV7_@1%;0I2GLK+NQ'GNI^+[N^RD'^CQG^Z?G(]W[?\! ^IKOA0C'5ZO\
M#[A7.3)R<GJ:ZA !GI4.21:C<F2$FL7*YJDEL78X*BXS0B@J+B-&*WJ+B-**
M"IN(T(H<5%Q&A'%BI N)'BI$6E3%2!,JTA$@% #\4@%Z4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 8H ;B@!I%,"(K3 A9*8RJ\
M=,"G)%5#*,D-5<#/E@JKC,V>U#C##(]ZT3ML!A7&E[>8CCV/]#_C71&ITD2X
M]C*DC:(X<$5T)I[$6L2VMY-9-YEN[1-ZJ<9^HZ'Z$&DXJ6DE<1VFG^.9HL+>
M()1_?3Y6_%?NG\-M<DL.G\#MY/8=SM+'Q#8ZA@12A7/\#_(WY'@_\!)KCE2G
M#=:=UJ,VJQ&&* $Q0 4 % !0 E !B@ Q0 8H ,4 &* #% !B@ Q0 M !0 4
M&* %Q0 4 03W,5HN^9UC7U8@#]:I)RTBK@<E?^-K2WRMLK3MZ_=3\R,G\%_&
MNJ.'D_BT_%BN<1J'B:^U'*L_E1G^"/Y1CW/WC^)Q[5V1I0ALKONQ&!6XA0,]
M*AR2+46R58B:R<FS1)(MQP5G<HNQV]3<1H16]3<1H16]1<#0B@J+B+\<.*FX
MB['%BI$6TCQ4@6%6D!,%I") * '8I +TH * "@ H * "@ H * "@ H * "@
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M?\![5Z]N561T+0L:=%TK!B9WFGQ8Q7.S-G5VRX%8,DTU%2224@"@ H * "@
MH \=^-7@+4/B%I%OI^EM"DL%['<,9W9%V+%,A *HYW9D&!@#&>: /4[?3+6W
MD^T+#$MP5 :58U$C< '+@!B/J: +#VL+R+,R(TB<*Y4%E'/ 8C(ZGH>YH ?-
M"EPACE59$8896 92/0@Y!'UH AM+&WT]/+M(HX$)R5B147/KA0!GWH ;=:=:
MWK*US#%,T9RADC1RI]5+ E3],4 3);11NTJ(BR/]Y@H#-CIN8#)Q[F@" :;:
M"8W0AB$[C#2^6GF$$8(+XW$8XP3C% %B&WCMD\N%%C0=%10J\]>  .: *MOI
M-E:2&>"WABE;.72)%<YZY95!.>^30 ^73K6>9;F6&)YH_N2-&C.F.1M<@LOX
M$4 31VT,+M)&B(\G+LJ@,Q_VB!D]>^: *\FEV<TPN9((7G7&)6C0R#'3#E=P
MQVP: +$]M%=+LG1)5SG:ZAAGUP01GWH 2:UAN5"31I(JG(#JK 'ID @@'% $
M] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !B@!N* &D4P&%: (62F,K
MM'3 JO%5 4Y(:JXRC)!57&4)+>JN!0EM0PP1D5:=MAF/-I@ZI\OMU%;JHUOJ
M3R]C,DM9(NHR/4<UNI)D6:*]62:MEK=[I^!!*P4?PL=R_P#?+9 _#%92IQEN
ME^0SJK3QW(N!=0AO]J,[3_WRV1^HKFEAU]EV]0N=-:^+=.N>#(8CZ2*5_497
M]:YG1G'I?T&;\-Q%<#="ZR#U5@W\B:P:<=TT,FI % !B@ Q0 F* #% !B@ Q
M0 8H 7% !B@ Q0 4 '2@#+NM;L;/_6S1J1V!W-_WRN3^E:JG*6R8'.7?CFUB
MXMXWE/J<(OZY;_QT5T1P\OM-+\17.6O/&-_<Y$96!3_<&6_[Z;)_("NF-"$=
M]?45SFIIY+AM\K-(Q[L2Q_,UT)*.B5A$5/8=NPX(36;FEL6H]R98:R<FRTDM
MBTEO47*+D=O4W$78[>IN(O1V]3<"_'!47$7XX*FXB['#BI MI%4B+2IBD!,J
MTA$H6D \"@!V*0"]* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MFBW,FV+YFR>*!"_#87#W&MB\$:7']L2"01%C'D6MJ,H6 ;:PPP#<KG:22,D
M]HAMT4=*0RT84=2/6@"&WB,)VGIV- &BHH \[\8ZL)&^Q1GY(_FE/;=V7_@(
MY/N?:O0H0LN=]=O0UBNIY@I-S*7[=!]/\\UNV:['6Z=!TKG;(9W%C%C%<[,S
MHH5Q63)+JBI$.H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@5BR#8C7%9B)Q2$+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 F* $Q0 TB
MF!&5H C*4QD#1TP*[14P*SPU5QE5X*=P*CV]5<94>WJK@5'MZ=QE5[:JN!4D
MM0>HS5)VV IO8+Z8^E:*;0K(JM88Z&K53NB>4A-HZ],&K]HA<K(C X[57,NX
MN5C#&P['\JJZ[BLQ,$=J=P$H$% !0 8H 7!]*5T.PNP^E+F7<=GV%$34N=#Y
M6/$)J>?LA\H\6]3SLKE1*MO[5#DQV2)EMZFXR9;>E<"PMO4W LI;4KB+*6U3
M<"VEO2N(MI;U-P+:05-Q%M(:5P+20U(BRL6*0$ZIBD!,%I") M(!X% "XI .
MQ0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 AH A=:8&5<Q9JT4<3K&F^9^\0?
M./U'I]?3\JZZ<^71[?D:)FAX;\1>7BRO#@#B-SV_V&/I_=)Z=#VI5:5_?A\U
M^J%*/5'H!%<)D59DR,4 &-@XH J291]XZ'@T 3 [\%>] 'CNEVC^/7N=1U*X
MNUMDO;JTM+2WN9K6.**TE,!DD\AXWEGED1W)D8JBE511R2Q%>+0HK_Q1=Z9=
MS7KVMAIFGM JWUW$5=Y+E6D=HID,DC!%W.^XDC)YH&4=4UC4_#T&MZ/%>2S+
MIJ:?<VUS+(ANUMKR0K/:K,X ENE6*1;-WS(S21J2S!32 KVGCAM!MM;O;22[
MEMK%+);2TU0S&\2[N28RSQS9NA:/))#M#9WNDPAXQD [#PAJ:0W<EAJ,NJMJ
MLT G/]I!8HIHE;:\MG!$[00HCN%:+"SHI02@GF@#T:U.5(]^*8%L;J0#FB#<
MGK0(EC!H&4-7U>+2(MS_ #2-]Q.Y/J?11W/X#FM80<W9;=64E<\5U?59)Y&D
MD.Z:3\E';CL!_"*]1)07*C=*QF6EN6.3R36;8SL;"TQBL&R&=E9V^,5@V9G0
MPQXK-DEY1BI$/I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M HMJ+@/%M1<!XMJ5P)!;47 E6VI7$3+;4K@3K;4K@6%MZ5Q%A+>IN!92WI7
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MDATP&*'$L_H/NI_O$=_]D<^N*Z:=)SU>B_K8M1N>1:IJTDTC.[>9,W4GHO\
M0 =E%>@DH*T=#9*QEV]NTC;FY)ZDU#8SJ;&SZ<5BV0V=A96N,5@V0=+;P[:R
M9)J(N*@1,!2$+0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@) E $@6D(>!0 [%(!<4 +B@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 )B@!,4 )BF T
MK0 TK0 PI3 C*4#(S'3 C,5 $1BIW B,-.X$9AIW&1F"BX$9@IW 88*+@--O
M3N W[/1<!/L]%P#[/1< ^ST7 <+>BX#A;T7 <(*5P)!!1<"004K@2"&E<"00
MT")1%2 D$5("41T /"4@) E AX6D X"@!V*0"XH 7% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 8H 3% "8H ,4 )BF FV@!NV@!-M #=E
M";*8";*!B;* #90 FR@ V4 &R@!=E "[* #90 [90(7;2 7;0 [;0 N* %Q0
M N*0"XH ,4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 )B@!A6F!"\6:8RG);@T[@9TMF#VJ[C,Z6P'I57*N9\FG>
MU5<=RD^F^U5S#N0'3?:GS!<;_9OM1<+DBZ;[4<P7+2:=[4KBN7HM/QVJ;BN:
M,5B!VJ+BN:,5J!4W$7XX,5-Q%I4Q4B)0*0#NE !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 &* $Q0 8H
M 3% !B@!,4 &*8"8H -M !MH -M "8H 7;0 ;: #% "XH ,4@%Q0 8H 7% !
MB@!<4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 &* &D4 ,*4P(FB%,97: 4[@5VM13N,@:T'I3N!&;,
M>E%P$^Q#THN \68]*+@2K: 4K@3K; 4K@6%A I")UCQ2 E"XH$. I +0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % "4P"D 4 % !0 4 % !0 4 % !0 4 %,!:0!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 )0 AI@,- #"*!C"*8#<4 )B@!0* '@4@'B@0\4
M .%(!PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
5@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img238320182_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %* M # 2(  A$! Q$!_\0
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M'Y#GD$,,=Z -:BJL6IV$]Z]G#?6TEU&"7@252Z@'!RH.1S5J@ HHHH ****
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MH_L*]_Z&/4_RA_\ B*VZ*.9@8G]A7O\ T,>I_E#_ /$4?V%>_P#0QZG^4/\
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MSK- '"W+8\J5T"ET7OE=XS]#6U=>(M%LKJ6UN=6L8KF*(S/ ]P@=4 R6*DY
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *S[?_ )#]]_UPA_G)6A6?;_\
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MKSO1= TGP]\7Y;71[""R@DT$2/'"NT,WVC&3[X KT2@ HHHH **** "BBB@
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M <[9$##/K@U(B+&BHBA44850, #TIU% !117,>,/#%[XDL##::Q-9G*GR_\
MEFV#WQAL_CCCI32N]0.GID4L<\2RQ.LD;#*LIR#^-4M&TZ?3-/CMI]0GOG4
M&6;&> !Q@=/KD^]<Y_8VNG2].LXV>V6VCDCE\F< LQQLD4_[//!]>AQ2 [.H
MX+B*ZB\V"19(\E=R],@D']017)3Z7XDEU2XE$@6T.T-$ERP\T"4'@_PDQY!Q
M@9..G-6+;1]3MM!TVUVL3#<R27,"71#.C&0J/,X)P64GIG% '4TSSH_/\GS%
M\W;OV9YVYQG'I7(7>C>(9I)O)NI(F:1R\@NVQ(AE4HH'\!5 PR/US1]EUB+5
M/LMO+-)]G_?!3*V#']IW*A<]_+!&#V&#0!V5%>=0+K]OK5O!=O<2S1XV1K+(
M5+,)3ECP#&-R;CR05&/2K<7A[Q!),EU+*$N(S<K;GSV/D"2&,*>IR!(KG!)^
M]0!W5%9'A^SO;.SD6]EE9W<$)))OV?* <'DX)!/)[]NE:] !1110 4444 %%
M%% !6?;_ /(?OO\ KA#_ #DK0K/M_P#D/WW_ %PA_G)0!H4444 8,W_(]V?_
M &#IO_1D=;U8,W_(]V?_ &#IO_1D=;U-] "BBBD 4444 %%%% '&C_DM)_[%
MT?\ I0:[*N-'_):3_P!BZ/\ TH-=E0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 4M9_Y >H?]>TG_H)J#PS_P BKI'_ %Y0_P#H
M J?6?^0'J'_7M)_Z":@\,_\ (JZ1_P!>4/\ Z *K[(&I1114@%%%% !1110
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M ?I>IC4%F1H98)[=@DL<F,@E0P/!(Y#"K]5K+3[33H6BM(%B1FW$#N>F23[
M#Z 59H **** "BBB@ K/M_\ D/WW_7"'^<E:%9]O_P A^^_ZX0_SDH T****
M ,&;_D>[/_L'3?\ HR.MZL&;_D>[/_L'3?\ HR.MZF^@'$^.8O#*7=I/XEN=
M7,3H4BMK4W)A)4Y+,L(Z_,!\W:JG@*ST:XU;4;_0HM4M+"V<0Q)-/<"*XW(K
M%C%-T*MD C%;7Q!O+NQ\%7T]C/<0W.Z)$:VQYAW2JI"D\*2"1N/ SGM2>"8;
MR'3[D7L.NQ.9<J-8N8YI",#[I0D >Q[T@)YO&>E0S:F'\_[/IBN;NZ"#RD*
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MI6)X._Y%#3/^N K;;[A^E8G@[_D4-,_ZX"J^R!N4445(!1110 4444 %%%%
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M!NKYI,B*,_Z0Y&S:XD&._P!Y>>IVYX-%EX=U:VTWRPY1H[2T@CA6Z;!V,3,
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MGXI5I8V0%[X,HR,<C:,CVR*S/"WPGN-!T1+&?QCKV\.S;;&X\F)<]@I#?SH
M]*)"C)( ]32UY#KGPJU[Q$FK:?/XKU=;))X6L#=W(F61-@W[U&#D.3@^PX[U
MTUK\.'M[2"%O&?BMFCC5"4U *#@8X&TX'MDT =Q17&_\*]/_ $./BW_P9#_X
MBM3PKIFHZ397EIJ%Y=7@6[<VTUU,)9&A(7;N/'?=Q0!O4444 %%%% !1110
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M(_A5NP\+Z?9W(O)_-O[_ /Y^KQO,<?[O91_N@5M45'-V$0&RM#=B[-M";D#
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M]3BNANKF&RM)KJYE6*"%&DDD8X"J!DD_0417,,]HEU'(# Z"17/ *D9!Y]J
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M_I>CZ9HOQBDM]*TZUL87T .T=M"L:LWVC&2% YP!7H% !1110 4444 %%%%
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M[4RK&R&0H1(I;C^$J>0<'OTKGKW0/&,^K7DT)FB9WG>.=-0(B^SM;E8[<19
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M0 4444 %%%% !1110 C?</TK$\'?\BAIG_7 5MM]P_2L3P=_R*&F?]<!5?9
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MR6$:2#8Y9259=IYR"""/:L.?P4;[P;I/AZ_OEE6PEMV:6.$H)4A8$+C=E25
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M\*/^$ \'?]"MHW_@%'_A0!4D^(6CQZS]@(E,8?RS<@#RP>GKG'O71_VG8?\
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MMZ3_ -!.R_\  A/\:/[;TG_H)V7_ ($)_C65_P *_P#!W_0JZ+_X Q_X4?\
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M^3.9F95#?+\O('K@&L^X^(NI027E@-'MGU33Q<RW:?:F$1BA2-R4;9DLPE4
M$#!!S6]=>!M+OK[5;J[FO9_[4A$-Q$\WR;5.4V@#(*DD@YXS4,WPZT.>#9(U
M\96,IGN/M+"6X$H42+(W=6"J,<8VC&* *NG^/I-0UJU2/3T&E75X;".<RGS?
M.\@39*8QMQE>N<C/2NVKG[?P;H]IK8U2&.5760S) )3Y*2F,1F0)T#;!M_\
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MR.MZL&;_ )'NS_[!TW_HR.MZF^@!1112 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JT-A:6UY=7D-NB7%UM,\BCF3:,+GZ#BK-
M% !5>^L+74[*2SO8$GMI,;XG&5;!!Y_$"K%% !1110 4444 %%%% !1110 4
M444 (WW#]*Q/!W_(H:9_UP%;;?</TK$\'?\ (H:9_P!<!5?9 W*Y'6])TRZU
M]88_%FH:1J=TN[[+:WZJ9@!C(B<,.W50.E==7G7B5=(/BO4;:;PIK&JW=S:0
M-)+;)'M159]C1NS*RL"3RIXP*D#K?#5G96VE++8ZA=ZA'<'>;JZN&F>0],Y/
M ''0 #VK8KE_!+JGP[TQU2>V5;4G#YDD3KUX^9OPY-<?;:]XNN++16A;4GN3
M%]U[(J+B83X=9LH-BB'Y@?E&>A.,4 >L4'I7D,>L^-#9(1+JQ#-F%VL0'>Z\
MN,F%QL^6'>91NP.GWN,G>T'4O%\R:JRV[75RNS$.HJ;:*.;S) Z1N$RR!!&0
M?FSGKS0!>^%/_)+]!_ZX'_T-J[*N-^%'_)+]!_ZX'_T-J[*@ HHHH *CN+B&
MTMI;BXD6.&)2[NQX4#DFGLP52Q(  SD]*XK3=7/CF^>W'D?V78RA[@Q.6%PX
M/R+R!\O&X^O ]::5]0-G0[>6]N9->O8V2:X79;1,.8(.H!'9F^\?P':MVBBA
MNX!1112 **** "BBB@ HHHH **** "O(KL_#:WN[B))M:M469UEALYKQ(6"D
MB20!3M\M2"&8< UZ[7B6MVVF-'KU[;>"O$TK6TEPCN+W9#P2SIM$F1"Y.YE
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M[R_AB%DH>6ZM)'<W(.&C<+$QVC&!G:".=QQF@#UNB@9P,]:* "BBB@ HHHH
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M>U@TMKMH8P-[.)%48)]B: .HHKE/^$PN/FM/[%D&L?:_LJV1N$P3Y7F[C)T
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M#<H%<!D#J>"1@JP/7ZX- &/_ ,)AKO\ T(6M_P#?ZV_^.5+9>,+V;6+&PO\
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M]IO@K1=)U*&]LXID:!<1Q&9C&K;!&9-I.-Y0!2W<5T-%% "%5)R5!/TH  Z
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M_%UT.Q?[H_*C8O\ ='Y4778#GO\ A,?^H%JW_?$?_P 71_PF/_4"U;_OB/\
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8_@1YK<HI<S   HP!@4M)12 6BDHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img238320182_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %B M # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;M9+^8Q1R7EIY2 A2W4GGITKM*XOQK_R-/@C_L*O_P"B)*[2@ HHHH ****
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M8S7JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %9FK_Z[3/\ K\7_ -!:M.LS5_\ 7:9_U^+_ .@M51W TZ***D HHHH
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MGF<I78&G1114 %%%% &9J_\ K-,_Z_5_]!:M.LS5_P#6:9_U^K_Z"U:=4]D
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MHYK36UTZ*?\ >);21>9@'OSTSZ5T']F?$&+[OB#3)O9[7;_(5T^C?\@+3_\
MKVC_ /015ZKE6;D[I?<!Q6WXC1='T.?_ '@Z_P J;)J/Q#@B=FT72IB 3^ZF
M.?P!-=O14^T_NH#Q+PEXJ\41:_?R+97&IF5B]W;@8*,.,C^Z>,8]J[?_ (6(
M+<_\3'PWK-IZ_N-_\JZ#2HHX]3UADC16>X4L5&"Q\M>M:U:5*D)/X1G(0_$S
MPO(0LMY+;,?X9X&4_P JUK;Q;X>NR!!K-DQ/8R@'\C6E-96MP")K:&0'KOC!
M_G65<^#?#=WGSM%LR3U*QA3^F*SO3?1B*&J>*M'MO%6D6CWD;2/O!*'<JE@
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MJHAVKN8Y#G@"NSKG-8T2[OO&GAK5H3']FT[[5Y^XX;]Y&%7 [\UT= !1110
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MO\/7%;:VWP^7_F7?$Y_[A\W^%>V44_9Q[&<LPQ+;?.U\SQE1\/U_YEGQ*?\
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M\R15 9\8W'')QVJA=Z'9WNN:=J\WF&YT]9%@ ;Y1O #$CN<"M*A; ]PHHHH
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M>VZP7*ATW'>B\;<YVGN*[ZL'P[X3L?#<EW/!<7EW=7>SSKF\F\R1E085<X'
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MHTVW@??:)=VT[)_"7R&A*]V!YQFC1O3^M_\ +\0U_KY?U\CW"'Q'I=QXCN-
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M=XR3]* /78I8YXDEB=7C=0RLIR&!Z$4^O*/@)?ZY=^" FHJDFG1.4LIO,RX
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MR>YU..0"+:V0 K$@YV\BO9O"OA'2_!VGRV6E"<0RR>:WG3&0[L <9Z=*W:*
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MEYC'<HWEJ.I;!X'N:\UBE_LSXGS0:)YM\FHWLCZA:7.GL&M&V$&:.<C&TX
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M_O3M[S0KZ)GIE%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 $X&37&7?Q0\-VT<Q26XEDC
MR @@8;B.V2,"NSJO/86EU#)%/;121R AU9 <@U47%?$@/._#_P 6;6=9TUR,
MV[[RT30(7!7T..<CU[UW.B:_I_B&T>YTZ5Y(T?8VY"I!QGO]:IZ!X.TCPXL_
MV.#>\SDEY<,P7LH/H*W5147:BA1Z 8JZCIM^X@.4\>^(-5\/Z=9S:; OERS[
M+F[:!YQ:I@G<8TY//'M7'7GQ-UB.VT'9>:,GVZ.X:6[CBEN(F,; +M5?F4D'
MD'H:]$\0^'(]?6U<7][87=I(9(+FTD"LI(P000001V(K 7X7Z?!]CEM-9UBT
MO+9IG:[AF3S)FF(+L^4(Y('0"L4-F)=^.?%$O@+3/$]B-)C$\JV\\+H[Y=I?
M+5EP?E&,$J>1TJ;7O'?B#PYKMAI-TFF32F.%IF1' F,DNPA3G$6T8.7ZGI72
M+X TE?"R>'Q-=FW%TMV\QD!EDE$@D+,<8Y8<\4:[X"T[7M5DOIKN\A6X2..\
MMX7 CN5C;<@;()&"3T(JNOS_ $_S)>W]=_\ (S3XG\4Q>,SH\EAIDJSQSR06
M\,K&6%$'[MY6^Z YXQC(]\&LF'XA>(?)NM/EMM,.KC5(--AD7S%A#2*68LI^
M8A<$ ]&[5T%K\.K6UU?4=0&NZV_]HES=0&X4(^Y2HY"AAM!^7!XP*A7X8Z=]
MEG$VK:K/?R20R)J,LRF>(Q9\O:=N.,GJ#G)I+I?^M2GU+WAKQ=_;'AJ*[NQ;
M1:F6FA^S+*%$LL;%2$W<D$C]:P? _C?6=<U_^S]5>PCE:%I);+RI(+BU<'[N
M'_UB_P"T*Z:P\$:%8Z3:V#6:77V=7"7%P TN7)+MNQD$DD\8JIHO@&TT?5K7
M4)-5U/4&LHGALH[R566W1N"!@ DX &23Q0M]1/;0ZVBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img238320182_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# = # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:\CTGX6^)=*\510_VS'/I"Z/+9M<K9QQ[M[',17>6R2=YDY]*]FHI6_K[_\
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MN=0BE,$R[#N!SD<MT) Q]:(?'?T_/].H3^'[_P OZL>^T444 %%%% %#6_\
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M>'].;P_!)IR6-NL][)?!'3]V-W[O;G(],\XK@K;4S\/=<T\>%/$UCK>@:OJ
M0Z4'5YH2YY*E3GCWQVR#UK2W[SEZ;?B9IWAS=?\ @'O-%%%24%%%% &/XDUJ
MPT;2I#>:S:Z3).K1V]S<%<+)@X.#PV.N*\YTCRM>\5:,^I_%+3M:>SN//MK*
MUM8H6DDVD?>5B2,$\=ZZ?XFZEJ>G:%;_ -D^&AK=S+-LPUJ;@6XP?GV 9/IV
MKB_ 6EZ;%XHM;_4_#?BJXUN1CMO;O21;6EL<'[J*V%';)S^%$-9!/2)[/<))
M);RQQ2F&1D(20*"4..#@\''O7FECX&\4:GXDMK_Q1=:24L[2XM3<6*%9KWS4
M*;I!@ 8!S@=Q7I]%*R>X[M;'E/A[X;:]'>Z=#K]WI[:=H]C<65F;3?YDPE!4
MLX88&%.,#O4_A#P#XATW7-%EUNZTY['0+::VL?LV\O-YG&YPPP,+Q@5Z?157
MUO\ UU_S8NEOZZ?Y(Y[6_#FA_P!@ZB?[&T[/V:7G[*G]T^U4OA?_ ,DQ\._]
M>:_UK?UO_D :C_UZR_\ H)K!^%__ "3'P[_UYI2 ZVBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P[O
MPCHU]K\.M3VH:[B'_ 7/9F'<CM_]88W**:;6P!1112 **** "BBB@#&O?"7A
MW4=174;W0].N+P8/GRVR,YQTR2.<>]2ZCX:T+5YUGU/1--O9D78LES:I(RKZ
M L#QS6I10!633[*.P-@EG;K9%#&;<1*(RIZKMQC'M4;Z1IDFE_V6^GVIT_;L
M^RF%?*"^FS&,5=HHW Q[#PIX>TNVN+:QT33[>&Y79.B6Z@2KZ-QR/8TVU\'^
M&+&ZCNK/PYI%O<1'='+#8Q(Z'U!"Y%;5% &+;^$/#=KJG]IV^@Z=%?;MWGI;
M('#>H..#[T^]\+:!J.IQZE>Z-87%['C;/+;JSC'3DCMV]*UZ* "L:T\)>';#
M4SJ5IH>G07I)/GQVR*X)ZD$#@FMFB@ HHHH **** ,'Q?XJL_!WA^;5;Q))
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M6GB.SN+D6XME3[*T8W (5&6&WCFJMK;^NO\ DQ=+_P!=/\T>GZW_ ,@#4?\
MKUE_]!-8/PO_ .28^'?^O-*Q-9^+/AI]%U",1ZMN-O(H+:=*H^Z>I(X_&MGX
M6L'^&'AXC/\ QZ*.1CH2*0'7T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YZWA/Q##\2)?$/]J@Z8$+"#>_W>?D^]GKSC[O/3->A4R5#)"Z X+*1FD[K5
M;CWT>QY1I_Q2\0B'1=1U'1+6>PU>*X-O;Z<7>YWQ D\'@@X. .GK75>"_$M[
MXF2XU*YN]+CM2 D=A;.7E@;/_+9CC#=MNT?C57P/\,M*\*6]C<SPI/K-O&Z&
MX65R@+$Y*(QPI(P"0!71:IX4T+63(U_ID$KRE#)(H*.^QMRY9<$X/J:K1/\
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M@3SI9?X5$K'Y%]?6LC_AH;PE_P! [7/_  &C_P#CE'_#0WA+_H':Y_X#1_\
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M0P';W':M#6-=T_0H(Y;Z8J96VQ1HI9Y#Z*HY-?/\6HL8K*VTVPG@U*%G=KF
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M1P"Z X_.O.?BGH>B+IT.H/(EI?!A'&J+_KESR-H],YS^'<5M!WM%B78NZO\
M%?0[2WB;32U_*SC>FUHPB]\DCKZ ?_KY/QWXO\/:Y=:9):67VMX662>1P8R4
M[P^OX]NV<FNG3X:^'=6\.V']GW)R,.;V,9,P/W@1V]O[I]><X'CN;PKI-WIN
MD6^E)+)8R*;CRSL/E]2C-U8G.<]OQ-5#EOH-6.E_X69X12/3EC#%00-JP?\
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MO4W+3X>792"=_''B\-A7:-[Y3[X/R5WM,BD6:%)4.4=0RGV-/KI/GWN%%%%
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M_:?Q/_Z%W0/_  /?_P")H_M/XG_]"[H'_@>__P 30!WE%<'_ &G\3_\ H7=
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MO'4D>N,''TR:T?[3^)__ $+N@?\ @>__ ,30!WE%<'_:?Q/_ .A=T#_P/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img238320182_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ =D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;1L#P=K#! (Y&1Z4VQT^UTVSAM;2%8H88UB0 DD(HPHR>3@>M"TO?K_7]?\
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M2-ZJ(\;OO#=DGI6Y)\3HXM*M;I_#^IK<ZA<^1IMDP42W2[01)R<*N#WZ4?\
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M!! QWYH Y?\ X5#X@_Z*AXC_ ._LG_QRC_A4/B#_ **AXC_[^R?_ !RO6**
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MS_4EZGE[^ _$>N3>)-7UJ33;?4]2TPZ=:V]N[M%$O7+L1DDGT!J^G@34UO?
M4QN+3;X>@:.Z&YLN3&J?)\O/([XKT&BA:;?UO_FP>N_]7M_D>0+\.?%0\*>*
M/"PFTG[#?W+7-G<,\@?<TBMAP%.!M4] >?:ND\5^$-6OAX:U+1IK3^U=";*Q
M7)813*5"L,@9'3CBN[HH6B27E^ /5_?^.YY%J7PR\0Z]I/B6[U"YTV+6];EM
MR(HW?R(8XB,#=MR20/3M7KM%%&RL@O<**** "BBB@ KP#5=%L(_&_B.;7_A_
MXC\1>=>%[:\ABE"A,#Y!M8 J#T/<>E>_UY!XKN?)UG5&C^+Z:9*C,5T\I&?)
M..$ZY_3-2]'?R_R*6JL>A^#X[2'PGI\=CI-SI-L$.RQN@1)"-QX;))]^O>N>
M^)GB^30M-&DZ9=0P:Q?12/'++(%%O$H):3)[]E'<GVK3^&^J7&M?#W1]0NYY
MI[B:)O,EFQN=@[ G@#CCCVQ6CKGA30O$<;C5=+M+F4Q-$D\L"/)&#G[K,#@C
M.1[U55.[1--I69Y?;:QJ?B>T\":''XAOK9;[3YKB]N[.XQ,\D:#"E^3UZBK>
MB?$_6K/P/H5S+X:U;7[F=)5EN;2,D9CD*#=@'YB!GM733_"W1#HNE:?8W-]I
MLNEAA!>6;K',=XP^XA<$L.IQ73Z%HEEX<T2TTC3T9;6V38FXY8]R2>Y))/XU
M3:U_KO\ \,39V7]?UW/$&\67GBKXW>#IKOP[?Z.8!(BQWBE6DRK9(!4<"OH"
MO)_&O_)>/ G_ %RF_DU>L5)04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5DZYXDTOP[%#)J5QY?G.$10-S'U.!V'<
MUK5P/CSP!+XDO(=0L+@)=?+%*DS'9LSU'H1GIW^O6HI-Z@CNXI8YX4EB=9(W
M4,KJ<A@>A!I]9GA_18?#^BP:;!))(L0.7<Y))Y) [#/:M.D_( HHHI %%%%
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MF3M*9S&T\AB,A.2VS=MZ]L8]JL:_\-_"OB75%U+5--\RZVA'9)GC$BCH&"D
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M?$__ * 7AW_P.D_^)I,#NJ*X7^T/B?\ ] +P[_X'2?\ Q-']H?$__H!>'?\
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MA14-G;+9V4%JCR2+$@0/(VYFP,9)[FIJ@04444 %%%% !1110 4444 %%%%
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MO"'_ $->A_\ @QB_^*H_X3KPA_T->A_^#&+_ .*K'_X4]X _Z%R#_O\ 2_\
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M_P#"GO '_0N0?]_I?_BJ/^%/> /^A<@_[_2__%4 ;'_"=>$/^AKT/_P8Q?\
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M_A3W@#_H7(/^_P!+_P#%4 ;'_"=>$/\ H:]#_P#!C%_\51_PG7A#_H:]#_\
M!C%_\56/_P *>\ ?]"Y!_P!_I?\ XJC_ (4]X _Z%R#_ +_2_P#Q5 &Q_P )
MUX0_Z&O0_P#P8Q?_ !5'_"=>$/\ H:]#_P#!C%_\56/_ ,*>\ ?]"Y!_W^E_
M^*H_X4]X _Z%R#_O]+_\50!L?\)UX0_Z&O0__!C%_P#%4?\ "=>$/^AKT/\
M\&,7_P 56/\ \*>\ ?\ 0N0?]_I?_BJ/^%/> /\ H7(/^_TO_P 50!L?\)UX
M0_Z&O0__  8Q?_%4?\)UX0_Z&O0__!C%_P#%5C_\*>\ ?]"Y!_W^E_\ BJ/^
M%/> /^A<@_[_ $O_ ,50!LKXY\(NP5?%.B,Q. !J$1)/_?5;]<0OP?\  *L&
M'ARWR#GF60C\MU=L %4*H  & !VH 6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?$WBRP\+0VOVF&Z
MNKJ\D\JUL[2/S)IFZG:,C@=R347AGQE8^)7O;=;6\T^^L2!<V=]&(Y(P1D-P
M2"#ZYK$\=6.HVGBOPWXKLM.N-2@TPS17-K:KNF"R+C>B_P 1'I6/XEO/%7C/
MP9KXM_#MW86?F0_9X)E,5W=Q!@904SQD#@=^E)/3^M/ZW_X8;6IZ;#J%E<6[
MW$-Y;R0)D-(DJE5QUR0<"L>:/PO9:M?>)W:T%_;VGEW5RLFYDA'S8*@^WID\
M"O++G1I+]?%=WX8\-W^F:/-H/V8VC630FXNLY!2+&20O!(')J6[\#M!>VT-C
MX>D2*X\)RQW.RV(62YP"H<XP9-P!YYR*'HGZ?Y_Y?B"U:_KM_G^!ZW8>(M)U
M#2;;4XKZ%+:YB$T;2R!#M..H)XZBKCWUFES';/=0+/(,I$9 &8>PZFO%-!\)
M6FMW_@6"[\-W2Z;:Z;.EZD]F\2"X 7)?@<ELD$]2*KZ]H%R9?%%A<>&K^[\2
MWVI"72=3BMBR1Q979B;I&% .1D=JIJSMZ_G;_@^A*U7]=KGLFE>([/5]7UC3
M+>.=9M*E2*=I% 5BR[AMP22,>H%:]<'X%T[4;+Q9XQEO[>9!/<VQ29XRJS8B
MPS*2,$9]*[RET7HOR'W"BBB@ HHHH **** "N6\1>.;70=7BTF'2]3U747@-
MPUOI\(<QQ9QN;)'?BNIKROXC6D$GBFUN-1T/7! EKBWUG02YN(WW<QL%Z#N"
M<]?K2;U0ULS9F^*VBK8:-=6>GZMJ!U8RK;P6ENK2JT>-ZLI88(SVSTJU9?$6
MRU#3M0GMM$UU[S3Y4CN--^R 72[_ +IV;L8QSUKRZ_L?$]Y8>#;O7['Q-,+>
M>]WRZ? _VV.$A1&7V#Y6/?/49KL_A7I]_9ZUXBE%CJ\&CW#1/!+K<>V\ED"X
M;<3\Q4=L_P"-4E>Y+=K?UW-'3/BQI6I6UW=G1->M+&S60W%Y<VBB*-D'S(2K
MGYNV,=345YXL\(>+=(O5\0:7>V\.E)'J+V^HP&-MO.R10K'(.2,9YS@BLC1]
M(UR'X4^+[.#2Y?[0N+Z\:"WN8,&5&8<A6'S9&<=B:S_!OVGP_<:YJ=AH>OWN
MG)I<*F+4+5C<S72G'E1Y&XH >0,@5-]/DG^#?_ *MK\W^:1V=E\4M"N;349[
MFVU/3FL+=;IX+VUV2/$QPK( 3D$D#\:DM?B=H4VD:KJ%S#J&GG2PAN;6\M]D
MPW_<PN3G=VY_*N2\(:SJZC6_$%WX4\07/B:2W#O'=6AM8/*5@!! QR20"6Y&
M6Q7/W.AZQK.E>++C2-(U?[!-+:W:)J<)%U/,C@R*N?F90,X![\"GU_K37_+\
M1=/ZU_K\O0]A\,>+K#Q5'=BUM[RTN;1PEQ:WL/E2QDC*DKD\$=.:H^(/'UIH
M6L'28=)U75;Y(/M,T>GPA_)CSC+$D>G05S?ANWU_6-:\7>(M*@DT=M1>UCLS
MJEJP)$:X=C'D''. :R_%MA<IKEO-XBTO6FO4LPL.N^&%D#N^3F-D&=H],TI=
M/ZZ!'J>IZ#KECXDT2UU?3G9[6Y7<A9<,,'!!'8@@BM*N7^'C:\W@FP/B-91J
M/S9\Y0)-FX[-X'\6,9_7FNHJI*S%%Z!1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img238320182_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $7 LT# 2(  A$! Q$!_\0
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MCTV)ECC4,&#G<<LV0/PXKT>LS0]936]+&H)%Y4#R2+$6;.]%8J']@<9QZ$4
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M5Q;7J26ND6,ULX=2'E>0[BP[ 9)XKI['Q1I6I:Y>:1:3/)<6D>^5MA$?WBI
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M(TKA!C<['+,?<FIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH P?$/AL:]J&AW7VHP_P!EWHN]NS=YF%(V]>.O6L36_A]=
MZWJL_G>);T:+=7$=Q<::T:L"R$$!'/**2 2!7<T4 5)]*TZYE,MQ86LTA !>
M2%6)_$BN/^$RJGA&Z55"J-4O  !@ >:U=W7"_"?_ )%.[_["MY_Z-:@#NJ**
M* "BBB@ HHHH **** "BBB@ HHHH YCXB0R3_#[6EB7<RV_F%?55(9A^0-8&
MN^'(?$6O:[?3:>]W;OH,/V"3!*F7,QRF.-XRF".1D>M>B.BR(R.H9&!#*1D$
M>E,MK:&SM8K:VC6*"% D<:C 50, #\* .>FT^_U3P-86LD"RWS6\!ECN;B6#
MYPHW;FC^8'.>*D\*:-=:/!<I=6MM 9&4J(+Z>YS@=S+R/PKHJ* .!>YDO/B'
M>I'IFJQ03:6;!;EK&18A()').[&,8(.>AJEH-MJ5U'X-TF72+VTDT 9O9YXM
ML64A:("-NC[BV>.@SFO2Z;)&LL;1NH9'!5@>X- ',?#[+^%OM !$5S>74\(/
M:-IG*_@1S^-=345O;PVEM%;6\2101($CC08"J!@ #TJ6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BFNZQQM([!44$L3V K@)_B]HK,W]E:5
MKFL1J<&:QL':/\&.,T >@T5QFB_$W0]7U.#3)H-2TR_G.V*#4+1HC(?0'I^M
M=G0 4444 <'\0/\ D9/ O_89'_HMJ[RN#^('_(R>!?\ L,C_ -%M7>4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&K-&IAWF=7ZY#Y&>F.*]HKSW1-&\77'B"TU'4-*\,Z/;VY.5M8?-N'4]5#X
M4$]2*[C4FF73;DV]Q%;3>4WES3#*1MCAF'H#0!:HKQ6?Q/XF\,V/BBQNM9GN
MKN"&V:SENXDWGS'$;S)M^7R\G@'D=ZZCP]K>HZ#J'BC2M6O;W6HM'%O-%,L
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M@:M[2LO5K\MSIM+_ .1@UW_KI#_Z+%;5>)>!O%]^/&<K7Q:8:HX67 P$?HI
M[ =*]MHA+F5PQV&EAZBC+71?D%%%%6<84444 %%%% !1110 445C>*+^&QT.
M42:J-+DN&6W@NS'OV2OPN!WYH \SU;7O'6HPWVGP"XL9=--U=7EP]@'CE56_
M<01C&'##J1S7IOAK3+33])BF@TRWT^>\1)[J*",(/-*C=D#OVKP>WN$L[&_T
M75/BV+97N)TN+>*S,F06.[YL9!// Z5]":0L":-8K:S-/;K;QB*5CDNNT88_
M4<T <9XMUOQ+IWC3PY;0M;6VC7>H);L5.Z6XRA)SQA5&,>IKG]:\8^(K?5M8
MUFVU%(],T?5X=-.G>0")U8J'8OU!RW&/2O1M;\.6VN7ND74\TL;Z9=BZB"8P
MS $8.>W-8M_\-=*U#Q#)JCW=\D$]Q'=7-@DH$$\R?==AC/89 /.* +>L_$+P
MWX?U1].U&\FBN4"LRK;2.,$9'*J163\()X[GP7-<1$F.74KMT)&,@RDCBN^K
MA?A1_P BI=_]A6\_]&M0!W5%%% !1110 4444 %%%% !15'4HKEH&EM[V2W,
M:,V$16W<=\@U#HBW<EA;W5S?23F:%7*-&JA21GC %*^I?)[O-<U****9 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5Y-\1=<O_#GBB(6NIV&EV1TUYD2[LA+'<S*_P#JUP,AB,=^G:O5Y%9HG5'V
M.5(5L9P?6O*O&4FIZ%8Z/'J_Q#M+"<1LKF33%F-PX;.\+R5P"!Z4 97AOQ_>
M:MXRLIK76;06]W>I9MH<42_+&8=[3!AR2'!&?PKVRN)\$:2;>YOFU'6+'6M0
MM9 BRQV"0/;!E#%>!GY@0:[:@ HHHH X/X@?\C)X%_[#(_\ 1;5WE<'\0/\
MD9/ O_89'_HMJ[R@ HHHH **** "BBB@ HHHH **** "BBJ5YJUC8/MNK@1'
M&[Y@<8^N*$K@7:*KVM[;WJ,UO)O"G!.".?QJQ0!1U2[>SMEDC=$)8#+Q/(/R
M7FLO0M>GU68"1X "SKM2"4'Y21G<>.W2NBK(\/'&E2$G %S/R?\ KHU%^AHE
M'D;>YKT&N9U;QYH.E2F#[4;N[Z"WM%\QR?PX%<#XG^*&K16D[1QPZ7"J$E2?
M-N"/]T<+^-3S7T6IM#"5)+FE[J[O3_@OY'H0U"TB\<W4,ES$DBZ?&6#,!CYV
M/?ZBGWGC3PW89$^L6NX?PQMO/_CN:^?9X]6FGFN+O3=1EE2'[3,9H23Y6,[S
MG^'%>@:+X TN[TFTU&]U]88KF%)EBB1(R%8 @$DDYI4^:5[Z?>=>)H86CRWF
MY:=+?G_P#H[SXM:% #]F@O+D^HCV#\R:X[Q%\3KW6%MX[*T%FL$ZSAB^\L5Y
M /'2NIM_#WP_T]ANS>R#_GHS29_ <5Y_8:!I.MMJ=T\>L,?[:DMHH[=]D20E
M@ JC'#8JJE-\NC_ G#8C"PJ)^ROZN_\ P/P-I?'?B'5%W2:I-:H?X;'3C(1_
MP(T%[2].=0;QGJ9[KY?EJ?PS6G\.KO4M*N?$FE6=C?7=O::@(X5NIP6B78#@
MG]:[G[;XFE^YI=K%_OS9_E5*$+>\K_,QECIJ3]E:*\DK_?8\2\77OAS3H;:U
MAT>[TBY<^9OO<[Y5Z=2>F:M_#SQ'>P:M<Z9H4=C?7<PW>3/)M*E>K ]>G45T
M'B6[N[3XG64FM7.F6H;1I4#3+NCP9!QSWJAI,5IJ?C3P?:V>KQ-LLKD2+9J%
M:'Y5."1U)Y_*BU-2NHK\2Y8S$SP[A)MJ_P#6IVTP\>3*6NM5T72D/4*I<C\Z
MXOQR+VWT -+XXO[N:2ZAA>*T'EC8SA6Y'L37J</A/2HVW2Q27#^LSEJ9KWA7
M2-8T1]/N86AM]Z2YM?D<,AR""!GJ*T=32R///$+[P,^B:-KFMVNKZG"VD%/L
MF9&21B[KR_X-^-?1<))@C).25'/X5YQ_P@>C:G<7]E=ZIKTT+/&&1[ESYG (
MW\<X/3->D(H1%4= ,"LVV]S2HTW=/M^0ZBBBD9A1110 4444 %%%% !39(XY
M5 D17 ((##//K3J* /!7\1WFI:IJQNO'?A_07@O98%LGT^*4A5. V\_>S7N&
MFMNTNT;[0EQF%#YR*%63@?, . #UKQ7Q4FIZ5#JNI"[^'LZ0,\GD&U4SL,]#
MGJ_\S7L^C2BXT.PF79MDMHV'EIL7E0>%[#V[4 7:*** (YIA"FXJ[<XPBEC^
ME<1\+B;?PY/"Z/NDU*[<,JY7!E8CD<5UFJVL]W:B. *6W@_-,\?'U7FN)^&E
MK</I2W(5/)2[N$)\]\Y#L/N?=//<\]Z-"E%M7/1:*04M!(4444 %%,>6.+_6
M2(G^\P%4YM<TFW'[[4[./_>G4?UHN4HRELB_17.S^.O"]OGS-;M./[K;OY50
ME^)_A9"0E[+.1VB@8_TJ>>/<VCA,1+:#^YG2:I;QS6,[/NRL3XPY';VJKX<M
MXXM"L)%W;GMH\Y<G^$=C7':Q\6-)^PW%O:VEZ;F2)A'YT80<C&3DYQ^%6?!O
MC_1Y]&LK&_NTM;V&,1,)1M1\< ANG(J?:1O:YN\#B8T7)P>YW]%-CD26,21N
MKH>0RG(/XT[-:' %%%% !1110 4444 %%,::)&VO(BGT+ 4J2)(,HZL!_=.:
M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D?Q72V_MN)8=?T
MO3M0O-.>S>+5$81O"S9W)(!A6!'XUZY7F/Q:FUN*WA^Q:IH-KIY3]_'?F,2O
MSSL\P%>GMUH W? .E7MM#?ZKJ>IV%_?:@T>XZ><P1I&FU%4]SC))]ZZ?45O'
MTVY33Y(HKQHV$$DRDHKXX) Z@&O-/@<=";1M5;18-1C8SK]I>[9"KO@\Q[ %
MQU[>E>EZG81ZIIES83231Q7$9C=H7V. 1@X/8T >56VK>++/3O%/V+6+K7X+
M:R"0W@MU!^W$X9(=H^=5!SWP>*UO!7B.>SL-:76)_$%WJ.GK%)<65Y;HTR*P
MX,8C^\#S[\5L:=\--#T[3;G35N-4GL)X/(-M/>NR1KD$%!QM((ZBM7PYX3TS
MPNMP;'[1)/<L&GN+J9I99,#"@LW. .@H X#Q#XLMO$7BSP5#!INK6ACU<.6O
MK-H5/R,, GJ?:O6ZX/X@?\C)X%_[#(_]%M7>4 %%%% !1110 45#<3FW@:58
M9)BO\$8!8_3-4+37!>7+0IIU\I23RW9T4*AP#S\WH13M<#5I#2TA-(#C;E-3
M76H+=8M2"RI*^P:B/FP5P1Z8ST]_:NNM@RVT8<,&"@$,VX@^Y[_6N+UOQ5::
M7XOT^&[NK5"MO+ND&2J;MNW=CN=M69/B7X:B  O)+A\<B"!VY]N*GG75G6\+
M6G&+A3>JZ)G85S/C&VL'TB[EF*_:1& O[T@XW#MFLX_$B"8XL=!UBZ]"(-H/
MYUR'BWXDSW]O=Z.ND-87(*B5IG#.@X8#&.,\5,JD4C;#X#$NK%)6^:_X<]9T
M^WL;>-UL2NPMEMLA?G\2:JZMXHT70T)U#488F'_+/=N<_P# 1S7C]OXVNO$,
MMQ;:EK%]:+$JDVFF6NTS _[>?YU-9EDF_P")/H=O9,?^7N^S=7!]P.@/X5I"
M,YJ\59>9%2A2HR:K2O)=%_F_\F=#XA^)T@T_S--TRYBA<[8[NY;R@Q_V5ZM7
M!:3JLM]_Q++JYU*\$KY@L;><()I&.3N/7WXJ[XDTDR^)O#+:_+<WT=Q+.KMJ
M<HAAX3C:/X0#44/A[1X=7\+?9;VT-S/K'E2"VD5I0@5P#D=!P/S%2Z2YES2N
M;T\;3IT)*E3L^][O\5_D=+!X;:VC":I>VVCP'K8:6-\[^SR<G]:L:[X>E?P)
MK%GX=\-B$3VK+YLWS3S?3//->D6&B:?IW-O;('[R-\S'\35YU#HRGH1@ULYZ
M<JV/,E.4WS2=V>$W=_<WNGW=I<:'X@N+R32Q;HI\M=K8(!.'^YG\>O%>F^%/
M"EA:>%])2[TY1=I:1+*LG)5PHR/SJ5-%M?\ A(I8-B;5M4<'R8^N]A_=]JZ4
M# Q4:H=1Q=K$,5E:P >3;0I_NH!7F>M>!;6WU2YEM-=O;1;J]$\D"7,@57<Y
M+ #@'T(KU.LC5+/4[R2-8'M%BBF25=^[<=IS@XHLGN*,G%W1G^"_#-IX=LKM
MK>[FNY;V?S9YYI&<NP&.K<]!73U#;?:/)'VKRO-SSY6=N/QJ:D24M0M!<1[]
ML!95/,D(?^=4?#EJHTNSN?+MP7@4@)"%(R/6M&]L$OE57FN(PN?]3*4SGUQU
MJ+3])@TP!;>6Y**FQ4DF9U4>P-/2P%^HYS*L#F!%>4#Y5=MH)]S@XJ2BD!AV
M<6LPZC<SR6=F$N70MMN&)0!0#_#S6Y113;N 4444@"BBB@ HHHH **** "L7
MQ-JEQI&G0W%O<:; 3<1H[ZA-Y<>PGYL'^]CH*VJY'XBV[77AV*)(]!=FNHU5
M=;!,))R !C^,D\?C0!Y=?VMN^K75S!IGPUD5IWDCDFO?F89)!89QGUKW;3W>
M33;5Y/)WM"A;R#F/.!]T_P!WT]J^?I[>&WFD@F'PGCEC8HZ,C JPX(/->_:5
MC^Q[+'V?'D)C[-_JONC[G^SZ>U %RBBB@#D/'/C@^#?[-5=-:]>^=T4"81A-
MJ@DDD'->=^&?B)=:%9KI=OIT$SW-ZQAWRE?GE8G;^9/-=3\6-)O]1DT&>UTF
M\U*WMYIOM$=H0) &3"D9]_Y5YAI7A_6?$#Z=%::)?0G^T$+WVU&BCC4_-N]6
M!_E42BVU9V/2PLZ$*$^>'-+IV_-/U/5WU[QQ)_RZZ#9_]=;K<1^M5WO_ !=(
M#YWBK0[8>D4>\C]*C_X1GQ1HS%DLM*UN$<X8&.3'\JGA\6Z/ISB/7/"MQI;]
M"[6XD3\\5M["^SN8?6FOAA%?*_YW*C#49<_:?B#-SVMK4BH3I6GSG_2O$_B*
M[]0F5S7>:7K7AK5 /[.NK"0G^%=JM^1YK:"JO10/H*S=.*W0?7:ZV:7HDOT/
M*E\,^&F()T[7KP_]-96YJ[#X:T./_4^!YI#V,SD_SKTJBA0AV)>-Q+WF_O.&
M@THQ?\>W@O3X_3S IK0CAUY<>3I.EVX]@./RKJ:*:LMD8RJ3E\3;/"_%T<<G
MQ):+Q-J&FVG_ !*%:)I'**6\PX4'N>O%9FF_V"_C/1+2.*TU.V>SG:\CM93(
M=V!@L/X2.:]XU2RM+BSN))K6"618FPSQAB.#W-5?#EC:1:)IT\=I DQMH\NL
M8#'*C/.*EJ+=VC>&(K1I<L9-*_<XVT\,VH<R^#_$ESITW7[),VY/IM/_ ->K
MW_"2^+= XU[0A?6Z];O3SDX]2O\ ^JNJO_#^FZB=TMN%E[2Q_*P_$5G?8->T
MGFQNUOH!_P L;CA@/8T>S7V78?UR4M*T5+UW^]:_?<=H_CCP_K1$=O?I'/WA
MG_=N#]#719R,UPVH1^&M;?R?$&CBSNCQYC)M.?4./ZU#'X2UO24$WA7Q*\EO
MU6UO#YD9]@W:D^>.Z'[/#U/@EROL]OO7^1W]%<&/'&KZ*PC\3^'IX4'!NK/]
MY&??';\ZZ72?$^C:X@.GZA#,Q_Y9[L./^ GFFIIF=3"U::YFKKNM5]Z->BBB
MJ.<P?%&GV4VD7-Q):0O/\@\QD!;&X=ZU[:SM;-66UMXH58Y(C0*"?PK$\5WT
MT.E7,0L)Y(_D/G*5V_>'')S6S97,MRC-+9RVQ!P%D*G/OP33OI8MP:CS="S1
M112("BBB@ HHHH ***0T +17B%MJOB/7Q:Z@DFA6PO;Z6"")Y[@,S*S+\X#8
MVG';OBN]^'6KW^I:=J=KJ45K'/INH269^RLY1MN.07)/4TKFDH)14N_D=E11
M13,PHHHH **** "N/\22> U\36:^)?[,_M4P_P"CF^7C9N/0M\O7/O77LRHI
M9B H&23T KRKQOXDLO$$L6GZ;K?@S^SVC/GW6I3),Z-DC")TZ<YH ]0M?LWV
M9#:>5Y!'R>3C;CVQQ4U>3_#WP#I&FSQ7V@>-KB^:"8-=16LJFW<$?<,8)V^Q
MS7K% !1110!P?Q _Y&3P+_V&1_Z+:N\K@_B!_P C)X%_[#(_]%M7>4 %%%%
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M80G'W>.PZ?A0!<HHKQK7]1U>S\<ZAJNJ_P!NQ>'H+ZWMHI;*^1(H^%&6BY+
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M97DD\LQN> 58$$'G'XUN5Q/Q8L[J_P#A]>6]E%)+<--!L"(7(/FKSCOCK^%
M%/\ X5#I6["Z_P")5@_YX#4VVX].G2NH\.>%-&\*6LD&D6GDB4AI79V=Y6'=
MF))-<G-H/Q'MX'FF^(&GQ11J6=WTM % ZDDFN^L2[:?;&2X2X<Q+NF0 +(<#
M+ #L>M %BN4N_AUX<O?$!UF:UE,[RK/)")V$,LJ_==H\X+"NKHH *X7X4?\
M(J7?_85O/_1K5W5<+\)_^13N_P#L*WG_ *-:@#NJ*** "BBB@ HHHH ****
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M6K.QM=/MEM[.WC@A7@)&N!5BBBM#S&VW=A1110(**** "BBB@ HHHH ****
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M)_$),?V!]*6S'S?/O$A;IZ8KJ: .(_X6IH/_ #Y:Y_X*I_\ XFC_ (6IH/\
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M 5V5<OXJT"]UC6?#-U:^7Y6FZA]IGWM@[-A''J<FNHH **** "BBB@ HHHH
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M\.3^&=,O;6XGCF:XOY[I6C! "R-D Y[B@#*_X3?Q'_T3S6?_  (@_P#BJ/\
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M!-8.J?#OPQK-U:W%YIH+VT:Q!8W9%=%.55U4@, >QKIP H    X % "T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #7;:C-Z
M#->9:?\ $[Q!J.@2:_;>#'GTJ)G#O%?(9,(2&(0C)Q@UZ9+_ *E_]TUX?X(\
M7VWA_P"&T^AS:;JLVK,]R([:*QD.\NS;?FQC'(H ]5M?&?A^YT"QUN35+:UL
MKU-T+7,JQD^HY/4'@UH1:UI<]Q;6\.HVLDUS&98$29294'5EYY'TKPI-)O\
MPSI_A?0]7T<!5L97-^FF?;I4ED=CY"@Y53@C)(/-0:587FA_"_1_$XLYDU#P
MUJTKRP2IL<P.V'7]1[=: /H&#4+.ZNKBVM[J&6>V(6>-'!:,GD!AVJS7$?"W
M2YK;PL^KWJXU#6YWU"<GJ Y^1?H%Q^==O0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTTK?:-2W_9@JDAMHR>>W!K4!S7@\MKJ5W8^#H?$6AZI=+H\MU:WZVT;DLBJ
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MUAMK.^73KJ2X?3H[N)Q<R[HOF+!QYC9?(!?YB/PI2TBVNS?XA&S:];?F;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img238320182_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ++ [X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@'Q%7Q
M_P",!X@A>$:9X8TD2RY92GVL1C(Z\OG&1C"_C6Q^S?\ \BAJG_7[_P"R"O1/
M'_\ R3OQ'_V#9_\ T6:\[_9O_P"10U3_ *_?_9!0!S/C>&7QQ^T)9^&[O<VG
MVCQQF+<0"FP2R$>A(.,^PJK\5O#]E\-_&_AW6?#2"R$N7\E22H:-ER>3T8,
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MG\FH ZKX4_\ )+O#_P#U[?\ LQKL:X[X4_\ )+O#_P#U[?\ LQKL: "BBB@
MHHHH **** "BBCIUH **3>O]X?G1O7^\/SH 6BD!!Z$&EH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH *\D_:'_ .2?0?\ 7ZG\FKUNO)/VA_\ DGT'_7ZG\FH
MZKX4_P#)+O#_ /U[?^S&NQKCOA3_ ,DN\/\ _7M_[,:[&@ HHHH **** "BB
MB@ J"]LX-0LIK.Y3?!,A21<D9!Z\CFIZ* .3;X;^% I/]F-P/^?B3_XJN=\%
M>"M U?1);B^LC+*MU+&&\YQ\H/ X-=KKGB?1] 3;J-ZD4CCY8P"SG\!SCW-<
M?\/?%FB6^FOI]Q>I!<R74DB"4%00QR/FZ?K6J<^5L>IVNC>'M+\/QRIIEL8%
ME(+@R,V2.GWB?6M2BBLF[[B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *6K:1I^N:=+I^IVL=U:2XWQ2#(..17G.J_ 'P;?-OLUO=-< X^SS;
ME)]2'S^A%>IUYS\:[C6[+P*+[1+^2R>VN5DGECF\L^7M88SWRQ7B@#F(_A/X
M_P##OE#PSX[=HH^%@NBZ(H]E^=3^5.MO%/QB\/S0QZSX:BU2V,NUYH$#.5SC
M/[LX [\K7"Z/IGQGUS38M0L;S5S;3+NC>6^$9<=B S X]ZH6EQ\5KGQ+)X?7
M5]4BU:-2_P!FGO?++@=U+'#>O!/&: /K3M17A7PZ\=^,-,\?)X-\:EGDG0B)
MY]N^-@I889>'#=._..>M>ZT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7DG[0__)/H/^OU/Y-7K=>2?M#_ /)/H/\ K]3^34 =5\*?^27>'_\ KV_]
MF-=C7'?"G_DEWA__ *]O_9C78T %%%% !1110 4444 %4=9U#^RM%O+_ &[_
M +/"TFWUP*O5S/C?6=)T[P_=6NI3E6NHFC2*/EVR.H'I[FG%78'S_?WUQJ5]
M->74ADFF8LS&J]*01U!&>E)UKO-#W#X5Z[<ZIH4UG=.9'LV54=CDE"#@?ABN
M^KPGPWK>L^ 4\VZT9S9WNU]TBE2>#C:W3OT(KU70?&NB>(0J6MT([@_\N\WR
MO^'8_A7)4@[W6Q#1T-%%%9""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH BN+F&TMY+BXE2*&,;G=S@**XFZ^+/AVWN&BC2\N%7_ ):11C:?IN(/
MZ5SOQ?UF<WEKH\;LL*IYT@'\1/3\J\NKHITDU=E)'TMH/B?2O$<)DTZY#NH!
M>)AM=/J/ZCBMBOF+0M6GT36+:_@=E:)P6 _B7N#Z\5]!V_B_P]<PK*NL62A@
M#MDF52/J":BI3Y7H)HVJ*BAN8+B,20S1R(W1D8$'\:EK(04444 %%%% !111
M0 45%<7,%I$9;B>.&,=6D8*!^)IT4T4\8DAD21&&0R,"#0 ^BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\E_:$L+V[\!6\]M&TD-I>++< =EVLH8^P)'YUZU5'6-0TW2](N;S5
MYH8;"-#YS3?=P>,$=\],=Z /*/#7Q\\++X?M(=3BN;.[@A6-XXX=R$@8^3!Z
M<=#C%<7/XJ/Q)^.?AV]T2QGCM[.6$;FP',:/O=VQP!@D8S_/%:6I7?P&NKQY
M?(G5G8LWV9)T0D^B\ ?0 5U/@SQQ\+-'NH=*\-0O;3WLJQ _9W+.S' !=LG&
M?? H Y(:C+X[_:0LWAMC!%I,K0LZG<&6!G.XD#C<>/Q%?1=8^B>%M$\.M</I
M6GQ6\ERY>:499W).3ECDXSVZ5L4 %%%% #)98X(GEE=4C0%F9C@ #N37$>$?
MBGH_C/Q->Z-IEO<_Z+&T@N'QLD56"Y'.><Y%9?Q#\$^*O''B*"P@U?[!X86%
M#<*&^:23<V0%'+<;?O'%<!\#[&+3/B[XBL(&9HK6">%"_4JLR@9]^* />M?U
M_3O#.C3ZKJD_DVL(&YL9))X  [DFO-K/]H;PG<WJ0S6FI6L+L%$\D:E5]V 8
MD#Z9K _:4OIA%X?TU6Q#*\LS+ZLNU0?R9JU?BCX<T^S^!-JJ6D2RZ?';-$R+
M@AB55C^.XYH ]@%W;FS%X)HS;&/S1*&^4IC.[/ICFO*KS]H;PE;7SP0VFI74
M*,0;B*-0K>X!8''UQ7+Q^(KIOV6I2DKK+&_V N3DLAE&1SVVMCZ"NA^$GAC3
M;SX,7$=Q;1.=3\\S.5&XXRHY]L9% 'IWA[Q#IOBC1H=5TFX$UK+D9Q@JPZJP
M[$5Q?BOXU^&?"VKRZ4T=W?7<)Q*+9 50_P!TL2.?IFN#_9WU62#3/$UJTC>5
M%&ER@SPI 8$@>_'Y4S]GBPAU76_$&M7RBXO5"KOD4'F0L6/U.W]30!ZYX*^(
M6A>.[>9]*DE2>#_6VTZA9%!Z' )!'N#47C;XE:!X$\F/4WFENIAN2VMU#/M_
MO')  ^IY[5Y)X9@C\-?M-7NFV3>5:3/*IC' (>+S N/0,1CZ4C0P^)OVH7M[
M_,]O;2GRT;D#RHMP&/3<"?QH ])\'_&/PWXOU5=+A6ZLKYQ^[CNE $A]%()Y
MQZXKT.OG3XZ6D>@_$+P[KFG8M[N8!F9% ^:-QAO<_-^@KW'Q/XHT_P ):#)K
M.H^:;1&53Y2[F^8X'% &U7DG[0__ "3Z#_K]3^35+_PT'X+_ +NI?^ X_P#B
MJX/XM?%3P[XT\)Q:;I0N_M"W*RGSH@HP >^?>@#V'X4_\DN\/_\ 7M_[,:[&
MN.^%/_)+O#__ %[?^S&NQH **** "BBB@ HJ"[O+:PM7N;N=(84&6=S@"O*=
M<\::OXPO3HWA>"9(&.'E'#./4G^%?U_E51@Y#2-_Q=\2+?2F:PT<)>:@3M+#
ME(S^'WC[?_JK)\._#V]UF[_MGQ9+*[N=PMW;YF_WO[H_V1^E='X0^']CX<5;
MFYVW6HGGS2/EC_W1_7K]*[&J<E'2(7[&5J'AK1M5M8[:\TZ!XHQMC 7:4'HI
M&"!]*IZ?X'\-Z7<BXM=+B$HZ-(S28]QN)P?>NAHJ.9[7$1S017,+0SQ)+$PP
MR.H((]P:X+7_ (5:;?%KC2)387'4)UC)_FOX?E7H-%.,G'8#QY->\:>!)%AU
M:W:^L <!W8L,>TG4?1ORKN= \?:'K^R)+C[-=''[B<A23_LGH?Y^U=,\:2HR
M2*KHPP589!%<-K_PNT?5-TVGDZ?<GG]V,QG_ (#V_#'TJ^:,M]!Z'=T5X\M_
MXW\ %4NXS?::IP&.9$ XZ-U7\>/:NR\/_$;0]<V122_8KH_\LIS@$^S=#^A]
MJETVM5J%CKZ* 01D=**@05R]QKGBF.YD2'PCYL2L0DG]H1KN&>#C'%=1133L
M!Q">,?$4FI2:<OA'-W'&)7C_ +03A3P#G&*U]+U?Q#=WR17_ (:^Q6Y!W3_;
M4DV_\! S56S_ .2FZE_V#X__ $*NJJI-+H,****@0444R66.")I)9%CC499F
M. !]: 'T5Q6M_$_0=++QVSM?SCC$'W,^[]/RS7+'7_'7C-BFE6S6-DQ_UD?R
M#&?^>AY)_P!W\JM4V]7H.QZ5JWB/2-#CW:C?10GJ$SES]%'-<%J/Q7N+N?[)
MX<TN2:5N%>52S'Z(O^/X5-I/PE@W_:-=OY+J9CN:.(D*3WRQY/Z5WNFZ-IVC
MP"'3[.&W3&#L7EOJ>I_&G[D?,-#Q77_"_C'4;237M7A:1P #'QO">NU>@'YU
MQ.*^KJQKKPGH%[<">XTFT:4-N+>6!N/OCK^-7&M;=#N>%>$O"]UXFU:.!$9;
M56!GFQPJ^GU->G3?"'07R8[F^C/;YU('YK7=6MI;64 @M8(H(AT2) H'X"IJ
MF563>@KGELOP;3?F#7)$7L&@R?S#"H!\//&5FQ6R\0@1C[N+F5"?P ->LT4O
M:R"YY.FG?%'3E*0737"^IECD_P#0^:/^$E^)&FD17.D&Y;^]]E+_ *QG%>L4
M4>T[I!<\G'Q4URQ<IJ?A\ CJ 'B/Z@U<M/C'8L2+W2KB'T\J0/\ SVUZ60#U
M -5+G2=-O!BYL+68?]-(E;^8HYH=4&AR=M\5_#<Y_>&[@_ZZ19_]!)IVJ_$W
M08-)GFTZ[%S=A<11&-ERQ]<CH*UKOP/X9O<>;H]LN/\ GD/+_P#0<5QGCKX?
M:5I_AV6_TBTDCFA8,ZB4L-G<X)/M3C[-L-#S'4]6OM8O'NKZY>:5CU8\#V [
M#VJ71M=U#0;U+JPN'C8$;DS\KCT8=Q6;17596L4?3FAZQ#K>C6NH1843)DKG
M[K=Q^=:.1ZBO'='^%-Y?:/;7CZJUK),@?R3"<J#ZG</Y59;X4:U'S!KR9[9W
MK_6N5PA?<FR/6J*\F7X=>,(O]5XB5?I<2C^E./@CQ\.GB4G_ +?9O\*7)'N%
MCU>BO)?^$-^(2'*Z\[$?]/TG]13QHOQ-M?\ 5ZCYF/6=6_\ 0A1R+N%CU>BO
M*"GQ74X#$^X-O2@_%<'IGZ_9Z/9^:"QZM17E#:E\4;;[]GYF/2*-O_0340\6
M?$6(X?19&/\ UY,?Y4>S?=!8]<HKR@>-O'ZCGPV6_P"W*7_&FM\0/&T?W_#J
MCZVDH_K1[)A8]9HKR5?BAXCB_P"/CP^I]<1R+_/-2CXP7$8_?>'R#_UW*_S6
MCV4@LSU6BO*O^%RM_P! $_\ @5_]A4B?&2+_ ):Z)*O^[.#_ .RBCV4^P69Z
MC17FZ?&+2B/GTV\4^Q4_UJ5?C!H9^]97X^BH?_9J7LY=@LST.BN 7XN^'SUM
M[]?K&O\ \54J?%GPVQY%XOUA_P #1[.78+,[JBN/C^)WA9^M](G^] _]!4O_
M  LGPG_T%/\ R!)_\32Y)=A6.KHKE5^(_A1S@:J!]89!_-:N1>-/#<WW=9M!
M_O/M_G1RR[!8WJ*R/^$J\/G_ )C>G_\ @0O^-.7Q-H+?=UK3S]+E/\:5F!JT
M5136M*D^YJ5HWTF4_P!:G2^M)/N74+?20&BP$]%-$B$9#J1[&EW+_>'YT@%K
M(UG0?[9>)O[4U*R\L$8LY_+#9]>.:UL@]#7/^,?%,7A71_M)02W,IV01$XRW
MJ?84XWOH!S/BC0+C1;6PDMO$>NLUQ?16S^9>DX5LY(P.O%;G_"#C_H9?$7_@
M=_\ 6KQ75O%6MZU.);S4)F"N'1$;:B,.A '&1Z]:ZCPA\2M0L+V*UUB=KJQ<
MA3)(<O%GOGJ1ZYKH<)V*LSVBVA^S6T4'F22>6H7?(V6;'<GN:EI 0RA@<@C(
M-+7,2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y#^T1;W<W@.
MTD@5S;Q7RM<;03M!5@"?;) ^I%>O5P7Q;T7Q'K_A&.P\-!FN)+@"X02J@>'8
MP(.3@C)7B@#!\-_!+P-<^'-/N98IK]YX$E:X^T,H<L > N !S6[8?!KP3IFH
MVU_:Z;*EQ;2K+$QN7.&4Y!P3ZBO&+#X:_%W2[86VGO>6L .1'!J:HH/T#UN>
M'?!WQ>MO$VESZE>ZBUC'=1O<!]4W@QA@6R-_(QGB@#Z)HHHH **** "OGOX0
M?\EP\6_2Z_\ 2A:^A*Y'P]\.=%\,^)]0\06+W1O+[?YHDD!0;W#G QZB@#S3
M]I/3YC;:!JBKF&&26%CZ,VUA_P"@&K7Q,\9:-J7P0MH;?4;:6[O8[91#'(&=
M64JSY Y&-I'->PZQH^GZ_I4^F:I;)<VDXP\;=^X((Y!![BO.;'X >#+/4DNW
M.H74:L6%M/,/+]@<*"0/K]: .57PS=Q_LN2QI"_GR'^T&1A@J@D!)^FQ=WXU
MI?"KQMHNF?!V=;R^MX9]/\X&!Y '?/S+A<Y.<X'N*]H$,0@$ C00A=GE[1MV
MXQC'IBO,-0^ '@R^U)[N,W]HCMN-O;S*(QZXRI('MGZ8H Y']G?1Y9M(\27K
MQ-Y4ZK:QDCASABP!]LK^=4_@'K%GX<USQ!HVL3Q65RVTYGD5%W1EE9<D]?F_
M0U[]HVBZ=X?TN'3=+M4MK2$?)&N3]22>2?<UQWBSX.^%?%VI'4;F.YL[MSF6
M2S<+YONP((S[@"@#S/PC<+XJ_:4OM7L5\RSA:5S(IR-JQ^6&SZ%L8^M-NKJ#
MPE^TZUYJ(\BTN),K(Y"J!+%LW$GMNSGZ5[5X/\#:'X(L'M=(@8-)@S3RMNDE
M(Z9/3\  *B\9?#[0/'-NB:M;N)XAB*YA;;(@],\@CV(- 'C/QHU.#Q9\0_#V
MBZ-)%>31 )NBD#*7D<?+D=P%R?K7OVLZ%IOB#3&TW5+5+FS8JQB8D D'(Z5R
MW@[X2^&?!=^U_91W%S>]$GNW#&,'KM   ^N,UW5 '$_\*B\!_P#0NV__ 'V_
M^->;_&KP'X9\->"X;W1])BM+AKI$,B,Q.T@\<FO?J\D_:'_Y)]!_U^I_)J .
MJ^%/_)+O#_\ U[?^S&NQKCOA3_R2[P__ ->W_LQK8U?Q3I6AW*6]]+*DCKN
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M73'NG5?J/SJ#6OBSJ%[IL<&GV_V&X;_72@[C_P !STH]DWL%COK/_DINI?\
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MEDMQ&4><*<[<'+<]#G QV->P444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7DG[0__)/H/^OU/Y-7K=>2?M#_ /)/H/\ K]3^34 =5\*?^27>'_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN.^%/_)+O#__ %[?^S&NQH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBP^"O"LVM"R-Z8I$3R1)LSN.,YP?Y5X3XSU6W^*_Q:T:PT"62>QB5(S-Y17
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#1R$C R$' &>YKOZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&\NH[&RGNY@YBAC:1
M]BEFP!DX Y)]A7C7CGX[Z7#HL+>$+V.XOS.!(EQ:OM$>ULGD#G.VO:R,C!Z5
MX]XW^!.BZG:O<: (=,O'N#--)-(WE!""2 O1>2/IB@#0TOXX>"WTBS;4=2V7
MQ@0W"I:28$FT;@..F<US'BCXX!_%.C6_A&=;FQ>1!=*UKAG)<#:I89Y'M5BS
M^'OPA@L;>'4-;TV2]2)5G==5"AG ^8@;N!G-;?A[PI\)-+URUNM,O]+GU!)!
M]G5M2$IWYXVKNY.>G'6@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!GW-=)X+^'>F^#GGO!<3ZAJ]T/\ 2;^Z;+OZX]!GZGWH XW3/^3G=4_[!O\
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M+K[;>P36]^0 ;NTDV.0/7J#]2,U%X6^$WA;PI?)J%O;S7=^A)2YO)/,9,^@
M"@^^,UU.O7,UEX=U.ZMWV306DLD;8!PRH2#@^XK@?!NM^*_%?P:;4+:^1_$4
MID6"=T10"LF!D8V] >U 'IU%9/AE-8C\.6*:_*DNJB/_ $ETQ@M[8 'Y5K4
M%%%!('4T %%%% !11UHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q/XET[PEH-Q
MJ^IR%8(1@*HRTC'HJCN36Q7D'[1-K<S^!+.:%&>"WOE>;:.%!5E!/MD@?B*
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MTGPQIOAK3]'LH[6W4SDA>2Q^3EB>2?<T ?06BW3S^'-/N[E]TDEI'+(Y'4E
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M5*<:<)*FM;_S=_4122H+#!QR/2EHHK0\\**** "BBB@ HHHH **** "BBB@
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MW1Z658>GB,1R5%=69;UKXEV^JW&ER+ITL8LKM;@@R [@,\=/>M?_ (7':?\
M0(F_[^C_  KR*@=:Y56GW/II93A9147'1>;/J:UG%S:0W !42HK@'MD9J6J>
MD_\ ('L?^O>/_P!!%7*[T?$R5I-(****"0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \_P#B'_R-/@/_ +#'_LAKT"O/_B'_ ,C3
MX#_[#'_LAKT"@ HHHH *@O+.VU"SEM+R".>WE4K)%(H96'H0:GHH \TF^!/@
M>6]$ZVEU%%U-NERWEG\^?R-=E;>%=&LO#CZ!96GV73G0HT<#LA(/7+ [LGN<
MYK9HH RO#WAO2O"VEKINCVHMK4,7V[BQ)/4DDDFJC^"]"?Q6OB86CQZL!M,\
M<SH&&,890<'CU%=!10!X-X9\*:+XO^)OCZRUJS6XC2X#1L&*O&VX\JPY%>B^
M&/A7X4\*7B7MC8M+>IG9<7,AD9?IV!]P,UU%MI.G65Y<7=K86T%S<G,\T<2J
M\I_VB!D_C5R@"AK&BZ=K^FR:?JMG%=6LGWHY!W]1W!]Q7"P_ KP-%>M.UE<R
MQYRMN]RYC7]<G\2:])HH KV]A9VM@EA;VL,5FB>6L"H @7IC'3%<!J/P.\$W
M]Y]H2SN+/+%GCMIRJ-^!SC\,5Z/10!C>&_"FB>$K%K/1;%+6)VW.02S.?4L<
MDUSWB/X1>$?$VI/J-W9RP7DC;I9;:4IYGU'3\<9KNJ* .2L_AGX2T]-/6UTI
M8C83&>%ED;<9#_$QSENG?-:>H>%-'U3Q!8:[=VQ?4+ 8MY?,8;.O8'!ZGK6U
M10 5Y[K7P6\%ZS>/=FQELYI'WR&TE**Q_P!WD#\ *]"HH P/#/@OP_X/@DCT
M33TMS+CS)"2[OCU8Y./;I6_110!BWOA31]0\267B"YM2^IV2E8)?,8;1SV!P
M>IZT2>%-'E\4Q^)'M2=5CC\I9O,; 7IC;G'Z5M44 4=8TBRU[2;C2]1B,MI<
M+ME0,5R,YZCGM3M)TNTT32K;3+"(Q6EL@CB0L6P/J>35RB@"&[M8KVSGM+A=
MT,\;1R+G&588(_(UB6_@C0+;PE)X7BLV72),[H/-8DY;<?FSGK[UT-% %+2-
M)L]"TJWTS3XC%:6Z[(T+%L#ZGFLR_P#!/A[4_$MKXAN].235+;'ES;B.G3(!
MP<9[UT%% !7 :[\&O!FNWCWCV$EI<2-ND>TE,88_[O3\A7?T4 <YX6\"^'?!
MT<@T;3UADE&))G8O(_U8]O8<5:T_PKH^EZ_?ZW:6QCU"_P ?:)/,8[\>Q.!^
M%;-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<_XT\)67C7PU<:/>,8]^'BF
M"@F*0=&'\CZ@FN@KSSXQ>,[_ ,&>#TGTLA+Z[G$$<I /E#!);!X)XQ^- 'E1
M^%?Q6\/?Z%HNJS-9[LK]CU%HD^NTD8-=1\/_ (+:I9>)8?$GBZ]6XNH7$T4"
MRF1C(.C.Y].#@9^O8\5:^'OC3JUK%J$%UK)AN5$J$ZF(\@\@[2XQ],5L^'/"
MGQAM_$VES:E<:L;&.[B:X#ZJKJ8PPW97S#D8SQ0!]&4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7DG[0__ "3Z#_K]3^35ZW7DG[0__)/H/^OU
M/Y-0!U7PI_Y)=X?_ .O;_P!F-<#\6O\ D<(_^O1/YM7??"G_ ))=X?\ ^O;_
M -F-='=Z+I=_-YUYIUI<2@;=\L*L<>F2*SJ0YXV.[+\7'"UO:25]#YBHKZ6_
MX1C0/^@+I_\ X#)_A1_PC&@?] 73_P#P&3_"L/JS[GN?ZP4OY&8W@SQEIFN6
M%O9*_D7T401H'/+8&,J>_P#.NNKSWQ1\-(+MSJ&@$6=ZIW>4IVHQ']W'W3^E
M9_A_XAWND7?]D>*X9$>,[!<%?F7_ 'AW'^T/UK53<=)GE5,'#$)U<([]X]5Z
M=T>I45'!/#<P)-!*DL3C*NC9!'L:DK8\IJVC"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#S_ .(?_(T^ _\ L,?^R&O0*\_^(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KR/]H?4;JS\ VUM [)'=WBQS$?Q*%9MOY@'\*]<KF?'G@ZV\<>%I](
MG?RI<B2WFQGRY!T/TY(/L30!R/@;X1>#5\)Z;>7>FIJ%U=VJ2R33N2,NH. ,
MX &>.,UYYXW\/67PS^*GAV\\,EXUG=7-F)"Q7Y@I7)YVL"1@^]00V7QE\!Q#
M2-.2^DLU8^4;>)+F/'^R2"5'?!Q]*Z/P)\,/%6K>,X/%OCF60/ XFBBED#22
M..5X'"*#SCVQB@#WNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\D_:'_Y)]!_U^I_)J];KR3]H?_DGT'_7ZG\FH ZKX4_\DN\/_P#7M_[,:[&N
M.^%/_)+O#_\ U[?^S&NQH **** "BBB@ HHHH YWQ/X,TSQ-"3.GDW@&$N8Q
M\P]CZBO.QJ/BGX;3-:W""ZT]LB$N28_JIZJ?;_\ 77LU8/C1%?P;JVY0V+=B
M,C.#ZUE."^):,]+!8R2:H5%S0;V?3T/.3\8-4((_LZTY]V_QK,T+XCW^@V#V
MD-E;R*TKRY<G.6.<<5Q=%<GM9[W/JUEV%47%0T9[SX%\8W7BO[9]IMH8?(V[
M?+)YSGU^E=E7E7P;ZZI]$_K7JM=E)MP39\CF=*%+%2A!62M^04445H< 4444
M %%%% !1110 4444 %%%% !02!U-%<YX[T&;Q)X,U+3;9RET\>Z!@Q7$B\CD
M4 87Q"(_X2GP'R/^0Q_[(:[_ '+ZC\Z^#+B[U!)]D]U<>;"Y&&D)*,.#CG@U
M['^S]I%[JWB.[UN[GGEM;%-B"23<#*WL?09.: /I&BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH S?@;_R2S3_ /KI+_Z$:\[\.I+'^U->+-G?YMP>?0PDC],5ZK\*=!U+PWX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .1^)^N7?ASX=:OJ5@=MRD:QQOW0NP3</<;LCZ5XU
M\-?@[I/C7PV-=U;6;EY)W8>3:LH:,AB#O+ Y)X/0=:^B-4TVTUC2[G3;Z(2V
MMS&8Y$/<$?H:\"OO@1XKT*_FNO"7B "+!V#SG@FQ_=RO!^N10!U'_#.7A'_H
M(:Q_W^C_ /B*\\UK1'^#WQ/T=M#U26[BN&5FMR1YGEEMIC?'!SV.!].*MP^
M?C/-<>4^J:A$A.#(^K$K^C$_I77> O@;-HOB"'7O$NHQWEW;R>;%# 69?,SD
M.S, 3@\XQU[T >U4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D
MG[0__)/H/^OU/Y-7K=>2?M#_ /)/H/\ K]3^34 =5\*?^27>'_\ KV_]F-=C
M7'?"G_DEWA__ *]O_9C78T %%%% !1110 4444 %%%% !1110 4444 %>?\
MCGP*=18ZSHP\K4H_G=$./-QW'^U_.O0**F45)69OA\14P]13IO\ X)P?@7QT
M-7 TK52(M3C^56;CS<?R;VKO*X#QUX%.I,=9T<>5J4?SNB<>;CN/1OYT[P+X
MZ_M;&DZL?*U./Y59^/-QV]F]JB,G%\LCMQ&'IUZ;Q.&6GVH]O^!_7IWM%%%:
MGEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*K95G67)8>@.>E 'UK1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'X.?$?0KS1=0FGMYV#>5(P\PKN"NC8&""#P<?RH ^H:*!R** "BBB@ HHHH
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M(TSQ1HFL ?8=2@D<](RVU_\ ODX-:]:)I['!.$H.TU9A1113("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **@^VVH_Y>8?^^Q1]MM/^?F'
M_OX*+E<LNQ/1427-O(VV.>-F]%<$U+0)IK<****!!115>_O[72[">^OIT@M8
M$+R2N<!0* +%%>5M\<](N)I%TC0-<U.*-B&FM[;Y2/4<Y_,"M[PC\4_#OC"_
M;3K9KBSU%<D6MY'L=@.N,$@_3.?:@#MJ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH R_$6AV?B3P_>Z1?C_ $>ZC*,PZJ>S#W!P1]*\"3X+
M?$.R,VD:=K\:Z-,S;BEW(D;J>#NC'<CJ.?K7J'QM)'PEUD@D','3_KLE8OP;
M\4Z#IWPUL+;4-<T^VN%DE+13W2(XRYQD$YH Y?5/@]XN\&ZA;ZCX!U&65S$L
M<Z"58W+@?,<,=I4GG!)Q4W@WX4>+=5\96_B+QW</_HD@D2*6<3/*RG*C@D*@
M/./PQSFO7_\ A-_"G_0RZ1_X&Q_XU)!XP\,W,\<$'B'2Y9I&")&EW&69CT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^_Z#W_DK-_\ $4?\+L^'W_0>_P#)6;_XB@#T"BO/_P#A=GP^_P"@]_Y*S?\
MQ%'_  NSX??]![_R5F_^(H ] HKS_P#X79\/O^@]_P"2LW_Q%'_"[/A]_P!!
M[_R5F_\ B* /0**\_P#^%V?#[_H/?^2LW_Q%'_"[/A]_T'O_ "5F_P#B* /0
M**\__P"%V?#[_H/?^2LW_P 11_PNSX??]![_ ,E9O_B* /0**\__ .%V?#[_
M *#W_DK-_P#$4?\ "[/A]_T'O_)6;_XB@#T"BO/_ /A=GP^_Z#W_ )*S?_$4
M?\+L^'W_ $'O_)6;_P"(H ] HKS_ /X79\/O^@]_Y*S?_$4?\+L^'W_0>_\
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M (B@#T"BO/\ _A=GP^_Z#W_DK-_\11_PNSX??]![_P E9O\ XB@#T"BO/_\
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M_P! '_R:F_\ BZ/^%)_#[_H _P#DU-_\77H%% 'G_P#PI/X??] '_P FIO\
MXNC_ (4G\/O^@#_Y-3?_ !=>@44 >?\ _"D_A]_T ?\ R:F_^+H_X4G\/O\
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MNO0** /E7PKX/T+4OCA?>';NR\S2HGG"0>:XP%''S Y_6O:O^%)_#[_H _\
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M^%)_#[_H _\ DU-_\77H%% 'G_\ PI/X??\ 0!_\FIO_ (NC_A2?P^_Z /\
MY-3?_%UZ!10!X%\8/AMX3\+>!'U+1]+^S78N8XQ)Y\C_ "G.1AF(K;\!?"?P
M5K7@31M2O]&\Z[N;97ED^TRKN;UP& %:'[0'_),7_P"OR'^M=)\+O^28>'?^
MO-?ZT 9O_"D_A]_T ?\ R:F_^+H_X4G\/O\ H _^34W_ ,77H%% 'G__  I/
MX??] '_R:F_^+H_X4G\/O^@#_P"34W_Q=>@44 >?_P#"D_A]_P! '_R:F_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ9?PC[=>J?LJGI%">X'JW\L>IK&^,=S+XJ^*/A_P;$S-;QM'YR+UW2'+'\$
M/YU[[!#';P1P1*$CC4(J@8  & * )**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O+/&GP/TCQ3J\FK6-]+I5[,V9O+0/&Y[G;D$$]^?PKU.B@#A_
MA_\ ##2? *336\TMWJ$Z[);F4 <9SA5'0=.YZ5W%%% !1110 4444 %%%% !
M1110 5P/A'X86_A/Q?J?B"/4Y;A[[S,PM&%";WW=<\^E=]10 4444 %%%% !
M1110 4444 %<%\1/AG'\09;$SZO/9Q6BL!$B!@S''S<GKQBN]HH \+_X9LL!
MT\277_@.O^->G>!/!\?@?PX-'BO'NU$SR^8Z[3\V.,?A7344 %%%% !1110
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MUP+73=1"W9&1;W"F-V^F>&^@)H ["BBB@ HHHH **** "BBB@ HHHH ****
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M],[GY R/08KB_&_PM\41^,V\7>#=1!NF?S3;S. R/T.W(VE3Z']:]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img238320182_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #0 ><# 2(  A$! Q$!_\0
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M&12N=R[ =Q88(V@9SQC- '04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69
MKGA_3?$6FSV&I6RRQ31F-FP X!]&ZBM.B@#!'@_1EU6+45MW62)TE6-9"(S(
MB>6LA3H6"':#].X%-\=_\D\\2_\ 8*NO_135T%<_X[_Y)YXE_P"P5=?^BFH
MZ"BBLK6;[4-/A-Q;06TL*[0WFRLK9+ < *>.1WH U:*@M#=&$F\2%)<](7+#
M'U(%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%9^J:YI6B+$VIW]O:"7.PS.%SCD
MGZ#N>@[T :%<G\1],@OO NN3S27:O;:9=/&(;N6)2?*)^=48!QP.&!'7U.=P
MZ[I2ZHFF'4+?[:X!6#S!N.06 ^I )QUP">E9_CO_ ))YXE_[!5U_Z*:@#H*R
M_$/_ "!9?]^+_P!&+6I7FOQ"\6:AI>IC2[=8#;O$DA+*2VX-GKGV% 'I5%<Q
MX&\07GB/1)KR]6)9$N6B'EJ0,!5/K_M&M74=8_LUAOL+R5"R()(E0KN=@H'+
M ]2!^- &E14-M.UQ )&@E@)S\DN-P_(D5-0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 45Y]\1=3URUTZ5(K8V]D
M)D"7D5SAVXSC:.0,Y_*N/\'ZWKS^(X1;O-?R;'Q;S7)56XZDGCB@#W&JUUJ-
MC8M&MW>V]NTAP@FE5"Q]!D\T^T>>2SB>ZA$,[*#)&K;@I[C/>N/OM.NYO%6K
M7>C2:1?S-%%!>6.I1LK( N5"R '"L&)P589SSUH ZJ]U;3M.*"^U"UM3("4\
M^94W8ZXR>:;+K.EP6L5U-J5G';R_ZN5YU"/]"3@UYQ8;[[7?!XT>VM[)5T>\
M18+P-<+&JR0KM!# D C@^G:M_P *P%+;Q39WEO:FY@U&0RO;J1"[/!&X**<[
M,*R@C)Y!.>: .HMM:TJ]$AM=3LYQ$NZ0Q3JVP>IP>!4L&H65U:&ZM[NWFMAG
M,T<@9!CKR#BO-+:U,OPE\%P16\#I</8)<+*VQ'7 (#D Y!<)QWZ=ZLZG*GG7
M>EWEE8Q/'JNFF]GLT*17*.X"B0'HP*@%23P4['% 'H2ZC8O8F^6]MVM ,F<2
MJ8P/7=G%-MM5TZ]@DGM;^UGBB_UDD4RLJ=^2#Q7#ZE;1-K/B&Q@O;?3;26XT
MPF7RMR_:2^64J,#+*L Y_O#.>E0ZK<3B2YT.^FBNK2UU73O,N!&L>])) ?*E
M"X4D%5/0 AU!'7(!Z';75O>P+/:SQ3PM]V2)PRG\13)-0LHKR.SDN[=+J092
M%I '8>RYR:PM#1(?&GB2*U2-+79:NZQ@ ?:"K[\X[[!#^E<I 9K&UUS6+_3M
M+NHO[?D$R7 )N'VSB.$J3PK*OE[5P<\$$;J /4:*YSQG)=II^G1V=[-9O/J=
MM"\L.-VQG 8#/'(R*Y&]NM2TRQUV]CUC4)/[(URUM;:.2;<IBD:V+J^1E\B9
MA\V<8&,4 >HU"]U;QS"%YXEE.T!&< G=G''OM;'T/I7G%S?ZA-86NLMK5W;W
M4GB9+%K5)0(_*6\\KRMGJ4&XGJ>>W%+X@FOY576=-MXKJ\FU](+..5O+4K"D
MD>"WIY@E;/<-QZT >F45Y[IE]-K%SH%@=7OO)O+6ZN[J0/Y4K7,;QJ8>/N!"
M[_(/[HSGG.W\/[NXO?"$,UU?R7\HNKN/[5(06D5;B15/''W0.G% '027MK$X
M22YA1VD$05I "7(R%^I'.*D,T0G6 R()F4N(]PW%00"<>@)'YBO)]8TZ+Q#X
M2\)K>/*DFJ>(#/-+&Y617:.X*E6'(*84#V45H:?JU]=^.(K"_P!ZZYINB7L,
MY@1<RGS+<QS1AOEPXY / ;*GH: /2Z8LL;2O$LBF1 "R \J#TR.V<&N:T6;5
MWU.,7;ZX8<'(N[>U2/IW,9W5C6FG?V+>^-X["6YDN38Q2^=)(9)7E,<GS9/?
M@8 P!@   8H [F&_L[AIEANX)6@.)@D@8QG_ &L'C\:G5E= Z,&5AD$'((KA
MM+@L;?4O!?\ 9<=N@DTV4-Y(&'M_+C.>.HWE,$_WCZUL^#V*:??6(.8;&_GM
MH..!&&RJCV4-L_X#0!T-%%% !1110 5RGCV"XO\ 0+G3(-*OKLWEK-$L]FT8
M:)RHVJVXCY7Z$], @\&NKHH \O@\-ZXFN0PSZ>,R:Q::D]U$5$,<<=JL;J.<
M@[U*@8Z,#TS6SXZM?$C>#_$K#5=*^Q&PNB(?[,D\SR_+;Y?,\_&['&[;C/.W
MM7;US_CO_DGGB7_L%77_ **:@"[%XATJ:<01W8:4D#;L;OT[5P7CK2[?6/&,
M$4;2;H;96NRI&%4N%4#CK\WY8KN8I8[?7=6FE8+'';0.S'L!YA)KEM)BDN_#
M^J>(+A2)M4NHW0'JL2R*$'\_TH ETA?^$"U4Z3<L6T>^EWVUVW5)" "CGIR
M.?\ Z^.GU_\ Y!T7_7[:?^E$=6-4TRUUC3I;&\C#PRC!]0>Q'H17G5WXHD\.
M1/X=UD37,EG<V\D%S& 2\*R))ALD<[5Q]?S(!ZC16;H6MVWB'3%O[1)4B9BN
MV4 -D?0FM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/-B==RDKDX8$,IQUV@\9Q6=K&IZ_I,Z7DDUIY,NI0VEMIZQ$O-&[JI;?G.\
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M%4*J+DDD#!))ZECTZ5EQ:%KB>*+G6)Y]/NB7*6HE\P?98/[J*.-QZENISCH
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M=% &%/X.T2:SNK;[*R+<P26[E96SL=2K8R?0FJ]IH>H+JFGWVJ7EHT6EP/'
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M!3ZX?P9XNTG^Q+'3;NZ-M=QQ!<7(VA_0JQX(KMP00"#D'H10 M%%% !1110
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MNY,D%"0!D9(XSC)).U14F9R2^"Y+*YTJXTK5#!+I]M-;[KBW$OF^:ZNS$ J
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MT =;17.V/CGP_>OY9OA:S9P8KI3$0?0D\?K701R)+&'C=71N0RG(- #J***
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M!+#WP /TKQ;Q9X0U&T\3/'8Z>[6UU+FV\A,KR,[>.F,'\!GI7I__  G?@_\
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MGSL8QQM[YXT** "J=EIL-C=:C<1-(7O[@7$H8C 811Q87CIMC4\YY)^@N44
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I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img238320182_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &E DT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*I9B H&23VH 6BJ7]
ML:7_ -!*S_[_ *_XU<5E= Z,&5AD$'((H 6BBB@ HHHH **** "BBB@ HHHH
M *YCQ[XL?P9X<758[1;IC<1P^6S[!\QQG.#73UP_Q6\/ZIXE\'+8:1:_:;D7
MD,NSS%3Y5/)RQ HZKU7YC[^C_(OZ+XNDU7QSKWAUK-8TTM(76829,F]<\C'&
M/K74UY6MEXO\._$OQ'K6G^$WU:RU)($B==0AAQL0 \,<]<CH.E=3=Z5KGBC2
M["YFO]1\+W:[_.M+6:*;^+ W/@@\#/']ZA?"OQ%U9BZE\2[]?$%_I^A^&VU2
MWTV98+J47:Q.TAZK$A&7([_Y->AQOYD2/M9=R@[6&"/8^]>":_\ #'68]8\1
M16_AM-7DU:99K'5C>+&;-B<L64D'.>>.OZ5[GIL$]KI=I;W,WG3Q0HDDI_C8
M* 6_$\T1^'7?^OZ_S!_$6J*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBH;B\MK3;]IN88=WW?,<+GZ9H FHJM!J%E<R>7!>6\KXSMCE5C^0-6: "BBB
M@ HHHH **** "BBB@ K%\6ZZWAGPIJ.M);BX:TB\P1%MH;D#&<''6MJN:^(&
ME7NM^ M8TS3H?.O+B#9%'N"[CD<98@#\34SORNQ4;<RN<S/\1]=N==TS2-%\
M.VUY<WNE1ZDPEO/*"!NJY*\XXK?\$>,W\6)J=O=Z:VG:CIEQ]GNH/.$JAN>5
M8 9Z&N*C^&=YJWB_1)=:L9ETRUT"&UEDANQ&RW"]5^1MQ[\CCWKN(? NGZ7X
M=ETCPY//H@ED$KW-LV^5F[Y9\YS[UH[*_P _S_R(5W;Y?E_F4_B#\1K+P-8D
M?9I;W4FC\V.V12 $W8+N^"%7/'UQ4OB7QO)HFGZ(+/3#?:KK+JEK:><(UR5!
M)+D< 9':JGC+PMJE[\++_0K2>;5]4DC55FN&1))OWH;DG"\#/Y54\7^'-:=?
M"&LZ78B]O-"<&:R\U4:1610VUCQD;:E>?=?<4_+L_OZ'0>"_%O\ PE=E>^?8
MM8:A87+6MW:F02!'7T8 9!KIJX?X<:!JFEIKFJ:S;+:7FL:@]W]E$@<PI_""
MPX)Y/2NXIOIZ+\M25U^84444AA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3)8HYX7BE17C=2K*PR&!X(-/I"< D]!0P/!?$]IH%CKVLP
MI:^$-&32PI@LK[3@\E_E V0<C@D[1M!/'->V:))YV@Z=*+06F^UB;[,!CR<J
M/D_#I^%>,ZAXJTL>*];U/3_&NCQ1F562WO\ 3VG965!DQ$L,9/ICFO9]*NVO
M-#L;UB9&FMHY21'L+$J#]TGCKTSQ1%^Y]P2^(O45Q$'Q,LVU<Z=>Z!KNG.MM
M)=227=O&J1Q("2[;7) XP..35[PQXZL/%%X]G'8WUC<"W2[B2\C53- QPLB[
M6/'UP>:%K_7]=F#T.IHI-R[MN1NQG&><4M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RGQ!L].;PK>:G>
M:'::M-80M)!%<P^8%)QD^N.YQV%=77(_$K4]/T[P3?QW^I'3_M*&*&=58L'Z
MC&T@YXSC(Z5,MBH_$CB_A\=,L_&EM;6$GAG56N;225[K1[(0O9XV_*Q!.5;.
M.<'(KV*O*O /B)7\16^E0^)M&U59H'=TT[33$V5 ^:1]V._IS7=^)/$MIX9L
MX)KB&XN)KF9;>VMK90TDTAZ 9('8G)(K26R_KJ9QUO\ UT-JBL[1-6&M:8E[
M]AO+(LQ5H+R+RY%(.#QT(]""0:T%96&5((R1P>XZU)0M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 45PVK^-=9@\37VD:7H^G2+9K&7EOM2%N9-ZYRJ[22!TSZ@
MUV%A/-/IMO<7211S/$KR+%)O121R W&1[T+:X=;'D'B+2)X?'.K276D:Y<QW
MDR-:-8:M':*P"*" F]2QR#R>3^'/KVFH8]+M$:.6,K"@*3/O=?E'#-W/J>]>
M.>*;&UO+O5]96#PWK&GZO,MM;:K?7FPV,@79L4[3P&!8%2.]>PZ7;O8:+9VT
M]P9Y+>W2.2<_\M"J@%OQQFB.D-?+\@E\1S,?@VYNE\7MJ4\)N-<+00RQ$MY5
MN(]L:G(&""6) XYZUF^%O NIQ:F;OQ.NF31PZ3'I$5O;EI$EC5LEWW*.3@<<
MU%H_Q9BU:6[N!I]NNEP03W'F)J,;7"I%GEX.&4-CC&>V>N:T/#GQ#.I7<EOK
MFG1:/G3TU.&0W0D1K=CC+':NUAQD<]:([Z=OT?Z7"7GW_5?\ ETK0]*T;XES
MKIFG6MFKZ.I801! 3YS>GT'Y5VE<5I6N:5K/Q,G;3-1MKQ4T=0Q@D#@'SF]/
MJ/S%=K0 4444 %%%% !1110 4444 %%%% !17%>,?'Y\):I!9G2_M2RPB42?
M:-F#N(QC:?0<^]9>C_%=]7UFSTY-"V&YF6/?]KSM!/)QL&<#)Q5JG)JX['I-
M%%%0(**** "BBB@ HHHH **** "BBB@ HHK/UW4SHN@W^IBW>Y-I \WDH<%]
MHSC-)NRNQI7=D:%<]XYL+K5/!&K65E&\EU+ 5B1-NYCZ#=P/KVK.\-^*-?UF
M_MUO-,T>"SF0OOMM5$\@XR/E"C/YU>\<B"Y\+W6EOJD&GW.I#[+;/*^W?(QX
M3CGGH<=B:)IVL$&KIG)?#VU5=<\R/2=>M]D3))-=ZTEU$K<<%5<\^AQ6_P#$
M/P?-XML-.^S+:RSV%VMP+>[++%.N"&1BH)&0?0USG@K2/+\>$IINA:%-IEJT
M-W9Z;=>9)<%]I5G7:,*.H)R<GK7JM5+5)_UN3'2_]=#B/"W@"UL_#<>G^(;'
M3[YTN99X8-GFQ6BN0?+C+C.T8'85>^'L$5KX2^SV\:10Q:A?I'&@PJJ+N8
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M0%B<*/0<5Y(/B+J]WXNU*^%S?0+)HUTUEIIMY56%TY1G!7:SD DMT&0N:V_
M.I:C%KZVMCJ5SK$=SX?@U"5+R]9U6Z9L$;SNV9!/&.W2B.MOZ[_Y/[PEI?\
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M/-Y^F(T @;)\];@KD/T  ;VQ7N5%%"TBH]@>LFPHHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT#2P2'SKT::6B#JZJWSXY*LZY(X&>:(_&@?PG:^+-?7PUX?EU#[*UW(72&*
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M/0$,O&:O?#AE?X>:*R3&93;\2'&3\Q]*IJPD[G44444AA1110 4444 %%%%
M!1110 45@>)O%^G^%!:F_ANG%SO"F!%8#;C.<D>O\ZQK+XJ:%?ZA:V4-OJ'F
MW$R0H6C0 %B "?FZ<U2A)JZ06.XHHHJ0"BBL[7RR^'-4*.R.+24JZ'!4[#R#
MV-" T:*^8QXAUL# UC4 /^OE_P#&O=/AW/-<^!=-FGE>65O-W/(Q9C^]<<DU
MK.GRJXVK'44445D(**** "N&O?A9HVI:E=WUU>7YEN9FE(1U 7<<XY4]*[FO
M(=<^*&OZ7K^H6$5MIK1V]P\:%HW)*@\9^<<XQ3Y^17O8Z\)@ZN*DXTNAVGA[
MP!I7AG4S?V,]ZTIC,965U*X)![*#V'>M36=!76+BPN!?W=E<6,C20RVWEDY9
M2IR)$8$8)[5QO@;Q]K'B;Q"UA>P6*0K TI,*.&R"!W8^M=!XO\0W>AW&D06T
MMO"+V9XY)I[62XV!4+#"(RDY(QUI.7-K<G$X:IAJGLZF]BP_A*VN1=F_OKV]
MDN[/['+)-Y:G8&9@1L10&!;@X["HG\$:=]CTV&"YNK>;3XWCBN4\MY'#X+[P
MZ,K%B Q.WKTQ638>.Y9(+2:Z-GY!OY[:XN$1T'EQPM)O",=R'Y>C9XY[BM7_
M (3C38XFDO+:^L@8/M$*SPC=.FY5!0*3SEE&TX/S#BC^OU_S.;^OT_0OZ+X=
MM-#FN);>:YE>=(T<SN&)V @'IU.3G],5KUSC>,[*+S(9[*_AOU>.-;%XU\V0
MR9V;<,5(.UN=W&TYQ4_AK7)]<CU)Y[5K8VUZ]LL;KM<!54_-R1G+'H<=,4;O
M^O+_ ##8W**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^</$<?F>)-7OH]
M1T6+RM5> :)+-<B6?=(N6,*R#=N(5CC ;:#[5]'UXE?VEQ'XPU"ZU:V\1RW*
MWKFWN+75X;>-8<_( F\$ #\_QQ2C\:_KJ@?P/^NYZ7X-U^Z\1^&_M]S';K.L
MTL)>#=Y4NQRN]-W.TX[UY_H%UX]UC5M*O;F2Y>UANHXI OD-!*-SM-(2N?E"
M[50CG]:]@5%2,(BJJ@8"@8 KS[1?AO/:^)DUZZU&"QF5]YLM$A-M!)STDR29
M >_ IKXK_P!?TP?PM'H9&017*)X#L[;PU9:+8ZIJEF+*9IX+J&91*&+,Q!^7
M:P^8\%:ZNB@#!TO03X7\/-8Z(JW$_F-*SWTQ!E=VR[.RJ>3ST6J_P\\S_A7^
MC><%$GD?-L.1G)Z9K5UQ;9])F6[@NYX<KNCM-_F'D8QL(;\JQOAL$'PYT,1Q
MO&@MQA),[E&3P<T =51110 4444 %</J'Q4T/3=1N;&>TU$RV\K1.5C3!*G!
M(R_3BNXKYK\7_P#(XZQ_U^2_^A&M:4%)ZC2/<_#'C'3_ !9]J^P0W4?V;9O\
M]5&=V<8PQ_NFNAKRCX+?\QS_ +8?^U*]7J:B4960,****@1Y;\9_^/31_P#K
MI+_):\X\+_\ (VZ-_P!?T'_HQ:]'^,__ !Z:/_UTE_DM><>%_P#D;=&_Z_H/
M_1BUUT_X92V/IFBBBN0D*SO$'_(MZI_UYR_^@&M&L[Q!_P BWJG_ %YR_P#H
M!IK<#YBKZ"^&O_)/],_[:_\ HUZ^?:^@OAK_ ,D_TS_MK_Z->NFO\)4CK***
M*Y20HHHH *X"_P#A5I^IZK>W]SJ5YON9VEVQA5"@\XY!SCUKOZ*#>AB:M!MT
MG:YQ_AKX>V/AC6#J%K>W,K&(Q%)=N.2#G@#TK:UG04UBXL+@7]W97%C(TD,M
MMY9.64J01(C C!/:M:B@5:O4K2YZCNSF/^$&TR0E[RXN[R62=YYY9F3,Y:$P
MD,%4  (< *!TI&\#6$\1COK_ %"]VV_V>!IY$#6Z;E8;"BKSE$.YLGY1S744
M4&)S3^#+69Y+BXU'4)]09XG2^=HQ+$8]VP*%0)CYWX*G.XYS6EHNBQZ)#<HE
MW<W3W-PUS++<E2Q<@ _=50!\HXQ6G10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\\ZSX<&H>)-0FTG1[^_<ZE/'/?_ -DK($S(K':QE!+HRLH.,%3C
M%>W^*KNUL/"FJW=ZL[6L5J[R+ Y20@#HK#D'W[5YI=^'=-\/>'M-\03Z3JD<
M=S-&^H)%KTQ, <@*W7$AR5STHC\:?;]7_P  )?#;^M/^'/1O%\AB\,7DOV/4
M+Q44,\&GS&*9U!Y"L"#TZX.2.E>>:!I?A[7#8W5I\-[V"VNBI74TO4#(I_C+
MK+OX_.O5[Z9H+*:1)8(I A\M[@XC#=MW(XSBN#\"W?B1=;U>/6M2TI[1[U_)
MCC=]QRJX\G+D"/.>,9SFB/Q,);([&\O+?PWH1GG-Y<16R*@VJT\TA)  XY9B
M2!G\ZY>'XD?:O"NC:K;:-+)>ZO=-:VM@9PIW*6!+.1@#"$].^*[HC((]:X-?
MAS-;>&-%T^SU@1ZAH]V]W;7;VVY"69B5:/=TP^/O=J6O7R_X(=-/ZTT_$U--
M\56_B+PM#?V]]%H]Q,S)BZ*.8W1]KK@D!N01GW!I?AR2?AYHA,RS'[/_ *Q0
M &Y//%1Z7X2@\.^%8;%;&#6[N%WD+3HB>8\C[G(SD*.>GL*D^' (^'FB PK"
M?L_^K4@A>3QQ5,2.HHHHI#"BBB@ KYK\7_\ (XZQ_P!?DO\ Z$:^E*^:_%__
M "..L?\ 7Y+_ .A&MZ&['$[WX+?\QS_MA_[4KU>O*/@M_P QS_MA_P"U*]7J
M*OQL'N%%%%9B/+?C/_QZ:/\ ]=)?Y+7G'A?_ )&W1O\ K^@_]&+7H_QG_P"/
M31_^NDO\EKSCPO\ \C;HW_7]!_Z,6NNG_#*6Q],T445R$A6=X@_Y%O5/^O.7
M_P! -:-9WB#_ )%O5/\ KSE_] --;@?,5?07PU_Y)_IG_;7_ -&O7S[7T%\-
M?^2?Z9_VU_\ 1KUTU_A*D=91117*2%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!3U62RBTB[?44#V0A;SU,9DRF.1M
M)/'8"O)K&[^%%O?P.NHZM/';3J(+2Y2^D@ADS\H",N >1@&O7KV>2UL9YX;:
M2ZDC0LL$9 :0C^$9(&3[UX3?:D9/$%QH,O\ ;EG;:C=_:+C1C=V&YI'8,0&+
M^8H)YVCGTHC\:02^ ]2^(\=C-X'ODU'2KS5+8E,VMD3YK'<,$8YX//X5X]X'
MTQH?&6F2P:3]@LQ<(5AO-':>93GKYXMX]GU+'%>U^-\#PK<L+G4;:1&1HYM.
MA,LR.&&TA!]X9ZCN,UYMX6U_6?$GB6T/BQM?B:WN4%I;6FF206DI&,2RL1D\
M\X; %%/X_P"OZN$_A/:J**R/$?B.S\,:='>7D5S,)9D@CBMH_,D=VZ +GGI0
M!-KCVR:3,UW<W5M""NZ6UW^8O(QC8"?TK&^&Q1OASH9CD>1#;#:[YW,,GDYK
M4MM1N]9T(7FG6\MA<2'Y(]4MF4K@X.Y P/(Z<^E9WP[\W_A7^B^=L\S[/\VS
M.,Y/3- '3T444 %%%% !7S7XO_Y''6/^OR7_ -"-?2E?-?B__D<=8_Z_)?\
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M **** "BBB@ HHHH JZEJ-MI&F7.HWCE+:VC:65@I;"@9)P.37F3>$I-;O\
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M TB(%<WI:)?+Y'>0%>>G([UD?#DAOA[HI6;SAY'^LX^;YCZ<4V[@D=11112
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MW2[L=,XD]S5O_A#=)_YZZO\ ^#F\_P#CM)*R2,,=B5B:\JJ5KV_!6.-^,_\
MQZ:/_P!=)?Y+7G'A?_D;=&_Z_H/_ $8M>WWOPZ\-:D$%]!J%R$R5$VJW3[<]
M<9DJM%\*?!T$R2Q:;<I(C!D==2N05(Y!!\SK6\:J4;'*F8?QF_Y!^D_]=I/_
M $$5YGH'_(RZ3_U^P_\ H8KU^Q^'.FZA92KXBAU"ZE6]N6@$VK7+[83*WE8Q
M)@?N]GOZ\YJS'\*?!L4J2QZ;<I(C!E9=2N05(Z$?O*Y90O-2['N83-H4,,J+
MBV]?Q.SK.\0?\BWJG_7G+_Z :H?\(;I/_/75_P#P<WG_ ,=ILG@G1I8WCD?5
M71P596UB[((/4'][6B/"/G.O>O EU]A^%UK=F-I/(BN)=B]6VR.<#\J/^%4>
M"_\ H%3?^!]Q_P#'*B?X?6,&K:=:V2:E%H@M[D7,*:O<A-Y,>P;?-SWEZ<>O
M:MIU%)6*35U<S5^,FFE 6TF\#$<@.I%=KX:UQ/$>APZHENT"2LP",P8_*Q'7
M\*P/^%2^"O\ H%S_ /@QN?\ XY5^U\!:#8VZV]JNIP0KG;''J]VJC)R>!+6"
MOU.S$U<)*%J,'%WZN^ATU%,AB6"&.)"Q5%"@NY8X QR3DD^YYI],X0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.L/
MJ4>FRMI-M;W-YP%BN)3&A&><L 2.,]J\OT/P7XVMM4TFWU!H#X?L+M;B*R6_
M#"'!R,'R0SA<Y +=A7KU%"T=P>JL%%%% '/>.M3O]'\#ZQJ&EKF]@MV>,A=V
MWU;'? R?PKC[/4],\.B#4K7QCJ6KW#:9-=OITMT;E;G8FXL.HBP?IGICBO4"
M 001D'J#5"QT'1],EEEL-)L+2288E:"V2,O_ +Q Y_&E9ZV_K<>FE_ZV//1\
M1M<M+5I+R'2;E[C1)=6MOL>_$.P [)<L<@YQN&.01BLWQ%X]\6P:'J41;3;:
MY;1H=4@GM4?=$CR!"AW$@MS][ ^E>G6OA?0+&.ZCM-$TZ!+M2MPL=JBB4'J&
M '(]C4TVA:1<*RS:792!K<6K;H%.80<B/I]W/\/2F_Z_'_@?<):?UZ?\'[SA
M[CQIXEL]7U&U^SZ7/;:1ID5]>.JR!YLHQ*Q\D#)7J>GO69?>/->?1;J"[?3_
M #+[0)M2M9],9U>U*KP')8YZ\,,<@\5Z;9Z-I>G9^Q:=:6Y,2PDQ0JI*+]U3
M@<@9.![U!:>&- L8[J.TT33H$NU*W"QVJ*)0>H8 <CV-*2O=>OZ_\#[O,(Z6
M\K?I_P '[_(?X=EDN/#.E33.TDLEG"SNQR6)0$DGUJGXVU&[TCP1K6H6!Q=V
M]H[Q-C.T@=<>W7\*VXHHX(4BAC6.)%"HB# 4#@ #L*5T26-HY%5T8$,K#((/
M8BG4]Z]NH4_=M?H>;^ -8FAUW5-.N-<FU"PCM+.>.XO+@.4FE4[D#>YP0O:L
M@:WJ4/Q*-Q>ZE=RZ;-K/V"W@L]50K&0H $EOM)(R"3\PQGIZ^F6WAG0;.T-I
M;:+IT5L91,8DMD"F0'(;&,9'8]JD70-'75SJZZ59#4B,&[$"^:>,?>QGIQ3O
M[RE_7]=!6]UK^MOZ9HT444AA5'6B1HEZ1J T[$+'[80#Y Q]_!XXZ\U>J&[M
M+:_M9+6\MXKBWD&V2*9 Z./0@\&DU=6&G9G!?#2[N+ZZU2XBUJ\U#1F$8LQ?
MSB2=B 0\N.J(QQ@'TS@5Z'6=IGA_1=%>1]*TBPL&D #M:VR1%@.F=H&:T:IL
ME(****0PKQ?5O%.K1?$;47NKO4(=/T_4;6U2.VNT10C@=8""9=Q/)R,#I7M%
M9\^@Z/=:I%J=QI=E+?P\1W+P*TB8Z88C(H6DDP?PM&A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% %35;X:9I%[?F/S!;0/-LSC=M4G&>W2N.TGXB7=
MQ)HCZOX?;3K+6@!9W27BS*6*[E5QM4KD?6NPU:Q_M/1[W3_,\K[5 \._;NV[
ME(SCC/6N*L/AM>&+1[36_$(U#3](3%K;0V0M_F"; SMO8G )].:2O=_+];_H
M-[??_P  W+;Q_P"%KN:6.'5XLQQO*7='1'1/OLCL K@8YVDTL/C[PS/875Z-
M3V06JHTIF@DC8!N%(5E!;/; .:YZT^&5TD.GVEYKL<]CI4$T.GQBQ4,OF*5S
M*69EDP#C&T ]ZHP?!Z0:7>6<NNB,2F%X(K6!T@CDC;<)#&TK<GH0I4>E/^OZ
M_K_@+^OZ_K_@^A:1KVF:[927>G70EAC<QR;D9&C8=0RL RGV(KGK;XEZ ;"*
M\OYFLTN!+-;)Y;RM+ CE?-PBG .,X[#FK?A?PD= TW4(+FZ2YN+^0R3211&-
M1E=H W,S' [EB:YSP_\ #^\%A:+?W'V::RTRYT8)Y0<2([_+,"&Z;<?+CUY%
M#\NWZ?YV7S!>??\ K\+OY'20_$+PI<174L>L1>7:P"YE=HW4>63@,I(^89X^
M7//'6H9_B'H;:7?W6FRM>W%HL6ZU,;PN6D;;&IWJ",GV]ZYO7OAE+_8 %O<R
MWL]IHD6FQ0PQK&TCQRK() 6;'5?NGKZU#X:\)Z]K/BF\UO7FG@A,UI+LGMDB
M:X,*OQL21MBAF4Y).=OY-6;M_5KB>D;]?^&.IT/X@:7JL\UK<E;2\2ZN(%@W
M&0E(3AI"0ORK[G ]Z4?$30;R&5=(N?M]Z+>2X@MO+DB\]4&259EP1Z'H:Q+;
MX5QZ=?7^HVFI,;F^DNC>((MHN89N1%][Y2IZ/]>*Y[0-#\6P:C8W-QIUX\>C
M:1<6D$4\4,6YF 6-%*R-O/'+':,#I4:\OG;\;/\ 6W]6*LK^5_PO_7]7MZYI
M.IVVLZ1::G:,6M[J)98R>N",\^]7*Q?"6C/X>\):7I,CAY;6W5)&'0MU;'MD
MFMJM)64G8F-[*X4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img238320182_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img238320182_17.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H Z+PA_R'-._Z_K7_P!'QUE4^"7^%_DQ,YVM1A0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4D[)WOSJRUWY;7'8\_\ %.K:3K>AZ<(KEEOM.MDMS:F%_F/[M6?SO]6%4(2
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MXRMQA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<XP.])M1U;27GH!4I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M2O:V$-D]I#;%S+;M'<*Q==SI>@O%=B1?E**<KNW.^XK'6<)OVB3DW=O9Z?\
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MO744% !0 4 % !0 4 % !0 4 % 'T]XQ\6:7X1UJZNDBNIM5FM$B +1BT"L
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 'TW_P 11]:AVE^'^8<P?\*@UKUA_P"^F_\ B*/K4.TOP_S#F#_A4&M>L/\
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M-:]8?^^F_P#B*/K4.TOP_P PY@_X5!K7K#_WTW_Q%'UJ':7X?YAS"'X0ZRN
M6@&3@?,W7K_<H^M0[2_#_,+B_P#"H-:]8?\ OIO_ (BCZU#M+\/\PY@_X5!K
M7K#_ -]-_P#$4?6H=I?A_F','_"H-:]8?^^F_P#B*/K4.TOP_P PY@_X5!K7
MK#_WTW_Q%'UJ':7X?YAS!_PJ#6O6'_OIO_B*/K4.TOP_S#F#_A4&M>L/_?3?
M_$4?6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\
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M_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\ $4?6H=I?A_F','_"H-:]8?\
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M_$4?6H=I?A_F','_  J#6O6'_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\
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M_OIO_B*/K4.TOP_S#F#_ (5!K7K#_P!]-_\ $4?6H=I?A_F','_"H-:]8?\
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M-=.J]17/HRP_X]XO^N:?^@BO+(+= !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!YW\+_^0,W_ &$=5_\ 3E=4 >B4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % %>;[R?[_\ [*U(98IB"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H KV_1O]]OYTD,L4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MI::E-;_896EN(7@\T3;&MYY(&'F*J*V3&3\HP,X!8#<0#JZ "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * /S$\0?\A6__P"O^\_]*9:]2E\"^?YL
MU6QDUN4% !0 4 % !0 4 % !0 4 % !0 4 % !0!]+?"#XO_ -F^7H&OR?Z+
MPEK=.?\ 4]EAF8_\L>T<A_U/W6_=8,7'5I7]Z&_5$-=4?776N S()OO)_O\
M_LK4AEBF(* "@ H * "@ H * "@ H * "@ H * "@ H * "@"O;]&_WV_G20
MRQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %>?^#_?']:3&6*8@H X
M+Q9\.M&\56MW&]I917U[$Z"^:SADGC=DV++O(61F0 ;?WBG  ## H +OP/'#
M]BGT.2/2[O2T>&$I;JUL\,Q1IX9K5'@W)(Z"4&.6)TE_>!S\P8 H0Z#K=EKT
M.MWDEOJR/ UDRPQ&S-BCR(YGMXI;FX699&5?M8>83A41K<N ;=@#4\;>%KSQ
M7%!:V]W%;6L<GF7-O-:O<1787:8XI?+NK5Q"K M)&'*S':K_ "*R. )J/A>^
MUFRCAO;NW6]LKJ.[LKBULWACADA4J@>WEN[@RJ5:1) LT6Z*0HNQAO( VV\*
MW\<M[J<U]&VL7ELMK#<QVFRWM(H][((K5[B9G;S9'FD,MRXD?8H"1KL(!%X.
M\*:EX4A6T:[LKBWS)).RV$\=U<W$G+W,]P^I3AYI)/GE8P_,/D3RT"!0"GX;
M\'ZUH%S+=RZA97DM[.LMY/)ILRW,R*<+"LHU0QPQQ1YCMU6!HXLES&[,Y< ]
M,H * .<_X1__ (GO]O>;_P N'V+R=G_3?S_,\S=_P'9L_P!K=VH 35O#_P#:
MFHZ;J7F^7_94MQ+Y>S=YOGVLMMMW;E\O;YN_.U]VW;@9W  YK4_AZ-234P;G
M8VJWEI>QYA#I#)9I;"-)$:3%Q&SVP:128MR,4!! >@"Q8^$=3M[V^U:;48VO
MK^UM[=&BLA'#;FV>9D*Q/<3/)&_F_O8WF,A)D,<\0>)8 #*'PQ$\6HM<W,<=
M[JEQ;72RV-JMK#;W%F_FPSK;22W7FS/.6DNI)96-PI5,)M#D [K2K75(79]4
MNH+G("HEM:M:QKSDLPDN;N1W/0$2H@7_ )9EOFH QO''AJ^\66$FEVUU!96]
MRFR8R6DEQ(<.K*8V6\MU3&W!#1RYSP5H Z?3H[N* +?R0SW )W/!"]O&1D[<
M1//<LI P"3,V3D@*#@ ')0^!+=M*U+1;R5IH-7N;^X=D41O&+V5Y=J$F0%X2
MPVNPVLR@M'C*T 6+;3M>M+=_ME[%J#Q6SI%'!:_8I)Y=F%:>9[FY =B.&A2W
M179F*E0J* >2> -%D\/MIBZ3%>"\=(8M52YT:"QAC@$!,^+P:=:2S2I<",1X
MO;PS$,["5<S( =I>?#:[GM9M)AU%8-+EO_MZ0BS#3*QNUO6@>=KC:]OYP9D"
M00SJ?+#3NB21S &IK?P^36SJ_F7&P:W%9H!Y*L('LM[1LP9RL\;N5,D16,,@
M:/=\^Y0"Q9>$+MM2GU;5KR.ZDNK#[ 8X+7[-&D?F-)N0/<7+Y.]MPD>3+'(*
MJ @ *%OX#O(=-T^R:^C-UH4D3:?<K:%5$<4!MO*NH3=/]H$D+.DC126K9*LF
MQE)8 EN? <VIV^J'4;M9;_6K/["9HK<Q06\"I(L:Q6[3RNV'FDED,ERS.[84
MQH%4 %CQYI9?PK=6:)-<SPVJ_9A;QEYOM4.TVTD<:[FRLZQN<?=4,2< F@#<
M\(Z(WAW2;:PD;?/''NN)./WES*3+<R<?\])WD?V!QGB@##O/!ESJFJVNHWUU
M#+'IUS)<6VRR6.] <2 6SW@G*M;+YFTQI:Q/*D<7G22.'DD ,:_^&UW<VMSI
M4&HK!IEU>F^$/V,/.CO<)=/"T[7 1K<SAW54@BF7**9V1660 VKOPGJ4>JWF
MLZ3J$=I+J$-O \4UF+F)1;B79(NVXMY/.4RML/F>2%9Q)#*QC>( 73? 4.DR
MZ2UM,_E:'#=Q!74,\YNUCWR,X90C!T9R!&0Q? V <@%:[^'_ -JTG5=(^T[?
M[9O)KOS?)SY/G/$^S9YH\S;Y>-VY,YSM&,$ UI_#%P-3O-7L[K[//>VEM;1Y
M@$BQ-;23R!V#2#S4D\[8\8\IP@;9,CLKH 9>D>"[W13?7=K=V\.H:E/#.[0V
M CLAY0PP-G]I>1WGW2//,+Q)7<H0RB/:X!1T_P"&BV-M%"+B-'CUB/5W$%J(
M+;=&H06]O;"9_L\955)8RS,9-\ASO"J 6;GP+>A+ZQL+];73=6FFFN8FM/-N
M4-T?]+6UN?M"1Q"8%RAFM;DQ.[,"PVHH!O6/A2+3M674X'VQ1:;#IL=OM^ZD
M,KR*_F%\GY6";2G;=O.<  L>$_#_ /PB^G)IOF_:-DMU+YFSR\_:;J:YV[=S
MXV>=LSN^;;NPN=H .DH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ%U*L"HVG !>\->*]*\7VOV[1;A+N ,49E#*RL.=KQR*DB'!! =1D$$9!!H
MZ&@ H * "@ H * "@#SWXC6E[K%A%H6GJP;5;A()YS$\L5O;(#/.\VUD&R5(
MOLX1I(S(9MB,&(( ,.#3M:\/>)TU&<)J$&JV;VUP+"SDMECFL@9K1I?-O+E
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M;QS2Q@QNI:&.0!AM/S$ @&K=^(+"RTUM:FF5=/6 7)F 9E\DJ'5PJJ7;<I!
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M9XH0Y R0ID90Q Y(&2!0!=L[R#4(4N;22.>"4;DEB=7C=?574E6'N"10!9H
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M)J=KXIFO=-E@:Y@CBB;3XX5:949;61X#YC?NRSCS<MU4'#@';^$O^2E>)/\
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MYFBGM4C?<5+C:LCC:&"G=EE) ( ."T'Q#KB:9H&NWM^UW_;%Q:VUS;&WMHX
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MF(>/:54N )5D3*$ [?5=,O'\6:=:17T\<BZ1?>9=^5:M<NHNK,_(# +1'+;
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M)H W-(\):9H=PUW9Q.)VB6 /+//<&.!6+B"#[1++]G@W$'R8/+B)5,H?+3:
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M0#%T_P "Z-I<\=Q;PN#;EVMXWN+F6WMV?.XVUK+,]M;$ E5,$4>Q&9$VH2I
M+3>$M+<,I@XDOTU-OWDO-[&T;)-]_C!B0^6,1';RA!.0"27POILT5] \.8]8
M+&]7S)1YQ:%8&Y#@QYB14_=%,8W#YB20"TVAV37%M>&/]_I\<L-LV]_W<<PC
M61=N[:^X0QC+AF&WY2,MD RK3P3I%C.+BWBDCVRF=8!<W7V1922QD6Q,WV-7
M#GS%98 5E_>KB0!J +4GA73)+6\L6AS;ZJ\LEVGF2_O7F18Y#N#[DW(BC$;(
M!C*@$DD =<^&=/N;N#4621+JS3RHI(I[B$F+<K^5*(946XBWHK>5.)(\Y^7Y
MFR 7=4TBUUF-(;U/-2*:&X0;G7$L$BRQ/E&4G:ZAMI)5L88$9% &1J_@W2];
MF:YNHY5FEC\F5[>ZNK0S1#.(YS:S0^>JAF"B7>%#,%P&8$ T!X?T]9K6X2!(
MWTV.2*T$>8TACE5$=$B0K'M*QHH!0A OR;>: +6J:9;:U:3:?>IYMM<QM%*F
MYEW(XPR[D*NN0>JL".Q% %R.-8E"(,*H"@>@ P.O/2@#GH_"6EPV5MIB08M+
M":*XMX_,E_=RP2^=$VXOO;;)\VUV96Z,"O% &=J'P\T+5)9I;JW=_M4@GFB%
MS=);O,%11.;9)UM_/Q&G[X1"4E0Q;=S0!=O/!NE7]U]MN(G>0RQS-']HN1;O
M-$%$<LEHLPM994$<>))(6?\ =Q\_(N !E[X)TF_N9+R6*19;D*+A8;FZ@BN0
MH*@75O!-'!<Y0F-O/CDWQXB?=& H .EF@6>)H&W*CH4.QVC8!AM.QXRKQL ?
ME=&5E."I! - ',Z1X*TS0KI[ZS^UK/,=TK2:A?SK*VP1AI8Y[J2.5E0*JM(C
M,@5=I&T8 -#5O#MEK3I+<B59H0RI+;W-S:3!'*EX_.M9893&S(C-&SF,LB,5
MW(I !!8^$M*TUK5[6W$;:>LRVY#R'9]HV^>[;G/FS2[07GEWS,2Y,F9'+ %J
M]\/V.H7*WUQ%NN$@FM0X>13Y$^TRQL$9596**1N!*$90J220#%T_P!HNFM 8
MHII%L=AM8[F\O+N&W,8"QM!!=7$T,3QJ-L3QHKQKD(R@D4 =+J.G0:M;O:7:
MEXI,9 9D8%6#HR/&RR1NCJKQR(RNCJKHRL 0 8*^"-'6TN;!X&FAU JUTTT]
MQ/-,R*BQL]S-*]R3$$3R2)08=H,6PC- $MYX/TV_BMXIQ<,;$N;>87MZMU'Y
M@*R#[8MPMVRNIPZO,RL @(.Q-H!#'X%T2'3WTB*U6.SDF^T>6CRILGW*XEB=
M7$D+JRAE:%T*$?+C)R 6=(\):9H5Q)>V43+=3QK%-/)-//+*J.[IYLD\LCRN
MI<JLDC-((Q'"&\J*)$ ,KP'X3/A6VNO.6%;K4;^ZOIQ 6,2M/(3''&75&V1Q
M!!@JH#[]HP<D Z6;1K2>]34I(\W44$ELDFYQB&5D>1-H8(=S1H=Q4L,85@"0
M0"C%X4TN&TL].2'%MI<D4MHGF2_NG@R(FW%][[=QXD9PV?F!H T-4TBUUJ);
M>]3S8DEBF5=SKB2"198FRC*?ED16P3M;&&!4D$ CDT2RENWU"2(/<2VWV1V8
MLRM;[VD\IHR3&06=B3LW$':25XH S=)\':7H<B2V<<J^2I6%)+JZGA@##!%O
M!//)!;_*2@,$<96,M&N(V92 4K7X>:%9S0W$-NX:TF:>V4W-TT5O(Y<L;>!Y
MVA@1B[;HHHTC;Y<H=B;0#1F\(Z5<6MS8R09M[^X:ZG7S)06N&9',JN'#Q.'C
M1D,3)L904VF@"S;^'K*UN(;Q5D>YM8'MHI99YYI!#(Z.ZLTLCF0LT:'?(7D&
MW 8 D$ YKQ1X*2_T&_T724AA;5))))#.TK()+F<2W,X_UC>8,O)$@"QB4(/D
M3. #M;"QATRVBLK9=D%M$D,:CHJ1J$1?P4 4 6Z "@"CJ7_'K+_N&@!]A_Q[
MQ?\ 7-/_ $$4 6Z "@ H * "@ H * "@ H * "@ H * "@ H * .$\/^&+K2
MM&N],F:)IKJ?4949"Q0+>3SRQ!B45@5610^%(!!VEA@D R])T/7HO#X\-WD%
MA&L6E?8$N(KVXE+R+;"W1VA?3H0B,1N;$SL@X"R=: +$?@^[LY=$OK1H5O-*
M@2QO26<+<630*LL:L(RSF.XCBG@#A!E6RR;F! .6N/AYJLVFW&@;=/:*ZO7N
M_P"UFEF^W*[S^:+C[-]EVM>11DP12B_0*JHW"J82 >C^,M&NO$.ERZ5:.D(O
M#'#<.[,I%H\BBZ$>U6S(\'F1HIVJ2WS.H&: .9OOAW':W6G:CHLDR7&F7*DB
M[O[^XC-G(C0W,,:W$URL;-&59-J*"T2*S*OS  \B\.W$5B\-\MQ9WNHMJL[C
M1)#>F_BEGO9HY93;?VG):V]U!;R23R2KI:)&@D D",9V /49_"&MVUGJ6A6#
M61L-7GNY!=323+<6L>H,S7"BU6!H[EHO,D,#&[MPV4$BC8Q< Z73_"TFFZXN
MHQ,ILXM)@TY%+$S;H9WD#,-@3:491N#9+9^0#!H YS2O E]8V^CPR20%M*U.
M_O9MK28:*Z:_,:QYB!,@%U'O#!%&'VLV%W %C2/".HVNO+JYCLM.BQ/]L^P3
M7&-3D<GR9;BS:&*""1"\DS2^9=SER(C,R98@&WX#T6_\-:<ND7RVYBLRZ6\T
M$LC--$TLKJ98I(8Q ZHR JDUP&;<=Z@#(!VU !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % 'P%)\,/$GB2ZO-1TRS\^UEO[X(_GVR9*7<R-\LDR.,,I'*C.
M,C(P:[Z=2,8I-ZZ]'W9HFD@_X4GXQ_Z!_P#Y-6?_ ,D5K[6'?\'_ )#N@_X4
MGXQ_Z!__ )-6?_R11[6'?\'_ )!=!_PI/QC_ - __P FK/\ ^2*/:P[_ (/_
M ""Z#_A2?C'_ *!__DU9_P#R11[6'?\ !_Y!=!_PI/QC_P! _P#\FK/_ .2*
M/:P[_@_\@N@_X4GXQ_Z!_P#Y-6?_ ,D4>UAW_!_Y!=!_PI/QC_T#_P#R:L__
M )(H]K#O^#_R"Z#_ (4GXQ_Z!_\ Y-6?_P D4>UAW_!_Y!=!_P *3\8_] __
M ,FK/_Y(H]K#O^#_ ,@N@_X4GXQ_Z!__ )-6?_R11[6'?\'_ )!=!_PI/QC_
M - __P FK/\ ^2*/:P[_ (/_ ""Z#_A2?C'_ *!__DU9_P#R11[6'?\ !_Y!
M=!_PI/QC_P! _P#\FK/_ .2*/:P[_@_\@N@_X4GXQ_Z!_P#Y-6?_ ,D4>UAW
M_!_Y!="CX)^,"<?8,?\ ;U9__)%'M8=_P?\ D%T?5GPU^&EKX"M=[[9]2G4>
M?/CA1U\J+/*Q@]3PTC#<V $1.&I4<WV71$-W/4*Q)*\WWD_W_P#V5J0RQ3$%
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!7M^C?[[?SI(98IB"@ H *
M "@ H * "@ H * "@ H * "@ H * "@"O/\ P?[X_K28RQ3$% !0 4 <WJGB
M#^S-3T[3/*W_ -J/<IYF_;Y7V>W:?.W:=^_;MQN3;G=\W2@#I* "@#-FU>UM
M[V'3)'VW5U'++%'M<[D@,8E;<%*+M,J<,P+;OE!P< &E0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M G)H JW=GX<TS5[RS\6K:)86EG9PZ0FH;/(6UC@"W LQ+^[,XE4"7R1]HVB
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M*E^S_8=4N+S4%B$.'AUG2R((X\1XW/)I2112RF,I;0+%+N5[A)!N /?Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *.I?\>LO^X:
M 'V'_'O%_P!<T_\ 010!;H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /._A?_P @9O\ L(ZK_P"G*ZH ]$H * "@ H * "@ H * "@ H * "@ H
M* "@ H * *\WWD_W_P#V5J0RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!7M^C?[[?SI(98IB"@ H * "@ H * "@ H * "@ H * "@ H * "@"
MO/\ P?[X_K28RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@.9]W]X?:YO^>C_]]-_C0',^[^\/M<W_ #T?_OIO\: YGW?WA]KF_P">C_\
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M_>)]JF/\;_\ ?1_QH#F?=_>+]KF_YZ/_ -]-_C0',^[^\/M<W_/1_P#OIO\
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M /?3?XT!S/N_O#[7-_ST?_OIO\: YGW?WA]KF_YZ/_WTW^- <S[O[P^US?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#6M=<O;*
M,0P2;(US@;4.,G)Y*D]3ZT[FJJ2BN6+LO1$*:K=),;D2'S6!4L0&X/;!! 'H
M !CM2%SR3YKZDD>M7D,/V9)2L6", +D ]0&QN'7L>.U,:J22Y4] CUJ\BA^S
M)*1%@KC"Y /8,1N ],'CM0)5))<J>@^/7KZ&(0)*P0#:!A<@>@8C<,=L'CM1
M<:J32Y4]"O9ZG<V 86[E!)][A3G&?[P.#R>1@_I2V)C.4;\KM<6RU6ZTX%;:
M0H&.2,*PSZX8$ ^XHV'&<H?"["OJUTYE9GR;@!9?E7Y@HP!]WC X^7% <\M=
M=]]BWHVJKI2S-\WF2)MCP!M#<X9LD'CC&,]336A5.?L[[W:T_P""8T<C1,'0
M[64@@CJ"#D'\#2,EIJC1N]:O+V/RIY2R<9&%7..F=H&?QSSS3-'4E)6;T%.M
MWI$8,I_<'*<+D$ KR<9;Y20=Q.0>:+A[26FNVQ937[B66-KQC-'%(LFT!5.5
MR 05 /&<XS@]_6BY7M)-KGU2=[:(U=3\20W5N\,8E=I""IE$:B+!S\AC^8XZ
M#<2?5NN7<UG54DTKZ][:>EC$EU^^FB,$DI9&&T@JF2/][;N_'.:5S!U)M<K>
MGHBC:7DUBQ>!MC,I4G /RG&1\P([#WI$1DXZQ([>XDM)%FA.UT.0< X[=""/
MS% DW%W6Z-VVU][6U>.-F6YDG,N\*NW# !L@]R03C;CI3N;JHXQ:7Q-WOI_7
MX&:-6NQ/]J$C><1C=QT],8VX]L8SSC-(SYY7YKZDTFNWLLB3/)F2'=L.Q!C>
M,-P%P<CCD'':G<;J2;3;U6VBZ_(K?VG<;%CW_+')YJC:O#Y)W=,GDG@Y'M2)
MYY:*^SNO4=_:ESOEDW_-<*4D.U?F4C!'W<#CNN#0/GEJ[[Z/8L6^OWUK&(HI
M2$48 *HV!Z LI.!V&>*=QJI.*LGI\C'I&04 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M^% 6?9_<'V>7^XW_ 'R?\* L^S^X/L\O]QO^^3_A0%GV?W!]GE_N-_WR?\*
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M&'_ 3_A0'*^B?W'JUA_Q[Q?]<T_]!%:'M%N@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H \[^%_\ R!F_[".J_P#IRNJ /1* "@ H * "@ H * "@
M H * "@ H * "@ H * "@"O-]Y/]_P#]E:D,L4Q!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 5[?HW^^W\Z2&6*8@H * "@ H * "@ H * "@ H *
M"@ H * "@ H KS_P?[X_K28RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M']:3&6*8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@"CJ7_'K+_N&@!]A_Q[Q?]<T_]!% %N@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _./4O%>LZ7?WMM97][;0
M)?WNV*&YFCC7==3,<(CJHRQ).!R22>37I4HQ<$VE?7HN[-4M"I_PG7B+_H*Z
MC_X&W/\ \<K;DC_*ON0[(/\ A.O$7_05U'_P-N?_ (Y1R1_E7W(+(/\ A.O$
M7_05U'_P-N?_ (Y1R1_E7W(+(/\ A.O$7_05U'_P-N?_ (Y1R1_E7W(+(/\
MA.O$7_05U'_P-N?_ (Y1R1_E7W(+(/\ A.O$7_05U'_P-N?_ (Y1R1_E7W(+
M(T=)^)?B32;J.\74+NX\ILF*XN)IH9!T*O&[D$$9&1AE^\C*P!$NG%JUDO16
M"R/N+P/XXL?'5B+RS.R5,+<6[$%X7(Z'IN1L$QR  . >%=71?-G!TW9_)F35
MCM*S$% !0 4 % !0 4 % !0!7F^\G^__ .RM2&6*8@H * "@ H * "@ H *
M"@ H * "@ H * "@ H * *]OT;_?;^=)#+%,04 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 5Y_P"#_?']:3&6*8@H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"CJ7_'K+_N
M&@!]A_Q[Q?\ 7-/_ $$4 6Z "@ H * *0U*T-U_9XFB^V"+SS;^8GG"'=L\W
MRL[_ "]YV[]NW=\N<\4 7: "@"B-2M#='3Q-%]L$7G&W\Q/.$.X)YIBSO\O>
M0N_;MW$+G/% %Z@ H * (+FYALHGN+ETAAB4O))(P1$11EF=F(554 DL2 !R
M30 6]Q%>1)<6[I+#*BO'(C!T=' 971E)5E92"K D$$$'% $] !0 4 % !0 4
M 5I+R"&:.VDDC2><.T43.HDD6/;YA1"=SB/>F\J"%W+NQN&0!+.]M]1B6XM)
M8[B%\[9(G61&VL5;#H2IVLI4X/# @\@T 6J *WVR 3BT\R/[08S*(=Z^88PP
M0R!,[M@8A2^-H8@9R<4 6: "@ H @N+B*SB>XN'2&&%&>21V"(B("S.[,0JJ
MJ@EF)  !)( H DCD651)&0R, RLI!!!&001P01R"."* 'T % !0 4 % !0 4
M % %:TO(+^,3VLD<\1+*'B=70LC,C@,I(RCJR,,Y5E93@@B@!%O;=YVM%EC-
MQ&BR/"'4R*CDA'9,[E1BK!6( 8J0"2#0!:H K6EY!?IYMK)'/'N=-\;JZ[D8
MHZ[E)&Y'5D<9RK J0""* +- !0 4 % 'YB>(/^0K?_\ 7_>?^E,M>I2^!?/\
MV:K8R:W*"@ H * "@ H * .A\+^)[[PA?)J6FOLE3AE.2DJ$C='(N1N1L>Q4
M@,I5U5A$HJ2LQ6/OSP/XXL?'5B+RS.R5,+<6[$%X7(Z'IN1L$QR  . >%=71
M?+G!TW9_)F35CM*S$% !0 4 % !0 4 % %>;[R?[_P#[*U(98IB"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H KV_1O]]OYTD,L4Q!0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MN;B^DD;<TMRT>X\!0%2"*""-0 .(H4W'+ON=F8@&I0 4 % 'YB>(/^0K?_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * *.I?\>LO^X: 'V'_'O%_US3_T$4 6Z "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#SOX7_ /(&;_L(ZK_Z<KJ@#T2@ H * "@ H *
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M_P!PT /L/^/>+_KFG_H(H MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'G?PO\ ^0,W_81U7_TY75 'HE !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!7F^\G^__P"RM2&6*8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * *]OT;_ 'V_G20RQ3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M%>?^#_?']:3&6*8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@"CJ7_ !ZR_P"X: +,>D/$H19Y
M %  &V/H!CNAH =_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_
M #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% !_9DG_ #\2?]\Q_P#Q% &=I?A>
M/1H3;6DKQ1&6:7: I^>>5YI#EPQRSNS'G&2=JJN% !H_V9)_S\2?]\Q__$4
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M (VE.V,SR<'(^6/K_P!\4 +_ &9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\
M\10 ?V9)_P _$G_?,?\ \10 ?V9)_P _$G_?,?\ \10 R71VE0HT\A5A@C;'
M_10?UH VJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M+*B-E'4@,C  $]I>07T8GM9(YXB6 >-U="48HX#*2"5=61AG*LI4X((H L4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M9&';G(X- ';T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M0QW,4LCPQNC20[?,16!9-PW+O4'*[E^9=P&1R.* )J "@ H YC7_  POB [)
M;N\@MI(_)N;:%XA#=0EB6CE\R&22,.K/&\EK);3/&VUI#LC* %_6]#@UZV%C
M<LZVWF1O)'&559DC8/Y$N58F!V5?-1"AD0&-F,;NC &Q0 4 9NCZ5%HEHEE
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H JWMC;ZE"]K>11W-O*-KQ3(LD;C.<,C@JPR <$$9%
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ9,-C EMETC@99IKAX2 (S,BJ >N4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M[?>9O(W&3]Z3YGS4 =#0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MXG7EO;274.E28LM*M]5O1<3_ &<VZ3"9GM0/(D9[M%BWHC)'&Z[O-EMW5$E
M++^,=0L-6U:>\2(Z-I<=K"B12[KEKJ5?-4+$UM'NFNA<VL/ER74<4)","WFR
M.@ ^Z^(5[I N8-3TY1?VJZ<\=M9W?VD3C4;E[6*-9)+>UV3))%)N1D\O:%83
M88E0#:\4ZWJ.CZ!)>,L%OJ1V(D4,OVD%WF";+7SH[4W5TT19K:W,*F:YV0A)
M ?G (? .H7FI17DMQ<S7EJEVT5J]W';PW@6-$25;B&V@MEA_?!VBBF@CNEC8
M&=5)5$ .^H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)C( :FO^'H]>$#&:>TGLI_M%O/;^49(Y#%)"Q"W$,\+!HII$(DB?&[<NU@K
M FT+0X=!A>*)Y)Y+B9[B>>8J99IG"AI'\M(XE.U$15BCCC5$550 4 ;5 !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
G% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>sbtx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T11:06:57.7054+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:label="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:label="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:label="sbtx_SharesUnderlyingOutstandingEquityAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TaxCreditCarryforwardExpirationYear" xlink:label="sbtx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicensingAgreementTextBlock" xlink:label="sbtx_LicensingAgreementTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AccruedResearchAndDevelopmentExpenses" xlink:label="sbtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LoanAndSecurityAgreementMember" xlink:label="sbtx_LoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_PaymentOfDeferredOfferingCosts" xlink:label="sbtx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SiliconValleyBankMember" xlink:label="sbtx_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" xlink:label="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RestructuringPlanMember" xlink:label="sbtx_RestructuringPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AmendedLoanAndSecurityAgreementMember" xlink:label="sbtx_AmendedLoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized" xlink:label="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnvestedCommonStockMember" xlink:label="sbtx_UnvestedCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" xlink:label="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="sbtx_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicenseFeesPaid" xlink:label="sbtx_LicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_BenefitFromRDTaxCredits" xlink:label="sbtx_BenefitFromRDTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmployeeStockPurchasePlanMember" xlink:label="sbtx_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RDTaxCreditCarryforward" xlink:label="sbtx_RDTaxCreditCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesWereReservedUnderTheEspp" xlink:label="sbtx_SharesWereReservedUnderTheEspp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:label="sbtx_SharesAvailableForFutureEquityAwardGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LiquidityAndCapitalResourcesMember" xlink:label="sbtx_LiquidityAndCapitalResourcesMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OtherTemporaryAndPermanentDifferences" xlink:label="sbtx_OtherTemporaryAndPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_CashCashEquivalentsAndLongTermInvestments" xlink:label="sbtx_CashCashEquivalentsAndLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryequityValues" xlink:label="sbtx_TemporaryequityValues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_WuxiBioMember" xlink:label="sbtx_WuxiBioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:label="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" xlink:label="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" xlink:label="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" xlink:label="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:label="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="us-gaap_LossContingencyLawsuitFilingDate"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCMember" xlink:label="sbtx_SeriesCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsExpirationYear" xlink:label="sbtx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuanceCosts" xlink:label="sbtx_StockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:label="sbtx_SharesUnderlyingEsppWithholdingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicensingAgreementAbstract" xlink:label="sbtx_LicensingAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EligibleEarnings" xlink:label="sbtx_EligibleEarnings"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock" xlink:label="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EsppWithholdingsMember" xlink:label="sbtx_EsppWithholdingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:label="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LaboratoryEquipmentMember" xlink:label="sbtx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:label="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TermLoanMember" xlink:label="sbtx_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmployeeStockPurchasePlanPolicyTextBlock" xlink:label="sbtx_EmployeeStockPurchasePlanPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:label="sbtx_AgreementPaymentAndLicenseTermDesciption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:label="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" xlink:label="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease agreement description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities transfers from Level 1 to Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Shares Reserved for Future Issuance&#160;</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Issuance [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Common Stock Reserved For Issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock for cash (Note 8), shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series B redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of new stock classified as temporary equity issued during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average price at which option holders cancelled shares when converting their stock options into shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at December 31, 2021 and 2020, 35,133,934 and 34,801,537 shares issued and 35,107,651 and 34,701,274 shares outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial public offering of common stock, net of $22,386 in issuance costs , values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Stock Excersible On Agreed Upon Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Stock Excersible On Agreed upon Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable Stock Excersible On Agreed upon Milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingOutstandingEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Underlying Outstanding Equity Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingOutstandingEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Underlying Outstanding Equity Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingOutstandingEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Underlying Outstanding Equity Awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy followed under emerging growth company status.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertibel Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Commitments Due Under the Operating Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised and employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, shares issued under the employee stock purchase plan, and vesting of early exercised common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion to Redemption value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Minimum Rentals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual minimum rent payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of workforce reduced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicensingAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicensingAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicensingAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for licensing agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Investments - U.S. Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan And Security Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and Security Agreement [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial public offering of common stock, net of $22,386 in issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_PaymentOfDeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible executive compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of redeemable convertible preferred stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of redeemable convertible preferred stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Inputs used under for the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate milestone payments upon achievement of certain sales milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate milestone payments upon achievement of certain sales milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial public offering of common stock, net of $22,386 in issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RestructuringPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ROU asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money market funds, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AmendedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Loan and Security Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AmendedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Loan And Security Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AmendedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Loan and Security Agreement [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets and lease liabilities recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets And Lease Liabilities Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of use assets and lease liabilities recognized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_UnvestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average per share fair value rights granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potentially dilutive shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award options grants in percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options grants in percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Fees paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_BenefitFromRDTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit from R&amp;D tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_BenefitFromRDTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Benefit From R&amp;D Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_BenefitFromRDTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Benefit from R&amp;D tax credits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) in operating lease liabilities during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value,assets transfers from Level 2 to Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RDTaxCreditCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D tax credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RDTaxCreditCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">R&amp;D Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RDTaxCreditCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">R&amp;D tax credit carryforward.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesWereReservedUnderTheEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares were Reserved Under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesWereReservedUnderTheEspp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">shares were reserved under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auction Market Preferred Securities, Stock Series, Title [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesAvailableForFutureEquityAwardGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available For Future Equity Award Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesAvailableForFutureEquityAwardGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Equity Award Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesAvailableForFutureEquityAwardGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Available For Future Equity Award Grants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LiquidityAndCapitalResourcesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Capital Resources [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LiquidityAndCapitalResourcesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity and Capital Resources [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LiquidityAndCapitalResourcesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and Capital Resources [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OtherTemporaryAndPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other temporary and permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OtherTemporaryAndPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Temporary And Permanent Differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OtherTemporaryAndPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other temporary and permanent differences.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Life (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_CashCashEquivalentsAndLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and long term investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_CashCashEquivalentsAndLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents and Long term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_CashCashEquivalentsAndLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash cash equivalents and long term investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less accumalated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, assets transfers into (out of) Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryequityValues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock converted into shares of common stock ,values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryequityValues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TemporaryEquity values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryequityValues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TemporaryEquity values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Weighted Average Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid initial public offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid initial public offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Subject to Options Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Subject to Options Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_WuxiBioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WuXi Bio [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_WuxiBioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Bio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards amount not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Amount Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards amount not subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of series C redeemable convertible preferred stock for cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Series C Redeemable Convertible Preferred Stock For Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of series C redeemable convertible preferred stock for cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Present value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation Arrangements Stock Option Grant Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation arrangements stock option grant contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expectation of workforce reduced period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost Number of Positions Expected To Be Eliminated Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring and related cost number of positions expected to be eliminated period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash outflows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options, shares issued under the employee stock purchase plan, and vesting of early exercised common stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised and employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised And Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Deferred Tax Assets And Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Underlying Early Exercised Equity Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Underlying Early Exercised Equity Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Underlying Early Exercised Equity Awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate During Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equalization of employee contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock, common shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional&#160;paid-in&#160;capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock converted into shares of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual term of sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering of common stock, net of $22,386 in issuance costs , values</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of share options (or share units) cancelled during the current period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Options Outstanding, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyLawsuitFilingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Action Complaint Filed Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyLawsuitFilingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Lawsuit Filing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_StockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Stock Option Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingEsppWithholdingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Underlying ESPP Withholdings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingEsppWithholdingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares underlying ESPP Withholdings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SharesUnderlyingEsppWithholdingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares underlying ESPP Withholdings.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicensingAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LicensingAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options and vesting of early exercised common stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Options Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series C redeemable convertible preferred stock upon conversion of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock upon conversion of convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds and Available For Sale Debt Securities Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money Market Funds and Available For Sale Debt Securities Fair Value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EligibleEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eligible Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EligibleEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">eligible earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of other information related to Companys operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Information Related To Companys Operating Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of other information related to companys operating leases table text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Expected Dividend Yeild</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EsppWithholdingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP withholdings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EsppWithholdingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESPP Withholdings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EsppWithholdingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ESPP withholdings.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Assets [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price Vested, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share Based Compensation Number of Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Options Outstanding, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Change in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan payable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable to Bank, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Redeemable Convertible Preferred Stock Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock for cash (Note 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues For Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock classified as temporary equity issued for cash during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock , shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Life (Years),	Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock options and vesting of early exercised common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Option to Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Years Ending December&#160;31,</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options and employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Subject to Options Outstanding Vested, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards amount to expire if not used</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Amount To Expire If Not Used</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards amount to expire if not used.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at the federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series C redeemable convertible preferred stock upon conversion of convertible notes, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock upon conversion of convertible notes, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares of new stock classified as temporary equity issued on conversion of convertible notes during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on term loan payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Bank Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds and Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money Market Funds and Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmployeeStockPurchasePlanPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmployeeStockPurchasePlanPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_EmployeeStockPurchasePlanPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total present value of lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, liabilities transfers from Level 2 to Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auction Market Preferred Securities, Stock Series [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash&#160;lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AgreementPaymentAndLicenseTermDesciption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement payment and license Term desciption</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_AgreementPaymentAndLicenseTermDesciption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement payment and license Term desciption.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B redeemable convertible preferred stock for cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Series B redeemable convertible preferred stock for cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series B redeemable convertible preferred stock for cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Equity Award Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liabilities - Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities - Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money market funds, amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value,assets transfers from Level 1 to Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceed Received In Advance For Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceed Received In Advance For Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceed received in advance for issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:to="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="sbtx_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:to="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:to="sbtx_SharesUnderlyingOutstandingEquityAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TaxCreditCarryforwardExpirationYear" xlink:to="sbtx_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LicensingAgreementTextBlock" xlink:to="sbtx_LicensingAgreementTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_AccruedResearchAndDevelopmentExpenses" xlink:to="sbtx_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LoanAndSecurityAgreementMember" xlink:to="sbtx_LoanAndSecurityAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_PaymentOfDeferredOfferingCosts" xlink:to="sbtx_PaymentOfDeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SiliconValleyBankMember" xlink:to="sbtx_SiliconValleyBankMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" xlink:to="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:to="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_RestructuringPlanMember" xlink:to="sbtx_RestructuringPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_AmendedLoanAndSecurityAgreementMember" xlink:to="sbtx_AmendedLoanAndSecurityAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized" xlink:to="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_UnvestedCommonStockMember" xlink:to="sbtx_UnvestedCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" xlink:to="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="sbtx_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LicenseFeesPaid" xlink:to="sbtx_LicenseFeesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_BenefitFromRDTaxCredits" xlink:to="sbtx_BenefitFromRDTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_EmployeeStockPurchasePlanMember" xlink:to="sbtx_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_RDTaxCreditCarryforward" xlink:to="sbtx_RDTaxCreditCarryforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SharesWereReservedUnderTheEspp" xlink:to="sbtx_SharesWereReservedUnderTheEspp_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:to="sbtx_SharesAvailableForFutureEquityAwardGrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LiquidityAndCapitalResourcesMember" xlink:to="sbtx_LiquidityAndCapitalResourcesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_OtherTemporaryAndPermanentDifferences" xlink:to="sbtx_OtherTemporaryAndPermanentDifferences_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_CashCashEquivalentsAndLongTermInvestments" xlink:to="sbtx_CashCashEquivalentsAndLongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryequityValues" xlink:to="sbtx_TemporaryequityValues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_WuxiBioMember" xlink:to="sbtx_WuxiBioMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:to="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" xlink:to="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" xlink:to="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" xlink:to="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:to="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" xlink:to="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyLawsuitFilingDate" xlink:to="us-gaap_LossContingencyLawsuitFilingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SeriesCMember" xlink:to="sbtx_SeriesCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_OperatingLossCarryforwardsExpirationYear" xlink:to="sbtx_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_StockIssuanceCosts" xlink:to="sbtx_StockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:to="sbtx_SharesUnderlyingEsppWithholdingsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LicensingAgreementAbstract" xlink:to="sbtx_LicensingAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:to="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_EligibleEarnings" xlink:to="sbtx_EligibleEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock" xlink:to="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_EsppWithholdingsMember" xlink:to="sbtx_EsppWithholdingsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:to="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="sbtx_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LaboratoryEquipmentMember" xlink:to="sbtx_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:to="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TermLoanMember" xlink:to="sbtx_TermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_EmployeeStockPurchasePlanPolicyTextBlock" xlink:to="sbtx_EmployeeStockPurchasePlanPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:to="sbtx_AgreementPaymentAndLicenseTermDesciption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:to="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" xlink:to="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>sbtx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T11:06:58.5067+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:href="sbtx-20211231.xsd#StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2" xlink:href="sbtx-20211231.xsd#DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3" xlink:href="sbtx-20211231.xsd#DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="sbtx-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="sbtx-20211231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:href="sbtx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="sbtx-20211231.xsd#FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:href="sbtx-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="sbtx-20211231.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail" xlink:href="sbtx-20211231.xsd#LeasesSummaryOfOperatingLeaseCostDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sbtx_PaymentOfDeferredOfferingCosts" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfBankDebt" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" order="9" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_PaymentOfDeferredOfferingCosts" xlink:label="sbtx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="sbtx_AccruedResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AccruedResearchAndDevelopmentExpenses" xlink:label="sbtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="sbtx_DeferredTaxAssetsOperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="sbtx_RDTaxCreditCarryforward" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="sbtx_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RDTaxCreditCarryforward" xlink:label="sbtx_RDTaxCreditCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>sbtx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T11:06:58.1363+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/CoverPage" xlink:href="sbtx-20211231.xsd#CoverPage" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:href="sbtx-20211231.xsd#StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="sbtx-20211231.xsd#StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="sbtx-20211231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:href="sbtx-20211231.xsd#StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="sbtx-20211231.xsd#StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="sbtx-20211231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusiness" xlink:href="sbtx-20211231.xsd#NatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="sbtx-20211231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements" xlink:href="sbtx-20211231.xsd#FairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="sbtx-20211231.xsd#DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses" xlink:href="sbtx-20211231.xsd#AccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/Leases" xlink:href="sbtx-20211231.xsd#Leases" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayable" xlink:href="sbtx-20211231.xsd#TermLoanPayable" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit" xlink:href="sbtx-20211231.xsd#StockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation" xlink:href="sbtx-20211231.xsd#StockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LicensingAgreement" xlink:href="sbtx-20211231.xsd#LicensingAgreement" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/CommitmentsAndContingencies" xlink:href="sbtx-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/EmployeeBenefitPlans" xlink:href="sbtx-20211231.xsd#EmployeeBenefitPlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="sbtx-20211231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="sbtx-20211231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices" xlink:href="sbtx-20211231.xsd#SummaryOfSignificantAccountingPoliciesPolices" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="sbtx-20211231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsTables" xlink:href="sbtx-20211231.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="sbtx-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesTables" xlink:href="sbtx-20211231.xsd#AccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesTables" xlink:href="sbtx-20211231.xsd#LeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables" xlink:href="sbtx-20211231.xsd#StockholdersEquityDeficitTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables" xlink:href="sbtx-20211231.xsd#StockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="sbtx-20211231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#NatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:href="sbtx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="sbtx-20211231.xsd#FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:href="sbtx-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:href="sbtx-20211231.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail" xlink:href="sbtx-20211231.xsd#LeasesSummaryOfOperatingLeaseCostDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" xlink:href="sbtx-20211231.xsd#LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#LeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#TermLoanPayableAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" xlink:href="sbtx-20211231.xsd#DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#StockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail" xlink:href="sbtx-20211231.xsd#DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureLicensingAgreementAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:href="sbtx-20211231.xsd#NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="us-gaap_LoansPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableToBankCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryequityValues" xlink:label="sbtx_TemporaryequityValues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_19"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_21"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryequityValues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuanceCosts" xlink:label="sbtx_StockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_StockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesCRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized" xlink:label="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_PaymentOfDeferredOfferingCosts" xlink:label="sbtx_PaymentOfDeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="us-gaap_RepaymentsOfBankDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" xlink:label="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sbtx_PaymentOfDeferredOfferingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/Leases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LicensingAgreement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicensingAgreementAbstract" xlink:label="sbtx_LicensingAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicensingAgreementTextBlock" xlink:label="sbtx_LicensingAgreementTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sbtx_LicensingAgreementAbstract" xlink:to="sbtx_LicensingAgreementTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/EmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock" xlink:label="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmployeeStockPurchasePlanPolicyTextBlock" xlink:label="sbtx_EmployeeStockPurchasePlanPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sbtx_EmployeeStockPurchasePlanPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock" xlink:label="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:label="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LiquidityAndCapitalResourcesMember" xlink:label="sbtx_LiquidityAndCapitalResourcesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_CashCashEquivalentsAndLongTermInvestments" xlink:label="sbtx_CashCashEquivalentsAndLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sbtx_LiquidityAndCapitalResourcesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_CashCashEquivalentsAndLongTermInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LaboratoryEquipmentMember" xlink:label="sbtx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sbtx_LaboratoryEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AccruedResearchAndDevelopmentExpenses" xlink:label="sbtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sbtx_AccruedResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToTerminate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TermLoanMember" xlink:label="sbtx_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SiliconValleyBankMember" xlink:label="sbtx_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LoanAndSecurityAgreementMember" xlink:label="sbtx_LoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AmendedLoanAndSecurityAgreementMember" xlink:label="sbtx_AmendedLoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sbtx_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="sbtx_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sbtx_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sbtx_AmendedLoanAndSecurityAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:label="sbtx_SharesUnderlyingOutstandingEquityAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:label="sbtx_SharesAvailableForFutureEquityAwardGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:label="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:label="sbtx_SharesUnderlyingEsppWithholdingsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesUnderlyingOutstandingEquityAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesAvailableForFutureEquityAwardGrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesUnderlyingEsppWithholdingsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:label="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCMember" xlink:label="sbtx_SeriesCMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:label="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" xlink:label="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" xlink:label="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesBMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="sbtx_SeriesCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnvestedCommonStockMember" xlink:label="sbtx_UnvestedCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmployeeStockPurchasePlanMember" xlink:label="sbtx_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" xlink:label="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" xlink:label="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EligibleEarnings" xlink:label="sbtx_EligibleEarnings"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesWereReservedUnderTheEspp" xlink:label="sbtx_SharesWereReservedUnderTheEspp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sbtx_UnvestedCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="sbtx_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_EligibleEarnings" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_SharesWereReservedUnderTheEspp" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_BenefitFromRDTaxCredits" xlink:label="sbtx_BenefitFromRDTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OtherTemporaryAndPermanentDifferences" xlink:label="sbtx_OtherTemporaryAndPermanentDifferences"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sbtx_BenefitFromRDTaxCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sbtx_OtherTemporaryAndPermanentDifferences" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="sbtx_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RDTaxCreditCarryforward" xlink:label="sbtx_RDTaxCreditCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sbtx_DeferredTaxAssetsOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sbtx_RDTaxCreditCarryforward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:label="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsExpirationYear" xlink:label="sbtx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:label="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TaxCreditCarryforwardExpirationYear" xlink:label="sbtx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_OperatingLossCarryforwardsExpirationYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_TaxCreditCarryforwardExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_WuxiBioMember" xlink:label="sbtx_WuxiBioMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicensingAgreementAbstract" xlink:label="sbtx_LicensingAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicenseFeesPaid" xlink:label="sbtx_LicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:label="sbtx_AgreementPaymentAndLicenseTermDesciption"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sbtx_WuxiBioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sbtx_LicensingAgreementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_LicenseFeesPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_AgreementPaymentAndLicenseTermDesciption" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnvestedCommonStockMember" xlink:label="sbtx_UnvestedCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EsppWithholdingsMember" xlink:label="sbtx_EsppWithholdingsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sbtx_UnvestedCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sbtx_EsppWithholdingsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="us-gaap_LossContingencyLawsuitFilingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RestructuringPlanMember" xlink:label="sbtx_RestructuringPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" xlink:label="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LossContingencyLawsuitFilingDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sbtx_RestructuringPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringPlanAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringCharges" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>sbtx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T11:06:55.5535+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://silverbacktx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sbtx="http://silverbacktx.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sbtx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sbtx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sbtx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sbtx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2" id="DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2">
        <link:definition>100020 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3" id="DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3">
        <link:definition>100040 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1" id="StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1">
        <link:definition>100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100080 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusiness" id="NatureOfBusiness">
        <link:definition>100090 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>100130 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/Leases" id="Leases">
        <link:definition>100140 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayable" id="TermLoanPayable">
        <link:definition>100150 - Disclosure - Term Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
        <link:definition>100160 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/LicensingAgreement" id="LicensingAgreement">
        <link:definition>100190 - Disclosure - Licensing Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>100200 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
        <link:definition>100210 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders" id="NetLossPerShareAttributableToCommonStockholders">
        <link:definition>100220 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100230 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices" id="SummaryOfSignificantAccountingPoliciesPolices">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Polices)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100270 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>100280 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesTables" id="LeasesTables">
        <link:definition>100290 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
        <link:definition>100300 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>100310 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100320 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables" id="NetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100330 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail" id="NatureOfBusinessAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100360 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100380 - Disclosure - Property and Equipment, Net - Schedule of Property and equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail" id="AccruedExpensesSummaryOfAccruedExpensesDetail">
        <link:definition>100400 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail" id="LeasesSummaryOfOperatingLeaseCostDetail">
        <link:definition>100410 - Disclosure - Leases -  Summary of Operating Lease Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" id="LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail">
        <link:definition>100420 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail" id="TermLoanPayableAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Term Loan Payable - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" id="DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail">
        <link:definition>100450 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail" id="StockholdersEquityDeficitAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" id="StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" id="StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail">
        <link:definition>100480 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" id="StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail">
        <link:definition>100490 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail" id="DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail">
        <link:definition>100500 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Inputs used for the ESPP (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
        <link:definition>100510 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
        <link:definition>100520 - Disclosure - Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100530 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail" id="DisclosureLicensingAgreementAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Licensing Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" id="NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
        <link:definition>100570 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100580 - Disclosure - Subsequent Events (Additional Information) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sbtx_LicensingAgreementAbstract" name="LicensingAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" name="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" name="AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_AgreementPaymentAndLicenseTermDesciption" name="AgreementPaymentAndLicenseTermDesciption" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_BenefitFromRDTaxCredits" name="BenefitFromRDTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_CashCashEquivalentsAndLongTermInvestments" name="CashCashEquivalentsAndLongTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" name="ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_EligibleEarnings" name="EligibleEarnings" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" name="IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" name="IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_LicenseFeesPaid" name="LicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" name="MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" name="OperatingLossCarryforwardsAmountNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" name="OperatingLossCarryforwardsAmountToExpireIfNotUsed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_OtherTemporaryAndPermanentDifferences" name="OtherTemporaryAndPermanentDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_PaymentOfDeferredOfferingCosts" name="PaymentOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" name="ProceedReceivedInAdvanceForIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_RDTaxCreditCarryforward" name="RDTaxCreditCarryforward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" name="RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized" name="RightOfUseAssetsAndLeaseLiabilitiesRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_SharesWereReservedUnderTheEspp" name="SharesWereReservedUnderTheEspp" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" name="StockBasedCompensationArrangementsStockOptionGrantContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_StockIssuanceCosts" name="StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" name="StockIssuedDuringPeriodSharesStockOptionsCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" name="TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" name="TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sbtx_TemporaryequityValues" name="TemporaryequityValues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sbtx_AmendedLoanAndSecurityAgreementMember" name="AmendedLoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_EsppWithholdingsMember" name="EsppWithholdingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_LiquidityAndCapitalResourcesMember" name="LiquidityAndCapitalResourcesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" name="RedeemableStockExcersibleOnAgreedUponMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_RestructuringPlanMember" name="RestructuringPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SeriesCMember" name="SeriesCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SharesAvailableForFutureEquityAwardGrantsMember" name="SharesAvailableForFutureEquityAwardGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" name="SharesUnderlyingEarlyExercisedEquityAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SharesUnderlyingEsppWithholdingsMember" name="SharesUnderlyingEsppWithholdingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SharesUnderlyingOutstandingEquityAwardsMember" name="SharesUnderlyingOutstandingEquityAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_UnvestedCommonStockMember" name="UnvestedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_WuxiBioMember" name="WuxiBioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_EmployeeStockPurchasePlanPolicyTextBlock" name="EmployeeStockPurchasePlanPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_LicensingAgreementTextBlock" name="LicensingAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock" name="PrepaidExpensesAndOtherAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock" name="ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>32
<FILENAME>sbtx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-31T11:06:58.3093+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:href="sbtx-20211231.xsd#StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="sbtx-20211231.xsd#StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#NatureOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:href="sbtx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="sbtx-20211231.xsd#FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:href="sbtx-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#LeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#TermLoanPayableAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" xlink:href="sbtx-20211231.xsd#DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#StockholdersEquityDeficitAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail" xlink:href="sbtx-20211231.xsd#DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#StockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureLicensingAgreementAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:href="sbtx-20211231.xsd#NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="sbtx-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryequityValues" xlink:label="sbtx_TemporaryequityValues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_TemporaryequityValues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuanceCosts" xlink:label="sbtx_StockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="sbtx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_StockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sbtx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LiquidityAndCapitalResourcesMember" xlink:label="sbtx_LiquidityAndCapitalResourcesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_CashCashEquivalentsAndLongTermInvestments" xlink:label="sbtx_CashCashEquivalentsAndLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sbtx_LiquidityAndCapitalResourcesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_CashCashEquivalentsAndLongTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" xlink:label="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LaboratoryEquipmentMember" xlink:label="sbtx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sbtx_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingSubleaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingSubleaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TermLoanMember" xlink:label="sbtx_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SiliconValleyBankMember" xlink:label="sbtx_SiliconValleyBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LoanAndSecurityAgreementMember" xlink:label="sbtx_LoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AmendedLoanAndSecurityAgreementMember" xlink:label="sbtx_AmendedLoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sbtx_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="sbtx_SiliconValleyBankMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sbtx_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sbtx_AmendedLoanAndSecurityAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:label="sbtx_SharesUnderlyingOutstandingEquityAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:label="sbtx_SharesAvailableForFutureEquityAwardGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:label="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:label="sbtx_SharesUnderlyingEsppWithholdingsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesUnderlyingOutstandingEquityAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesAvailableForFutureEquityAwardGrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sbtx_SharesUnderlyingEsppWithholdingsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:label="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SeriesCMember" xlink:label="sbtx_SeriesCMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:label="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:label="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" xlink:label="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" xlink:label="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesBMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="sbtx_SeriesCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" xlink:label="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnvestedCommonStockMember" xlink:label="sbtx_UnvestedCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EmployeeStockPurchasePlanMember" xlink:label="sbtx_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" xlink:label="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" xlink:label="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EligibleEarnings" xlink:label="sbtx_EligibleEarnings"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_SharesWereReservedUnderTheEspp" xlink:label="sbtx_SharesWereReservedUnderTheEspp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sbtx_UnvestedCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="sbtx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_EligibleEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sbtx_SharesWereReservedUnderTheEspp" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:label="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsExpirationYear" xlink:label="sbtx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:label="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_TaxCreditCarryforwardExpirationYear" xlink:label="sbtx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="sbtx_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_LicenseFeesPaid" xlink:label="sbtx_LicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_WuxiBioMember" xlink:label="sbtx_WuxiBioMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:label="sbtx_AgreementPaymentAndLicenseTermDesciption"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_LicenseFeesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sbtx_WuxiBioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sbtx_AgreementPaymentAndLicenseTermDesciption" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_UnvestedCommonStockMember" xlink:label="sbtx_UnvestedCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_EsppWithholdingsMember" xlink:label="sbtx_EsppWithholdingsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sbtx_UnvestedCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="sbtx_EsppWithholdingsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RestructuringPlanMember" xlink:label="sbtx_RestructuringPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="us-gaap_LossContingencyLawsuitFilingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:loc xlink:type="locator" xlink:href="sbtx-20211231.xsd#sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" xlink:label="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="sbtx_RestructuringPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LossContingencyLawsuitFilingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringPlanAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringCharges" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685340472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Silverback Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text"> No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Fairview Ave N<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">456-2900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,143,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Portions of the registrant&#8217;s definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031686038328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 254,045<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,447<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">261,492<span></span>
</td>
<td class="nump">390,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
<td class="nump">64,780<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">4,733<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,212<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">333,467<span></span>
</td>
<td class="nump">394,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,727<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Term loan payable, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,892<span></span>
</td>
<td class="nump">9,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">4,760<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,652<span></span>
</td>
<td class="nump">11,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at December 31, 2021 and 2020, 35,133,934 and 34,801,537 shares issued and 35,107,651 and 34,701,274 shares outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">500,349<span></span>
</td>
<td class="nump">479,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(326)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(186,212)<span></span>
</td>
<td class="num">(96,734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">313,815<span></span>
</td>
<td class="nump">382,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, and stockholders' equity</a></td>
<td class="nump">$ 333,467<span></span>
</td>
<td class="nump">$ 394,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685284456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock , shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">35,133,934<span></span>
</td>
<td class="nump">34,801,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">35,107,651<span></span>
</td>
<td class="nump">34,701,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683668744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 61,501<span></span>
</td>
<td class="nump">$ 24,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,083<span></span>
</td>
<td class="nump">8,341<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">89,584<span></span>
</td>
<td class="nump">32,918<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(89,584)<span></span>
</td>
<td class="num">(32,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">106<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(89,478)<span></span>
</td>
<td class="num">(32,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(326)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to common stockholders</a></td>
<td class="num">$ (89,804)<span></span>
</td>
<td class="num">$ (32,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.56)<span></span>
</td>
<td class="num">$ (11.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">34,926,403<span></span>
</td>
<td class="nump">2,907,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684944408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,714,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (58,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash', window );">Issuance of redeemable convertible preferred stock for cash (Note 8)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock for cash (Note 8), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,760,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes', window );">Issuance of redeemable convertible preferred stock upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,095<span></span>
</td>
<td class="nump">$ 84,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Issuance of redeemable convertible preferred stock upon conversion of convertible notes, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,673,388<span></span>
</td>
<td class="nump">24,926,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryequityValues', window );">Redeemable convertible preferred stock converted into shares of common stock ,values</a></td>
<td class="nump">216,567<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">216,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (216,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering of common stock, net of $22,386 in issuance costs , values</a></td>
<td class="nump">255,339<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">255,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering of common stock, net of $22,386 in issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(32,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 382,877<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">479,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">34,701,274<span></span>
</td>
<td class="nump">34,701,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock converted into shares of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,758,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,074,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options, shares</a></td>
<td class="nump">261,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and vesting of early exercised common stock options</a></td>
<td class="nump">$ 1,555<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of common stock options, shares issued under the employee stock purchase plan, and vesting of early exercised common stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(89,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
<td class="num">(89,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 313,815<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 500,349<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
<td class="num">$ (186,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">35,107,651<span></span>
</td>
<td class="nump">35,107,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised and employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options exercised and employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued on conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock classified as temporary equity issued for cash during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryequityValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>TemporaryEquity values</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryequityValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031688401528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 22,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sbtx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sbtx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sbtx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683678696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (89,478)<span></span>
</td>
<td class="num">$ (32,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19,187<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash&#160;lease expense</a></td>
<td class="nump">1,146<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,360)<span></span>
</td>
<td class="num">(3,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(1,074)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(66,760)<span></span>
</td>
<td class="num">(31,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale securities</a></td>
<td class="num">(65,106)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,372)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(66,478)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">153,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">258,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_PaymentOfDeferredOfferingCosts', window );">Payment of deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Principal payments on term loan payable</a></td>
<td class="num">(846)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of common stock options and employee stock purchase plan</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">408,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(132,624)<span></span>
</td>
<td class="nump">376,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">386,919<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">254,295<span></span>
</td>
<td class="nump">386,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Unpaid initial public offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized', window );">Right-of-use assets and lease liabilities recognized</a></td>
<td class="nump">3,699<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes', window );">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering', window );">Conversion of redeemable convertible preferred stock upon closing of initial public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of redeemable convertible preferred stock upon closing of initial public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in operating lease liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_PaymentOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred offering costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_PaymentOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use assets and lease liabilities recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid initial public offering costs included in accounts payable and accrued expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689681512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Silverback Therapeutics, Inc. (&#8220;Silverback&#8221; or &#8220;the Company&#8221;) is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company&#8217;s ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. The Company&#8217;s platform enables it to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January 4, 2016.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company completed its initial public offering of common stock (&#8220;IPO&#8221;) of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,225,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">255.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and offering expenses paid by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the IPO, all </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,074,884</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock outstanding at the time of the IPO converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,758,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock. Additionally, in November 2020, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s certificate of incorporation to effect a reverse split of shares of the Company&#8217;s common stock on a one-for-3.713 basis, which was effected on November 30, 2020 (the &#8220;Reverse Stock Split&#8221;) in anticipation of the IPO.  All references to common stock and options to purchase common stock share data, per share data, and related information contained in the financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the Company&#8217;s existing products under development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company had cash, cash equivalents, restricted cash, and investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">319.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily through the issuance of redeemable convertible preferred stock, convertible notes, and the sale of common stock in connection with the IPO. The Company&#8217;s currently available cash, cash equivalents, restricted cash, and investments as of December 31, 2021 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern for a period of at least 12 months from the date the financial statements are issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management expects operating losses to continue for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical development activities as well as the commercialization of the Company&#8217;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689715656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the coronavirus (&#8220;COVID-19&#8221;) pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trial and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing tissue targeted therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents, restricted cash, and investments are carried at fair value. Accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. The term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At December 31, 2021 and December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company&#8217;s cash equivalents consisted of money market funds.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the operating lease for the Company&#8217;s headquarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.095%;"/>
          <td style="width:1.512%;"/>
          <td style="width:2.003%;"/>
          <td style="width:17.496%;"/>
          <td style="width:0.942%;"/>
          <td style="width:1.512%;"/>
          <td style="width:2.003%;"/>
          <td style="width:17.496%;"/>
          <td style="width:0.942%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254,045</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,569</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">350</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash and cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254,295</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,919</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests excess cash in investment grade intermediate-term fixed income securities. These investments are included in long-term investments on the balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Realized gains and losses on the sale of these securities are recognized in net loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company periodically evaluates whether declines in fair values of its investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the investments, duration and severity of the decline in value, and the Company's strategy and intentions for holding the investment.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to credit risk from holding its cash and cash equivalents at a limited number of commercial banks. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings and U.S. Treasury securities. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prepaid Expenses and Other Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses consist primarily of operating expenses paid in advance of when services are provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of furniture and fixtures and laboratory equipment and is stated at cost, less accumulated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">depreciation. Furniture and fixtures and laboratory equipment are depreciated over the estimated useful lives of the assets (each three to five years) using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Repairs and maintenance costs are charged to expense as incurred.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leases consist of the Company&#8217;s operating leases. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s leases include options to extend or terminate the leases. Periods covered by an option to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate a lease are included in the lease term when it is reasonably certain that the Company will not exercise that option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and non-lease components. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets consist of property and equipment and ROU assets. These assets are reviewed for impairment whenever facts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses through December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#8217;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#8217;s program pipeline. Direct costs include expenses incurred under agreements with CROs and other vendors that conduct the Company&#8217;s preclinical and clinical activities, expenses associated with manufacturing the Company&#8217;s product candidates including under agreements with contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#8217;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#8217;s research and development efforts and have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. General and administrative costs are expensed as incurred.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#8217;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) became effective, pursuant to which eligible employees can purchase shares of the Company&#8217;s common stock at a discount to the fair market value at semi-annual intervals. In determining the grant date fair value of shares expected to be purchased under the ESPP, the Company uses the Black-Scholes option pricing model. Black-Scholes inputs are determined in the same manner as for stock option awards. The estimated grant date fair value of shares expected to be purchased is recognized into expense on a straight-line basis over the requisite service period.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company is more likely than not able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes in the period in which the adjustment is made.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the basis of the technical merits of the position and (2) for those tax positions that meet the recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. The Company did not have any uncertain tax positions as of December 31, 2021 and 2020.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company presents one continuous Statement of Operations and Comprehensive Loss. The Company&#8217;s comprehensive loss includes unrealized gains and losses on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689649064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.963%;"/>
      <td style="width:1.0%;"/>
      <td style="width:1.0%;"/>
      <td style="width:93.037%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1: Quoted prices in Active Markets for identical assets or liabilities.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.963%;"/>
      <td style="width:1.0%;"/>
      <td style="width:1.0%;"/>
      <td style="width:93.037%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.963%;"/>
      <td style="width:1.0%;"/>
      <td style="width:1.0%;"/>
      <td style="width:93.037%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3: Unobservable inputs that are supported by little or no market activity.</span></p></td>
     </tr>
    </table><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table identifies the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.954%;"/>
        <td style="width:1.218%;"/>
        <td style="width:7.39%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:11.566%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:10.905%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:10.522%;"/>
        <td style="width:1.079%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:9.06%;"/>
        <td style="width:0.661%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross unrealized gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross unrealized losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term investments - U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,106</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,780</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">319,051</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the periods presented.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s long-term investments portfolio contains investments in U.S. Treasury securities that have an effective maturity date that is more than one year, but less than two years, from the respective balance sheet date. The Company evaluated its investments for other-than-temporary impairment and considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. For the investments, it is not more-likely-than-not that the Company will be required to sell the investments, and the Company does not intend to do so prior to the recovery of the amortized cost basis.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031688875112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are summarized as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:ARIAL;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.849%;"/>
        <td style="width:2.935%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.701%;"/>
        <td style="width:1.114%;"/>
        <td style="width:4.374%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.55%;"/>
        <td style="width:1.114%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,679</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,401</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,046</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,834</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,052</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,212</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689651336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.816%;"/>
        <td style="width:1.949%;"/>
        <td style="width:1.706%;"/>
        <td style="width:12.671%;"/>
        <td style="width:0.766%;"/>
        <td style="width:1.949%;"/>
        <td style="width:1.706%;"/>
        <td style="width:12.671%;"/>
        <td style="width:0.766%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,528</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,063</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,605</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,634</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional services and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,727</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031688873800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.478%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.682%;"/>
        <td style="width:14.049%;"/>
        <td style="width:0.742%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.561%;"/>
        <td style="width:0.742%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,452</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,388</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">459</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,911</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,774</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash outflows from operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,841</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 1, 2021, the Company entered into a sublease agreement for additional office space in Seattle, Washington. The commencement date of the sublease was August 1, 2021. The contractual term of the sublease is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend for one additional year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to terminate after one year subject to a termination fee</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The annual minimum rent payable by the Company under the sublease is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million annually. The ROU asset obtained in exchange for the new operating lease liability was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of the lease commencement date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining term on the Company's leases was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years as of December 31, 2021 and 2020, respectively. To compute the present value of the lease liabilities, the Company used weighted average discount rates of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% as of December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, there was a change in the expected lease term of the Company&#8217;s Seattle, Washington headquarters, whereby the Company became reasonably certain that it will not exercise its option to terminate the lease. As a result, the ROU asset and lease liability were remeasured using the present value of the remaining lease payments. The re-measurement resulted in an addition to the ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The change in the expected lease term has no effect on the classification of the lease.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum commitments due under the operating lease agreements as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.706%;"/>
        <td style="width:1.654%;"/>
        <td style="width:2.974%;"/>
        <td style="width:17.677%;"/>
        <td style="width:1.989%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,513</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,917</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,070</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total present value of lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,847</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689659416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Payable</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Term Loan Payable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (&#8220;SVB&#8221;) and borrowed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a term loan. The outstanding principal amount of the term loan accrued interest at an annual rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per annum. At closing, the Company incurred de minimis debt issuance costs and owed a final payment fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate of the Company&#8217;s term loan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term loan&#8217;s original maturity date was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. However, in April 2020, the Company amended the loan and security agreement to defer principal payments for six months and extend the maturity date to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification and amortized the remaining debt discount over the remaining term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On May 1, 2021, the Company made its final scheduled payment to SVB under the loan and security agreement including the final payment fee.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031688873800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Stockholders&#8217; Equity (Deficit)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Authorized Shares</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s current Amended and Restated Certificate of Incorporation authorizes </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to its conversion to common stock in December 2020, the Company&#8217;s redeemable convertible preferred stock was classified as mezzanine equity on the Company&#8217;s balance sheets as the shares are contingently redeemable upon a deemed liquidation such as a change in control and in that event, there is no guarantee that all stockholders would be entitled to receive the same form of consideration. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accretion to redemption value was recorded during the year ended December 31, 2020 as a deemed liquidation event was not considered probable.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company issued convertible preferred stock as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,701,054</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series B redeemable convertible preferred stock, including </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,673,388</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued upon conversion of then outstanding convertible notes and accrued interest, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,027,666</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Series B purchase agreement provided that the Company would issue, and the Series B holders would purchase, an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,732,862</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the event that certain agreed upon milestones were achieved or the preferred majority approved their closing. The Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 1, 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,669,834</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,063,028</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,926,685</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its Series C redeemable convertible preferred stock for cash at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Series C purchase agreement did not contain any embedded features that meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved shares of common stock for the following potential future issuances:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.528%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.963%;"/>
        <td style="width:14.279%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.963%;"/>
        <td style="width:14.279%;"/>
        <td style="width:0.963%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying outstanding equity awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,316,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future equity award grants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,931,012</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,506,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying early exercised equity awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,283</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,263</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying ESPP withholdings</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,328,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,928,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689624184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.777%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.433%;"/>
        <td style="width:13.524%;"/>
        <td style="width:0.649%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.433%;"/>
        <td style="width:13.38%;"/>
        <td style="width:0.649%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,856</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the total unrecognized stock-based compensation expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.49</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company&#8217;s equity incentive plans authorized a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,564,798</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,931,012</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are available for future grant, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are outstanding. Not included in the outstanding option balance are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,283</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares pursuant to stock options that were early exercised and subject to repurchase that remain unvested as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options granted under the Company&#8217;s equity incentive plans expire no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years from the date of grant and generally vest over a four year period, with vesting either occurring at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% at the end of the first and thereafter in 36 equal monthly installments or on a monthly basis. In the case of awards granted to our non-employee board members, vesting generally occurs on a monthly basis over three years or in full on an annual basis. The Company issues new shares of common stock upon the exercise of stock options.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s stock option activity for the year ended December 31, 2021 is as follows (in thousands, except share and per share data and years):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.416%;"/>
        <td style="width:1.033%;"/>
        <td style="width:0.859%;"/>
        <td style="width:11.312%;"/>
        <td style="width:1.079%;"/>
        <td style="width:1.033%;"/>
        <td style="width:1.613%;"/>
        <td style="width:9.99%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.033%;"/>
        <td style="width:0.847%;"/>
        <td style="width:11.301%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.033%;"/>
        <td style="width:1.613%;"/>
        <td style="width:11.858%;"/>
        <td style="width:0.661%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stock Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares<br/>Subject to<br/>Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,316,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">511,773</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">261,567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">195,902</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.58</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,385,117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,974,776</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.60</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.14</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,887,808</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock for all options that were in-the-money at December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value per share of option grants for the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.  The total fair value of shares vested during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.272%;"/>
        <td style="width:1.412%;"/>
        <td style="width:1.078%;"/>
        <td style="width:13.638%;"/>
        <td style="width:4.942%;"/>
        <td style="width:1.078%;"/>
        <td style="width:13.638%;"/>
        <td style="width:4.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"/>
      <td style="width:1.0%;"/>
      <td style="width:0.982%;"/>
      <td style="width:93.036%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Prior to the Company's initial public offering in 2020, the grant date fair market value of the shares of common stock underlying stock options was determined by the Company&#8217;s board of directors. Following the closing of the Company&#8217;s IPO, the fair market value of the Company's common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#8217;s common stock is traded. Prior to the Company&#8217;s IPO, because there was no public market for the Company&#8217;s common stock, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included contemporaneous valuations performed by an independent third-party, the Company&#8217;s results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#8217;s business, progress of the Company&#8217;s research and development activities, the Company&#8217;s business conditions and projections, the lack of marketability of the Company&#8217;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#8217;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#8217;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key personnel and the experience of management, trends and developments in the Company&#8217;s industry and external market conditions affecting the life sciences and biotechnology industry sectors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"/>
      <td style="width:1.0%;"/>
      <td style="width:0.982%;"/>
      <td style="width:93.036%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"/>
      <td style="width:1.0%;"/>
      <td style="width:0.982%;"/>
      <td style="width:93.036%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Given the Company&#8217;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"/>
      <td style="width:1.0%;"/>
      <td style="width:0.982%;"/>
      <td style="width:93.036%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
     </tr>
    </table><p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:4.982%;"/>
      <td style="width:1.0%;"/>
      <td style="width:0.982%;"/>
      <td style="width:93.036%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero.</span></p></td>
     </tr>
    </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company&#8217;s board of directors and stockholders approved and adopted the 2020 ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">698,015</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were reserved under the ESPP, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">627,185</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares are available for future issuance and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,830</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued. The weighted average per share fair value rights granted during the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.489%;"/>
        <td style="width:11.076%;"/>
        <td style="width:1.301%;"/>
        <td style="width:13.51%;"/>
        <td style="width:4.906%;"/>
        <td style="width:1.301%;"/>
        <td style="width:13.51%;"/>
        <td style="width:4.906%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689717048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Income Taxes</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s effective tax rates for the years ended December 31, 2021 and 2020 differ from the U.S. federal statutory rate as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.649%;"/>
        <td style="width:4.467%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.888%;"/>
        <td style="width:1.114%;"/>
        <td style="width:3.84%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1.114%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax at the federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Benefit from R&amp;D tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">586</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible executive compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other temporary and permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.348%;"/>
        <td style="width:2.494%;"/>
        <td style="width:1.671%;"/>
        <td style="width:13.527%;"/>
        <td style="width:1.114%;"/>
        <td style="width:4.536%;"/>
        <td style="width:1.671%;"/>
        <td style="width:13.527%;"/>
        <td style="width:1.114%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,671</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,832</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D tax credit carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,746</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">227</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">237</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities - Right of use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">994</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">458</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,039</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021, the Company had net operating loss carryforwards for income tax purposes of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. If not used, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of this carryforward will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142.1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has no expiration. At December 31, 2021, the Company also had research and development tax credits of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> if left unused. The Company did not have any foreign tax provision and did not generate material net operating losses in any states with an income tax.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FASB ASC 740 requires that the tax benefit of net operating losses, temporary differences, and credit carryforwards be recorded as an asset to the extent that management assesses the realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits from the net operating losses or credit carryforwards, if any, is dependent on the Company&#8217;s ability to generate sufficient taxable income within the applicable carryforward period. Because of the Company&#8217;s recent history of operating losses, the Company maintains a full valuation allowance in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company may have already experienced one or more ownership changes. Depending on the timing of any future utilization of its carryforwards, the Company may be limited as to the amount that can be utilized each year as a result of such previous ownership changes. However, the Company does not believe such limitations will cause its carryforwards to expire unutilized.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future changes in the Company&#8217;s stock ownership as well as other changes that may be outside the Company&#8217;s control could potentially result in further limitations on the Company&#8217;s ability to utilize its net operating loss and tax credit carryforwards.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have any liabilities for unrecognized income tax benefits associated with uncertain tax positions, including any interest and penalties.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689659416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LicensingAgreementAbstract', window );"><strong>Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LicensingAgreementTextBlock', window );">Licensing Agreement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Licensing Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Bio&#8221;). Under the license agreement, WuXi Bio granted the Company a non-exclusive, worldwide, sublicensable, under certain of WuXi Bio&#8217;s intellectual property rights, know-how and biological materials (&#8220;WuXi Bio Licensed Technology&#8221;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#8220;WuXi Bio Licensed Product&#8221;). The WuXi Bio Licensed Technology is currently used to manufacture a component of the Company&#8217;s ImmunoTAC platform. The Company has paid an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in license fees that were recorded in research and development expense when incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them through the termination date. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party may terminate the license immediately upon written notice to the other party.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LicensingAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LicensingAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689714824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 5, 2021, a securities class action complaint was filed against the Company and certain of the Company's officers and directors in the U.S. District for the Western District of Washington, captioned Dresner v. Silverback Therapeutics, Inc., et al., Case No. 2:21-cv-01499.  The complaint alleges that between December 3, 2020 and September 10, 2021, the Company and certain of the Company's officers and directors violated (1) Sections 11 and 15 of the Securities Act of 1933, as amended; and (2) Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission (&#8220;SEC&#8221;) Rule 10b-5 promulgated thereunder, by making allegedly false and misleading statements in various SEC filings and press releases regarding the clinical and commercial prospects of the Company&#8217;s product candidate, SBT6050, which is now discontinued.  The complaint seeks unspecified damages and interest, as well as attorneys&#8217; fees and other costs. The court recently appointed lead plaintiff and lead plaintiff's counsel. The Company and the other defendants have not yet filed a response to the complaint, and do not anticipate doing so until after the filing of an amended complaint.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company cannot predict the outcome of this suit, and failure by the Company to obtain a favorable resolution could have a material adverse effect on its business, results of operations and financial condition. The Company&#8217;s chances of success on the merits are still uncertain and any possible loss or range of loss cannot be reasonably estimated and as such the Company has not recorded a liability as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions or related to any indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global COVID-19 pandemic continues to rapidly evolve, and management continue to monitor the situation closely. The extent of the impact of COVID-19 on the Company&#8217;s business, operations, planned preclinical studies and clinical trials, and manufacturing timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#8217;s CROs, third-party manufacturers, supply chains necessary for research and development and manufacturing, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the Company&#8217;s key scientific and management personnel. For example, the COVID-19 pandemic has caused the cost of obtaining animals for our preclinical studies to increase dramatically and, if the shortage continues, could also result in delays to our development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and some of the Company&#8217;s non-lab based employees working remotely. Management will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter Company operations, including those that may be required by federal, state or local authorities, or that management determines are in the best interests of the Company&#8217;s employees and other third parties with whom the Company does business. At this point, the extent to which the COVID-19 pandemic may further affect the Company&#8217;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689678104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Employee Benefit Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#8217;s U.S. employees. The plan allows eligible employees to defer, at the employee&#8217;s discretion, pretax compensation up to the IRS annual limits. The Company did not match contributions made by employees through December 31, 2021. The Company began matching </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of employee contributions in 2022.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689665896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.997%;"/>
        <td style="width:1.591%;"/>
        <td style="width:0.809%;"/>
        <td style="width:17.292%;"/>
        <td style="width:0.809%;"/>
        <td style="width:1.591%;"/>
        <td style="width:0.809%;"/>
        <td style="width:17.292%;"/>
        <td style="width:0.809%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,316,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,283</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ESPP withholdings</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total potentially dilutive shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,397,156</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,421,225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689625304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to December 31, 2021 through March 31, 2022, the Company&#8217;s board of directors approved the grant of options to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,815,926</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The unrecognized stock-based compensation expense for these grants is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Additionally, the Company&#8217;s board of directors approved the grant of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266,744</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> restricted stock units. The unrecognized stock-based compensation expense for these awards is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 28, 2022, the Company&#8217;s board of directors approved a corporate restructuring plan to discontinue the Company&#8217;s clinical development programs for SBT6050 and SBT6290 and to prioritize resources on the development of SBT8230 and early-stage discovery programs (the &#8220;Restructuring Plan&#8221;). In connection with the Restructuring Plan, the Company&#8217;s workforce will be reduced by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, with substantially all of the reduction in personnel expected to be completed by </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 15, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company initiated the reduction in force on March 31, 2022 and expects to provide severance payments, continuation of group health insurance coverage, and other benefits for a specified period to the affected employees. The Company currently estimates that it will incur costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for termination benefits related to the Restructuring Plan, all of which will be cash expenditures paid in 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683688680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Polices)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the coronavirus (&#8220;COVID-19&#8221;) pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trial and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing tissue targeted therapeutics. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents, restricted cash, and investments are carried at fair value. Accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. The term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At December 31, 2021 and December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company&#8217;s cash equivalents consisted of money market funds.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the operating lease for the Company&#8217;s headquarters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.095%;"/>
          <td style="width:1.512%;"/>
          <td style="width:2.003%;"/>
          <td style="width:17.496%;"/>
          <td style="width:0.942%;"/>
          <td style="width:1.512%;"/>
          <td style="width:2.003%;"/>
          <td style="width:17.496%;"/>
          <td style="width:0.942%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254,045</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,569</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">350</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash and cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254,295</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,919</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests excess cash in investment grade intermediate-term fixed income securities. These investments are included in long-term investments on the balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Realized gains and losses on the sale of these securities are recognized in net loss.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company periodically evaluates whether declines in fair values of its investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the investment until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the investments, duration and severity of the decline in value, and the Company's strategy and intentions for holding the investment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to credit risk from holding its cash and cash equivalents at a limited number of commercial banks. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings and U.S. Treasury securities. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prepaid Expenses and Other Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses consist primarily of operating expenses paid in advance of when services are provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of furniture and fixtures and laboratory equipment and is stated at cost, less accumulated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">depreciation. Furniture and fixtures and laboratory equipment are depreciated over the estimated useful lives of the assets (each three to five years) using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Repairs and maintenance costs are charged to expense as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leases consist of the Company&#8217;s operating leases. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s leases include options to extend or terminate the leases. Periods covered by an option to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate a lease are included in the lease term when it is reasonably certain that the Company will not exercise that option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and non-lease components. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets consist of property and equipment and ROU assets. These assets are reviewed for impairment whenever facts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses through December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#8217;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#8217;s program pipeline. Direct costs include expenses incurred under agreements with CROs and other vendors that conduct the Company&#8217;s preclinical and clinical activities, expenses associated with manufacturing the Company&#8217;s product candidates including under agreements with contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#8217;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#8217;s research and development efforts and have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. General and administrative costs are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#8217;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_EmployeeStockPurchasePlanPolicyTextBlock', window );">Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) became effective, pursuant to which eligible employees can purchase shares of the Company&#8217;s common stock at a discount to the fair market value at semi-annual intervals. In determining the grant date fair value of shares expected to be purchased under the ESPP, the Company uses the Black-Scholes option pricing model. Black-Scholes inputs are determined in the same manner as for stock option awards. The estimated grant date fair value of shares expected to be purchased is recognized into expense on a straight-line basis over the requisite service period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company is more likely than not able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes in the period in which the adjustment is made.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the basis of the technical merits of the position and (2) for those tax positions that meet the recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. The Company did not have any uncertain tax positions as of December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company presents one continuous Statement of Operations and Comprehensive Loss. The Company&#8217;s comprehensive loss includes unrealized gains and losses on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy followed under emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_EmployeeStockPurchasePlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_EmployeeStockPurchasePlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689755736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.095%;"/>
          <td style="width:1.512%;"/>
          <td style="width:2.003%;"/>
          <td style="width:17.496%;"/>
          <td style="width:0.942%;"/>
          <td style="width:1.512%;"/>
          <td style="width:2.003%;"/>
          <td style="width:17.496%;"/>
          <td style="width:0.942%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254,045</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,569</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">350</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash and cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254,295</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,919</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689701752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table identifies the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.954%;"/>
        <td style="width:1.218%;"/>
        <td style="width:7.39%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:11.566%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:10.905%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:10.522%;"/>
        <td style="width:1.079%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.613%;"/>
        <td style="width:9.06%;"/>
        <td style="width:0.661%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross unrealized gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross unrealized losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term investments - U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,106</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,780</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">319,051</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386,369</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689748456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are summarized as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:ARIAL;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.849%;"/>
        <td style="width:2.935%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.701%;"/>
        <td style="width:1.114%;"/>
        <td style="width:4.374%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.55%;"/>
        <td style="width:1.114%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,679</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,401</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,046</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,834</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,052</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,212</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689643880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.816%;"/>
        <td style="width:1.949%;"/>
        <td style="width:1.706%;"/>
        <td style="width:12.671%;"/>
        <td style="width:0.766%;"/>
        <td style="width:1.949%;"/>
        <td style="width:1.706%;"/>
        <td style="width:12.671%;"/>
        <td style="width:0.766%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,528</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,063</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation and benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,605</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,634</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional services and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,727</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031686510712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Operating Lease Cost</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.478%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.682%;"/>
        <td style="width:14.049%;"/>
        <td style="width:0.742%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.561%;"/>
        <td style="width:0.742%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,452</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,388</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">459</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,911</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,774</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash outflows from operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,841</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Commitments Due Under the Operating Lease Agreement</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum commitments due under the operating lease agreements as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.706%;"/>
        <td style="width:1.654%;"/>
        <td style="width:2.974%;"/>
        <td style="width:17.677%;"/>
        <td style="width:1.989%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,481</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,513</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,917</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,070</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total present value of lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,847</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689738248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock', window );">Summary of Common Shares Reserved for Future Issuance&#160;</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved shares of common stock for the following potential future issuances:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.528%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.963%;"/>
        <td style="width:14.279%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.963%;"/>
        <td style="width:14.279%;"/>
        <td style="width:0.963%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying outstanding equity awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,316,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future equity award grants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,931,012</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,506,806</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying early exercised equity awards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,283</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,263</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares underlying ESPP withholdings</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,328,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,928,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031686520760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.777%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.433%;"/>
        <td style="width:13.524%;"/>
        <td style="width:0.649%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.433%;"/>
        <td style="width:13.38%;"/>
        <td style="width:0.649%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,856</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,460</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Related to Stock Option Grants</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company&#8217;s stock option activity for the year ended December 31, 2021 is as follows (in thousands, except share and per share data and years):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.416%;"/>
        <td style="width:1.033%;"/>
        <td style="width:0.859%;"/>
        <td style="width:11.312%;"/>
        <td style="width:1.079%;"/>
        <td style="width:1.033%;"/>
        <td style="width:1.613%;"/>
        <td style="width:9.99%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.033%;"/>
        <td style="width:0.847%;"/>
        <td style="width:11.301%;"/>
        <td style="width:0.661%;"/>
        <td style="width:1.033%;"/>
        <td style="width:1.613%;"/>
        <td style="width:11.858%;"/>
        <td style="width:0.661%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stock Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares<br/>Subject to<br/>Options<br/>Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,316,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">511,773</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">261,567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">195,902</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.58</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,385,117</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,974,776</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.60</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.14</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,887,808</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.272%;"/>
        <td style="width:1.412%;"/>
        <td style="width:1.078%;"/>
        <td style="width:13.638%;"/>
        <td style="width:4.942%;"/>
        <td style="width:1.078%;"/>
        <td style="width:13.638%;"/>
        <td style="width:4.942%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Inputs used under for the ESPP</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.489%;"/>
        <td style="width:11.076%;"/>
        <td style="width:1.301%;"/>
        <td style="width:13.51%;"/>
        <td style="width:4.906%;"/>
        <td style="width:1.301%;"/>
        <td style="width:13.51%;"/>
        <td style="width:4.906%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.14</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031686507928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s effective tax rates for the years ended December 31, 2021 and 2020 differ from the U.S. federal statutory rate as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.649%;"/>
        <td style="width:4.467%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.888%;"/>
        <td style="width:1.114%;"/>
        <td style="width:3.84%;"/>
        <td style="width:1.682%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1.114%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax at the federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Benefit from R&amp;D tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">586</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible executive compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other temporary and permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant components of the Company&#8217;s deferred tax assets and liabilities were as follows (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.348%;"/>
        <td style="width:2.494%;"/>
        <td style="width:1.671%;"/>
        <td style="width:13.527%;"/>
        <td style="width:1.114%;"/>
        <td style="width:4.536%;"/>
        <td style="width:1.671%;"/>
        <td style="width:13.527%;"/>
        <td style="width:1.114%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,671</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,832</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D tax credit carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,746</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,502</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">227</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">237</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities - Right of use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">994</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">458</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,039</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689688840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.997%;"/>
        <td style="width:1.591%;"/>
        <td style="width:0.809%;"/>
        <td style="width:17.292%;"/>
        <td style="width:0.809%;"/>
        <td style="width:1.591%;"/>
        <td style="width:0.809%;"/>
        <td style="width:17.292%;"/>
        <td style="width:0.809%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,370,873</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,316,569</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,283</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ESPP withholdings</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total potentially dilutive shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,397,156</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,421,225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685139688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (186,212)<span></span>
</td>
<td class="num">$ (96,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,045<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_CashCashEquivalentsAndLongTermInvestments', window );">Cash, cash equivalents, and long term investments.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,133,934<span></span>
</td>
<td class="nump">34,801,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,714,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after deducting underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 255,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">13,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of preferred stock, common shares issued</a></td>
<td class="nump">20,758,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding</a></td>
<td class="nump">77,074,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_CashCashEquivalentsAndLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and long term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_CashCashEquivalentsAndLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685325304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 254,045<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash</a></td>
<td class="nump">254,295<span></span>
</td>
<td class="nump">386,919<span></span>
</td>
<td class="nump">$ 10,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">254,045<span></span>
</td>
<td class="nump">386,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash</a></td>
<td class="nump">$ 254,295<span></span>
</td>
<td class="nump">$ 386,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683696680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">$ 254,045<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total Amortized Cost</a></td>
<td class="nump">319,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue', window );">Total Fair Value</a></td>
<td class="nump">318,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value, Recurring [Member] | Long-Term Investments - U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">65,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">64,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">253,945<span></span>
</td>
<td class="nump">386,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, fair value</a></td>
<td class="nump">$ 253,945<span></span>
</td>
<td class="nump">$ 386,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Money Market Funds and Available For Sale Debt Securities Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Money Market Funds and Available For Sale Debt Securities Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031688776600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Fair Value, Recurring [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value,assets transfers from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value,assets transfers from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value, liabilities transfers from Level 1 to Level 2</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value, liabilities transfers from Level 2 to Level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684934760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,046<span></span>
</td>
<td class="nump">$ 3,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,834)<span></span>
</td>
<td class="num">(2,052)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">2,212<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sbtx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,679<span></span>
</td>
<td class="nump">$ 3,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sbtx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sbtx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031686507928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685360328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_AccruedResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 6,528<span></span>
</td>
<td class="nump">$ 2,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">4,605<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services and other</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 11,727<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685227864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases -  Summary of Operating Lease Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">1,911<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="nump">$ 1,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684841096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">6,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of lease payments</a></td>
<td class="nump">$ 5,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685215208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Sublease agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 1, 2021, the Company entered into a sublease agreement for additional office space in Seattle, Washington. The commencement date of the sublease was August 1, 2021. The contractual term of the sublease is two years with an option to extend for one additional year and an option to terminate after one year subject to a termination fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Contractual term of sublease</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToExtend', window );">Option to Extend</a></td>
<td class="text">option to extend for one additional year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseOptionToTerminate', window );">Option to Terminate</a></td>
<td class="text">option to terminate after one year subject to a termination fee<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Annual minimum rent payable</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease Weighted Average Remaining Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease Weighted Average Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate operating sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123403832&amp;loc=d3e34039-112682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683854408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Payable - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember', window );">Term Loan [Member] | Silicon Valley Bank [Member] | Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember', window );">Term Loan [Member] | Silicon Valley Bank [Member] | Amended Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=sbtx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=sbtx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sbtx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sbtx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sbtx_AmendedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sbtx_AmendedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031685222760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">9,328,168<span></span>
</td>
<td class="nump">7,928,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingOutstandingEquityAwardsMember', window );">Shares Underlying Outstanding Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">6,370,873<span></span>
</td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesAvailableForFutureEquityAwardGrantsMember', window );">Shares Available For Future Equity Award Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">2,931,012<span></span>
</td>
<td class="nump">1,506,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember', window );">Shares Underlying Early Exercised Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">26,283<span></span>
</td>
<td class="nump">100,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEsppWithholdingsMember', window );">Shares Underlying ESPP Withholdings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingOutstandingEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingOutstandingEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesAvailableForFutureEquityAwardGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesAvailableForFutureEquityAwardGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEsppWithholdingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEsppWithholdingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684981304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock , shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion to Redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember', window );">Redeemable Stock Excersible On Agreed Upon Milestones [Member] | Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,732,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember', window );">Series B [Member] | Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,701,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash', window );">Issuance of Series B redeemable convertible preferred stock for cash</a></td>
<td class="nump">10,669,834<span></span>
</td>
<td class="nump">11,063,028<span></span>
</td>
<td class="nump">4,673,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes', window );">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,027,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember', window );">Series B [Member] | Redeemable Stock Excersible On Agreed Upon Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=sbtx_SeriesCMember', window );">Series C [Member] | Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash', window );">Issuance of series C redeemable convertible preferred stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,926,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B redeemable convertible preferred stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of series C redeemable convertible preferred stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=sbtx_SeriesCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=sbtx_SeriesCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031680578904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 19,187<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">8,331<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,856<span></span>
</td>
<td class="nump">$ 1,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683703656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Options Outstanding, Beginning balance</a></td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Subject to Options Outstanding, Granted</a></td>
<td class="nump">511,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Subject to Options Outstanding, Exercised</a></td>
<td class="num">(261,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled', window );">Shares Subject to Options Outstanding, Cancelled</a></td>
<td class="num">(195,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Options Outstanding, Ending balance</a></td>
<td class="nump">6,370,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares Subject to Options Outstanding Vested, Ending balance</a></td>
<td class="nump">1,974,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 10.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending balance | $ / shares</a></td>
<td class="nump">12.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Vested, Ending balance | $ / shares</a></td>
<td class="nump">$ 9.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (Years)</a></td>
<td class="text">8 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (Years), Vested</a></td>
<td class="text">8 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance | $</a></td>
<td class="nump">$ 11,385,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested Ending balance | $</a></td>
<td class="nump">$ 4,887,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) cancelled during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031688762760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684703528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted Average Inputs used for the ESPP (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.14%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683485112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,564,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,370,873<span></span>
</td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,397,156<span></span>
</td>
<td class="nump">6,421,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair Value of Shares Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share Based Compensation Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares Available for Future Equity Award Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,328,168<span></span>
</td>
<td class="nump">7,928,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.15<span></span>
</td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,133,934<span></span>
</td>
<td class="nump">34,801,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares Available for Future Equity Award Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,931,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=sbtx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
<td class="text">In November 2020, the Company&#8217;s board of directors and stockholders approved and adopted the 2020 ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_EligibleEarnings', window );">Eligible Earnings</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_SharesWereReservedUnderTheEspp', window );">Shares were Reserved Under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares Available for Future Equity Award Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted average per share fair value rights granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember', window );">Unvested Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,283<span></span>
</td>
<td class="nump">100,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_EligibleEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>eligible earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_EligibleEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_SharesWereReservedUnderTheEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares were reserved under the ESPP</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_SharesWereReservedUnderTheEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sbtx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sbtx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031680579096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at the federal statutory rate</a></td>
<td class="num">$ (18,790)<span></span>
</td>
<td class="num">$ (6,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_BenefitFromRDTaxCredits', window );">Benefit from R&amp;D tax credits</a></td>
<td class="num">(1,244)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Non-deductible executive compensation</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_OtherTemporaryAndPermanentDifferences', window );">Other temporary and permanent differences</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">18,082<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_BenefitFromRDTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Benefit from R&amp;D tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_BenefitFromRDTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_OtherTemporaryAndPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other temporary and permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_OtherTemporaryAndPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684700904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 33,671<span></span>
</td>
<td class="nump">$ 18,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_RDTaxCreditCarryforward', window );">R&amp;D tax credit carryforward</a></td>
<td class="nump">2,746<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,151<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deferred tax assets</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">40,033<span></span>
</td>
<td class="nump">21,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Deferred tax liabilities - Right of use asset</a></td>
<td class="num">(994)<span></span>
</td>
<td class="num">(458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(39,039)<span></span>
</td>
<td class="num">(20,889)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_RDTaxCreditCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>R&amp;D tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_RDTaxCreditCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684661400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 160,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed', window );">Operating loss carryforwards amount to expire if not used</a></td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration', window );">Operating loss carryforwards amount not subject to expiration</a></td>
<td class="nump">$ 142,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">39,039<span></span>
</td>
<td class="nump">$ 20,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards amount not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards amount to expire if not used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683678776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreement - Additional Information (Detail) - WuXi Bio [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones', window );">Aggregate milestone payments upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_AgreementPaymentAndLicenseTermDesciption', window );">Agreement payment and license Term desciption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LicenseFeesPaid', window );">License fees paid</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_AgreementPaymentAndLicenseTermDesciption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement payment and license Term desciption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_AgreementPaymentAndLicenseTermDesciption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sbtx_WuxiBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sbtx_WuxiBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031689662536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Equalization of employee contribution</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031684702680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">6,397,156<span></span>
</td>
<td class="nump">6,421,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">6,370,873<span></span>
</td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember', window );">Unvested Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">26,283<span></span>
</td>
<td class="nump">100,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_EsppWithholdingsMember', window );">ESPP withholdings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_EsppWithholdingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_EsppWithholdingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140031683366792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restructuring Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduced</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod', window );">Expectation of workforce reduced period</a></td>
<td class="text">Jul. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost number of positions expected to be eliminated period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=sbtx_RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=sbtx_RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>sbtx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sbtx="http://silverbacktx.com/20211231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sbtx-20211231.xsd" xlink:type="simple"/>
    <context id="C_494bd466-afac-4c94-b8ad-1da406d99780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_67cef16b-8904-4ef1-a280-f5782cc3332b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_babe8ce4-149b-4c33-b021-b0e162ec46a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:RedeemableStockExcersibleOnAgreedUponMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_86a8a0b7-29df-47b1-afc9-35b1ed2b1497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_360c64d4-e8a6-45e9-bf20-6dafe7757ce5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d7fa8844-58a6-4654-9ddd-9b5375a9b363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sbtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8cf07191-8e06-40b3-853c-f995a1f625ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a6798eb1-f0de-4695-9641-5ea592a32344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cfaeded9-f33c-4994-a098-63eb660e83ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_e1043a11-9233-4df8-b363-ce3a0f3f3bb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sbtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_270d424e-2ea7-451c-a3be-3e4a447e5b40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d5d577b3-d7af-45d0-860e-6ec6922cad1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sbtx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0b97d231-61a7-4be6-94e9-44926c823685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sbtx:RestructuringPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_828913ed-d805-418b-ab38-3ca1860cfe83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_13e17b88-9a3e-4334-afaa-25c79b7864bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_860dbe58-a733-4b54-b5e8-6248758d43eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_45c71f8d-3cda-45b7-9581-ba0f5e84dd52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">sbtx:RestructuringPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-28</startDate>
            <endDate>2022-03-28</endDate>
        </period>
    </context>
    <context id="C_e29ac877-2d55-4d24-814b-9d73b1312fe1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="C_60f52c8b-32d5-4e85-b1f0-31ec9fab4c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_b60a8ab1-2e21-4152-9230-5951eda009db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2022-03-28</instant>
        </period>
    </context>
    <context id="C_74e41f57-c0d7-4daf-b14d-df2e105f7efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_37ebbd60-fda0-4900-9609-d33c5ffa0fd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_10924f8e-1bb8-4859-a19f-53e9eeda573c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d2266970-9935-4502-9c86-ada2228e4e21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e5a118de-b5ae-416d-953c-fca753351c6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7ec30bfe-5f48-45a5-b118-07bc27b0ff78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sbtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_40425c84-7c43-4d68-9c93-740efc67f686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sbtx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b7066a98-3245-4333-b828-b75b16bd6d9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:AmendedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_95368c9c-2ef3-4cdf-bc71-1cff6b42577a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e6a0662a-dd26-49c0-af88-491b9b800275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4dcf4afe-a66f-4353-a22e-83f64aa9613d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_954e4039-8ad8-4dde-9cc7-9b313b208185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_71b567b9-dd67-488e-9bff-940240379336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_62d36620-ca03-4b03-8439-9f51726efcf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_443c7d79-857f-4272-94c9-734cc7988aea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c2f82abf-51d1-4cd8-bb42-2d8d43b73153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="C_e4fb8c88-21a6-408b-bd27-cec75b99333f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="C_e77106ce-582d-481d-b3e4-30663c6abfa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6ebc2a75-c6af-4453-bbcf-d1d071452f7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_eccc60cc-900f-452b-bd4e-6dc984c5cd7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="C_a05456f3-88fe-43ff-b244-8a5ee75b83e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3eec66cf-b934-4764-b8db-f29c238527a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c3166a85-f0b6-454d-9e3b-4e94972eab35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9b13a7ea-2f2e-41d9-8210-704162e848d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c917bb6b-c19f-402a-a7f9-3796e47702e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sbtx:WuxiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f23b5346-4ed5-45a9-a974-16fe675333f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="C_21761b55-f888-4dd6-90d9-c5d5d39d5076">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_3d3afa03-0c39-46e2-aac4-cf6089a8b67d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:RedeemableStockExcersibleOnAgreedUponMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_14436cef-6d24-48bf-b8b6-de5a96e7c9a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1f92b4f8-fdec-497d-8f93-b488d3246949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">sbtx:SeriesCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_de83bac2-93f2-420e-9e2b-4c5157a75113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a83a64a1-7741-4e16-9288-99ee9079606f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_5733b7d9-e5ce-4ff8-9092-59c9faf284e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:EsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3839233e-c975-49e1-a075-fef15f80e6d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6cac55f6-3aef-4c64-94d0-8fe6535c4bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="C_ea504935-5339-4904-9013-2798d8f23b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_12ca2440-8311-4748-a39b-7117c1ed0a1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="C_2cc1fdc9-b760-4892-a859-13fea165b6d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1d8d0169-89f0-4155-948a-25ed3e8d9d13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e80f94ad-bad4-4970-8eac-4cb3f027e658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_225e24dd-9d34-41db-bc46-1555b81b2a47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_1374f92e-f597-4ff4-b276-ec1b04dde34a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4efba159-4be0-4651-ade7-fb31bf28b994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c706ed5d-e2ad-40ca-806a-0467398698b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_f1589284-886e-47d9-8e01-e13b1c2af513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sbtx:WuxiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d3b5176-144a-4079-966a-a3f6e8176386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_14dc9fe4-584f-4c31-87a5-09ff8302a12e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_51f68c66-981f-4114-9f1d-8af004dee45d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_384f1405-e75d-4b1f-ba71-caf76e7127d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ebe0d08f-4b7c-4a30-a659-5090f617fde9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee566949-7a9b-49b6-abae-885b6d7b031f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_f17035af-547b-47a2-b23c-ce99dd795100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_415738ce-5fb5-4ca7-93ff-db3c98f51fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_57a90811-c613-469c-93e9-bd4b4838cbe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4e9ffb89-6ff5-4676-b044-c5c124536efd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sbtx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_95651084-dc63-4d7f-8062-7d70db969b9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6eefba5e-4e7c-4fd7-92ec-5996101fb022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_b1bdc0b1-781e-4d6a-9638-314ec56b0e99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_032f1a5d-9136-4a8d-bfd5-8652354d9726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f1306218-ebfe-4f46-b53a-08722ba81bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:EsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f6d7fae1-66f6-4760-b28a-988192f19155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">sbtx:SeriesCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_54e777a7-e252-4927-8dfc-437c38de5255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sbtx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a51e457e-525d-410b-a470-5e6bf9556468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_2765e183-1081-430a-a0a8-58ce32c0c954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9fe4ab25-1247-4234-81ff-cc9c1674c66c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_6dd793ec-6f70-46ed-8a3f-fa231106ddad">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      id="F_bccce8e7-b750-4510-8968-19eaaaafc25d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3b0dfa37-784d-45c7-8f21-ff9ebf044985">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3b4ac3f3-428c-4001-b111-9d1d1e14ee86">0001671858</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_ca838e9c-0123-4130-b628-3d17164372f6">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      id="F_83270064-b0cb-4fde-82f9-0810d07e13c1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_ac8701aa-ad39-482d-80f7-8ded69555b25">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_a1f91a0f-aa8d-444a-a0e4-16fe0268f30e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_edb2c4af-b3ff-4dd2-93bc-86c16d87d1b6">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_db78d427-be30-4bb5-bcea-80e88127a5e4">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_788cf80e-b966-4ea9-9b05-a57c9788cee0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_354adca1-0784-4af0-b66a-c669c9ecb8d8">001-39756</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_e8a186ca-a1ad-4b5d-ae9a-25c70afa43e2">Silverback Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_235972b8-1a52-4af0-bf35-c87238d7fbe1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_6b3cef92-c503-4a78-919e-71fd85f1075e">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_23e37d72-dc82-4d15-bc34-29d4cda50299">500 Fairview Ave N</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_88c5840d-9bf2-4385-a2ff-0927635a0ba2">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_8732d783-41e6-40c7-b4c1-f441cca60dfc">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_20be1cb4-9055-40a9-879e-b11305b394bf">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3b38b438-7886-43a0-827e-2fda4a7aea02">98109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_a1740f63-e16e-4697-9ad5-3b6aaaaa6c3f">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_f55bd76a-f44d-47a4-9d7b-012b5818f969">456-2900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_6b3bc659-1151-4b44-9867-e172053e4aaa">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_f921c00c-d2d6-4243-9fe0-d1e15ed20bc1">SBTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_fe458de5-496f-4ace-8f9b-504754344a76">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_0b42c4a6-1905-4297-8ae0-668fa7e352fc">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_bc6588c3-333a-4916-9f21-27552fec86d2">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_38472115-c51c-4f5a-8ea5-69cfc875b757">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_7e898a8c-61e2-4b65-8819-5b0da2879eec">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_346cabeb-0373-4994-aba5-cacf1dd9899f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_95aecd37-fba8-425e-bc2c-4cc1f130d0ac">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_8f2f9be6-2566-4539-bf79-097fad94d886">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_497e02c0-384d-406b-874d-0347d4219089">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_7e823422-eb67-4bf5-ad65-85840084778f">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_c6558799-f7a9-4682-b488-4086122014f3">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_b60a8ab1-2e21-4152-9230-5951eda009db"
      decimals="0"
      id="F_4310f66d-2de1-4bf8-96cf-30a20a0cd1d4"
      unitRef="U_shares">35143186</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="C_225e24dd-9d34-41db-bc46-1555b81b2a47"
      decimals="-5"
      id="F_b29f4fd9-3ecf-4eb5-953f-544407123ddd"
      unitRef="U_USD">676800000</dei:EntityPublicFloat>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_11285903-aa77-44c5-9f9b-b45eb4454b49">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Portions of the registrant&#x2019;s definitive proxy statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_b3e70b60-9cbe-41ab-b1b6-6c0a752b7bd6">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_cbd6fddb-08ce-49f0-998c-03e52b7a9eee">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_591841c4-6bf9-4bcf-b1c9-90ae0e71dec6">Seattle, Washington</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_b632a5e4-cd7b-4450-810c-84de1c144bd7"
      unitRef="U_USD">254045000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_13f856d8-ee6f-4448-83e6-0ba7da36ee37"
      unitRef="U_USD">386569000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_8561af84-8825-499f-8700-b552757ca12d"
      unitRef="U_USD">7447000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_4d9475ed-233f-4821-bcf3-c918fc73e3f6"
      unitRef="U_USD">4087000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_109980cb-3a99-420e-8e8f-f8a75213e6c4"
      unitRef="U_USD">261492000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_4ab42095-75e0-4518-b992-2e737eacf8c9"
      unitRef="U_USD">390656000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_d1eba484-1dd0-47d4-b1ad-e4d41cd23874"
      unitRef="U_USD">64780000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_f9ec03c7-d154-47b3-ba08-976fa3ba85c3"
      unitRef="U_USD">0</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_cd11e032-540b-464a-8a36-247c42d99d15"
      unitRef="U_USD">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_b83e1884-e088-4f00-a1a1-a5421bdc06dd"
      unitRef="U_USD">350000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_e51d3fad-1c46-43d7-875e-be7b6bd419dd"
      unitRef="U_USD">4733000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_777d1d19-537e-40bf-aa51-093a61c44df2"
      unitRef="U_USD">2180000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_8339eeba-f9ed-432a-bb7e-97890e65af8b"
      unitRef="U_USD">2212000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_44513b18-3883-4568-870d-1cea90f5c6d3"
      unitRef="U_USD">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_238d5af8-a854-456d-b94a-5d00e5ae6ce0"
      unitRef="U_USD">333467000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_eaf24fb3-ba92-4cf2-b861-8b0be6c28c7e"
      unitRef="U_USD">394804000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_580d1c72-66a4-430c-a872-e2c5ac068528"
      unitRef="U_USD">2078000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_739c2211-6a41-43cd-b77c-c1d6676ebbb5"
      unitRef="U_USD">2583000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_70db9856-4437-477b-b419-b13ca39fbd2e"
      unitRef="U_USD">11727000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_a86d46af-1ac1-44cb-8d17-9513d2c52e70"
      unitRef="U_USD">5278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LoansPayableToBankCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_16bf35ce-e965-43cd-9cc3-e28e6fb0f53e"
      unitRef="U_USD">0</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_d7f8caf9-68d0-4bd6-ab19-7179666305de"
      unitRef="U_USD">844000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_b0ca6b28-c61c-42b8-b9cb-71ee5c7762ed"
      unitRef="U_USD">1087000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_1fbb173e-aa43-45b6-a81e-d310a3a0abff"
      unitRef="U_USD">896000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_a2ec6834-1a20-4ef3-85ec-df04d1b80973"
      unitRef="U_USD">14892000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_f04ae9d1-1772-425e-af3d-2de80778659b"
      unitRef="U_USD">9601000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_bdaa39de-fc4e-4d3a-82ec-1dfab2fb8064"
      unitRef="U_USD">4760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_55804153-9d05-4dd2-a429-fd4be2b6a7c0"
      unitRef="U_USD">2326000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_98bc6907-02ca-48b6-9d86-8aeb270ea6c3"
      unitRef="U_USD">19652000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_8838ff90-b5dc-45fd-9941-f877b34bad24"
      unitRef="U_USD">11927000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="4"
      id="F_a7cc416a-d9c3-4d67-8590-a49531b73110"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="4"
      id="F_b4148ffb-f55a-4345-99df-f5caa995f9a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="INF"
      id="F_511b3d73-768c-433d-802c-855c1dfd3fae"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="INF"
      id="F_6a087116-74ee-449c-9815-05c784b92b76"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="INF"
      id="F_98dfa270-6250-42a1-8354-fbd50647b7ec"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="INF"
      id="F_324c223d-c481-439e-8b0c-d4db76bf2b67"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="INF"
      id="F_4a7618d2-9d73-47e8-b81e-b307958e00ae"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="INF"
      id="F_69ecff3f-1f97-4ff8-b1bd-d87b094c1916"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_79b8801b-a170-497c-b690-ec16ff8e4a2f"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_f0d60ce4-9a70-4f3a-9968-c86e083c7fa4"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="4"
      id="F_0ccee07f-3910-4b32-9844-31859d875cbb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="4"
      id="F_c3584671-578e-456f-9fb7-21dc9bb29ae4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="INF"
      id="F_1b3a7f75-bdae-4edb-a8fd-2096b163b598"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="INF"
      id="F_356505f6-4630-46fb-863f-923a8f1400ff"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="INF"
      id="F_c4f48202-54d5-4fef-ad01-e14cc3572d60"
      unitRef="U_shares">35133934</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="INF"
      id="F_5f352a96-2ed2-46e1-a04e-3506a176e7ae"
      unitRef="U_shares">34801537</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="INF"
      id="F_32a2f350-b89e-46f0-b444-37f47a0d50f0"
      unitRef="U_shares">35107651</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="INF"
      id="F_06cd82b0-d056-4d98-b37c-af2d1ebd4462"
      unitRef="U_shares">34701274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_3be29756-caf3-4ef4-af17-242cd5c59d1b"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_b2d20647-cf97-4adb-9e51-ae0bdc522232"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_669fcfa0-9533-439f-99d4-6bc8106a3f50"
      unitRef="U_USD">500349000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_d49c7790-a835-4d3e-aae9-32a24747b8ee"
      unitRef="U_USD">479608000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_3e3709ec-ffc8-4045-8abd-faf069268b5f"
      unitRef="U_USD">-326000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_eb72c812-685c-44ff-b819-90a7730616ed"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_a18adf29-ccdc-4720-a13e-cb60d73265ee"
      unitRef="U_USD">-186212000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_07b093a1-c2e2-4ecc-86ff-93aa54c73e13"
      unitRef="U_USD">-96734000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_26ffdf74-6036-4dc9-b10c-9c57766c5c93"
      unitRef="U_USD">313815000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_79d4baa2-7c9e-4041-b590-7f27977307c5"
      unitRef="U_USD">382877000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_46bd222a-2d7f-44d6-b27a-0fbf860d936a"
      unitRef="U_USD">333467000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_ca141177-5aac-43cd-a764-6b81487b7cbe"
      unitRef="U_USD">394804000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_e2239501-32a1-4b6c-a3e4-dd5bbaa65054"
      unitRef="U_USD">61501000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_17beb5a5-5924-4235-be0f-d64fe1354e0a"
      unitRef="U_USD">24577000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_a443618b-2da2-4be7-88a8-7a783527647c"
      unitRef="U_USD">28083000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_8a1faca4-1b94-4cec-afd1-dc66a9d2f865"
      unitRef="U_USD">8341000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_abced928-ed3a-481e-96de-86810ea2e29e"
      unitRef="U_USD">89584000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_c622b3ca-fea3-4363-8c9a-979dab2ca19c"
      unitRef="U_USD">32918000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_b7e499a6-3448-4436-835f-335e2d210998"
      unitRef="U_USD">-89584000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_2734748e-a47d-47e9-ac00-3d95c5394053"
      unitRef="U_USD">-32918000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_5ad71160-652a-4009-92c2-aaa87e845869"
      unitRef="U_USD">106000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_eda56e70-2941-4d7c-8042-af5eca21cfff"
      unitRef="U_USD">-29000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_125c1aa5-f1b3-41a5-828f-7aaec017dea5"
      unitRef="U_USD">-89478000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_fb428470-2a05-431e-9c76-03c963c69c77"
      unitRef="U_USD">-32947000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_ea3b8409-40ec-463c-afe3-2ed6c515026f"
      unitRef="U_USD">-326000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_aa6dd4ef-f337-4057-89f9-bf59b29b9641"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_ea68d3b1-40ce-4497-990f-7cee9e787041"
      unitRef="U_USD">-89804000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_0aea9577-3442-41fc-b880-a28d62258a52"
      unitRef="U_USD">-32947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="2"
      id="F_defe7542-c859-45fd-a369-bacf90dd654e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="2"
      id="F_261eb47f-507b-4778-8b76-28216a405f15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-11.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="0"
      id="F_e6a7cda4-d509-4c57-a87e-fe88b0dd4b88"
      unitRef="U_shares">34926403</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="0"
      id="F_2bc1e98d-aab1-4434-9c88-765289b16134"
      unitRef="U_shares">2907542</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2"
      decimals="0"
      id="F_50319925-1f42-412b-9579-55f17c477910"
      unitRef="U_shares">15714283</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2"
      decimals="-3"
      id="F_a2c82dbd-148f-44ae-baea-c5af255546b9"
      unitRef="U_USD">53174000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_21761b55-f888-4dd6-90d9-c5d5d39d5076"
      decimals="INF"
      id="F_485356ae-4e6f-4117-8081-731d35883cce"
      unitRef="U_shares">664431</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_384f1405-e75d-4b1f-ba71-caf76e7127d1"
      decimals="-3"
      id="F_a1dfd089-6572-44e9-92c4-e87c35291580"
      unitRef="U_USD">5010000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_360c64d4-e8a6-45e9-bf20-6dafe7757ce5"
      decimals="-3"
      id="F_3398fb50-2a69-43ea-923e-313cb68ed0fe"
      unitRef="U_USD">-63787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_270d424e-2ea7-451c-a3be-3e4a447e5b40"
      decimals="-3"
      id="F_4ae78a20-e351-421d-81a3-951c1adbf600"
      unitRef="U_USD">-58777000</us-gaap:StockholdersEquity>
    <sbtx:StockIssuanceCosts
      contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255"
      decimals="-3"
      id="F_b02bd6f6-c40d-460a-8bce-c216b30d6e08"
      unitRef="U_USD">76000</sbtx:StockIssuanceCosts>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255"
      decimals="0"
      id="F_69db4a7b-0296-41e9-a53b-fad4fc5132be"
      unitRef="U_shares">31760528</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash
      contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255"
      decimals="-3"
      id="F_8a1cb032-a582-4886-8490-57ed23eb2f67"
      unitRef="U_USD">68401000</sbtx:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255"
      decimals="0"
      id="F_a76dbfd0-e320-4a04-9f93-0d2791650ea7"
      unitRef="U_shares">4673388</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes
      contextRef="C_54e777a7-e252-4927-8dfc-437c38de5255"
      decimals="-3"
      id="F_f7b7e841-1178-4578-8f70-d772f86cebf0"
      unitRef="U_USD">10095000</sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="C_40425c84-7c43-4d68-9c93-740efc67f686"
      decimals="0"
      id="F_d64e621d-cce2-49a8-b5b9-866358146104"
      unitRef="U_shares">24926685</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes
      contextRef="C_40425c84-7c43-4d68-9c93-740efc67f686"
      decimals="-3"
      id="F_09a49798-2960-4a0d-8b88-dd6da1df1b51"
      unitRef="U_USD">84897000</sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_86a8a0b7-29df-47b1-afc9-35b1ed2b1497"
      decimals="0"
      id="F_6227f8b9-a95e-405f-83ec-c560944fea98"
      unitRef="U_shares">77074884</us-gaap:TemporaryEquitySharesIssued>
    <sbtx:TemporaryequityValues
      contextRef="C_13e17b88-9a3e-4334-afaa-25c79b7864bb"
      decimals="-3"
      id="F_8c4025be-f4a2-4531-b34f-742835d41e28"
      unitRef="U_USD">-216567000</sbtx:TemporaryequityValues>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631"
      decimals="0"
      id="F_dc5c2057-4acf-4f8c-ac86-5920e2285963"
      unitRef="U_shares">20758098</us-gaap:TemporaryEquitySharesIssued>
    <sbtx:TemporaryequityValues
      contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0"
      decimals="-3"
      id="F_114f30a9-b9b3-4b98-b12a-3e760a9370bf"
      unitRef="U_USD">2000</sbtx:TemporaryequityValues>
    <sbtx:TemporaryequityValues
      contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100"
      decimals="-3"
      id="F_98019034-a7d0-44c1-bbff-69cd53be6dc2"
      unitRef="U_USD">216565000</sbtx:TemporaryequityValues>
    <sbtx:TemporaryequityValues
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_c0b02270-c467-4169-80eb-79677acb5490"
      unitRef="U_USD">216567000</sbtx:TemporaryequityValues>
    <sbtx:StockIssuanceCosts
      contextRef="C_95651084-dc63-4d7f-8062-7d70db969b9b"
      decimals="-3"
      id="F_fa417b79-501e-4a39-8bd3-0c34a4dcad56"
      unitRef="U_USD">22386000</sbtx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0"
      decimals="0"
      id="F_c13a915c-e164-4f56-b51a-f3a7a74e144a"
      unitRef="U_shares">13225000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0"
      decimals="-3"
      id="F_b75257fd-3a49-43bc-aceb-9319cce9ee47"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100"
      decimals="-3"
      id="F_b042100a-1854-4320-9956-f8397885c690"
      unitRef="U_USD">255338000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_c10d92d6-7851-4247-b32d-0b67baad0618"
      unitRef="U_USD">255339000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_62d36620-ca03-4b03-8439-9f51726efcf0"
      decimals="0"
      id="F_aff40967-d705-4b55-8b5e-f222f19aad06"
      unitRef="U_shares">53745</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100"
      decimals="-3"
      id="F_c80634d6-f538-441d-99a4-c2048e2e1cab"
      unitRef="U_USD">55000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_08ea1452-6511-419d-954e-cc9c4b9765a3"
      unitRef="U_USD">55000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f17035af-547b-47a2-b23c-ce99dd795100"
      decimals="-3"
      id="F_b83c741b-8692-4977-b727-ecd9b0df4454"
      unitRef="U_USD">2640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_8b5e8082-c297-4ea4-9297-d46fbaec1010"
      unitRef="U_USD">2640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e5a118de-b5ae-416d-953c-fca753351c6e"
      decimals="-3"
      id="F_be1669b1-4f7f-4844-b607-0b63f62a3cd1"
      unitRef="U_USD">-32947000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_d7d07ec2-525a-41cb-9f13-fad9c75bd2d6"
      unitRef="U_USD">-32947000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631"
      decimals="0"
      id="F_5aaa7ad4-fa6d-4c74-bc99-f4458f746176"
      unitRef="U_shares">34701274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_100341d2-0b5f-4ef6-9c6f-a0b4ffba5631"
      decimals="-3"
      id="F_643d0d97-8c9c-478e-917b-b496d284b789"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_de83bac2-93f2-420e-9e2b-4c5157a75113"
      decimals="-3"
      id="F_823f6290-ca9d-4f58-94be-0879a32c9dfb"
      unitRef="U_USD">479608000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e6a0662a-dd26-49c0-af88-491b9b800275"
      decimals="-3"
      id="F_784e51a5-0b26-40ef-bc04-43d7b468b4d5"
      unitRef="U_USD">-96734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_5e166e1a-a7ce-45d5-a8b0-477a5f7201f2"
      unitRef="U_USD">382877000</us-gaap:StockholdersEquity>
    <sbtx:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_ebe0d08f-4b7c-4a30-a659-5090f617fde9"
      decimals="0"
      id="F_50005ad0-9901-4b07-8744-9153ac7af008"
      unitRef="U_shares">406377</sbtx:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_ebe0d08f-4b7c-4a30-a659-5090f617fde9"
      decimals="-3"
      id="F_79c6f5fa-f24a-4c69-9ff4-452c01eeb775"
      unitRef="U_USD">1000</sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_828913ed-d805-418b-ab38-3ca1860cfe83"
      decimals="-3"
      id="F_40521e77-6f08-4f64-9afa-32deafe257aa"
      unitRef="U_USD">1554000</sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_c4d9a198-adc0-4ed0-825d-d23e8e7f1db3"
      unitRef="U_USD">1555000</sbtx:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_828913ed-d805-418b-ab38-3ca1860cfe83"
      decimals="-3"
      id="F_7c99f56d-0c4b-421d-89b9-6d483d964b71"
      unitRef="U_USD">19187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_4ff025f0-32a7-4a4c-90e7-930d90d910af"
      unitRef="U_USD">19187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4efba159-4be0-4651-ade7-fb31bf28b994"
      decimals="-3"
      id="F_13dc134c-95f9-47ca-ae58-dfa75b59d3c7"
      unitRef="U_USD">-326000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6ebc2a75-c6af-4453-bbcf-d1d071452f7a"
      decimals="-3"
      id="F_a4c28f7e-48e6-49f6-a764-64d82bc90b5f"
      unitRef="U_USD">-89478000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_d845fa7f-46fe-4217-847e-8f2053c19481"
      unitRef="U_USD">-89804000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_494bd466-afac-4c94-b8ad-1da406d99780"
      decimals="0"
      id="F_e3dd5919-aad1-4d69-8bfc-20196b5f0e65"
      unitRef="U_shares">35107651</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_494bd466-afac-4c94-b8ad-1da406d99780"
      decimals="-3"
      id="F_2f0bc6f4-ee80-43a8-8236-5a494bd9002d"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b13a7ea-2f2e-41d9-8210-704162e848d4"
      decimals="-3"
      id="F_d41e757f-b0b0-408c-ac9e-1f4ae3755df3"
      unitRef="U_USD">500349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d2266970-9935-4502-9c86-ada2228e4e21"
      decimals="-3"
      id="F_3332aae7-d335-4093-bbb4-a3ec68095d03"
      unitRef="U_USD">-326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_74e41f57-c0d7-4daf-b14d-df2e105f7efb"
      decimals="-3"
      id="F_28320e5a-644d-47c7-b7e1-930b607da85c"
      unitRef="U_USD">-186212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_c99cfc98-a3d2-428f-9c98-5a0892e22068"
      unitRef="U_USD">313815000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_c1cfce95-23dc-48fb-9144-b3e5173f0bfb"
      unitRef="U_USD">-89478000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_9ee3012b-5547-457e-85b4-ecca9d58e7ea"
      unitRef="U_USD">-32947000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_192f2092-b20e-4f9e-9911-6cdd2f9a17aa"
      unitRef="U_USD">783000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_df7a2b69-6003-4bff-a8e5-a8a9e1de6416"
      unitRef="U_USD">637000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_7cbbeb1d-6280-4030-8bbf-9a0af144d45f"
      unitRef="U_USD">19187000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_6e4335ed-82a5-4cf9-815c-c2f041d012f8"
      unitRef="U_USD">2640000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_b488dbdf-5f36-4f4a-b32a-074fd381ea80"
      unitRef="U_USD">1146000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_1099be86-ee47-470e-bc05-0b312f3a1c0f"
      unitRef="U_USD">1073000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_3b6dfbae-2a9e-43c2-8439-a234739e20a4"
      unitRef="U_USD">2000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_bb69ec70-7065-4cd6-9a43-59d5353832e5"
      unitRef="U_USD">31000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_8f8bc1a2-2b70-4295-8b77-26ddb4606aa3"
      unitRef="U_USD">3360000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_0831861b-1a98-47f4-b112-7e8b4758a54b"
      unitRef="U_USD">3535000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_de6c775c-3731-4d8b-adeb-a6c1fbaaab07"
      unitRef="U_USD">6034000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_6a4f3e51-1f68-4088-b1e5-9c47e1fd84df"
      unitRef="U_USD">1790000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sbtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_a14184b6-5aba-4009-b07c-aa07974bc9de"
      unitRef="U_USD">-1074000</sbtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <sbtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_3bb23745-392a-45ea-aef5-405808ecfaa7"
      unitRef="U_USD">-885000</sbtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_08046855-b677-4bb0-a3ee-11749891a5fd"
      unitRef="U_USD">-66760000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_535129e8-2442-403b-bf8d-0a330878c9d4"
      unitRef="U_USD">-31196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_21c4a6c9-2837-4c8a-afb3-b23a5768e22a"
      unitRef="U_USD">65106000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_41ab00c0-0874-4ca0-869b-b30330a8a73f"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_5adf4c09-ec21-4fab-8905-d2e338e793de"
      unitRef="U_USD">1372000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_5e54d046-aeaf-4b09-8e78-9ac41c8140d1"
      unitRef="U_USD">917000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_c9e7652f-32c8-41f7-ba29-c5f76267a91d"
      unitRef="U_USD">-66478000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_776ea7d9-e973-4b2e-b19b-648c4cc91dcf"
      unitRef="U_USD">-917000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_b4160758-48b0-489e-a177-1ee1b9968b28"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_2a1151e4-51b9-47ab-ac74-7439fcfcaabc"
      unitRef="U_USD">153351000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_9941b1bf-a999-4a0e-a1b6-b3a5f752945c"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_0a643e35-7e6b-4889-b37b-1bf4e0c35ce8"
      unitRef="U_USD">258284000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <sbtx:PaymentOfDeferredOfferingCosts
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_e0ee2cc6-35f8-4c0c-a389-4abd02aec860"
      unitRef="U_USD">0</sbtx:PaymentOfDeferredOfferingCosts>
    <sbtx:PaymentOfDeferredOfferingCosts
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_b1245fdb-80ab-4338-8d01-701930112de1"
      unitRef="U_USD">2606000</sbtx:PaymentOfDeferredOfferingCosts>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_8ff9f977-f997-49d7-9c9f-a5cb67240a25"
      unitRef="U_USD">846000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_2d021acf-ed71-400a-852f-0d2b34b0ea51"
      unitRef="U_USD">700000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_1cd7e7e5-b756-43fe-a4e3-db60bc7091f8"
      unitRef="U_USD">1460000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_683325f6-8fd5-4575-9e3b-9175707fcaef"
      unitRef="U_USD">177000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_30c14f98-99f2-441c-93a3-6160b1d95ea2"
      unitRef="U_USD">614000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_d9bc26cd-0e41-4fb8-b9b8-1116d524dd6f"
      unitRef="U_USD">408506000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_71ee832c-2b2b-44a8-abb9-d987c9220eee"
      unitRef="U_USD">-132624000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_d7775d52-5f3e-41f1-a8ae-985ac91f1738"
      unitRef="U_USD">376393000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_41ffe5bf-f26c-4785-aacd-872ca4151897"
      unitRef="U_USD">386919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_270d424e-2ea7-451c-a3be-3e4a447e5b40"
      decimals="-3"
      id="F_149812ea-d138-46e6-b09f-2681f84fcd8c"
      unitRef="U_USD">10526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_d1d4b6fa-d4bf-4e2c-b5ec-282a74c27cd7"
      unitRef="U_USD">254295000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_d9150be9-3208-410f-a5ee-3dfb5502b7ed"
      unitRef="U_USD">386919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sbtx:UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_72a289ee-fd28-4701-89b8-44ce4d63df42"
      unitRef="U_USD">0</sbtx:UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <sbtx:UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_39667f47-61b8-41eb-9a22-e7e56929e14d"
      unitRef="U_USD">339000</sbtx:UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <sbtx:RightOfUseAssetsAndLeaseLiabilitiesRecognized
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_f476b4fc-c19e-46a1-ba22-2fee8ebb342d"
      unitRef="U_USD">3699000</sbtx:RightOfUseAssetsAndLeaseLiabilitiesRecognized>
    <sbtx:RightOfUseAssetsAndLeaseLiabilitiesRecognized
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_eba433e4-509d-4d47-a48f-7332cf84c2c2"
      unitRef="U_USD">0</sbtx:RightOfUseAssetsAndLeaseLiabilitiesRecognized>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_fd26034a-854f-4010-b5bb-5fc42756b0db"
      unitRef="U_USD">0</sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_20098acc-03c0-4347-856c-d3a23e8c2e4f"
      unitRef="U_USD">10095000</sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes>
    <sbtx:ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_a1ba3ab2-57e0-4617-a201-383a567a17b3"
      unitRef="U_USD">0</sbtx:ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering>
    <sbtx:ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_55714236-a041-488b-8ea5-455462b1524f"
      unitRef="U_USD">216567000</sbtx:ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering>
    <us-gaap:NatureOfOperations
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_a278a00a-04ee-4e61-8045-df39314b25ed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Silverback Therapeutics, Inc. (&#x201c;Silverback&#x201d; or &#x201c;the Company&#x201d;) is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company&#x2019;s ImmunoTAC platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. The Company&#x2019;s platform enables it to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January 4, 2016.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company completed its initial public offering of common stock (&#x201c;IPO&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,225,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;255.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriting discounts and commissions and offering expenses paid by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the IPO, all &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77,074,884&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of redeemable convertible preferred stock outstanding at the time of the IPO converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,758,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock. Additionally, in November 2020, the Company&#x2019;s Board of Directors approved an amendment to the Company&#x2019;s certificate of incorporation to effect a reverse split of shares of the Company&#x2019;s common stock on a one-for-3.713 basis, which was effected on November 30, 2020 (the &#x201c;Reverse Stock Split&#x201d;) in anticipation of the IPO.  All references to common stock and options to purchase common stock share data, per share data, and related information contained in the financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the Company&#x2019;s existing products under development.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;186.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company had cash, cash equivalents, restricted cash, and investments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;319.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily through the issuance of redeemable convertible preferred stock, convertible notes, and the sale of common stock in connection with the IPO. The Company&#x2019;s currently available cash, cash equivalents, restricted cash, and investments as of December 31, 2021 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date the financial statements are issued.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management expects operating losses to continue for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical development activities as well as the commercialization of the Company&#x2019;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6cac55f6-3aef-4c64-94d0-8fe6535c4bb5"
      decimals="INF"
      id="F_aff04ebb-933f-4d49-bb17-05825393ccbb"
      unitRef="U_shares">13225000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_6cac55f6-3aef-4c64-94d0-8fe6535c4bb5"
      decimals="2"
      id="F_6e2bb0b1-5b21-4ca4-a5e8-415a9f97506f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_e4fb8c88-21a6-408b-bd27-cec75b99333f"
      decimals="-5"
      id="F_a7a56740-2c7d-4d1d-b0df-8274cce41690"
      unitRef="U_USD">255300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_eccc60cc-900f-452b-bd4e-6dc984c5cd7a"
      decimals="0"
      id="F_8e4b83d2-e68a-4fda-933a-62cf576a18cb"
      unitRef="U_shares">77074884</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_c2f82abf-51d1-4cd8-bb42-2d8d43b73153"
      decimals="0"
      id="F_e95a0b5f-a92a-4e91-bc81-0a64d1b074b4"
      unitRef="U_shares">20758098</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_c69f956c-69bd-4860-bfe0-35ff0afee0c9"
      unitRef="U_USD">-186200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <sbtx:CashCashEquivalentsAndLongTermInvestments
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_bf68eb33-15b6-48da-a0f0-39983dbd3e59"
      unitRef="U_USD">319100000</sbtx:CashCashEquivalentsAndLongTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_cd13f93a-4d6f-4a69-b4e2-9ce4f1f0e4f4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The full extent to which the coronavirus (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trial and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing tissue targeted therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents, restricted cash, and investments are carried at fair value. Accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. The term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At December 31, 2021 and December 31, 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company&#x2019;s cash equivalents consisted of money market funds.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the operating lease for the Company&#x2019;s headquarters.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.095%;"/&gt;
          &lt;td style="width:1.512%;"/&gt;
          &lt;td style="width:2.003%;"/&gt;
          &lt;td style="width:17.496%;"/&gt;
          &lt;td style="width:0.942%;"/&gt;
          &lt;td style="width:1.512%;"/&gt;
          &lt;td style="width:2.003%;"/&gt;
          &lt;td style="width:17.496%;"/&gt;
          &lt;td style="width:0.942%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company invests excess cash in investment grade intermediate-term fixed income securities. These investments are included in long-term investments on the balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Realized gains and losses on the sale of these securities are recognized in net loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company periodically evaluates whether declines in fair values of its investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the investments, duration and severity of the decline in value, and the Company's strategy and intentions for holding the investment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to credit risk from holding its cash and cash equivalents at a limited number of commercial banks. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings and U.S. Treasury securities. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Prepaid Expenses and Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses consist primarily of operating expenses paid in advance of when services are provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consists of furniture and fixtures and laboratory equipment and is stated at cost, less accumulated&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;depreciation. Furniture and fixtures and laboratory equipment are depreciated over the estimated useful lives of the assets (each three to five years) using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases consist of the Company&#x2019;s operating leases. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s leases include options to extend or terminate the leases. Periods covered by an option to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate a lease are included in the lease term when it is reasonably certain that the Company will not exercise that option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and non-lease components. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets consist of property and equipment and ROU assets. These assets are reviewed for impairment whenever facts&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses through December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#x2019;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#x2019;s program pipeline. Direct costs include expenses incurred under agreements with CROs and other vendors that conduct the Company&#x2019;s preclinical and clinical activities, expenses associated with manufacturing the Company&#x2019;s product candidates including under agreements with contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#x2019;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#x2019;s research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. General and administrative costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#x2019;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) became effective, pursuant to which eligible employees can purchase shares of the Company&#x2019;s common stock at a discount to the fair market value at semi-annual intervals. In determining the grant date fair value of shares expected to be purchased under the ESPP, the Company uses the Black-Scholes option pricing model. Black-Scholes inputs are determined in the same manner as for stock option awards. The estimated grant date fair value of shares expected to be purchased is recognized into expense on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company is more likely than not able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes in the period in which the adjustment is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the basis of the technical merits of the position and (2) for those tax positions that meet the recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. The Company did not have any uncertain tax positions as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company presents one continuous Statement of Operations and Comprehensive Loss. The Company&#x2019;s comprehensive loss includes unrealized gains and losses on investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.&lt;/span&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_97b202dd-765f-47c2-8c18-a10129a69038">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_8dfc1ad6-c434-41ed-9586-4c4786347f50">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The full extent to which the coronavirus (&#x201c;COVID-19&#x201d;) pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trial and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_6dabebf2-f4b0-494a-9dab-2af8dc15ff2e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined that it operates and manages one operating segment, which is the business of developing and commercializing tissue targeted therapeutics. The Company&#x2019;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_84828662-3706-45fc-abc0-d561be96b9ee">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents, restricted cash, and investments are carried at fair value. Accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. The term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_43a697b3-b38c-4f87-a22a-5f97d72d88a7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At December 31, 2021 and December 31, 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company&#x2019;s cash equivalents consisted of money market funds.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_93950d9f-9de6-408b-9334-8c054448616d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the operating lease for the Company&#x2019;s headquarters.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.095%;"/&gt;
          &lt;td style="width:1.512%;"/&gt;
          &lt;td style="width:2.003%;"/&gt;
          &lt;td style="width:17.496%;"/&gt;
          &lt;td style="width:0.942%;"/&gt;
          &lt;td style="width:1.512%;"/&gt;
          &lt;td style="width:2.003%;"/&gt;
          &lt;td style="width:17.496%;"/&gt;
          &lt;td style="width:0.942%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3111d0f1-5e19-4861-9bc1-5f7246d59774">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the balance sheets that sum to the amounts shown in the statements of cash flows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.095%;"/&gt;
          &lt;td style="width:1.512%;"/&gt;
          &lt;td style="width:2.003%;"/&gt;
          &lt;td style="width:17.496%;"/&gt;
          &lt;td style="width:0.942%;"/&gt;
          &lt;td style="width:1.512%;"/&gt;
          &lt;td style="width:2.003%;"/&gt;
          &lt;td style="width:17.496%;"/&gt;
          &lt;td style="width:0.942%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;254,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb"
      decimals="-3"
      id="F_601fa620-ccb2-4104-8730-e46d26fc5b18"
      unitRef="U_USD">254045000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0d3b5176-144a-4079-966a-a3f6e8176386"
      decimals="-3"
      id="F_735bf811-7c92-4bf5-a0f1-59d7f77def68"
      unitRef="U_USD">386569000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb"
      decimals="-3"
      id="F_89d8a932-78f0-454b-a9de-c65dd3c0d8f0"
      unitRef="U_USD">250000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0d3b5176-144a-4079-966a-a3f6e8176386"
      decimals="-3"
      id="F_cc531557-5e42-44e4-afb9-b5a9b71358fb"
      unitRef="U_USD">350000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c1092c70-36be-47b4-b61d-7a83f3cd37fb"
      decimals="-3"
      id="F_a00099c7-1e7e-4f8c-a600-14a40d3de24b"
      unitRef="U_USD">254295000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0d3b5176-144a-4079-966a-a3f6e8176386"
      decimals="-3"
      id="F_d11e5345-afe4-4b39-b648-904af3e67787"
      unitRef="U_USD">386919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3f6cf90c-5eba-429d-a765-70a12c089e16">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company invests excess cash in investment grade intermediate-term fixed income securities. These investments are included in long-term investments on the balance sheets, classified as available-for-sale, and reported at fair value with unrealized gains and losses included in accumulated other comprehensive loss. Realized gains and losses on the sale of these securities are recognized in net loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company periodically evaluates whether declines in fair values of its investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the investment until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the investments, duration and severity of the decline in value, and the Company's strategy and intentions for holding the investment.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_cd7c87ae-105b-4477-867b-2616b43c41a7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to credit risk from holding its cash and cash equivalents at a limited number of commercial banks. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings and U.S. Treasury securities. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <sbtx:PrepaidExpensesAndOtherAssetsPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_84b02dac-e47f-4886-8bc1-44425eab9098">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Prepaid Expenses and Other Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses consist primarily of operating expenses paid in advance of when services are provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</sbtx:PrepaidExpensesAndOtherAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_88ac2cfb-70b0-478e-bd08-7497f1e59be2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consists of furniture and fixtures and laboratory equipment and is stated at cost, less accumulated&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;depreciation. Furniture and fixtures and laboratory equipment are depreciated over the estimated useful lives of the assets (each three to five years) using the straight-line method. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Repairs and maintenance costs are charged to expense as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_721572f7-ad58-426a-87bc-13b37f47becc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases consist of the Company&#x2019;s operating leases. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s leases include options to extend or terminate the leases. Periods covered by an option to extend a lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate a lease are included in the lease term when it is reasonably certain that the Company will not exercise that option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and non-lease components. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_1bd3b905-de2e-4352-98ee-5769f76cc671">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets consist of property and equipment and ROU assets. These assets are reviewed for impairment whenever facts&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;or circumstances either internally or externally may suggest that the carrying value of an asset or asset group may not be recoverable. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses through December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_4a465dfc-04dc-414b-9d4d-f9f81224fc67">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#x2019;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#x2019;s program pipeline. Direct costs include expenses incurred under agreements with CROs and other vendors that conduct the Company&#x2019;s preclinical and clinical activities, expenses associated with manufacturing the Company&#x2019;s product candidates including under agreements with contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#x2019;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#x2019;s research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_1943b6fe-fd11-4d0c-86b9-f3582e0b3e1f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. General and administrative costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_983d88ef-9cb3-4a07-8dc0-d98e72156d5d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#x2019;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.&lt;/span&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <sbtx:EmployeeStockPurchasePlanPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_1767b3a5-47cb-4114-ae01-5d4c572abbc4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) became effective, pursuant to which eligible employees can purchase shares of the Company&#x2019;s common stock at a discount to the fair market value at semi-annual intervals. In determining the grant date fair value of shares expected to be purchased under the ESPP, the Company uses the Black-Scholes option pricing model. Black-Scholes inputs are determined in the same manner as for stock option awards. The estimated grant date fair value of shares expected to be purchased is recognized into expense on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;</sbtx:EmployeeStockPurchasePlanPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_e492a4c4-1bb6-4196-82e4-4e977c685fd1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company is more likely than not able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes in the period in which the adjustment is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the basis of the technical merits of the position and (2) for those tax positions that meet the recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. The Company did not have any uncertain tax positions as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_8ecf119f-3a36-4636-9a34-f8be642f34e7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company presents one continuous Statement of Operations and Comprehensive Loss. The Company&#x2019;s comprehensive loss includes unrealized gains and losses on investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_fa69d44a-9ae0-4aba-b18c-e600a40784a3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <sbtx:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_659aff0b-70bf-4404-8053-3048ea53249c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;</sbtx:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_ff22f63b-54a1-4505-b530-09aa83d2c2ee">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_cfb00e37-fe8c-4171-a2ee-5b0bfd48fcc2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.963%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:93.037%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1: Quoted prices in Active Markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.963%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:93.037%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.963%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:93.037%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table identifies the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.954%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:7.39%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:11.566%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:10.905%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:10.522%;"/&gt;
        &lt;td style="width:1.079%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:9.06%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross unrealized gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;253,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;253,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term investments - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;319,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between the Level 1 and Level 2 categories or into or out of the Level 3 category during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s long-term investments portfolio contains investments in U.S. Treasury securities that have an effective maturity date that is more than one year, but less than two years, from the respective balance sheet date. The Company evaluated its investments for other-than-temporary impairment and considers the decline in market value for the securities to be primarily attributable to current economic and market conditions. For the investments, it is not more-likely-than-not that the Company will be required to sell the investments, and the Company does not intend to do so prior to the recovery of the amortized cost basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_8bcc016a-82fb-41b6-8ce6-d36ec90f2892">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table identifies the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.954%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:7.39%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:11.566%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:10.905%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:10.522%;"/&gt;
        &lt;td style="width:1.079%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:9.06%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross unrealized gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;253,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;253,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term investments - U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;319,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a83a64a1-7741-4e16-9288-99ee9079606f"
      decimals="-3"
      id="F_dff97513-a830-4ea2-9853-3f446b9c6b6e"
      unitRef="U_USD">253945000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a83a64a1-7741-4e16-9288-99ee9079606f"
      decimals="-3"
      id="F_b885a6af-e387-474a-9622-eb8ab0d02f79"
      unitRef="U_USD">253945000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6"
      decimals="-3"
      id="F_5268ed54-784e-4965-98c0-ffd442f80d0e"
      unitRef="U_USD">65106000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6"
      decimals="-3"
      id="F_cfd81ed8-b889-43e2-82cd-5b79d98f6a85"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6"
      decimals="-3"
      id="F_56518bb8-cbdc-4ee4-814a-dbba44d016c5"
      unitRef="U_USD">326000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_62d8769f-c5a5-49fd-97a1-fac6854c0aa6"
      decimals="-3"
      id="F_805b03bd-93bc-45e3-8984-ec8614c802ad"
      unitRef="U_USD">64780000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <sbtx:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_84cc9a96-c096-422b-bf87-12117369f5d3"
      unitRef="U_USD">319051000</sbtx:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_4134c640-f90a-4158-aa6d-507fcab37b67"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_dcd710ac-512c-4da2-9137-837217e14101"
      unitRef="U_USD">326000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <sbtx:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_f2c52902-9d3f-4e25-bc57-a430f2e2a52f"
      unitRef="U_USD">318725000</sbtx:MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_57a90811-c613-469c-93e9-bd4b4838cbe5"
      decimals="-3"
      id="F_f4b6e757-ee8a-4069-b529-e7c08b8875f5"
      unitRef="U_USD">386369000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_57a90811-c613-469c-93e9-bd4b4838cbe5"
      decimals="-3"
      id="F_0fcf4bd8-abef-44e0-b2d0-fdb67629020d"
      unitRef="U_USD">386369000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_ebae4cff-5957-439c-8b0d-694905e98a6a"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_d4071b70-f2f1-44d9-96d0-1003f5e6ad0f"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_73768fca-3f19-484e-be71-ccb85d76a978"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_e80f94ad-bad4-4970-8eac-4cb3f027e658"
      decimals="-3"
      id="F_a74f1705-0dd3-487b-bef0-368d251c8127"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_2e57d9e9-804a-47b2-a188-16bb4e5adb2b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:ARIAL;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.849%;"/&gt;
        &lt;td style="width:2.935%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.701%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
        &lt;td style="width:4.374%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.55%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_0f292537-9b29-4adb-a622-1f3267d1fad4">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:ARIAL;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.849%;"/&gt;
        &lt;td style="width:2.935%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.701%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
        &lt;td style="width:4.374%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.55%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_95368c9c-2ef3-4cdf-bc71-1cff6b42577a"
      decimals="-3"
      id="F_53e85eaa-1e04-4609-b105-632d3d444030"
      unitRef="U_USD">367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e77106ce-582d-481d-b3e4-30663c6abfa7"
      decimals="-3"
      id="F_02339c44-83b8-496c-89c6-ebdec709c24b"
      unitRef="U_USD">269000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e1043a11-9233-4df8-b363-ce3a0f3f3bb8"
      decimals="-3"
      id="F_b5514c1a-0057-4dce-84c1-3aecc947ccd2"
      unitRef="U_USD">4679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d5d577b3-d7af-45d0-860e-6ec6922cad1b"
      decimals="-3"
      id="F_59b41e04-8029-4b8c-a5fc-18fcc4e445c6"
      unitRef="U_USD">3401000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_c180519e-021b-4803-95b5-d3122747bd75"
      unitRef="U_USD">5046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_3b129087-3c88-4f38-bcc2-7c416075f1cb"
      unitRef="U_USD">3670000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_5586cc61-56b7-4c7b-9d8a-62190c423a44"
      unitRef="U_USD">2834000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_6603ca7a-06e7-4bc5-a5ae-2c56f9949cda"
      unitRef="U_USD">2052000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_7c4f9c1e-fb57-4f5a-a2df-862ec84bfe15"
      unitRef="U_USD">2212000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_8b678116-e627-4fe0-afbc-e2b528a50fe1"
      unitRef="U_USD">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-5"
      id="F_f97f31b9-04bd-4b11-8b2f-1c698c9fcbb0"
      unitRef="U_USD">800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-5"
      id="F_a0dec216-ff5b-4f8c-ab78-e0d95db80b65"
      unitRef="U_USD">600000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_e20d39e9-d268-4a0f-8329-73bd18067fef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Accrued Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.816%;"/&gt;
        &lt;td style="width:1.949%;"/&gt;
        &lt;td style="width:1.706%;"/&gt;
        &lt;td style="width:12.671%;"/&gt;
        &lt;td style="width:0.766%;"/&gt;
        &lt;td style="width:1.949%;"/&gt;
        &lt;td style="width:1.706%;"/&gt;
        &lt;td style="width:12.671%;"/&gt;
        &lt;td style="width:0.766%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional services and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      id="F_cc4fc332-5beb-4103-b7ce-dd261f5eda46">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.816%;"/&gt;
        &lt;td style="width:1.949%;"/&gt;
        &lt;td style="width:1.706%;"/&gt;
        &lt;td style="width:12.671%;"/&gt;
        &lt;td style="width:0.766%;"/&gt;
        &lt;td style="width:1.949%;"/&gt;
        &lt;td style="width:1.706%;"/&gt;
        &lt;td style="width:12.671%;"/&gt;
        &lt;td style="width:0.766%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional services and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sbtx:AccruedResearchAndDevelopmentExpenses
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_d8c54b4a-df09-42be-8a05-3233d8064242"
      unitRef="U_USD">6528000</sbtx:AccruedResearchAndDevelopmentExpenses>
    <sbtx:AccruedResearchAndDevelopmentExpenses
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_65cc88f3-70f2-4b45-a1e9-dbc8d6c55c6b"
      unitRef="U_USD">2063000</sbtx:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_64eebbaf-afe9-4b04-b593-6e8a2468ef17"
      unitRef="U_USD">4605000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_265d1b1d-7a28-4ea5-a760-806a87e71baa"
      unitRef="U_USD">2634000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_aa27cd99-f4d6-4ee7-974a-b02d911162d6"
      unitRef="U_USD">594000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_a756527b-cf45-49d4-a510-a8dc69330952"
      unitRef="U_USD">581000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_1004d5e1-56f5-49af-82ea-2e84fab385d0"
      unitRef="U_USD">11727000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_2a4faa53-0eff-4dcb-b8f1-68a8766a17ed"
      unitRef="U_USD">5278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_6137da14-0ed4-4356-9995-9034fa452030">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.478%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:14.049%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.561%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 1, 2021, the Company entered into a sublease agreement for additional office space in Seattle, Washington. The commencement date of the sublease was August 1, 2021. The contractual term of the sublease is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; with an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option to extend for one additional year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option to terminate after one year subject to a termination fee&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The annual minimum rent payable by the Company under the sublease is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million annually. The ROU asset obtained in exchange for the new operating lease liability was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average remaining term on the Company's leases was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years as of December 31, 2021 and 2020, respectively. To compute the present value of the lease liabilities, the Company used weighted average discount rates of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2021, there was a change in the expected lease term of the Company&#x2019;s Seattle, Washington headquarters, whereby the Company became reasonably certain that it will not exercise its option to terminate the lease. As a result, the ROU asset and lease liability were remeasured using the present value of the remaining lease payments. The re-measurement resulted in an addition to the ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The change in the expected lease term has no effect on the classification of the lease.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum commitments due under the operating lease agreements as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.706%;"/&gt;
        &lt;td style="width:1.654%;"/&gt;
        &lt;td style="width:2.974%;"/&gt;
        &lt;td style="width:17.677%;"/&gt;
        &lt;td style="width:1.989%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total present value of lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_b1b57b57-156a-4082-89d9-ce6609d9a8ca">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.478%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:14.049%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.561%;"/&gt;
        &lt;td style="width:0.742%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_916e653d-542b-4a65-a3e8-e40e5676c4c6"
      unitRef="U_USD">1452000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_f8c8b14d-e455-4433-a5a6-db90e9363c29"
      unitRef="U_USD">1388000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_57de1630-6345-4385-94c9-37925ea298ca"
      unitRef="U_USD">459000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_9914a56c-9247-4866-926e-f7dd6be0e314"
      unitRef="U_USD">386000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_d87456cd-8a5b-4ec9-a25b-11acebb193b6"
      unitRef="U_USD">1911000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_bf04abcf-050c-4d1f-9366-738b9509fc6c"
      unitRef="U_USD">1774000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_6546a9b5-ad6f-4887-adad-6eee94513c38"
      unitRef="U_USD">1841000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_a4e38f96-4c49-444b-8a04-9bcc4c55e1a3"
      unitRef="U_USD">1591000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_6a2fff31-99ba-4ee9-8280-a8ea1628da6c">On July 1, 2021, the Company entered into a sublease agreement for additional office space in Seattle, Washington. The commencement date of the sublease was August 1, 2021. The contractual term of the sublease is two years with an option to extend for one additional year and an option to terminate after one year subject to a termination fee.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_2cc1fdc9-b760-4892-a859-13fea165b6d3"
      id="F_7d34b6e5-8f39-4434-9fe6-021d328bb7ec">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingSubleaseOptionToExtend
      contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e"
      id="F_bed4536e-0a33-4d12-a8ee-f0738da10379">option to extend for one additional year</us-gaap:LesseeOperatingSubleaseOptionToExtend>
    <us-gaap:LesseeOperatingSubleaseOptionToTerminate
      contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e"
      id="F_4a5b9918-d3ea-4b9a-8870-615c73aac65c">option to terminate after one year subject to a termination fee</us-gaap:LesseeOperatingSubleaseOptionToTerminate>
    <us-gaap:OperatingLeasesRentExpenseMinimumRentals
      contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e"
      decimals="-5"
      id="F_dad8c312-6599-444d-82d2-9c10418ae64d"
      unitRef="U_USD">300000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_b5d15e9a-a781-4a56-b1f6-7dcc2b4a4b4e"
      decimals="-5"
      id="F_a257a926-9699-4fcc-84e4-c56c142fc027"
      unitRef="U_USD">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      id="F_49637932-0b6a-4e99-a9d7-b9955a749e6a">P4Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      id="F_fec9d82b-4e65-4577-a0cf-c9dc77814168">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="3"
      id="F_07d37d58-6d3c-417f-a6be-0f9d6b158301"
      unitRef="U_pure">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="3"
      id="F_6d0a1e86-e139-4c7a-82c5-e80274fd4aa3"
      unitRef="U_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-5"
      id="F_8dcd74fe-0a30-4c73-95b0-f3c97ee6d57b"
      unitRef="U_USD">3100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_cc482d51-2270-4386-b29c-69b4aa4ba95a">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum commitments due under the operating lease agreements as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.706%;"/&gt;
        &lt;td style="width:1.654%;"/&gt;
        &lt;td style="width:2.974%;"/&gt;
        &lt;td style="width:17.677%;"/&gt;
        &lt;td style="width:1.989%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total present value of lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_04c101c7-ade9-4829-8b4b-c89b874f7448"
      unitRef="U_USD">1481000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_59bb17ce-2d8c-4d5f-8154-689ed7edfced"
      unitRef="U_USD">1513000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_64178ec4-fd1d-42c2-a415-4f0ad85a94c6"
      unitRef="U_USD">1348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_012798ef-8e1d-494a-8937-3abedfccaf97"
      unitRef="U_USD">1389000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <sbtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_a8187fe4-2540-4466-bdbd-925b003c7eae"
      unitRef="U_USD">1186000</sbtx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_fcaa204c-b577-4c5d-bb7b-bb57ff32af17"
      unitRef="U_USD">6917000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_f209218f-63c4-4145-99fd-b96867bdf29f"
      unitRef="U_USD">1070000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_6c506fef-1c77-426f-8119-188deff4f2c8"
      unitRef="U_USD">5847000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_17932d14-b9e1-4c48-abb7-7ac9b4c3706b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. Term Loan Payable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (&#x201c;SVB&#x201d;) and borrowed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a term loan. The outstanding principal amount of the term loan accrued interest at an annual rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% per annum. At closing, the Company incurred de minimis debt issuance costs and owed a final payment fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate of the Company&#x2019;s term loan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The term loan&#x2019;s original maturity date was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;November 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. However, in April 2020, the Company amended the loan and security agreement to defer principal payments for six months and extend the maturity date to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;May 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification and amortized the remaining debt discount over the remaining term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; On May 1, 2021, the Company made its final scheduled payment to SVB under the loan and security agreement including the final payment fee.&lt;/span&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_ee566949-7a9b-49b6-abae-885b6d7b031f"
      decimals="-5"
      id="F_3836bdfb-bbcf-402c-9c31-d92ca31e0431"
      unitRef="U_USD">3500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_ee566949-7a9b-49b6-abae-885b6d7b031f"
      decimals="4"
      id="F_6df9707c-a70c-4ffa-bdb2-b799f96f0cab"
      unitRef="U_pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_12ca2440-8311-4748-a39b-7117c1ed0a1c"
      decimals="-5"
      id="F_9ba799ff-51c1-4a6a-b93f-75e6b4b29cf5"
      unitRef="U_USD">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_3839233e-c975-49e1-a075-fef15f80e6d8"
      decimals="4"
      id="F_0c5def97-6a9c-4cd1-b103-1be3870dd242"
      unitRef="U_pure">0.0514</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_12ca2440-8311-4748-a39b-7117c1ed0a1c"
      id="F_67257117-3659-4779-8a9a-a197484d2411">2020-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_b7066a98-3245-4333-b828-b75b16bd6d9b"
      id="F_17737762-04a3-4efe-94f3-f855cac4a4fe">2021-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_212ca7b7-da81-4c8e-83b5-7152a17e158a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Authorized Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s current Amended and Restated Certificate of Incorporation authorizes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to its conversion to common stock in December 2020, the Company&#x2019;s redeemable convertible preferred stock was classified as mezzanine equity on the Company&#x2019;s balance sheets as the shares are contingently redeemable upon a deemed liquidation such as a change in control and in that event, there is no guarantee that all stockholders would be entitled to receive the same form of consideration. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accretion to redemption value was recorded during the year ended December 31, 2020 as a deemed liquidation event was not considered probable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2020, the Company issued convertible preferred stock as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,701,054&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its Series B redeemable convertible preferred stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,673,388&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares issued upon conversion of then outstanding convertible notes and accrued interest, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,027,666&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares issued for cash at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Series B purchase agreement provided that the Company would issue, and the Series B holders would purchase, an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,732,862&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the event that certain agreed upon milestones were achieved or the preferred majority approved their closing. The Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 1, 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,669,834&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,063,028&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of its Series B redeemable convertible preferred stock for cash at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.16&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24,926,685&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its Series C redeemable convertible preferred stock for cash at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.41&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, resulting in gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Series C purchase agreement did not contain any embedded features that meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has reserved shares of common stock for the following potential future issuances:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.528%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares underlying outstanding equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,316,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for future equity award grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,931,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,506,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares underlying early exercised equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares underlying ESPP withholdings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,328,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,928,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_1e68e606-73c2-4ebc-87c1-2d9a1cae57b8"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="4"
      id="F_c76b1335-587a-4ccd-a570-da95e862f948"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_06b4b588-dc52-4754-a7aa-0394ec8fc84b"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="4"
      id="F_b2a1f7a5-3835-4865-a3c9-ff0ebaab4384"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="C_13e17b88-9a3e-4334-afaa-25c79b7864bb"
      decimals="-3"
      id="F_36877a87-6261-405b-ab9b-7e3cb36af4c8"
      unitRef="U_USD">0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4"
      decimals="INF"
      id="F_e2ed3858-086d-4acf-bcbe-e44f5a3fe34e"
      unitRef="U_shares">14701054</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash
      contextRef="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4"
      decimals="INF"
      id="F_69a6f759-e250-4174-9707-5e094e99797d"
      unitRef="U_shares">4673388</sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes
      contextRef="C_9f9adf54-43ab-4c26-9e8f-90a47c5f76e4"
      decimals="INF"
      id="F_f842da5d-7472-40c0-b2ac-af263bc7d238"
      unitRef="U_shares">10027666</sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_a51e457e-525d-410b-a470-5e6bf9556468"
      decimals="INF"
      id="F_040053b7-df54-4411-979c-d7efe0fcec8b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_babe8ce4-149b-4c33-b021-b0e162ec46a0"
      decimals="-5"
      id="F_dde81a71-71f0-4987-86ad-aa3e19025235"
      unitRef="U_USD">21500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3d3afa03-0c39-46e2-aac4-cf6089a8b67d"
      decimals="INF"
      id="F_844d55a0-2c66-48fb-a86c-60a2ea5c3cdd"
      unitRef="U_shares">21732862</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_3d3afa03-0c39-46e2-aac4-cf6089a8b67d"
      decimals="-5"
      id="F_ad25927c-c22a-4c57-a2f5-673010578736"
      unitRef="U_USD">46900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash
      contextRef="C_f23b5346-4ed5-45a9-a974-16fe675333f0"
      decimals="INF"
      id="F_0264d041-9fd9-44cd-b55c-e6aa0583632f"
      unitRef="U_shares">10669834</sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e29ac877-2d55-4d24-814b-9d73b1312fe1"
      decimals="INF"
      id="F_fe0f9565-c647-495e-bfc0-12622c64d91c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_f23b5346-4ed5-45a9-a974-16fe675333f0"
      decimals="-5"
      id="F_211acc7f-89fd-4369-861d-8c8996631157"
      unitRef="U_USD">23000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash
      contextRef="C_c706ed5d-e2ad-40ca-806a-0467398698b8"
      decimals="INF"
      id="F_04c3221b-108b-4edb-994d-2c23bc618da0"
      unitRef="U_shares">11063028</sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_6eefba5e-4e7c-4fd7-92ec-5996101fb022"
      decimals="2"
      id="F_e71bc89c-1677-44df-9b76-458b64416d68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_c706ed5d-e2ad-40ca-806a-0467398698b8"
      decimals="-5"
      id="F_435b9f04-3f5b-4e3a-8d9b-df17854907e7"
      unitRef="U_USD">23900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sbtx:IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash
      contextRef="C_1f92b4f8-fdec-497d-8f93-b488d3246949"
      decimals="INF"
      id="F_2042e124-6411-407a-a72b-f2700abb841a"
      unitRef="U_shares">24926685</sbtx:IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_f6d7fae1-66f6-4760-b28a-988192f19155"
      decimals="2"
      id="F_0956f3f7-63ec-40bf-80c1-6592dc242152"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.41</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_1f92b4f8-fdec-497d-8f93-b488d3246949"
      decimals="-5"
      id="F_bc5cacf0-5d08-4770-99a4-fb4ffe90703d"
      unitRef="U_USD">84900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_d98240ea-b0cf-4ee6-96d0-a6ba475d15e0">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has reserved shares of common stock for the following potential future issuances:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.528%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:14.279%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares underlying outstanding equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,316,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares available for future equity award grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,931,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,506,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares underlying early exercised equity awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares underlying ESPP withholdings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,328,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,928,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_71b567b9-dd67-488e-9bff-940240379336"
      decimals="0"
      id="F_fe8176b4-a0fa-4778-9940-47c9f5ec33de"
      unitRef="U_shares">6370873</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a05456f3-88fe-43ff-b244-8a5ee75b83e1"
      decimals="0"
      id="F_661d1864-340c-4770-89f9-fc4972f584a1"
      unitRef="U_shares">6316569</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_443c7d79-857f-4272-94c9-734cc7988aea"
      decimals="0"
      id="F_43189cdd-65ac-4f5c-a835-1df3058ba815"
      unitRef="U_shares">2931012</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b1bdc0b1-781e-4d6a-9638-314ec56b0e99"
      decimals="0"
      id="F_746c7230-4980-430e-9fff-586fd56f9a4b"
      unitRef="U_shares">1506806</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_67cef16b-8904-4ef1-a280-f5782cc3332b"
      decimals="0"
      id="F_87f6d99e-0b6d-4a51-a545-478aba4090b0"
      unitRef="U_shares">26283</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2765e183-1081-430a-a0a8-58ce32c0c954"
      decimals="0"
      id="F_3835a575-7e49-45a2-9200-df5fe4deef2a"
      unitRef="U_shares">100263</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_14436cef-6d24-48bf-b8b6-de5a96e7c9a6"
      decimals="0"
      id="F_56a2f2e5-fc92-40bb-9209-e0d6017fc50e"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_954e4039-8ad8-4dde-9cc7-9b313b208185"
      decimals="0"
      id="F_86351fa2-4478-4f52-ab16-b11877ded921"
      unitRef="U_shares">4393</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_98530b85-cde1-4a6f-a610-5755357c2bd5"
      unitRef="U_shares">9328168</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="0"
      id="F_61b46557-202f-42de-a6e4-85f93844ecb1"
      unitRef="U_shares">7928031</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3ecbe504-2214-4029-9993-5862cd432ce0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.777%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.433%;"/&gt;
        &lt;td style="width:13.524%;"/&gt;
        &lt;td style="width:0.649%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.433%;"/&gt;
        &lt;td style="width:13.38%;"/&gt;
        &lt;td style="width:0.649%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the total unrecognized stock-based compensation expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which is expected to be recognized over a remaining weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.49&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Option Awards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company&#x2019;s equity incentive plans authorized a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,564,798&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,931,012&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares are available for future grant, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares are outstanding. Not included in the outstanding option balance are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,283&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares pursuant to stock options that were early exercised and subject to repurchase that remain unvested as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options granted under the Company&#x2019;s equity incentive plans expire no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years from the date of grant and generally vest over a four year period, with vesting either occurring at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% at the end of the first and thereafter in 36 equal monthly installments or on a monthly basis. In the case of awards granted to our non-employee board members, vesting generally occurs on a monthly basis over three years or in full on an annual basis. The Company issues new shares of common stock upon the exercise of stock options.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s stock option activity for the year ended December 31, 2021 is as follows (in thousands, except share and per share data and years):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.416%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:0.859%;"/&gt;
        &lt;td style="width:11.312%;"/&gt;
        &lt;td style="width:1.079%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:9.99%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:0.847%;"/&gt;
        &lt;td style="width:11.301%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:11.858%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;br/&gt;Subject to&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,316,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;511,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;261,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;195,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,385,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,974,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.14&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,887,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#x2019;s common stock for all options that were in-the-money at December 31, 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average grant date fair value per share of option grants for the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.  The total fair value of shares vested during the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.272%;"/&gt;
        &lt;td style="width:1.412%;"/&gt;
        &lt;td style="width:1.078%;"/&gt;
        &lt;td style="width:13.638%;"/&gt;
        &lt;td style="width:4.942%;"/&gt;
        &lt;td style="width:1.078%;"/&gt;
        &lt;td style="width:13.638%;"/&gt;
        &lt;td style="width:4.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.982%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:0.982%;"/&gt;
      &lt;td style="width:93.036%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Prior to the Company's initial public offering in 2020, the grant date fair market value of the shares of common stock underlying stock options was determined by the Company&#x2019;s board of directors. Following the closing of the Company&#x2019;s IPO, the fair market value of the Company's common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#x2019;s common stock is traded. Prior to the Company&#x2019;s IPO, because there was no public market for the Company&#x2019;s common stock, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included contemporaneous valuations performed by an independent third-party, the Company&#x2019;s results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#x2019;s business, progress of the Company&#x2019;s research and development activities, the Company&#x2019;s business conditions and projections, the lack of marketability of the Company&#x2019;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#x2019;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key personnel and the experience of management, trends and developments in the Company&#x2019;s industry and external market conditions affecting the life sciences and biotechnology industry sectors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.982%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:0.982%;"/&gt;
      &lt;td style="width:93.036%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.982%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:0.982%;"/&gt;
      &lt;td style="width:93.036%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Given the Company&#x2019;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.982%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:0.982%;"/&gt;
      &lt;td style="width:93.036%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:4.982%;"/&gt;
      &lt;td style="width:1.0%;"/&gt;
      &lt;td style="width:0.982%;"/&gt;
      &lt;td style="width:93.036%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2020, the Company&#x2019;s board of directors and stockholders approved and adopted the 2020 ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;698,015&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were reserved under the ESPP, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;627,185&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares are available for future issuance and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,830&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares have been issued. The weighted average per share fair value rights granted during the year ended December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.489%;"/&gt;
        &lt;td style="width:11.076%;"/&gt;
        &lt;td style="width:1.301%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:4.906%;"/&gt;
        &lt;td style="width:1.301%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:4.906%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_c1aa1267-e255-46b6-8efa-786074f855a1">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.777%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.433%;"/&gt;
        &lt;td style="width:13.524%;"/&gt;
        &lt;td style="width:0.649%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.433%;"/&gt;
        &lt;td style="width:13.38%;"/&gt;
        &lt;td style="width:0.649%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1d8d0169-89f0-4155-948a-25ed3e8d9d13"
      decimals="-3"
      id="F_0cf18680-ff20-4a61-9063-22195e8131d8"
      unitRef="U_USD">8331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_37ebbd60-fda0-4900-9609-d33c5ffa0fd1"
      decimals="-3"
      id="F_493d325f-6a7d-4083-a2c8-64f7f0e35728"
      unitRef="U_USD">1180000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9fe4ab25-1247-4234-81ff-cc9c1674c66c"
      decimals="-3"
      id="F_2404a0ca-5a4b-4107-9c2f-4f607fae12c0"
      unitRef="U_USD">10856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3eec66cf-b934-4764-b8db-f29c238527a9"
      decimals="-3"
      id="F_f6516818-6561-400e-9789-927e4d8326c6"
      unitRef="U_USD">1460000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_8183d13f-4dca-42e0-87c3-dda1b9461611"
      unitRef="U_USD">19187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_10439835-b13d-4af3-aea1-56cfb3b9c597"
      unitRef="U_USD">2640000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_70d0ab66-9c56-4ccb-9a63-d8d7dda1b56d"
      unitRef="U_USD">50500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_142dfc7f-ecb0-4217-8390-a627cad88d7a">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_0c519572-aa4a-46c0-84b3-28a068eec9ee"
      unitRef="U_shares">9564798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_860dbe58-a733-4b54-b5e8-6248758d43eb"
      decimals="0"
      id="F_d6fecaa3-037d-4363-96fa-7016ecb68eb0"
      unitRef="U_shares">2931012</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_be2483c4-874d-42c1-84ce-11f096ef84bb"
      unitRef="U_shares">6370873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_10924f8e-1bb8-4859-a19f-53e9eeda573c"
      decimals="0"
      id="F_06262e43-cced-4018-890b-ef8671899860"
      unitRef="U_shares">26283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_54070967-7d3e-4ffb-8a9e-7c1a63fe490f">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="2"
      id="F_8be2871e-f48a-45f4-a0bd-f5d860a0158a"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_beeef8bc-fe3a-4374-b1f1-8818e72fabf4">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the Company&#x2019;s stock option activity for the year ended December 31, 2021 is as follows (in thousands, except share and per share data and years):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.416%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:0.859%;"/&gt;
        &lt;td style="width:11.312%;"/&gt;
        &lt;td style="width:1.079%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:9.99%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:0.847%;"/&gt;
        &lt;td style="width:11.301%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:1.033%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:11.858%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;br/&gt;Subject to&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,316,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;511,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;261,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;195,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,385,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,974,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.14&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,887,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="0"
      id="F_4a04d84e-c156-4355-bb10-ef64a43af662"
      unitRef="U_shares">6316569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="2"
      id="F_2aed5245-36a2-4409-b51e-dba599b85600"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="0"
      id="F_9fe38976-fc43-453e-b875-6dfd5fe3dbb9"
      unitRef="U_shares">511773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="0"
      id="F_e40cef18-a72b-44a4-bd03-26e5d26244aa"
      unitRef="U_shares">261567</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sbtx:StockIssuedDuringPeriodSharesStockOptionsCancelled
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="0"
      id="F_4c715566-e854-4064-8079-dac8862e2a5a"
      unitRef="U_shares">195902</sbtx:StockIssuedDuringPeriodSharesStockOptionsCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_c68fa4b1-c474-493d-91e0-01fe4513c5ef"
      unitRef="U_shares">6370873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="2"
      id="F_5fc24b2f-a810-48bd-8077-92dca4f06bf4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_39a8393d-085d-40a5-9b12-a7692bf6cb27">P8Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_5042577e-0961-4595-b3e7-d884e2a8cedd"
      unitRef="U_USD">11385117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="0"
      id="F_8b1812bd-b5a3-42e0-b4a0-ca9b39d377d0"
      unitRef="U_shares">1974776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="2"
      id="F_914095e7-7bd8-43a2-8133-f3a9090a2881"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_2c0c0956-5331-4847-bca8-b781929b9501">P8Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_7e5daed9-b4d7-4128-ab7c-4fea73f98871"
      unitRef="U_USD">4887808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-5"
      id="F_e79d4196-486e-49dc-866d-cf4e08ce1bd8"
      unitRef="U_USD">7700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-5"
      id="F_ea935df9-9cf0-44e1-9aa5-ad9475ae37f0"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="2"
      id="F_a58378f4-5655-4273-bb7b-94b54a2a89a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="2"
      id="F_d001c7ea-3cc1-49cd-8a6f-22e42e58f673"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-5"
      id="F_8c127b22-1f26-4c0a-acbe-eb85d7d34958"
      unitRef="U_USD">17000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-5"
      id="F_05423998-051c-4809-a630-9ee59d948eff"
      unitRef="U_USD">1100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_492a035a-9897-4037-952e-c3b973f929a9">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.272%;"/&gt;
        &lt;td style="width:1.412%;"/&gt;
        &lt;td style="width:1.078%;"/&gt;
        &lt;td style="width:13.638%;"/&gt;
        &lt;td style="width:4.942%;"/&gt;
        &lt;td style="width:1.078%;"/&gt;
        &lt;td style="width:13.638%;"/&gt;
        &lt;td style="width:4.942%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_e5c153b7-b845-4577-8eff-c97d45aedf52">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      id="F_355775ef-0706-4894-a81e-3a165ad3412e">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="2"
      id="F_55158488-d417-47a9-9c5b-873f09d238c5"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="2"
      id="F_5cd7f652-f125-4008-a5bb-528c19837f0b"
      unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="4"
      id="F_c90aa162-f0c5-4385-87ce-0f9658f8d2db"
      unitRef="U_pure">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="4"
      id="F_9439153f-11d6-466f-a007-3e54d8af11ba"
      unitRef="U_pure">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="2"
      id="F_039a79be-8189-4a87-8f0c-adb18cf6c709"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="2"
      id="F_e749fd51-9281-4b0b-9539-dc7336dfd7a3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_4e9ffb89-6ff5-4676-b044-c5c124536efd"
      id="F_113ded34-14d8-47f2-a98d-22e82a4f0fb6">In November 2020, the Company&#x2019;s board of directors and stockholders approved and adopted the 2020 ESPP. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <sbtx:EligibleEarnings
      contextRef="C_4e9ffb89-6ff5-4676-b044-c5c124536efd"
      decimals="2"
      id="F_1218d60d-5054-41af-ad6b-7273e0508d3a"
      unitRef="U_pure">0.15</sbtx:EligibleEarnings>
    <sbtx:SharesWereReservedUnderTheEspp
      contextRef="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3"
      decimals="0"
      id="F_5ca38fa2-f3f7-4f80-b5ee-ebc06abc741e"
      unitRef="U_shares">698015</sbtx:SharesWereReservedUnderTheEspp>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3"
      decimals="0"
      id="F_277556c6-4e6f-422c-a0d4-16e3bcee424b"
      unitRef="U_shares">627185</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_288b2e0c-d944-4d8d-8beb-e76a8e415fc3"
      decimals="0"
      id="F_11667b3b-b11c-45ad-9807-6025f9252b31"
      unitRef="U_shares">70830</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="C_d7fa8844-58a6-4654-9ddd-9b5375a9b363"
      decimals="2"
      id="F_ce4c2216-78e7-4ab5-bd00-a7c2a8e06fa1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_79d5321f-f7a3-430b-ac8e-20ec91ca4fc0">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.489%;"/&gt;
        &lt;td style="width:11.076%;"/&gt;
        &lt;td style="width:1.301%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:4.906%;"/&gt;
        &lt;td style="width:1.301%;"/&gt;
        &lt;td style="width:13.51%;"/&gt;
        &lt;td style="width:4.906%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35"
      id="F_1d611f63-e449-42a2-aedd-886bc43b33b7">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025"
      id="F_59138ce0-27e6-40c3-a4fa-18e183c128cc">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35"
      decimals="2"
      id="F_0993e13c-bc5b-47b3-b0ef-8b300df86e8d"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025"
      decimals="2"
      id="F_520c3ac7-737e-4a7c-9a95-36be215796bd"
      unitRef="U_pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35"
      decimals="4"
      id="F_c61c01be-e1a7-443a-9ea2-3aa21d4febf1"
      unitRef="U_pure">0.0014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025"
      decimals="4"
      id="F_fa124862-63a2-4801-b0c9-10957e3c093d"
      unitRef="U_pure">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c3166a85-f0b6-454d-9e3b-4e94972eab35"
      decimals="2"
      id="F_6bdf5f77-2dc8-42f0-bb46-1ad686940b30"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_8ddd0e60-568d-4ee5-b73b-fc9dccbfc025"
      decimals="2"
      id="F_ab0bb71f-f09e-4dfe-828f-cb7fb75f47ea"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_c114b9a0-f082-402e-a653-ca4879b36458">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s effective tax rates for the years ended December 31, 2021 and 2020 differ from the U.S. federal statutory rate as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.649%;"/&gt;
        &lt;td style="width:4.467%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.888%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
        &lt;td style="width:3.84%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.563%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax at the federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Benefit from R&amp;amp;D tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other temporary and permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.348%;"/&gt;
        &lt;td style="width:2.494%;"/&gt;
        &lt;td style="width:1.671%;"/&gt;
        &lt;td style="width:13.527%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
        &lt;td style="width:4.536%;"/&gt;
        &lt;td style="width:1.671%;"/&gt;
        &lt;td style="width:13.527%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;R&amp;amp;D tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities - Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021, the Company had net operating loss carryforwards for income tax purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;160.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. If not used, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of this carryforward will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;142.1&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million has no expiration. At December 31, 2021, the Company also had research and development tax credits of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million which will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; if left unused. The Company did not have any foreign tax provision and did not generate material net operating losses in any states with an income tax.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;FASB ASC 740 requires that the tax benefit of net operating losses, temporary differences, and credit carryforwards be recorded as an asset to the extent that management assesses the realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits from the net operating losses or credit carryforwards, if any, is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the applicable carryforward period. Because of the Company&#x2019;s recent history of operating losses, the Company maintains a full valuation allowance in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.9&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company may have already experienced one or more ownership changes. Depending on the timing of any future utilization of its carryforwards, the Company may be limited as to the amount that can be utilized each year as a result of such previous ownership changes. However, the Company does not believe such limitations will cause its carryforwards to expire unutilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future changes in the Company&#x2019;s stock ownership as well as other changes that may be outside the Company&#x2019;s control could potentially result in further limitations on the Company&#x2019;s ability to utilize its net operating loss and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have any liabilities for unrecognized income tax benefits associated with uncertain tax positions, including any interest and penalties.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_698a692b-218b-40dc-8b92-f747f359aa71">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s effective tax rates for the years ended December 31, 2021 and 2020 differ from the U.S. federal statutory rate as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.649%;"/&gt;
        &lt;td style="width:4.467%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.888%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
        &lt;td style="width:3.84%;"/&gt;
        &lt;td style="width:1.682%;"/&gt;
        &lt;td style="width:13.563%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax at the federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Benefit from R&amp;amp;D tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other temporary and permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_af1d90a5-51d9-4b4d-aa3a-cd007366a403"
      unitRef="U_USD">-18790000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_7bc668a1-71da-4e0e-96fe-1f97d3bd4760"
      unitRef="U_USD">-6919000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <sbtx:BenefitFromRDTaxCredits
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_b4dee961-7fbd-4bbe-90ba-2aa777240435"
      unitRef="U_USD">-1244000</sbtx:BenefitFromRDTaxCredits>
    <sbtx:BenefitFromRDTaxCredits
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_8787bea0-873c-4b7d-9918-573c933a5f0a"
      unitRef="U_USD">-586000</sbtx:BenefitFromRDTaxCredits>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_2338f6bb-5e22-4e54-b5cb-94974a9a1289"
      unitRef="U_USD">1102000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_139f19ca-2803-4a30-a2f5-5f7852308400"
      unitRef="U_USD">331000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_1ec2ae38-bf2b-4239-9035-3f03a4f0c4f9"
      unitRef="U_USD">817000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_640654ea-aefa-42d5-a779-3cd53efe50f3"
      unitRef="U_USD">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <sbtx:OtherTemporaryAndPermanentDifferences
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_1b26266b-e1da-44cf-8152-ad1e4691ce00"
      unitRef="U_USD">33000</sbtx:OtherTemporaryAndPermanentDifferences>
    <sbtx:OtherTemporaryAndPermanentDifferences
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_3f6fcdd2-c9ac-4d3c-b37a-3f0afcd9b37f"
      unitRef="U_USD">21000</sbtx:OtherTemporaryAndPermanentDifferences>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_b0d306ba-170f-47b3-b16b-3dcf3f392ba9"
      unitRef="U_USD">18082000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_1bacdcad-6ed4-415d-a1eb-f4dd0c4d1bb4"
      unitRef="U_USD">7153000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="-3"
      id="F_850b4d0f-f642-4e0f-95e4-ded8a347a6ba"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="-3"
      id="F_9addd2da-ae02-4b66-a8c4-5de911700e89"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_f3ab0677-45e4-44e7-aed7-e2c9ebbfbb2c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The significant components of the Company&#x2019;s deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.348%;"/&gt;
        &lt;td style="width:2.494%;"/&gt;
        &lt;td style="width:1.671%;"/&gt;
        &lt;td style="width:13.527%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
        &lt;td style="width:4.536%;"/&gt;
        &lt;td style="width:1.671%;"/&gt;
        &lt;td style="width:13.527%;"/&gt;
        &lt;td style="width:1.114%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;R&amp;amp;D tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities - Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;458&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_bcc23dd9-c528-4546-8b25-8d9fb1f5516c"
      unitRef="U_USD">33671000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_542a0a05-4bad-4041-ad73-53dc19ff5e07"
      unitRef="U_USD">18832000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <sbtx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_1ed1ab96-740e-498b-b767-7bfe8d2841b9"
      unitRef="U_USD">1228000</sbtx:DeferredTaxAssetsOperatingLeaseLiability>
    <sbtx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_75e34d01-17c5-42b4-82e8-5874cd1fc77c"
      unitRef="U_USD">677000</sbtx:DeferredTaxAssetsOperatingLeaseLiability>
    <sbtx:RDTaxCreditCarryforward
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_bedbb2dd-2a66-4441-965c-829f3edc854f"
      unitRef="U_USD">2746000</sbtx:RDTaxCreditCarryforward>
    <sbtx:RDTaxCreditCarryforward
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_39d9f168-71c9-4d1c-bf77-35a88aa47b37"
      unitRef="U_USD">1502000</sbtx:RDTaxCreditCarryforward>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_fb052f3d-0755-40ac-a7c2-5842aa189793"
      unitRef="U_USD">2151000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_f93173ac-e3cd-4142-9e55-e472eac3738d"
      unitRef="U_USD">227000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_973e624a-2a10-4087-bbc3-6ff4e42dec28"
      unitRef="U_USD">237000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_291e9da4-9685-4b8c-a48b-76394d2ace37"
      unitRef="U_USD">109000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_e1edb9f5-33e6-4472-8790-b57eafe7f412"
      unitRef="U_USD">40033000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_5b081685-04c9-40e3-a26d-46f66bfdaa94"
      unitRef="U_USD">21347000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_fdc98f4d-e2d1-4d41-9f33-3e332279af5b"
      unitRef="U_USD">994000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_0b4708ec-41eb-4d5c-9468-a589eb6ac775"
      unitRef="U_USD">458000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_e9973c3f-65bb-4fc5-8527-f2427ce13d6f"
      unitRef="U_USD">39039000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_bc9cd764-8a95-42b3-9c3c-8a97f40fb1d7"
      unitRef="U_USD">20889000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_4b7e66bd-f768-4d94-8b25-767078b62776"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_4758271c-15a9-4716-a617-fa378679aa52"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_a2e65472-5134-41aa-80c8-423ecce5fc64"
      unitRef="U_USD">160300000</us-gaap:OperatingLossCarryforwards>
    <sbtx:OperatingLossCarryforwardsAmountToExpireIfNotUsed
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_cf5917b9-4c95-4487-ac87-1e251dd9b0c8"
      unitRef="U_USD">18200000</sbtx:OperatingLossCarryforwardsAmountToExpireIfNotUsed>
    <sbtx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_a0214c16-4cd7-4c40-ab47-5a8ba2ed1740">2036</sbtx:OperatingLossCarryforwardsExpirationYear>
    <sbtx:OperatingLossCarryforwardsAmountNotSubjectToExpiration
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_6dfdac86-7578-48c8-81e8-98b503ace1f4"
      unitRef="U_USD">142100000</sbtx:OperatingLossCarryforwardsAmountNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_7ec30bfe-5f48-45a5-b118-07bc27b0ff78"
      decimals="-5"
      id="F_0bbee95c-7389-43d5-bc41-70e334809776"
      unitRef="U_USD">2700000</us-gaap:TaxCreditCarryforwardAmount>
    <sbtx:TaxCreditCarryforwardExpirationYear
      contextRef="C_415738ce-5fb5-4ca7-93ff-db3c98f51fea"
      id="F_f4134c31-bc3e-4aaa-a6a2-a2a8f6e35fd8">2037</sbtx:TaxCreditCarryforwardExpirationYear>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-5"
      id="F_97c9025e-adc0-4a48-a73b-b1c4aad00beb"
      unitRef="U_USD">39000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-5"
      id="F_5ea35365-8506-4841-a6f7-3911b60679b7"
      unitRef="U_USD">20900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_51f68c66-981f-4114-9f1d-8af004dee45d"
      decimals="-3"
      id="F_a28482e2-082f-4f33-a7e1-eefa64af9425"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1374f92e-f597-4ff4-b276-ec1b04dde34a"
      decimals="-3"
      id="F_51acb122-add4-4f0e-87a4-199433ee6cbf"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <sbtx:LicensingAgreementTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_1300f816-5a53-49c2-9e70-3f389c769bcf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. Licensing Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Bio&#x201d;). Under the license agreement, WuXi Bio granted the Company a non-exclusive, worldwide, sublicensable, under certain of WuXi Bio&#x2019;s intellectual property rights, know-how and biological materials (&#x201c;WuXi Bio Licensed Technology&#x201d;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#x201c;WuXi Bio Licensed Product&#x201d;). The WuXi Bio Licensed Technology is currently used to manufacture a component of the Company&#x2019;s ImmunoTAC platform. The Company has paid an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;150,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in license fees that were recorded in research and development expense when incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them through the termination date. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party may terminate the license immediately upon written notice to the other party.&lt;/span&gt;</sbtx:LicensingAgreementTextBlock>
    <sbtx:LicenseFeesPaid
      contextRef="C_c917bb6b-c19f-402a-a7f9-3796e47702e8"
      decimals="0"
      id="F_c3ee64bc-f56d-40fe-8786-2658e35dff92"
      unitRef="U_USD">150000</sbtx:LicenseFeesPaid>
    <sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones
      contextRef="C_f1589284-886e-47d9-8e01-e13b1c2af513"
      decimals="-5"
      id="F_f276341c-3522-4cff-9517-3221aaa28f4a"
      unitRef="U_USD">10800000</sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones>
    <sbtx:AgreementPaymentAndLicenseTermDesciption
      contextRef="C_f1589284-886e-47d9-8e01-e13b1c2af513"
      id="F_8751bc03-0c30-4cc6-bb13-3397f7cff03b">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.</sbtx:AgreementPaymentAndLicenseTermDesciption>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_5b51cb2d-aca3-46b7-a60c-3797f0f47580">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On November 5, 2021, a securities class action complaint was filed against the Company and certain of the Company's officers and directors in the U.S. District for the Western District of Washington, captioned Dresner v. Silverback Therapeutics, Inc., et al., Case No. 2:21-cv-01499.  The complaint alleges that between December 3, 2020 and September 10, 2021, the Company and certain of the Company's officers and directors violated (1) Sections 11 and 15 of the Securities Act of 1933, as amended; and (2) Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission (&#x201c;SEC&#x201d;) Rule 10b-5 promulgated thereunder, by making allegedly false and misleading statements in various SEC filings and press releases regarding the clinical and commercial prospects of the Company&#x2019;s product candidate, SBT6050, which is now discontinued.  The complaint seeks unspecified damages and interest, as well as attorneys&#x2019; fees and other costs. The court recently appointed lead plaintiff and lead plaintiff's counsel. The Company and the other defendants have not yet filed a response to the complaint, and do not anticipate doing so until after the filing of an amended complaint.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company cannot predict the outcome of this suit, and failure by the Company to obtain a favorable resolution could have a material adverse effect on its business, results of operations and financial condition. The Company&#x2019;s chances of success on the merits are still uncertain and any possible loss or range of loss cannot be reasonably estimated and as such the Company has not recorded a liability as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Indemnifications&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions or related to any indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;COVID-19&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The global COVID-19 pandemic continues to rapidly evolve, and management continue to monitor the situation closely. The extent of the impact of COVID-19 on the Company&#x2019;s business, operations, planned preclinical studies and clinical trials, and manufacturing timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#x2019;s CROs, third-party manufacturers, supply chains necessary for research and development and manufacturing, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the Company&#x2019;s key scientific and management personnel. For example, the COVID-19 pandemic has caused the cost of obtaining animals for our preclinical studies to increase dramatically and, if the shortage continues, could also result in delays to our development timelines.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and some of the Company&#x2019;s non-lab based employees working remotely. Management will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter Company operations, including those that may be required by federal, state or local authorities, or that management determines are in the best interests of the Company&#x2019;s employees and other third parties with whom the Company does business. At this point, the extent to which the COVID-19 pandemic may further affect the Company&#x2019;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_b379e1a0-ab75-453b-bf51-17199e14f747">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. Employee Benefit Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#x2019;s U.S. employees. The plan allows eligible employees to defer, at the employee&#x2019;s discretion, pretax compensation up to the IRS annual limits. The Company did not match contributions made by employees through December 31, 2021. The Company began matching &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of employee contributions in 2022.&lt;/span&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_8cf07191-8e06-40b3-853c-f995a1f625ad"
      decimals="2"
      id="F_18d5bf47-2518-462d-be95-c523fa527941"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_3c7f2c83-2537-45cd-8961-098000300d11">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.997%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
        &lt;td style="width:17.292%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
        &lt;td style="width:17.292%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,316,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ESPP withholdings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total potentially dilutive shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,397,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,421,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_7e26b493-bb39-4d85-b4b6-13f12ed40ddd">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.997%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
        &lt;td style="width:17.292%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
        &lt;td style="width:1.591%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
        &lt;td style="width:17.292%;"/&gt;
        &lt;td style="width:0.809%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,370,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,316,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ESPP withholdings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total potentially dilutive shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,397,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,421,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_032f1a5d-9136-4a8d-bfd5-8652354d9726"
      decimals="0"
      id="F_9cc0e816-6a56-48c9-a205-cc42ff5a5bcf"
      unitRef="U_shares">6370873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a6798eb1-f0de-4695-9641-5ea592a32344"
      decimals="0"
      id="F_0de2ba4e-ab53-4c40-aa90-6c8692a75d4e"
      unitRef="U_shares">6316569</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_10924f8e-1bb8-4859-a19f-53e9eeda573c"
      decimals="0"
      id="F_d7d14940-1ed1-40c3-ba88-5b52b95ebd03"
      unitRef="U_shares">26283</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_14dc9fe4-584f-4c31-87a5-09ff8302a12e"
      decimals="0"
      id="F_55a5759a-ff95-4481-8b4d-c87968e6c938"
      unitRef="U_shares">100263</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5733b7d9-e5ce-4ff8-9092-59c9faf284e9"
      decimals="0"
      id="F_d165f6d9-fb9c-4ee4-b510-7e81de9b7e87"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f1306218-ebfe-4f46-b53a-08722ba81bc1"
      decimals="0"
      id="F_3dd47e5e-3153-45f9-89bb-6f1eca2e9fbb"
      unitRef="U_shares">4393</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      decimals="0"
      id="F_ae179e9a-f0c3-43b0-8c12-b775f9967858"
      unitRef="U_shares">6397156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ea504935-5339-4904-9013-2798d8f23b79"
      decimals="0"
      id="F_42822c2d-24a3-4fac-a7ec-a8c1f8695fc2"
      unitRef="U_shares">6421225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_6fc848d2-853d-4bbf-a56e-c3070c9174c1"
      id="F_4868e1e9-b9f8-4745-b941-38e3253c7787">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Subsequent to December 31, 2021 through March 31, 2022, the Company&#x2019;s board of directors approved the grant of options to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,815,926&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The unrecognized stock-based compensation expense for these grants is approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Additionally, the Company&#x2019;s board of directors approved the grant of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266,744&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; restricted stock units. The unrecognized stock-based compensation expense for these awards is approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 28, 2022, the Company&#x2019;s board of directors approved a corporate restructuring plan to discontinue the Company&#x2019;s clinical development programs for SBT6050 and SBT6290 and to prioritize resources on the development of SBT8230 and early-stage discovery programs (the &#x201c;Restructuring Plan&#x201d;). In connection with the Restructuring Plan, the Company&#x2019;s workforce will be reduced by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%, with substantially all of the reduction in personnel expected to be completed by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;July 15, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company initiated the reduction in force on March 31, 2022 and expects to provide severance payments, continuation of group health insurance coverage, and other benefits for a specified period to the affected employees. The Company currently estimates that it will incur costs of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for termination benefits related to the Restructuring Plan, all of which will be cash expenditures paid in 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4dcf4afe-a66f-4353-a22e-83f64aa9613d"
      decimals="0"
      id="F_a621f524-168a-4459-9bda-ebcd2370c213"
      unitRef="U_shares">1815926</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cfaeded9-f33c-4994-a098-63eb660e83ee"
      decimals="2"
      id="F_f6613147-1447-4e8a-8741-dd4d54631ae5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.85</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_cfaeded9-f33c-4994-a098-63eb660e83ee"
      decimals="-5"
      id="F_37686382-43fe-49d5-8c45-65bec887e47b"
      unitRef="U_USD">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_60f52c8b-32d5-4e85-b1f0-31ec9fab4c12"
      decimals="-3"
      id="F_bde0c80a-79c7-44be-9c74-8a2a9ddc4e5c"
      unitRef="U_USD">266744000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_cfaeded9-f33c-4994-a098-63eb660e83ee"
      decimals="-5"
      id="F_b280db1f-ca6f-438d-91b9-3c7be56e9d47"
      unitRef="U_USD">1300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_45c71f8d-3cda-45b7-9581-ba0f5e84dd52"
      decimals="2"
      id="F_a3c36a57-6b75-4a1c-a82b-805d050c59bf"
      unitRef="U_pure">0.27</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <sbtx:RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod
      contextRef="C_45c71f8d-3cda-45b7-9581-ba0f5e84dd52"
      id="F_57e1a2c3-3f2e-4687-acce-97edfb9889c4">2022-07-15</sbtx:RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod>
    <us-gaap:RestructuringCharges
      contextRef="C_0b97d231-61a7-4be6-94e9-44926c823685"
      decimals="-5"
      id="F_132e7b8c-dcde-418b-b7a0-d06c65b12eee"
      unitRef="U_USD">2000000.0</us-gaap:RestructuringCharges>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MM)R1=]__2+XG/"-W/$D@,NIBH.$[YNU!6&%>EYC>$4S7(W<BT[$B-UG$HK<
M R!8L_3V+*\]%''&PE/BNR?$<SS70FB*F]]1>4J\<6'N6<QGN/FO>09?=VQ?
M?S,:O_:Y7^#YJ,__GJR4EC#O_T$@@QHR*""#8PX280ZK49/'URVS10PW=YW^
M;PB+8<UBB,),@$)4T+A-Z,9& [=?TT0QA,>HYC%"<6XRS?4K>6 ;;EP,?.YI
M:G4+CK/D"41J1<,G\A@S2;<LUSQ4)V2>A:<(S[.:YUD7GE/PF*0)H$;LA?S&
M7FU,<23'<=S1F3L>CA%:XYK6N-MD6C#)1616,0%QL3JP!:E:M]]^\TW+VCFO
MN9VCB--<RF*"<16"R[XP*E%^.%J_[WI]'^/E.HV0.MV\=DCM%F[:%10':_&6
M>R#O[O]B587T."\<[O8+QLIK6'G=6$VR+ =6#VPKI+;RP8&TS#'!<!M)=OTN
M2_$S%"#]ITSL,K)D5(F,162N5,ZDE1R.>2\P:HVTNUVU':1,\:)<0AR&@[5)
MK-MHO8N+=>6Q>::9+*LWLP@IJ5:HE1N.^(4IC%FC_FXG^=]+1>DKGFW(4E-]
M9-KCB"W,&KUW.PG^'R+),PUE-JS*A$D[(Q3)M /OU9:&[+('];YB\IGUK@@^
MXQK]=W'9?N0Z842LB>N]6_T(*R',)?"VTL21IB)-8;HNM0B?,&J-_+NX8L,:
MB(I0OJ8KD5@9X0#+Z\<_L8JTT7L/E^B]5\C-2QC3# KH8T5&"]#]9#F;_(YQ
M:M3>P^6YFE]F5I'[/%W99:L%!$J)OG]^-AQAE!JI]W"%KB@]TA<RCV Y\C4/
M::%A"$$<<NSVW6!\[IX[&,-&^KU.T@\UG9"@% 6YDT(K8 U(,A6P5F&I3D5D
MCRZ./KO!2#9)P,-UNR(YB2)8[5"!5C_(!WB/?,SLS'#(H>.06\KEL^G.)R#?
M]QC3)B]XG?*"G>GC3EB9XI#+G$,L1@X:[R8]>)W20TUP:JX@T(^0]:WD6IH$
M1C7()4:MR0]>I_Q04ZLGX4**9YZ%]C#CF)\G&+4F)WBXDG]-;2&4ALKM+[X]
MOC)PQ/.QZYQCW)JDX+4T!04SR>AQ*CB YV!BYS<YP<>E_(,H:NP8ZD9$WEI
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MGP4W1>4F%!"\8T#N5O/V0&+7QPZAMAZGT^%TC#A_*&1+1PG9S*6^[W=8=IU
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M/C_M;B0OFF\3MUQ*GC67&Q9".ZD%X/<UAW-^>U-_[N@^ B[^ 5!+ P04
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MB=H%V/M"*3HXKD"W?--?4$L#!!0    ( &J!?U3W(;JNG 8  +<9   8
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M64Y0RC>LRLP7^?@;;Q4*[7R)S'3]BQY;V6""DDH;F;># 4$NBN:?/;6&.!F
MHX$!I!U ^@/F P-H.Z"VW*Q!5JOU@1EV<Z7D(U)6&F:S%[5MZM&@C2BL&Q^,
M@K<"QIF;!\,,![<8C>0&K9C>H8_@6HVFZ.O#!_33NY_1.R0*].=.5IH5J;Z:
M&5C6#IXE[1)WS1)D8 E,T&=9F)U&OQ8I3U]., .\1]#D /J.C,[X@2?O$<47
MB 0$>P"M7C\\&(%#CS:D]7QT8+[::IO::ALE<P0YII@1Q;8)4F$$UY<CZ\R/
MZ\SK=>8#Z_P!69U)[75!,W)1C[2IN[^9+N/Y8GDUVY\:QB-&"<@=Q5X "X_
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M5_OX6.*W%#LQP/?"X@1K7\1!_^OL\E]02P,$%     @ :H%_5&L92H3$ @
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M@M7"/JCU>]SU<^[P<B6,?\*Z\<TH8UX;J\I=,.DEE\V;;79S. @8QF\$I+N
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MQ7AXN1!;LD% DOBI8HZN/02>%Y'P)LOMW_\V'R>S;UR$CRY3F(?47>624-'
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MN#B:,M/>@ML'IVM_\UQKAWNL_[G%] I#!OA>:#2Z>Z  _3]%G/\%4$L#!!0
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MF,8"J?=U0&M03)[G4DE(X1^/[58"<8.T-41"^Y-:L2P5W^U!]D)JJ02^*&
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M14@,RL&!CT>?_A8P $O883RKA/I%='C+(?IU>C/EW([>%%&<S*,_H#KY9O@
MJ3]T6"/JT343>&_#"D*=:WBW@35W[#5[1WZIBUL.IM<;:J,IPD1];HKI1*&-
M:(O?*R EO#!5BS>+^7%Q=SR;G[U^G1)@,%A;2ZLNJ984MX1HH^*3[T[%=S,Q
MZ88V,8W.9YU+_ZQS[HRS$K@7\Y?80*(1U'PNT^;GG9R;(6[ODY/FKT^A&X*E
MD3. N;>RXL5B+&7V8OE2AA>S%_KE([(^WA=KC?H:"3T;"YUDN_L%_-HODNH/
MTAI?_/4OKQ:+V=N;CU?R-'_[4GUO42?SV?+XG'.V;NU*#(4*GEI(]Q.UY)J_
M1:QS%$I41Z5M2)4#X18]GC^'B+4)9^#<.]2^:X/";IRK BV\ )0@<.U@52!^
M6&DOR]GL O-0:#:%":J3+PQ>H5O8P&7A(&9LQ_SGMU+S90O_H$A+4T*/B;KY
M\,M/LW,DP79M !0HV 987 *X!;!:+NW]+ M$MT&U#6^%@H<?2EWK578I9L I
M(8KOMZ '$H.(#&EH%[(FJJ(\W;$/(3S$T.W3^@A["W@(+M2;C6.1I6+_J:2"
MJ2I9O#^$S,3B!A3E !@SLJ2M0#&0#YK=+_C<N*AV*+,,%-@Y;)!Q"=;'=J<$
M*IVLP'I3F T\B!&)JH-'HH&U%>R7E2F<' K 9L["0=R^C@@(BT742T8.4;>-
MF$PIE A+:$W6H=+&,E@CY<8U"X7=4BI68\J=\X+NL,?9-B-C:\MDM>:.0)Z3
M1I< (-A+545<.LU>NYFP % R22EP5Z]308H>Z%.-)!YR!4T#'_:LZM..BZP@
M$8%N5'!FNX2DR%S>3<,:X#Z2I6TZV.$=V*R-0UVR)2 26.>5EXJ%+!G(GGNB
M+24I(37!L;/6.D@@D6AHN!+YH6UJ474 SDR7I@#EDNK4Y9(;/C_9LP<'CK>E
M1MHPXN_0E#QE(!# 9LI@FL*V)7.!O8VX<.\,PQ.JY!NV:+G+0H;8-0AZR$$Z
M0;N)6CN)OJ^MJ"79+,7 ^=EO"%=LM,_<@3U,[#WD!K=P#$'#UO-SSKX'"]'3
M^K2ED>*)3E@#EM7)E1)S#)$@0%PKE9"JM?&=$JFG!_8\2@QB"X;#R?[.V4<B
MOT.M41TFRI'F9*UZCZ5\Q0' U&V-5(L8DZ(0[L'3,S':Z%T7JE'52D%)Z@T<
M!UV E#0%GAOV7&!2TG4TB MT'P<D+0D%.?BY+U0!R<2B)&I6;QD3I"8"Q6BY
M,6A32]M(_<EE%9Y.)RFH83KK<#AY2*^'NDH^4YD2^NF%B WH'NLZT 5!_XY)
M] 60/7D(;'T:/R>D8WD/^#4+3AQ[N<LPD3/!>.G';7:BOX,D+O]A!XP/6J:6
M4+7H\-B'[CE=U(9C&6,JB6OX<LMP!EC9 (+1(#!P /8<6.ENZ_%676\<V]2-
MP:[6,XA"+K(#W399!M^WC*SL%7#W=-1B 23)%0[]R'#'V:61Z[ZK"/Z6TSSE
M/8B"-N6^TDNR!HD9#D@Z>A%XK+9M5_&/9-LH#X#K=)\:0,6]W6(.8_LC]J%6
M4"+8!NW\ZNMOGZ^/YZ]%HY7%J<$.8U /^YFBKWT)%*BT80Y&=PX,.\%=K1M(
MEH-)CQ-<L:XQ,9/X@+-/TIH/KF1WR0LYU!D^#%R26&:O1.YGAYUOZ )#[YPP
M96GX'(!VWU.Y$-NRHZ7]8.3"#[WR;85MP5^9!N+$R<?8S!8AD,N>KXW"T$/3
M0L'%DOA@QVIV_;5$-*W;Y+Z1&D]',,O6Y]!A3;J>ZFP'+5GB_3:1/0YI=L;C
M#KCZ_E7@&I!^G"!]L /Y/4%O01;LF"*PZ@UQ<G GK028 FG/'4YZ5:_O0W],
M1F1RZ!^&,O)LU])7AFPN'8V#,Z*J^R:!=[< 1P>%=(M>-3H[/&;M+>U4* PW
M$63_8<XA X \#?/33[".[C6X8'=O\"";&1L*W89TSA#T%PXF%$_.&5(<03P%
MVO%H-@ET%@QY"*H'38_\V0HI1M!32 /LBEQR?0%-<FN#>)<)H)*4L7HG0GF_
M<4#Z=$2Y))#LP#&SM\G8$28(8\1)A.T8;C:0NF V=I*"-N0"# 1+-4&@HG;E
MB(!!%X(7W8Y0RA[4-AV*PHB"' :I<<VQU4NY?2S[U4'N.UD?E!%X %?^ET'E
M?7+!G5+N/^'),7KL@8X<"WHX&379/M8I/P#,3!DJG'LX?3/ER3=#EEE,E[5C
M#!D7+%.HOM&-Z0@:4D5@(NQ3.7<J(75R=!S2>:)$?5G?&]Q?U21VGF\^EMSW
MNB/>D\?,P:=_HBJGZGU,)Q\Y 4[&604GIN/JXZ7#;NC=F8XU_RTX[^/OHRD^
M(.XA;*9*X;<!07KF/[Y92Y=I&Q.Q1T-4RC'K +P3P#+Y7OXN%CB5+BNFCUV@
MGHSNK'&H6LG-?#H0QW1]W8_VE__OTYWW,#W]Y^"+]BO6Q%*%I;/IS^='RJ?;
M^/02W49NP)<.Q_I:'M?H$.1Y KY7#O637WB#_E\BE_\!4$L#!!0    ( &J!
M?U2O%5))Y0(  %\&   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*55
MWV_30 S^5ZP@$$A3TZ1E&Z.MM&X@]C!1;0P>$ ^7Q$E.N]R%.X>N_SV^:YIU
M:%1(/+2Y'_;G[W-L9[8V]M[5B 0/C=)N'M5$[5D<N[S&1KB1:5'S36EL(XBW
MMHI=:U$4P:E1<3H>'\>-D#I:S,+9RBYFIB,E-:XLN*YIA-TL49GU/$JBW<&-
MK&KR!_%BUHH*;Y'NVI7E73R@%+)![:318+&<1^?)V7+J[8/!5XEKM[<&KR0S
MYMYOKHIY-/:$4&%.'D'PXQ=>H%(>B&G\[#&C(:1WW%_OT#\&[:PE$PXOC/HF
M"ZKGT6D$!9:B4W1CUI^PU_/6X^5&N? /Z]YV'$'>.3)-[\P,&JFW3_'0Y^%?
M'-+>(0V\MX$"RTM!8C&S9@W66S.:7P2IP9O)2>U?RBU9OI7L1XL/3:O,!A&6
MJ+&4!"LEM)O%Q-C>(LY[G.46)_T+3I+"M=%4._B@"RR> L1,:F"6[I@MTX.(
MEYB/8)(<03I.DP-XDT'I).!-_HI7\DGQ5"@(7<!GJM'"RCBR2-(BUQS]878I
M7:Z,ZRPZ^'Z>L267TX\#K*8#JVE@-?WO_!_&228C>!X+OM0(%Z9IA=Z ;U/B
M'PN'/;$M&Q[!NI9Y#=+!STXH64I.5L<ODUNX;Z'I.'E]_P9,"9PQN-*$5@L%
M-_@+=>>#%.@ODW>GQT<@. :#<S$< 0^/X-+3>/7B-$U.WCNX&]V. 'O:;A2H
M>BX@%$\+!ZAD)3.%CS9 QC<=6@Y  7-W-8 6_*Z\-L.2>%"1>("<X_(@$4%%
MUWJ0H.#FE@M LUI0LI'4,]@EJY %:$.<-.*\Y%S>5F:=QW!\QEJSS3ZQVIJN
MJH'K%IN,L[:KW:>@&5:L+T!*7<$47OJ4[6#^B"*U1TA'SQ5:O-?T#=HJC#;'
M )VF;?\/I\/T/-\.C4?S[>B]%K;R-:&P9-?QZ.1M!'8[SK8;,FT8(9DA'DAA
M6?,7 *TWX/O2&-IM?(#AF[+X#5!+ P04    " !J@7]4T5"A  4#  "7!@
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M<DHB9P89'#9.=T%Z"NU(R,*RH2\'&F] ][6FA/8;'^#P+5K^!%!+ P04
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MCM/C6<),?(7$#Z>[</.OM,,[(@R1NHJ,WX#UM=9N]^$=[)^"RW\!4$L#!!0
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M1^.HP#;9"1Y.JFOOT=O&'S67OLD@!1IJ)KV3WJ6B-:%.&B*D]5$[\AL<C.3
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M;[2C'A&&-35E--Z ]BNMW7[B PQM?O4/4$L#!!0    ( &J!?U0'CQE'\@(
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M6"?LG=I^P"&?L>,KE##^%[:][W@<0-$9JYH!3 H:+OLO>QKNX0 PB?\"2 =
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M2Z/&FS7-=M3.@<XK1:\\+%R _;_%XA=02P,$%     @ :H%_5 Y[!V/T!
MB@P  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULI5?;;MLX$'WW5PR\
MVT4+*+8D7R2G20 [32\/18,D;;%8[ ,MC24AE*B2M)WLU^\,):ONUO$&Z$,B
MDIK[.3.BS[9*WYL<T<)#*2MSWL^MK4^'0Y/D6 HS4#56]&:E="DL;74V-+5&
MD3JE4@Y#WY\.2U%4_8LS=W:M+\[4VLJBPFL-9EV60C\N4*KM>3_H[PYNBBRW
M?#"\.*M%AK=H/]?7FG;#SDI:E%B90E6@<77>GP>GBXCEG<"7 K=F;PV<R5*I
M>]Y\2,_[/@>$$A/+%@0]-GB)4K(A"N-;:[/?N63%_?7.^EN7.^6R% 8OE?Q:
MI#8_[\=]2'$EUM+>J.U[;/.9L+U$2>/^P[:5]?N0K(U59:M,$91%U3S%0UN'
MYRB$K4+HXFX<N2C?""LNSK3:@F9ILL8+EZK3IN"*BD&YM9K>%J1G+VZM2NY/
M%I17"I>J)*R-<.5Z>2>6$LVKLZ$E-RP\3%J3B\9D^(3)((2/JK*Y@:LJQ?1'
M T.*KPLRW 6Y"(]:?(/) $:!!Z$?!D?LC;JD1\[>Z*FD<Z'Q9.F2OA:/Q#$+
M<ZU%E:%;_S5?&JN),'\?<3;NG(V=L_%3SAJZ@UK!OM\?BGWUP&L\5.NCQKEE
M3TTM$CSO4T\:U!OLMY@V;I)]-]BXH69*5%85_]![:FL04@)^6Q?V$<16Z-1
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MI*$;VBU7]$F$RAK0^T)*L]O8!-U'UNP?4$L#!!0    ( &J!?U3<X"I*'@,
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M"PDS!I^T<HV%:U5A]10@(?:C!/8HX9*]BO@!RQ/(LQA8RK)7\/*Q)'G RU_
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MG8W. ]#MA+:&5;5O\J6R-#)^6=*CAMHYT/E**;LS7(#^F<Q^ U!+ P04
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MH[(&]#V1TAP7=J)J1N[%_U!+ P04    " !J@7]4V>K6+E8#  "#"P  &0
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M'6U C,(6CEOA&NQM<21J1NWML%MU7JU#8%_,S)M#1QS0S?+-6D6-ODM:Z(.
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MW2]0!C31_GP6B_P_VI6VY@CYF9 L*<&*01*EQ2]]+!/1 &"[ T!* !D*L$J
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M"#*QZ3N^LUVX9<M4FP5WT"OH$F:@[XNIQ)E;LR2,0ZZ8R(F$1=\9^I=CWS,
M&_&#P48UQL2D,A?BT4RND[[C&4600:P-!<7;&L:0988)=?RN2)UZ3P-LCK?L
M7VSRF,R<*AB+["=+=-IWN@Y)8$%7F;X5FV]0)=0V?+'(E+V2317K.21>*2UX
M!48%G.7EG3Y5A6@ _&@/(*@ P2Z@M0<05H#0)EHJLVE-J*:#GA0;(DTTLIF!
MK8U%8S8L-S;.M,2G#'%Z,-,B?CP;82$2,A8<WPY%;7W/R*QTEH@%F:54PMG\
M;=35DQD#.9Z IBP[0=C];$*.CT[($6$YN4O%2M$\43U7HUJSIQM7RD:ELF"/
M,C\@-R+7J2)7>0+):P(7TZQS#;:YCH*#C!.(STGHGY+ "_QW!(W_'>X=D!/6
MI0\M7[BO](VB3NDS?AN:#*6D^1+,^'1;W(1@ <F8%DS3C/V!Y)0,N5AA],-W
MI"37&KCZ=4!0JQ;4LH):>P3="=R */M&E++BIM=0RGG/R9*W8WG-P;$>^!=^
MM]-SU\WROHT*HI97![W2W*XUMP]JO@4%5,:IK5$":SR7"EO)2BUYN $^!WFH
M/E&]5_0Y#.O4@CH?9%C)&S6LZ(:AO^/7VR#?[^[QJUM+[AZ4_!5RD"C:5(@F
M>* QI24U1_G_.'91[W;Q.1SSO9?SUOL@SRKB5U^9UVU'.ZZ]%]:*=FUS&RV#
M@US:3JI0"R9=GJCU:MVMA[9'[:R/3!>WK>B%IOP%N*%RR7)%,E@@I7?>P2]9
MEEVUG&A1V,8T%QK;G!VF^"<"T@3@\X40>CLQ&]3_-H._4$L#!!0    ( &J!
M?U3?JXN<U@,  /8,   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;*V7
M;6_B.!" _\HHV@^MU)(X0%Y6@ 1T[Z[2KA:5:U>KU7TPR1!R36+.-J5(^^//
M=B!DEY#N7?N%V(YG_,P+GLE@R_BC6"%*>,ZS0@RME93K][8MHA7F5'38&@OU
M9LEX3J6:\L06:XXT-D)Y9KN.X]DY30MK-#!K,SX:L(W,T@)G',0FSRG?33!C
MVZ%%K,/"79JLI%ZP1X,U37".\GX]XVIF5UKB-,="I*P CLNA-2;O)\33 F;'
M0XI;41N#-F7!V*.>W,9#R]%$F&$DM0JJ'D\XQ2S3FA3'/WNE5G6F%JR/#]I_
M,\8K8Q94X)1E7])8KH968$&,2[K)Y!W;_H%[@_I:7\0R87YAN]_K6!!MA&3Y
M7E@1Y&E1/NGSWA$U@:Y_1L#="[B&NSS(4-Y024<#SK; ]6ZE30^,J49:P:6%
MCLI<<O4V57)R-)<L>KR>*+MBF+)<!5M0XZYKF)>! K:$L?9=*G=PAQF5:JMD
M8"3A\]KL_IW30@JXN$%)T^P2WH$-8D4Y"D@+N"]2*:[4HAK_N6(;08M8#&RI
M^#6%'>U9)R6K>X:5N/")%7(EX$,18_RC EL97EGO'JR?N*T:;S#J0)=<@>NX
MY'Y^ Q?O+H_HY6_+,=W*R5US3/><D[6BZ\6ID\=<^2U!E>42%CNH[YO1G5D>
M;RF/X=M'I1)N)>;BKQ:@7@74,T"]-B"A(KSX6_T[=#3+. KXO)%"JO"D17(%
M$TS2HE!#E?@9+2)LBEEYDF=.TG? T\CK$J_OA0/[J0&Q7R'VWP+1)-[/N5""
M]4_ ^H3X?K>9RZNXO+?@^O",/$I%,YEW0G;M>J3O^<UH?H7FOP7:5$<RRYK1
M_%,T$O9#QVU&"RJTX$V\9IYMV18T9)OO!.>B&E9\X>OYX &%RK5?P0Q/,$GH
M]WS?:\8DSO&Z=EI!OY@R@_$UC)^0J[I991K,>!IAPY\6OM>NX\9;MSPRK-,Z
MG?",2TFMM)!7LO[HR)=!][7,J9.ZG>!,<A+W2.J^BO1,Y%\&=D\\&W;.Y<"Q
MFI#N?Z2]0]V :;*I*I!<M3H;FL''=(EP\14I%Y>-=.W'!+#3HN!!7E9=-X28
M[MH*(CD6(-)>@?Z/#5?[,#3:TG[<P192VJ+J_8NF' L5::]4XR3AF*BV"&X5
M=ZH:U@@>:+9IS.]&]E*_7\]JT@UTM3J3*L=B1=JK50M;Z<M?1?1.$'M!X =.
M\!.A76M%<^2):;@%1&Q3R+(KK5:KIGY<MK+'[>47P2?*U4TF(,.E$G4ZOG(3
M+YOL<B+9VC2V"R95FVR&*_5A@EQO4.^7C,G#1!]0?>J,_@502P,$%     @
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MM"D.73,Q]3M*.\&\GPNA=QV[0/&/H/\'4$L#!!0    ( &J!?U1:1Z@3N08
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MT5USG20LA>BI<OY'-5?$I*8P2<H!&JT:C,&PR<CJU@'L1CN5SXRKTO08D-W
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M4%D!^IY*:9XFUD'SD)K_#U!+ P04    " !J@7]48"*!D4 #  #:"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6R-EFUOVS80Q[\*(11#"RP1]6!+
M[FP#:8QA!;HMB-/NQ; 7M'2VB%*B1U)Q\NUWI!1-M60E;VQ1O/_=CR?RCLN3
M5-]U 6#(4RDJO?(*8XX??5]G!91,7\LC5#BSEZID!H?JX.NC I8[42G\D-*Y
M7S)>>>NE>W>GUDM9&\$KN%-$UV7)U/,G$/*T\@+OY<4]/Q3&OO#7RR,[P!;,
MU^.=PI'?><EY"97FLB(*]BOO)OAX&SB!L_C&X:1[S\0N92?E=SOXG*\\:HE
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MII<$:0/,]Y4PXM03NT'3G8[_ U!+ P04    " !J@7]4[QF_:*D#  "/#
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6S-5]N.VS80?4Z^8B"DP"[@
M6!?? ]N 8R?H%DUKK.OV(>@#+8UM8B72(2E[M^C'=RAI96]65HT6&^3%)D6=
MPS,7#D?#@U1W>HMHX#Z)A1XY6V-V[UQ7AUM,F&[*'0I:64N5,$-3M7'U3B&+
M,E 2NX'G==V$<>&,A]FSN1H/96IB+G"N0*=)PM3#>XSE8>3XSN.#6[[9&OO
M'0]W;(,+-,O=7-',+5DBGJ#07 I0N!XY$__=S.]90/;&[QP/^F0,UI25E'=V
M<A.-',\JPAA#8RD8_>UQBG%LF4C'EX+4*?>TP-/Q(_O'S'@R9L4T3F7\!X_,
M=N3T'8APS=+8W,K#CU@8U+%\H8QU]@N'XEW/@3#51B8%F!0D7.3_[+YPQ G
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M.(-SMP92M'S]NZ3U;ZJ^_0902P,$%     @ :H%_5/,@BWGI 0  $B(  !H
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M4$L! A0#%     @ :H%_5 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !J@7]4>G?,^NT    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !J@7]4F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( &J!?U3+NIS7) <  #0=   8
M      " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !J@7]4[@9%C8,%  !"%0  &               @(%F#P  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ :H%_5&8>4>;& @  0PD  !@
M             ("!'Q4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( &J!?U2W:A]4OP,  +\+   8              " @1L8  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !J@7]4'MK)OB8&   0
M'   &               @($0'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ :H%_5 7$1X57 @  B 4  !@              ("!;"(
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &J!?U3W(;JN
MG 8  +<9   8              " @?DD  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !J@7]4I+2CAK4)  !,%P  &
M@('+*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ :H%_
M5)65\M""&@  :$\  !@              ("!MC4  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( &J!?U3;T]9A[@4  *D-   9
M      " @6Y0  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ :H%_5&L92H3$ @  + 8  !D              ("!DU8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !J@7]4)FEF<XT"  !\!0
M&0              @(&.60  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( &J!?U0)%/7;,P4  )<,   9              " @5)<  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ :H%_5%GR;G'P
M P  VP@  !D              ("!O&$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !J@7]43^J"\2T&  "A$   &0
M@('C90  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &J!
M?U2BC)K_+@T  . C   9              " @4=L  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ :H%_5+N%IF?#!@  EA   !D
M         ("!K'D  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !J@7]4![B/M;\$  #."P  &0              @(&F@   >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &J!?U0N^"B=& H  !X9
M   9              " @9R%  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ :H%_5*\54DGE @  7P8  !D              ("!ZX\
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !J@7]4T5"A
M  4#  "7!@  &0              @($'DP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( &J!?U3E*G-T700  !8*   9
M  " @4.6  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M:H%_5&1EE0WO&P  U%H  !D              ("!UYH  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !J@7]4NGLW*+L"   J!@  &0
M            @(']M@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( &J!?U1>C!1?%P,  )<&   9              " @>^Y  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ :H%_5"K+ 9RK @
MO 4  !D              ("!/;T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !J@7]4G%Q)#)@"  !\!0  &0              @($?
MP   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &J!?U3H
M J,;: ,  /('   9              " @>["  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ :H%_5 >/&4?R @  .08  !D
M     ("!C<8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &J!?U0A+RVVN0(  ,<(   9              "
M@:G:  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ :H%_
M5#8"XUZ? P  W0T  !D              ("!F=T  'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !J@7]4#4<ISV("   X!@  &0
M        @(%OX0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( &J!?U1JAK0<U (  /4(   9              " @0CD  !X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ :H%_5 WRV[!+ @  ,@4
M !D              ("!$^<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !J@7]4H]I=!HT"  "+!@  &0              @(&5Z0
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &J!?U2=6ED
MH (  !4'   9              " @5GL  !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ :H%_5%"-,*S! @  :@<  !D
M ("!,.\  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !J
M@7]4'"NEH<D#  !^"P  &0              @($H\@  >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &J!?U39ZM8N5@,  (,+   9
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M970T-RYX;6Q02P$"% ,4    " !J@7]4V\*$A-8"  #S!P  &0
M    @($*"0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M &J!?U1UE*<.,@,  !T,   9              " @1<, 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ :H%_5%I'J!.Y!@  6!D  !D
M             ("!@ \! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " !J@7]4DF^$3%T#  !4"0  &0              @(%P%@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &J!?U1@(H&10 ,
M -H)   9              " @00: 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ :H%_5!1NXH8S P  # H  !D              ("!
M>QT! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !J@7]4
MQ ';#>0"  #'!@  &0              @('E( $ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( &J!?U0CD@\8*0(  +<$   9
M      " @0 D 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ :H%_5)_K<FL5 P  J0H  !D              ("!8"8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !J@7]4[QF_:*D#  "/#
M&0              @(&L*0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( &J!?U2W%LKC'0,  # 2   -              "  8PM 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ :H%_5)>*NQS     $P(   L
M         ( !U# ! %]R96QS+RYR96QS4$L! A0#%     @ :H%_5#<$8>O"
M!   UR4   \              ( !O3$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( &J!?U3S((MYZ0$  !(B   :              "  :PV 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &J!?U2R:$G8U0$
M +\A   3              "  <TX 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !! $$ OA$  -,Z 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>280</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Term Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayable</Role>
      <ShortName>Term Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Licensing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/LicensingAgreement</Role>
      <ShortName>Licensing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Polices)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices</Role>
      <ShortName>Summary of Significant Accounting Policies (Polices)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Property and Equipment, Net - Schedule of Property and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Leases -  Summary of Operating Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail</Role>
      <ShortName>Leases -  Summary of Operating Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail</Role>
      <ShortName>Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Term Loan Payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail</Role>
      <ShortName>Term Loan Payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Inputs used for the ESPP (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted Average Inputs used for the ESPP (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Licensing Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail</Role>
      <ShortName>Licensing Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sbtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Subsequent Events (Additional Information) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events (Additional Information) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sbtx-20211231.htm">sbtx-20211231.htm</File>
    <File>sbtx-20211231.xsd</File>
    <File>sbtx-20211231_cal.xml</File>
    <File>sbtx-20211231_def.xml</File>
    <File>sbtx-20211231_lab.xml</File>
    <File>sbtx-20211231_pre.xml</File>
    <File>sbtx-ex10_15.htm</File>
    <File>sbtx-ex23_1.htm</File>
    <File>sbtx-ex31_1.htm</File>
    <File>sbtx-ex31_2.htm</File>
    <File>sbtx-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img238320182_0.jpg</File>
    <File>img238320182_1.jpg</File>
    <File>img238320182_10.jpg</File>
    <File>img238320182_11.jpg</File>
    <File>img238320182_12.jpg</File>
    <File>img238320182_13.jpg</File>
    <File>img238320182_14.jpg</File>
    <File>img238320182_15.jpg</File>
    <File>img238320182_16.jpg</File>
    <File>img238320182_17.jpg</File>
    <File>img238320182_2.jpg</File>
    <File>img238320182_3.jpg</File>
    <File>img238320182_4.jpg</File>
    <File>img238320182_5.jpg</File>
    <File>img238320182_6.jpg</File>
    <File>img238320182_7.jpg</File>
    <File>img238320182_8.jpg</File>
    <File>img238320182_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="398">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sbtx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 94,
   "dts": {
    "calculationLink": {
     "local": [
      "sbtx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sbtx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sbtx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sbtx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sbtx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sbtx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 440,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 42,
   "keyStandard": 238,
   "memberCustom": 18,
   "memberStandard": 21,
   "nsprefix": "sbtx",
   "nsuri": "http://silverbacktx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Cover Page",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Leases",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Term Loan Payable",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayable",
     "shortName": "Term Loan Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders' Equity (Deficit)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit",
     "shortName": "Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock-Based Compensation",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:LicensingAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Licensing Agreement",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/LicensingAgreement",
     "shortName": "Licensing Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:LicensingAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Commitments and Contingencies",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Employee Benefit Plans",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Subsequent Events",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Polices)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices",
     "shortName": "Summary of Significant Accounting Policies (Polices)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_ea504935-5339-4904-9013-2798d8f23b79",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_ea504935-5339-4904-9013-2798d8f23b79",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Leases (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Stockholders' Equity (Deficit) (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables",
     "shortName": "Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Income Taxes (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Nature of Business - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-5",
      "lang": null,
      "name": "sbtx:CashCashEquivalentsAndLongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_c1092c70-36be-47b4-b61d-7a83f3cd37fb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_e80f94ad-bad4-4970-8eac-4cb3f027e658",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_e80f94ad-bad4-4970-8eac-4cb3f027e658",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_e80f94ad-bad4-4970-8eac-4cb3f027e658",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Property and Equipment, Net - Schedule of Property and equipment (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment, Net - Schedule of Property and equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Leases -  Summary of Operating Lease Cost (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail",
     "shortName": "Leases -  Summary of Operating Lease Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail",
     "shortName": "Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Term Loan Payable - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail",
     "shortName": "Term Loan Payable - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_ee566949-7a9b-49b6-abae-885b6d7b031f",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
     "shortName": "Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_71b567b9-dd67-488e-9bff-940240379336",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_1374f92e-f597-4ff4-b276-ec1b04dde34a",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail",
     "shortName": "Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_13e17b88-9a3e-4334-afaa-25c79b7864bb",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_1374f92e-f597-4ff4-b276-ec1b04dde34a",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail",
     "shortName": "Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "0",
      "lang": null,
      "name": "sbtx:StockIssuedDuringPeriodSharesStockOptionsCancelled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail",
     "shortName": "Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Inputs used for the ESPP (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
     "shortName": "Stock-Based Compensation - Summary of Weighted Average Inputs used for the ESPP (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_c3166a85-f0b6-454d-9e3b-4e94972eab35",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_b15c1db3-dc8b-4bb3-a8bc-57d0215acab2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets And Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "sbtx:LicensingAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_f1589284-886e-47d9-8e01-e13b1c2af513",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Licensing Agreement - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail",
     "shortName": "Licensing Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "sbtx:LicensingAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_f1589284-886e-47d9-8e01-e13b1c2af513",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_8cf07191-8e06-40b3-853c-f995a1f625ad",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Employee Benefit Plans - Additional Information (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail",
     "shortName": "Employee Benefit Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_8cf07191-8e06-40b3-853c-f995a1f625ad",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_032f1a5d-9136-4a8d-bfd5-8652354d9726",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_51f68c66-981f-4114-9f1d-8af004dee45d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Subsequent Events (Additional Information) (Detail)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events (Additional Information) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_4dcf4afe-a66f-4353-a22e-83f64aa9613d",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_95651084-dc63-4d7f-8062-7d70db969b9b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_95651084-dc63-4d7f-8062-7d70db969b9b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Cash Flows",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Nature of Business",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "sbtx-20211231.htm",
      "contextRef": "C_6fc848d2-853d-4bbf-a56e-c3070c9174c1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r483",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r483",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r483",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r483",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r483",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sbtx_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments upon achievement of certain sales milestones.",
        "label": "Aggregate milestone payments upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_AgreementPaymentAndLicenseTermDesciption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement payment and license Term desciption.",
        "label": "Agreement payment and license Term desciption"
       }
      }
     },
     "localname": "AgreementPaymentAndLicenseTermDesciption",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sbtx_AmendedLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Loan and Security Agreement [Member].",
        "label": "Amended Loan And Security Agreement [Member]",
        "terseLabel": "Amended Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "AmendedLoanAndSecurityAgreementMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_BenefitFromRDTaxCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefit from R&amp;D tax credits.",
        "label": "Benefit From R&amp;D Tax Credits",
        "terseLabel": "Benefit from R&amp;D tax credits"
       }
      }
     },
     "localname": "BenefitFromRDTaxCredits",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_CashCashEquivalentsAndLongTermInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and long term investments.",
        "label": "Cash Cash Equivalents and Long term Investments",
        "terseLabel": "Cash, cash equivalents, and long term investments."
       }
      }
     },
     "localname": "CashCashEquivalentsAndLongTermInvestments",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible preferred stock upon closing of initial public offering",
        "label": "Conversion of redeemable convertible preferred stock upon closing of initial public offering"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertiblePreferredStockUponClosingOfInitialPublicOffering",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accounts payable and accrued liabilities.",
        "label": "Deferred Offering Costs Included In Accounts Payable and Accrued Liabilities",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liability",
        "label": "Deferred Tax Assets Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_EligibleEarnings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "eligible earnings",
        "label": "Eligible Earnings"
       }
      }
     },
     "localname": "EligibleEarnings",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sbtx_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy followed under emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_EmployeeStockPurchasePlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Policy Text Block]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPolicyTextBlock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_EsppWithholdingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP withholdings.",
        "label": "ESPP Withholdings [Member]",
        "terseLabel": "ESPP withholdings [Member]"
       }
      }
     },
     "localname": "EsppWithholdingsMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in operating lease liabilities during the period.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B redeemable convertible preferred stock for cash.",
        "label": "Issuance of Series B redeemable convertible preferred stock for cash",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock for cash"
       }
      }
     },
     "localname": "IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of series C redeemable convertible preferred stock for cash.",
        "label": "Issuance of Series C Redeemable Convertible Preferred Stock For Cash",
        "terseLabel": "Issuance of series C redeemable convertible preferred stock for cash"
       }
      }
     },
     "localname": "IssuanceOfSeriesCRedeemableConvertiblePreferredStockForCash",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment member.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Four",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_LicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees paid.",
        "label": "License Fees paid",
        "terseLabel": "License fees paid"
       }
      }
     },
     "localname": "LicenseFeesPaid",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_LicensingAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement.",
        "label": "Licensing Agreement [Abstract]"
       }
      }
     },
     "localname": "LicensingAgreementAbstract",
     "nsuri": "http://silverbacktx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "sbtx_LicensingAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for licensing agreement.",
        "label": "Licensing Agreement [Text Block]",
        "terseLabel": "Licensing Agreement"
       }
      }
     },
     "localname": "LicensingAgreementTextBlock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LicensingAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_LiquidityAndCapitalResourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Capital Resources [Member]",
        "label": "Liquidity and Capital Resources [Member]",
        "terseLabel": "Liquidity and Capital Resources [Member]"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and Security Agreement [Member].",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money Market Funds and Available For Sale Debt Securities Amortized Cost Basis",
        "label": "Money Market Funds and Available For Sale Debt Securities Amortized Cost Basis",
        "terseLabel": "Total Amortized Cost"
       }
      }
     },
     "localname": "MoneyMarketFundsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money Market Funds and Available For Sale Debt Securities Fair Value.",
        "label": "Money Market Funds and Available For Sale Debt Securities Fair Value",
        "terseLabel": "Total Fair Value"
       }
      }
     },
     "localname": "MoneyMarketFundsAndAvailableForSaleDebtSecuritiesFairValue",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_OperatingLossCarryforwardsAmountNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards amount not subject to expiration.",
        "label": "Operating Loss Carryforwards Amount Not Subject To Expiration",
        "terseLabel": "Operating loss carryforwards amount not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountNotSubjectToExpiration",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_OperatingLossCarryforwardsAmountToExpireIfNotUsed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards amount to expire if not used.",
        "label": "Operating Loss Carryforwards Amount To Expire If Not Used",
        "terseLabel": "Operating loss carryforwards amount to expire if not used"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountToExpireIfNotUsed",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "sbtx_OtherTemporaryAndPermanentDifferences": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other temporary and permanent differences.",
        "label": "Other Temporary And Permanent Differences",
        "terseLabel": "Other temporary and permanent differences"
       }
      }
     },
     "localname": "OtherTemporaryAndPermanentDifferences",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_PaymentOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of deferred offering costs",
        "label": "Payment of deferred offering costs",
        "negatedLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentOfDeferredOfferingCosts",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_PrepaidExpensesAndOtherAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other assets.",
        "label": "Prepaid Expenses And Other Assets [Policy Text Block]",
        "terseLabel": "Prepaid Expenses and Other Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherAssetsPolicyTextBlock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_ProceedReceivedInAdvanceForIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceed Received In Advance For Issuance Of Common Stock",
        "label": "Proceed Received In Advance For Issuance Of Common Stock",
        "terseLabel": "Proceed received in advance for issuance of common stock"
       }
      }
     },
     "localname": "ProceedReceivedInAdvanceForIssuanceOfCommonStock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_RDTaxCreditCarryforward": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D tax credit carryforward.",
        "label": "R&amp;D Tax Credit Carryforward",
        "terseLabel": "R&amp;D tax credit carryforward"
       }
      }
     },
     "localname": "RDTaxCreditCarryforward",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Stock Excersible On Agreed upon Milestones.",
        "label": "Redeemable Stock Excersible On Agreed upon Milestones [Member]",
        "terseLabel": "Redeemable Stock Excersible On Agreed Upon Milestones [Member]"
       }
      }
     },
     "localname": "RedeemableStockExcersibleOnAgreedUponMilestonesMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related cost number of positions expected to be eliminated period.",
        "label": "Restructuring and Related Cost Number of Positions Expected To Be Eliminated Period",
        "terseLabel": "Expectation of workforce reduced period"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsExpectedToBeEliminatedPeriod",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "sbtx_RestructuringPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring plan.",
        "label": "Restructuring Plan Member",
        "terseLabel": "Restructuring Plan [Member]"
       }
      }
     },
     "localname": "RestructuringPlanMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_RightOfUseAssetsAndLeaseLiabilitiesRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets and lease liabilities recognized.",
        "label": "Right Of Use Assets And Lease Liabilities Recognized",
        "terseLabel": "Right-of-use assets and lease liabilities recognized"
       }
      }
     },
     "localname": "RightOfUseAssetsAndLeaseLiabilitiesRecognized",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract",
     "nsuri": "http://silverbacktx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Issuance.",
        "label": "Schedule Of Common Stock Reserved For Issuance [Table Text Block]",
        "terseLabel": "Summary of Common Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other information related to companys operating leases table text block.",
        "label": "Schedule of Other Information Related To Companys Operating Leases [Table Text Block]",
        "terseLabel": "Summary of other information related to Companys operating leases"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToCompanysOperatingLeasesTableTextBlock",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SeriesCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Member.",
        "label": "Series C [Member]"
       }
      }
     },
     "localname": "SeriesCMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Redeemable Convertible Preferred Stock Member.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grants in percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Percentage",
        "terseLabel": "Share based compensation arrangement by share based payment award options grants in percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPercentage",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sbtx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders cancelled shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sbtx_SharesAvailableForFutureEquityAwardGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Future Equity Award Grants.",
        "label": "Shares Available For Future Equity Award Grants [Member]",
        "terseLabel": "Shares Available For Future Equity Award Grants [Member]"
       }
      }
     },
     "localname": "SharesAvailableForFutureEquityAwardGrantsMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Underlying Early Exercised Equity Awards.",
        "label": "Shares Underlying Early Exercised Equity Awards [Member]",
        "terseLabel": "Shares Underlying Early Exercised Equity Awards [Member]"
       }
      }
     },
     "localname": "SharesUnderlyingEarlyExercisedEquityAwardsMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesUnderlyingEsppWithholdingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares underlying ESPP Withholdings.",
        "label": "Shares underlying ESPP Withholdings [Member]",
        "terseLabel": "Shares Underlying ESPP Withholdings [Member]"
       }
      }
     },
     "localname": "SharesUnderlyingEsppWithholdingsMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesUnderlyingOutstandingEquityAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Underlying Outstanding Equity Awards.",
        "label": "Shares Underlying Outstanding Equity Awards [Member]",
        "terseLabel": "Shares Underlying Outstanding Equity Awards [Member]"
       }
      }
     },
     "localname": "SharesUnderlyingOutstandingEquityAwardsMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesWereReservedUnderTheEspp": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares were reserved under the ESPP",
        "label": "Shares were Reserved Under the ESPP"
       }
      }
     },
     "localname": "SharesWereReservedUnderTheEspp",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank [Member].",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_StockBasedCompensationArrangementsStockOptionGrantContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation arrangements stock option grant contractual term",
        "label": "Stock Based Compensation Arrangements Stock Option Grant Contractual Term"
       }
      }
     },
     "localname": "StockBasedCompensationArrangementsStockOptionGrantContractualTerm",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sbtx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance costs.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_StockIssuedDuringPeriodSharesStockOptionsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) cancelled during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Cancelled",
        "negatedLabel": "Shares Subject to Options Outstanding, Cancelled"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsCancelled",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options exercised and employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Stock Options Exercised And Employee Stock Purchase Plan",
        "terseLabel": "Exercise of common stock options, shares issued under the employee stock purchase plan, and vesting of early exercised common stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock options exercised and employee stock purchase plan.",
        "label": "Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan",
        "terseLabel": "Exercise of common stock options, shares issued under the employee stock purchase plan, and vesting of early exercised common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.",
        "label": "Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertibel Notes",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes.",
        "label": "Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of new stock classified as temporary equity issued on conversion of convertible notes during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Notes",
        "terseLabel": "Issuance of redeemable convertible preferred stock upon conversion of convertible notes, shares",
        "verboseLabel": "Issuance of Series C redeemable convertible preferred stock upon conversion of convertible notes, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock for cash (Note 8), shares",
        "verboseLabel": "Issuance of Series B redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Notes",
        "terseLabel": "Issuance of redeemable convertible preferred stock upon conversion of convertible notes",
        "verboseLabel": "Issuance of Series C redeemable convertible preferred stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock classified as temporary equity issued for cash during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues For Cash",
        "terseLabel": "Issuance of redeemable convertible preferred stock for cash (Note 8)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TemporaryequityValues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TemporaryEquity values",
        "label": "TemporaryEquity values",
        "terseLabel": "Redeemable convertible preferred stock converted into shares of common stock ,values"
       }
      }
     },
     "localname": "TemporaryequityValues",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan [Member].",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid initial public offering costs included in accounts payable and accrued expenses",
        "label": "Unpaid initial public offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "UnpaidInitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_UnvestedCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock.",
        "label": "Unvested Common Stock [Member]",
        "terseLabel": "Unvested Common Stock [Member]"
       }
      }
     },
     "localname": "UnvestedCommonStockMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_WuxiBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Bio.",
        "label": "WuXi Bio [Member]"
       }
      }
     },
     "localname": "WuxiBioMember",
     "nsuri": "http://silverbacktx.com/20211231",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r106",
      "r110",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r106",
      "r110",
      "r179",
      "r268",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r36"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r166"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "terseLabel": "Less accumalated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r50",
      "r51",
      "r52",
      "r442",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r60",
      "r61",
      "r62",
      "r98",
      "r99",
      "r100",
      "r343",
      "r452",
      "r453",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r304",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional\u00a0paid-in\u00a0capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r301",
      "r302",
      "r303",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r270",
      "r272",
      "r307",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r272",
      "r297",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r69",
      "r79",
      "r217",
      "r373"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "verboseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r138",
      "r146",
      "r150",
      "r160",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r341",
      "r344",
      "r361",
      "r400",
      "r402",
      "r425",
      "r440"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r46",
      "r92",
      "r160",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r341",
      "r344",
      "r361",
      "r400",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": {
     "auth_ref": [
      "r17",
      "r231",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of series or issue of auction market preferred securities.",
        "label": "Auction Market Preferred Securities, Stock Series [Axis]"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": {
     "auth_ref": [
      "r17",
      "r231",
      "r249",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both).",
        "label": "Auction Market Preferred Securities, Stock Series, Title [Domain]"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r156",
      "r162"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r155",
      "r162"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r273",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r81"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Money market funds, amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Assets",
        "verboseLabel": "Money market funds, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r82",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Restricted Cash [Member]"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r89",
      "r92",
      "r111",
      "r112",
      "r113",
      "r115",
      "r117",
      "r123",
      "r124",
      "r125",
      "r160",
      "r183",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r232",
      "r233",
      "r237",
      "r241",
      "r361",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r178",
      "r429",
      "r446"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r182",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares Available for Future Equity Award Grants",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Shares of common stock"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Initial public offering of common stock, net of $22,386 in issuance costs, shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized at December 31, 2021 and 2020, 35,133,934 and 34,801,537 shares issued and 35,107,651 and 34,701,274 shares outstanding at December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Initial public offering of common stock, net of $22,386 in issuance costs , values"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r257",
      "r258",
      "r269",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r67",
      "r432",
      "r449"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of preferred stock, common shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r211",
      "r218",
      "r219",
      "r221",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r91",
      "r96",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r223",
      "r224",
      "r225",
      "r226",
      "r374",
      "r426",
      "r427",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r222",
      "r427",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r38",
      "r214",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Annual Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r39",
      "r197",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r91",
      "r96",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r223",
      "r224",
      "r225",
      "r226",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r40",
      "r91",
      "r96",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r249",
      "r252",
      "r253",
      "r254",
      "r371",
      "r372",
      "r374",
      "r375",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Deferred tax assets:",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "verboseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Deferred tax liabilities - Right of use asset",
        "terseLabel": "Deferred tax liabilities - Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Equalization of employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r164"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r47",
      "r346",
      "r347",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r309",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r60",
      "r61",
      "r62",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r122",
      "r161",
      "r248",
      "r255",
      "r301",
      "r302",
      "r303",
      "r331",
      "r332",
      "r350",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r452",
      "r453",
      "r454",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Fair value,assets transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value,assets transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r209",
      "r223",
      "r224",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r353",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r355",
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r209",
      "r259",
      "r260",
      "r265",
      "r267",
      "r353",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r209",
      "r223",
      "r224",
      "r259",
      "r260",
      "r265",
      "r267",
      "r353",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r209",
      "r223",
      "r224",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r353",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Fair value, liabilities transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value, liabilities transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Fair Value, assets transfers into (out of) Level 3",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r209",
      "r223",
      "r224",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r168",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r318",
      "r320",
      "r325",
      "r333",
      "r335",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r108",
      "r109",
      "r137",
      "r316",
      "r334",
      "r336",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Total provision for income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r314",
      "r315",
      "r320",
      "r321",
      "r324",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at the federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r136",
      "r370",
      "r373",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest Expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income (expense), net",
        "totalLabel": "Interest Income (Expense), Net, Total"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r159",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r394",
      "r396"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Operating Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Sublease agreement description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail3": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Contractual term of sublease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingSubleaseOptionToExtend": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend operating sublease.",
        "label": "Lessee, Operating Sublease, Option to Extend",
        "terseLabel": "Option to Extend"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingSubleaseOptionToTerminate": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate operating sublease.",
        "label": "Lessee, Operating Sublease, Option to Terminate",
        "terseLabel": "Option to Terminate"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r92",
      "r147",
      "r160",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r342",
      "r344",
      "r345",
      "r361",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r92",
      "r160",
      "r361",
      "r402",
      "r428",
      "r444"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r92",
      "r160",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r342",
      "r344",
      "r345",
      "r361",
      "r400",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r34",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r34",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableToBankCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.",
        "label": "Loans Payable to Bank, Current",
        "terseLabel": "Term loan payable, net"
       }
      }
     },
     "localname": "LoansPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLawsuitFilingDate": {
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States the date the complaint was formally filed in a court of law, in arbitration or mediation.",
        "label": "Loss Contingency, Lawsuit Filing Date",
        "verboseLabel": "Action Complaint Filed Date"
       }
      }
     },
     "localname": "LossContingencyLawsuitFilingDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r126",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInContinuingOperations": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.",
        "label": "Net Cash Provided by (Used in) Continuing Operations",
        "totalLabel": "Change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r53",
      "r56",
      "r62",
      "r65",
      "r80",
      "r92",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r114",
      "r138",
      "r145",
      "r148",
      "r149",
      "r151",
      "r160",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r351",
      "r361",
      "r430",
      "r447"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r145",
      "r148",
      "r149",
      "r151"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r388",
      "r396"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Years Ending December\u00a031,"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total present value of lease payments",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r383",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "ROU asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash\u00a0lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r393",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease Weighted Average Discount Rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r392",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseMinimumRentals": {
     "auth_ref": [
      "r376",
      "r377",
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.",
        "label": "Operating Leases, Rent Expense, Minimum Rentals",
        "terseLabel": "Annual minimum rent payable"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseMinimumRentals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r54",
      "r57",
      "r60",
      "r61",
      "r63",
      "r66",
      "r248",
      "r362",
      "r367",
      "r368",
      "r431",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "verboseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r71",
      "r72",
      "r154"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of available-for-sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock , shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares, issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at December 31, 2021 and 2020; no shares issued and outstanding at December 31, 2021 and 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from Issuance of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r74",
      "r300"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of common stock options and employee stock purchase plan",
        "totalLabel": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r165"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r167",
      "r402",
      "r436",
      "r445"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r167",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock [Member]",
        "verboseLabel": "Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r266",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r266",
      "r397",
      "r399",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Principal payments on term loan payable"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r312",
      "r410",
      "r478"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Member"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r11",
      "r86",
      "r473"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of workforce reduced"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r79",
      "r171",
      "r173",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "totalLabel": "Restructuring Charges, Total"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r255",
      "r304",
      "r402",
      "r443",
      "r455",
      "r457"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r161",
      "r301",
      "r302",
      "r303",
      "r331",
      "r332",
      "r350",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r391",
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds after deducting underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Deferred Tax Assets And Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r272",
      "r296",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r272",
      "r296",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Commitments Due Under the Operating Lease Agreement"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r8",
      "r86",
      "r424",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r273",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r280",
      "r285",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Stock Option Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Inputs used under for the ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r43",
      "r89",
      "r123",
      "r124",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r241",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A.",
        "label": "Series B [Member]",
        "terseLabel": "Series B [Member]"
       }
      }
     },
     "localname": "SeriesBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r271",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Weighted average per share fair value rights granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Share Based Compensation Expected Dividend Yeild"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares Subject to Options Outstanding, Granted",
        "verboseLabel": "Share Based Compensation Number of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r282",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares Subject to Options Outstanding, Ending balance",
        "periodStartLabel": "Shares Subject to Options Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Shares Subject to Options Outstanding Vested, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price Vested, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r291",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years),\tVested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair Value of Shares Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Preferred stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r89",
      "r92",
      "r111",
      "r112",
      "r113",
      "r115",
      "r117",
      "r123",
      "r124",
      "r125",
      "r160",
      "r183",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r232",
      "r233",
      "r237",
      "r241",
      "r248",
      "r361",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r60",
      "r61",
      "r62",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r122",
      "r161",
      "r248",
      "r255",
      "r301",
      "r302",
      "r303",
      "r331",
      "r332",
      "r350",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r452",
      "r453",
      "r454",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r122",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureLicensingAgreementAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares common stock",
        "verboseLabel": "Initial public offering of common stock, net of $22,386 in issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares Subject to Options Outstanding, Exercised",
        "terseLabel": "Exercise of common stock options and vesting of early exercised common stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering of common stock, net of $22,386 in issuance costs , values"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r248",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options and vesting of early exercised common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option Awards [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r92",
      "r153",
      "r160",
      "r361",
      "r402"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r369",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r369",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r369",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r369",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r403",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageInputsUsedForTheEsppDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion to Redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r42",
      "r92",
      "r160",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary Equity, Ending balance",
        "periodStartLabel": "Temporary equity, Beginning balance",
        "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Redeemable convertible preferred stock converted into shares of common stock, shares"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Ending balance, shares",
        "periodStartLabel": "Temporary equity, Beginning balance, shares",
        "terseLabel": "Redeemable convertible preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StockholdersEquityDeficitAdditionalInformationDetail",
      "http://silverbacktx.com/20211231/taxonomy/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r95",
      "r259",
      "r267",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Long-Term Investments - U.S. Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r313",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r389",
      "r396"
     ],
     "calculation": {
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://silverbacktx.com/20211231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403832&loc=d3e34039-112682"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r483": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r484": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r485": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r486": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r487": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r488": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r489": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r491": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0000950170-22-005202-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-005202-xbrl.zip
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M34!;E_>AP\9Z&G0+AAARO+JW.G_*?MF;0Z$B=<U!:1YW<'9%'X>6M>NQ26%
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M=H<'#"#FU;HF B7;QX^]JK)7YR76WZN&OI1/-+)42O"C^H %2KU*'OH0>Z
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MH^UJ.54FA^-J4!228QB>A0)O;T">+'9/MGX-!H/PBC,N='"^G)F%UL1S_.9
M:CV'ZJBRLN(Z4OC"79:LY$C>IB;U7NX98;=29->@G)[&%A\[W@_Z=I)B#2B-
M52[S65+T^>D94JHA7K;C&I?I+"=3DFAK]Q<RJ(BKD> 8QJN+_HZ+P>Z$G\(O
M" ZLC-&IU[<[3H6.S4QU]VZN@AC&R#V#L>VG*\N,E1T=+R)=4IG5:E5*>DCD
M*4"T)O7^(*KA"C *H:6S 7$*>U) E(@MU:T2%P):_MKS*GHK-D"N_DO]U*QG
M_Q*FJ>AB@>\3V#S#Z'[-R\B=,*!K8WY@SFT"'I/\KO7@X!S^^O6GL6TIFHGS
M8$S[VEUB.;_@TAU>3$C>BPPW7!GD6N,47'0I,VZ!4_;;F+@3OX ZUU)FU!\4
M/8LMI,O6UVV_R'.9MJ8UP\J1,47ICV1I9&DBJQ5KZO_5V1XK6B1@E0/0@//P
M*SPKQ9]BJTC(I^YT2OCN;<":ZU/7N;KKEO:]L;"TFBF1(R]YF6E"J_@0O<E;
MFQF:+1,QRB\*MK:;TCMF[;V7",>$Q*KV*JNKZN^4!Z*J+'31#,PQ1]ZG%U@'
M\RHTLG%B=5!6I;%HNFHD*VD@ZLYO7QO[9S?$D%9EKH7']TXOH4YZ1AY$5[RB
M6%^F9R/C)32V'-91I[/(0L:2/&DNO1EI-8!>N5SCY'<^R<3+SU\RWO'6O?8:
M<DBM$57V"IGOWK6C5!?EP?Y@L5=4DVK#E&Q"/2H0'9:5QN2_=&C6'!0!BSI+
MJ6N^'XF1@[U7"?5'HOD5RY%P^JR*5O[K'&IXK JM,O?+]PGRC$3P32\Z <UF
ME_5KS\/@!![-V]>D&3M2C&377M ?LS$8T(83+3M+8@0[>XBVF/IHU'L1*B.Q
MTLV ^NHGU2,^P=*[WR1P6"*X#KVX:%V^&!@:+Q@L#/DY'/.&>W.:4^T-RAM+
M5IZ(L% 9P!@3/!I['3-4V)C) U^?7R$)(XJ_;Q/]A'\@:PCU$T)[TU^3-"@,
M%J&W@:; RGNZN@_ 1*R)05H-'ZB22M$7FUR.V2";B/.3;Q(91/8$CE*@ED#5
M450C4<I*+*CMC>X+_ZU47A]3"K#^Y!.,K_4!*X22HR0_!EC*9TQ@8])U;D[U
M N_?>7+<>:C)-V@G='B.]UQ0Q6!R@R+E+>;1!D-<:9^M&@S,M9K/O]'Y*MII
M>*X;,*C"XK_3:I8WK$8,[?HEK@N?6!M;A\@%NY$$*=6&D%J??'WF]B4'Y<I\
M$LW<\-E@V49R&@+A<Q5LTN%L<<LS.2\_?IYY-B#<V?D23P0MU6+H 4"FU-IS
M5#K>_,"TG!Z$Z9+_LQKBN*K\=9]*&'<)-%E!]JA1 K+N^SGKHCTQ0\8M 46N
M?8L:YD7.V;:Q8!ULHGG3-IS[[4> LCF$*S>J:CU:I#'BXKL"!V,ZTR-!V5 Q
MJ@1>D/ X/QZ>G OZ1&&RMYN/B;"E"5[G#[F::4G57.<7F7O7G)H]))'6FO>6
M59M1BOQAC^XKW'LB>-L?=X![<Q%%FQ/^GH<3DT8\Z6G^A78C9?:CG+CC^XTW
M+_CL9\C4!R-#*LH=W4F4S#E%0"Y,#:L)RXPZI6JIIN>IJ<Y**GXFD& )W)^"
M_B_&O7Y-<QBQIMZH)78]=[H8?:F6%9BAEK%0.TBFS3RG$M-8J@+-RA42\>%B
MGEH.%FJ=^^WCV\)$P39FN]+?IR=V.@]$@SHA%#VHIB\X*;GX391=.+]?14F\
M!Z)_)E\6X'GGVUPU09T/]_$'-T]\@Y7>&=ID]*+:?C,]6.LN^[B:!2:0$&44
M[EU_1('Z"O[#6S7@9'U<[5>JYL[4Q^#T&-JT(M^R(?E)EOJ&+R*&;^=?-I2O
M%T:B%JFOG!AW1S4F7=E\'T(@7Q6IC++![!;-C"#WYM 1->J?&2]TB7L;(M,(
MU3!APM?64QDKPY%C ][M\R,ME*'])@0-XV5&$!4VY73_.8.E4\UM>/SN-\+,
M8_+GT/?RC@@)"LY4K+675#8-3>\YH!\&TN*/#3[2\5'0]SUB8A/2MKJZ,LZ$
M!SKG#OE>!\F\SW4<Y_SW'W^H0;R$/L0\K6OFSQ]L=M*8/!NL39#MZ$-/!O\\
ME^$W,/6QM[;Q\>8<[JX3X!NP80$E@4')27Z"%V-(-EN:\.:/)L8JG!-QC:E@
MFG6JH .:*'/8+[\?4*5HI0$0PDB&1R02BA-EGGKBYZ*[]"+1LBD5;,F,*<J^
M)S\NI=O+7QA[JC5 DA&MM#,#?L(T#@V.>:<!A<,B1O*3KI]$*/@/?([2^5!
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MS4'VV@"7Y]WSEPAYA,K+BO YS<=B4["K[A0/!ILY8Z*BBU@8BQC<YX,MC5@
MW/N$--9/:&CWX_3<SN:FOS;'36K.LX]:8SHQ[,??]B5>KU6G<N@7YOK3"S:;
MK-D>FURUVO7 .>U)--"7-WK?AB]#1:QCA+UCG?L<,EPO-#9:SA%!>2GQIE *
M=33$T$VVW.U\DU5C JOZ"4*Q0T%N83T+-PMW11.LH%B8EAH"FIDA)^Q#'1\
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M.T2$5NQW,+2IJ+C4U;7$.L^\^9#$5F6;R.(&*COI'V(* 7S0(KV1M-&=$D@
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M72=QZJ6)D&.^8Z\= 447HUH_KP%6$A/$B=A*>L5[F'\FH?"7F/^C>P:F! ]
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M_9-JKZ<.J%R 7N8AR\T#<,.A26GQ,?3O6HQC_LSE<OYJ_#FG%L'?G0#!*P]
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M7<+O2QSJBBKK?1\Q;96*8I?EU=7LE16]%Z5^#&Q6MK+X.A^"<\TBSLU4ZZS
M&X1J'^<4M&7&_$R]#;)ENFVK7B/+H#Z6[GF/XSAF/&(>E%091F0\BJM54$C(
MO0TB'" ",^;M;I1G)? EH0%61@&>1R;KI2YX!7"PB0;Y'JR <YT]-O,5.A@%
M%"*1P(IB:A9#2_)6X[XW4)[0%W02#?F0E^R]&&%.&<+K\N$M/?V1JQVR"T&
MVM'7\&KTS++E/A>OD\VG2?U:KKBMYM$B^K6%O*?8MX4BBV)Y.%),OV)6#[%
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MF.AH'ZZC>V%MM*?1H:6.\+%?2B^4^"7JV C9!+-/:.F=5:MR(S@9Q"4;BB.
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M C.AD10>)(F3B;-DREH$BOBD"RA4AIWF+7=U7T[@WN4.E!&,B&NNT@MHC!T
MAY:S[A)8W[D6EI?%2U!^!OT<E ];H4>>,Y1^6.O$YPJT^)(%&>T)4WV:T?_N
M%/LIUO<,EMF^M.*0"HO NUYV^"L^M\HP^+I@4BW7DD N-D/\, FJ5BQ2J!F$
M%!DH\-M@]UA].2<*YOR&0Z+6'$4AZ6BW->P(=<O.:? (+3"=)(ZD)H,NB&NZ
MLB(JH!5YK1HE=?VB.BY#9*N&@\?)VSP<U]4;L'-S:E"=J#!4P&YC:P@CURZ.
M^/U%LE1;;S\V^<8,7H;RXWU]%F8!-Q7H5DSYDIOB'LL(P305T'GWL/9$&7Q&
MW,07B=5# CMR<]<KT=-+,W.THT0523_#P.W'3;>2QZ#GRAPT)65#SV4"]NSY
MTS7URCP>?!K)IZ4;$Z"'7\.698H3N<8F1UFESJN/G4S/4YF)(C+,X^GE*<%$
MIK,_TP7&%>8Y..&G=B2:W,J6QO6*UM.J%OT+ND*)^^]&6SUJKP2IS:UWP#H?
MF-#8G1_*=Q_ZFSGOJ4S %&_[&LL_GE%GHV;-G5V_T[33<X/5F\<P1+8.R[N<
MRYR+ONH-O%%"'C"/J9UZROP,6*V:Y3<0U)XNJW" _V*W'#K?4&@),57TACZ,
MTH4;L2.OZ+%WRU?OV"7=:+1,>9HCI9ZNAHIJ5'2;E.EUOCU;&248Q_JM&,I3
M$UV$M;BJE_QM,6@C2DJ&](=9A 3VJMF< T14Y^O632KLN&UQ2"<<RS57ONDM
MDN:%+=.FY#1ZANZXNYN1DQJNJ _S0IXM5B)ILE*$MU.FY;8T!='(UV<.J]<R
MO3F*LYQ)JO4\UT-)2>CML*&P/V@F CA\]6H3=[H&>IWYZ_FA_ HA8!?#<R(M
M<3>>NXG,#"ZNH(8$!N6X  :8GY[!S,F/0G?6<-(?%O7O+:*P2%(/;([BULLY
M1+_KT,$%/VJ7Y<#4NJ3T4(BYL+$DB+Z+,U)3*SC(?7'W<D=ML7X6)J54\)GH
MZ&$BGLTBS5EI0P/CV5(U[D? _1' C^E=QU$E@VL:O' RN QVH:.M058'C\X<
MRNIG)J@; ]BMO*_;Y_G+1'3BQI0X5E]599#8;-7;'(\.A)O;UM?H,P4^91IN
MLB&Z&R0$@;TCP902'RKXQ9"ZFYYD4VV*M8[^K/N<*$>*3"V[W%.)^G0[K4)<
MF(IAA0/Y%6Y!#$(63B:Q5[]:I5VKO&+<@YT?SS$I",.Q@/%+GD605;"9RR,
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M!2;21*"+O8"S(>&9QO;/RYA$W>SYN%_+BQJ?+.++0F]?#%-F0"-;:*P<:Y&
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M G&SSX30>_=8,[B]29"+P3D,\\:$ #\($3S^BS\HP2TJ^0@\TWL$?CT"+8_
M5(K=3-XI9^;.J&:?DH/*O^5LDK_03' O6Y8W,:%0=A:!RACF7H%^:" Q),<4
M9]7@(O"EJ6KYH/:OT."\(]>]QISW.<I42Y?/%!=2G1\*%RTU_BG*%R$H ,@H
M<^3)"RZXR2DM_0AM._=O?P2JZXSI>KG_^K:#%FQO]01VD?LW(AH0?U>G\^'Z
MH3;YCX &A&&[#)QI7WDZI4*L)&X^AW"JGS_P2GH6-V--88UASU@$1ZH_7B
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MVH=7I$X68<Y87\[ )(5_(-(V-@8//6]H= LF_=P2I]")AR>GDYX<I*&"P:8
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M>5C33)/%!5R'9_2%O F?(.[RH"--*EUS?9,W-LGP\X36C<!E&;S&"\95XH4
MX=;G&X8%)>$&<G,KD,,3!WKE:L;XXINJ1<BS$'U_6[Q+#&PS^_.L(+.%-H;T
M%.1RP*M9?_;G$4&/VH)?E-B++G:IGEXV5XK0NS1+O93$=0:\[JJ4N^34.2.^
MWKJ\4 M\&83ONFAW'Z 2W^%/[PEK$2K^U(&H)*&_+6$\OT? T%/B%\,>4O<=
MT@;R*6HX?^2<(5-M"=2V2]R5;KFO1*S63^[DB+B+J7-TRXR4+N#9Z>ZB* ):
M&,<@Y">KGIWB/OQ5K8NAHAW_R WF0)^$\((Z*_-Y5X LX(.R&E+._A/Z_+5&
M]-#LLY8X4VE'35@8FB39"H \L ACC0,ZW\2!11V5,C5@DVXH4\=?:_6B<8VZ
MUG,2E;;+ZSP1C3@.EB".'T6.!BBVSK?P*Y+J.D26S7H\7U =EP_CI"WOMU%'
MW1XAHLJGFM_:G&^)NTHL2'<W"?EV#;;^UNP]QUE8<VV,<^P</]J/)"WGFM:]
MID3<4BSJT@Z/7(GW<Q,2#P04MN3I5F9CAW#)/%70\+*\RHV>["4F)I:DI2MJ
MSFY"<.I&-[IB#5>4V(+G1OQRUBNSB?FL.U8LO#7H6=:HT]9&W]WJDG ?X#91
MZ&B8-@IX>N MR^U1BGK,-V8(1(:&@0UEV;)G3]?5D>K_-))[SM#N@AP?@>\/
M%X_ 2XL*M:2.-O\T?CTR_L;_WK9#6/#"4IMS&[5$.SVUX32'!CX;>O4I*4HU
M1K049Z0GFI/:V-P<FS<U/'SWF_+(/7G P&11B@:(!:NXRD*S8XDHK,CX"=BT
M6&'7>M]0/CN4_5]9B?\E,<+?\@"9$%O;Y1X!O_9TT-]P HEV'YY>]?_,[7-I
M$YOCAZ+)I]Y*UCY,MD4[# @T;Q$CI U'E,9!*0^ER)K)33F]Y-5F^/WHYJZT
MZV]1?DP>IZYF+M=OH&$K,O[$?-##/SO^ME4=#Z9F./O0H_NNYDE!CK*WHR-Q
M@N4Y?_,XI:NAT2"&CW4<SP:$KDY3)QF%Y8H3,:*N)0QX4;1;=Y98E;?/<;9B
M7:"8<?]5'E_/4!FGMQ0]'LHH/+4<#MD6V+H \SQC:@;ST4X?W3%O#(M0D?/5
M5L^R58 ::]_+>&SH:=;AZ9<R(3L/#=-+'6=YAQ$*L86 T<PVTG"(-^:/WM%%
M8=@?2K]Z-X.TF+U8.S#19NH-,)A9RL5Z5O=(QGX O'HCT[?+@W)M/,/96Q-K
MRGGNXZ0Z<Z9!>B5I/ABH$'6W,/XX?"<ZR_<=%#. !_F[2*N\ZXPK<%6([GYJ
M<"S1R-Q<;]F&SMT-5%<AD8 T$)(-KQ9EH!IAZCE6F4% "ZYM9FHQ<A4,7@\;
M?U5=?4OT""RHFM:GJ1!@F(4/1[#Q*-L0*#!^1@+).=8THKD4HOB,(KVN/WN=
M9K/>0 ]KJ;9QJ-,+<6T_C.O3,&U+8SAF;/E2&EMZPM8_%+>VAK.%-.MN8+LJ
MBSZ/X;(A!;[E3U]>(.WSQ%)@9!)>:U!9.GJ.!A"YC1/HVD[[9:"?J%XFCO:E
M%^KFH_+>+J9IFRZ/8[4[[P)K$VC)7M5B=,JD3'.'47GHDZ\'^C(%LC0>OJUR
M19$^YXYK5*5'-O0X09Y M"%Y>'8Z&QR:@Q+J4,>:]NW38D1\:UDQ0^]H@RME
MQS"(>"]L,N6=7P[-"][;6:"]Y'I5/?#7)J36NK<O!5O<[:O\K.-F0V/J,R9U
M13)M'1G""EYE9WH26@XZ=B;47'&V6??!0[?OZ&93Y<=NC\ 11;8_=DV:.T=E
MN,5[AAK/ST.C*50;6)3>W,0QZ!V\%=0;$H125R582YS!%2/%[U-1G3TM&H!K
M,PJ\*ST0,URGJB% ,O>Z1+WI4_<EN;JN7^9E_><KY60++O@-LZ4&]&@C56QR
MPS+2A*?_?57/:C/W$+!_9^#L6= Q/W?INKSH%;6HF.3V:N*$)!2W"28?FTHF
MXU MI0O!YO'T54&3+_C^MJ_=VP/N7!/<_[I50(FHYXWH%<Z3;E>Z<<I]JNIH
MKEP6:+DBX<JV=!#XB:OF=:AK@=%[PL0K@? B21,VE6\'^,CX(S'$+QI8C3GH
M>=CB%KU!?>MEHG,)OET(S>L2-Z1W\K\-> ^:7W9U63B*RGCZRB6V<%<V4W8.
M"N%GM *7=B$%GOA46[C8=C#;;.!+HA M4GSU67U5L606>[%.OW/%@K(S[U \
MZ9IU#BS>3;4T.U=U1^A<5YWS_.%!K, )*?=LY:N=HZL9F\>4':YM_2]U%Y:!
MQ#A^>#^?(#M>PK9LU(K:5,=S#\^0XE=MIH= A8W80_K&XF"=#5OZT0_D6"ME
MGJFE/IAKVWY/A0LT@<*E.=2!9%A5< @2"C!,M#@7VJ9^?JN5AMSN6)6Q,[?Y
MVP>HCA*FXSJZ<7QN!.OZS@6]/)?L<H6-2F619E"<.91E7<OA:*FD\),Y%"CJ
MJ6[IUY:PS5=+MJW/^125)_!0T06B;[,$(J^,E6=1M7^\4RRR];S0-NPY[XIA
MFUR)Y%69VF0S,ENL%=R1LP$6Z5I<JJN)40CSM9$F_]V=9%'+DS6'3ZYL*P9]
M>5 +3^;43>7 LZ_5"=^VP[LK8<\IV3Y8 XP3 $"5NX(ZG:DZS:]P-T C&68-
M?1:2TT&?2D-;4B1GBB_QTX>*Z]WE>B]@NN++/%EQ])-5,=Z9SD[+]-+4'#PQ
M)JP)LXCT0!%#NDE!#F;+#0,^0*XA^3:\X]Z7Z7+'.Y==T!?>Y<<RYZ*\/-RF
MH]0R(7AJ8@V16L*1R8E9B!?K'.GN!0LVL2NV'K'[E6+5$#NWRF$V?%Q#D< J
M^U@]ZP&\BN]@[/9KL:\&6'*UB;>*::_KB6/'S5R,4XXZGP\E##6ZLVG'"52Q
MR3D'  +L;90V O.KCHA6:! #PD[Z3T&E,T7=%J)S,4'H8Q:T1<(&_>Z B?4C
M@.H&I3M8V1V?<5BOC!^MJ6EJYH'K#CS16/]D&J-RWIS2"'R)305::;I:N=W=
MYW(;9ABYER$^1%^29$MS&A-2X-I9WS#KKRR1WJTX1SB#B:#B>-K[GG:N^;;D
M?9D.->'1E7I&A-7L+2+,'_OZAV,B7IQL0U3 6<AS#T_VX-L_9V]'_>WY:<7G
MH5 WT_H&ISQ-B"FZ9U-\ ^**CF^BW-)Z@!B)W-3&Q"%[[;#+$4Y"B^9938Q^
M+G>IK7YQ<2)+5A5FUI=U\$8 WU_VV(2&VU%!28(D'B0PN)[1D2#$>FZ1(?;-
M,('I#GP].[F/B%S1(^@+':_%C!B@D]0)]Y$L@'=1K^"0KW- XP3&#(7R0S!T
M)>D'<E\?;E7&KF)/$30[(6NU84[_))DQW!V-L>/6ZW5*"RP.MW FD-*0_AIX
M>T5L_Z)(I8$V0-)L+:2LCL+/\.#RU\/Y&+-QZ+$A3@YSH,,;2N)3^0;"Y9V/
M!,+V2J#"F%)C#.C:Q^G2[,KIBI-#S<4C4J^,A93>D3Y/?-#E-/AEX_U,..8H
M^;;F*]&T#GJC3Y>:H99-^O.ZYDW0QMI@.\N@7#N/3NL\O4('DUC%XL'$\+<#
M/!%9E;3D&&NW$K5E2R=BP^49O^Q"EX02R4 Z(!N(RA%K]5K,4)KV>U+2#A0L
M&@0]. 2Z:["RHF=32CTVM;[&I5<=6<7%O=@K.HJ('Y-6M M_LIF"V !49SR)
MK%B?X7 X<9@;T[&L@Z6O<W6"BO=T=&@54P3DZ?M)&QI25/7>)TAEX>V_PXR6
M<X\:N_S%BI['DY\!^JB7S69D.L#>N_<1<G$C87<>S<W#WVBM@"*FO#Z;G\MI
M0J(U-_>VRJ.Y-E!!C8PA%I$O.Q6M(3(-\QSDFLO+<Y3*3.^M!GZR,;9@GQ4%
MYWDI%4J>V*<@BXG1@21$N8:0T17 ]N>&-8+:PR@_E@V4 <30XTA U&%<S:RF
M'@.FI>9!'U>Q1HIINO;.6^&(J_$N>P30KR/TJ(:PP_%[B!RXDF,]N[%[F"1W
M^DJY$-00\IY_M+=*4DMT.B^'$3HMRXT(>#MW32!0SVH9#/0[<_1[8";T I8V
M&4C!7>?3*JF7#[_\!)AI8;>O8NRU<V6E\H78U^3LF1A-VWR^8%C$:A"!21YP
ML?BFC:>R,PX0++RNYJ[0)[W/QD$78SV.06ONHSU5AW$D;R@ 2>>V );KS,Z^
MXW&-QCJ;<G=V:=EX)0V/($TYA7+?_'4ZF42(U;-%%QFA+CF$+ P^&F2&>.WE
M57U# \4"*=FZUIXJ4<UJ1?Q^9KDHAD0K]65\L9$K!KPO<MW.($3)TU]](D)0
MVM0##/OCW=;ZYLA-$EPE9[;JT=I:):R^[WPQM6^DZ?C8@['7A( #OC+^']\6
M+!H;VN+DEJ:6:GVB$<#J@4RTD6"DD&RE?H[;])00U+S_B=VJ_Z%4VK?=ZQ7=
MBD8(NB=^-0=O"B]V^S%?W*A:)410%P3'!N]TH(=NSQ3NW'*$##9G9&O'_4>>
M&O#P'Y'3X.Y?D6L,OY#VP>JFEU,7TB$L8M(QD#8^?5GYQ_ 2T3Y-KZ^XM)&)
MAQOLW]SR+S?39G!U:LK<;[ET@UR*WX-<NNDH43')- )0&=H_G+BUFHHYK%PJ
M2>G0$\/L"M&E*:#K,W"QLA9F1Q TT;HEGF@>49KRO94*CA'AM9P$$849^^QL
M5E72N"SLECL*(B<*2Q5)LTO>XHK1I55'\> ,/ @"\$^ZZ-6J;XFS?;P]]E_H
M2_ZVPBS"-N#:E69>2G6EN-ND^*+?S'%:XY3.T@,0$A]PHE!:/%I:$V_50HT3
M[S.(FJ) FMI3JT.!(E[(%LLS_0ZY0T?TB;Y<@&.P+Z4O.Z% 8E/08;W'9/)F
M?9R8D'S@TY%1G(^\-<>,<J[<-B"&;0Z=:@1E\"F!EW-HW:P[(X0#9V2?9;_<
M 62)<G?C7Q/4?0(\H[-PBT .C6&! C_^&!<$MYA/CXR.6J?\OAYFFBTFG-^U
M"XXM1S;#CC=%+H\V';RSD%0GC&<J[.O(=&63%.-L3##5Z?DF( X;8/4X1(5>
MCVK<#GR%H1CLX1,,MJOQ8NT50YLD0?38)0JC&IXQ^@UZD*?'O.JG"/SBLU('
M]2.7#B85Q$>@"W=9$>H.=?4V\[1 J%=,-H_2R0TX&GF3-E >YZ2#+W7^57$'
M9P.L<P6(^3ZSYS!K]7:P2&47-Q!QBV--"K.AB]UV>>.<W/)2&I$>J,3;=)A
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MI,O>M:OGE2U\,U+0K'HIR7YNR\I8I'I*K)[TKGCDHH3IQ+0?R#M&1:>TM<%
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M6$C%X/9U\=WI#R<.&-C=K=&W]L3K$#</D'MO2&@M"TQDM#][_;H(L%I/UWH
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MP30G-4Y(.,M5"#^.,D.OUB2G*0]T# M0 S?\'N%O]X+4)QQ@!7%]1NQ$/9.
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M5G,_1'$L"SD"OO-?^,G[)T:PY4VWZ?6XM17;6$9Y9TA(RO)\,KW>RDZJ$K@
M?VZ@YPKT:8RL$ /1!+IWH:FUF<=R?BA \]%PUN[XQ((FMZ3H0Y$'$>$K#8GL
MXD)NW!$2RH /XJ?0XUOL2OA(\$[QB5'KT4\KK":+M7Z/7(_*RZX\O*&H:;9
M@_S,J4YJ)+/!HRL/EQ-6"9 $PG+$NK0'WNL4O\GAQ,6GNX9&=ODI:H8W; !+
M^ND_PB+B3_S10/5K]G\!4$L#!!0    ( &J!?U0C-?5#@G   "Y[   2
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M6[2H!I#KK0C%BTS;VP02)/J9IF"YO=23,@\>"(!O&P)HH0<]T.F@0P##KA#
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MXP($@)'#EB10H2(M!0',MLPNSPYN>[\<OE>I.35Q_FBK&5-<EZ<Z]Y@P+9N
MS]5&;L,R39KJ*]NWS45PF:>XK$R).'%TM#UN6-U8.9OS+4X\4'46"X[@9GB
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MYEO5MV+$ARIQ %F, R%_ZIHG]Z5^P^2A([U @Q26^/1X1.N#188L(*NH3NY
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M@[A^YD4NL>X\XQP-=%Y0Z)J(K'2X8#EPF/P&VYXP :#^F95>Q?GGVX+TVNK
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MXQ\I(%:F$1#-97)VY7G7,H[!Z[7>JF@;+28 BU>B?Q%'%I]IRJ*;X=S^'<%
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M!T _L^0UP5FEJ 1]6\C1)5H0Y0>JF1C<V"I&YX^B\B@#HLWI%\H/@!NTO@<
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MRE7,;^<@.74!%;]F?^T([YSN?)<BI_ L=Z%)+EE<42:$4<OH/B&SDCY_K&V
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M@2'^ C.OO&+<$VW?+PQ9A6UDHLL[O:;RK#B*3]9[585;8!($PJR4Z?5DLQD
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M/ #H4N\C[TK)$HB$\ 05OT$/M1QTQIOU,"V8GV!797B_G-5.4V1Q&97J)=
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M'IN1K'%N_3["X>N3!MBR=TR>;Z4SB]X6I:#(L*S0;2-5<:^(>T5$A/#F[ZL
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M7<7O/N%-E**V_.>"\5<=+'>O':F$]9A$X[7IO[7T?Q23_]W0T/5OAVVUZ"U
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M-BL"Y_\#[O[ Y/S= ,D];@]S_PM02P,$%     @ :H%_5'(B=@8J9@  K'$
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M7T@TY(#_U\B9CE (-(S?1CF2E5>OG/_J;N%CS.<H 9BU4#],P'1*L$C2?/K
M]4Y9O0;D^2"\>TH/KX ^AH:QCURD7VNB^<G1S/+UA)%ROB;(,RH[NJ[/2E*F
M^!"UXYHGX' S4+X\8IKIU80]4RAA6S]C*N8+L@3,0GF,M/6%A3+2W0::[8!J
M&N'#?@[&6=5OOQXZM6DZ(SV3=$&/= W_%WLJ'C*I"+=><X&JT^^%L/[?I:9U
MG:E;V2R?YY,2=Z^S)\J.DH@):W1J@I_05!QOAG6%79+N7 R".UK'6B&,\ 4.
M%ZL;A?F ^CH+!Y8>B16>W&,OL4!YS\OD]5;"^86%?7=D#@%]TIFLQJD[2"+5
MJ;;![R.)4.S%%*J F)&"#.TWIRB'EY9KPK,7[(*X#K4'PMD>1^LXQ5$3IGGM
MGJ\$FM)."N$4U;U*59,2-2=0$9!0SP[DY[3S4.\M91_]XD.:[:&Q':MVH]S/
M7_Q&.7%>5W_V*#-V7%X5'>?Z%KSJVW:Q<+T QU]^LW"K6%4W4[7$5R7I,*/\
M*TRCW]-V\]%C95>6U!2.JE*>GM9301@#O*,, 60RED[\[VOB?PFR^B5<K2#>
MD>2+2OESL$##J9>$K!631"KE>)Z<.?)&DJ-V6YL3/N05WXZ;1-?Q\<2C&%KJ
MSE)%1N2Q'O_T,P_(E\0'9R:3WV-$J7V0A3F3\I36=2W%?'EV+2^@L]MMQ3KD
M0#@!Q+#M @JOHQ-N$7,OD_&WJJN-L-33<<5%+="EN,", G5*,2I9T75A98O9
M&9./2VP(\[-\?X&W>ON-?!>V50(3[IU?#H=(2JN:X8X6<-[7-NE]UZ5T1AQ]
M4[D?T5PHF>T(2AGE*>FGZ!8>*KNS\[8BW0J%2AM*^N#[PEX@"P1;[4]K#F4K
M[6)!". C,A939<TKU$NK=X%YUEJ'SD59OC $,X7C"7QYQ=;/^=[?PO6=>,&P
MS_3:X0L3<+?[56W\[),8_F<5"Q('N-@DVQP?4WK1='L[C\EMX7AU4S/'A^]E
MWE60A%L1D;ZZ_T8\J,<CYY#!F[+I1T-NGOV=]-#5-<?H&JP34H]'P4.\3YFV
M,6WEQPG3:%A<Y)E!O6.[4;SBN_["\HMB8=SX,YBXB8U%12[P9JP<'F<E]=A#
M!P%L\=U' )[ZX!<^T"/E=G/=\Y7%D:20[<E>6O+8HWW=M%#SXKR0*BRIHPHK
MV! Z]?B1;*>N4?O=T%2B;#M]@B5N]D,M_R97S.IW3K;1:21JECX&Q53:E2$Z
MTO.H"=RK9Y%RU'HZ3FLJV%1*ULFZ%:<:.*+$'#Y99<#&+%&J\ FGZ:/ZQIC3
M?D[*&4&E,+K'[X:CI$SK&*KQ='_FJ]L+,Y[K27*ZD&@C$7 7X2@.9H@<7I@8
M@;Q, 7O$N\P02).>;7I-QILSPXHZ;]CG X;8;6/JL A\!_0'/_,[--U"ZA?'
MM:N^%6=,C@O"PG3;4@IU$C E3A:GY]$F58?8O^05*.?)_V!.=O>H8PIO&8W"
M-QEJS;6[>P_GAG)'9GFZ-40&T4\R)3%S4.5;/-I=I#U'TUD*5Z$RL'^#]MTV
MH:9<B6B0.H'6E$;?\A4'\>04]E0I1]LR\WCU?:ZJ1AZ"3E]7]$Q4NT+4YR2
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M/A]8C5ZI=@;C1<0B "PRSFQH_3<CX<$2AU-@?<K"/6_]N?!KKNB]*61"]D
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MV:1N'\5LYJOW5UI9"JT% \^_+_ ,!JRKO>.RUO98I7N$A845J0E_YT_#E]V
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M_SP?\/ST(.8B2DKE*"P&G?IGF%8Z@[9X]'"6H.YO-^WO=JH/L7QO\&$@S7O
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M =G3)JH]@KKCWJ^[L_J;/>%[I<CW<ZQ6 J^:P3?1A>D+G0(K[(6+O6KQME/
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MWC/TJJ_O*57,G[#E_ZD7D9;O>_R[RU!X+ &;46[,DSR6[R]D"!/KY7?E/V(
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MGJ).XMOXGFWXB]HD+;M)D&G&FZ3[G*B6TBQ/CQMG%8.0@1V[2GXTIUT\,DV
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M;LTFF)HY_FK($J?=RAZ6W\22*?+0)8=O<)2K57#,Z:-S/;KMY$O@WH7-\EK
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M4<$?>VD@,1#T>SZTAI7" <FH%=W3[S('+NB_=R1E<6<2OFY7%PC7?**&6'#
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M)/$*_\4KNJN*%B-('*#95%O;DMR#=!I0]V+>=8K!<LK#DUQ:\:=K$VF<_?Q
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MD'30]RO:F0G#*Q!ZL1QXQI9 P>=NAMS++/&??DO\WRD0W.S_ %!+ P04
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MC_MN@ 0;A1)U' WE"8!*@H)&@G+?!S ^O"<&RE\'\+>!@HJ&CH&)A8V#B_=
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MAD8]WP-'=7U6/BR4O5L-F,_]NAK_7LVX]Y(&66K%TQ@:X<Q<'Y%6XMR&IF0
M#Y7 /</E0(N'AT2<!YGW&1&"B]0M4AULW[[MT.>XF25:VTYPY+H'</9IYL%K
M0=I:S9"-#)6 <$_ZNLY!0TK[G[F*])ZF'60HOY&4"$/1*&^\5_8-M%FJRF.U
M9LKV6\=Q*2B2C6&"EQVMNCF2:Y\OS(E+YA/RJ:?G_:IYWH7E3)NHY!O>29+*
MXAX)2[^@9U=IFW7!(5Y\,=,ID50HQG"VSU7:4M/8G,M7/\KM>(CS[C.+G4O
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MHZ,2:3B-!C/Y%AH<#T;G)PP:U,X<8'XY5:3_W;FSG<9X9V2%_HSJ" +VC_L
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MA 7_=!,\$A(2,E(R!G)R!L&;+#<%_\L;K@V@),;O [6 \&X!^)1X($H\7"<
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M&:C[;9+M#BZV^TOL^_MQ)<,(;2?JG!.)WOL-4TIPZB2%@W[3#LCTN^  (HQ
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MIF<U9/#3&XMMM8:&H':SZFU3&_8?U?6)O.QQ1005;V95=ALESO5J/&!MT]!
M/K9)Y8 @E2#A@]I-3O8O&AIM (\ HX_LD+2+?7BQ47WFS;"RYW:5-XX&;\2^
M( <\!KNCU:_LW$/D262N"NW*,)">$R>8$M_3%S]+V'L^V6HK29>^3'Z_>DY[
MG/_-[V*&#W$D8/8\YWD*M.I2%N%"S>5[=WJQ9BKO.C(+<-D0 -J.FG238]'
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M<)5Y5,L/+O*<9"TU0U3>]^5;3= EL)'*OPG36"8$/+-"[%NXT7TF%6-NC]3
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M0/P_B\.%J&33&V,8*CYIF)5]7GW]L_HPQ?(/M158_JQ[IDJWFJ]52!LL1T+
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M=1=GR2DMD=G==(IWB^9DBR$<T/Q2P,K#BW 49J,ZX^U3XL"WZK_?0+5^+%&
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M&(?BVE0?#Y[_-VU!<+,;&RL:@6#5ZVQXG>'RV7J3<'S,\4>? _=- W\.*O0
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MD3ZU"HXV+'/&U'2\P9QK&W-;?T"U FHT.DTXQ1 =B]S2%:PQTML15E 3Q$
M9)3=%#IYAD\:98NW*7Z+IZ^:%#WTT")5C=FZJV[EW"*JZ@U^[;'P?8&^9?5$
M!W?>9$>!9XE*Y^*C1I>ZU TSUGP>5H0RY1-S3DNY&A]N4P&;\OFN'&-$8;E]
M5_C=;]HOOZ^FMMQC# MJS/R;U3D SUX])0"&+)J>-HZBDF.+[#-((D8UOV3L
M+4)55V1T*QPN_I3AK&,@F;?Y%RYN"CP./LUO#$$@C:*V/HELPY<>;3C]Z"S?
MV7]K3<9* !B9@U\U6B.!=!L2TW89U(W#3QY1?=I7>R3QC*8Q:_4]GH&D%T96
M&4( M/I?J:A3X:7?$._B!B$-PTE \47-ES8H._2Q:6WU']IHH^5G[PXX4U,F
MM'+-L>,IC9HI;.HS0I?\#&D>=/O*/ANSN*L>5V3U/9A'\0O-4]A3=$&83ECV
M!$[(5J'"[I93P0*56^^T2Y\O'0)'$7 -^]QZW+$1BN%>OI"\V,<9]R2]_,H
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MV)5G%D3,QA6].]^P\2\PF\'U)ATPFC^& *BZN,[6X>WS!BXHCUDAHAFG58M
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MTM7CXCX^B@/\2)P.8(KH'X'=R=UL]CS2SK/W_1''N\<+K)#M=CF0ROL[U06
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M1P=3$)H_(D7S->H.0M!O[;W;DY^9K1.'#"0H#RX6;-V2C&&?VJ1DO[Y.Y(]
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M!R>ILN#'$4A6[CB-'\5%^I-#D^;W&(<9K2S;RPPFB@6C37:6[C'HB_^W)[&
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MP;O/=;(O)VY?+D4ER%&051$#Z0<\T8(H"0"^?*(%;1  OX-N7' "X*(.T38
M\#T[)[QH+/8!G&@59 1 HCX<X[[VJWH_\:7$7Z:J#,*E$DTU,A?/D$DT4@!1
MC[$%G+G/N;\5>/_ME]:(9LI/--, \$\IHIDR6P3>^V-CP4OJN%]F"L1K:1$
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MG0LX6%/$6/19D)R"[8SLD8J^]X(VC _"'O:>M_Y:M!#0L:$HM/![GU-<I*G
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M_-.IG^O]AO'5D9+=)ZDG<^2)=]@=Q8*<I2VSCS:5V1CTS':C%*SSL#SW(P@
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M"TO"$1SX5H/A-U4I#TN"M";;E,M=[3-E5'++9X6Y\F:%\.XL(V9&6UD]V_E
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MQ-1R9?%+2Y2:)-@N!H%$JP;A;XON@?*TN_>02**]0KS#":N-SG+ H]='-""
M0D"%1B/NEW[_"IJUO0_Z!JIHO3>:2Y/<0W?EE-5A.'3!%K6G'T8[7DR#4;:
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M9C]KB[.>WVOTRDLNL=:OIY:-$)>]B<@J%6(-4IGF2L.JZ.?U]5R)Q%OF3[Q
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MI@K9U]%922\^<#.-=KIM.%-AC1R__D':!7-P=I8=*M+M;'4C07DKB]++(2L
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MP(1^3AR,OUV __?"P,3"QL'%PR<@)$+?4'L?@(F!A86)C86#@XV-_M0?_3D
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M?(*N>XX!]Y;!K,; ;N#5P_? O7$4P,9^4YH$?5MK' I@BG5%NQ=S/+#MSZ!
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MBE.+)^(IX'+19.B1V?-=656A_MS<\$Y8N3$8X:T:S*\P/R-!3WR^VIBZV4R
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MI,:UDVX/]W]"FB#)+\/IO"T;WQ(K)>4^=&"[/Q#X!#3<;&K#F+]J>G]!SZZ
M3^0N6U<)9E5SX\A*@BSUZA[#U1 V25F1$5"N'M-! 91K0%[G"FH070O#3?D:
M%R^,#P!ZXM=!S8;^#B@ Z>D$6ZV*=ZI/7O:]N)Q%>UV:$P=S[PPG;0IRYRM=
MUI7AL%#MIO@EH_'5T=/\O'SB* \V18AE9.4CCXHUUL7& UV-4-TQ 9&YJ':Z
M>A-JG@E<;/H ]P&O_V3918OA? [)=%XA4_,'\ 5JF=)ZF2*I>).9CF/MTI4N
M5)4V_7/%#D_UUB2[G8>XSZ!4S2048R]F;W'BPN/#]@D8/Q.3'?* M."FH2+^
M"KSG##::-<T? -%VDZ9X>2Y>3 8SV$^P[\NODST[Q&.U@ZNUB5>+:"'"!PG+
M3JPYV'LF/])LY0JMK4(_'3@RXL%)JH76^.[;4:S;A+R2+PLU';\'61G45"6_
MXK@8,S1_9#PGGFFT%KDFPSTA]*O\0B%=+)5->S2$[N,V 8.<A,@9-__CF]X-
MOE8>+Y;##>:83JK^HS2:YXK-Q">_ 939* #!UF?PMO48^)@/V-U(6W(=G&;P
M68?4E7SQ913;!RJZ!=U"K'H:BD -X#N]56F'-2"Q,4+\=>!2)ZU5M;09-_L8
M>8 Y6L;0W6AT(,'H;(8&MC84&:17YFW7M6^]@=95?:P;9>\LIDW8)I !*;]9
MUR&W>;", M C=#6.=3(8EL+<IG-#,,<4'2GJ 0F7\GVRTZ6BB,)EZU<=G4E>
MK-*'3&-UM/U$43[#G5J+G;!1/77 7&!)E;1FLZSS1]8[GXE9FS W=7L5UK':
M"**M2%SWV@85U9C7-6EOQ#U$UD"U=_[=ZN6=3KB+SS<[5HU%^%61)^8TPZ,5
M]F"$IC0K"O#\CZ+SR0XI.C*JK#$U<FP:CF0;%67PZ%?C,^C?H)H#B;PN!G@R
M2H@.(:0,QP[\S'.'G0MFN\@UB*3Z 5I!$U/CB91=OZD\3HR,!NF?*#:EJSSD
M+CAG.\:Q+YH5(SJ3;$"R(?CGNYDZ9^U.A6MZGCCW&"4. 6FC6KF\'CEGD$^[
MR#UT\4$RE1H=6^YD',>4T)J4@@H[Z$^%U=_O_J*.R\##7HZ:+@NIIG6N*T:S
MDH^N2\?I7DK($ =.% !S_-86!?A\V@X\$[8#(J@RUHQ)*+[(*B>\J1 2O+%B
MT+RMH=Q=(O337UD05FB-OC$:/_AQ*/\V=>4-I/^IU53%E.3JSMFWE7'%PI*9
MG4"I;4=6<2'NJSPQ/-L^I@Q[V%NCQ%!?M/1I[SLVT0.WJ^=MJ+Q."=72C%@5
M"++V> ,72TD$I,US,:7L&7-7-89HTRCW,J^3J>GCK(WDYH%H':NQ-/-,YTQ>
M1%6F+[Y:%A,.5 I0,,X*Q_[[3B+*/L1F/XQ.S?2!FNC$Z^V74V1W:7E6.K^\
M>@/NK?18[AB_,_-:7&T?;S.HN?Z1TE*E1YKB2.>4D@Y8N)5>2U^P4U-PDRAN
M8C2DRL]%N/8X>X5H$GG%J)I6#?+,5G6:O[%HM2IJ.JF7X,4K<S;YOII!T1KD
MD%<:%=O:.G&H,SM&E=ROK<SI*G8/@#76?"1W/)B3>OM4/%P$[G:=F"U3,KHG
MM'#ES,KS,'J?\O7)B81$EX] ^"T_DCE(PY=GU-P_;[YTL*1;0! +(*]C%!E(
M6OIZE/W.X#J^%HU9NG7!QM2K]V+\,Q4*["%BC2\&1>J.< ;[(U7HS-LKNU?&
MTSPI?^^D"QS/WDK"^+X;CW\^Z2O\&CF?MTDJW?5$>/Z^4IF"1ROY\2I"]]D-
M0:/X:^DQ(R,CBIE-Y8.&Z/DTTO<7A2)'E BGUQ-,&N/NI;*K!RH<^#8Z3J\_
MDLHBLLN"3F7-D.,5*$!&+_!HN=P>X;W&1**'X%B</3(=-\OP@S;%;U"VPO?5
M??RM37<X+@W&W$FES"KL#*WGCQ:#?;8B;41S=AMX[FT-@ JG'9AV8L%+;2:U
MQ_E=Z8SCS3*^E(>0_+G>J7>! Q^*E*>;3_R+86;U(;N/^)I'!VC8\**"B(."
M>L^8P^,;UN[I2WK*O+=VDG[+J:&ENB7SSV#3/+ Z]:6&3]N8<Y^V*VHJB7UI
M?:@<(B68QF1I,@ JT%^2:9\UZA(V[#?_IOCKRO%IX9ET-/<@B,:E*?V9K-Y(
MK;'L4J>!U;A)&[V=YP/AFH\X&-TJHOM(+D1YENT%[&3'\]HZ;_BQ"KE45S^Q
M31VHXKO)&%^M7DW#N9I$+8&B9:WWA/+B-Z/U23KW\5M6.W_GPMVZNF/C)17G
MS?G&]B(K28(D"<YPU\+!8I%\49I\K@4/Z06DU,]GBC]L20N;AI$#)A'_[$\=
MKSL1G_8H_]E-/?]!AI1UH#R+V+U[^,NG.O8RZCRP?.WY6*TSAZ4CR:,_0<]I
M:U/Q3K57J':2U(U-U&'NNW>Q]^5= WEV4[E79)]C[WN%MIM2;-/J3\ZB /H5
MM?<>S5K7OUF(NNK6K+_=JZQ'#"P/^/8=S&GQ;<@N"0*LP.[,)SRNW0EVIM.F
M[R;=(]3Y.-(Y5!RMWA)K*_@1QV4TQ;R'W0HK.!.J8W_AU>:R<C/K_W7&')WU
M-??WH1$[]MTY^$<TCSH"LGR@<5Z:/6D9]-Y:4VP#)B+]"<)VOB7#8XI\,(S_
MQ_P<F@<M&X"CW$3>A#ORW13UI/@IP4-#RIOIG''R6O*&!>.%R*6^6GSHJ!!=
M!<]Z,)U>X=W=4IX/4I9PUQ>3_XB1#5H5#SD#8\T,,);F&QO/S3Q'AD'"RGKL
M V4JAQTG(V6EMZ=I*K>0K0FW/'7A:\J,P'KSTAFQ;/9(CZ69U;>GBCUQEY:2
MVW>"<Z)C.IZ[3JJE7#P:&<+GH!.)@P>KIB&UZHR+)WNZX^^MOY+#3DPRK3KN
M"WGM F2DIHPI*H<)U8DCV/[P7I*8E#EH_O5VCJ58VG?5@0JT1"#_JXV/E/1[
M//(L[;OQB8]HDA\9TI-+37Q]A9=L#R5Q7W!]I7:G^>IX86'6C.#=J) R \;=
M%C :-'; FL0CP9HRNJ$\:1PG5F@FR>Q!<_!:2TD-SQ"MI.48E2N-O'R.NF ^
M&9\%SOMJ#:?29Y4=FJ?+6,PP%4]<-X)WAC6RLN"\!IT^/^8]=5+O:@AR.QO9
M6]'"Z]4\CE1BI!=VR"\<I/'/J0HMU5GV.P?S)4.T_)J'#RJIP1VSKIOL'X#L
MG)U6MMD_O<]+DE@\XW&<J_@XF+%"LS>>:VVT,WO0<O1%0)O$W]UW 7?R8#W8
MYBIO6KKMY/@A8[@WC00#:*$@[QSZ P6@0X/)\N<:R, QY"J ]T1=4P4ZYECC
M)4H40V%L*V##!B&U$SG1O.B>B]H$IO$+?[J4+_3CLUS5A0,_"XC.@;I3^80.
M.-/U^AXG,^K%->+Q1)/*@"8+\OV=[MQ1 . OG;&E*<V3F_;FRU7*YDJOA(ZG
MS;/O8-FY,W>Y_.80B'!5=<]GBR"VR'6;6A]*2CZCG'WOC)#2<S[@BI$);>.X
MNV!!:Z)TT$#H9^+!.IFM#7+S$(I)<+"')XRV=+"9*C70MM"2_(L[GPQ?GGY;
MF]RS0G>LAF&9.W_M\.*;(6-T$J, *6)_>P2T8(UMKVA^QUX30-$**J7UMW[R
M,P*?14AD,*[&#-,YC=S7 F*;,SDR7BU]N?+9B15$F[B9 K8L7%*A3Q8<-H-5
M_"1\EB/?>C$BZ9B3>L;-5?3^:V X5\Z3<D;$]US[GNXOA6TD^TDQ.3(U'',:
MAB/6BYI)V_UM;ZN$IB\&?4DH4J'G)[0>PLVR$+65!5$GAZS:1JK*+V9?GN4X
MU+R3HP>0/BREY2IR/%S/?6?V]SFBO\T3$74V>D *YY1PXPKT9KO;DE8$>)$C
M5858D8X/C](;!AU'58H#/20$<!"XI^VIS1!%!^J^1,+>.A^GA$<RK2Y;6+--
MLUQ%]7H]<.L,SV(O)=WQ?:9W"X,Y<2]F>GZ_^2@\)\,3?GS^ZYL72%438U'!
M,U^1RK!IP(F#1^Q-FY4?V2/.BKVTJ;Q1->@Y6D/_9BR^WO5J#6_E1(Z.$3"R
M,#+?O(?.<6P-WM! KEHWP9[CC@MIYX72DCE>4< 5TOJF[YWJHB<FSXN)OFP]
M>@#R]OTD$;GU4)K^LMPJ*[&F0KC=3V#ESL"8M=V 2Y:MXJ.Q"7_I1LWQYRN7
M(.?EQVL/U]@N.<I-NE9MS]6VU]!L*!(1[/[&6#(N5\S4$L<9+3*+61T]':^J
MPR_"N<M+48"RC*G<MMW2OR5>&[W-QY*R_:-FO2F=:CE.V$82*^^[%V%OGPRD
M9P?UE@V%/W93JX4"=F=69=&D4-+O;9D^1XRWZ&%V\8RQOFEN@^U:,&#^90NU
M(WZ;S%X.(I"Z\ZG[I_@.T_"Q@=?FPH9Z!&PX;SXQ1WU:H.$, 82?%3TV7- Z
M0 &P;D/_5^8+?T6XB;X]=JC:O>A>=&8+%+6EHA8\E*(9E2/L=%'D*<X*SSM4
MU?DC*8>E$-_=+@ZLDM#Y/E%+$+=*/6IWY%:G)7[/HZ#-<MKYJ,<DNZTNJ8Z1
M=.R =[DY9/$A)HM)I^4WR[)S&0+IM44(5Z9M*EYQ_=]GNE=:F<:DY?.\=ICC
MVS=77Y>I2R\&?(L"?*KR.Z_GB;T#8+14FFPH4/"Q9$\S5KW_JPT5_YEM2!NO
M1BD]FSA3%U<;-VMIG'P7+_)@_F&B&/]AIN%2[9L*1 2(PB='EK6.5AV9(O)A
M$%.RGIP&U_+DHDP/(FTIZMF53M$"Q\W.MJ<-*$MUAR7SQBN.&5SM=DTYL?I<
ME-C)/NQ[.@R6;3Q!!*IM.P5?U6(^@6,6M+YR:@H$1\B>)6><0V[O!YC"4(!C
MD@0X:0?8G)IEU\/5^<*TJC0G;VVPV\/;T'.+_BS?R$_N^* VZL><L<:>%WT'
MA4=\<P[G$L>3IJ\"+G)E 9<K_MW9#OZBA\4VKH6F"[F# ^KYN)\".285U&_&
M 7<;'^RK_5A_\)Z-WVLUN1ZTCOG=$+P>UO-H:-+TB5#P09+L5?Y= -,FT]3Y
M'?C70:T A5T=(]GWSD*N^@HUL*Q8) I0BG?XZ5 %"UY2B&2U-= 3NQ[LF%V2
MI^?SI? XZ4_JEL.?7WF")]%7<!Z#4WW+_[T=)L0SR%!_OT'NT[K./0EZ@%X
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M%VF1Z\U'#)0T(6[W)H_R;'GSXM@#'V,R\1W>8R69\V2-7*T'8BX@XMQ;3&1
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MWQS]YGYGYIR9>>:Y<V?N5/]83U=UUWYKK56KWE55^^'[PPI H"0/E@>0D)&
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MJ7#/6\%-4J2P&9'R&5 1$RQ<7#P?N\3K:GZ:3_6NN:UY?,\)ZX;U!%2;<5M
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MIH,G4Y65;_5W4JLTB)[$DG />G/PHVEBV8).$C?B/%3*G#7#DA&7>3?+UP]
M*%<#JXH;[Y'R<WM[Q]=<!\4-B=,+\$*-+E['U0@)%A1<;GR48%4Y3>5YDX:J
M9,-YW1G$]CJ-:O1R)]G$K]11WSV&0*[Z*1MS5)O9(H8CHXV3N6?8!(J<\E1Y
M_2.3#EEI IN;!X<NHYVM[Z17[H2X!%7X3X94WFDT-K=8PS,48ZN=HP3*X%\V
M:<JB.TX(U4!DKHY*\:=9UBPD!9]:JHO7A VG][BJ#INU!(\5.%,O+D:(X1R"
M3I!10^%72L1O!A-\:3]\FHLCR03#@I\^KQGO68U#[AU=6E*VRIDVDK-->LJ_
ML[,F[_4U@Z>RJ\)O="637W1.Q_L'MU_#G+?]_FB2J7&UFX/[M?,;>Y_5RH3O
MS]*0.^TS'&-LN!@X/N10G7$GIHP>N]"?XN-$CBG36 N7.;(X6U7D+*D^#0SF
M.Y?RKG[YY2_,&=_Z2.U[\"KI[R4(*OD U%Q-M]K.-K=)W%DXS6[>Y@8[[R]W
M(*C7&AU._?7=#2^\6^?]B"YU)?"Q?\&7NS.^*RN:2CR5!F=03-L,U[+:\5N]
M,D(-Q[G\>&XQZX3+KN6Y6GY9)+C88+3WI,*<2D*-Q!YN6H 6GE+4G0$WK'V1
M8\PO%T7GE._W2H=4/WM8=0WA ZGDWAYT=4\V3IO1S4UP\LP1.%H,_9E&%*-L
M[N;BA6H'J;":&'UL]\,*GXE.DK\)V5H*#"+@;ZK8'C7>-IDM;OX %YEP4>D@
M],WM$B9W-?JXEU<#>QR>162SN.]L"::Q3'F95^_C,'_"'!?*+6I/"?Y$G.2R
M!#D9J'3.AAJZT,F\6!+Y=F:D(G[!4UO(A?IJ_FEKFA>A@CHFT3*:[Q,]4;0H
M.4J&*/.$4B5G#9]E_Q%IN$2>0N0O"K/62A>:=SG:7U&,.6G-T=%RGO:J9_DI
M*2Z8K5-2[IJ<^VG3"35XM\#JYH<_.]WJU>7@$YJH<;J#M.IM6*RLP<@=!!:Q
M,OCU1_/@CI53C7>.LX4Y99<G4U%.?BU>)'_#"C$FEOB.;=)6:1QVMAGAF3H9
M8XQ O<4W#D#[**!SX=&LUK=PCB3'@6)5'?J4\5"?/T;*\KMBB*/M:CE5)H?C
M:E 4DF,8GH4";V] GBQV3[9^#0:#\(HS+G1POIR9A=;$<_SF0&H]A^JHLK+B
M.E+XPEV6K.1(WJ8F]5[N&6&W4F37H)R>QA8?.]X/^G:28@THC54N\UE2]/GI
M&5*J(5ZVXQJ7Z2PG4Y)H:_<7,JB(JY'@&,:KB_Z.B\'NA)_"+P@.K(S1J=>W
M.TZ%CLU,=?=NKH(8QL@]@['MIRO+C)4='2\B75*9U6I52GI(Y"E M";U_B"J
MX0HP"J&ELP%Q"GM20)2(+=6M$A<"6O[:\RIZ*S9 KOY+_=2L9_\2IJGH8H'O
M$]@\P^A^S<O(G3"@:V-^8,YM AZ3_*[UX. <_OKUI[%M*9J)\V!,^]I=8CF_
MX-(=7DQ(WHL,-UP9Y%KC%%QT*3-N@5/VVYBX$[^ .M=29M0?%#V++:3+UM=M
MO\ASF;:F-</*D3%%Z8]D:61I(JL5:^K_U=D>*UHD8)4#T(#S\"L\*\6?8JM(
MR*?N=$KX[FW FNM3U[FZZY;VO;&PM)HID2,O>9EI0JOX$+W)6YL9FBT3,<HO
M"K:VF]([9NV]EPC'A,2J]BJKJ^KOE >BJBQTT0S,,4?>IQ=8!_,J-+)Q8G50
M5J6Q:+IJ)"MI(.K.;U\;^V<WQ)!69:Z%Q_=.+Z%.>D8>1%>\HEA?IF<CXR4T
MMAS64:>SR$+&DCQI+KT9:36 7KE<X^1W/LG$R\]?,M[QUKWV&G)(K1%5]@J9
M[]ZUHU07Y<'^8+%75)-JPY1L0CTJ$!V6E<;DOW1HUAP4 8LZ2ZEKOA^)D8.]
M5PGU1Z+Y%<N1</JLBE;^ZQQJ>*P*K3+WR_<)\HQ$\$TO.@'-9I?U:\_#X 0>
MS=O7I!D[4HQDUU[0'[,Q&-"&$RT[2V($.WN(MICZ:-1[$2HCL=+-@/KJ)]4C
M/L'2N]\D<%@BN Z]N&A=OA@8&B\8+ SY.1SSAGMSFE/M#<H;2U:>B+!0&< 8
M$SP:>QTS5-B8R0-?GU\A"2.*OV\3_81_(&L(]1-">]-?DS0H#!:AMX&FP,I[
MNKH/P$2LB4%:#1^HDDK1%YM<CMD@FXCSDV\2&43V!(Y2H)9 U5%4(U'*2BRH
M[8WN"_^M5%X?4PJP_N03C*_U 2N$DJ,D/P98RF=,8&/2=6Y.]0+OWWERW'FH
MR3=H)W1XCO=<4,5@<H,BY2WFT09#7&F?K1H,S+6:S[_1^2K::7BN&S"HPN*_
MTVJ6-ZQ&#.WZ):X+GU@;6X?(!;N1!"G5AI!:GWQ]YO8E!^7*?!+-W/#98-E&
M<AH"X7,5;-+A;''+,SDO/WZ>>38@W-GY$D\$+=5BZ % IM3:<U0ZWOS M)P>
MA.F2_[,:XKBJ_'6?2AAW"3190?:H40*R[OLYZZ(],4/&+0%%KGV+&N9%SMFV
ML6 =;*)YTS:<^^U'@+(YA"LWJFH]6J0QXN*[ @=C.M,C0=E0,:H$7I#P.#\>
MGIP+^D1ALK>;CXFPI0E>YP^YFFE)U5SG%YE[UYR:/221UIKWEE6;48K\88_N
M*]Q[(GC;'W> >W,119L3_IZ'$Y-&/.EI_H5V(V7VHYRXX_N--R_X[&?(U <C
M0RK*'=U)E,PY14 N3 VK"<N,.J5JJ:;GJ:G.2BI^)I!@"=R?@OXOQKU^37,8
ML:;>J"5V/7>Z&'VIEA68H9:Q4#M(ILT\IQ+36*H"S<H5$O'A8IY:#A9JG?OM
MX]O"1,$V9KO2WZ<G=CH/1(,Z(10]J*8O."FY^$V473B_7T5)O >B?R9?%N!Y
MY]M<-4&=#_?Q!S=/?(.5WAG:9/2BVGXS/5CK+ONXF@4FD!!E%.Y=?T2!^@K^
MPULUX&1]7.U7JN;.U,?@]!C:M"+?LB'Y29;ZAB\BAF_G7S:4KQ=&HA:IKYP8
M=T<U)EW9?!]"(%\5J8RRP>P6S8P@]^;0$37JGQDO=(E[&R+3"-4P8<+7UE,9
M*\.18P/>[?,C+92A_28$#>-E1A 5-N5T_SF#I5/-;7C\[C?"S&/RY]#W\HX(
M"0K.5*RUEU0V#4WO.: ?!M+BCPT^TO%1T/<]8F(3TK:ZNC+.A <ZYP[Y7@?)
MO,]U'.?\]Q]_J$&\A#[$/*UKYL\?;';2F#P;K$V0[>A#3P;_/)?A-S#UL;>V
M\?'F'.ZN$^ ;L&$!)8%!R4E^@A=C2#9;FO#FCR;&*IP3<8VI8)IUJJ #FBAS
MV"^_'U"E:*4!$,)(AD<D$HH399YZXN>BN_0BT;(I%6S)C"G*OB<_+J7;RU\8
M>ZHU0)(1K;0S W["- X-CGFG 87#(D;RDZZ?1"CX#WR.TOE00%$YJ\N::2_*
MMW_5:O-H.54T2#<S-=''=$=M\]*B9OW40<^'2$%P0AF4P%ZA>B(AZ/".M:8&
M]"D?5**)G)SXUB2:S014<3GA'N,CQ3#%0]+GYN?%3U18D3RX\D%,\[D8I=9@
M3E]BM!*AD1S/BS"Y.VCPUH#71>;[>M4<X]JK<;^D)R1./HM-$]@%CD2\97PA
MK!MQ2;6ULP8&2":'!U9ON&@-'B\Q_BE5'^ L49WZK1^ A>6I0T4R7.GN.K;T
MY?]N"_QJGF8Q<YKN*/_/VPW7]'4+,Q:BG[)4;I6J8JG-_5 9L\[<?:M)576-
M:Y-SA6<@^L,GCS!6+1PO$M703K&VWHU@7; -L[O=5U:=,.+BH[J[XTTY[&<'
MR4_$1\VOZ3T [3[L%_Q<0;0#)0I%7VVE,\FJ]JE@:;"]KQ1/Y)B&GYB4)=4F
MUOFDW4J$&U4.C196_*BZ67;.\+SIW#(OM^,2B:CP="0GQ_5*K_SQH3JU2K91
M9=WZHAKUW++>=JXF=E]3*S5GS?LF?&;= _8 X'%]BCC[[J!A:K*M.&YB=(5/
M^RV='Y* X/@PUQY.@2M<HV7(/GJ\^5;)2&(YL)YFR%"ALV?:Z4<CK,5%RLA-
M-'96E1ZU1,H \36EF;@^!,=5\1D:F]ZZM]N81(#2?3,B?$^DTQ0[E.'S[N.X
M,V\7'\\X>Z<Q@?I[[?(.UW:%QA D]D&1SZI;.')*U4MA%HNI51?0;R+?MH*8
M'X#^@< 'P(3\ 9!3,/QV3QTHK5$93P9'_^.B3B3'T;[+^5+C6X2NYG,.E(1!
M>4SZV% QC$3Y:UX>J9J >^_=]/E]_Z"Q="LI[V7$YD:;'TR:^_8'5(U3I]X0
M\FEBXLLC<>CVB8>;]#5]-UU+\$*\:,SFW?>5P&%/V@_NE9Z&AY_O6]IS@@D<
M?(S5?+Q8%ZI/OW($;%]2;5J>LAS!=/;DF#$K/Z4-8,8)M3R32&U5S@R'NT5D
MJ="G1 !=BE1^%#H4+'FTH?'Z\ZF#BQ65ET@@P_LB%\XT0I.%/L%?IU8&&WK)
M=NU+'6^E,%#<1&E8UV/ HN5<*:DA(C<>&L0Q;5#CP'P]BY$M\"8J73N=]TK;
MWMOW#F),SD8<WK6P!521QY4;"S:46QGZ&<_Y%%)F7Q826+,/RR:$R@8XTR?F
MV)<4E8$EC)RS6]#5I%I*%I]?&!Q468>\\E,3C*/%D/U28RKAUL.,6>R9%+A7
MQ<BS[[_7N6R7ZY77TW1JQOLFGE&BS5N4^HDX=D#-C%S5M<ON@LU!]MH E^?=
M\Y<(>83*RXKP.<W'8E.PJ^X4#P:;.6.BHHM8&(L8W.>#+8U8 -S[A#363VAH
M]^/TW,[FIK\VQTUJSK./6F,Z,>S'W_8E7J]5IW+H%^;ZTPLVFZS9'IM<M=KU
MP#GM2330ES=ZWX8O0T6L8X2]8YW['#)<+S0V6LX107DI\:90"G4TQ-!-MMSM
M?)-58P*K^@E"L4-!;F$]"S<+=T43K*!8F)8: IJ9(2?L0QT? .FNABD>#"=&
MT'^) S.@$.! 4$"X9_F@JG%PR^V=3*ND7!DG^C=3$QSW" '\7)Y4];@B;)?Y
M^GCL'ZANL=HG\I<;>H?6;@3<=4&IFP/.SF23H;C(]J@O:!5/NIPZ0,E]@E>6
M08X<E[5M2WR[53L<]+_#:!09#X.Q"KTYGL<&^F(BF=])QWS.9!,3-*4Z,/7N
M+J!;[WX<<;+V;C1ML,'BJ/CCC86[#UF<1YC%,I\UL)6UF<L^-6ORV_$*F#,-
MVAJ)*F "_3#FEZM%B6%%?%\&<>AX/Z./7\V_B7VE7D#J"*ILB%%3;2=R%#DU
MBF'C=J:=E4$F2WU.@!.7)V_T"N=-+!XOGP*GUB;8K"7E_H@3O/945W^8W]2D
M60[7^O&:9A$^&G9:QS-1CEC:M320;AG[S5Z8[:*9L1FI8ZE55F^H(+^$F/Z,
MA(8R,92<!9L7715#",RZE[2;-Q15[:#1<2&(:#)R(CUY<1+9D!C:J@]I9 KE
M^X/6;J?_J#6CG;34A!9H\ZD<ZBS1BR3Q/GHF^Z7H#B.FMXW4\>):;BJ+15YU
M#5U<S]>X-!>)6%VX"^+ISNWJ!LNR"$]87<E#%08Q4*.-$U\W5OJ,858[EB_K
M=T]?S!!WX#8M4[O#F=9?'>B\JDP Q##H+3)CC1!@Z"*NAZ/>@8U-4Z,-',GV
MB3U6NO8K+-7#)4 4Z018<5/XZ[R/J@R0*S-XP;5?S9T?YLH4OZ8M@V_,WJB1
M6\2""?,A6?Z$S%"Y@^-RP>#ERN7VGF4T>;!C?^-@]KV3QA#5J<$?E<F_T_O7
M<P('B=U(<W_]C43ZCZ5)S-Z$_=H;RGD2^J5 U8JK'_5X;<M>54.@.HYML$>Q
M6-*X =?BAWR[[ *+8DI-[5#M%2M:/'2Y1RP%X.N0C<FJ).8&@R*"/I:,Q"AJ
M1B5QQ=+LLA\L6X#(4WOW\J7!&]-%"23GW6[Q[!V**A?NSW$7!V"6E*F&[*$4
M6_I]R2H%C,019LP^'9(6(D+2 VAP*6./GX>;:Z1[.>>X8IFKO+8$ 1X6)4H^
M8T:L986F:13]D\QNPZ+N)]..0Z7TKTBZ+XGJK?!D6(U+@3=O8MW S]@6Y7Z/
MMKW8LM3$WMFF-L/(GE(I+4(A+CH)2[-?.X59EDFT'^/+Y[6BPB3'$6.KM.N6
M@S+M96,U3\O1K^)Z:<Y[MLX7D*;V4;ZLW[-.GN^7IFET1TVV]M_F9X;-K8V3
M5J<'&TEKF@ /1_W[-^U46<EOOMM&@UFW29).OF$9Z32[L @,!PV\=4DWNZ2@
M?\^R>;>$74HE?))W0=*D"^?RF0@V7=%_9S:Y/P=F0#3%;4D46>?H\(M4A/%R
M!\X_20.9)$=/0,AR0LFD"1Q<AR_Y%A=!$VA$BG6#-)V/RFBZG%^5GU2MN8I2
MD+C+E?\I$,M!*LUFE4[GC1>><Q;S@ZG'F9H&Q+QU<?M .>#U7$-G/H>1)ZF#
M_=:.0[MQ\L^?+M0:*\F@;7@G]J, 9!9@P%5L10LL9\C&O)'W>'MMT9F7U MG
M2@< N(L!I'8 8P6OLV"VZ\KRDD&_W89;F>\WX5 #)4\F[QKB0O[5!YGX\?)1
M;WO_=$Q!_S9!ECH4GSY>MJ ?A]AL84'MHJDH53FVW&]T;]S9& )93QU<@8CU
MM_?)@D%I[&#N1:#&K=*!W!'D0RY"5+A7S=X\SM^_0ZJ3)4"P5U96-I*$7((!
M:)?T&!2F-(S9,>#5!=G$_USXNM6>SY@VDCP<AR[S(G ^4<8&23M$A%;L=S"T
MJ:BXU-6UQ#K/O/F0Q%9EF\CB!BH[Z1]B"@%\T"*]D;31G1)( %\2UC]WB;(Q
MXT59H&@%;_)=91\K4&'0YAC\H/E=LZU3!M6[:("T3.EP /.GYWNJ1?O4N3!-
M2MNF*3*DB\_9W36":!<-:Y0+JR%TXJ38O&I.&V!P3SDSU3:$IK-/^'KD-@WG
M]:7((\^W.'P9S]GCY5'#86]"%3":SH6J.34WP$;0E-;5^.;I\T<R: AX8Z,.
M9$59, GXU7M$&4]%[4S](W9<(S:().V3XO-EL\GU%&[3@XW/D:3QSR6+OM'F
M4S=L8#2BHBB -&NC88[T1#],)ZO6X_UC$.G6(<G$S2<"O:K\&NE1SUP%ZF-7
M7JOGDWHF@0\_(7&?C\C?X?KHZ1$7) S7CC"5<ER"<;N)FD19$N?"*?KT"UN(
M9+0CKM?FQ.@C#)BB73]I*UB#D9.T%?-"5L',/BBAJN)3!A+"*=-+IF^9(;K'
MM]D3OZ?#^[I-/2EY3*:!JS:?T#+YD49V?'/E%(Z?T&65._^0ZG+3P=J"!=4!
MSXYB+8Y$ ;:%2E:N* H"3)XD?*8,,4UHT@1$^&P/Y?=BXY>T7>7\J%N)D)F_
MWTJ.LK/\8*&,WQ4)L#H>H:Y1_@.%J4 ]^16CG:.XE7JRO?'6Y\.^&X>D?\BC
MFIBDS!"DAL0$]->:ZM&Z&KK^/Z&$.+MZ)\9<NPL+0N.XG)OVN&5B% 8X+BBX
M"R@+UQEB%FE<*0@#HP.*7] [I25;>/3!IMAF7SK[5_;^7RLNKAV9*&\:LS0&
MJ QZ#)PJ*L)>9+2<>8#=TX@K)MC 5D2-?H0U*3Z/FB;W*75!U+CQ:%+Z<].Z
M1AQ._$PE)A1DDR-LL"A8H:FEG]WM[4[Z7.7 50A&\E=! ],+O4.(#,+C]WIS
MP5.WL&2B@M5KF>1G(J6)?5NQX4O_FS(@L['*<^^P26TS$"SMZETG<>JEB9!C
MOF.O'0%%%Z-:/Z\!5A(3Q(G82GK%>YA_)J'PEYC_HWL&I@0/0,)F]@-@-MUV
M+24^^,>SO8&HK'T'WG]PY4W\*Z5O[CW1_$;K2=!( TF,S0,@<.!\!7-21< M
M8[V$XD3]64^6KI>_)-4LVRU3X*6X..+,"M8:R*2NII[H__"4P\:"88[Y?43A
MY_7>A0$K'LKXP_.;T,5[DN7EEG#S5I1CPU_!77-1&?HO$H5W*=(G1UE2!8C%
MY54/N9XS<!90G/KMJE9*O4ZL];Y1*TIN?0!F9!RUDNN.)^%!F=;%\YUD)L*G
M^S$"4L]SEX+V"[[SXIW@8 G$AQ GUA5F%3TY^^ 'N70,_H524UUR*P_+H!HK
MWJXQ,'$H&?!RVVI&3)UN0F(_E9$/$<ENQ&_B+DRR<XF>@J$T*97;)140_0!+
M8;=G[RU,%;FF%U*:4QBM==K-(37Y>OT8?KH!UL^1)D0B$$$7<<NK>C>7.-07
MB<?H5!Q41A+[4AS;GGVV==E%=L-RF3[#T<7#79; %[,4?D2"D",[U\ @OYOF
MKY3?20]]3;]OIN$#$!:CF:MU<ON^GM>%Q_NN4<?8>2[]INFFH(K#3F&VY]GE
ME^D(4KM_9*G_1D*<!S.XWT/U :C>-;NCH['66DG[9;;>/=HC1>A(Q.III_0%
ME6:D7_+M)4?:KOH^3]=MS[#$/2DZ=!?_[FSY5H[.\)U]$-TF=<<#@/W6\/S=
M_;7+/>/[RN?U;?BG>*\>@'#9RM==#T"@R - J#"=/V?V[NH=;W!GWG2+^0/0
MFOD 1!;\J=NNC]*KZHZF7QZ 994'H%OCO,0[;?7>?)CNJ$2H6C_X\/,#L,9Z
M/2FA?/0 \&[B_])^/%,A?3D1?$P2Z$!3]"OXHP?&+?LCQVFZF^VV7]%24+SQ
M6^EAL;?_^5 ) NBG(T?-M^Z*Z?)?COWYMV[!_ST'^W\(:GC7_S-#_8^ RKJ]
MC'M.8\CD9LM)U U*96SO1_]E95=DEL'KGL3$]@,U-E3^T5^@]1S^UQG7?R$3
M_'-0,8,(=CE"#)&2WYR*F+8M_+G?SK4'X/]US?RG0V6\99PV*I#M8#H4T9CY
M]5>PC6W_=8;P7TC;_\+"><LPK4=IAZZ*,;P8?/@79-P\_W>B_2^DV/^!^C]0
M_P?J?S>HXV.ME YPH;N& K'('GLWW /23#?]0KU7_'E6X>T#*$]WF*-B/ZTE
M3PE-E)V3?BW@E/ZQQ'.]F7N-6<T9NOAO>)'B'PI:GZ.V>YF1!\"<1N\!4-73
M1OKYX>_>NS=U:<X]? #V*A6MHRW^?LI:[3+6MNRR!<:M>?FW5[C_/X'F]P"\
MO3N^L^=+98O\/Y9/%Y0&]U6T'3P& M_=^O<\ ,83#X L"9+S?^1S\*E_^:^U
M4"F/KS>TM-4V9 O1:'EJ&7=1QR TX.8??'0I-3'[UPD4T"OEU;2S6RCV?.B.
MLGU][D/A/O?H\\''@V+,M]4'YC;_4_OW:EF/O[X#MT\)KJG=2?V3:J^G#JA<
M@%[F(<O- W##H4EI\3'T[UJ,8_[,Y7+^:OPYIQ;!WYT P2L/0$"PX4M;CA_+
M9+_I/W[!2,5=CO(RD]U)@430*=K"(?2"<8OSA@H%RD?>S+1&]TOI+,;$LC_I
MZW[B5<[+MD IBQ971&(-7&0.\<,ZL$ 4H'4[5C-H1=1-<IY%;=2IT(XJ(^8S
M?>R*B"G2]SE_)"I:<_6,](Y3/&.(O87)APA[*2.R'?4G;H59,N:FSK:%J/I"
MY2/\NC7GY4@XW"@-\K5 L:>":M1)K(17T453[:"&TP">-2,((]8!-Z>0D7)I
MF)X>L8DD.5F<,TZ?T-"0=!JG^^HG>VP,]>.])S+M-/%-A1VEO94^;AX0%Y=6
M!;)+S=F(SD2X0>426X,\(GZ,OQN\R-BD. CXCJ95[B3_-(24+QA'0BMME)7]
MB]UAD,('H'"(^&HD"G7B.?(G8S>1-/IT:G#-3Y3JB=5,U6.TK8A\>/,-\U(:
MS1X/5]?"@N%+ZZ1I+=1+FS63JD]LI,S\+Y+*^5GQ=F08QY)4I'M.[>'6/0O7
MGH\=H&<^(GKD48_FAQ]/@M(T1SBUP,[C MVUG!#,N$41/R<9CAVR9+L@AG'.
M,\30;F9Y<6.:>OS:@6-D1H_65HZRCZ6+@]S0B]3-.2K/A1$2QR\DZOA*4UYW
M(K*8<T6+T.A!Q><>DNH8''$=+V,1D?W]E+WRK[^AF0CTP+GK1&;K]Y\-G@06
M-2/\2YX$%E!"$A'"8XG)L;BQWS"R?.LT)E:/E>9V,V+A7N\O9%-('/0>OQ9\
M !RL%R1C(B5G)9M#BOWH R?>R%#O0^]KZ(^@/9/N)LN!==KZ<AUDXRKXWP\M
M&S+6/PP;P$XVLL-4^&2&OX#Y"'DQBK_[]CK&/'VF'&.WTC+VV<Z9X48S,"OH
M0"PI&#I$C01I3M<UL/+551QCGL>M**D%S+<? )*\IH:I)[[[!U9CD*3]MCH>
M<O4(NVQK>M"22I.!>N>:MMV7:(TN40L2%-G;(,$[TO-%>0D-O%_CBWN'!7!H
MUO :"9U#$H<&V4 ,5Q>8+H6(^Q@4)DZ/TLQVC(Q/Z$"T#9I]VNV]MFVFVF;R
M;+'@%/5E)6O$XEHZ3<+'.4Y^\5H)\] 0FUO3]YHQSW.N.^\A4A**7;5&2-03
MX*T7Q"(2L#ZBN/D?41H;"RA*!/RB&.7?,#[.WS[_T%&RXZ-KL:PT5MP*RPBN
M=\G1JTOY,=+2&,+!B="V,8I44NP!/-6$0AB_23WI*'?@W7:_>U.(B#:P$/<N
MHOVDWIF_)/$A'C.66STI0D#2N7\'U&^R@CL>1+^\,_-87QG'JF[FQ?C\H,ML
ML2*#!H-]Y73WIT%+IDM[U^/"7'B2ET5X" ]=),4WNFXZFP= [[73[7N)ZMN7
MO=F;?CEZ- '[F?BWIXNWGDA:J@A'?,)?\1M:(WQ&]BYUK^7Q&. LGDG\GUBI
MZ_@Z2UA00S#1'-4B)QP)=\A2F50SK@?[3;HO7B<T0ZUM$BDD=VTJJ<><EC>H
M;/4>47#G#ZAC_,P1FF+Z=I9^N+_:-'G^ 1H_9='(8&O/)=<-(W\)8322TS9@
M3A5E@L^')$2!D4,$N0/\I-+1R^!Q&7+!GV;OFKM(!U)Q(BF9K?B,A9KYV4X9
MDMA04P<U0JQ/2>MDB'Z')UM_^[M<X2*+U 9XR_B\_*ZG=2JQY,N+-KM8(Y##
MJ7BD 5..=KR"^I-D>@*\=\]F1IN>GBB0]7-RQWUZ:285D-@;X4YL][U&J9?Z
M(' O/LC8(H2OOIIBJ'QGQM"*[.A*EQC:W%,U:?J9@+?1D1@3>5I>PN*#<9KK
M\\B:1E8TA5]OZF0;9^Y'<FN7!FS7KY;];?(X [X*#%YYY(K8=+UO:KR[!KHC
M3C4;CKWKX3J%/O%.9Y\MGWZ=M5 /O<%J,6]*+$J '<P,$$+ N'4OEC0'D<JD
M&%JNM\UFA6TV5;PYT@EMLB$]",/(VY[T, ^:_.RI#.;$-[(-8BC6,@+S:SIG
MNC[BL7,6?9#"12H5V=:YBL%M\1ZF6?;Y9,_$@HK*B[<6PWC=>J_LD*?+USAX
M\!PR1HYJ_;B=!,N-2C?B=6URZ"_]&0F^G*P1[/G8RX+*D[H(8T-,FHZ'X4$Q
M3V >:!6)48R*5O5MY,*:G.,@1KUFX6-!#3DFNGJQ!O/'W.NGJCHR'(Z/FWU2
MX3K3Y;:X(\*5-EP92^=%L$>,$K+^J-O4\FN\L<$^G'P<-<Z4J.Z-J#-!8LVS
M@?[%WYFG,PN5!?7X6Y:37?<=U.;NAUPN_(C,0.@ZIU60YEG2%%>$U2L<8M_1
MG5W-]\IC%3\0 MO?=M@D+^7G&$AJ)<W-("W=^9$Z;+5B*&0,MU\0'U'RCJHC
MB7L>6SW^)/^-LNM=5*0E28WBT0CMQFJ#,E6)*_H*BKE'"-*W;__XS4L%S0?@
MO4'P@B!P@__K,N:^J?@^E!7Y'[!2),.3 RXI+.XJ"A"O_$E_WZ=/;#:6>R3$
M,M0N89(. 6![-S<_ISE(3PQ/MM/73;@"B'"AZ\E*U'TM&\80;,/+<P@R *1U
MMC)/2H))'K\UD$//#"1,7=)&$(V6!-FU3B#!HABY<WV?NWE:)F/.FHRSHCE*
MD^Z\OFZ9?F/IXO:JXKC/S>?UQ>?5 F\%?]^UVF8N](U.98YGX]0I[X=PF$*4
MRW^5W0]NJ4SL<UHZMNAR1.'ZZ 7)P(2WB>$2\_/+G'$WBTWOV5+Z+?!DD.U-
MA47@@8L+TSYT#A/<ZS6-]5 Z!^]L7-\;B?!(,%7A6%LF>WM-J:5(:LDP("A)
MO@:6-"CZ7"34]MW:WIG!5W),N!>6HTCA%UU2F4PIS=H^BO1*A "OZA^Q2913
MXFZZ$]*V!Z#ZYNL=6VJ+DAGRU;W3E)/5],:_J/0S6"=^S ,PVVKZIGK@/J;3
M<%'L =":-4]_?UNS3_WN3FW19?%53Y]NRMU/ERF"&>U K^E&W/XG-P/W#\#]
MX&2$_F?ZOTMPL2_NJ.XN[CT3ADBZ_Y[Y]7)_22_332?_D82)\I %B(\UZSCZ
M4,T9R 7Z$^>U.HI:Y8A8?:\]9+"RD4%?7F)K!WC;\Y /VX^[+MC.Q)C&#\[J
M?<W9G"N=CH8UBB,<M7U%0/&AZI:I+.!@7^K;CA#6YWF[WH9GXHOKJ=>UDH^L
MAG#EA[\7],?;PJ*-,L/3K:S-H.\^JI(25@Z%0+ZC:/4ND34?&ZL;SB_V0!RI
M<ZQ'FJ>KW4B_FWP6+3HYJ#1^5H$#IG"OHRE[ !AK19$=I,A;IYT*(BX.%EV<
MJ@H0M8W0.E_+"$7M,@Q8ZL'*8)'ABP3.,>?H9S$U$2? O OV<A_70;'0&:3"
MU(BK0H1OS@E6'_UT+Y1#KS$]NWF6UAX7Q@T*C$:61V"BFN(=?2Y:5=0=J]JK
MXCH%)==^5Z.9&NG.:AF^Q"]5I;4'76U8X@]+O3CY1J^.'41U% 3-,Q[RX<ZW
M]N/:V^5:/[&OXQKN+\;!'A1Z3LW70VL)TWE3$,,\[#R\T?Z4_[>1MJ17Z1Z
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MD K$P3[%\SS$.#W$Q@Q4XN5:5C3OGB"CP^D.H![+/.[OF.0=I4#FQ\[Q6R?
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ML"O476FI6E0B'+=_T!^F##LB3$8S?P]ANJ8]LA= %\I"_\FN.RS[Z>A%9(^
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ME5<X"2IC5GAU8[N60LE,(NHJ:%:_+4/5F?;-.:,K'$"\^T%LXQ$HMWD$LL*
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M5(IWE[GR,.M)<+]>2UIGK!TGHV.FK&)]DBWVF/W'/J7WONT_,P4FTD2@B[V
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M*3X>>>KO>7&,//3%_!NZ?;=/0-N"@.:UYT;:.(D-MRW)9;0-*(3BG<DYX_!
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M#@!GN;Y\$^']UG._/ @J+5=[ON:EH3+H4@F+9WTED+[0:2QN$I6\V69=Q5-
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MI"(80("-SMW+.88SNST2IV\+</;A3L(W:2$55J&NU<<K\JI6?"Y.,DPK[S
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ML^<P:_5VL$AE%S<0<8MC30JSH8O==GGCG-SR4AJ1'JC$VW280*\=1]&Q42Z
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MH?N'6:0],B7,3>O:)7Z G'-J>8\[L\(PWLL0"A,>6I=%C9:*7-UCW!5X42,
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MQ]<I]O/OMCFA6PT*81)I\-6W]BVP*ZQ3 7,CKB@7Q7X(6*Y;"7]QXX;WL)X
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M1>F0FPI8GG 4&FC!#R\KA<#A?N<6<N6:")(5JR'8(P4E":<ZH\R?8US6S?3
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MK! #T02Z=Z&IM9G'<GXH0//1<-;N^,2")K>DZ$.1!Q'A*PV)[.)";MP1$LJ
M#^*GT.-;[$KX2/!.\8E1Z]%/*ZPFB[5^CUR/RLNN/+RAJ&FV0(/\S*E.:B2S
MP:,K#Y<35@F0!,)RQ+JT!][K%+_)X<3%I[N&1G;Y*6J&-VP 2_KI/\(BXD_\
MT4#U:_9_ 5!+ P04    " !J@7]4DDU4WHE3   R6@  $@   &EM9S(S.#,R
M,#$X,E\R+FIP9ZQ[9U13W=;N1A"0*EUJD*HB(!UI01$0$!"07J(BTD$4I!.E
M=P0$!!14NH#T'@@=%>E-0@F$)B604$-)<N/[GO/=[]YQQ[CGG/'M9/[(6&NO
MLO><\WF>M5:(OX@+P$5=+1TM@(R,#'A(^@#$&4 #(#]W[L^7=%&0ON>ISY^G
MH#A/0T5%24U'0T='2T-+2\_ ?)&>@8F!EO8B^T4F%E8V-C8Z1HY+[*R7F%G9
M6/\T0D9.NH?B_(7SYR^PTM/2L_[;%[$=8*(FRR.S(B<3 ,XQD9$SD1&[ 1
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M8@&N[!EU27&M*"F(%W^N4T\6L]O0Q/Q<3WYR:(YMW];/<&NO'#'GBIAXJR:
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M\->QK&LGOH0+)- 2#5X$GQS\?2QK(H22:FNU!"4NH[&;6%!LY8PRO@-U^2"
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M-CPYC@BT*X&Z27IB@^\25CQZO%;_EJF$NUZU)UD86=-=P32J, 3,FL![@.&
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M!^X5,8?#E4NX_\=JHO\+Y,GT?P!02P,$%     @ :H%_5(;9&]$U1P  )U
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M$7@ZL0>3DAU)L;SMC?6GNI+1E9VY0@:]1=]KBC/J73WJOME(]9VM,&H7\2"
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MJNPC'2_+^Y?D&7G?C\/[FJ"[G_)7-*<VUT4HA)/!\@P YR?1OX_<>J0Z2S_
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MW3*H\-+S[VYU\OY9%AQK@5A=A\;61NO+#Q]7,KP/Z@@267E'5'0@8B+F4,2
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M_OGDDM?M(T]UGLHSC8K\<ZD0:6LK^JL<XJQ-*6R2^U-!W_I>8FNX<-SE@4S
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M<->*+= SF$0<ZG'E?&+')<4&&IH;\]_@,E*)P\YK-W3K42%CC? $:L]SOM/
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MH:^&IC""MA&VY4QE.LR8R*KM?C7#H*R-8SJ&8?+]=B->\C,%1OS<*L82),'
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M.X'!S$4K!^A;Z&6(]AX"N*P/7*'_1M\9@NIB@W]#1&#$[H;KNZ(/0N;4"26
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MP=ZJG6X:;_SF?'$FQ3I"]\H,^2 S5CR.)H0E</CZBT*=-&^+&,+BR4.)%OC
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MP 7451*Z0Z;.?R92:6"MGIU?D;D,/.8'&O[YW@Q-,$"X-^A*%M#^XHW_SU>
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M4NB$:D]!]/9$O'XQF1@,TN4?B-4']QCO/G-XB8E%0DI&3G&;B9F%E8V/_YZ
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M*"$"P-3N/^9F^(K9=;E**29@NQ#W <X>U'G^"+HW_MER69\/EZH8LP<X/A\
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MR8AK"UI?BDKMG1A%M:<X5]7>L8SIO14X4#K=ZD0@QR5N^^9B )1CF<8XY&R
MZQS,7=*9UK;?^+ N(/H&5*B-@2&T,L^JP:7,VI9O\@+<@_0A%O-^OOB24QD!
MM)1O<O>5#WFZY$VFMV!OT'&]HKJ)P@,33C8<.Y36,JK134I\YSRWB1-I&%I@
MKJ=C+IJG#7UOR:*Z\$UA6S8R8\<^P&6&#K;=G):=,;%6F^)\VC+RZNU8[X/
MVX+K57ONNYWZIWX+>NG8I_;FPT-"_.Q%K[<Y":02N+H+J/>0KMA[.$N]F.V9
M.ZH&2HCY13Q["%43Z)[?"J%EK[FC\_Z9,,SP%<S\Q-40MR[:;(;30>+N@#D9
M\SX?T@13_;MWQ7P*1]C.HXFW76I-JM,9"OU'3&G0+:'G*TFY1KI/K$@')OI=
M&WN>I%I$AYLBN_4SA"XU>=I.7)T-E(C2\2MV2BZJU=LQ4>JOHCX4?R9[UT_3
MMFIRFK+]'@WEJ%-!$SA_BI3%5%\&@^QBJ)8-W4U,"7"E&,MOX$JZ?:!K8)#
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M91,((-^H^VP 3>\_=43?3SV_"]U-*<!_!/_Z4)-*&A7C8_CFAGA:?*#@Y[-
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M=A>F&)YA%1)T4&?,AVOO.-O2U=F\:*(/-XOT;4+Y<ED!Z(WG*"VFVZHB['E
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M35YA(0Z;KQB0\XT6,?X?4$L#!!0    ( &J!?U0X,2$K:R4   0M   2
M:6UG,C,X,S(P,3@R7S<N:G!GM7H'6%/;MNZB2Q-!>@L""M)[D1) *0$!49 .
M*B!"Z$4B+121WC=%T-!!I4GOO8I"4!"D5^D!@H 10G+C>>?L>[?[O'WO.>_=
ME6]\WUQMK/G/^8]_S!+\%_PB<$%7"Z(%$!$# !'A!^!G@.O .7)R"G*R<Q04
M%)24YZAH&&EIJ*EIV!@NTC%RL8.XN=@Y.7GXQ01X>$7X.#D%Y:^*2$C*R,B
M!!15%*24Q:1EI'XZ(:*DI*2AIF&EI665NL1Y2>I?/O"= /TYHL? "@D1+T!,
M3T1"3X3O!4"$>I(1_>T _GX0$9.0DI%3G*.DHB8\4'<!("8B(2$F)2$C(R4E
MW TBW =(Z<D8+DFJDU\TND_!Z\DH%9J<=XY/HZJ+Z?;'?7[I!UYAE%3,+*QL
M[)>O" A>%9*1E9-74+QV_8:FEK8.1/>.L<E=4S-S"SM[AX>.CYR<O7U\'_O!
MGOB'/XUX%AD5'9.2^EM:>D;F\ZS\@L*BXI)7K]]4U]36U3<T-C5W]_3V]0\,
MOAOZ-#;^>6+RR]3TTO+*ZM>U]8W-+?3!M\.CX^^8'R<_<1$!)$3_./XI+GH"
M+F)24A)2BI^XB(C]?CY 3TIV29*<0=V(XK[G15ZIT'.,&LEY55V4?-*W]YD>
M>'VD8N:76;J,_@GM;\C^9\#"_BUDOP/[3US3  T)$:'S2.@!,/#]1# _A(I@
M"@M,6P@I?6=1<(\<>^#C]X\FI;>NI>,! 9[%&W+)SW8A.T&E6768YQ685,A^
M&3>HJBK<;.*37UHE=2:/&>0NC[B )P67Y^C)6+N0#2SUUKAKH,K]@FV&#897
M00;K!I$^-5>1N[=2  H2O\DQGCX_5[@3? G$]*B=8?SVP,VPY2%7 >?R7J/D
M.M:K8'D>1--&0!;@'V@P44='NREW+"<GB<G_;IRJEZX8&X2@Y%O3[E2*FC9>
M ?<ML*J8A@;JO]I^ZUQO,<Z\OS6MOV)A%92M:A5"4Q9#QT._O;D7NC[1?@'-
MG9:_,7_9E6M]/'_231;:)L5&E*0M0:5Q+$+\>J!CHGF!=(,]_G-)3)W*;>IR
M7OB%.26M:![+6-AC%ZW!D2ERR+%"+IUZ?FME;P?=PX^MPJ5;Z;AKZ%)#!P?9
M7NB5"MWT&R)$W>%QB4;6 V'K6=N=[=R-C>F0DHR;]4_XDV.EJZ(A_ B(P(M1
M\J^,1FID_X9QXH$$/+"*@&7@NDQM3ZZ^VA? IB)IX5^$)O& IBBW$AY(>;)L
M>TIF#=\H+NC,.3!4EL4#]TIMSQAKB4:--!F!?\.(D)@]'&0]&K[#Y(L'\K,2
MB>'OE/<GS\+*X8>W/ZYT_!! 7,8#;TTF<3'.RI1X@/];C^TQ51T>^*BGQO7/
MD1B;2I>7UZ96ZVRSIPLS.GPY)>-,W1$DMA#.RAY@]VV*TK]?KN7@R7F_MJE_
MC><%749J"%SHXYCO%U^]9\^45'3)C1>:MX9TC _(B>Z1/]E48__-2!-@_+LQ
M92_36OO0G=^ZUM+]T%+8[T4_!]EQF"=B3EBW&@LYR\8#Y_I+SVIR=I#5D.,R
M1]6[8RVLZPI(@T<D&:G+B!?3CB^AA<Z?MLC7.!S&[!LD#8:%:O)Z/&O?*%*<
M96W+B#Y8Z&7G0I0Z5_/+&T52"O;D;9A$ON()/ZP\/U;;Z!OO/ *5QV0P?3C0
M&'4VS0K4)ZX6%I&2')BEVCN:U0_PBZPU"U1:.A7EI;1/5S([?I(">C[B97::
M LFE9D>4V!4X'2QLF1I93&L0I3A94C4I@)[S!,M:WD5?B<_;W%_8RHICKD^5
M,/N:_)8UR8P(0PQ%!BL]DK2!,>,!BZS=;[Z_>8K(E8KQS(_E$F0:N.CZ@-R?
MV&E>9*SR*!M)_&6S^5FRNR>CH<?;A:\?XBX1Z?:K[I,$!RGDGE\39\5XN9[7
M=Y+-!N\,SO9/:JE=D/_NY8_09H+?_.PB6WINK_;]H!O*_K2Z>^FWE5<GIZ;1
MVN7#RP%(BJFM"3FCH,3>#&;3Y)DKHNM9@N.E$> ].XI*L.ZV,NG#L3KQJ.1-
M.8@G;7OQ@85%89AL"EQ<E%4@8E40J9[C#&P'^OVD3&_',54S@3+ZVJ%@ K^A
MN*Z['2=7H9%HQVBLG^?BG!<',M+6OB[5L!%2 :Y?3!VZSD$>E.OP5LKCVG++
M'Q@Y2J&NR7B+Z$_&A":/S)MQ?FPH\^EF634CT3D25HK&[V_BK%XF@6PQN1=5
M0\!;PBRXT,L^3.@<+.]=T+?I==R)+>Y*(N9&&7B]#GEVV('5MZU*VD'6"%:2
MG[VX;QFPP*KQ-"U!SY[TJ%.:ZGO6X.]?MIJ,/=+G=#(]N9+W1MU!=BW'8RJ=
MC\<L+&G7V(Z'9(Q/]M,DQ\K[#L;-QRS7ZN,]"XHB7KY(F;V\PP#A<R5-:M%A
MY3E/YP\L*_-5GCNR!MT,7\9:I#4K>PS<\S&Y^UR;2+DGG8V$(WHX0/\)<_:R
M(?/,%C=3SIVF_9HOV]*%#BZ7'J;)7_),S)XA>Z;&[UMIG4N#O+#!S"TP6N$3
MI,^ULROW(R;!^&49JY?*N EM0!<[2]3.CNL1QQ/6+_"!LH^Z']^S !Y#ZJM$
M/Z@V7N6>M["-#&9-[1Z%>9_*7'GI+I!]#L*JD^+E%SF"FD5XHS[58E66VL2[
MIQV/@U/='CQMT?V:V3*X7BK-#5$.UJ@C.( /P E"I/=3B"K/&,=A%PEJ\JQC
MAPE*4)/T1"X\\$X9+7X65M%Q>,=HT9 @)^P_Y:02%V,!; CFQP"_FO *F!(^
M*&1[L@L_9*JL^<-I^2/L=<OL<2--WW0_<,T -B+0"0]8H_# X=7M.6AWAV/B
M#RK,&*YE!@]LW)ELGB29_4!PJ?8WX<BI=&8^,8RLX]+:O:A21] G/897#[;>
M0*RX%4DZF/*LUF/J.!RJ6SZ)B?KZZ952SA6-H>(BC,6HGG41#2H3*^:>9^EF
M]]F'UE][F=/-H2_%$58F2X<R>YD;'[E O\*S>,BJO-SVN-6P^_&)=7%#X8RY
M;:"A67X:@Z#X=='\T$Y3#C5*U!@3ZK?_/=T-=%P2_T%&Z AK)"ZL[MCAC^?E
MH"BHMW^,8$7UR/HQ# \D5<:#M]LZ<!$J >4PTQTT'KADRPZ?#("?4?E_MU@,
M>![!:*1#'".82]P(BD+PCLL,F_:<Z*=W..1>R7?CS[[=$L]E1R^4E.G%LB:>
MT+02LU?Z BTR3^U4OH0VSB)*8VRE?".C%(:@-!*PJ_4Y/,ZE$]O?BW7;/0*=
MAR*7O_F^WIJN,;=YY#EW*8R5,MDD7<S<LXK#+ZAG,L>G0D ?3-U?XGJ601!S
M^ RVZQA>?98]O##S<-[[L&(ZA$H8J2H,F[3<3P^7WL@R_J1359:R)25X()KV
M@H?S[#M_:,-;Q4V]91 #])NS*LO^<:2W.Q1>.J/RX7M-S]JYY OR0R^((0*5
M-P-&*?*,;*[3];I?V+(!?3R<\79P7]8;MK$66E[LMQ&,LVIY>M1E0\>)>-F\
M & B[WS.,/]TU!!F;:C=)E=M2(4R3V73GL'RQZ%1:NRJ?Y6;8?_WCOXI9TPY
MK[>\-N=-TXIL;=U'@@?YE"036E[ZK]?[WR*/8/J@N7(EZR! !RM;(7.\=//U
MUYZ#9R,+/Z +Y UE8O/''QU31I8_9B:OSI*=EPA \0?7$CW\V6G_L';I_0QL
M6!$>J%C' ^H6IU*_7)A([)5M:M-D-#5W]#Y5A@^:]N<<S2_@ 0U$VT2K\*]$
M\5#YT!TC6/A_1' OME7@_K(K^['\V.&FKT!="H=E::E]4G<O5R$#)7 1(9Q?
MYLZ<G;R(@N[<'F::_%)\X1U5S;7VGK"\)R-!BH>Y=#*C@1SE<%>,!XC$B1MD
MS>V0$F3 D?DUH.Z<\2L3CFB7\ S^.$?%[9VT96Z:NOU7XS[FH!YNB4@S6N8?
MNRG>#,,)YM&N+=X(#]6PMO80A;V8++F\9;IGT_4913,<V5/8'#&>3N89*<G5
MI&O$<*HA-'-TY9>M>4:T6&*16(EGT71;^>=$1)6BJ9J\,+<"S_IDXJM#9T&2
M?IY]@>C:<A+MR4MC2RV3J*/7=0%MBHY4K#<)R3XGP\/$UJT1&5S:A6!N2^_I
MG0P6J-*Y@N;Z$"^;\KYQP,WT0<&U[].&?)-5BWZUMRA2,35+%*$R2/+MC&-_
ME@Q?:,FL/O59A7?=A)R0ART%Z?FZV7]%+[_B9#$EYON)X2Y[ATK(:FO(*WX1
MW&W(;Y*#.CUAUUYA2_O 2ZY8"![(2P!C2<+Q0/SD:]S'A0-#&3QP2C5 ^$!1
M)5#NI*[[G5T;PM*[$"4Q/VNC7=DO)D8L4GEL9K#8-#.0$1J'0-2)=+"J\E]G
M2VZ]\91.3P&,F?/Z;'.*4U[%@C/++^M>E5,".6(,3E;N[+M%PI\(//?U+9D9
MED:1>-<ZFRUZ2$$V+9F0F#\ :Z9:X__?5OCXY:F]\D"N<BNG;-P<4QR22/,]
MQ3F=SEWO4?^)X?N8(;V-UHL5D.+:4O]T:1ER4#OG)3XW162Q(,F@3"SU*1WG
M1M+ &TSZCPHW4;%<\UT'F$/=(_F;NS V<W*/@ L2W@-MDR$-O=NEA=;G#3DM
M@@^.1[D>4!M1\XMSQO.BW%3OZHPWG 9^K[3>O_+:KQP&TAEW+_SF]C!<7&RN
MW8V2"#WC052UI\9%^_]CL$\(W5H_;.HP&-==16B(U]!.84+,/MK[(9 %/XNP
M(R2)VY,AIIKGBVX(M7W'/GF'@4O>_;UD@5RR<_R"(_WY@:7*4S(+@H>BBK F
M//!?E6E2W>K&_WIJJ9:%BKJMK00_+]-T8)DJ,A1%D9:,\*VF\B>PC+5!)RBB
ML.!74'>7"56^CD^DZN&QFAK\(Y(O.P\'MM4XB_HBHV6"KA/8_C2R[S%+O6E#
MJ>.Q47[NM]BP/GE[%.G5=\=,F_3]R5I5_3%1N4)OX@ *-3*/*NRUMHP[8VY'
M8%;GYM\>LSCY<5XL#+@9FT1'HD*)W6XEJ*8P1R]"^*,RGQW3;DO L=X3!WJ^
M'X97+$E7SE%NT,D0U6AZH0-O[!>VLZ7V0LMX/MVVY1]!ZS3!=R.$V!)50O<V
M+::Y.XHP&3?U];3;$G8_OC/BM;^7D!L>1E?%EDOU[R>*G#]%<B7\K*!C%4$(
MD&.F1 )I]&R(K!FOI5UX\WT!O2ZPA.TS^[T$!4?$Y]C]&I+KV#\.+*S)/"_\
M/M%"YSSM6&42/_,#GU!-3J7]U].)VN!+Y<-;@OG-[Y5RIE9P&NV$:E4<XX$3
MQJ/=NB7;/\5MZ.Y#@D^>GZL05.N!AN+1+O9UX[6L>>UAM-W?].'ID-$5VHN'
MYQN5N<\)M OG5Y LVX:Z8^UEUFMP(XV6AM*^Z87?"L4LW4 2;UV'&$-?)&:.
M4EQ= M%C>GKGI>4?>V_1WLMZ&NU'@].=F>ED"]'(V696(X[S'3'DDT69]#C9
MGB\86QK=[<\389]'\$'V1*O)QM6^T81&SV<'FPBLL=Y!2%H/ TSKH L[%;*V
MK##=D8'>]&;90W=/&6[?IN>%02'$,5K=:G/?HTYG'[9Q5[5J+^G3]=5[3D.S
M OV2M692O:6J00]OG\,2Z+%Z 4.(ZU[_R'"#MLNM X9HV;ZG&4)Y=HT^FI+O
M$D)29NT:EYN1Q'JR[:5H=E>A+]8#W*_V7-VJ2<W=2)_XT,!N6SX2J(>6YW2I
M<C3M#\&\K'EG-\]YI?<(,:XKA9,TR@N\6$_=-JW5I]#;GW_.G5TPI>WTZ&DR
MN_TJHC#U/<@+DDNG\*_/JOZ;\28W_%2;\/08'M@1!N%BTEN)VPB<2_C)Y!(\
M\.4N^(Q)%$;F<VO+6*-T 3[P(B?R&].#WTME.&:YH,0_IK(-X9P_ZIT/4Z_:
M/U8E3/N#&0@J8MQQ-$N0)F';A[]<L/B(>=8@_RH_9EMD%_YK0H@(1H(.F- E
M9WX->&"TI-*W@J(ID^ UY)_--=:Q?S$]?81>(-20\.$O0MN$*LIR_U$Q<^G
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M%!V<DZ]Y]IRYJGAZN\&I?DBXW[4%264E>-E4982H#]!<R6'37GHI$90> &Z
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M$O<59;]4D7]6'!";6SU+'0E28KN6FO.>9-081[*/17!_M.!O;+6D'$(ZE=@
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MR]S+*O!&5E)&$@!!@0#]UP_P\@Q@?) 0>_]94?'#)S(7=E9F5N!E ?@*P,#
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M.@9@ZEL%T?G..8O.ONI?C[75#U^NF6<@ZU*H$E7*<T/'8)"_4EJ$D2-;CD)
MHH*,FKSAS3*WXF.N+O<1MM8ER@>@PS_O_"S[:@V@=:96"21H<&5#!<FUJ6CL
MW3C90!I2/66Q .4R18P1F*.A47+C>\ =P23 7]=IWO>F-GW#3Q29;Z/+/8*]
M&K;1+^=Y,+9:G[1#9=2PY!@&V370/BO"MN''R$"Z$*X_]Z73%I6%J(5;VXUJ
MX3I'4=$>)ZG[D1\$\$?* *%\_'&;!7^_]5;Y#H !4\WL-VW^<?JC_(0F*@95
M0SS8P7/%JQ.%6^GQX(P]"\$PVL='6N"#EX78NA*G>H8J,5?FL(?CPKT^IK=0
MF/)ID+\P/2GO<QAH\3$D4+H)CU1.W/D\:JJ_D$UMXU=E%5<T1'[@7R53*QG:
MD\MUOD1 SQLS +(K"V+4.N'WS$@WD3#UF#-TED'LR2<Y*4D1RM/?B4FILLJN
M),VQ;L7J*RL?33)QO*/K>0Y]!"\,U$?LH"J?Y.2L,%>-97' 05<<OFZC*7Y%
MV=5I5H[++<E>7>7ET"C=((JR-2!Z.+DFZU3#'[.+V#VW7+!.KM7K8A]:MF<V
MDKN0>3<FMBW?I37OI$&YH95F8'70Q=!BETK"B?BJYK%+!!:*D-VC$'H4 0PG
M=CT]16F^X7Y6XAT0'3>O9KTKI4C"P3)N4B@I?N?HRH+0GD;:BC:?E*3A8K@,
MB2Q%\S)9)X#U23&5NB@&$Z-*MAO'."29#'M]Q>S4+7]CXB P6)'B^EE*O8G7
MM,1]?29-+T:^53:L.=64!HL#UU@.2"+$)#@*&B^<P? YC'*P#K3&<GD"2LBG
M&1L(4"2AK)'U<TE9LCUM-)X_N>,^BE \(N^G:"+-Q92WV:L)KP]+K8VQI/W5
M4NO(P96)I"8V<?5]YMQ_[J<?J:K^8_J8FQ"B8"ZRE @] LMPQ"B#<Y*@PI8Q
M5/%H:L(I^<B=^-M=Z8+^<0W63-="L?P7S*+Y<.:ZP,&Q? I)"AH+DVO[ZGR/
M,K5!+E&48-9XOM;DFFX_44Q S&A]2-2.E="B,H2J5!F]0KY2VLZE]IK-L^:'
M9K&H[N^K\=*P"S,D+Q*\\G5O/74NM2.N2%_(V!]O[T,IZ>5;-2&Q'LG0)TZD
M'<$,"V\6Z:YO#/?> 5<NM[_Y$$=H)[OK]U?GV=<,<:1Q9!=-DFNBR0.*!O,;
M3"W3JM=N'2:G]LF% 2X$-=]"5$]TDX@W3X&(C\9CG_L1T3!! ,.[*?7VRR&U
M-E*3^74+V:>R=F%[4F$*QIR(Z85N%,)7S[_<BUEFJ#0G)MA/-U.,G%=&6GW'
MFYHVDN#G%Q4,.S0JI$< 1!TFTVS[%1M"2[)^)*S;CV9"*7:=S3E[#4^F%2&_
MKFE(F1_*+4X(&5=8$1GI5U#5@<I<$:K28!$NN>;DY7Q$)LMAIO+9\&:6TRUF
M4^$5^17'!2E'VBUQ*]^N<I)54:N$!PX(#,@G,7D@3-M9.8U6]79C8X'U:*V-
MPOMC^4WF^:JJWPWCD,/#1\2&Y2,8.7'DU:%I1B@EV1MB;=Q*;SQ-:E'A!PGT
MC[_7JA$;XJ0(4<.3@XVSE%K5K(GE>DO=/K'Q90]5CAF^ Z!<:E)FX',\->+M
M$X=9WW9^;SV_\+3D6Z4Y$L\>'&J7#>/!<*ZH,E)!")0%9,7H_FN'UTU>HA>^
MQH?(@H)X)^:$8MP>#<@@"CU98OXF2_IO?D\7Y&"M 0RPYAB[7_TGI_2\V3_S
MXJX(; ^[&Y#%K4K_H G#T*8F%YNUMFI/$T$H)/5F:K.Z*)GLOY\R5UI@PQ*I
M-&$==#'CU_-E5T7=<02C!V=,+U,,I44%<'7C0Y^\$'JPUMO9V92:W0O]2$S\
MA@XUH,2"N?A9$3Q!O^Z37&D\ 7H;RL7R0C?Z_=VOZU'.HUCN"0-%",8C!?^5
M.=C[+.AUC =UTZU(.$UG.>Q@0Y\'C8#D>?#0NR0_R3J$Q#TP(AYI-4!%)F1=
M,#?5%]]*-?54<T>G$*]XL@B1&"!X$#\EION !AKEB)B.'3_.:V!74UYS?6H?
M5OE=LU5!E(6%I1ABP:K%.AM#++8"?G,3H#SNT00L_R'PHF9C,!$])41SU=0U
M($TZULXJO!L(%V8H1ME+/C(BHLX!Z0W=0?H@9+IM4D8:<W>UHC*3+:8W3^BN
M,5QMK:;EJ3?>?(6IPE2U%D#@;?' U,VVCI&AGOJJ]PY0-<U%\FO1^1H&L=:,
MB-Z;X=\(ZSO$K0,V]?N_3M7C DBHO/WF5O5A%#0<L=0^.*>NV?B0(X9:]M!'
M,3>I%(Y&?HP+;NUC ?7!W!U1F#^X>LH'>S?ZX.L?[^KQC>,N%+@,W"?F=%F/
MP/O4=P N[I5S;FKU-+3R+U?:-=48JTKID6M6[.=LT2,(T4V35K;=@$-,M225
M9 EDE>+=&&EM.3MMB421B_1W0+*GJ']$(G560LCD-:%OWY>DQ5@#.GQ&"@(/
M9[(CNW.MV-[2->VI[;MQ$J^N0_M.).)= ?MOMC=PT_BSD _JK['=;_@"@W*Q
MOE=G]H(Y,2?V6\<P6#%0%"H&/N)*H (DDMYQ/ !N%@)B!#$HD#S0F3_C8OR_
M9:W!7&7 H K O\]UE5.78B7HH2D8Q'8!G$A3-!$G61>XQ1=<&NM(]'Y/3F<>
MKM(=>02B_9[-'SV7]ESKW(Q9&A%&&>MAGZNM[BG")'Z&/K*@T>K+2,]Z -(P
MV+B#Q]RJ/.5XN#%Y[>0VN"ZDRK6_+IJTWAKF.>8M0'TSF,'HF2=1":H'*GVE
MD[<M^_9'+02U2XY6(\7\V1K^^$S$H+A9Z2NCW%^9ZK^*32<NROU3UZ;HTWW[
MF-B*LSUB 'ULS*H*M XE2NLN-D@,;J6Y]<KII'DUNDNBL(?<;',E+=S6E&NU
ME"=P$[:N.\=HZN2F(-@V,US'&.P][FC?;A:%O2_$<1:=RHLI47%Z*_&_4E1I
M\]NM-1X"^]F44 XOC]&7'=)+!<QYIAK]OV^EJ$?21/=-B"%!$-T+.._]S$L)
M0VFO6"_6MO0U';%D;0&:NEG-]2[4M<L+7ZPZ<H9B@[]MU+.ZT;H?U-?%7Q61
M=?$UZSU#X9#C>I?(22E'=!QW)+3>D,K:^.<7MI67G[1+I?9IX59?*!7FKO]F
M2)5(+1?AHIC&$WE6;"MY,TUB8DNZW.1+6B)(BTUOFF"TDY-;HGIB @K(VUA/
M-UHIV/(RT9MC>196_E[^(0O#D:=;.FI_N88=1*SHU!"NN#(*=T79%DT$:NU3
M%[Z] \6ST&M!_9PL29K//FA\J:U>,0@L<W:27.!6SP=Z6,:RW"5S+V#2<@\3
MB0DR+/=^ NF"^1F1-4?!WJ/DQD4D^HEBX-AY+?'& WUTH&6B9OE$[^+P7L+0
MW()"'[>]*5A\&$?'&\]6PJ5I[>JEC(*#782[15.SX\0F)"U_O#P]YB2"D4?M
ME+D[*[1868J7V()8\S%\'P;6ZNK;XRJOU6HPT[VGC$V_N:&GN?GPN!43C<6H
M!\>CU:YK^T&O)AKS\2@<ZQ)U7D<C?3)BQ^F(4]^8:H0J"71_Y)BUK;5YND+\
MK.6=L5 ^-@N:>:[_C$.RNQMK</[J@6-*S;I9\1"O1RJVF+X[_J,INXMX1@G3
MN3K+R6->RR%^1@'5?5JU!TMBR>PUYA8/5J^@%[)9 WH1'7-I:[>1R)6^8AUL
M$8C>9^+,-B@.[FD*MF'T&U/M\\_]HAE <_33>XPGY4 6"V71VKFZ<4Z2^3Q$
M+=JJY2C3O>AD@[B1#JWOMK0/RZO5"N"TC&TK,9(%-RL)?>3 ?O9!S<?*5X_!
MV1YM+3A;C>-J@@_MI[LM_J'Q9$FX0OI\_MZ*U5-T+8W6D[E5)NW+/OI0AD+S
M*'^IP#@6QA_<6#GBB4_V6&E:DCUGN)$B\D>%U:\(UL*F4$U<?4K<B>H7-T],
MEGQMWID)_)QN[&\H3WCK\<?R)24NO!N[PF5ZW5PKK \3GU\BJ_'B2\7%QUBY
M:/CDU;,C6W9*W@&R1WR)KEMI.#Q<*61VKA2E,"#9?V3@$5#NZTB]&$KI7YW]
MC_C__1X:B)#"S*E#J2HUW;9ZJ.G TE>;>.O/[$1'("\?$N8=X,^S>?X$OO0.
MV(!\,0$KS>QYTNP_[2BFJ9-VT\O0;.MSOR3%L!#*@, -W#8!>0=<A)MF+FNO
M9!I'/G\3W?,HQ&^[N@Q/GOQN,^/-Q W<I 'K'ZLQ9Z77',98KN&,CZ+3[-!#
M\V@^,/UA$!MA B8D=-$1OY6J5#53KE??8*NZ+?RHF?1)[W'85N$32? 0P#X+
MWG9V2]J?FBY1H6&6)KLEN"_H=UDVKM3F,(85C1AW&$'W(3^6VKVW/0+*ZJ!'
MR9*0G1T$J'AW?)=\LX"!(76)K6#')J,U!S-(9O$+]45#M>MR^EVJ!<]<>/NN
MS@:7E\L4O2A9LR''>0K@_&LPH7 $R^<@T)(B$$7^+@ \ ,P;\L\3OC?_$94_
M4:VQ+LA>]:_*3A#$DX6.R:QK3!\8A$99'\;6!Q)Q8P'HZD8U)67IOD8X!"BD
M,'P-@*(V9AAJAC3/WE.Q11#BQYA]H!-J[M344H<1[111_@*!>NU4N>;Q,.S0
MM3Q(34\O0@YJZDZ1)^G \I+@>.K@!*,^21',-@X#*,<)CTQ7Y9?#YI !V03A
M_T)KSP4S]+6NJ3% W4TI?"MX1TDL!>^K@=QG>8RMSV FA_PHXP7+JQK";M2R
M[>-5#@%*,@9AXH H(J1X>%0(0'@7[!0D2]'#C\/IM;4'K?6!2>5.JGT-"4SH
MOL9Q:A_"%E'^B:/"P%CL"2AF$*<>3RS?'BP-3L5:3'#"%* *8%:2Z$N"$IBW
M071R];0 -#NH-^TQB@MK#5(W59U75]-;_:Z1@T<$?-VO\-YXU_&BMT(E/.YY
MG;;S>S-C9S7<:B#=?1+Y$_GDM=GC&V[^J'BYUWY*R$U(YP%=U^F@Q'H8%]7K
M^1O(#$-E([=/_""EJ!!_B. /G\(FHA W$/$)C)/R_C2".O'/?7[-!#%2VTLT
M:1GM3>4D;!R<D2+/5!Z_%H/Z!;E##3>TQVICJJ."F[ZF%V7!;EIGV6/^YE(H
MUZIT*O5*6@\5;I2>\JB_&@1G7*=;TK(MW6L&+PN?9FP&?V4OU^1SE2UXC+,\
MJYMVF!N7_K;;K/[[B7>0;#ORB]#6X3N@)J^!A!:5+64F3K+&<GU)T1':W_IT
MH&=$;&7<125D%$YR8D)[36HF?BV3<JU^R7SJ]N+A4XA?.7/\LKDRC>)YR_33
MC4<D]V5D\,P24<8O9-BH052]'T,U9.OVT5)Z!@,SQ$JT@SY?TAQUR$09TXNE
M6$/N9SW?(E6N.OM+%Q_'C-35XA5/">+1T/#<K@?,SFY6M:([(I,K+ >_Y#Q8
M.'# K1=MGH^>@NMG.'JWT6FW#G#::"L=8,$L;6W'= I;I9Z92OF94@F+4!P;
M-K3<'!^Y?N=D#4+]%@7!?L#C:K"S$++M0'FV%I&/5B.*5OP@-RKKI\'O^%U$
MBFOGY^RBLB'G3.B>:VYFM&VIR00TU^@X5 JR^Y!*D0-?7U'?"6\1D$.^FYVG
MJ-PW-UBRFUSR5D)TCZ16.WA/J4?0-"^.^-0Q(0:XD6"C)!?:VC)]VWR,AW\I
MW+)2=E<$MIR+B4VH'TU,%Y0/K^5X-4F%C)_V.I/EJPT747(U+!(NQB:GO+OW
M0-PZ8B76SQK;T2%:'&]H5TD;%4YF*LY[7Q]V]HCL/EO'=I\2?L=#U.WYM?W7
M?L+,T>><N@"^N$<+%';'K\A(Z=U ),T@@,6C '&LOU\?M20+\<Y874KX*:87
MI97=[VIG<16Q 7JK]98]1U.2_9C6UN5!*T "_3'I>'9D B(BN+L%Y&M%\R#:
M$IZAIYM5?JM]9W(W"7A.,6DYVKB;NZ:%97K8J^ =%_NR>3#RYT3L#)'/N<3D
MHPP PR PLAC^(W-YPE\H M83U2UB%PW#:"H,X1?8^MY D>7NA@;XS^S=J"!E
M&B)0[ #8/U/QY65XP^].@<E=87[] O65F<0)"HPBTNJ^T;?1JL/FG!]%;4W(
M!2-E;<9D)7=@Y,CF]X@8W\\L>/5^^JV<)*=/TEM#;T:=/-N42O%8QR5Q^",S
MVJD\8^!U:3SXO]\!0G$UL?IH-RQ/Z.B5O^CGS-\!/.QLQX9> P?I<MRQ<6ZL
MCHYRUE1&=JF7>%2,$H)Y@E.?W$KCZSZNY.(^((-:4E0)[<Y;6<>2;*@SCAO*
MYBFSOJ6T8N<5;T*;31%;3@/=@8U614=\6"V*Q0N1/)@4=+09I?:OPNSBJ7LI
MM23E8SW_O.-_WK.!1/,B6WZ4 DL/A$VASM"(8:)0A;__GH43(9/AA@6X$?_S
M3=C"!?N'\T2@>9#P2Y"!NA6#^[8WLO;HQ&83Y#X!6 0<P*[&^1T@%=I7O 5:
M^]JA;F>-(?KLG<6DTW&ZTE#,L53+1WLZB JR,O5?Y^-BH%%]^=98DI(#]/5"
M^E4]\W#QNOZE;(2+8?5&NXH!Z&6K(55K\_#"*I9F'(&ZS45-)Z1'RKA^XY*#
M.N-?8"!,-:BQBU>I[3COBJ(C:TIM>^^3V GT"9W/UEXAYV0]#Q0I+9Y_W;P#
M^*)'U,X.<.![I^#C=NQJE%AD,6[+RW36(O3[\J>WNXGVK/:ICAGSSQ3> <@O
MD6EC6/*!#]K[=C!,@U,+G2,N.,/!=P-R;+;MF-*""%>\ =5QGF<#(VMLOR=E
M+M:K8D5H,#OL\4FE@!K&5MQG4CO/>4A=[-=4,[M.$9,7QIJ8UU02#H^X)C%-
M)_9_9 V4T$P5<EE<&:-A3$&7.%X4<D >>'8QX,+T?^,3_YU>.+K,7<$I2:AG
MM,AKL#&(0;G$&;XO;_5 UI, %Z/&2MZ" ?:KA,T+KLY6+^'3C92;PQF9^1?M
MQ&RX9%8E)C/D()H%N\PA^+U('1XOD'$+"G*J45V\UAP3Q-_#T<%DNM=BHK\[
M0I\RWGR'BA7G9@U77D;%![98)E1Z%HMQ@T(5$O70S5+C]=!=4Q.B87B$1\3\
M\XJ;31%KYU9;D9CF5DN1F./9*/M(Q5,3]9A(J.)'1 Q8V"A[V; @]:F49F@<
MAF)@YFFC)=%Z &--">@;V(9BQ!"[Q9LW7U,L.2NEVQ+1:/#=7GO,75DJ@\IV
M9^L_,:J/U[4$&)#IEU:.Y='WDG/CN=KGT/2O62*'Q.RY8:9L^-F?>IJ<58!7
M:_+G$S4UI$BX]*#$8L:0R@U)<ZD3X$2'I=BD1H1:3BI\+RXVNS]+3QY^F.Q^
M\XPTSU<99-F5*%Z6Y!RGFCA%2/I^2AS+H=<J3<0.V/H@E\\34J.BEAD!=H5G
M1?ULYZ1/3^FDB9L65&*MZ@]^U]+0-?P+;$P:,/:6T%TDCD@^O!J1J5:8 V8X
M*THS:S_*O>2%I1B<E%N63UM=46D]L4R4C6RH[9)HUW83%C4F&M9_9+HJ_M3X
M.IR91(]/I1L'"H%53&)1]P$>;9GZ7SQ.GC17?@U45&^^<FF@#VQ*XB0 RMNJ
MI(F9OL8K&EP3Z?2K*D! 5O!,R*6&GRYX0-O/E;L=UJ<GHY=OEK.I-+/-P(2Z
M%0J@QBRO2ORX&F"'8@B.$P-LHF-[;^+H^;.A6=#L5\"G&9R7>$HMW-(T^M4%
MS+P#JL+KO)86!Z,G0"9.GVL[Q]:N75(;SPX<3>U&7A;F/">XVQ)FJT4F!1HN
MW%'6EV">#]&IJ>GL:$9KBH<B4)/O*,BR,=AWR+(MI1RE1O>LVN(_2;)6W"S?
M/X?P@E^<?%!<%@]!\M-;7*/-54E4 _J?$-]DSG"8BJBOJK;R] \5.;2F(Z:5
M;J_1V-G7Y91LG1JMB,SPH0[OEO-2YKZJG%GR+5".$_@H+>V=Q\ ^6FXYPRI7
M\KFE1!A;:H5:O@-<W(,EDJT6-'EW&#>VSF(-Z1/FUE9$B%%@3*QHB>K7L3W=
M_:,(/C63TP<6K-HHGA+?-Y;'OUWQQ"DM: %;/08=FGX9_<+!"?FD)_ A14;$
M:A0U4I'+XC^T2(ZX$VG?R*WRU[Y2$L7A:LYVQ:%JQG;-/XN/(KE9:[2>HIG!
M8AQ6CL"TD3R.-V-5-[@!HAN20GJ]('=G'R^:.>SJDL^%@\'1]/-3W/U1^Q5'
MI5R\I96C*^_K.V S:CZ"!3=79\A:5)"JNO3W,&<HCR5/9P>7BBNHP/U.X4Q;
MV;?< (WK%O]3-S8K=8LC>T':W+V(MP:6[5^GG1U>YPGO .BK##Z$E_-W $CB
M(RZ^<O'*I4B8ZUKC_>3KU<:6:ELOW-\VF*-YOL1+[7U-2<N%YX.W1ZN+HK?I
M7B^N=T"7X9O K5GGZ$/E-0UMO?GK]3O O?'A R%-MCK3/YQD? <0/-5K[[TH
M/\;2UOZ+W537ZS_88\*-_MYY_FN^_YO3.\![],7WJ-[KSY&YGO7^:2S\CT:Z
MN_[*?_@L>I?QY?$=<*7J%>6A5'GU1O72^\^*N<_2,'_' SEO]@Z@V^X<XVN@
M\?K[5/#5771.?&@JS/^I^C]5_Z?J_X]537_]'ZJ.X5K)!6SCTY(.4T-M1D!X
MB%90'=2F66 ]:!N**%OF6>6J$6\HM"R>]4RE<Z;-*BEY*)TL3Z$8QGC5J7:R
M$CTI5\?TQGZ2? <PI74\LCP2VVRO'4N,C%Z(@NV4!NLNV+/O.'V+,EN95_%>
ML;\S7 7IM;!4YNC>M=,6M(YK@RD3-=_"9;R72]>3KN8WR'"A9^P":(GRJ 9A
MDA&GZ,@^A'[5>O!P2*=\TZ;%#I4)F+ F3&J_;:/;YW8Q_EP@O$C\60+WJ%\$
M$7<AE%F2]^A+VYQEQ8G%C^WHU96U45.LG]>8:3VRZ5.P!$8&!]A0S'TZSE(2
MR=Q\A4>N+[/"-A9?,JEP<CEQ>YAL0SCTH<+S-,#VC8DX*E(T)FZV4%=OE-4J
MI<8.B@U-A^MR*U+=GW.+FEN:E%VV32KT390DS*WBB8UQ$M<'L\'U(Q,:P_0-
MT=.TF>02#FE_:<_2QZ58BH^K749,O!52;9NW<C45IFP+H8W7D;>JQ*EDR#;+
MIE$@4V5@JG#:#&&.ZRK3YH?)%JI]48X-V\F;K[/D/+1X!XRM)_ 6H#6**'F>
M;M'Y=P0_'IN7LGA@<8MCMY;+$AN!Z#A^%_1%/,?OK^7ZJ1OCWL"/#=E(!Q.K
M6_,H6*=1&!3(=FZ8EZ85S((M?%6.8MJN>J(TJ-0O*!.S%Q:G;V@T*_4.0-$8
M9YL==K^SF-Z4)D<7AFL%#\_%08GU<?V99F#_V+)0L][H>,N]6$PRLK#6..Y$
M R1"@P1/LQCQ:0(KQ7G=7AK4!UJ:S#0*UF@DSWV*BLKRYM0!BX$46)A)D;!5
M>X&U$)^F54F+YYC QZ'3CX[I2[LH\:(\]%NU?VE]!T1/RE%8N*T=[AW)3=/J
MSU3\6D9=ME0A6Q8O3F$4 !N1CY.1XCRSY+T3@[EN;E!]S4H@;0<VR49>?.E:
M.]M]KFM4^EVN/]V];2B(W#LKZW?$9A:NM6R2YCDC;; <OEZ<*?)@9N"\C3X]
MD)#-..:I^G)Y%7/$&<-!$G'RK->&9=M(68A18NK*0B=]F%Y_:+MQC!QW7$S%
M@X-C<4E6J!FC=&+VVL(C0N9BX$97+9DL<@MI9LL]9HPT!'^"@R-W%Y)C*3F[
MF]!2GNA%:GIB*"@;]K74S<PQL.74Q>31L2WGIF.! S^T),99ZNX;!]R=X.??
M FV-W?@_*P5IN%AJN8N%^YOJC>K,:PDON))8Z) ,\%A\IQSZXPNE[1:5 HPE
M[UKIOBQ+F[L9VT:1RTVOK]11$6(Z=-$\]ROQ:TJ/#L%^9L]"(*IW2-UZ\S7&
M0%G3X/%NK---JB0.$4E:D8X![9H>.*=J$ 0'SWT= )R]X5@VS-VFJJ<ZS-+A
MN;DE5/F5JHN"]>X)<R,3*$:M,DO-LB6B0,J4)6,G@;5?4EK6P[TN:,\AO9KO
MUC[8Z:*^ Q+RM-?S.A5<G<G,PIU"7S'W3KW0RKM%V;GQ ION*L8R,<4QL&2*
MJ<2Y+Y?:4=<:-),;OH;ERS:5X[94#,KKEZW NO^%2Y5**B^<SUZ/U)U#NT_M
M4ALAG"8LJ1H>_Z GREQCUJ6GG2\0VKMTI8IOVOU>R0X.H=KGF<][G3W_@F@P
M?_,/OO\3.9&9N\6@)3#9^5%-%(8TY;NJG!PQ,%4IJ% L?F7)JE&CSKQ^-*@(
MC48Q)Q=3LU!R8E<U=G?:P:CP[*6M/="AE*XZE<A#P3[:\JHT[L+T*XZ(993%
MWC[!=;L#>=.";QW?Z1*W4_:FLKS7:#H^.T2C\G&AYU7I^%(K,%+Y\TXYC;)Q
MYVAS1QF&H1C!#5&^!Z,94)R&^<Y<89*AH,Z5P<S/.A/)TO+'32Q-13%DX-U(
MAN')95ZV'J$OL2DIZLB@9??<YL_A+ 30"X1^[,47;:NMC=.?VQY,,N%=3>;R
M%L0H)6+/_.3Y@6<7+O:4F^%E>8APYM)(SHW;F4$L5%8(9E39AVK$'?PVH%+7
M(YASZ/",0AAK0:LEP546CL13$-I=TT5T(6TR+;$#+)]T:H$8KPMII$G,(84/
M,'";.-8V/V>\.2)17X#S;42AH]+HZL=.E^(Y'KQ<:.AC?B];9.'BB.WPN#AA
M\3J]X&#3':0OWQ9NCB?A,N$Y15_;,4G7%47"UW5_$")SR!T5&0]?+0$'.0[Y
M,5,6@K@-+W)59@L6ZLEOVZD4TP0X7S/8O].*!USU $2F5G:X&II$E(79S0"[
MMQX(??(O<N;JFHHZG0F_@#JMS]3?"1MT"27LD!XU<MPS3!\CU[FG((L;@V^#
M.HC5'TS/[(R6M0X! 8CC;+%$F&!)8Z&),EML)Y/88EFP&R OW^=NGJV05!]*
MO.HV'BSRXS7R;)()%0WYT5F$"?.$*6UB#XHFQ0%[7EMFSK&];W#5<P[821M*
MEV@KY7D+2'U12\L4"DR, R'E8<$@UKT_?@;IM*J :A)M:YX'O @5+#8&$5PJ
M!I23-S;!P-H S9EJOG)B/"YJ#H"P4U:P0BS/@=S._Y?&VQ 70F%AP^@QP\;X
MDW#18YR/U:_&-!NN.1%1J[6E[(7ZDW69,6<=U&TN:E;Z^"INP'[!)JE)4R]S
M!8AP%SD8DTJ[.8Q1#-]MX.?DP^86E+??H_H=#-]_I;GL&3><7+,OKHII/A)D
M2,NYQ9X?2YI-*CZ7#'V@:%=%4F[$]SEAT :Q[C2KD"%5O7> 3><-H;9RO#L:
M7U\GT=XUF^GL.P#F94(L;6%:Y1*US'C"1F9Z'@IY29N9NL*OM.(S41%1V"L_
M7X*HD"I[,15+<_VJYFQ]Y];;OIM69%&Z^#R9;OT0X6 N1?<+@NR)>4\:3UJ:
MZE&/QJ6<2)&[DA(S";+<7[D7\)&;C_=#<=7P_-&/CX)WLCH:@3A6%'P>Z!3H
M?R./];%B_3,P)J%1 816;K%0P8!A>D.$-T+;X+2HW1-\WD\U$7C+:<P]M89:
MUI)W -LP(A^US@7/RO/X^91CI1SJ/$O!ZQ#!+/-PO:H?(H*C_KV,:_6;4#$W
MM%U*027=@S5/I/B,SO3V53:F_OWJZP%OX90K^::'K?E0NJCLVDNBWDQUEJ2.
M+#8+$(A8JU>PE\<_*:?V#8Y$>%3LYU]9F+KX+[1]<"22HW]G99CKV6B^HGR4
MJWIN G5;B^%[C/[,3(&9Y0@[!?)GD@H0G35^%:9_>;')H,/- 9JSP)@_^3J
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M('J=:U^O=NU_:7$M9<K(QU!\2&C_=:"N6T1SP2Y7UBXJ^\ FW;6YL+)Y63U
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M?T'C'\28_?0D/"=OUFC6F%_@RC F'[>G)12'J\X77\N8*I:+E9D=]WFR)]=
M(0L70R0\)CXV4Z<5.;&UR[0EE/RMY<;.#>YQT /Q%MR&1:J%*Z0Y@I(WBMA]
MJ1 ,YAT?PUY]9.?.J5D'YGSH$Y8 J_PTZ6XQ..-J>R')(?$!XEM$5KN;]ONH
MDA\J/('6]7>O[4='N;)'?^$SURV@2'"/(9A<:SC!<9,R.-1XF92!1G_+;HWA
ML02:;G**8]]PBSBC5X<]H*69]K0S<&GC ;#*.N=UC^D=R/W'E00T@3SX,U7(
MHRR#J82E4@$![C:PP+ PZRFC+;>^5NV&;-9)#W*'"H96%7;&FF#M=.Q?9&#B
M5F] TF0=G8K&Z8?H\C8U]D).>?86DZ6-AIM,-S5-L/*E[@YDZ3X&MC :"8(>
M/=NYLBVR*[/Y>151^Z:?3L,-X[B.WL%@]6Z[;WMP\ARRXLAI8H8BYQQ*G*AK
MN)=>M?KDU$VO.^-0#])7=.1RWXM445Q()9@7+D^1MHX_EAY_K[1(=3]*E(19
M[08R$&C9V[%D.)SPL1D_\-U[7Q0CB-3<Q4/2')0O5#"-.7)N!#'B940KL94/
MC#>!LC639[5$17K)BQ$*53.G3'I3XK9.W5GM89>])R8_KH/RP#<"4Z0?YR@X
MTT> #X!Q-*#!.C_.&/JAISI'82>.0\M.D8O1XHPO)>T3!$%%X*S/ ^"//0@N
M.3]GY$2JO]4K5/TV5?K5)DU5@SGCNNQGMII3!=FZQ$#(M;J7!G+B7JY!H\=E
M9ZPLT-7H/#"/@(K#5> M]1/L'9,*,P7@K+X97MBH K7B'T.&#F^T)B-SS"+0
M+3SGU\4G$"DH-K=1N'C%R:[]-?.%C,0+&9'_39(UOIVYF^&M8P/S77G11>]%
M5<8HW6AP @KXPRR6_4]K8^4>W]@5+ C>HL*J"/K;?W-?47S9.@LT''R5(T6@
M>,,L@CS*>  XTO!)U#LM,-\&A+=FNIF]\_[%\-E-AL**JZ#)KYE25QX[2,G#
M6>V2,_.I @]OM_VGT_R$K9:6]FCWWR/CFXY[R0,#\*7* IR\^KKFTQ .KY3X
M:@Q\I4'RO18,O[2^81"-%][N3M?!F##J(]^&)BS"U4PHY8:J?C6KVLB4(YBE
M4I.",0V8O%X\I,DN%\6%*D 9X[\X-T>Q_IAQ=E66QN<^82J87HB5LK<9N-0$
M-K2VB%=);9)<0.%975@'G!1)"U'QWU\Q..8IQ^$UJ1ER'SUFF/G 4-*K9C3'
M^!$!JG :,RL96-UB%X<?N8/''@"ZG-?3<_O@Q?&!N?7P-PL2&5:\]R.E!>O1
MY*B]S?BIB. 614GVM9,+%Z(B;@O-=W8'IXKIFD:N/0BS9BD$5]Z7EJP E4I3
M':9ZWP;KHJ6&56?774W]11E'C AM\D&IV0EF2K\,ER&-.+&&(5=T]S6)6(ZR
ML,O&]+$H':5*;>0N8N$.N-_BRLE5E6<0+A;FK8@G#UL]A#>'>)YY9;:H?("J
MSF][J+ZTRS4Q-.\/:A)S1&^47KR]H%4+^#X]EOV&3<1F1,'F(U3*Z#"ZE@PK
M)/.R[\_PFZW6]J1?%VH4LX-'4+"8NV@,2(A*B'GL"_Z$OJ>2W*V<KUN^0RKB
M)^JPJ4O ?WJ0S2.&EOU3^ML]N[Y\?Z9KCOC$&Y@HM;BN]R$N!QLB@Z=1RKAO
MPR4QT9W\ 9#L=)J$\<&:Y%BT#5<__?"3=[_R /],>N(!U-LT6:7*MWX!&8ZC
M%DURH*DQ50#2=-)CN(6=UQ?4(^9\.D($3)3A)XN'3Z?Y(*SQH2Y-+]D9*K_1
M/^<%;0\]Q7\Z,+N\B$6P7Q)P8M"R*#'_.QIJG/4^?6=B<KWG/>NPO&;"9;P_
MU+9"RU.O;L?>4;^U0<7W)R8T$D]BX$V("!"V*O"2<(F]F#%$B'A-L%ND>'(]
MI,YU"5KQ'74QO0514W-O*]!O8GR<Z=Z:YSL [%AIA%58E;9%'NL#W<% #/0/
MKK ^?:CL1Z=DSRS]I]J9K9^63TS>A>9GA+IK>L;4:#H!W9@G2D69-8GG+34A
MK;E-A>",PI0V52V[82"WIXE&P<<=<?&?/+Q*?HV6[%#Z'MQ&XY6<^$S+W+6(
M\Q*@\FG4#/N5):7A"-LP9X9$Q+'S1NA.O4BE#WAS<S-J876A$E*8(ZF*%!I0
M6M5IMN#(]1LALV&>Y!99;<[-_YX(=]T=KPVDCR@++5P@;^SJ\.1<*-B;K.8P
M-A8H?/OC'4ND#:4QD<KAKJM([VM932W7S2N0%:7#W;SCNTL[7-+T!$<OG^X*
M>A#49[X]LBYF*B]H]/J[:C5#X*+?'S_]Y0/@:U7DZHM,*.LXRB[E1H'[ BSI
M@.]_HP(%775<8R4[+KEN_5X[[:PJ&6"]XWA,(VDLVG$L*AJ@2K%*O0N\01SJ
MBG.*U_L,K5I;@'[KX@]-*@<1::)S&SP 8G5OJU"A[-U##X %JSU")"MUH]EJ
ME>(-_Y-1!;"?0$>+^OTG%'4'[4"[%T'29(7M-')>^M1ZN]FGH_&\=!6BKN0[
M?D\V6C5X)!9IKU1!YJ 2JS6/5/6/QI?D$/"VZ>8Z\D2:/@#R5D?R2UN&EP:_
MG\M'[/'A C8EC*H6/KGVF>C/&MM-M)81(1 @@F1\KQ9AG!<'/Z6>X%"0]P.H
M:,.E.-J+*F+Q[9NM>KZ4J#Y+7F",9P(FR?$B7K'A'RC2HR7N6W&08[XDG^F@
M@MFEW#[)RC>U$XO)XG\3;U1MP49GP3#210B.\ 1@NPXMXWODXKW0ZWF]&OMD
M]T5VFH4;LJ#P&?$T($3 8;TXWLB:G88:X6[7^6M7VUD)B^18KK>Y]ZM 2?E%
MAA'BFO8 #"P%TO$^I3<[-_?<4.,C^V/+&XG1%N[1FL8=6X5&\XQ4K4"7<T$Q
MJR[B:4)O5)RP/W.-EQ*S],R#@0R?W1\ 1.UT53]]100I#AA:8>DN&-&4H3S)
MF$E?V1!!N,B9N,<!%C)/K_=6C6D(Q!S>(6 0EXJWKV 1K"0X6!\9^G5O5(#D
M5(&D;EVY3Z1_>AERWW-$OZ>T!ZY-:0Z_\ UO7,"(A/U.BJ'.A5"/!:M4WSR9
M,NGY_.JXM[?QWL@+9%%DJ^<Z*#B:X#Z@TFV%XQPI4<OPQB)F#1H*8!W*7/W,
M??UE=;-JY<S%@_D+]TB*%7U^"HA#29D^D2]?W"!*D3+I"H/M-0<D';#<86/B
M.O.K_<EXO=%C;I!7($8-F&?6AHNO7)POLPP_DX>>Z;-4^9=#[CO(S3N,Q'_'
M(FJBL2GPI(</T#/5.7QGLNNJ!=-QZL,,WWR8YDRQ"/WG-&ELR:_A\DWIO2:Y
MYC\<QCRXYIR/<,TQEI]OLXVW*"G&77\//&^()5_A1:JOI4]7_?*!2F&>W0^W
M"8?>?#K0(X#RE[073O*6XT&%::Z9!9N-B_B]O&IRO/F#0G<R$R;.4?6)&=L@
MC.9L_S57A 7+K'GT?;=_@,8]6S+*ZH96,+7@P+80NA&8M@4S?TKD4()50D'0
M3R\192DINL4\02M'>2'A$S'CC( -4PJ3 L7*% ;"L,UUG%TE3S])(NUNC";L
MQ0M=?AA'%V:TQ^Q7%$>?$/F<C&YH:?B6;T/RP8I&RX^7? +G@F*ER@>C @ S
M65^]@E7:.Z2O+7\7$!<B%D>6V)EOLKM,#;8Q 7_0T5PN%GH$(-XP[CG[^WP\
M[+\(25+U<VVLED6R3JE,UM\,)(*7_S]NL?_'!? ;717P9I_XPS$60_9DYQDH
ML!O$*I1NRY  '6@#2H!B.^[Q2E"TAN>L8PT=6H</ .E3LKQ>8WUD) [OT%:R
M\;IBMHSEPJBF&,L%<TP]%TCOY\0H"O U+^R0^OU74J^7+-1 0=7BLK:XV ^_
MSS^,F2-^OKWFD^ZX4KQCO\U6;XC5A13?)_>-L5.^)-OIO*ATA?'5<SHN 2FE
MIU61G=ZT1[0K- O^F)9B-46%1PTW6<3% Y4MBATW7B+L!W:^9W?3/R[E5Q17
MEG;=3!UVE7W;Q-TET]TM5%8,KWP? *;A@5D&E%^R9+#^VP>0>)F+/OSJ,U/P
MK8KN$AZQQ3SMUFRLI7;^ZA'9>T8205MV2'7U"8=PV:7_:VW'-4\I.=0QZOG1
MQ([)[_*"PTDSJ9QC0J["%]I+DJ3G.U,^7J@&-CL4C;VS==U0O ?K5*)/"8H1
M*7-1H!G=MFW70J;R;/A0>^QJ&^G+GT"D1[&-UQ[W#Z1YY)3[WBE7UBG7XA]L
M\W]"<12UMIZN\I(="2]ZO5M'GCWR+GQ=/S?PV: /Q>?E++JLXR8PT8[P?CY0
M/I7<<C.?#4=W_  &TGA74@$%:C$(Z;^NA?)C@T6Z3E?EQ9^Y-;A9S:5.;F[^
MZ;='%JJ:QC4(?Q7?/?[77K])R?P?D?T#L[Q^T\G]73_:99=1T_0-]ZM82TXS
MY";AG@V/!E-3S_/N/I[/K_0!X'KX8^2YXQ?O!8XO[M'(3:GLB%S,UW,R1PFJ
M+0>ULQJQ;#->90&!T]V=%XR1[4'/X'($R0^ NN_=FWWC[;\?W]!29M5,9: S
MG#JS52ZNGQ; LI3YKJT56G5B5GNF=:*S)B58N@P5N.DHJ)Q<33I74L$*]O*B
M7.7=$Y$+W(WS&>JU;3!2X:=RG,4 ;%,!F\^FQ!CT-HA[$73J&E5@A>ZZ2)DA
MW).^[G@DVAK/R&C.L/LYU'$[[GOXIU0)AUD*2\K/?6J>U7W=MD-W::>,WY6V
M T;1YQG7%,)7!6S&-1]?1 _4Y3KFZ9>"Q8AR+PMS9%_L&M7"&FK/I$9?R&_U
M3:C4R!XEG;0K].HYX->L+^L4?IR*U@97\ M%LEQ\$-#7+>.WR0@GEPB9U/FN
MSG(B%81,8X:_I-T^I<DY&XX]?@ T!X9>WK6G711/;AE7K9I]R] 5C?2&S_VL
M6I54+'!79E,>>EX#-S3!T>;+)KSI]CZ-9:\3%+)(KK,A4,HO?A8@7/S,UC#N
M6U ^>O?_)@9./MG9-_G^[+W[A=;-)=(^@41QC]P'*C9 I#(]8Q8=O:,"=LGY
MV+&<BB+-(6!@;GPB_83PC.3X7MQPO"+<7S/=-'N_0R2[4DQ,X?N964#9A5B3
M=H,R$OMX:$Y*[FR+MH 7OQ&\+B#]X1G4ZD3H]/6SY=-4*MB^\Z=N6QHCE>RK
MAA9'5(#N*^,98UC]18<3-R]C8YQ)OBS1&-2QQZ_R61" B7 XA>JDEVJ*H8FJ
MJ?PPA:OYYO)W^!*?<;/!'=QV8TD+G*,5-FT5_+'=MR?-_&MP#>1-BRDWK]XZ
M!8I)M']Y)C=WACU1FYC8./N@1)+1?F\[A@(H?MINS31NQ# ^90KWJ<N8+&<,
M9J3#K7U3#4]]8<USH,$0[*EUQK4.)W_46^2S7R3(=+'0I)XF[V9O-= RM]A+
MM;R:G,&N,.,Y?H@R)#F2T/ &440YQ5"\$W#0?)W(F^Q*O)%:EI.F7T@*C:$A
M\AJ#[E\8+:FK5,Y@?<W4:392I;7\,L4Q[8U;?.8E$=E@040Z6Y[1\#QUD-1]
ML)@^;-ACO\6F><>^Y6 &,I99TFY_T3&"E!ZVB_)5-3P#KE#D1STE<V9X=F85
M4JDP!ET[HNFI3=1:L+_R'!^=Z3M?,8%/Z)G,C)H(;'O$[<V\@/1:2@08Y-@[
MKD14#75^5L1(ZER+.F7?/'LKU[G"MGI\Z18&WC0].*RJV_?5%W,_$4QBR^P7
M:1* >JJH>C#E_/+2Z*GYZGQ [)0$?VZ_SLJ9R<T68*IT5=SUD=S/1%2[);*(
M$8>I(84M86/JKGD;86JM1H\I(:G^$9YT.-7";"])VIYR*K+WU5'0W#JM :3W
MO@D))Q&A^\H82=-+CE7O^KX&7$&&*[4A+KY7U@ 4G.BW7:B;^FFQ)FL/MQ?O
M5E3UW_#M5E$5:ZB *4U6C_VR&R^MW=?AHF2,-U[NP\+=J2;"6MH2/..?J_>P
MJ@+[^TVU6X\IJ#9V0P^7V U919#)%RXI@BFG.Y9C4*0:"M_H%WIW\NFW!:(!
MLDTT?2LR%S;B;"-\WG2-,@W?&D3A[N7,6$"1P/'YB\L$SZ04/MV,$!^3"H:#
MCPNP9L'R=6OX905]7>M$OBQ/#1AB+WO*L[;5K[?<H-$-PFL1,8%M,%(:>'=W
MF*0-ZC!^FM*(T @3%F8?9CHL5<#9.]Q>J[T0G!+&63,3&UC5>MZ:-E]P&:Q+
M-*=)_*B2F-#P,-2[Z7M3R? I[/X Z@2!C?1FB+JRN?DEE72I\4:73SJ.>Q#5
MJ39X>-HB#*%G9$TQ3$I*]A\IN'",11V.GWPBW[=O>MUDZA+]?2)D%SJ]E;W+
MHJ4!82U1%=0!D2:T:N[.^%X(A-7YYQI[QQ#3J;/3#S)D'M%3S(NA9R=5L6]M
M;7K6-_GXW*;>O2EI-JYI :=(P^'S#0<SD[^UTB<[,]]AX:U&QEGCP(G[_UCE
M;<P ^^SA55[WX[BI;A;$W13MC6O.Z^!81E%M?[,5VIUL+\L44&\942!_.O+]
M4VV+%QKP9U%Z^9IF>>O]9T)W+<@M[R)NY>'4NDH8.4D(P[@A&,@*>$IHJ,K<
M"*K6^M?(='-T&7+"5;1RAX==;IW^8^#R:*"CM0%K.)P[!<W 6W/@@P4TW))<
MQEGI)0TOA( @@-[&^F>*<'I8X1S)X>&B@<3<?5GPJG#2N[C2/BJVL">_GMB@
M3[0_1WL X&%U6S>FXB.M_X GNIMWF(2AU0*H5R=07GQH"E>I)-QH&6M5%:"%
MS/'3LL#Z<MC*SB_A U7UYY<9:T3.1J,+';2@Z0XD?B2,OW(9!H@OFX71G7P)
MBDZ\(DNVIRD3R-LOXE%6[B(ZL,:=DVL%-ZZ'B:Y^EE37NU9W>@!@PPI6[GPC
M![=:M034_:7AU%ST.C:RO#KPL#7CV,N,;!OTGP%X]3._) -^7+U3./6C+RPH
M)LQ)7V^MZ>E%YI$Q2X2' 0]DJ!M".]8K]QX %\LYMX]S9/"1J4&QLE.,W^14
MD! F+-EN\Z^E"3M@EYW&['.T5?!U^$SW"ZD*K]4V1<V$7[Y;$3/*T45*]&A\
MTL[?-FY<&M(VOUCAQF=UI6Y\%KS7=SO.^;ET@5JZI;X ^&\0SIM=*9[FXOQ;
ME'%)].2J<E;/GAL(:3P7?#\'?)J@+V033R$88C5K(9A@I6\AF#5 J<G[EUON
MCVO_3RESXDY##.).[#YZ.#1F;PK[E--1J(7(9,"%@1GP)$-XF;#X*',:W%JY
MI-YW86%CR#N'^CB=_EJ^++S'0_CC:8_XC'R,41K\>SRY/NJN6N-@/J?SD;UH
MA8!@X<7,!^^CZ/.%_B>]-Z&@D&R<>9&JL@'(7>DW2>_D#OK-LQ>M]24+M@,/
M /[D:IUD3"XI1SGTV9!@:;%;?>43/5U?P;F*T:S2^8_C/HYM-,75H#'% 5[#
M-%:I0M-\6:.<JHMR.W'YNMJ8.D75Y3DCM:8@+8++N#(F17DV);C/(5;"KHAD
M67#^\_P<[813^):J6$>;'=RDVVNJ(% UUJ:*X>)O.$;L'7KQ?\8SRC3_>.I*
MI/&[#IB)/I'XM16:F&$.VD$L I^=\_\'JP7@@ HW-^K\CP:IKU[V6_X.O!@U
M%Y4L!;MZ&@5M-%<V>:RR!G2_+Z>3;":C78P[UZ;)DG3]5*5,O";O-AHX.#$D
M#['%"JNX7V1LBWM:[L-ZJ.VI<^A3T[GLHN5E@+#A[*WI%D]A3 4/N0)W@;OV
M#:!G6,6?].3N, (=,@-0KT]#IIX^ )@<42&QAJ=[VIM^\7-.FX-*>U-OO\ ;
M!V97_>17S^N81OI"7JZL4S^?TIMJ4Y>_DA0IG=ZXHNO00TP,G1=;W+3=9KB;
M(/TZ^$=>7/-R]#*< D49;A-,7?8-X712L]#/?PZTK?38R*K<%C!VE 6I:F1B
M/Z"/?B];:1VIGDNR\R/4BH39M]Y_5%;@U1J%^&[5 Z#@ 7#*G%MP;(5Q!4"]
M;YT8I;[LSD>[[,Y%/XB4>6;O<PYGC-(3"N8[5=Y=?.]$KI\6_EA!RH'JSC)/
M</M=<-)-7)ZJ;D9H!I#A?,*[1SK!\MS$%>2DGGRXKU"KZ&QIQNE)D&L9GY 0
MI^9_\AM79QGBJ.-T;87Z,((;+8\-FXB^./+L>+WD8+C,\;?N$S:F7"#>4"VB
MRZT&776/RPNS0:PJ';;*[%A]E&G.NHONS]+L<_><K3V4M7SE=HDWV65,QA=\
MX=HB1>HY:3CJ]&KKNE&2A+6$VU;]>&_;5:-\&9EDPOG=J2CA] Q)*$4F^,,G
MI'U,"?V .)S6)A?C3A[ #&<!_+G\N?OS$.#__3,A]!W:901 '?J.Y\]S;CCK
M5S/HNT?([W%XEQ'O"?_Y^IEX/HR"&>#Z9[2)NC.(GLRQ#R!^]%)K3MT &W6>
MU?+U6(1C"G*EQW9S>WD3\-'E*D<<L7_K=8-22&TL'\8D(^[TRI$).]M&VW.+
M>,^IZ*7]U::#>DKSHRH9I*E, 41FV?CW#,FNX&>*K!DT9/HXYL)0\2Q#/M$'
M(OXDG?P08F.%%M]#3K/\ ,@FM!RV)5T];'B3S5VQ0PB9)\]@$MH40IW>/0"@
M;>0!DMA5=IE3\AX=VM8UIC_V$5*$\X[MO3/W-IG>2=/;MK/[YNF-A@*"*\EU
M[P5?@7/EU^WB.$I*GK$( %;^1S#X7ZLT*F2(K4ELK,F>/P ^FH5O9S0] #QN
M409(]M/^!\ /-=OA>F'Q!\"\6,L#8)FSXQ[CEA$U\:4!WH!2I3U#JLM531)F
MODQ#QW\!Z$R^%<=Z$Q],D?/!(D88QE_OK\:N]$-3M5OH>^7!F-<'498YH:2%
ME R.+\E:0=U*0Z*54KI@ZFIY>ZG!E";=Z+>?!@7>F%.!>7J#[6$\<\JGKM'+
MN1->V_D=<F#-A9XQC:3\]?**J:HS4429+Y[!."5KJ/,7>Z.O0^ 8Q]?Q?JT?
M*("B>LRX8GKNQO/&190# RZ>L;-C2_V>NR[*/*H*3P8..4V0%>YG9_2-#4\E
M:D9?S$OF6SP?\HJAK1F0S1%2')#(?634H=PXL"/20,+L]2&S:;J9L3364E1A
M1M6DV]:W8.!\JHV2?VML<E[L\,MPM$Y!6F(O_K.H#" )83][[@WYX4X,NX[6
M@MK(\)RB-Q )7=R1G X/&-6KGSZR(KDT@8% 37C79@<-9*1E#)JIX_P,84 K
M/0NZT#=Y[^@ M2*,08*198/DPX65"RF>24V5%QT*,.$HK@WBB5H]_P2O>EB#
M=9-C[\_8XKFWE[@,E$.P47[A(]RM*X=\]E=' \42^(\^51'R0BXB-'^*NJKF
M%WR UJGM+ [73U[QD"2]B*C/"&_S@":H%ZE]K<J_5C*R)?0H?QD-*V6KY:N.
M$3*O8'LT:\U #<D%7+S'BE0GP&>P4]9TY$L1;ALS8+=M+]WZ/?-+Y9DISX\]
M:XBNGN^.>SD8Y)U"=]SUB#&)GD"$=YC#\3V=@@&&^2E04M&T\%OW74F!MRTK
M\V#A[J^>4C7')YXAFZ&,) *+XYN^#,W2LK_25;YX"[<Z1+,9,0P4*J38H/<Q
M!M?R!3]JE #;!SN#&CRSX!%)E0OMHQZ.4>>V4U&6Y*X]P&*QVA [-K(9N*T'
M ]Q+=U^,_5.%[@=]T.HG^?+NCW$K5!=<$%8*4\]]!EZ)R1XVB<%DUDJ@H;KU
MUIBW?LF(EOOZK@XXHP)C!=-;$6IZJJYRQDG:L]"B2C(+MCJCD7?G?KXJ\AW+
MW0IB.10]\8E<Y+SR6D'9MM\$.K5Z'N6EIUYVZ"W(K#KN4GAC248V*')WECT!
M!5_KG<*DG)./WU@;<.<'H10[;=%%V5LV.G^$!/NB[9EPX6:^7R_0Z-Z^2D+4
MGQ],;D4#=;*4)ISS*'H7H^$A&GJP!B^0[:99NB@#-I%BI&595NK-Y]WHN #=
MHQC[RG>N]?EK'[.S-+?OTWZJV>4("]"+=W>[F2TXV;)[F!#DI\7:36YQT=.^
M?<<'ZB*N<R;^@,1\FY^;N;X/!K7WV\V.M]0N9 M7+::] 0<2'P2=2R]#2&YZ
M=+#2/CJ1"1YV#92=PA)G^A$/ #3KL2ED-XFJD]4?K7Z+%))*NIV,)<@ZS$Y]
MU#27(9;AT5EN@'E1\O16YK^H&XDO3TSH(MP-+!TIJ.58:78[0ZXC !'B>#:R
MV*O1&,8*),0.6+7F?AWA+(^T&R*8;)^1F*#., $-=[_P<WH^8Q^LAJ6MR2NX
M);/EDDJ5R_1+9+=#T7!M+\<&9G#P5?BC!(*(Q=$G^=$:0PYM'MF8QRQXRD:^
MV!+1P>7?^PP8!JC(/.UV(FGWR]>_HH)-X27L.C]6;\K%-/H4/U0:P6 1O"+S
M7F09QJ>(7K+/ @A?9#?7)=;O$J4C9F&>7'[BO_T(K<CPF^&R'%G62_BIMVU;
MXK&<D/"S&!X@,>#,RK'O%:^"I5:2;"24QALO"KU_6SP=4/=O9;'D\X:NUEG^
MG=RM);7KJAVG8ZIV@'[M+Z?D?,5G3SI(KBK?(Y3_S\3N?VTJ\_91*IY,<.H3
M$I77-%J5O3!1B&FA9<LL6\CM]-GIT>T?AP:$>G;[-O0E5CT+7RE]^==U/4,1
MTU O.B/ 64@GS1I&P*O$+]1"$DL]R2[?Z!B GV,0:"+]CNI4MU='X^UEK!'K
M)<U7R2FG4FY\&5O!QAUX4P7^ER)WM(DD>\F<.<8YI]*XMQ\J;G*DM=KA#(9)
MEQ$?712%2X'-DI"9>U1CI?+1O"U-%J:M6=_!/2N.?9F@Z'Q0_RT++:JJI[;L
MTWC=#J7?Y:N<-@.$XX<'@) OYZ>BQO^0""= Y 7 620?8V#R<W6L)F:^3P::
M+4VN5?[?I):21Q9*F,3_9E(+&@LZO];4R_'W9Y64M L:5ZFW+"CKW$-[I=?#
M<.GC3N^,MJO(K4[D0C.M_U?I2V_L!P ;^]@5SUYK!QE*R2@KJRVK,L01(:6C
MD>)VE4%3=,.R5ETIS*H3"*;I3;73.RH>F9 &')<AIZBQ+J0*VT3D7[M^5XO]
MD<Z,8+@S7KOBI4VDB5F[*;V0*D*?;BJ;7#>.7T!AV])D#$4'7<\DV]9T^KT^
M,?:13S"$&RN23(@IS-)ED7Q=^OQ$SD&\-F![BRIB^=?4>F2T4%-EBF>*V4^M
M#@+%;.,STR-U891BHIGASG0#:9R<GZ%XU<60,:\I'[;3\ORG\_.NS=8=ENXN
M!2_U5?]V?^Z:O2*F_'F'Z<4/\08[5:7 HOH3TIH>:K.AGV2B VEB61 LBM'A
M$06>\5BH\]85T=C-94?*+I>MJYOKW4($[.FLB9P7QTRWX52J7#@NA=YAC6EL
MRPP&3:=V;U))D]J(-*%*9>S(AM!$A(IB1[Q)>T^S[*Z90S>"YS%G9W%_EQDW
M;"PAN_4#F%^KJ&YK$[F!HATVZO/RNX==^<;MFA+]SF^&)CEF=7<1.*_J=HZR
M_2KY876,):.N9E^4]1/,4WICUEVW8=K&=2X09EC*KRS&V=J @!T="2[73GR8
MW)@8/B']W4-!+H+1(*K%K(OWV27S?GXKZD.BB2*6M <GK=>4V> %CVL*&SBV
M;8K$_7J?:[DYW7XUVFZH>B4X7.>N7 ]R>&M^^>B[D)V:5EWLS_$]2(-1$M._
MVH*18QD+5'UC&EC0-_!"(AC"\/B1%.*Q>A55PHA6;6%AP=&2/LK'^\E13O+B
MD>O!!2S+5C*?9XE4I>KB5^-["$6?TW+_C;_H,OJP<>+[98AXB9]Z0T[2):.H
M('O/-&+HUW7($Z=] 7'1K .>6E*"9.NT KD4JC@B#K2<52<'G\D#->[XI:&+
M6KA+R8NDW0JM^JIQ7K? B*\/  S9W^HE.V1NS48*X%%*?E?PKY-'KC[A!DU:
M<9XQ_)G#1FID"77*5Z@V["'6'[C1=BJZ-Z8=5MU _Y$-J)"U$DBU2F@A)(AT
MI:%2Z"9PYLAKA+WO 9#B6"3<$?CEO&9SX<P5L0!;A^=["CTSE"#KAN\D60T^
MGBTJ"QKCG;B#2,2PCHQI.&?=M'/!3,R2@CEA$[HJ3GP+W=D93PH(@LV>.[&1
M>2[BL>-;R%V@U:KQYZ1$X6_"(XISBP[KR_;OS$;/&96-*XW;3^>HS8);%4&0
MI859R5W)1'W639Z]J51I/__IWD+UX?[M/!U9UY"<1EC'6E5R+].KA!(20=K
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MSE,99+AW<H3TS@XSM=T.^\]WG%L9H"%#B$6,QE:O1*JQ*P/]@R6A=D')2:6
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MME3(W>C!;YHF"3TK-HG%\_/8K0< 0,$S<L4ZJ1U1:I45LT))!0YL8WX /'L
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M$G[$:=/D4G2?\V+)\KR0ZQ',X-3QB"#$GN)V'('_0O40:\+8R^A_$]<&X U
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M&=8ZH]$I)N,-.:J$N2W4<6VWZ\H)7&^J%Q#! 0R<-4A,2*54T(SC#%B.<M\
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MD35[)G"TOF_<NPD!.4^7SF2%:[J 3D(3+ .0,6W]_!2/9$VK+&W>:$1$7,*
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M[?VS,^0\-DC"$"O&G_W3#[=ESJW]^R9FD?5+%C2Q<Q'X"WN(+)B$P4B,.A_
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M/#T5/[_720AJ.U/N-'L#)(O\@U470]]$4?#T#>J-+3][SF#L+N.NDE=( D*
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MR$D2<9MP+FHJMM7/E:?J[K?CBK)Z"7(;&CK_4M55.>2'A-94<#8W- ;FZ_U
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M#KFG&V3!D";1UM(VJTO/A)]54VV:>PU7"S;T*>6QX%J%IMSVJ2P\02]7+X,
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M1)ZE<C4.G7C'_[XNXO[*RCM#[JR[O:CJ_IJUT-O&TU?O3A!/Q]C< 9N+'?3
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M@OE5%[T;V,9S"%,\:SI[*P=G@Z7?T-C:F;YMR8E?V&"2<"[];0;\%>LI;I-
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MWLS?V*=6GVJOI^&=BJP@W6'5MCNSV7/R<PT9OXV;9%VSM7;#*2Q[E@408:6
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M6\[*_G0ILP%D_R(A293(@)=KPGFLG,RCTB9#RY$NS=S)^!)HTSZR]I2]LF6
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MRU0?7;)5;DJ_8.S:,@V9L;4KTK)I%L$<0P;('\"2U";LIE!729_T8"]Q,_)
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MTK=/(*G-[7K+\L/;]PI<CJV64*3UGS:IK!B)DVC<I&[$YC PQ&9UEF?FC1^
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M$:+XIZ;W>J0_$&WTWNIA9XC6P#?S$5=(]])YN1F=.GO/I2\#8.O,[/;$ZB>
M\Q, U]=;S+#PRG;",.\)('<7,) >W5/*5:%JY!J-FC]HMRHBOUG<?%UO1CNI
M>Y@J^R-XGCU.E:#*TUK6CO$K3!K[)[:)$'9=%#OMO(:IY6*O-[B7-TJRAJ\G
M)H(4I/H$8-=X F"#D7L]I8^ H%99X6K2!(O[LB"*M9%'_&U?(0,1\&D9ZI4%
M:NU,4E):8NU+_5^'F]<X!5;9R@%*KO=U9A/BYA-R((^=$5S:!*%SC(LO9!DA
M"]HIXP>C-S9=JE''CR\FC64F<[Z;:.D**KU[/%3T<I X:-&X#S6V44PN5N3Q
M@YW"_3DYRRKUU.-'9/;J4(;C\3(55F^S>,MQM E3XA*I3'74_K--OA_*\"YZ
MV07>9';Y:>!1K/.1D&K!^G[<, WNDEJ:Q":?WZP\\#$1M_&Z*H8R+B4TUK((
MGDI)/T9"%,,#RB.S>5-*2\$>HO6)MI(/R/FNSSIV,;QB: >(V602P)-",]=L
MTV(#]UT0NI#*/ZATO/\0.^\_8B5+9VW^<OF\3>A=K < 0K8_"(%TJH R0E??
MH,@[=MTV:T&*0F ["L1,=%( 7_/D';U:]:+GY[=FF8BR5Z]=XIO(C/)#EM_&
M9VFJ%]X/^M\']4AT^$2\ 1*0?2O37302G-QO;S/0S#2ZTS?=AAGHN1=)_@Z]
MT?W3$JD,H'=V?8GC0U0HDCTG!C,NTUM G!-F82%L9Y/_N3KHLO60,T;YQ\5W
M.#ED])3GMP&^V/[MB"1D9E3ZZUPU+-$@NENSJ=8*95S%(/V>D<79^,J'='T_
MY)+<9.4]6.7[J(_-$\!JZ_WQGXL;M=6O#OMVERJ:<UPZ[1&%1S36)H-XRR4K
MV3E;S_UBGP"J?^<+E;WT]MD8YS4#]Y!W,VUAH)@V"1L9H(=W>T(9;.VLSZX)
MHROI,YKEUUMQ&!]-[O%AYQ5_G38KL/A@7"4<*0A)/GVTREI<(W'I@+/[C'O3
M;!ER>(I2.D"EW2C(R/P2MGOQ_VJ9NXLG2S<):KE4'^3;H"3O%B#/6GUL13UF
MKO],P8O2+.>1Y+/#GO^3+<@+IF1^IFG[4;-EOL*]^C'-A5!B?%WPX2)K[6=1
MZ; QCCZ27/9-6G>&\- CB[5G*WO2%SG4150ULKU+GYU#;I)+^U%;4,<W(<^H
M(B?PP[Y"=Y=KS_[K)P L G*@?DHS@(JYJ[N'_!.O43936#U][N STB6D@MJ9
MIHC0H^0VC198MH,&(<+&%1U(T])Y_RDL>UIV3_*T@NA?0%2.]8UUX&AM,E]0
M*F\_2!I:,UOI073!P1CM<14W.[!5EQG(/\2L2*[ ?U!ALKF5K^0+0NLJH??F
M^T\E&L]+[_R9S>_O!+N&DECD%]]]B0<D90X"(ODGE9/!K9?1*T^ G]$BQI'9
M"H%K96"1C28-L8K 3'=Z3_0=8[<Q@X."MBP.NK5R]"K&)EG>D/!G_R.[\1(6
MS-94ABYAIA7A(Y$O">,T3ZXVQ?SK+/G)J("$70WQ[M2?P*X&RU%%E_3='?/0
M@_YE%;OTK%Q#A_?D'-"@Q%+C4/\==Y5:@[1PS*"=>[_"AB'PGNDKUOM>;:&X
MVK\"@;*H\:D "GXBLPDJ0;TGP._%O[>UBFXBRZ2ANMV5=*09YM^EE'?W+UYS
M:SBBI^[YE.3R.^K?'R\9:C9S7?!8;\5Z<?<]%.RM>@QA/<^)I=F(LXA!<Y85
M3$QN3(X/\USEN.>[C*\QSLI^#$.&@61ZE:A3$WF'!"=HR7B3WHE"V1Q6*$[H
MWLNQJH@'%V4=0/,F16W!!Q7$>R*B9%4G!NS*DPM5V.F>K?8^)C5H:08.+"VD
M0Z14R4FQ6F4(Q.3U='%6Z"5K85MG7;+:PA.@PZ&4V1EK8C#;7&?A$^G:D#!#
MDYCFJMAPUEQ&N?]*]F,('"B1Z$*9"O,.#_$74A%*,<G_3EJUM_#F!>&WD-U"
MQ4R]%.!QX7%5QV_]G#V^PXR8_>Z^]P(EA*69I485SANN6[D4P?WR=W@NL71E
M-V#$*6*/>&:<6!OS"^A(]IXJT^D-P'7TXZ@W8MQ[0O+8H[-2.*WN:W-S0^J#
M%XE4X[3FE0^Z5!S7G03PN27ZT62#?[]:YWEFR;CWJ5X3+-8>IIT];VQ7XWD_
M_I)MTW:%R7JJ_LY0\?KX;Q+;[Y,YOR%:GPK8\Y2\E)0N-!@W=V>$Z!\2EVZ\
MR)Q2%Q>7(I Z?$?)IEEEYR[#3T<QN6IV']'$-WNIW0Y^;S(Y;)/V5D^?73ZL
MVMTD+)SA)Q$@ A"$9?\V.02D5K8BWU^PY$=_57]3?\T7SJRF-!7V+<"85;7#
M;M'N@G-9UX#>$]JN'Y[R_<5%E"<>3RS!#X0SEK*&.<Z<K2(B?':NH0$4&/3!
M<;2A67S4:\SRFW#6\Y#G8W4_N8$"@LEQC<8M,]O4K.(%/H2GM?7'=_;$<WU"
M[B/E,3:J=*.I[+)Z*BG8E#D:Z'8 GL8_(Y3;7N5NL>95E^#4FS5CQ +'[1L%
M)]X^XI*231;Y./#H: UF/R8=P4[TPW2*VD>F0OK9%;;R2K6&Z#7PA/,%.Q6C
M-R=&3 _"L#1)**S8<:N'+R%NX'NC45A2H%ZV^]9X=O5D2R#0!/JIV@;J]4*>
M2-!P@;*\]O&$.Y^9"-#CW[BJXS\@//%U>8M"\?'H3E\[X&I_F_A^TDEI:G<6
MQXN;KD*],7IC%-SZT_Q$:"]769EPUX3NG0 L:DR]U7QVJE6SSOCL"0!>Y8L*
M9+&=W(/9BQ!EH_W&/4Q&=-%\E!=&+N.APIWT!K!(A)LO]I\ A9((Z11)&VJ-
M8^C&WCS<_^A/"@#OI2C4?!>Y%9^S)7%UZH;'MVP)WX;9S@5QI0&/9X,IT"-4
M&:]@A3&6 L]?'WY'L\?MX*:COLI+@11?.:EDIR[ R\/=LEC42_;[,S,S-1\.
MAQ2NC.PTYMFS,UX;#,%92[[^_@BIST168#'*+0_ A7=)*9U9EY3GM*#%2*X+
M-MP(=_&\4M49]63;0_-3CY;9U?$Y/3:&TG*3>6BL(Z/6;Z'7?6PMK!6)SS=4
M7] [L6WW< IDGHRIV\@T<37/U[:W*]ZM-5=O*L>Q>N2&=LTX7SME.]NJJ=VR
M-V7'];,PD-38 C6<O$^>-S7%?]MIK<2QU'S+M-I%\5F?5GX!+3A3LEB8ORNR
M68EM4="!>A7J<'<4("Y2EG1SDO<X6Y5\86/(92B:W;)^;-#%F9W6T&'*93N9
M?SQ^;?::(CKAUVN1!@ ]OH%/RKZP;'XQIYV" *1F_G3V4MA*C7"75 'ET"\B
M;IC9KL?4=,R_21'^'V>$&7=;QA9'Z]?; +WWSI[,0@>(_9S@W!GW(6,(6=_"
M]GT64,:K:89G-33"%A0CXX00WE"24O.:<A#<65T#CYY#T-D94<.JIHFT/ZLL
M8F7UK=<+2J2_\R V?E]WT;;IG:[4G$#R.U:SP8FS0N.@G5_+6W[%]+_2DFUT
M'X;NTKWFR9.0T#<5X87V!??+"H0VS212(>TRSIZ6GQIS )3:YCXV?<R+QM.&
M8 =C0ZJJJ[F!\3+W\X5BLF&#.C6U8OH9"Z;1*E#J^+6M:HN"ZWV-5S>4 =MU
M234$P$.%A/G Y$^CL[A*+_G-6#[U)ZNFI&1<Z=D?%T4M+OF1F!EAQ_7LXA7[
M(.7$S'+-$B_.O M@>QV0P]P1<DV-+9:95@T.^I2JH]-))_?3_&F94D_2X>86
M?#Y,O,&^[TUD]TO8V<7"SRFCPQE(@MC<IZ?V(9W>(,XV)L7,%<'B5DB-5VVM
M\D0E*-!\$O8S0QX9<\IK<?.:$!!&S*PIOXREMGC@HC2C5:,U/Z(4P+73UAIO
M_8V!/'O*PT+(CQ\3<Q91TB0J:F?%083,N*G,-=%[FYGDUC4D]A!@AV<V/6G=
M3,1561#R>8N#G&"729+OX\7?B.[8$VS9KXTT K TU>ZI5985".?AF*/K7%Y9
MOTO,=F;^R"A4\69))7M\!3ABT5A;8B"L)57Y'I'&OD0K.LC<%<QP0XD6.N9X
M4 0"!JEP>*X!]RW*_VY&O''.8HVO Q53:U.( H-.'<J,;C[4F95YF4WUF)6O
M"\FN5(\<B1$D)*9$T@L^=WUA2Z>><@ I3CL ;\9GRF :X1'"]X<:H0R!67PV
M!2C0O"KM]*CMV^^:,4XC3L*:%"IC4&S9=:F(H>WLXQDE7;:@G@ZVJX;K:5.6
MC1WEVDK6FE\&&C[4\XJL]TM':_+%/J(-%5$8$2_I'2E"B>B/3<6=/Z$^31!A
M>XK83E\GVG+TM=BV-EO/)52""/@VFP9QL[<;Y+Z8P;OZ\7BQ=D$0ZTJ[(&.7
ML2L;EG[;@DH*O[;5-+\E0Z,)3^ #>)#^&9K:,'!3J;(QLN<%,G+8,[%S,ZG4
MLF[2U[,!Y'_5J(*SBYT8NVPARFEG_POB,!=_+"JT7Q_)$&*XC%/[C(*KB? %
MM=K.#YZL3E0G=%BXZ)\B%>>]]G=VVK/8ZWW)IKO'B5AF/0H97C(+U9^+BALU
MS.VW%)V2WB^MNEC*02CQ?/%M!WY?R0#?%'K3O.OGO67"W!6RC]BF24,/Z3,6
M.48&I5VY12XHCDM,:;NVH>JG@R12]3@$J1L8/I*)N=_=/03<S?D/F"I@LW.[
MRIY?O*G0=]25QT749):*1@I-&+%NJ:=Y!'!,M]T5MT\,;O1^6[%&3&<4(7]E
M:,\#W6WV\_5@^X9\PNS8P?A,[+J(); +Z>HK(B1/."M:%SRY!*3 IG]W'."[
MTE;'FH*E7BXRGO_+JDYO2M1G"6AC7N=X\_>GSD9H(AQWT=QUR3C6Y)AUV;DG
MNXPY3MGPCD-@ZK$4TLGV]_JO2S&3LE)?$]OA2&$6R//23B-2SN2K"6*1OEW?
MC443#7\,:KM%ARXL!E+.LQW2OPO4/G2XH[7YFR)255O*PD1$K=5<D'+3L%]O
MGK7#H5==ZF0O*W(^L+%_>5U!(3HVXOURP$C$+X"-N',)&DEZ7:&/[OCR7*?A
M12^63C7Y6:S6%UR,KSTVVP2AE^)VW&*,UPN+RPIH3X!4QY%;] $XC]&,,:_:
MR0\.G0[22_YPF<HQL^K))7XWWK@ESXJ%.&\ERR&^US-H%O]ULO3_=;[P_]72
M-X4<;$%07-OWDT:/A+]OA^Z8MQ^?5?&X3C';&)LEM9Z#.&4J+#I@;G5!:W1,
M%[3-^9\>BIVD9OS2Z33F/+BNT+K!2'B&W,-UT&W9?%*F('3L,5SW_59/<]O\
M!QZR1U3!8[1>@IVR:.!+SD3F,Z7)^ZE>R=/:)T!-M-&J^%L4QFCP+>UVP*+I
MO_ ^\I(OP%0<O$XY^.-67QT*9\2D64Y,0QX7'Y>VS:]&COX &=HIP3^QJ#[L
MO.&"?T#MU;,<.PV*S^DUG+M!2 A"#[ZN/P'6F% RP%P4Y)2$RZRX9J[RU#NJ
M__0DFP(A'H0SSU<Z+ I!O"\G'^&W^/:V?(K@G2W F2]8[_]+/@-/O;]YNYUZ
MJK %"AA5'""C>V\D"R.-OY?5Q_S^$3/4H#$ZNS\#M&9Q,'[$0/2CG-SUUL-I
MTAV9S96_N&S+<1W9VD2B-/X$$.Z:6%\8^$-Z'*L]W-UZH(@Z!LZ"=;4R6>32
M%@?2H*SO9^V=ZEJ2/=SN)QE?#1(^&RBZQ@8L!T4%DXEE)BGT$"EK<K'X&]X_
M ;JHL!.C=R*[FST11K+U*?WK]#_FAX==\SG'J&KJY@HKY8.L/VO>A72=@FW[
M=8:$9:[D>(ORW1-4S@*K[OHS(3RC9]41Z@=#L3PW%JP#RZ ',PSC0SXZ592^
MI.8\/"&N=^J:WT"[^\HHH7@HBR[Z,$E85;?/58$\KU:;,BX1J\I39_A[6"FI
MZ>__:I8?3IDD_;D(KCJ07&AXLQ)+(K-$*K[M2B0)&&!:()^J2,%V+;OC$/?%
M^R5>*3]]<G6IGZV9_P3(1?^ 0@P"/U K6 K3@]5\(!-;L0_;Q1R&$Y7NIT08
M>6]5VVQ<$91H6H?#K?%ESG$,N8.?B.9*76OT2GJ5FH#,WQK=156&/;-E/Y&A
MOXN^9H986*;L(-^J*2KT*T\N'II>5Q;;?@77C7DY3\=+^XR_E%@PP?P+8,OS
M*.N[4%8Y_5"(S6OP,\SAD=!W(KA^\>J8+Z.G>1,F_:I#A1M#2UMHRP4W8D#M
MPVK;,+]XI815^\"H&7.%N)&./X<AYPKYY9%'%1L+7>)K<KCE=XU89O315BO.
M^X6M)T"V<^AMK>#EL]"9'C:9#LDALFL%_3YRI2P<X)VVE##9F'(_BY%$AD[(
MY8&D%%OZ'DS4K.R+OZ-"+E:^\FL[#=,QG7X,6[<:D_K/J:H\6HFXR6@:"B&5
M8X2XKX;#_PS J3"5\3O\?;5E!/*;#_Q(F8==2DD5.(BSC+:;X;_NBD 1D\^3
MTM$;%%F#T4N1F64G8LYX=JM=,QIE@N)OX^J4K@P3TD:W6"!6'B<*NH)6EN!U
M'S>]M?VD2!#9-^MQ'R/,S8+8U]Y';L:?EUG[2NJF'SO0X=8C"YIJAU1Z[0WU
M(&1Q;I,GV.Y' Y9!/I-!T3;VR,.R?\P %1Z@2L0I25%47'UJO^ZD]:YVIE))
MF;?T7'H%Y+7C$IN2?>>8?]'<3!MN50\KPPE&2!-U8N:0"JO/B]U0^E[[:[=G
M50;-G!7EU<4]>CYP=KR5>IQCT#EY3R%M+G+5@Y88ZWLQ4>\VU*[["<FP!S,N
MK7S%FA@ X4*]X#3.Y6B 1V$_ =#=+I\+N!T?+EU4L%;I7>Y.*3H'><P?>*C>
MG'F#N+R'4W20 D@&)T-.S5D3 FG^9<JWB324EE)ELN+]FYBYUU5[;68D#_IW
M<LDD8QZ<&7?4%AYHNFK>(4OO]] V(E61CTU5/=[BE$:'B#V[WO%8]%A B7"_
MJZP*V82:G3CURL*:8WNJN%UW/&XY\]$38#3HJKR_C\M'DFZR6S):(N%")/HB
MX>O_:4V*GED1HO4<MHM73V%%T%RV!+O4?$"$[DT,3MRSDK68:&LP*_IV>'@%
M;7M(A167WVA[/<KRB5C%B.D)#O<HU#H&G\1%@V7(TCO690AG%8NH(V+6TM9N
MCSK>%K)JU %!QD$H=,>!#<<XBXLU(/]1EK+^L%1@3)ID;,J0F/OJ3T6VTZ"=
M6]S9C%LUX-UC@X@U7P"F\N8K-A,YSUCYM<R,A$,#M5[-U(NT-:?A7ICKJ@J"
MJ_(J,XA5&OL.C1Q_NSZR+DWK\9IZ[";(IXD8;.&:L_P)?;=6ANS13DDS":;D
MOQBCY,_Q %?.73?&6RVUL=^0"HI^9RJ)Q($<X+H/$&F1EW9D=_R6]2".ZL@N
M?NMUYDDH:3W)Q5CSRS5WZ-NM? :]\4" ES0EK-ZZE(L+X66<"(7Z*;- #K<M
M&SHVU] I[5X_ :P7(=2N60O4[:ZQD(<&Y0 [)RMI A33$.?:F>10) -K!_I.
MFM,MS;:O=D2K6]%MBHL=XU!UZO<O[*'SZ/1"-U(!YP9$ULH)O74G#4^ D MA
M*T6-&STO?:HR>?(F=A-76'8+.R)+4H':H6MC^_%EI%MV.G4;VE;J9O,W)88)
M;?E+0YVV5S")4.*4= /DO,K(\')F=J[;('5QZ>D>K0?EI9Z,?:29;S4:,UK1
M_Y1# OTF,N>7M^3,ETQ\-?0P2Q_@,G"HUV=8",?\I5UBZ:<5XG"M)$&XI^@D
MJ8WL2'S6&IT <D NG3"WO"N1_@#7FT1+%/,H0W]V0+[(+6PWR&8^+(ZOTO0$
M"&N13U/QP=$&TJ2.XPL/##$UVG][ JP;\K)% Q<TU(' E<!R5)0U<DMKEE])
MD%QS2XDR54T6L&5MJF_WXI$>AJ8UCG5H]+V<)DXN8*4E?2':F'@MHZ!E33*#
MTA7MYX=Z!=*E:6&RP (TD-$4BVN)35L%,873IM\>0V;^1$;D*T:>)$5$0,V+
MM^BX?8*JHDRX#=,FU9K^<G[7#/7XW%&>S9< &FZ,W2J2<O,SS_@L%1N()&?;
M$?&>?D:?2,QRG[-1$"\!+>155GEL<)O@&UXY(<,"RS3QY.B(! ^3/TM!;VUY
M#("T8EW%/%$\4/H_9!(]9%@AX]H2N^)'F7SZ-G]TBL0^^;/C5NVW)I%=[[C\
M/  P":\GZ1?QMI5<QZ-0[3=^&,U4'UL;]1>*V/NU[)S'^N7O^4QNN@8'*2_
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M-9O6,"\>7:^5ETWA_=5F*]CZ</!F@W0J+O$@$'-R278JT9+"LM$R^Z-OJ;-
MZ8W&*[!THK&%+/5P4LS*P:-5G^G!O>_4KT"B$TCJZ6G35)O%AZS_'8IQ6$*V
M)=ZE3<S +Z5*)->9FQX4<JZMV=2-O"Q:^#JK?J>/94Q683C&:[F)U.ESNDK&
M:3S2L3VP@?)J1?8E/5=^#Y(0,3?8=;*9N]5J\5>JAG+DF=;)C]5TZN5A'A=A
M_'Y6X7B<_!U@-*H,P!3S$/?#WB](K6QA:$$P'O/EU0?Y/B9.V)&\SI2BMXCC
M'1A"=X33=QA)I.\!()9Q.M,QO\PJ,UKKG@ 1LIK<1.=):K]FWM8HK(&&='T;
M=#UJYHZTEH(98G]LFQ1]/'!N$GL;6O?:3SLKLG\F^3K9LV[9@JC EV^J947T
M[H"(FR!76"Y1Y*?"A;X6R,[/4V7;9V5\Q+MUQ-4?DJ)#K5BS+F3O+AKR[HX:
MGUY[NDL8F.JK. :1*'T8P%#HSQ(4TBOP24K29W:@;YAZX"A<E!7_1&O/;2I*
M$#*P9?3])@VTXFDU.IM_M%/<>15Z2@*=Z$B?[,&_KOCV_ENP*Z:RL]RXJ$LF
M=79ZE6WV@=<:"N0;T)V'9)5IJU>9+":YY:U[/D#QT5LTV,E)\T$8U6:73$8V
MG&GWM6V#@=]AV7=);G+-:L\WW;YT&L(NP3A,](W5*6-#K=FEO;RLX5#?-M([
M_G/]=$Z#.2=C(GC'(9(',HANLGX2],49;1VD8\6N82$T_G5JJ)B$P0NRJ" N
MBD] [DV.2B[&JCO9W!*:7O)S:U*P0PT9/20(W#O!)O-A73\XB99NIR.> UHS
MK:B$Q;3+E=_$^E@( RT\DU*S;1SO.IH'&!2Z-#3?*V9JKDS!7>KJXY(]%<4E
M*7Z9-EIEIDK\I@KN7,<+#F#S+B2R^!L%91KC6!M!3#),<A <KKX"2Y@'=C[*
M/0$@1I8<?J5(T(9A&?]*H)R/D?#1_^&XN%F-5GN*>^=).&FC>5(M]R1[LX/Q
M%-8UF9LD=,IKDES]J_6R]6 1E><O/&LGN^K_2$=9V5?)W=L+;[N'2YA*( >4
MX:4;VN*&5I-!:<C:R3BAKP;3<X8D5\C:OY=<V#9&!%_/2K+W\!P9 '_$4?7;
MLI(KR#:=^01](A&8H/43@/7!+ZI)<TUF,4@OV?@VC-.GZL58KOPVI__G\:77
M.U&=SW);;,<7)@4N'QC]_M(W)@^K+WB@G@"=6@9/ /HOE52T56-6?TU"9OK8
MTHQ_OQ!6CU8&;JBH,P\KV:9$/0'JNR53)$_2/TGD_O* !<CE'A^JCJU)M:6F
MQ9>,U)^[^\8.6&X16KVJ>YOIM04MQ"Y<2U3!'VPV.,R=WT+_>2 ^,W>0V[O7
MGLJ?.Y/7:/ =.QLO*)&H#*SAIIB1(#WBKW1VKS)+!G&/-!1!2&82B;ZWI-P.
MAS,^ 1PEQ#6N($81O,#ETM.^_94G0->EY60I,YN*#O+TP3>UE8NQK7SQ(?7N
MLZ;4YS2Z4T*:;IUOAO>I!BYQ U4>9:7J:7S:!?X/(I0>E 8='M"KZOT[1[!3
M8>_[!E(JH(>E1,'-]9$H]L4.DZ!/P$IL U\Y]YM@;(!-SK>/$2 30C2RHN<<
M7["30 4?DL[IVPU+C4]K((?)J/*RI)NVY^-X+V,1]-+E-27_4/^U9*67H/F:
M*;X_C.YK3.=7P!U:]!EJA*U-C4!*<1(M@[OR->G-*[T<X9'&N[E!2Z4L5#/_
MU,JG66^+HP/?TKMK\7A\VU(9)=>.6]/X4Z.SG<CXRHT9$_0QJ<+J+@^#DX@O
M06^VCYF*/WHVV"5EKKS8X"_>ON/?EI;+5#+;&*S/Q4EH(/P1B>-,_"5KV-69
M(CE%8CMV/B=+[E5!TVEQ+DVBG KT;%\?GOKE]=C.FP%ZL[C6[=C4+C*F8L4F
MM_O6TB!OR0)M;F]_&ZW=T2> O W=!0F3IR#N?? N*4<VMZAGV0T25K-="X6H
M')Z2P&W&G#8@QSH:\K@=O[PR42%#U+=#&(T3XBI")4;3B2N<?OM[DH.0XIZ-
M'O[SU"_,3$/TV;*3-\JN@?8(7E^S6/7D4FM$85 ==0=M2.1'<M:LW6.9>=?0
MBRWGE<3Y(C\S4KI,S57_>TZ@S8)Q>E&B#I7JF9MC$1WQ<F*B=6$0K>C-H2;C
M+*G1\NH3X#'56>T)X W9!SX!%"P-?VF!S;/6G!N)$^T'A>![+P:<OMP_\D^R
MW;NGM(O[H40H.R[0 K,'Z]E%:&V\7FBQ^277^TJHK'0>AH9?TU6Z&OD?S&T?
MWF5/J/ XF9[M06L0:W#.=N?G9XW":\LX6\+;GEM\3&J(9BUHR^$V=41DR@;X
MV-Z)Q@KAN[NSEOQ3> EL?#XF<X"P;SJ]^'.)))NSV3BM64VGC!(<VM[.ZG6#
M.OJ\VXWU&)H@RO<0SK?35W::,9ZB:U3!?P)8PH[-=M/I+CZ.'S<A;]#&A>UW
MYW>*"M6SM:$<66V^0<;>@9:_]O]I7?[9'X%'U54WQ NA_J!(,>C5+A'(PX?<
M$]Z>=20N(6>\0?/2!NHZ4<JG7^F_O%0']IC]R#!#@[2D\!*GP"13-:@_'&91
M5UF%MCF"SX(J^]-0Z.#S^6A)J.4]5>D30#JD.3ZI<<OK/F92W,=Q"R^<R[*I
M\%RRB[P2#WVHSRLWA=&POHQ,;7CZ>)IIC'I"\)OA@#.ZS7*/C:;L$%K4P/ B
MZ8MF\IU(0:.UH*T=> +_YA,@@/U#J +]K-Q9PW'17$.#\GU1186'!./,?,_^
M0YIC$:XRTX4:G GCL]/X3#\F6T]P#MK%%GJ\HNHUN-7Q$@9E,]36OJ-.8?6?
M2$>Q'$*NEN&7*OA9FA:S'L2(XUS[E7+S+YK].(FAWV^'D$V<;7@;^N/%#*4]
MFT'X=E4)T#T'D6CJ'8G46I71Y2F47<%^4E4,O41@+)1,\+FE5D)9JAJOAH"@
MR0FSA&HV&\O?4H;CO&/M-,<HI,_UA3!E0"'RJOU@*?LAU_O#I^^C 5'$<)@9
MO/_X?;+CT7HW<MBC?_O]A*Q9]-GAIIUFDF96)@E'1=K:VBY"V'JC]%O3"BFB
M:02D!_6":A</]IQC=B\I?7:J3CQ>J8;GB]:YH=T S;.J.KK7!2F)Q%Z7;E+R
M@50:0)!;3-T)&U]V7XY#O0,,QRJ]#[CM3*/#-2R<25Q8M%0Q4)\+D> P@A_E
M>F_K:*><M$F05>T-?\?J XW:XL<ON@2RZ: -;X'L//JB\C^[$S]G) S[+\ $
M,&9*R3IA7H 72E;8\3'^478/UFI:>E2!Z7DP&ZP:&'>3:'H"YU@PK\[%7P"@
M.Y@[!X^-15!PC./.A\3/VI8@&U\QD4; >[=7CT_08>-LB.'7-#+-5394X$A9
ME\[C?L 3B($^,KZ<_+-#)K)8=6");R:I3CV(),-0\JO"P&I\G+VSR&YD^(\$
MK6F*L8;&GQD6-(>:),]'WE&6" V97; >&XEHN[.Z&67.%J2UP4[S3MR[RY*V
M2Q</UP;7SL9K^/L<!,X4O$J7>3'2%UB?2X,Y[B  @5E65[Q-8:'^ O&L,MG)
M(DB>WLJ5K*8-XGYR2IR?QP.(7K!2QU6/+G\02G>KC^'6*31XWVH2'QE282SF
MDV;AQL!72<:7,6D(>\Q:])RQK+7(^"NGTZ!02LF?-<3^XV-I8S3TSKLM9@1S
M)%'>NX#R][:1:N<)VD;:[<^:;-*9-LWV4\9G-O.2#C%ND#0^>S.01 N]@2/Z
MK/S[R8YH :U3!=&[JZMG-ZFLP8;?@PD9 $(,[RA?8P.<%?]='X7>Y6 L?L1;
ME,=\GH/YO.!YV6^^X+]A6O:6F5*U9GRF%0ODJG/VKR;G["UZ2]'#SU?:U; &
M+,TE?^!()E:-BLZI7II:97_V;)2X6N'XS4$VN53O\L',=Z6<40&*]@^KY>,L
M:0_4_D/4?>_^6[5(-*P<'$-CW4B%+QUC= &]5"I-E\;JMS@@&.'R:H:'!8-;
M: 3LON^#3[QG;_$IY=&GO="6P(Y5VA;]< R+CLT');ZH/1''!(>"JO<&[1(V
M%*F2"=^.N"7J>X2'_8Z7<I.]^*!S4J1ZP<(TE-Y)*MA[:;[US?13,%DJU8L_
MR;2,%#:8I/9G,@ W6%5+U<KA<:[UH6D,,1CW<,B3DS29?:JO^C-G*SX[M9S;
M&,!J:$NTDJ[WZYY>A?,/>FC]F@>!<U2 JQ5!KW32YP\!65.,3K\5ZDF3-G_'
M1]!0+,$FRN)4-VKKIAQSH+J_$UO&&R*"P,)(Z+ &!OH.&=UW&YR#("C[V+ .
M?<F-6M?UKSAEA> _GS@_LOVI1E.0Y+EOZLK!XJM4Q-6CJ5MJN$4-F0YA!'I;
M>)N3OJ-)E5^PRNV7_42(5MSX]5E$#C;4\ZLMRX[!.Y>E&;_2 _SI\_+83*K-
M([[CZEV]HA"7/"C,(3W[/4KZ]-VELTA"8':.MC^K;'$+QWU08IG-WA@NFP&)
M4/P7=G!^@/A#!^NP.])#/U#*=D 3M]\.U$LR]67F92;Y<XG_M3G__Q(^3K%B
M3+3#L"I02WI38[@OM.*'*/1F)N"T5<(^ EDQ@'Z<7"GCMZ)V"&^]KRK^NU[=
M/CYCV^%UU+ZJ,E*[O^<RY\7"C1.).=7!5SFAL*01P&8K8^CH1LY>YD+_I2K,
M Z> :&"3S9](+WM6Q9!<>)=P<_/:=J EICQ "Q,:KS.:]%DSA4KW9\U/5S1Z
M$]!#%:OJ3F:ROKCJF8KLE(3HU$ZR;$KEC@'0\9@RVH_W384DC[$*_\0I!Z@9
M&44=GZI%S0AE!2@$;T'Y^\9850:ME-9/R<:^.3?C-6Y7BW(X&B!6PM2J#U;R
MW6[:#_T7F!(((M5C*F5\AMDNC,O(/?]>[>HAFWI7>#-BM9\G-K^G_6,1C<$7
MIB-35?(/T<?$'+:T:Y+O*>2$V^RQ"BECG(/"_<A^[#ZFQZN,?J11".MFX7+0
M]<LBN0BZ[D@?8W&7HW,JTO/V79MH>MCI00VXC!"+)?4B%,22?/@/FQ3SZ]SE
M1R\27MLZ^.)AK@IIHB>I - .5)ZUV S\^G(W\DFG5;QP<6$52*DF[41H->JA
MIOOU!;H+6=<@*22[U+<V<SU#66FOV0"?Z4\[EY>;*VJ$'O'V^.(GYC\+?4UT
M^RA*(.(=-5;I X8'U+/:3,5J+9<C2+ZV8>,D014OZ-2\HXS5F['4M62AX:V<
M=[_*2P]8M59>6K__%OJ>LB(>_S.5ILJ:$-/._9I;2-<]7[FFD8U$N]/(A=@7
MRP]RLC'S-OS30SXWQP>^%7%&R]O>6$24\SCIS;05P/],+7C7+_FDS>,>BH'S
M"1Y8KL0;;90E(J[*SMC*F/CBPM>UBH7';)W@!NM!ST)N$4&5;BJZ.L=%E10W
M9KF*;]Y:]K5ZU,B)I9>3FS;(=]7 "JTM%4D(AZBB 9US)R#ZUYS*%YF>ET.2
M\1\6K"@SX[Z1<(@8.YX6HM(V?1>$&%?DIE7F[U!^$B+73-\UK=@'G=<X73+!
M:90XOE=W6LGPV'JGM+,G %O [E^U7U;$>4FIL-/#M;^+?]I9'%I&D#G)S!\/
MX<S#QZ28/[&HSD0\JKP;2X<Y;#BUS2L;TJ8-'5-_7+!-&<U)W Q@DGC5QK2=
MH)*AHYV-(*"%\,K]G&70[S))\$\#_&;Y+IP"_^)WU!'MW2E%R6UU6E/'0@]I
MLSY\_D4,?BPBM@0WA@60X4R+NF86<?YF+Z_J+WQO^K^]*_V1^%T6;24T-'8+
M,W8+M**HJ!CP[VT#?2EGF;NFW#?36OP8CZ95#/5O T[9;)OSY>27')B]0Y;%
M552,/UV->0)7XUMHZ+@\M9X D48J8\09#KW)"C0K5NSB>!1)$DT36SKJK9)>
MG""(@GV[\N'4@(QYX9"N1ZO%(W.AUQ/ B1%<.9S-B<N9@3/R\YN-1F(71CY[
M\1. DI_/C)R?:20/I+S"Y1<H*#ONVBO+#6[=;Z.81>R?M._33W#8M':P'GG9
M0]'_OD"=V<W(B4/&@ VK&9!&W3SB&W.N%9.*#BDTF@VI PUCOK>'98&EV5GK
MZ9*!<F6@]3XNE[M\17+-A F$5;%VF%_N?QDC]6>%Q]M:K]OZ>EYNQCI:BD=>
M,>6@)SECJ"DKR8K^HV5;-D\?1W#Q*DJEC7>D?4FNWMYE-N%&NU:QYU20[4TF
M3I*@EZ)JM^SP>#Y*<CW0*O]D(]^B8NWJ)M"J<H2A/=*QP=/ZC_3K[KS8 (43
MA0.=[>0A_HT932;?I-:6MB? 1N($6;_:S2JD'>PE/<'O]'I+;!YWPC:++JNV
M;D9,ZK9>K1J,M$:^NO5])$I.DRE'25PTE:AJ@U?F3T3M)"/@RUB%34Z"--TO
MT*['@_340I-:/!&&XX(QVCNQ?.W'ETB\1I'X5&Q>K/P?%H8ZSV2%AZ\EX]E2
M%8[N/$1H2V=J8VH=ERO%)0* S8'5E&<9J?:\VT1,)XDS?N!BP@VG'^/NR\8,
ML?HF_I\DLW?M7\I_%8&:@4U94'J7'(_[NHY>Q+R+"TQIV*Q'6SE4K+/RW8?5
M?2*NI>7?.'.2..5?)7VD47X"* I/S^[Q*\,X(]$]2H:M4APR;$L!\;TW7<>P
M-AP&9E/*F24MV!P4#,D=BRXY.R!6N'#*=QIQ2+VQ/W)7PMY2DTE"@M@<7RK'
M<5V].IVYICKL6.[9Q_<-N..26;ZP4IW=MUAZQ%J=,,.Y?@*8J^[(OB!D(AU0
MQE0]P#>&\'_/4(.O('^VK2A[#I\8TAI7_P/W\D?,(TQ[FA,PROU>^TM>&:>W
MTRSA[)6<425HAY>>,)@9#1?]30@N7R?SLP]?7I+_)BSDE[?"W$P7BI;T=!H!
M!'TPG-$Z2K7T=L275 WQ8W.2/ /H(T/T9CW#VCAN?EQ;0=[EY<_F, ]IA5F-
MZ;WC+2(J0\?;9]/ %'4CMM-098RI4MG81PT^>AM3F_MT?CL0I_24#-G,<]8D
MRGX@'2_NS2:H/F^E@8'T60VWLKNE,)=_!>&$YCCE"!L0C"D7E$@H@O%WX*U1
M8HRGLJ!^+6BC;+2&D,6W[Y*]U+WF!(/\AXP%37DG8=KW)/6:P<9_[E6_O;KF
MLF7G">P[E@FSR?\@1\^T?9&B 142%3AS&=2602Q#1!6$Q''[$,-XBN>ACC"/
MM?-9@TV(-$R]G%PEJ5!G*<M8-B5MHPB4!NS6D'W_0XKS.7Q!+%M!E7J"*_"?
M.H-N.KPL3X- T.L8F!]0,C0-- EO.QUSBG00QV<ZX$^E6?"3&3LF1/J4N;HN
M<EF-!?H)GAJWIU8GBS<\Y(?^<=BB1VOZ\54?SAHMQ2+V,S]DZD^&VJ^"E&0O
M*$H =)I[_&U_.(Y9K9331U; ==ZXPU! >V[$4%ZB[UC5K,"XVD_5A.3(:$8'
M_3\W?+6SA)Z$.M,G@+8QYTJ@17B[VKI;LW(&W6GH]YXJ$@A8KSFA":B]!BW^
M/9+-=?ZC7;W(QLJB+ Y">T:))\ H\EGDC<3-)\3#7J%<VAJX;]+S(M"BT&PB
MB?P$C3[A625:N#^:K'K_)TJ/;>W/7E)VZ4*'979*U.7%8#/?KFG%^J0[[\HB
MW<A?JH%*"5![5]IWRX0FQ":OV(A72URUR@2U;%D:Z\L"R \R@F8K_YX[7Z9@
M!_:#^38A8V0,XY 6!>L'XE--S_$@J4D*W:PJKJW$H^.(PW13EU:FK_?:$4*
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MAYEQQL9<Q_IV:N@A]/%VQT4M'?/Y0-IEHMBC]/J42//8RT-E]MUIN)A"6:\
M[P2]2&[6%J(2>_ZG<CA$"Q4F.2IV9#+MF=V?P!3#%Y2U(QXQC,1W6Z\RZ5Z[
MZ3)L.SGJ?>G[44:QVHKYTY@#Q7\Z* Q=M[:&Z=G1S.7Q&YT0N?"99'9OD'QN
M\:\$.M6^8-/^-MK9@W(VS :-.[! C9[.?!,Y$O([,@R&'2K2KVY$_GR]D$[Z
M\;M2KXK62',$$*52$FF.>Z#;*&3:KD"$2F2HOI?B50L+RAJ!1$!TUHV.KJ#G
M_\ BN5F'YX@5B;2E[4YB5/Q'NI95%H6X4 ##L3C%Q\RUD0#+Q#? ]JF2HU^$
MG.PTN73NIHZ!L@ )>@]>S2:FRDS]TLBBIP#_[^PO'X_Z<B::%RKW_>ZUXEH0
MM5IEN2S;.;::Y/;MIZ0KL"/HX4OBME*#IY IM^32=B)C6K'K;B?QRW'7*26"
MXR,MLY]'KP0B#B._9CRHM_30F"5O4F3)SCVJ9RG+T]QHZQ]"*Z%E(J6JZNJ[
MZT)>!YT! =@\47NG=WW?S.':LG6H+@=$#2YO*E%7(;*R-LSK*W>MQQM, UJ'
MX +M>Q<;=R!OQ4/76%F)-&U'Y%0U[>FR@=G'QF0M?WB_[Q4]8NX4#;?$[B_@
M/+K%SIQ7Q)3] ,J->U$KWEUW0VM60A:CR77'NT#]PI53UD@T+SX:^6LQI6X<
ME-Y85Q%B9U]G:;_:^\\8;0'WQMSG3M1]A?@:R0WGY +);P#+B3? >J*#Q_/H
MV."<4R7W:#GZ*!%57,(0_TK %^P'W(562%N/V*'H8!2HD!"H%G@\,]G:&'-6
M&VA35_3]9&GM![93G5'/7FD3$IGS\8^I?>+;<N,.?D.]IVF8?EK0X>=S_HHG
M$.CH(DD@:&<MY@V@:.PRVZVC6]/<@$"[92GQNO)=A])(Y\ N@:!0.;$8"\38
M<#4'A=^^35>#@"UXB'WYS 8:+8=#CO&"@X1?*XPZ!$KC-*)G%!1GY+G-U#&C
MO)3UR_H?^QL><>I\8O]\]KXF?H17>,W4'D!;3RR8/GZU*GB@SHAY0'G5VM\*
M"GLU3FN@W!K<AW'-V_6(3/W7I603LI,>H;+]8NBN2,!L8;]:24L6D_@W9VKS
M.0XS<J=)6;: ]!OD2>]9Q>(QL&KH)C?IO9^\OXK%2\#)_?MXZ)<&169:[#_P
MIUJ4$'J(I1@7QTZ\?!4U,-XUN>+,6;Z%C]%Q JV/#VH;>7/WJ>U0-BF-VR<T
MJG3#F,D01]6M/A+A .OV+$AP;XQ!AD/KT,9K5(2U=1IFM!!$/=5MNO_N8EZ[
MDDW5?[S!LK)!OH/$+G_>4R190#H3( [/M&F";N*G,Z9P:;3WJ^YRY'IA.T>3
M+4,PO7^\8=0TB9;0C51G?B#-H:'3)_/#[[6$3*S<<YU N>4S)X64AG1%N77#
M.\,)+Z6+\O2?;.;-:'NX2>'!I7WHWV5<?<U=!OCQ.:(6W@ NT\#:8E:JYY9S
MSZJ"UZJC4>T5F<*__:CPZ[V",']VBC9Y@6>LO]H)O](%6@[GSPGW%_<,E3S[
M,H?\F\XJ4>-ND?'."9L[,A=6?? =&RB;DA1IK&SXM0'_Q.LRHH[>O;<\LZ@X
M5>5:!<^34BDI07&3@M5_H%E/HR<5KP&=5F9YWNHB'Y'Z#ZZ+Q=C#,X,''\ G
M*OG1R"T[?A_4"BDM9*47#,T?LY& M15L/L\I4FWDTO7QD]3"OZ)3R>!.1)!<
M->451LU3-@RT"JYY"SP&\1)D'#@K"TS2$V6X_F"J=;4&==]0/X)6<'>\]#VD
MJMP'IIVR4&J;M^1JW_F%K$+).W0.]>= #]MU9"F:'JCS$Y;R<HC<Z J(W+-P
M&  .2(CA88BDAG:8S^!O8X^1JGO50'#.194DJ#[0O/8-\-T4ZC_Y!A#>,GNH
M47NN4POW#&VKH9XS:I\!Q6@'%]("L7-8K8/'$[5+T'\OU$MR%,7PY([]WBQE
ML,R"K%N[^=Q5-#T-^<A21(K%$5'7%#) RA1?B0IFS-IGA-T^?#^4XK,5597#
M07@#?,TIJ'JB"=#I< $6D6\(#E[ *G_6.S\.!I]SUQI]O$N5O:2"!;\!; 3$
M0#L!S*U$X9.R9YV33@ET@_1W8K9'S:%/] V$<(&#I]+=QK7JS<C+(B7-:'<*
M;/ O"2L1P0'_5"$51=ZVYUKV^@,*]YXPU0#=VT?T'-L1#S.5K2"V A&"6?$9
M?W*BCCFP'AT9Y%M<VPP#C 5Z2A:WN%LEJF5E>"6A%Z1? W8.I+U,F@Q'^?[!
MI/YU4XP[^PI[]27D*GHWAF=6&51<MF"<4@Q+L2/K8]<1)^SCQ_O-9,"&9!N\
M3_>[TD*7&BE=!A5P)']JR"SM54LZS:E"LM9CYY[LLMJ0%\VCG[HG$*WMZ'4Y
ML,GU"S/>_$*%:A[MJH47G#&S3GB[,U7P987-NXFX*DSM(<%P4;<3LBY&#]$Q
MZGSMGC6MEI-B=46L-93@9V5!=]E];D:7$..]>$]V2KRN@UA(KZ]7TH"O5$@
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M98^5FS,;Z[0KNL6VFN!IMY8&4QJA#56*?;!O<Z7V$Y_'8_BAY'SP9GVPYPI
MM3[8&0APQ@L#AFM6<YN5+XT3E?&^^_E_6).SL0HKQTPXL$94-!='3$T+V:8?
MEBO,U)&/$2&S&< <#>1U;)25L+<C>'?:4IY&UT>7%SZE$,S"^A$'59SU_PT<
M&&P% E1F52*BG8F HW]G@>6&^Z+:&:,26IQR5G*XECTB,OP&(&GN'[[**PS
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MGT163A*1^-%U$':=_N9BIO]G*[LXK=PDWZ552+V21?K>'C5&S\XX@H_CX/P
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M()F6&^Z; ^UH0U+Y4^*=%*:Y1-5GS*]LIS.F4GBD0 P(D9>RB4WLW'FI1,4
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MW\\1-^>AP+":W(>&#)7V^).Q)AR9DSJJ->0QT""RJ+V]S (.[_MOW^&F Z>
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MSOXW1?D U= @CNC_XCO/>'3@D01O&$8)8[^JMU/C_) TJQ!B:--:UJ8IYN+
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MSL7LQFKGR?!SE=J&A,?1=UA+^K3L#DUC\(=J0U4,SLUI^S5 I9,I0Z4P&@P
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MXB^ 9(?/\-Y]G @R%\EA"N;1HU,INAA.ISNED;1=5_5'CA= ] M 9*[(?*)
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M$0WEPZ;IO^V&^)T\_.%[N3>:MUE@;N+3TYXV@W/)1VV]Y@-#F+C+PZ .,U7
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MSMS.Y<B+]J>EOT-@/5=1(L^FQ./(T:?,H@#@"M7M5PL1GYMMMH[E0<[$?;L
M<'CU)?--S!]C4K '?>Z!)7Z^_[ME0LT0B5(2;SZ?W!B#,_,?3R^ ZD"LV1?
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MXJ7\R >K&%F&\.M%ER'B"67-8#Y]@O"FO7QT4?,%==;)B"!55T?4")P:1=C
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MH*.$A^/[-%W= N7E.I@B5K!W+^CH:TQOX\',EF=$6_WIL][1<('&I!H;/A:
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M%X#5PA #)'2BCXK" CA8>,/@#(4-MP"1<,=_)RW-'C6@.!I^[79:]O)\P#'
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MQP)K#HX"['$\8^^UQ8<?/;+QIID-*_T8??,A,3*:@+F[.5FSYC0S*,K']?<
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M8&^'#4,?5!<0J$&PYA0AW"@R+NW994J>T%C*,5?M"Y[T."*O@4WA@UB":SB
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MKSP$\8*U>V1D=J#V5BNTZ]R_O0N0I->>WO 2(>;V[]CM=,DEOA7FVW3"\F(
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M$*GD[[1&\*24'?IH ,Y] T$*(!\-?-Q1>)J+)4<]R(6L*-0F?)?VGU,+, #
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MRI>_6X@FNL"==&GCV'@A,V+?L Y5U#QJ4-F>SQP\,<UEII>U7[T^[,O/HTX
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MSZ0;*YB4[#5A4GEKA%Q'8[L]LRK"KT)]&$4A'GP?#+#Z_UI8H*%;=S,9^F3
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M>%\[:6'FQ+JUFK/_5V8#&/3Y?0Z\0PNBF*"'$BJ[# 07GPPNMM?8\[X7'-
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ML"*7:(0'9Q05,>VW%,.-!8. R.D9$(PH\V_S<SAE4221^":18EQ655Q6@R@
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M*CC*DTE^=(0TM&0RHFX ^5^VP0#>2*][_M5"L+.LWX1R4":$<*ZH8 [_<-<
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M=!A1!4K),?W-*?^JYQ/6R_0/YQ;'OPI4(<1Z&3G/D36&'=ERG<YW)?<:E2D
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M9.>TLFLW>C=+7 !TF<NL>JS>5FEMU>F.Q,0Q61S=MFD>CWZ8VFJ$0/%G)J
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MJ]]U))!9$K,'H)][;H$RW=?GVOZ<=C2MB]G*C"5Z89[(PZ<)U#"/)(_+%P=
ME">CJB)ZU<=6R!L^XI9MPG^'5K&% <K1O+/PPPWUH^KZ7,?-O'=E*)2[9Z7L
MJ15HDU@UZ@;H"??<^D;0)J^B2D E7H)AMI+=]#"$P33/A# WNA6U=X 9\(TL
MXLJZJW'W]YOH%6A/*$(_K^X2RG]^-4XQ??R*X,4=XHIM[%"&C_]4;-=D3EE<
M1"X /]/OI81&PT[T-!<<=11 !.='Z@UMWPLPUC179L\X)I<*'W(F&+0S5Y*1
M-7@'$"VF[NZ'Z<G0Z1L#UT!Q(*)XX,.I-3;B*8\;>L[*9JT.\KASE"W#\#N
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M@^(SE]-GYI]E:J!QI9>4%RIW+B>TQ,VRQ7\U*>_L3M#UW@&6_V?[YVN]X3N
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M-="70SM5/*)37?8OJ<NNYKN&J0,R([HH1 Q1OIAGD-B\O]#3L:=.H/[4U08
M3W8=:[K@ETMSD&&"!G48"3*@]\X%4&]E(4VX5P?:9AR>-5*B(M8&D:OQVAV
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M1%@P80*3",KLMXA<U('&U@DOX*:CUT7#ISHIL^</Z;.8O1Z/1PDY:/"&/6@
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M:/AZW$?CF"/WI);@O]3$3)\7M%^J$@<2&6*=6-*[:VGH33\-VL)V_7RHYIW
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M,JV!>GQ3<W^6^BBTWR6!6^A_X%#A#"P((9U*\[?E&TI34VY+SV'RD$P(QY\
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M(N=.=0)E'DX-C7JHRP)^I:#A!!"'>4:Z0W,09T9B)D=OE'M/M6*(PI,8_8A
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MLA*<<5M\Z6HYWG:T;\ Q6P*"!VE]B*TQ"TMCK%LSNN'I8(3@ZA>?8N3K=]9
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M2T+=U!<3)+=(D++." F&5X2SRUFF=HH:G49%;DA@P7XA'96O!Y.;M-"*]!O
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M?;".>7"I)#^M>AKRB;J"^Z[=;8]Z\>1_&7Z$U(DJT_1MHKK+4%"2*(*/J]%
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M!6.JYC.17@/_%*DD@8?XL=VX&&(?,1TCRJLA:K8?ZW^Z<9-/^E-EO0>1B1:
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MD.@.V&)OX;EWH-Z%^02E/W8"!9Z>U5_8F1QE.G:TIQQI!?!'4NH30KB7@7N
M;^_^>.(9B5EPWICX%2\@TE\ZQ8E8?@6G%P$,TM"?Q?@)"T$SZ'PPI^SG\8MO
MQ8'T&)YC65TRO<[G;@^4B);!'[W81;\[ ?:[ZF]"RX*$[\ W)^D%)NO13;S^
M]A!+*5CY+B4P_QF'>-;":##N+7^MJY@?H=X"I1/5EF[-O)O%_)0_)]O@,$BX
MH5196AP!I60R6V&%UC#@$&W+R )MU)NC\D23(JLO#7<6E9##:&F,(K8:'UR4
M&P#O!Q,FT OO0E]^ZOO<..-"%Y%&-?<CE6DE4#L,/(AQ+U(H%;@%ZS7$"/P
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MB&=SX2STL8/X$+UX<.D,'QUH.1C5W 2!$(TD!GA5*)##U [FH0 J*@"4/#,
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MCL\"IOXL0>G/EQ.2'AP('<XO1Y&)MJJM]47W9<?+_ZI&@Y+QNFC:4&;TAO/
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MRY1GHL*"^]-(7RV)9H@']E7"_PX?Z!@SI(@S"Q ^VY$L1B!70S@/S Z!1!D
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M)%Y./ <G&&7-I.[C&32A$9/U4GY$Z1B1&6'9SX=+M5.J)_1W0.B8;.95([^
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M@.WC<&>;U,TP?&2HYRG5KO2BK_PVC=,S_0**\?3Q'*D2ZC"^WT&.#ECG/_9
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M&L\!<R%<T)NVF%Z9,T$;ID[KY"YEK40$@&Q4K%J14]%43#5C[.EFH#5IJ$Q
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MCDV4Z65;U3%58^86]=Q9W$"Y8'XZ+_P>]OA3#4N&<K'CL":7;%V*A#=O]CF
M(+*A7^'.*F.CP%4DN[H,2RTO9N2.2DD4552MMC^8I$@/32P7,Y92&)YNK:VT
M3@VO+Z06I0OY/Q% _.7%)=<K<(VNQ<$4B"H#5)#/N_J\6D*S\_&A%*(<]@XS
MUA0$LL%D"EKSB/&]37$NUTO;6ZFG3G-\"):X,$31:5WWZ!-)64RF;?8\^^]-
MYB*T43*,HH@N;)!3UU5]7@VZBB*YC'PI%V:GU$O(CR(9)S4">X?%1B0)(.Y6
M#(/O)V!BKP-J#+%/@Q&4[1Q_JT7_9R90,! +5)2OG\$QMD^V!#4>D>"1/.7K
MXL]NNA(UHW%WH.I=X]"<%Q3C7[3$L@9_U$'5[#+J*"A_R%5IYU?@6SOUC<3S
M) *NS1<8/?T3GVAT@K6PYV:GP6%*?4W%2'0EIDN1?T6A2_ZV8!H: M[(!:-A
MP-PU_XP[6<130JSD"YBKKU^A;#'7B>%\P&[R,$9"I 8+%PT\ZC@'-D7ZSH'8
MU7V9J_NE#CT!4-D]9LUU-^9WV/P&9 5[E>+,UZ]<OS8]8LST-'^=P^0$M9AW
MS+$:^/K6(=#8(Z?I:L'JZOZWO?*P?B&&<>MQS> 1DT]["Y7.3TJJJCID2LVX
M5Z$;!^.:L4XJSPNIK<GUP__RJR-_$ *21-Z'E5VR%8OFB7+Q(RYU.:H=0<UT
M$2VB8)OXMA>A!?(8&PQYG-YB^1B+&;E09^GU/13^"9P1^+V!/LQB,9]=E5O<
M'E\$#@7EBW:AP-?RW+BO#'+JTG-P4R/!NFR W'4.;A+$T]!</$P6T8/8WPX9
M_]G_Z1H=B!8JRJ]!>:&V3FFHL7S=C^;&7VL<4XQNK*[W/1)\J5G66S_M]"U:
M;IGDJLA]7WG=GLPVPYBD(!H+T4J[.TY?- H/4VATU\2CCVV"=J;:![&'9A81
M<B4OZZBBT69GSAZ\(TY4RP5[I>8DT-33B"6;L1W;%[^:)Z]%GX$*#R36W^YX
M5'2VW[0_!Y)"SJC_/2E'E;[BC7+6VR2Q6,D*6E$R$*#955RR->B,GLY[PQ'0
M9+>G([\G,&1Y#J2<M7NP-I\#D>7EXMQI#\X!'_GD<T#A*&;!R5OKRNJ/-62D
MJLCU$VEJ$8L%U^US@-9TIHD^A$;KX0VAH.1!+WJ*L(Z\YJ<UMI_*O0QKF39,
MI#0_XL9[V4IXNFZ2!3RJ2;-.C>N,#&9 M%^C6E7[5T_0_(-%^^])3KLH[66-
M> "6)\J$#(X6&\0C]VIQB,0P/<C'^Z48T!; L"P.N5'Q8&B[\\%',(P%#Q:3
M+0"X16)8.7/QVKR SW]37E8:S%6:8$HR-2*""_V]+"6'NJ0^^L>,_C8?6,KT
MOCZ.=022 B]W'(%@W:TRQK)M4*WU(\TE2CT-,<(91@7TV7%&?,UO(@93:WCP
M\>^^S4PT$NWJU=PXTEL&B]O!=_; SRRCI';O_,"R=R2+TO!D;NBYH]XQI%^*
ML2=:!X7.1E(;>Z<^I=,\RTO-&;*&:)Q3JVMM]@*,1DX__#4C7<C_0QC]7XA+
MHH6_;5$#GN>#T5F$&UGXTPB*201)Y7.2RN"(2@Q% I#&!TPB"'L \P2@Z?(G
MY20B=%J-8!I!.?T;8<(E3]/EJL,_=** )!*P-+U_>\?V>8^'V1.M>3L-6RK'
MIJB/22W^!JB2E%V'V3$CMA[M_!,#3\I%(LV#@CY&EK.T#>4/B]C\$]T^1BA/
M^H;Z0H,_5)ZMV$4P5<PX>"I[H2&'OI!>FCI01NPBFTX40W+J\ .;"7^-3_-/
M$827?N(_=9>U2_'0 (L],'WYQLVK ?2E<ES6D\1<,F, ?^_^.6/+U<$CU0/S
MA.M!S+/H-@E\:N@VQ0FKKR9<A.<^?UTWVG7%82QFQQ;.5T]3ED57CO_-F> B
M7[,$QT:,RR'!.O59BIC<WW8A_ 7>]3]7@/6 W/_B08LIXI\Z"ATP\WW103SB
M+"OB?#SW2YW2X0/-(T$+P51TP&<UHC\0+_#.)_\-4$L#!!0    ( &J!?U2;
MRA.JZFP  !9Z   2    :6UG,C,X,S(P,3@R7SDN:G!GS+ME5%W+MBT\<7=W
MEV#!W0D>@@1WE^#N'ER"! @2(#B!A;N[NP8/[AK<UL?>Y^Y[]S[OG'//N_?]
M^.9JH[4UVIQMK>I5HT;U/JHF^ ?X)X N)R4K!4!  @#$RP< +P$2 #PL+!PL
M##P<'!P" CPB,C8*,A(2,@$F%AHV"2$9*0DA,3$Y-0L=.243%3$Q/<\K)E8V
M3DY.,CH^(5YV018.3O;??@0" 0$!&0D9'P4%GYV"F(+]__H"=P 8\!!RD!-0
M$)0 ) 8$% 8$N <@>VDG#,3O%_ ?%P0D%#0,+!P\ B+2RP.UZ  D!!04)#04
M# PT],M=WY?[ #0&#"8%FQ@LEK(1'*4C-GM@_#=X*O'*3AR5R3-J#F.G( 1$
M7#Q\ D(:6CKZ5PR<7-P\O'S\$F\DI:1E9.7>JZJI:VAJ:9N8FIE;6%I]<'9Q
M=7/W\/0*_A@2&A8>$9F0^#DI.>5+:EI.;EY^06%1\?>JZIK:NOJ&QJ:N[I[>
MOOZ!P:&IZ9G9N?D?"XOK&YM;VSN[>_L'YQ>_+J^N;V[O[G_#!0% 0?QQ_4-<
M&"^X(*&AH:#A?L,% >G^VP,8T# 4;+"88LIP1HY8E.R!\-CB\=\J.Q&H.%3.
M<(R=)A%QJ3G7:<Y_@_8[LG\/6-#_"-E_ OLO7(L ,A3$R^!!80 BP,T]?4X
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MP<&\M%JZZSVVJ-'[K><[&OT65I5 T8X[CYMB5[10I;76F:S%!*I5SD-AV\G
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M^['O!HD"Z,3  7?JSDF$[VF3^$0DA$?EUL)O&#>]P*/0($PQ#2'!:=ZZ%C\
M:QN1'6TT?G_Y_8W&%Q*T 'N:61?9JZATM]"=^^TMGU@"*1PW,% % +XHKM0A
M!-00I_J.ZUDA&H2D82C1J^SS-]_H<-V%W\HG3JJ&4OTJ\M$Z2]CM(531%MMD
M=G8:JL)ISQJ/WA3I@OPU#L>9WMQ ^E4V#IZ 0 C&<T8?8BYG/OLE%WRL[XG)
M!46L\5P'10A/$(@"M@_-[F1E?-^]4CH?TM=PK1:;/,9U,+3+B$;3?3;+,08[
ME)S'8>-(\V7@J0.DI T^;(*!=<#^GMA' PP$P_QVKNC+Q#/F!T+[**[TA18M
M4)1\=CGVW T%37P4]YN/P0G9+*BP[FY]]%!SKR"0V>&I9C0PO,]VY$N(HES/
MLR+5\F/B\-J0<ZF(8W*IEBBK!9G/,C?%)C'[_/$/E[JK;2L;+HQUKQ$E_/F!
MRQSQZ 3@BK-VBW^W"^3=(UMB]>NV7$.'.A.W@L>=TBR>&^5AQG"+CU>X._9J
M6ON1U]M;AL*>X!:4QCN+H"!*SXO_TY:7=($38EE9U_Z1<1H,2'R*\C\S%;F-
MG#DK2RW:Y]9(3@O9GOVI4\\]K?>6)OX;A=N)H/M*+V#_+[?^7TS=M_TQ[+3]
M\*/(F-Q$Z8/_'=J:_SR\?\9GB&\O*QXL\MJ%T,)+7/';/Q&0V*O_U7WO"VP^
MNG+^^E&71!M5NOQCK&CG1I:MI6*@O &(=D(;*G2 *Z\U]: <NT;#U-4M%6;F
MOF'0W[&URGYC :$F(TDTV!7 #\"XMC'-L+B4H^JN:LMO+TN]-_'-&B-@@47<
M<G .<F+E.U;:NR\/-TM;7=,ZNU@BP(E:7M)CJOQ&\H68=;SN%$3._\=ZP?N2
M66GR7AK7)'*9/6^F:PD&$J;\C_3([I6LJ[+_,FG_P^!/6"AKZQ,V/'%YC55.
MCB=%M])^G:)XG(KB+2X)S41<1U4+DO?T##7C.&2;)L9Y'.J]CBX,?L:XJ]F)
M*6R<$:NK#T0EE*:ZA"H6"BAC[""%\17I2=&8=[>BVJ_F1(POALC(IJGR-FI2
MCY=/JN-T([,]QZWMC<G9QPU[UG^-YW,DLA#NT'Y&=:O6C(:T?^U.>>'/_0P&
MGOW*B48<GT_-R$X"=515G=TP(*IJ>(R/EL3M1#N^]/$$[C>#:+9#,K\AA%[/
M$86/GPWC&]W/1K[2176Y%5^=.9D\/:VI.\ D<.\% WYK5!>]GH4]>AH]BWX@
M:Q-O_R]&2()8G7B?J0W]SK<>AWS/C_67=$^C-F7)IR1RZA\5;,-&.!Y=\^C*
M<M]^ZE ?)PMAMBNC,&UM@?5.I1[TU$P,-?;<,HF=G5:6E'!WQY#_%_5@B_"3
M[?HI\T@BI.;^AI@-R 4H6YIW2*;1B&%=[AS"(=96CH6K6L-6T$KUB^CT3GC0
M90@#&U];)W@L_U1 _Q_4D/\SKM&BQK(YL9XR6*)\<\@$7QI:]EMIC=N_MEZ(
M[W*GOB@;C67&XMPGDV":.8'$UFXCU(!;4SR"U%S<]@;=4\FQO<XQ(WI>83WB
MZOV&@A^)F"N4'2%NO??''JV%"&B+:5=7%R48(8WCK!\W:PNW#_8+6P_"CL_5
M5DOSL0UE=+(-<]/=A*5XZ+=A+I7-"\,,H0WBE5($L@<(<6VK_%#1 &/=3*VO
M@'2@^4PYZ)C2?!$D& A%)I99:T5B*NEB.-#-,.0$?X4-D;H>8;=[5O?Y9I]?
M_RF9S:$>J4Z1E1ZEP6N+</:% .T(/HD)4X=W?5 H$'X1D5E[P]QG4FAE$VM#
M35ZFB9((8DSA(4O&=H8\/-E7@H2^ +M).#6?XT56 _N*@/?\9['7T;M54VI8
M>EI4GCC::HOR3T7H%N.J%V@DU9FWY4I9*I6U*+NK8K@+F+1KY/CNY Q9XDZL
M CN@%QX\'I/?'JQ0E?B.,/%MRAE'?J0=,WH< 13:R='*%6]9Z,$.$:-L69F9
M9G8(H2RU2<!W6%D1L3<:K..6*<H#R*A!DLX=#%)BNXL!@F6'SUA8Q;J<4>5/
M86.)QSG+,2]1JTAWM')]?'%C4J_OK)_T+6H]VZI;E6\&IL;?2M ?M,CCLEGF
MI6K2XT4QM3$+"S*UH7$D=A?VNK/KV82H#G*"[]6N;J]MQWI*=DT92,U.L3^3
M:55]N!#A!S8$Q;A;VBAG-RKU;$L7IV:"$7VR(]I]*$36+CZ1_,IP8OP:YR-Z
MH3- .+\HG@CAU"P\6/6.K'Z1HYI@E_>FW#@G@ \,P,:\L4SPMWPJ3R]6J&CE
MRQ!KWEI;X[W:Q1]U^5]OOHZ" :J5K*?@ C P&3]W]?<^SP0:_VVQO;,K:2I*
M8:C%K*D)^8.*9W1=<'06,X%\X@],.!SW]=!X^UQ+/-RS)6M'F6F[I%K+'ELJ
M0Z=(! AOD[M9M(@+H=+K:MKV0BM_JXKF2LK+X5\(W&;3%B]T@FZN7A *I%"Z
M5[YSX*6?;9MJA+F_\=:0_F'I;F4M4E3!?]-61';&SI:+R'I)+731^IM 7SYU
M+),]8RCSHP0!%-_&=]ES/(4(0I[I6C:_!'ZAL,^93C#1<F-^MLUN[)EH/JX;
MV7/") 6-I0;Z*P;]B,M+"C:2^461TI@ 7-J=L/EH=E''OK+"V<6)=\K,DCZ4
M9M+6+SO)+Q<C]HA=JM+-09"OX.@RSF/IH<1%PM.(4Y1STH,M*%3QGC4OH$/)
M>"GX5IJ'=PL$+ 350'A]7N95*<CJWF2TO(64MTS>.9^QB((36'\(.8CADZM3
MBR S&YG5Z$D9'+G&6SS0)?/<E=A?._B,7"[],B'QWHQLS[G%7!Q#^E);_&WN
MS=SU=3I=K3)9$JR;&0)YG6:"KQ>$* ZS/;.]'WM+<@KK6'#WNOR;]0 1R_UX
MO5'/YY3<_;37?:^8+T'\<WUX$U U;A.E'T:OHTU#H#(@] /_+BC44'34HZ3K
MM';JFU(1.A\X:<5;+*A1@V-K(/Q*#-:6K)*Q]%<&J()PF(Y\18JOOZ>QM-J6
M=4PO=KL3BS(R+HN:H**)YUWA)-J)K#//SIV'N@@0B$Q^OFQ.?2?8?1#I8?!^
MW$C-[J?FA V+_6NR'OY2*8'&:;/:9O_A4B%Q,-"VHOD$]\$ Q7] NL?@&E/D
MGIG1[F#=EMFLP35^CHM)G9.IGS3 2<&I#6\V_BI&A;9JAI*G/H93@3DWY_AB
MQDFF8UM1VZOFQUA7)'T1^N\I5SA_W19+H_E![3F+^-=/EFOS/7X7KDI)SL4?
MB-?JZHNN&6[)\?#9X4;HF X<F5?&_U7K!_X7!/SO#/5]#[]Y7AO3E.L#(_1,
M;FU=YL+QVQ(BBKAOF*_L1#X6;Q&3/C%FMDX(F@B#/#EI+5-7W6-=9N"CCH[M
MU 4<<461J]#=?[J,>?9ZF6%#;'=W/3/5!4CNZ*]HG50G;"P]*'RLCL<J73=E
M3KI[K*,B)RG$UO>P[YNR3LLXUU\N9=>1JTNWJ\HF\BW&,KLUHAMM>*WO[E:N
MG/.2Z/RA#\=I*K^RV!O6ME<URVS-:#928E;']38(#/".\?(>#GZ_->@C.XNI
MX6863(L9W9Y)E%O\G)ZC-[YE0S0K'J!!57^CX)7_TJ;#GV  7;)D3:\495=?
M=S\%4Q>I)8B2[>Y -;.=D?0+5>"^$AK2[<K1*14/GO)R"R3?#F$\Y8%!#95G
M9?3S'GQWM$^K:&>?]>Q>-IK K(N>\?QZ>=01+8="*HO^(*$)1[H-+%*"K!"^
M8<8O"4OM[>NJ^]:\&]@I[TL/])6*J",%JYI/C )2IIU]''W6D_39:#B*H9D4
MBFBT25NBMD;5H3OT@K-$]I%]";^F :H*X3+K]K,,)^[VC:6*TKKJ#Q\J(>&7
M!Y$MCX3J(3F.]?3^-3?]S[6<8VUIP?HFR)E\#9IW 4O$4Z0)E='\K_M+T'6+
M2;5;H;QO\P/&1Y&R^V<"U?=R EC-7\C"R?ASY[3_WL"A5\5?W?0]2!R4&:@K
M;!BD"8C+_)RX/V8F\5^X8]F?=]C_>CQ(M=9SHV[RE"93-9(-R6RE HZTUJWE
M9N,S^\$<=YI"L.#\]YWMX\1G3X:,9M( J&DA1;FBDF9(/)DF?W0/;YFSYZ]L
MN(<6&#,G)B('T_;W22)K-NB^L+Z2[A5B.* 6MS.IRF["CV^4 [)=(!O0/MZ3
M/*?FZ:ZN?(U;LTF K[?8[KP;+W 28;CD=UX=L*'/B0S\[ZJ7\&L.3XQ8G6L7
M]%995QWJ2[[=EZ6*</X#WPK\YR'4KD67<R(91/^\V?(W:QS'.]#P^K#G;_JE
M]_JK_N*J+N NU7.B[^LH2D*"T^O!TVO__59:)MDJ\_K",KRE*:!/?;;?4TIJ
MK4! @\UQDS'YC'T0+G+B$*5X65M;CA"H2DJJ(Y#5*\$7Q=\DP.]S8H<X_*SN
MEUK$=5E?69-<?FWU40RTL_I.66<7_TYQ=#J3U7G4\E^<B,.1UDK0=!$2UR1(
M5JV+CT\I,BS$OQD%]'-:ICLSZ6:0Z]WF$W37UFIC/L[-.?%*)W+OF3$80)UB
M*@HY*WN$]6BX+8Y'VAY=67?R[YW+XS1!4-1G.8<A OU(%8F#P$Z D'CDNB ,
MR&!Y85%'7P\A.D$O;AHO_JN*)+QQ(B!HR,W#C7#$RQ5ANTDB(9JNV]R8IJ<_
M-;9MUM0D;1P!-7!8:<(@V/A^:RA(3#FS!N)@1B-3<M, L]<G?M5R;N3[,')%
MYXYG@7H-#[Z*1P>5Q<RL+U;_,\7LM^FH_63TVM&1\!.2!17.L!'RS=PK?>]K
M$GJHJ;URVJDVB@]-(VY>GW?F%F$2G-0ACS D2V20!_*2B4+AQ!WC]]5=UB((
MKU9S<W7J$LV8W!U*JUI4V$^7Q[C[,TL#I=;'Z8J(X]"4<EIV._7)YWS$B@Y3
MQK<)TA7K/)C#OE!$OM]))++K'T&=Z/%"'/&/()RK+#"0AHWA*K.A;9(5=3$B
M=JCP(7;8<*SQ=HX$KM(8A\IJU[!T#QDM2&:K1FU+WU1(F21))\Q%WWT._E4L
M<GN19>-%%E;+QY6%:M64,>&)N;(DS=$[/J E1O7[29^_'43YD_A,^O;7S>27
M5?\EM2,3M&]Y5X.!"I>U>W;^U=*_N@7WO^6*@#^B]N_J:XZYS_*R8*#2Q7]?
MK&SHS^_P'5MK!DM68<G$<$ZQQJZN"NM;H4DJ/WFC6LK]E"@[-%AP[(6I$;&:
M*8N0US%T;+DQ%XISI:U:)1)!VJM_?^"NP)WKAZ_H1&G./EBS+@H<*T^@!M5P
M,I-Z6YG-<DEKU7IG0T>WNV$?4"I>2Y<[C]K.ZC'#.OO!S]C:/7*86",UIDTM
MTN](Q:28V.X/$.QY:<A*8J<WH_\9R#\SJ;\30W5+?]DC**^"W?[[ XU::7WM
M!7N,=JX(7U&&OZQKKGMJ_7AE#)E-%X#PR/BN<0W+LBDVWSO78-]YL=^Y8%FP
MTRXIDM<R3="G4-!N?%T4BPS?DJ\*H8BI[YJ-B?2-/8O2UV]C$VYE'L.&%I'U
MWB K-VU0:(J[,Z'^&BYW)7N";O;@+CY9+,=B8PQ1IW96Z.GQ2<VHU-Q[FJI.
M'Q9#^R\1^N+GQ_8IJ;JV@BZ/>AMDT >$<ZTLY;B5UYY&W'U#%.CT;>]/!2YX
MG'H^?8YERYB TQXU,ZO57>K<;8@18V@SB;^1+NX05,65?CM3BKDQAY^Y*"YW
M$F8GP_N0![4TU9!_ZRB2B#ER;]8S=_]]+>^BHW=7;TSF<^*P40>TOXL?@NW9
MZCW"T=*#GF##AHE# ?NJS9 9Z^#@,QE/_)KQ!)PW\\K75+5DRQPK=VS=@"E;
M EX2'<#MLG!13\+;"F6V&3?4LB<^(5]6A1T5%?YPM65<YE;#LS _:MS3Q)$+
M=+A,[_'E.V,7E6%;F .J@#E(^Y%KAKQMNL!7!4%X&!G1@JT]HX#7)Y>0Y <&
MVUVXX(77%4 :+^F4B7SF?:LXKBQH3SQ75UG5EV>N.5&:0)Q9*B/<XJRG]X]?
M\])0F6&^_,IRJMQL7#=7T3*5I!OW'8&7Y!;G0_75\>L'^^[%Y*1=3Q';NH2U
MD:5F\RO&#/<^2V#JJH39J*PWO9E(ZXW*B7B#<>0FP>%%TZS]K6PIX:9J?:3
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M)(7.QV1(<VK]UPUN!9Y#](C  & "!A!W[-O0K6X(!QOJ6JUU8&U'K8DEML&
M&:H'61B.P_:#A+I =ZE5@.D!=X")X%C[IO)7?ZGWH;.E<'/;(GW5[>O F;\_
MTC[T?3KOH$@LX]?SM>X53'OH@_B]3+SI]IHTBBW?S#FN1+?UB9\FT3-[E.,1
M;73[330SW-=L!04CS2OK&39BF:D$@]<EI'BMU7.Z'EE*K?4/JIT)BRMY@+9T
M!@[!,U6L3KM8K_GMIW7NK\6*R(M,R??">#9QO3;(ML\32E)$=^<Z_.[=_H@+
M/R3L'7-^&(Q$A34VU4DG2"PG2.__4*LGU>,AF/2W^N$_?E7_]&1P_IVP/9*S
ME;1G1=8AD?A8<]UAI/_7TX?Z1W+2EW7VFXX4&.B@!P-=WS^(H+8(.)I/6BW:
M9J;PD4<<VR8A7/-"42U68_B_.;=+ 2W6%-/7N?!Z[!KF>9ED2G[XTW^46<C?
M.G[3T?X\RW3LJA5E*C3;5*%H!L?[7)NZ7AZ61NSU*3PV=]V69]!7IC8KW8J
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MFE,J5%]Z>G-9VGM4$Z0/TX#A\]<Q!1.U6L?K%;+'1X9!.]=2GTN@D]\3WIG
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M>D6)<*W'L-I"0&;0X\S]8P<]]_ET-@\NWH62I$FD"7/EMQ*#6.6.BKX##KS
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M6I%3.YZ7_[VK^]_@@'4DMK+C+%5G0:*X%H12N4X-S?V6/@4F@"$%+:J@LZ*
MNHZN\ZKJ&$;8&9%Y(WV118TK3PQ7[#R5IY)JJJ'4?E]?2UP?A(U!;,^+V]38
M.INI6B!P*9VD=<FFI(30-.9T2 &P'P&$"PWJ?!'J<]N;V"=IJU6K:#$2J=XW
MN5TE'ZU/DUF7NM6O]DN:@90]X_ 6/2DR5O5%2$SZT,)>7?E?27F\C%!$+E+T
M4(_I+KH<F7WU8K>#TP3/$I/DH+&V-[!K.)YD4ZD!/G=IC=93?*+Q(X=%4374
MV:&!'3TC9XYN\X0*'5S[K@(!*\;':JN4"\YS1>$V]@[YOI;L#JVPHH1W1?I?
M'O]1/UY;&S0V!PH/_:,&==]-D9\&,H C]P* YQ=F#!MW=EQ+WJHAE3[7B4@_
M0'VOH<TG2G&,W-^UMM=REO/U#-Y4HB;^?%/>XYQ'M@3/N/(=?P!Z&M9L\B%9
MBTOQ'%UZ@]_?67W&GI+A=DO/AI!8:XM)7%--_1])L%=Z6:%4<.]_,<N\^F:'
MY@%UBZ^QSN'R.(/6!#3*,X)D[:)6+XR$7@PEOTG$K!-,%-OB3\-0A##Z/G-[
MJS)RNN4&'?G&G*X6\X/365CC>)8V+F+Z9<;EH79STZ@^1.9B8)2R;<J:2,<F
M7@4\3<M J3%QL3=L<7J)ODTI^'I#O 7:*2M&K.OOF?_12WSBUX<QHG=@KID7
M?',K-']\J7VGUZ26E7\;J<#IOOPAJX"[JW:-NR$#E9X[H)FM+7'(^S3N.J!0
M=E&2<WQ A$)_<$!FQ)8.GA^!B]-L)JI,8D1N;I"OJ3D\3_3?321C\&U1@;LD
MS-O)(W2IWC,W1:M'?/:" 2CT]V-O@7[X:V?5_UPUW]_/_,%!7%=_J=E/4MQ2
MG1+TX@.^=_"T^9X8.F1W:=YTCC:,>0MEDT^G>\0DNQ0'=O'Y]H-SL:10@+4!
M3P25@P2F8G M'4;_'N1LVP=GC/M.H*V36UC'6&9E[KQ9C/H]'ZF)@_UIH9VL
M[EKY.">B\H 8?*R"A58[+(M#83G2 =_0W<B3X*L2]@_V&3? 0=YAB7:ZJG"X
M3#2XA,7:*I&8 -)EE=BJ4]"_P6G=2HNOZ'Y5FX>U73G,PTD?[G'E+X$]3$X*
MUYV+?%PJ:@WJ> ".4IH:V1>)]"HH):AH>ZG$-$E _7 J/6PB#AX!B K+<>[V
MJRC)\W7._+.G\\[QH#T%6JOY=5;"V\*89Q?=^6GHQV$GY066J;/38[V.A25I
M+#BVY""F["P1%Q3Q8Z^M_JW"K1+.3H'%6\D\%)#9F; :$6W\7G^CI8KL>J@2
MJG$[#?8A"QP#"L"WZ2>,P!'/\'2!GU(H3.MD<HK;J',AG XB:,UB.1$TSX%@
M$C?4YZ<!F\_;P@E?Q<"Q%*T+M#U#$S:-/5"-::,T,]#\:N@N08F%_WK17\AQ
M&V[OBWKR8)Y;P$T7GI87:UY."M.']CA2L2=,W12B\=@V-JF"+Q>>#\C]Q-8R
M@Q!7C1^RKH1HTKG;%%.Y\I*O9-J5L\^Q^Z>D1;D2F_@)VX0AV7%._5]G^!T@
M#+#WH?H_WS9,4X^S8B2P7*:!9^CL9GJ41?2RR QU=!RONP,IIE@CY_<$-M+G
M\/HK?KH9KC6/=EF(-:PL:NQ!R"HF">'AZJ('CH<<,H6<X:_44M3+*W%QV>:*
MQH<H%#/D0E%ZEO:[8[UW.X%'YUGQO\5P</P+W"!S*&N9YF/2]L7-.,Q#=HD$
M"UME\+$"]TYC5LA[O"<+VKX&YA$B\QPFYB%]<QUN"](N0H$DUZ<X9(%"[!A!
MS"6O0E^1.B7WDUN!9UYTG!:C4;Z-?EME=$)H&0H:J*WU;>*$9%VCM[@ ST=R
MEN)_3T']^Z_4?2NTF?)2;4C)$2_$P'.1/L<QMVM#OO^ST7%H]T7T3W+U]&EJ
M^^7P\/!$$U(.&-=K:1;*J$WR_+CO@.$V';REYD3<^Z.SJ4SF"1=9;!%#!283
MR0@/* +NM2MWF[F/X-0!ZRG(,]$)>D&!=M21G;0L<US(@=E!'ZDD!U?[1(8V
MV\.DY8.A5SN^8-T@"K9YC04#=(B-/0Q8<T*YN9-81<^YN'XS9YB3_(3*82"6
M .]1TR'^;N']6U6GZ7'?9+HR2*'S^BRJ@XS)0FK+L 6>B]H;R"WV[9A6KQB9
M_B;%<BBZEY0*QK@9$J7F'E%G7TZN/8OD6-/=&IJ@-='SW4A*GPO!L /V=N6=
MSI3'Q9[_GVHI_VO^8?/^%XD&V>',T,^X+DN/NCNK<%M,,][@@ZM#F^[[^E?P
M#P IB@[BAUG@=V+@W[F"XN+[J:F*=V5R_.)@8C%<VQR9M&=YI1PPZ2CG<!UY
MYOV5.(4W8ITVE,J'J;J99&_W&D5742)UIR9SQ@[2.;KK<N>$,KRC'#_-AP&_
M,BJ\E'SMLR\_J$TP:ZJMSHUI&C+5P7V5)2#9X]6",=6S9 L*F7AJ<%4WF!G"
M>_*!5?12#<S@\S+J%"[?L8A8*NQK(I6?_ZPH?C3<+S?<&R)2@-G+K6B/> 7<
M_D?J\L4I]+X7IX,G05W$P6?3W47?98L)#@RGO]=E+T;"C=,CO2;+@NM];70.
MYFZ:B)]&>N/+UC+_<0.ZRSG=+#CSJ7/T+@4%]':?Q9H9!1>>68 2J>7TA)]T
M NXG8F1VT<7+5FOL#]IE[BF82&"_%B9/F.+'[23=0B;E74+GXO'V^^*<4.W2
M<>X!S5L)N5EN&GE^M:DAI&_OILU/L%Z)E8AN)+]XULK?;063+X<-'I2Z9Q0'
M?6E6G1PXOS#0K*Z48GO&&,/!YMA#^ET1V0X)"?DM8W#%Y5=K3\3]G:RED(P(
M69MYF9<',5(%L@ CKO$:;<![-^[\M#V!P &M_;F4.O_]@[?%S6?>8:^D6O0G
M7LCV;B4!.W0E)"*OWE/*E@@).J+5!2WMK/-B5??06!?,(%/_^%Z:-N3YX4#(
M+.;V=;CTC7=:U0+3>K7HWKM]B$'M V"$EA^M?IZ&/A6VYL6ZFKQ79UUT)B@K
M.I;3(.<YN!.*JEP[I^A0J\BFH),K<O?O'9$<)K.H$;Z!LG>,9*UKMI^=?GHZ
MBZ9RBX:R-'>O%$O9I[0AJ71?A+3=9ZE&TLSO:\EGEST \8H%/F*/FA+Q/\N&
M:YM>=G/L4IS+10K/\:U%N2EW:KGS",62JRORV6^LKT6064 9OX]5%:/NN5Y[
M1R;,9J,QQ0Z1:ZS5FLTP?6:[Z90#'/>6_/A+@ZZWRR[=,T&^QKL)I-I4[M7G
M\VNVB?4\[L5HGJMLHS[]#\ +$IFK,>L'0":ZK^<!,"U1J))+NRQMKTZR_AJ4
MH.]N:48;-/>T,0)1,VC[5^G363[:5(M]31Q8G83>NI$I\E0^]PR&8&KG=?&J
M4$*2[L_L.3KJV.EWI@EFN^^" V^1US0%I$,:.9'#8W>[VY8HXJ%I2PGR"+&"
M08JN4%JA3Q>%S4TPFF_<G4=W'8X-PR$I';[UJ-O[>8.0HKSNW+6>_--DJ'!I
MR:FEH/DK;WJ*D*!HBWUC01Y(EK[,+;TC&R=1-Q9#O @)C!9>]!C58[-1$%:H
M,'5Z<S-;B::[A,([3Q738BKY48T<+7="/7>*-I1FK/(7A@Y/IL&XADRK:1C^
M28,C7"P2WQ"'.=S09?BJEP!2L'T^;]#9YG&YOW#RZT1:,L[O@<03<[P=W[@C
M2:<5%=#=/C/!@I\(XH)]D8C9+DJF9,8TYOBQ=/#U"E$#1+X4%(3AB*G" W!^
MB(![:4@SV[R;K](X,UF[UCS1+,_]]4+;3 \916JS^S;[_%0]ZZ7\V@.0[MJ1
M>LGD$:<SS2532ELYR4P3*R_ 5SKRK0*%@"<WWK'?MN76TE!VDGR*ZZS1GSI2
MKM&:N+]JS<F@J$A8'$$1&=X<%C2WUZ6N2T9*./5)++FB>B.[!T@9-63@WTM5
MT)JOOPPU-2V33W<+U95OXQ*PW'R-70[_Z[G"B@ZH2#&1Y0UY[X]-ND07^)K\
M:W5JUD@O0<<[L*]PTR@BXL0'+E'8-O$W"=GA_EA-SXL=,0((YF65Y6JQB&?V
MT7TY5I@A*3,T:46!@(PC"D,H;/OG"OLCPTQC^?D !-3YMA5=VNJ.5_6;S[4M
M@6SII[V4.RAM4R0*]5R,];R]W0NUXLMMLQ=F)(0<V9N_@[I&<U0U J369NS,
MGI0DKWK**R@3>LSM\DS3X":J'8RNH(:IL",&\['\3+%6QV"-]N(_3\\C8MRJ
M#\+#!",/G7<SC=$-L]^O?X?X*'53"B:)AITN.MQ;RK&+]@3);#AU.*8Y1/0X
M]J"R.88!"__;IRSAU( 90X,CBYW<FOM>N51_P/:[^A&J)39(,"S3]L1-V+T;
M9W8*Z>>J-:]80S6HP7SS*SB;%54_ @M)U=1 YI7#+E_O^:H??[^.[P=?$MVA
M);R)V(_[EP;'J#$'<]1?@F\N6WM)'%M7:U([D@HRV8[B\V0(NA,Q1"_OF"]"
M3E-X.Y^94V<-NC-(HB8H=3SO;DKMD^(?'I!8!L1HOYM4.@E;H/G*WS@W<K8%
MF+]B'TK7T>*EFP4@N^:++O##Q4+.:\P62+@^!-^E*G!B5R?5'7PK<$V44GU\
MOB(T4Q(Z;PQ60A"G;*M2*XCB+:_T$B- U7'M,7A"^F+7ZCF[<]G-X=G:%KR>
MM]_PJ"@VOL7Y 0>RY!C%!KPAE9]'2X6TYHR[4XR)JR\ L9Q5[LBA4Z$U(,#G
M7'#<81_I?>0:L_%IN$GTRGT^H?6*GJ?3.]\*@E;XHYP]71$84HH!371+?4&Y
M74-.+*[2 ^#%S[W423'X_&W=W"Z^Z<CXKMA*7/=<?GW08"-:,?-$6>(4*\^O
M@R=I$*-]36D^H4??'.M6"<82763.$W.)>TN]D*QI:FP:%\,6Q&.,G+HJ&NQQ
M^#[;P$N'-&G* 4UB7X')E8:]LK,)GLYJ*_^U%'NGY0CRJP?@F4_= _":]/$X
M^A;_O(2J)W0G?>>M/G=PH]0"A?M!7[A7/P!LVC:/RC>E@K&F1.JD2^N-+?5$
MDLY^3;RZPZPTOK_70LCGDMYX_(],IGFT) **3WS;/I;XC@07/P"_]FSO!;6'
M@^_IW))5IZLL"1I1? PKO?/**@ISJ?0'(K#CIC=$OVTVB8SM,L[SL2Q;CPP3
M]A(9$J@1(!]S)=2\[NJSS G35*-B4:9>@$:U>(P@8^5Y24XX74&AQD=2%2P'
MGU--0OKA3MZ^<B%CA+2+]G,G+C\ H<U4,*2OS)/=_J7K1M^Z2$?!F/Y1[(ST
M/<-\/?>J3?9K"NB]/'&^CL:"OIG2KB3S+5F:1;NMO,0;<HCZQUNYPI:V[?>4
M53!4SD;<"YY#>(9>M#Y$.P+X_&5P0!'&QQ*TW]54;?HE#\!(X#\P\BO/NK6=
M6QMTM3W^,P=)JHGELA\6BJFP>3K\J;QW.[C*RE)@@9!8K4);W)Y"6[O3"I4.
MGU*F5:5:IJ47YY/C6B3.X6?;G*5A1X0-*_OG<?;D)H$1;VKP!5N9:R(@XFGH
M76&;7*4DYEI#Z9:6YCA+\^"0+3>_B-Z-T'?2WX.>.KAU6VW6>_PI%R_'DY\[
M_]8 <KY$CU<@Y(=UJ2HOLHG29'$OYYZ9)$J#LTB$1##PW4@1J>KW(*][VO+8
MQU.00KZZ*B3_[!2,OG$G5EBOFTY:F#W_4;)- =_+U^F"3-%!]'FEF)[XH?;0
MMP=@1N15\MN$C1_-+I#1:,FXPN[+NY4'X$F!5B'<^.C?TD1)0.GGZ.FB4J;E
M'IT-H6B]D3;X 9@J+"@(P5%AR&L!]. T1,AA-4&WS/8(A%/%B%GC)\16*.PD
M'&+(\ LPD)T"SF2C*^;;V':*8%G,#4T%\D\+BD\&45TQ>U%'B\ RV23X1FQ"
MF-+9AO-NTJ\K*^NJ@UJ]"K.P^DBE'7H$6#:I @GX #]&$]D7='.R)$J8N":&
M?L"N; &A6E/V7CC].*M!'18FF8G;L,0I'Y\P.MT3QD,T<\+0[PNS!^X;FHM3
MTE(G."Y(J%DX@FYKQ!]\5W!&12OU)T1:?IJ'T$PMS?2A,N(,$?@MLR-$:\WD
MC;EEQ<O$JIA3=IVB/M,^YA T\6,_PT"=T]ZQ-3=Z,:://2K!TT[[A9H_)I#V
M^\VX]*=*T2JMQ5XCJOIJ+*LO#:B5$D\[Q><TT"^'^'9 DXC9T*93!>I*B %5
M]$MBK" UAO;4UT_3T*4E+EUML[VK&0NO;*T.8@KGO](5N2*A_V*_ZN)CP"--
M8:]##N22,X..,3+_-*WCM:])NOF<6X@[]-XS0$9XSR0,Z%)XM@UN=;5A$@^
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M/(F \Y>3E23_0_$\S/XO4$L#!!0    ( &J!?U3\1PCS<Z@# /&S*  1
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M*Z3,)($5F<0V=4$"82)4OV,X'O4<P]CU2H%MQ&$V*)6I;U'7I@;Q/-L 76F
MKC01'"H0(M"]P-7=P:;FCVB!X0W\#Y[1-4WN'L][.+.YXLC3*OUJ7F'M9X^
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M+BJXI^;JZSB+VQ(H:QI2FR 0SS*YYUO$-H2+TPD]$L+YDLBV#<:HJ_.(;91
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MWGS3<?::_V]L"F5QXTF&JX4DP[80W]9RM+)4[% >8F!$<99R;+$26CC7V$0
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MH(,[EU.P>MI@4)9?T33^5YVT>'ET_K%XM0?NP6R6Q/(&2I4T(5<QZH*147:
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M\PP/TP=[AE<W*><B0B6MTE)5GF/P\3H6-W6@)A<%&B!H =1V-YK=I>Q,1:L
M?E5_'K4PL?WL&-)2TRO^)<UNTIJZU+\EO>TM$EN_95O1C<H$3.D<3)2J4"8(
M578%+*]*$*1V(2.'7T^PU;EN6,^T$"M$2X'ET<E<XW$4"?FFLM6@UYNWUOW
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MTDJ2YN[J9M*% 3,<?#2QKQUV^14>%ZPJ$+5K\0>U#])83O63]M"\OQ%P=]I
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M4F>)H_ZHX9%DG1R'DTJR&^5U55,\B0RU;)_^Y+'7DE1YFG6.4NU[%L)/KQN
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M'>3<@MQI8G;#VIZA*['C7O3I4VTOC&IL5&,;4V,R4UC<A=EO;%.TP^\OR%Y
M=FR&S:L\8)V_G.#T^!#N>[/UV>.;(IUAY$G6>>7U\R1;U4SQ%(R5G/WZ OYA
M6KYEZH9O_D/?_^?LZ@4XG>7J+YI]DCV1GN'/;M\T*PL\^ .389M0.CLL*1ZK
M=2YJ/+A1T^RZIME>_!#IZ"K#M%M1M\.GA6H!6I5%;%IU'NC44:'C*IV*4DL%
MJ)BJ:/J/5N@U6;Q>5P;*J"-+J$H\/=QWU!8"JAC:HI?1>5(JF(>A+Y$T ZRB
MU:"*TELIL\&IO['K?^SZW[:Z41?CB@YP_$3,8)G'_9Z3+GN_..$34]K?*R2\
M,>4UC,6MVG-LUP I/-Q%O_AM?^ )\Z:!%N<4H5Y:D1)9J!7)TKI(H$NBI7QE
M5?)2O&YQHFI=SJ#B<#])=P%6[,BLW-K] R/PS:@"=T@%ON^S^^K@?)_UART8
M9=9;E=XUA?(XI;KIUESH!5$M($G<]'0B?H]T!EH!4,^)ZT0 2B=L:J@K2Q:@
M]'#[E/60Q!'(MCE+1-O8TZLL0?FG_BS5GQ0DLX0/F,'WO1(3Y11@$Q )Y7C)
MGD.@U165TZP9];,D^'@F%"0LR[$&+DP0U>AWFGPX9'LJMUXGQ?NMD[7;<\\C
MM1&=]6G$Z8XUUB,ZZZ@P=UUAOFN*D>Z)!J%0[1+C31$:2F6RB(JR('H'[0X-
M6^DW+5MW(6F:F%VO) "+=Q=J E3+Y5+::;E<L%>"!P_N6TDU4D3;N"G#D& .
M=%59[80B"8;;:S/KZK1K$(5^I=MJXMKKE73)@4>KJQOO+UZ\656PJ-6 -.U+
M=0^)TRBGL+&50A'NPQ#UJBWKPL2ELL:%,HHE3ZQ=U?Z]9L4H_T?YOVW9MTK^
MG]6UR8EJ4P$::/Y4 !P+%5)M*H+*F#XM"BPTEOS69T#5WXR4I"0)<G_36]"#
M,;NW7+;'14.D0!FQDO %N%MI$5_W2X-E,&5%U?&2.*D%EVP-:A1H5\?\0!%R
M@S@DPV5-MW8GXGJP0DW41PKYY2KK&A(HZX6N]A5Y1V]D1&QE&U<IJ*S?HQJJ
MH R+U?!$9NJ<>Y&W>*$PNC49>%Y=]:-J7<YJL4I-^7FX8;.)S&!A95LO+#5<
M^V(5CPV=FB<(ZG-3TW0-QK&B9Z$_'+0#_5GHSXM3T)U*."Q(A!KF6XXSS'M0
M 6W*;P'H2G7F24'P=]$!#:TT,695CK9.,4\%Z#B,HO;F)$J+:6$>,6KKZJJ=
MX[;B+54)ZHBZ/RKRW5+D)S5^RPJ"9TPDLJEW49;#3?$5I11^+8?]3B0:G<(I
M;L?0+T1.:\Q2E7:1W6EY"9Q73.+9BK' PY9["VX+,)CJVE4828F4-^V;=Z-6
M>R\L(<EHLQTDG).F3P?X-:Z]J+N@L,T=L'U/0CZ#*LW99*]_.'N] ]AKSN=*
MX-UG$UD\V)O3W('Y*<CVFW2AI_F>M:-(GHADIB$@G43ZZ%JC%\9H:7E<?-GK
M4U%+.>W2VBS;59*%"OCV#OG<[QL-.2 X#(9714&78'UMNQ9F+.W:A.. _>],
M)6R*"8)&TA0L\L[$EJ)#BA8)0Y4C"'LN6);SI?:^5GST QCR/IU'(HWLJ&T1
ME"DDB@EV')DK)T1,@"#!!D<-(E1]UE1,0Y11S1 57)1<.1=BMFSH=^-!EYM6
M^U8]VF5M' ?$# US^#R-PST<S926%8@0&FK7@F?P\1Z.L,XE5"5>(4H*JT<$
M8;A-]T/8OHS1$!$?4\3US&DB*H8C?0NI .5%I?B7F(D$L3/ACXK1^G-<*VRO
M@!U(Z.W6^V#&;L5-F$&'7:(4[9CW->K3D0!?\DB"Y*EJB,O: WDG$3\N%T!)
M#A7@QQ9K>-?V(H=&H*/H?V!@B *X:3$OKC &+1L\]NZ@\"',RPK8,O1,BD4T
MNCQ+VC[HAX#ZTAKJ!?Z'**!_A)219;X=.JC"H&MP)!3VGNHR7P+UPP@-V+57
M"S&<!R#6T-J4^'RR, $^0>PC!0FT],QLT7J5&U-WC#88/BJ*)5-3=('=X3W[
M:]#*^4PL "KV,$Y[X*;X!@T6CU2]+9">?)/]=A$RX+$*2%5B!:9UJ X8@2.6
M,:LW0J'Z8!(M*SNDGAIO1VUIL\LU:'F]RVQ>2M3LHG?<35W78L/_I;S#6_76
M'4P3O<($2GD73;9[):RJ6'B52YQ(\U9+YM/9)(,5H)6/4$S+%(H=K2LHM  K
M!=''8UE7!B\#R^B!-_9>,)S#LSI4R+;88_$2]4ZX!D2@4!RDP#QI ;I?X<)W
M^:J%75G"5VIY8!<$Z38T_?<K.=F,1FQH^*^*(T_Z9/Q729L+ZO]22H-+C%,>
M2Y3/0Q27?Y/B\KSE&8G$7EL1@H\VP"Z3[H9V9IVBGW9G5K?D&?>UY!FK6O),
MO6O),UU_@RUY/U^=FC?6J3U_C^M/[W9VP_+4(+W@3;$P-@8MG*/FCSXTP4D7
M2JF#/CB&AAPW$"8]A[0$![;.G+;3:79!'PS=)]QF!<&5@O;$.R^&WU=TLTCZ
M6.Y+:3*I:F@*4PT=O5DVO(7^KY,3-4!G-YYEKZ&YU<.1Y'28!9A9,+\=O\,E
M7',T#\7Z!O9EEL5IV=6%XP@"B7J(I6+@">0TO6JQ274@ 6UZ]?K+5?N:QKY9
M?]+:_(E(K[#()&J6U-^SA?N9VHT07[H]LPWU@70X6_QXJA;4>L[2S5R<UM,;
MDKM4GX^@<VHX ,X[4/]:FG2D)CQ@1;R:<=1,$:AW#K,U^#E-[ONABJ-*[QS+
M(G!\@@++[]K_BM7(^FWK@/3.,355J 12DM2 2;A-W<E*D,NV@6!?T_Z:W6!)
MWY[TUI9&-"&=-$.0:M]_@2ZPWD^](A8?RGK\!LUW%;VLHI;N 6ID18%A9.4I
MBCFXG4 QEB*/%H;6Z%&J?)-U1BQ))%Y5$]&2!1=RV4A,"& ZQ<2:Q-]O$)=P
M+ 0&-9K'R1()#LX'NM@X#:#SRZ="@8:>GQR=78 3G,?8 D:7.R'@3-L76F?1
MB"\E"5N63,#C<P19U([?7=;)R :64F8AFT.6O=KIE<3!QU8*4LWVM+BL!WVI
M40?-I#.\D.!'BR,\\%*@K"21%4\XG4(6?O:>TK$D5@SA_"UKF:EP) *5J*K8
M;+*0+FA^,9G+;*(*$FFGL2Q4ZT\#6=@Q^?Y%%=9AHQ\"U70;NNJCXB05XYO@
M\*^Q_&J#V]MCUB[,M]0#*]&%:SU^%Q6TJ0CL-]'B .=O[W+;*FCNRI<L<UD"
MT8W:Z=2'%&FH"(9]OFUP5VKJGI+F[8"C73B@)8NP5GZHE>*<54DSKVO89W&Z
M"SN=BQ9$66XU]J:78)\U&_[_!?Y?T*B3X/XX\G&&R)?M_*Y^3WH$MVTN@(_J
M3$3OWMV=]VIC6IKA4AI1*88DWK.6Y5P!ZT[I50J6'Z\S5P,_;_E*8+/"2^S"
MR==8.<!IZ,CE=1NK]&SDD:EY>/4@-\RM**.GL<"Q;X:IZMO>X"W9H@L^!=IC
M7V*PT7+MY8<_7C6E6RH'T_<79/%^TG?+L!PMC6*T!*^:/!7(8RQ<Z3<CTS9S
MU9^;L=<:9WU/ 5M[ZKD64H[G8B:4+X@&Y!C6V%%3\>>"TE@/0F,@,SC#^?//
MX,1!CP^-VVS>\ZNS-A4ER!VYHCG?"8$P1LD7-ZTFFX-[8MAUZV3-'8<U9X[
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MPEL8&XW'9<..GY).W;+8"2U/*1+&5UL.452%]T_(/=IZ23$(AZ)4/-$)X=1
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MSR!<C2B,4A2A_KPY&.&QW1#O!$UR'"%=P0Y)-H4DCM-$5^F+(PR2%&^="31
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MN1(78TMZE<E[@7>TGEB(MC5ILR:T\UIS8PJ^Z.?3%Z>VCW)XF?''<-$[[00
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MQSX$P]X $#8,,6!3BQCG+Q,7168L.21-@:[<NR&"R<<>N<_<!SM!."H9T(G
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MSB%CQAF\]$20P]C[(S/UO8'-@#DAO;.:S\U\;F[UN4GMM6)%YI%!*< !<*+
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MD6<BU_K22#Z<?A2!R$D)0^$E:9+9G*AQKQD;;M19FCO/,"98>_\$2#@#*P=
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MJ9=#VV(S"Q?-& @BK4,0=AJZ07-+(GE]VV\NETV*0]@L!N"%02+60CNZOCQ
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M(!0'T[S%HC?DJFHY\B <1 T4TQ."O3Y&B!QYK49B="A,\4$+.@57;B\="%;
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MDNH>U&(5F_YE?9_,8/VE &M/\<3-HS2<A!(@ENN\?BRJ'3<%O&FVT753Y_I
MB^B\33'12R:U&7K:).^]1]7M".R_C?!X>V*,MZB _WU>^_9(WF?2TV94U[S&
MT!3Z3ILZP1PS0S_;A)WNYX2V/[&[8K*A4&MK9MS0<2L(Y?DYPE/&10=YP*.Q
M/Q:5%4M?3VG3EF>K8EM<<@\":45 "O"R::6HBG$3;=DU*GB5K@TLHL#:Q0#S
M@9$>$XCN( $FJ^(8]\9@AH'9.W4P)(F&WHBY(*IR#T?F23)9FP3[67RCGP;W
MARC7F*H%2@"3J2KHB4#;B_W:NTOA?T;W $.@F:$=/F2CM6.(!</C=85H56$Y
M1[K,-*:NM =PH#2>Q%T5T'?&_:AB+-U3IS-'R?OA^?@/LM',5"0?5A#_TT5T
M P#J"G.]A:=6WDJ50PCV5SF2[8BQZ!<RP9@B8^66QD!)1U3H8K7R-!QX][KL
MHFCS^&;1/2*?-A*,RO?+&&NA=]!&2TCW&;J5W=)I;&N@68=Q9NZ\]%^I63)=
M(50=\3,8[BR/V$!(ZJY"VP/4-3&%9]2J)58IGL2WK*U^"5FM,*B6CY:*NY*)
MKJORE>-65*3$U@<@FDK/)=O%$3-%0LCGA6=$2\&RDO6FT.&53AEEH$?*>C 8
M<@>;72ERM1>3KEM,:6'2@3S^6T9),9,\OFU4.Z[AF]Y"LN7B311O%F'&=7KF
MNB[>%70B<0[D$$=,N4MT[Z.=&/82ETR1,_P@HFQYTM1D0= ='9I?.-G+$R@!
MB[!K3GL5;UMY&HT<!-3B[6K@SJHTU:54J2!Y_\@TFZJR4Y-LIF&9@VMS<&VJ
M\;5$5^3 PG/:#MM Y-&Z!8N6YEKB5&E\.^"'_ ^X;>ES_I5A:A[/ >;Y#-SF
M,T#6'NDHZ7M39(NV8 <_(>)CQ;.V1GXW\ZZ$>-_16W72'Q2%^T=+]N=C,Q^;
MVWUL7N]D>TN_%K$2K73'4WOX)KZ<[D2CFG*G?BQ^]^B3!U\EF0*SW!C5M^*$
M ;Q3?S]?I#/KEOF0W(%#DN@6[&0?&[Z@*<B>!H_GLMAQ(1M\_;A^W'<5B;4,
MZX^ZN=9>L)Z]ZO,'?\YV34E#:M8G2'7Y6T(SK1$V:7IIX\CI-=97$1TKJRS5
M48@DV.F5,N-E*73]H5.P5>O9"TBW%*F)C"(OQG42OT3(J#9#;RWV_),7SLN2
M%-^M\S:?_/GDW^Z3;PWCDX/KVW&/7*R(C(*#>K+SY33@C:6!F[!'>@JMZTW#
M&3E7MTU528,W?U]A\5ME0N?07A9U^6\)WLY'9SXZM_SHJ&4IZD>.!3E03++!
MNN2 :93,Q>EZHZ*JA+NCDR"IUY3^%EY_(6,:,J_Q08-.3.U1,$\)KV4R1GK$
M92,=;90AUI_5DJO!.45;<%YTX6ADV<-'C_X\9NO:,87L/JO<E>.VL20,0,L7
M(8NC=J[O*%^.GOZYC/;M=N>C!W,9[5Q&.VN5NZ95?#=[$>"<B19"%I*M5DGU
MV\/=;)'Y(BSI/F8!0;'G6)M8=6N,C(RZ3$2]/O( P"_K#;ET*_QF#;91_$%+
M6LEG6]"V:*OPLOZ%VZ#/MMY\*F_UJ3P,D&@M^LD3M@/HXY\4Q(H^(JYHEURW
M+;RE;,X!!^= :"_\.\Q?'-JG*(5=4\NQ C)<H8$>-NL80$(?,651JT^![0A[
MDBTWH/Z8>0^8N8%%A5PU'[#Y@-VA R:'*O*AQJT;GM5U<Z45!4)L#(H#1-T%
M%"7? EBKF*T(FQ5 7=N&_F1GBWP<=^Q9'1<,H#I@Y-KXVJMQ"LY^(7C]^>3-
M)^\6G[Q@<%9T.+A^$$R@6W?=M*_X"*X;1"=.T!9,[<&HR]B[N.DS6FZ2-J=U
M$:.]$OQ>D:7@8;!J&C!T3<(^RPU0[P9),\-]U/9] M@V8M@O&2'W^4T(N1A[
MIY4]3"I3]I4F55\6K[,G@^)?_]XLND# @Z]BTAU7<0F$(>_ZXO7)@F$]W::
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MGW3V$&O;H&+OP#7HHFE"YCK8% BM:)Z85$1NEB*:I=+*TRY]^.#!GV6"<&U
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M>I@+? XG[LEQKFAN"7RPC=@(T9,S[&!?1SC.=:'=E6,78&(OAB"JA4[$6.1
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MD+^;!!0K#F;<ED1\$L;NDI:B2IT*B#C?WC4;C'G K1X[?H:RWE5]43-YY<:
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MJS\__>"/K_[$.X=B\3T=#4\&NVQ;=MK[RE95N7,SA=EJ5]'QB2IID*#,-Z8
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M+.B07M+7U2DDVI\[=@I5LW'5]K+KN @?5%WV146'(=G4$W(GFR*(K_"-=8K
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MJWAJ\ !F^-]/Y'__C[ "TA\_HQ.VP5P6@!2@Y*0;DDA0NG_U/_M;@SU,@C-
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M^@[P?*6I C0SZ4<>L*(Z9WM4@*:V,[5]Z%:EK+M3D6_QR?1SN:84$@BI@*:
M%1S_D8.ZWJR^#.-.$VW,E,#%0)9;FS5N98"*(1$)=B)*PENL-@>%4@*OA+8J
M;1NG")!Z.P(R#;O JD(\PGD_;H3W@M-["#[VDC+BIN\&W&D9S_(;$\>0'TY<
M2E\CGV9+0<Y=M-S9O\P6!HE> 4 AU]C*"%ZRW6A3 GJZBM*R?K-7,&#-<J*R
M>*#>>%!@'$.(N[X3S=T9X@48@S*7S#Q)T_*<'M_ 72%MD*IJ[J?G,?&;=\TF
MW.0L;<! 1D2G5_WTYI3#IM^G9PD"YTHL$P8C0RIH(/LQ6<J"V7D[#_2<4]@
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M?2LJ7OB6W%-^RIV.]P2JJWE@+DB"U]S@JMH/Y>OJR1XQ =9[=ILFIU\1-2U
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M>3L#QH(>P.2%62&=3GA!91OBG2YVM$F?9&62BER$<4<SWU0%AM4V!8](RA;
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M&[P60=(=H?IH-=@/QI\-KVPH4.%(V!..!1FLG88U3\A@*.FL2!,LH=PC#>4
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M.TV4?G_(YH^>+LCFA<?T%Y_C^C:%!]2G<MULSZMMVS/\^)_]+2J- ;O*1&$
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MP"A:  $VNH-!*QC-AZ+:\8VI]Q["U  5H"7)MW(Z&!T*^Y:P7HE?C=@=_66
MC*JSX7O(BX5>8_3?;>3?CJ ECV-5]-+-ZNN^A?5F$A0:G3+^7^[P"T:XRR'!
M37S:S/Q2I*-?;E<O%7VT^N,7W[[\$Y@<RHY1-</5ZLX=4GK^X?08T(:-X8K@
MF<>MU  A^#XLS==%L7JY(7_4*SCMOVT]O^M/-CGVO7)BHKK^O9ZZ+_E6I@DS
M#"05?L^.W4?AEI8AB/$0Q+-E".)G#T$LQ]UD=00E*"%AEF(4CS79E +BY(XE
M$#B#J&MA=H_<<PRJ;1XB.MI&2EA,!,)WWE/4!@@G;=^M V5FBF9CLCAEDZ_Z
M0FEQU,L><N;N$[*<]C:OE1U10WS'P5D5MV57R4!Y4 )@_IWFON9;L"=$K.^P
MH?\_>V_;'+>19 O_E8Z-G2>L"(@KR9ZQO8[8"(F2;<U:(X6DL>]SOZ&[T20L
M=*,':)#J^?6W\N1+9>&%I&1Y3&KP83PBV0T4"E59^7+R'/;APT-+1)"EA[3$
M#\Q'M)5#)=Q>F9-(&D+AH>'JH-=/!"64<\FUN6>+\[Q53S+X#D=F*&S#B?N8
MP/9LWS,W.1(G+99Y$]Z;,$@O"YJVX+*L'#PP-K*,\#XS+- Y_':B@EU0:9=H
MS(3OQE%HWW3(UYB*$5X_YNTO>[T$\A(14FQ5_9MIL":85$=?5HR1-8?#WV=*
MK:F,SYTX 6=+-=+8TAW05RG.< ^GNJ5W'6'3FG'P?))FK32QXD!J(AU2PF@Q
M()]2*H2-]^D8SH%<E+191+]CA^ O3&LKHB,Q&1,CB445[KAK$WK7X+Z>-3DT
ME19O:TW2]/"ZC=TV?B^\&S(0D:14GWI*DT7Y//,^]:8T6X!^H[7X_W[:3S-E
MU,%9@_T<HV(C)P"<&,/4=A.>%@C1.,NY)^V0L%"Z@QA(G6.R\.U"A&/E(<*D
M=O37GIEA(1PB7Y,WP!:E&I_JQ)+2?$')YQJ)A)&G)P/EC@1Y"T>&&1\HX8!R
M@XV?%YUO^N.$!6A/N2_D:EF!3-50.&ZJT%=_Y'"'%Z.<?CMHLUQ0)LEE&(6=
MCMM6=D<\.U(;TNEHU'8<1+F3/8D.=]:W14]+,28GQO7->4PV+<7S$E%S/RT>
MSKANC]]RO8NS5KN$07:LN;*0K";"W!$_8SHA.G?)?HJVS%$6R#9-2C.M,K>>
M%N\<GW5K4D-]9M95$?FMB ZB#NN@X:86$KQ8E?M\UIZ[C:OJHWM;-/5-J8V#
MQ!1DO!X3P?@:1NF4S--C,GQAY>1;INJ6ML8?V87$1^AKS\)J8H_T-:6&24>*
M?WS,/-:/'CQ\L/B"OCER@WL+T9)#EUJ57Y)W^8*:#!>/OLSP74WDD.=.5CTL
M5%*E(FTK]@Z>R,INPP.1H3]URYD&^%S4\?R0'GR[^.+)J]/GC^]I,S>% DCH
M!V.Y;* N5_BFE/QP3ESLM-VB:E>OEHD0H*S;8(CI7*)3NL&>;#C^P:,C?*/L
MT]/']]DW*:B& -KR53%R\9/@<&GZ$V.&WJ[T/^*Q^*!T=QZ3\NB6X7AP80FU
MIX:3I*1S-IB68Y$C3U=541]N;6VA?(SI&*VY-*?R4=.JDY7TOL(/232G$I?P
MNO&B+3,"6UU/+0_ZX2,=LAZ:&&V]<\VY-QGQR>*IRB &7^7AH_MT52<15[P/
MBZ\M+Z UE>^<"-*.^P+; \$&E$E6C6FX()W.KKXS'$RYL6>24(F6.!$>+)[\
M]-C2P_&*9OXYM-/7U.[#D>][0ZBURDL@H"\;W;=HT$:KN2;%F3*WJNZ+-U>-
M\.*'%;,NMN$F!VD4)@]E4SAI0",+-6W LIG#OCM^5OQ""8U*&-O)O%V99[)H
MGXZ,$3,F19P<:[L]!]8#PA*;HRWU*[??R>+'^K*XD-P(MT;FB=Y$^(7[?%33
M#7=KPMH,8Y-D6%CK$ SA% =K(T)]MSFX,JAF32[+E@D"S!32EC5E"PAEK%,"
MT9X\Q7)D^VNS9F]S>U$\(CZA<TDW>@U6!F:RIR\C< @NW4T<N,5+#AA3H1(Y
M3S2JC04-%[[@,\G$HLC2<M*/X3K4ZK@LBITDO#CT L!JQ>VB"JOS) ?T68AR
M(DKC>_MC@1HW5X6C=%&H&)5_P^-V*CF+A;DSNHF1J4;(2.<W7B%:>^V,#D;-
MLETZHW8'/5YW==C%(^=^R9V@1]*[KXI<,"17,('S0;&O\I4BUHP+0IH HR_!
M1XO H\(BF"WI';6DHD8PA,#A+<=,A7.)IO;TI58-D$; 0D,0E]+BIQ4$ [>Y
M1(>W);JOA/3D3BRS.6%P78S\G$V\>*;Q?:N$Y37'.:W,+12$;>%%;Z X+E P
M8G/+X@N2_HS:QRR^I(E<+U#)CG-'M-MS9N'6+;^/]A9IS6SJ52=4-O'@6AR@
MS2NLO'U\\RB"<'7>U"$($;'PJ&N=T2)=%7+0&H,-5-C6P5$C7J.HM?;FR=MO
M'GWY@%VM'Y_\;&(JOYI,-I%BK\E0,D7<@#!8SF-EKG":"'#LN'N8@U ;/\?X
MJK8"<5@NTPV3V<@9*/D/M1]LP1VS2 5L[ _X?$EHS8YBL>RW;/'H'\>S R H
M((G.!=[8EYPU8+:XB#WMV<_C\/@WA+E\.<-<9J[/?TD5HRE$G5TAWES,B[7C
M5ODSS\G:D76A&"W8J2*$PU&I2F4-6['+5**3.A>3X*D/32421%+$57;!J=2M
M!?2#ZYL_O"U;UY@,V#)=HJK;N2)R"U?HQQF^)X+TO2S2O@-;E"B:,O,A)U&E
M72GG2IOC.9PDIJ5B=]<>9$'W%QO#N;8GBU\*KMMQ>]8!.12^8EB!Q8$(",,O
MSW>4AH L+#H?EL<%SA9&;'%V:U.NV4E!<I;DSK8JTS;"GB@'>AC7KB4EG/B%
M#-DM:4%QUXGD@1*NNK_A@5!U7E^4+5B-BNV^JH\%LYIYLMU=N"<G/9BB$_?*
MZ2KAB>N&7:RPMG:>?]+M0TF<V?0$/Y$6 6>:W@*CX49V..Z%&0.1+J?E:>E$
MV8C^FP<&/&Y[B:+C_/H[>LCQP*B<+)X6A"XVG5<\N5!F2C9-YVG-;1.7=?..
MKB4KQ(V,W3[J:8MF,EU5T3F>&FW/?,8\*GSG]&H"C'NWH\K"TD 38EQ%O#AX
MI>0B'K@K8\A!B?F-RY?\4AI@B]0J7<!LZP(,ROA>\/_KR@!OA]X;/5G\@%8J
ML^-^+80#@=,G9<L>=J9;)E.GE1[H_GE]R7LY/6/\\1%+*V1(*:T'QCDY3LS'
M3B?-]DBW$Y;7?U(K0[*@R&A<P@TG;[ILDIF%WI0^A-)[WJP]TKSQ01%N:D<8
M,28*=7*.RG/]IHU,QJQ#XP^7GWQV&T2*PJ8Z<LQ3H1EZWAA$'/4V/VH-;*'D
MQDK8BWM)793W]LF"&DN*]SGA)[FC+U^%^U /4[F+:5X/90SG3Y4OL7IY^\$E
MD":QB-H-/H*@F]2.])\V#_N*[0&B6F$QUHOKBZ4Q_5J7U- W<M)X&?$VZ>KS
M;E*Z^&+'#-'$M3$U/G'Y>LR41YN%&!0"Y&W_=.J]LYYIX%XR];N&FT05VRF\
M8-Q5[UV/&;]D$WHJ8@+MN?<?KN8-GG#%ZF9-UJ^^$0B8/A[=^M=L]YMOXWY$
M_3D'TG?8G?QD6=CK$ZV)KFPJUC.$C(O(+?>M*H;0NBN!'50V:+W0*M^S22^9
M]!O^(I_*5VXU$S&(E[O*Q]6X*0[K@T4<&",I#I#FF6U^YJ#KUNV2CTX6PPKN
M:EZO68K=3ECB!XO76F6 WE8QZ:&8^V0C0@J:#-8;DMXC^R8<EX2M*?7V,9(3
M#AF+!4>_[OMC-&EQJ4E7)K]7TCY@B4W- 2=9<!G:L$E6*C^WZ7:2LS;X=[)9
MC4>:<\T&25^=UQ2YD+O2E41@;CGZL3&' [/)P^QW'-&* <BTSU[P!(LX883/
MXG=C@5]RG#*S@B(,_MA=/Y>]_P B=7J5%%U2\'115Q?&=4,4,G9N:=!,$>:U
M1QAX")*<1]XTA+"\ZB +5@-=3[R;HNI!$ATTP9OK2CM]@XO'.#O=X.$**R"/
MKMJ^<G#31N<F \\BPAT&*/ (NF_8>S#6]="S61AF;UB8%G,$)N:N;'E0DL]4
M+O.:*DIF,2DQ )NEX2FL]9Z:0\@L5.A0[W9*,%IRP$_EKK6UQO3]EJCV\9:0
M6E(N9LV:6")V30EF*BOJ9V-"%>&3$IL-R0GSK>GK8TLGO/B6VB>KV9#<44/R
MO4=& 9ZV.P^'\J$?EZ8>9EIS;8TZZG*GD/*9'GVF2)PI$H?KLNZSQ=EY \0B
M;*\AR!G;B!13Q.M?:8=G.NIY_=_J]<\\""X+SLO9%C B,.YWS#G4)/\RBH>3
M1XFVJ&)TF_A/<L@F."*1HXK\:*[#7X^Q>?/,F^?6;YXJC 8HOMI(*YIC],2X
M=%(3_I-[QGK[RU,K[3M2MEDD@ XZ8<)TY.N+/%SYK)!"TH4T=U!SEB4DF'R.
MV@P0K6E@15"Y35V5=3N35L^;ZM9OJH[J6"&N+G9.Q5(CZ@$5G74-09HP%LNN
M2U+.E->?H-.#.C1<?>7FB:E!)GP@F*I)JRS)HRH /]()0EG:G!=.R/0_#7 +
MDG.1^Q2YEDM%_'/&Y;+@-+!VN!*K$I>$O$'O43G7Q*-2711] ,)E(K_KF)&"
M)_7!";V;5::<LF^L2ZW#MVLX7ZB.6\=5U K']&#TZ;A\V7BZ9N%'GTE&C:>=
MDW?@2?)=8N!914.<9#-& 4E2^I,DF,@/'NO. W>2+^ 6,25HSF@T!%>66L+K
MK 6Q9%I"5!1!64)D&P^ <[!P8O^-C+BO,4:LCDB"TJIAY=X/J&'ZNF*FQ1B7
MWV&AXQ1H,88DT*+EZ(+TV21-3P_7UYU(*LZ ]R'@_:L9\#X#WG]WB,"0##[R
M/0@3QE7PD'AD%@!02=+!OM[T<MZ>G:E%"7F:N,T7I!D0.^"*XHLRG0.(*<2P
M&XCO<T5D?'I[>,O]5CHS 1FL_>%]TY6DJ(CH:3!T:5\=^=S==6&14H\>_>$B
MN!$,K[#>=T$T"KI\8]CER"IXEC= 5C/S",<_Q-:=KX(?<=IC+!'>/880$S6
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M5BX[O"H>X+?<]1$U%[.$L,?9EM@AZ66C^V94243."^9P UEN;YJ,'!;X^?P
M?J>2I2#85%.U&XN_N\(NF(42B0#CF3)5;PIC1H(Q!!L]2*@+U2+QD_ ;->@0
MJ"H>DK?TWEY^%E[XOR%6[\\S5F_68/X=%M9I&KNQ^C E]M\;1.1^I'4(-FA7
MG-6'4H63UO6J0W0_H-EKI$8"490\<?*B%HBHHUC*C/-Z.A8<GA4E$_M:G='3
MC=3DG*81 )&IT,=[18LH_D%*TH(C5%)UJELL/F+1Q@.:QE=8^FE$TG,8PL89
MZP7*$$9!NNA(_(QE"UI&1F7QE\FR9]&T*U0BS:,A1+:;,TU[3=3KR,3WPX!Z
M2L RDSES4;$3Q!07H/:D/PDM7R9?2H/S$:>OT?M@BE?UWB2\*;[>&2M/2@06
M278VFHD:>0)D-CGI+-E#\L/*@\E>X\0]Y.^*E#8OIG>EEV&$="R.0*@VJ3XA
M89R^F*(2CW5Z%!H _H;[1YB_ \=RE*'(ET'@Z1,ANCZ]=]2U8VMON/0\^H?T
M*\H5U +HD2:SQ!M6]/:],1,>WE*$Z(IMK^'&%&)[33QWPI^9SYTQ1>W1-6".
MLJ53-%5-%C<8)"%4)69@WT@3H]42[+N"4C5*4L46VC4D0C@O*L!?F8C7?/6D
M5<K72@#MVRKA#A6&0@11KW% =!23"8S/9?^3P)C*'!49">$]IECNJ.,4(<>Q
MRCOS%V^.-D)%RQG4S36Z509=.N!P(B8C/ P*;#7ZA-QOY93Q.%$Z;7L%"@?C
M]]+->O]8>R@M_"+),%5-*\0I"'-]5EYH,Y'G28T\ BRON"W2@,\4-F-C&F8'
M -,I^7$VO8GW817@&%<C 2*VR:HH1*Q$(F4XY2)M\YVP.',=XP8@OR?J=;ZT
M6M]G@.;[MWJS8P41>K6.I7L?7 K"=E="K$8RC&#R]A3=:7[24L*P*,7NC)*T
M5+XG_F.T543C7F[9BCO_S&?+R00BGF*]CSZHF2H%Z[Q9MV*0',29@6*<&H-
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MVU.E*]X7*^;FKBE(!I"2S[2$G-D[I!/W#B=%V?(99,&MFZYP4)!K53(%AVM
M'TI)L4[1PL6N?<*]81/_73A:YNT[FE72-C3G1%-87%7#!A'EIQ$:=9%Q>Q."
M@$,%7P^.Y1F<QI8"CW78B\V!H+_,@'^\ <,H4_V!B3Q?%UM9YB30G3>K<VN
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M93M?*:>@%3)F#=:L@:_!Q'GPW;[Y)9'F4Q%BG1_#2KJ_IMM&6E8O AZFKSZ
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MK&A_/#T#8\#U8)L(Q(WXO#<\ 8"1>>V"PT&PY'P77)F*<Q!7^2HR=*.V+UG
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M6F[8YZN1T6Z07(?M%/,KBKKD4H_=565Z\<OD@.0QV+?B->E2%W6Y)IXQ1ZE
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M>=C9.[P;/DTL_TO1#RRU0 A<'N(LZ0D&:^"J;IINSYL)OV !I"H'.@=Q8?"
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M0Q6K0>U[C?+92#2!]>7OPKG4JLC7O+.-^H7)_NUSM5-']892MJ^6POAL*(T
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M]9UG<.QU][JD&!E+*3%RW1#U*1S;?5L7U6M>(9&EY(&LL5>O']^;[@;\,F/
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M7J,\#K05,1S;.6QY#0P9?R,;3U\G2NAFW6(VR'I5_+=9EXM3,KK;[T0P-+L
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MOC2)V<*E8H/&B'\PMLS"?T6N*7SAO%R6PHIEK+: YY,?EUV_CCU%5WJFZNY
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M97WK6*[G?3/OF]N_;U;G-<4MD$P1D'<^UA2!E4T$![Z3T"@T^RKCJ4Q]0A"
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M/9A5>>A9]*VL).+/<N'[#Y%(_@>Z";,/^\?ZL#ARC1>9]QAEP'8>B)H3N1Y
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M<S[ &1+_B/3/=DQ]/^X1DG@VR636.Z"\6+TYE1$62GP:R+QGYCUSZ_<,YPQ
M/MPU*<AVB*>XLBMO7M7SJO[C)T\ZU)JR;D0RW0Z"&.#T4OQS)]AO+,MNJ![
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M\RXZV,X(3QSXG8;M"DF +JLBK_Q#_JL49A6\FP&(OJA=X57 5_"?++L08*B
MZ8#)VUYDUXLFS!'"T^Z4@917R;KP9]RMB Q&AV(P$4\TP$W?N 6@URYRN[#
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MB3!BMSA#+NKJY_E:H3P<>;EB#5ZG>@]X#=V<A''\.OSV6WSF?61LA&T[G0_
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MC*W,LA4N& O:Z,/M*<0HZ6NBQ"P7,3G%B$&VB4;>GERZU%]P>02BN3$MB'R
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M]##YZ<6SZ0XA"KVU,8HYJ[O#DO)8])?X%;"/85V2" (G_A*F/G :TR!_[*C
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MNE\XH9YOJS-N6Y^YTA%U)3K)J\L2-.%_(%NJ)4 2[FRS4L1XQNK$N#MNR^Y
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MN+-L472QF1W//HN_ ?+FC#Z@]3[S0T&5_+*7,-"CC@K^[_Q_UQD#)JI9(<U
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M8V[G\UOOLB84.@O[H.6?]XL/ONE@'/@.9X-9'(GJ52&M3.)OW+;JO5>'PW2
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MRTLT347:4!(TF)W!X).YZO_P1 [:E!K5=UHG?AGX"W8U:OIA%YO'THT9%BG
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M;4D"U*"+42AV1VX/?%.XN9^@NV@LJ'/7^K%/410A96_:7E/)W.E^9BMC2#C
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M=N?^\)NQS#?W";V4W1F*XP(D-8?G7:,D"QS7!@85%!]T[#O'GT?#O1%CTJ4
MP<N!U/ :(-)PJ_5OP,NZPS< ']94N6]("M^[0Z--ST39!D@8T$(^);WB92+D
MMSK]AI^!<><7*Z#ZP8IO8-6--\(7X$53R;?8L'9_;C]CZ0A&:NG=:M.-RT58
MED@M7PB^F\/='X7WR#60N(4$>5@'O&F;PZ+NANK[\%D)VFU"W'QQE"@P'YLA
M%JGFCD3D'M8!B4+;,>5C*WE\>WS' 18!.0'*&L6Y6EQRN* \7^=AM^K^=T@^
M8W'G!$(EELY(+)7AP=M*X]'?)S4N!$\30 /P#I<U?OZP^< 7+@K\>VTY#2]
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MG/,"B=HLI9O>^3_+MLE3Z=ZB_\C+SD56GX*_%(X9KKRE*W@ [-$?]2[*>:Y
M4J1\X&;%6"QC !05G"BO![%>\:N+Y>S3L;)NZ>U[@)*XSN_#N3W8/7ONG"KP
M;3(A']$CA%VA\;$$]@OC=6?LWLS@B^W)6KS#.'ZZ,'[$YKQCLQC8C+%#!#B
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M..BYP=$M0+A_FD]Q-@7)U"3<N".R/"8JV9.ECTXJXG0R<7N+QI=MU1?*X%I
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MW&^C6^?<^+#&LZ%%73MJ>Z)JGZXXT![(,NL6)X/!HTQ&?_Y<+1H/[96R"K<
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M4_AWZ'.3NG/FV'[$21)5'W'?TB_8BBMDYX]3%W*2*D2X1$2=!E'UP1 "^XF
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M_/'&^ 7GK<*M7O?7O)D9BV7=+'',+-P=W@H "H?M@EKG5W E!VTIF?@&VM+
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MF%>0GT@JRW?K J\KD0$7<:F$)>%U?8T?(F'$2%9N\7=8*'J>L+HT1^%?H)J
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M2$S_!/1:I,LU9'XZ!PH^@)M>=U\7WY(+7IX+_%2Y,IN> -YCBGOD.PXED!M
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MV )K==>NE*_"$CL\<+-:YRJB((JA4!S[8DO7"%BCFA2T-2_5GJDOBI1M5#$
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M"'OPDV9ZBIW>I\WZ#@U]UQ;963'I3I6A3>YJ' Q5Y/ @.*K!I%WSHS>SK@7
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MVK?,6#;LG//%&=JP=V6*?_VT,F#OVO>\KK&E_]_P?-TK8UGFZBE__<=?OWP
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M4]<]*W9XD 4>BU,.,BE2V$*'6<IL,_)CRW=B+PIWK'L'2:@ZGN^97N8SUW<
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M?&8Z2>0[B0__"'81X]JC6X)E0>ZN>M>26Z*G)E(ET619]]<2"%G Y:F,<1F
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M<KJQKI#&_4G7X''Y*:BUTOK*9<A8L>*H#C_;QQI=VP_M:U3RSV YMS+*7]"
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MEJT\::V741OPH5K3J09'+SCIYM/2.3T?\'+@>N/V'TTLFTE\EH5Q('A3-I/
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MY0/.]4!;7=E%0NS=W9G@\K*TOX+#Q%B+U6_H"7Q2FNY#->EOV=Y+P#EIVH"
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M+^P.K]WO+C6J6C\83F]S6=EKA/#)4-XGMOK&[N2GH6L$_$;K=-"KM+/A?+4
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MVU0_YM2G!A@UCM6?)WXZNU@.H:SL:DU>@#N51*FCQ!(IYBF8*<XC#<8UHL&
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M+W[RX$0#\-:*1)1RVR8N$D<6NX"2" !++"9"'R3>T.PG]_4MY^[:<K_DU\^
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M#/%'J..5*[C^>=(VX_PPG=OQGII77M.\XD[-JX:W9\MU<S=4\/TXKVAFW1?
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M7U?ZXUHX^OJ@Z5_?K-.1V&8V$H*_:F R^'1G=0[1 V5N']5>I&DGMV9ICU_
MQ MF_P(F"ICH')A0SDNI+4&*!(MXQ!$9F2(BR:C 7.!*;A6M1"LP-PP "&,
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M?\O+\R8('/G"(TL++Q0+KV@MO!E"%$>"%+QZF?&2W: ^'$3DC^MBQ=MY16.
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MP?Y5 8<^WN YGM_8?H]+>!ZN=N:T!'NHS"FJ")*^L [FV]!IM8/YSD<1]%?
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MY;\;OO@=XP+@HV(>Z]_\]5F5A^BGI>) P];S8/1PIV>8XDY&\F2J%B6Y9F*
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M ]U@;*5+JA;X+C5,775T FYTP!S5MY@/#K5O."&@#,>S[[1!9X#\K]E^@C<
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MT>(" H 651CWG0%K=!< :^)#&M"8Q\7W&GS-##4.*P!D-D:-,U,^P7SNX3R
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M%Z",>,?P$.Y%A:1D.?Q>G_Z:Y5-ELM ,7/+AT7P0AS0US,":2,KWU8\(V((
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MA"PZ% SKEPV+TVCILJG8@,P/Q2E7E^78$:9+B"HJK0EQ7.F0PJA89@#H[^4
M]10CDN;405-SIG7'H1I[IF_1^%%>9 #FQP(PFI@HZ@Z,ZM';L3 CS^?Q9DPX
MDA>?&V H+O1C'LE.3X>&X7A-O&^F-F34RIKQ9'E?5:$:G]/BFCZ]2Z=W:%+L
M.J0JD;I9KEQOS=@EXR"*'+N4AQ"5EABP*2[B(RXD9$,4GPZ4ZHPED[BO.&;^
M9$%]-@S?8L!9[;.'WN[Q]*0J3&@V)#) 65S?0P-JNY- $T2U0=*-$.D1W4QF
MQM=!77,2,0FF@OT>@/HW+TDNK:+< & Q(9!P()I%A\T>\M7J_V9IZXC$@& Q
MOU _>TT^A8UT"ZQ]@/R,$:X1QB&% >)B'J,)Q+J-#N$M=BK2@%95,.!7S'9L
MV+7HP-K3]D4:N+J5#2 6,R(56QD=D%OM::1A*R\R@%3,CN3W-SIDFFQTI ')
M/#'@4)(>T>=H.^OOEG?/3#$,E:HQ.BLY]F X^M5AMWTRO@#<IAH&U(K)DTV)
M^0ZO'3+TY1.(8@4#6L7\2#I;WR'T+IFN-';;D1I0+29-MLMZ=?AO=S9S:-M*
M'.K>\9GG+Y5*^IV:\F.;500&K(OIE>*)3IQFQBV05!/QFSX=P+7SFW72)G&M
M)V9YW')<1RFMCTWC5A'\A].7%^J&FT=/3$!WM"1396E?^:"V#6ZW4\HG4SDK
M9GPF7&V!X8^4K.IA(JTN[UQX^_Q1["M#(9CRA7N'3@$+O$\AK&@/94P[XH!6
MX/N )LSG')'VT_=LP.",]?-7&<\C6BCE52FQ2$1B$RK3G, [8^F($J]SOAV<
MSSA*-J8RN$DQ0[;93;KQ\EWSGW@SFQVX, 4JJU ^_.W"RN 9Q;1<5>ZT1Z(V
M,8ID:K*H9N<I>_(48Y38B8/!+XIIPFJ_Z*+&'I/MR=PA^SP-?C.2:K2_+R8<
M"\GYS/RAF+KO<*Z?NH^QRMZ(<>6)3/RO6]F ;3$M&5^<D88T?RD&-M#!NA6L
M.UV$4HK];AP-#O)MKUWJ7*F&*QF'?G,U ^C%1&D,>C>4[_'M*".2#>H;("WF
M0POO5'7H[B\=NFF+-P[:X1X&;CF(Z%;T6\_7@?1.B  O.-N0[]PK<X/?E"0T
MJW>;,^-"M'FB)(EO?R?@6=&0$4G3^=B.)PR,L60K2H-W-'T?L LQ[W)((=D!
MP8Y6* X78@5GV(V/P37JOXF8VR3!IGO38JVP]<Y3]N(IZJLBT#>?&"C'[&=/
MU1^ML-(_?8K+A_KN4IN9P6>*^<9Z/A.U3T(!<-]>WXRE92!:B,YU]N(ZR:[4
M[(9:BQ3,-T(Z2^4!"]\+Y@LOD/]FU/^*KU=>NM#NQ(*A@0E-,O9A3.#S!\]F
M;@-G>\?F#>Y93'O6<\_T7MF,H- 9OR2QW"01G*#D1(E.E.R]4/B0M+?2XA,E
M?^?96\W0IQN=[!>&'RQB]A#8TCF[XZM BJ]"3:.?%^Q&K%85D_-]\*WVQ?,-
MIT"-OA@)0$()B!:!( IJ7BX7C-Q,QN/.I78)EO5FXXW(# ZQX8 I*76(;A*^
M]Y.GR7[KS6S&U#?;XM(G".[9\SSEP6-7=@87,9QJ3>W?CF"8BII-52+8<OYD
M4N<T^W":Z_!&5WA<=B:H@;_4XV1PE6(&>).KP)@2M:A<)#P\-,P='NJ\9'LO
M:;#77Y/*@'XQ69Q#OQL_]O0%AL(%-@VP;D9L@+R8YRVY&*=#?F_(EUW T@#[
MIN0&](MYW/*K73H'^+:OQ"09-BX=V\'OZKZP"1ZV5:/JS9OE!C8L'GT/-_YA
M(1>>:;^A/H>>F[2SQ,/FF5<M6B"(P2F+&>0M7]?)Y@I3"I!$ Q*I0&:@ TDI
MH7,V6HUTPTJ3SN]WO0FG0=!K0FKPK9),<_[^'/*I/-1]]P?'_.=^[M.JX8/,
M!UC5YU?#KVLKE/!SDO\IF9%,A?2I)?777\MN[$MJZ&]"JL\Z7^"[+'Q^)]D2
M!3LB M"1C@QTKM<+5E%%!ZH<$?U[Q7S'LY\5&SO0G_6!AAW7Q>CP^4CZ ;"B
M88/AW_W-ZB1KJEVC7LX*[\"X=<8+3X'BGC_U+7S#ZIJ],-=3!X.3R["U06I6
M3BL)41YZH;_>04W]R6U9I>6,NNK#J8IVJC\[]_G(@L6N(RNUGX-_SZED#X[+
MA 19QW2M#L1]77E\:"T<T __'LVNF _1A$\H5(QK)Y;9G=&>K5;'.<K-9K.I
MR6IA4 AU5)D+#!@,#RM=,V$YJ[#IT#AUZW_S[J$M4*%K.*_&+OYT#>OJ*^53
M,>X;BP\'37P-L?A6Y;W'YXC.'7\!#PT_+*%U;D#0EDA@-H+Z;)-0T;O&AZ6P
M4U_!G 0<=#2[P^&;NN-@ZCK6: ;5X'%LK/TS/AS7BC*.D>QX'EW<<3UJWO'P
MY5H1'9OD=CC I#*2D1WWPJHUEC./3(7T</9X>*36.F\?<_V#Z9,WKC/''A+-
MIB)5B\^U2K;T>_A+H'PPO,B/'CO /7TT_C73_]_Q<E!2;MZ(I#7N;(0R.CXZ
MFDV@028N:X3"6\_'42:VS"XL,O,*=<KUPWTCI\[5[A9IQ*)]%KEG$+?8AK 5
MS::O S:<2>;CL9M;+_#C!>MVQ&V)A>;Q()PPWS(&8YQC9Q?JJ<>'$Q,>0+KU
M _5_8_(VX#;.(8<OU%&-@)OB^NB:366RW!XN/7#I_^%1#"'5!0:1%?;"JBV^
ML'_#Q4?QMK97BL/!F"D)!IX05]3WUS//?Z6^+71.^-&3DV#Z7V;)9^_F;>7$
MCJY,M"WU'\8\H5KL;@:JXM&WNI8I(?P#&"7!&$</LRWR]=,FF..CCQYN1W+!
M_&>V7'D^H $18 R+=\KQC5,'UUB,6\FTM&;EPQE\PBE!<@PGLZZ,U#;5:HV^
MYOG#V/<LAJE;BSDO:L5LOR MA/MD'IG:4(Q-T)BN-48Q.D$J8Y?NNY'J&XL/
M)IRIR\8"2P;HL^JJ-/7>!7KO8["<,G\T&WM";3YAP&*6>BODDL$*>^EPK#I6
M<L86V1N_M EM*/CH:/B$QZU',QBNDL-XN?4VGJ><<YPTQN9H1G0X':/\O;*A
M[U,^5U4OUTF5**F/?4._]"#T>SQW?*SS,'0>SSS?@W-+LS]&585!URM$RW4Q
MZ.INDWLKX>8-%'4$PS=DZAMXSZV6&%^Q;X7UQ2\P-8E>9U:W6X0O;V2L55%K
MKUF2VG&^2JWR]Q%2\.;?Z<,/L2'S@+JX/1-KOCNC3 P/,?MPV%'H:&*2F<N5
ME1Q01(ZD9_:U&GUUW]3^FT(JZ;X%O1M0MB\Y6%N+*#S9>(U:>#A2E8\#WUJ
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M2V(,[Q(4/Z"%4$<@>IE$%I/;F/*#K4GXM*JT,VM"D2"=-ZFL)!"R-3;_DH)
MB+Y',[VU7UG<=P9:>"L4@:"K=4(=_;E5PIW=G4]Y?D@@F*]D-RB06[A&?)7%
M03%P)U9ZHI6%RFJ'QI!](1_R/H(D_A5%$5Y<H/B;6MI519V!+*P$@W&?$*',
M5BS9Y67=1=5O"*'9[3BT^49>6>.G?:Z'Z&]YU&WEQV+7_F01:SWO>)E?;M&?
M$(PK[@?H:P#9=%<OP6G3PFBK6(.X/Y,*?GVDS2H" ?PV9IA@*H]-0R:"/)>'
M)WZD,H)?VX"[:9Z+2!V,;\(8Q0&7$9'84OG0L:X*P-&Z2L7U8@YVF*B"- PK
M.WSE/J-H:2)3<+%="LA8?$%,3NPK=1B)IH*'[N8*4T#>4E-Z[/;<CZ0Q):A9
M]S]MD=H4H>8Z?W0&S[O.D=J.>>@N5 ,K;95)9'W=8=M$ 91C(Y&O,F(4W&"5
MQVOP2.@F@$TH#F ZF!I3UM-":=0 "H'1_-!:.PI7Q^H>ML&CHILK7<%R /.F
MH=5E<YFNXA#N+3"-=>IM0PG,Z"3;RK5Z.X+)_QZFAJ&9REM\&L\0O64+9O2:
M[?FBV))@,F]7&/060&\C]:Q,AZ+IT-OXO!I8[%@:O0V_:RP 17LE\,BH3?K)
M(4N";],DXCA3D3F ,\#[#D(V3&<S1!8B)'DV2^+A%!$1<"F2<N+134)N4I$.
MYY;2E,]\[#B,ZC)"E [&DIF=,=NR&I>7!9!V4E)TL9#TF66:W*WASB/T'9%1
MQ0WJ8AEWB M1OD!4/,0V$^L5RM:?C:)XL=B4>4 +N;,+VC<,Q".1;J,RAJF3
MKH[ ->NJ@Y@:N2@^"P-5)$Z+@Y11AN(1_YBMI9*8\EB'!@TX&_CE%B!6FTLT
M#QF**K8#U=);NQW+0Y5_1##K*0?S+URX6.5@F3?1F9A=(_[_]1L_RH1<^)M)
M6F4;W5%/YW.1XELH'?S/.C27U_30UZO55\I3599H!S#-<@TRR2DUG\*)LZAA
MP&3>S,)?JBP5AKV3G18\9#KSOQ/,#L WT*72MO'#U5.$O 73>-UNH#%Y:T+>
MHX35T-^\-<(ZF;#5*J6W)ETW>"J47.!V0:4U$.+=R:/1S[G1+Y6^TR^(?,/L
M@;>,"<$K)VF(J21UB G_J#,+UFS%!W:?0A;I+5P-&_N1F7>?IS(CZ4*?Y+10
MYGAGSI-+9/8,7H]XA/%,K,Q2C*_? KZ;AOS/02SC1D;/<R[Z880I2V+%\TXM
M&K(U;)2PW)#QO[:'BW_UFXS\$( . \SQ#9,2*5.7VR^IRYZ?8SK'03@.\:AT
MC=*7]8]D *OF:O#S6I@NT[*RO#L/2(X2[<Y64M!=CM?U^G&9Q%S_9V+MV.RV
M@D3M"FI>W]TNAV?SA*#L%0A^9 T"@K,,68+XF3Q;R?=%53N?<7V+V28*74H8
MA16(S]=<W%!VH+S'W^5/.TMJ\X;L^76DGG.I<=\4"ECK=V4QXY,LT[0,Q/0F
M(9>(3LNH;-/<GF4B&T$ICH,X(X[*\+L<H?<):R,MYEVXC4*@&>D/) Q$.BKY
MG2Z4H+2\RY?[ JZ^T1N2S#;RIQ0W!6-U6[$FK<N.'W& PU>19ZX_>A6=\VF1
MIV-M 2\3Q]IM=+9^7-I=/^HT!R&@XP&1 <D"N.6TKYA-)C4AL+7T%Z1LFI#P
MWUAUA5]7P^'RD!<60TXJ*@%AIJ:T&58^1H" <J1V%@%2U]P,$Q[#&)%FMO6&
M>!5,MN!AT\:)N,+M &)%VMGX"ZM6T5 .%)'C=6PWERH;6LB!XJ65HDHCN01%
M;^L%SW?9>MR><? +JME[*57&[T+86(F9&2CS]8+EU#M%#2/U02"A5?9KF+-A
MA@MVI?KOY:;U'F,F*R6BC:O 6U3:ZY]EG@F8D:"V9XIFOX4)@+59TLHA!#.L
MM:ME5*.,P 1BSTMI#0^;MVD=S"V/:D>;M^D=C)FO[:+S]ATEL_E3W^?G[=-)
MS7:=6FY$N]C\!1 VM3R,=F'X&38,NWX\RWHZQ -ME2O3,@203G!U': ^7 W:
MN4:USA)4?LMJF0_*\46AZ]D\2A88\X7ZE:LQB@MAD21!:GM\ETLFL9#03"V4
M6<UV!GG+5VV[%P"7D^RP9':MR69?#E]<X#,(KT]9=TMB-;'.NAK0V- &/NOK
M' XK[L/IQ1UROE%-^_'H"K_B*)G/<N_@Z@.ZJVNZN_63S6T\TFXE"LX,*SMC
M[A<<8X(B#GQ_-./[-&7BJ=57;#)J9G4]C('J:%\NCYZRNI?!]$0UL!IVL,,7
M\X)J]D.8()IY=0TV>@,<@+MXS0*N;$(!WN5??2XT4CB*#G"#[=Q;./:PQILJ
M#MZZ16N+E*&VX;?%H1]PECCUCS@2@_^4R/(#R4&6"LBQV:$R\8PJ[TR5I<%"
MPP","\WS\ACF26G9/MPTNRJZ,]FGN>1K]ZDN487U?KR%+%LO;N-LR_F%)-3Z
MW-/TY/!BOB:@*+><TG5F,!4J]1NR=P_9M.]+X:Z+HATFFK;BK;3_BBG?,+EV
M(/2!0.Z=XJM]K1O&W7L+<(Z5KSB<3 6[7.5!$[R2?QE/T?VZK.T=+KS*G;ET
M$>T"8HL4^ OSB@^G2-<CPF[6\C9TK_>)!N"YH "NF+;>3ARLP2V)<CL8+]5\
MO]3>>QZQL%;()\)B1E# 4A2)5XT_Z$9@SY1X"WMM<5-A<-[1:%@DT-N%*L?L
M+><IC&D8Z')3==>?MQ!6BU%_,B%X@AC>"\3-Z?'076O/GJG(;]'6(.BMDZ0C
M9.W;$;UUH<!$N-3LZ.UMK8XP;F"C]/8NDUT(&YM'O;W> W.:F]M;O;U$!!-X
M8QN MW>5'.%NTT#K[5THH-C7M-IZ>P>KB[URST9??V\_P5SOVYJ"+8^'_[JW
M"VNPY4'P5GL':'JU/39[S'H <\'2F(0M0_W#GP5:F(Z!Q\E>A52,:4JR;(H[
M2\4Z8G9KGM_&<\[\,Y6OD3Y-L7BS\!@RJVS8G=,D?:'A*!1#2++L-5\PFR9<
MQWP5,HV'*)?_9[?PJI@V:M9F%_YY46]02.1<[U.:SE;'J.4RT857M+I#=R!N
MAEJ\=SH8Y_*Y:F_-&E1TQM3Z%DKEFT=E)0',_!RXNH>SE.7]\_CJILBO2<2;
MB<3E#[Y=VU[R:_1\&+ ^AO3;#<%"[\&$+^3[ K6TW\. ="4O5^%K..(JWK[E
MM-#O,=:@$TWJ&&Y@QTYAH'WY"[6Q-I6'LE1= 8J!61+T*D6F($@&F,$$PSP!
M0P='NO*%;@?O8PB/';-2'?WT&-+3'>;ERNLQ JA[*2_JML"-I.7)!/JC49@1
M>1N/$S++\BH<LQ4>LQ66']4.*UMA/V9<28A2D1ID\\C"]5L0I7RZB<S7@IN4
M+5FX1D1X!>DJ9>G%HKP!C8&JRQZ!P2A45ZV]M++:H3'4(G.BXI+F<Z8'CW)9
MEM7/D:L+.P/ZBB\%KS(SSVU,&4G%MBOT&<T,TE8!P,@J9D \V*.5%FV50V'$
M?;+07(2WUN^Q6\Z]LT:WM]XGR^DLU53ZE# 4Y7\7^^M]POZ)V6;GS4>[MU&+
M6O=M;0$L&(H>4A),.:T/$2H?:Z,JAS?LF<)UDY#E5Z*<RJ.[9R+\<W9D-Q66
ME_6J7R6WWX]_D/VX:;E:JOO]69)NG$IVCQ++MOV3)OF/B%Q;7^721J?8ZL*_
MH)X\%X\B\$V,?<!_11.M*]9Z7W8SG6FO)VRGP-R*X"W3!]HWNK^<.^:WCLK'
MN:M>_)L<A:#8U665M;&WVRP@)=WYMPS_X(DCN_0G+,M;![)6W_Y!>X5I0$+)
MEFWD\DW;.[M&X40\D;?2S$H/J]ME[.XU]"LF6.1?)Z]X]!R/\"H,7KEOJ&LX
M$YB</?,2S4-^%LTH75')SYPW*4L)7KU8J)".^NWX-T=,KB?+'Z\0P^OU8B\K
M>C45WL*]<R-96DSVDJ#)J&O_@%V% :T\ '3 IF(I0G&I;'4+=3MB(*R;V4*7
M)4FI7AT+I3V,K3T^NW3HSRYUZMB'.0AF<:A[B'BH'H>\(QT\F+J7GX"A>0"/
M1YE&7JPSEF@B((""8#1/30(C\J*A=]N#1T(WR6Q"<0 SQ"1 8R=]8#'^P5O>
M]Z"X[2GVPMM+"*;B9Q:= 1,&>/JL?@V$B>*!SV=%4(VW-UWV<2BV'W/C[347
MR'#O*_WU'K-?[>,55CNQ/MZF'H8LT:4Q0][F&MX7TO:#CKQ-,]PAY+8BF[Q-
M(]PYMAU$57F;-!CRVE$9DV7YH'-8EHM.(KG\3= ,&?%Z06#^)F6&/ :%:#%_
M4RYWO7GN!JGYFP)Y+XJ&)J3.,G*'=;9K$,7G;X9HR MCTQ!!RZ-Q&(>[_480
M6AZ"PS@#NHXUM#PHAW565,8@ L^FM$DY?QOS8O@)O6$*,9G28,X7;&&,N^/G
MN4M$R()3)KU<.^.R%?!I4M-9["K'^Y)@#G>>,%WF(DT%9TRH$:X]),!&HC)5
M3E4M9^P(=9,OD5-MKI"M0K"PU^3.49>'Q4);\;&?:$D]\S*_W5-R_38/^6XP
MOD^8>%%DB_"&C>R!?MFEW*G^R66Z'ME;=?>&-H=GF+[\"P<KR! +=R[]M6D)
MUG30IH'0U; V(*6=5$N.236'F:[&F'#J.)%]2C&C0E]?J[3?-1<%36HZ8^LY
M)FLMG!-X@6.N"BOO$JM*>WBKIX:FFS^!Z#1);P-E&V*A4TB]Q<)0P\CCL*T$
M N7=Z"9!I8Y8.1D.YKJ.32B@WR0PCF&N/DE7HN)Y%'+-Q;+I><#;R&"[^&QK
MC=Y&\'8A-JJ#C;=QMS:5,N\C9)M(C-')R]M(UH;B871T\S;6M"$HRH.?-ZZ4
MNS 0FHIXB)A@>4R$Z%$9,L0D<3NCL9-1>J>@PRS82UJTKSL4"UFS'F7CBF\P
MI@\H+#6-;A=Q!E3FSML,W=*WJ3&JZVI 8T-K5-?7<>Z1Z<>C*_R*HV0NJ!/A
MDEQ@C-PTNIH.V8HXT*,'1-@B][X;O5CD?]'(78T&0#"IE;V2@CX2;=_Q]#5]
M"R_"1)W.OEC 6K_]"=^#)YR]+V&$*4MBO I(?I[SQ2V8AGQ&B;\'XTM,^(8<
MBX?VZ+IT:3;#]HU:Y&^I8JPB?>+1<@\2MVE$<'!I)LEZ=3VTHJNUFV)2B:(Z
M =,&9O+:G);=<NT%)K/F20M*5<'\Z&IU()C<F]G"#90[ QR V\*KA=Y(.2SS
MAVA5,*!P& E&?66L",^NP@ >#9VCQ#8<T)TE!G-&K12N-XHM50VF/\3B-E%'
M2F""84=!L* J>^L;,H+'5-,&;JB\QTQ89-<).Q@CX4O*Q/1X2G*![-,DXL-
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M1"&CMW1)X._#[67M[/[P/;3X/J!/_!%Z5\XC97QL)/$<T65U/Q9%N6ZP+'^
M93G^'2S+KZJH)=LU_=,WL;]:,_K-]]E$&32"/2C; =V&M<1AY0H)NGX"'5(R
M^?'H6T(#CWJX,NF0H9MKQ&"?A%&9[YA/ 8=?.O$CSF$3'STYSIK/Y=/Q]Y0E
ML?KF"+XY^G@L=\:OY-=_NZ)Q3.EB32.^%8.G*\KWP1F-W<A?P]948^+T__1-
MUU[?VV+G[MF)Z F?C7<:KM8TB/$%FT>1$SQ1.#Q.MEF3&V<+7\U?G<C#__U$
M8V#GAD9^Z!W7\#[H$/86BC[!Q&[I.HQP0B'SW:WX_SW?E2=\\%_J5J!37VNL
M73A^])/#-O3*=QY]YB<^C:_H"V7']R'^_73/GU6\Y)?4?!5N@J2&S=WI6&,Y
M>Q/#.#YUHFB[#"/8;G$-;PT=K#&!I\AI&"?SQSB)'+?NN93;[3[E^#%YPWD<
M?Y*S@&_^!O>5MV%TL>3O]BH,[A*^D]5M?A%&EW&\@8OLWGEDM.XUZ4.IY^+'
MU/WN*7SYWJ,^KOL_?@,?C\1'9)/_\V_SC>=S.DK\*$R_JH6]C9T\TPC.V8@^
M\Z.6RXA<U@I7%+;M-4T6RWOGK6Z+=^EJ_XT]?X,[A,8MF[Z^O7T6LG5MF[S6
M<K!W]IZN^#WD1-OS?VS\9(LO&KQ=U#O;1.E5BU<R?^ZO^%-QHCT(#7?VM,D5
M<9U@L4"ABQ_C_#QAC'J7@9CJSQ34$>K-N3[F/-'S-QJY?DQO(M^EE6?6N#.P
MMG$+#QJO/_Y\Q27.MRC;>"C51,A^DD3^XR;!<SJ\#OD.#A(NY3/<S@GEFR&I
MV_<&!AKE@C@/N-:R/5_1Z(D/_CD*7Y-GV!).L*VX+)I:6WO&E\$+7R_8H-UD
MVOKV%EF PY+?4IE9I.62:.IADXU(Z(?B+S\;(KIV?.^,<M$YHIZ\T>:!AU?V
MG*N6M6_4GL3LJ5F9&.C$SWQ6\ =.@Q>'P8':*$CN2<0:L_)&B._#N<MG%_%S
M/N0W?[*]80Z_* (/YKR&)C6,[D!@N&N77U0T/KFE'J4K6,C3D!\%_$3F'_G>
M$KL*98$O=/5(H\J+<U<:UAZ1IHR@:EOS($K-!EON;(V0^OF;"[9B_L]%,'^*
M*/4>UF'PQ6?\, X#&M>O^7Z$1KP^YY['K^SX+G$2NHCX3G[Q@Y+<U=I\6/$R
M?@@\&C$00A:;!(RR(( (Z00%N88%WXV Q>M&B$KB+I37 =?W:B^4FN;VS""9
MM:G. **U&&Q_5,IOL!LW<;,$M6OOP[,-IX9 +DUL5D+5N?7C7R[X,:/VSRU_
M;8<V&'<>=V1=6FB^.+-%(*XZ</>!J4M>>Y1=ATD?+;O[$!,0[<Y7:Q9N*>5B
MP M7;&N>-V/2FK98WE(W? K\?_+'C=R",5-(<:T2X)!C36#I+C8)5U*^^(&_
MVJQN^<9WF!("+\(H[V#:55CN0]N>@,:<.%XL\;4X"U>.7^>"JV@X.2OM0\"5
M- 9[[\\A T'A,Y\F6/\6P1UU^>L.5]@\\F/^D_[V[VG9[3W<<,)6]:F&YQG^
M)@UFRB#F@6ZCWFSX_683N<]\7X+B4RF,#3K 5"QQ<Y=K]3#O^Q#$>W'E->DI
MW?M;8[%@ KW>@'C,WULXN#41FI_AOLL?TIG/-KQU#;][$K/O(A"'+!S"4L3.
M'<OM7LJ6[M88W-=LL'M_ S[..5<\/=@B_ 3-#DBN2;.-1[V+*%S!(;M)I"1Q
M[D0!?Q8Q/VIPP]48(PT-8O$1\QELW 2/6?Y2W5(&P4,@1ZGW[R:,?7'<,G_E
M!_"S.(_Y_]UZ<]<0E*TMRV<:\)>3\6G//3XS'QX3/&/U@C;M^FY]A]-JG+=3
M_C;YB1[HP,?R(]QT?Z%.I<&C2S=KRS]_<7P&YP879>\<IKU:9_0QR?YUNN$'
M2>T.W)7*-%["4WXP/-5:1RJ;V@]&$IX(ON4UZ\T7?JUQ%<5;!+>PU/(8N ZY
M'"O_"3=YHV8X''U[VJ#/]=.E[X*)WW7!-:IBRC@+K>I>M\Z#G2577.D.0(%
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M HZG4_X0G\+(_R<^PL8[J$-'>^*LB%CJ;*.H;V\Q.S< 'S>:@BX<<+<DVRN
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M("_(JN+'B/@BC6ES6.H_;G4T#SO(E$MJ-;MN._<?Y;";;_C%%D87?K2Z+(8
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M!F,6-A%7$/@J\0=[X;_!IWZ("2E!?%"*Y$A!U  ID(_T3&,RLOW0[QSYPG7
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M35K),BNN8J:,2SJ05L;E$+G5U2U@&=6IM<;R,F74&8%1+K^M? %CP$67S $
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M[ $#U5Q(RS NE"H@=$;%W\M@[KH091_SQ8?K&;1TUXTV5*]IT\MT)NF3M1@
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MOPR V9^"8*LX5JR*> !,R$>$]-*H2W[: 4F#6/QZZ:VL,+:&6W"CH"I00!\
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M.:DQ77#0=ET3[6MKJ![Y<),=U<)TU'AOJ#"4&=E^0#W 6A]FGLUR=!$MA)N
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MQNS7.MYJV7@O]OY<'AH*J];R!4,8D*P_V*Q'%'I@'TQBTGZ\PHU^33PL=74
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M1LV_]S*E:V!];*W- [PS47;O+6E849OU.,%+ "7!3#A%;_^%ULP9[K;KE<Y
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ME=;C:5-^'_%3A.,9@%XH(*".W&%UY2[P7H*0X%XF\OVY5Y.VQ0#VG . /8B
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M TL/X>Z=CCMHZ?Z*N?LMQ1S1E'NRL>ZSR'4VMKA?4802+P32'4V7011@VLS
MCI4Y$^3ZFM;HI([O9MJ4Q"'I>'"STQ.U68V6<_ZXFZ<@<>Q*H.1^/D<WYSH]
M;TLKI;N[)1UI#XV\)LD3]R2$]0AA[5OJ;I:&LC8AJ6#U48?*)B_1R <08)6/
M*,2,/HE)^S%9:5&A:XBNHFU-=1+RV2R[7"5A$\)=+[7"3R*S\\!!+?#*M*^'
M)5G[X<#Q;7-;;"?.FK?(^-8P\/! *:1'6JOA>9_SRC)H_\Y@(2LD[FU4G.:_
M)G&JG; X7S);/(>5/5D[D-)-,4,6*NH#Z2LT(?OM2QQN#\.]1;0=9;#4;DQ
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M\99G5 ;IE"DS=!+:Q.VF*I=K#W/W.ITWV-Z^C3U%4I1H3(XM1!JXG(Y8=1\
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MC2,JPR/_5]:&1^[OL_T?4$L#!!0    ( &J!?U0S_5%#> @  *)-   /
M<V)T>"UE>#,Q7S(N:'1M[5QM;^,V$OY^OX+8HD4"V([M;!:MG5O FSIH[GK)
M(DF!]B,M43812E1)RH[WU]\SI&1[X[S8VVSJ3;4+))$T)(<SS\P\0RLYGKA4
MO?\7.YX('N,[.W;2*?%^^'OSL-/J'A^$2P@<E!+'(QW/O63.K)LK\>\W3MRZ
MILQBD;E>N]7^OI_HS#6M_"1Z'5SGKI]R,Y99T^F\%VXHF8GF1,CQQ/4ZK<Y1
M&)+P5*IY[UJFPK)S,6.7.N59-7JDG=-I.8%?DRLYSGI*)*[_YOTQ35&I-)M(
M)YHVYY'HY48T9X;GZVH]MNB;]S]\UWG7[A\?D-3[XX-\IS9M:):[NQ[QZ&9L
M=)'%S4@K;7IF/.)[[8;_O]]?N]?9[S]LJ%E0=*15O*WEAK<3.9*.!0@%^ZWJ
M^6**L&?Q7J?[[.Z+L+ PN^J_D^'E]=GIV<G@^NSBG%V<LNM?ANSDE[/A*3L]
M.Q^<GYP-?L5M2 POV<??+J]^&YQ?L^N+5^#KYX_4W7;UU?#$._FPW:T<?36X
M_# X'UXU+W[_=?@'&YQ<TY-NNUW'\L;UYVNX-],FY6I;LYTUV']TQMV$9^RC
MY)\^\0:+A'$RF3/<=+UG<^J7Z5>[]8O,UFDQ_#MC$SX5S(BI%#,1PZ'2LD&6
M%5RQ2Y%KXYC.V"E68)UV\[\LT08R@B721A"9"VZ8@(EC]K.(1#H2!C6[@5CO
M=IA.V)544V%HT^QZ(J"X*)R,;(.=95&+[?WPW>';/DUGQ%A:9WCF_*W]?HVI
M;Q%378^I#]P"#X!-.F<WF9XI$8]%(T#+!$S%&B,S[5B$^;C,&,_FK,B<*01V
MQ9U(86 "$&<IKHP$UA(>X99A.@4Q=#K(K0ED@*&UW,Q)).4WPL-U,:?%O1C*
M8$E%&Z4U2""2)BI2B&48#DUB !E&BB;,%O1E.7XFC"@GH0VDTBKT-3(;LYET
M$VS0YB+R"M*\.533,;:),(!11O-5,]0H_R91?O@XRBDY9L 107*)FP8@#G$\
M-BO/99:0"DYB'IE%JJ!,"FRN@*0!7$NCY@P[L!05%"U*+6%?(L[>61J1%4N:
MN$$2A8( L*X!2+^<]?I$W$Y8HO3,5H&PS,2,T\V@-[1LK.#95LJL:5M#^IN$
M]%L/Z>L[E?BVV^[\U+<E:DO.1YE.)XG$Y9[=]^@X8]P(CT/@2HZ4\#1! /PC
M)>V$1I!8BD1/R9ZN8_ 'I6V!<50"C%8!D+G1D8AQV[(]X"\6 '0 V? V @,=
M"S9 =KTL%"0ZA[S9.=H308O.41RNPJ6DIBD+@4#S,TK!*_$1\$JZ;+Q0\ME"
M"1:JZ-!JU$"".-7.TN(2J 3(WMO6T>'A]_VM@N/=/RPV]O@^R*V%HL"'9P-/
M@[=!1"7BA=U\"#&&D0 0RY4"!]&%P03(NE-I?2Z'E,C\/-1[+:O :B4Q0G&/
M[)*$+-'9**L,/92H"-#%:B5C[KRB(RMCR8VD#<A E7QMRVBFPA)]\;G >J[C
M,[^V @HY5!H:E'.$5%0H3@4+V_)*+&D01@12M<H%\=-(D"!\AO$BWMD:4D?.
MEI$SNALY&R?EM0#:/)UO'$>(O:F,*3RXU1FGNL4M0HMZ (H9;N(*OX@HR4=2
M23<GHG3?LA3-'NH>Q2$0/Q-=Z2%\>;PM-Y07)D<464_LHDB;V"O@NXFQR,#7
M%(()3T1.44HBZ)1"P"":98X*]>"'##5DMX1LM,^&4ZX*GQ')GR))P*[E%)ZP
M][#D)4O:(,6'R_N9LX<H!B(]V\#/1[IP#ZNP21'B"VE!S4?R=$O*1E5;XZ-.
M!%- GSY-7B?F5X+R&(DYX&<=AW044S)@_^1^M&^1CXFGZ"@J#,%MA13<-VVJ
MK<,#^LBC.F/\LP"IP-Q[#XU)$#G(E7?$2]W1X0I_D$1G3/Y8,VBV'_2:<+O@
M4)1E?:2)V)<?;Y*R-,R9DC="E:=*=^0;?]U*.QU>=>_\F-F._F+O[ _@XRH:
M&\L,3 5A-1Z6R9@ O0656FL#ENIQ] ).&[N@+_X&YDQ3Z9P0CQ6\D09#(H%8
M0D,_RQ["!O7%4OW"=VI)JF@7?Q82&_"!7621/X/:KYOD5Q($U"0/%$@N5)4
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MG@#T/:YF?&X]43D^"']A[?C _VVV_P-02P,$%     @ :H%_5$$)LG3B!@
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M+FIP9U!+ 0(4 Q0    ( &J!?U0C-?5#@G   "Y[   2              "
M 2FI  !I;6<R,S@S,C Q.#)?,2YJ<&=02P$"% ,4    " !J@7]4<B)V!BIF
M  "L<0  $P              @ ';&0$ :6UG,C,X,S(P,3@R7S$P+FIP9U!+
M 0(4 Q0    ( &J!?U3!@U3@L#   /PW   3              "  3:  0!I
M;6<R,S@S,C Q.#)?,3$N:G!G4$L! A0#%     @ :H%_5.=4@J"F*0  \C$
M !,              ( !%[$! &EM9S(S.#,R,#$X,E\Q,BYJ<&=02P$"% ,4
M    " !J@7]4?5@/P?%.  "M60  $P              @ 'NV@$ :6UG,C,X
M,S(P,3@R7S$S+FIP9U!+ 0(4 Q0    ( &J!?U0[+1B:3HP  )"Z   3
M          "  1 J @!I;6<R,S@S,C Q.#)?,30N:G!G4$L! A0#%     @
M:H%_5-J:$+??-   PS@  !,              ( !C[8" &EM9S(S.#,R,#$X
M,E\Q-2YJ<&=02P$"% ,4    " !J@7]4I"(FM)E3  #@8   $P
M    @ &?ZP( :6UG,C,X,S(P,3@R7S$V+FIP9U!+ 0(4 Q0    ( &J!?U2=
M^(%F^:@   'X   3              "  6D_ P!I;6<R,S@S,C Q.#)?,3<N
M:G!G4$L! A0#%     @ :H%_5))-5-Z)4P  ,EH  !(              ( !
MD^@# &EM9S(S.#,R,#$X,E\R+FIP9U!+ 0(4 Q0    ( &J!?U2&V1O1-4<
M "=0   2              "  4P\! !I;6<R,S@S,C Q.#)?,RYJ<&=02P$"
M% ,4    " !J@7]4=0F#=-HB  "0)0  $@              @ &Q@P0 :6UG
M,C,X,S(P,3@R7S0N:G!G4$L! A0#%     @ :H%_5$KA[!T&(   &2L  !(
M             ( !NZ8$ &EM9S(S.#,R,#$X,E\U+FIP9U!+ 0(4 Q0    (
M &J!?U2+P_R]<B@  $$U   2              "  ?'&! !I;6<R,S@S,C Q
M.#)?-BYJ<&=02P$"% ,4    " !J@7]4.#$A*VLE   $+0  $@
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M,#(Q,3(S,2YX<V102P$"% ,4    " !J@7]4Z<P9/%4,  "%HP  %0
M        @ &IHPP <V)T>"TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @
M:H%_5#RB>&M0(P  SI0" !4              ( !,; , '-B='@M,C R,3$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( &J!?U1,,&@ 7(8  #%-!@ 5
M      "  ;33# !S8G1X+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !J
M@7]4A9VZMFX_   RR 0 %0              @ %#6@T <V)T>"TR,#(Q,3(S
M,5]P<F4N>&UL4$L! A0#%     @ :H%_5#31A#ZI&   ;>8  !
M     ( !Y)D- '-B='@M97@Q,%\Q-2YH=&U02P$"% ,4    " !J@7]4<IW=
M=40#  !X%P  #P              @ &[L@T <V)T>"UE>#(S7S$N:'1M4$L!
M A0#%     @ :H%_5.JUV/Z "   IDT   \              ( !++8- '-B
M='@M97@S,5\Q+FAT;5!+ 0(4 Q0    ( &J!?U0S_5%#> @  *)-   /
M          "  =F^#0!S8G1X+65X,S%?,BYH=&U02P$"% ,4    " !J@7]4
M00FR=.(&   470  #P              @ %^QPT <V)T>"UE>#,R7S$N:'1M
64$L%!@     = !T 1 <  (W.#0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
